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ABSTRACT
Cytotoxic T lymphocytes (CTL) have attracted much interest because of their
involvement in cellular immune reactions against a variety of targets, most notably
virus-infected cells, allogeneic cells, and syngeneic tumor cells. By means of clonally
distributed receptors (TcR), CTL scan the surfaces of other cells for specific antigens
made up of peptides (=8-25 amino acids) and polymorphic membrane proteins encoded
by the major histocompatibility complex (MHC). These antigens arise by endogenous
processing pathways or by addition of synthetic peptides to intact cells.
In the past 10 years, the central importance of peptides in T cell recognition has
been documented by functional studies, structural determination of peptide*MHC
complexes, and biochemical characterization of endogenous peptides. In addition to the
chemical identity of a peptide, the abundance of specific peptide-MHC complexes on
target cell surfaces ("ligand density") is a critical factor in regulating T cell responses.
To investigate the role of ligand density, naturally processed peptides appearing on
relevant target cells must be known. Purification, sequencing, and quantitation of
natural peptides recognized by CD8+ T cells in three systems has been undertaken:
HIV-infected cells lysed by specific CTL from HIV-seropositive donors; allogeneic
cells recognized by a mouse CTL clone; and melanoma cells lysed by human tumor
infiltrating lymphocytes. In addition, the density of peptide.MHC complexes obtained
with synthetic peptides is explored, and the minimal numbers of complexes required for
CTL activation are estimated.
Among the conclusions drawn: (1) ligand densities with synthetic peptides vary
by several orders of magnitude (<10 to >10,000 per cell), and densities of natural
ligands also vary widely; (2) low ligand densities may limit the lysis of HIV-infected
target cells by CTL; (3) "self' peptide-MHC antigens can escape immune recognition
primarily because of low abundance; (4) most peptide sequences recognized by
anti-melanoma CTL are not mutated, making tumor rejection an apparent autoimmune
response. Better understanding of ligand density as a determinant of T cell activation
may come from further measurements and development of a theory linking ligand
density, TcR affinity for peptide.MHC complexes, and T cell function.
ACKNOWLEDGEMENTS
I am grateful for and honored by the participation of the members of my thesis committee:
Professors Peter Kim, Hidde Ploegh, Susumu Tonegawa, and Don Wiley. Most of all, I
cannot express the depth of my gratitude, admiration, and affection for my thesis advisor
and mentor, Professor Herman Eisen. He simply could not have been a better example or
a more effective and supportive advisor, for which I will always consider myself
extremely privileged. His scientific acumen needs no elaboration here; but he also knew
when to offer direction and when to listen patiently, when (and how) to be critical and
when to be complimentary, and when to hear the unspoken word. I especially thank him
for spending so much time with me. I hope for many more discussions over tunafish
sandwiches, as well as during HPLC runs and perhaps a few more iodinations.
I was helped by others too numerous to thank here, but the following played crucial roles
in the genesis of this thesis: Rick Young, whose advice and encouragement was and is
much appreciated; Anna Aldovini, for showing me how collaboration at its best can work;
Bruce Walker, for scientific exchange and understanding; Ed Reilly, who heroically
persisted and stood by me at some of the darker moments; Keiko Udaka, whose tenacity
made possible certain critical breakthroughs in the laboratory; loannis Papayannopoulos
and Klaus Biemann, for enjoyable scientific discourse and collaboration; Paul Matsudaira
and Peter Lansbury, for generously providing advice whenever asked; Gene Brown,
Monty Krieger and Lisa Steiner, for their enthusiasm and example as teachers; Shigeki
Kageyama and Naomi Fukusen, for good humor and friendly collaboration in the
laboratory; Mei Wu, who led one of the projects described in chapter 3; Richard Cook,
whose constant willingness to go out of his way, to learn new techniques, and otherwise
to facilitate our work in his capacity as Director of the Biopolymers Laboratory made such
a real difference; colleagues in the Radiation Protection Office, who found a way to
provide careful oversight while enabling rather than inhibiting our work; Ward DeHaro,
who never failed to help solve a problem; the Beckman HPLC service team, for
exceptional technical support; and, not least, Ann Hicks, Mimi Rasmussen, and Carol
McKinley for unflagging dedication, friendship, and willingness to offer help.
Professor Frank Solomon paved the way at a critical moment, and deserves my very
special gratitude. I also acknowledge varied support from the Harvard/MIT MD/PhD
Program, Linda Burnley and Keiko Oh in particular, as well as financial support from the
Whitaker Health Sciences Fund and an NIH Immunology Training Grant. Joanne Barrett
and Jo-Ann Murray were both very helpful in the home stretch.
On another level, I was sustained personally in large part during this period by family
members: Harry, Blam, Dad, Mathew, and Melissa; and by teaching, for which I thank
David Durlach and all of my students. I also cite Margaret Handy, the late John
Marquand, and Deb Hughes Hallett for their abiding friendship and unwavering support
during my many years in Cambridge.
Finally, I wish to thank members of the late night MIT housekeeping staff, who were
always quick with a word of encouragement and who at times seemed to be the only ones
not under duress.
"If you can dream - and not make dreams your master;
If you can think - and not make thoughts your aim,
If you can meet with Triumph and Disaster
And treat those two impostors just the same..."
- Rudyard Kipling
TABLE OF CONTENTS
Title page ............................................................................................................... 1
A bstract .................................................................................................................... 2
Acknowledgements ................................................................................................ 3
Prefatory m aterial ....................................................................................................... 4
T able of contents ......................................................................................................... 5
Abbreviations .................................................................................................... 7
Introduction ............................................................................................................. 8
Chapter 1: Peptide binding to affinity-purified MHC-I molecules
and to MHC-I molecules on intact cells
Overview ......................................................................................... 42
Tsomides et al. (1991) Proc. Natl. Acad. Sci. USA 88:11276 ............... 50
Tsomides and Eisen (1993b) Analyt. Biochem. 210:129..................... 55
Kageyama et al. (1995) J. Immunol. 154:567 ..................................... 62
Sykulev et al. Submitted ......................................... ............. 72
Chapter 2: Naturally processed peptides recognized by HIV-specific CTL
Overview ......................................................................................... 93
Tsomides et al. (1994) J. Exp. Med. 180:1283 ....................................... 97
Chapter 3: Naturally processed peptides recognized by an alloreactive CTL clone
Overview ................................................................................................ 109
Table of peptides ..................................... 120
Udaka et al. (1992) Cell 69:989 ..................................... 121
Udaka et al. (1993) Proc. Natl. Acad. Sci. USA 90:11272 ................. 131
Dutz et al. (1994) Molec. Immunol. 31:967 ....................................... 136
Sykulev et al. (1994) Proc. Natl. Acad. Sci. USA 91:11487 ............... 145
Wu et al. (1995) J. Immunol. 154:4495 ..................................... 150
Chapter 4: Naturally processed peptides recognized by melanoma-specific CTL
Overview ................................................................................................ 159
Table of peptides ..................................... 168
Results and discussion ..................................... 169
Tsomides and Eisen (1994) Proc. Natl. Acad. Sci. USA 91:3487 ......... 175
Tsomides et al. Submitted ..................................... 178
Concluding remarks ........................................ 215
Appendix 1: Related publications
Tsomides and Eisen (1991) J. Biol. Chem. 266:3357 ........................ 225
Tsomides and Eisen (1993a) Chem. Immunol. 57:166 ...................... 229
Tsomides (1993) BioTechniques 14:656 .......................................... 260
Fahnestock et al. (1994) Biochemistry 33:8149 ................................. 264
Moro et al. (1995) Biochem. Biophys. Res. Commun. 216:234 .......... 274
Schumacher and Tsomides (1995) Curr. Prot. in Protein Sci. 3.3.1 ...... 282
Tsomides (1996) MHC Molecules ch.12 ................................ ........ 301
Eisen et al. Adv. Protein Chem. In press .......................................... 317
Appendix 2: List of publications ..................................... 376
Appendix 3: References ....................................... 379
Addendum: This thesis was defended on November 23, 1994.
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APC antigen-presenting cell(s)
BCA bicinchoninic acid
BSA bovine serum albumin
CTL cytotoxic T lymphocyte(s)
DTH delayed-type hypersensitivity
ER endoplasmic reticulum
HIV human immunodeficiency virus
HPLC high performance liquid chromatography
Ig immunoglobulin(s)
Ka equilibrium association constant
kDa kilodalton
ax-KGDH c-ketoglutarate dehydrogenase
(2-oxoglutarate dehydrogenase)
MHC-I class I major histocompatibility complex
MHC-II class II major histocompatibility complex
P2m 32-microglobulin
PTH phenylthiohydantoin
RT reverse transcriptase
SD50  peptide concentration that sensitizes
target cells for half-maximal lysis
TAP transporter associated with antigen processing
TcR T-cell receptor(s)
TEAAc triethylamine acetate
TFA trifluoroacetic acid
TIL tumor infiltrating lymphocyte(s)
VSV vesicular stomatitis virus
INTRODUCTION
It is difficult to imagine a more exciting and dynamic field of research than that of
antigen presentation during the past several years, spanning the period from the first
glimpses of a role for small peptides in T cell recognition to the present rather detailed
understanding of at least certain aspects of this process. Longstanding immunological
puzzles that seemed intractable as little as ten years ago have now yielded to explanation
in a way that threatens to make them appear obvious to a new student reading about
immunology or to those of us who have become conditioned. What is the nature of
clonally distributed T-cell receptors and their ligands? How do T cells distinguish the
normal from the aberrant on a molecular level? What accounts for the absence of overtly
self-reactive T cells in a healthy individual? Why did two quite different families of
immunological mediators - T cell receptors and immunoglobulins - evolve in vertebrates?
Recent progress has either led to answers, at least in outline form, or promises to do so.
There are even hopes and efforts to translate some of this knowledge into clinical
application in such areas as vaccine design and autoimmunity. The following is a brief
chronicle of some of the defining moments as seen by an erstwhile student of chemistry,
followed by a synopsis of the unifying themes and organization of this thesis.
First, some essential concepts and definitions of immunology. One traditional
classification of immune reactions distinguishes between the humoral, or fluid-borne
(i.e., mainly antibodies), and the cell-mediated. Cell-mediated immunity depends upon
the activities of various types of leukocytes, including lymphocytes that exhibit exquisite
specificity for antigen. In general, antigen-reactive lymphocytes are named "T" or "B"
based on their ontogenetic derivation in the thymus or the bursa of Fabricius (the latter
found in birds; in mammals, B cells originate in the bone marrow and fetal liver). B cells
produce and secrete antibodies and thereby support humoral immunity. T cells, on the
other hand, are responsible for a variety of cell-mediated immune responses including
delayed-type hypersensitivity (DTH), lysis of infected target cells, lysis of tumor cells,
graft rejection, some forms of autoimmunity, and inflammation. In all cases the stimulus
for a T cell response is the interaction of specific, clonotypic receptors on the T cell with
antigenic structures on the surface of another cell (termed a target cell or antigen-
presenting cell, APC). This is true for newly developing (i.e., thymic) cells, circulating
but immunologically naive T cells, and fully functional T cells.
T cells are further subdivided based on their surface expression of two
glycoproteins now known as CD4 and CD8. CD4-CD8- ("double negative") and
CD4+CD8+ ("double positive") thymocytes represent immature precursors of functional
T cells; certain double positive thymocytes progress to mature forms and exit the thymus
once they express only CD4 or CD8 on their surface. Mature CD4+ T cells generally
react to stimulation by secreting soluble factors ("lymphokines") that are essential for B
cell responses, macrophage activation, and other processes, leading these cells to be
functionally classified as "helper" T cells. More recently, two types of helper T cells -
Thl and Th2 - have been delineated based on their patterns of lymphokine secretion and
on whether their ultimate effect is enhancement of antibody production (Th2) or DTH and
other cell-mediated responses (Thl). Interestingly, the two groups of cells inhibit each
other, and for some parasitic infections there is a clear dichotomy as to which response is
beneficial.
Mature T cells belonging to the CD8+ subset react to stimulation by lysing target
cells that bear the offending antigen; for this reason they are termed cytotoxic T
lymphocytes (CTL). The antigen might be "non-self," as in the case of a virus-infected
target cell or a cell transplanted from another individual or species (allograft or xenograft,
respectively), but it could also be "self" if it is present on an autochthonous tumor cell or
an autoimmune target (e.g. pancreatic 03 islet cells in type 1 diabetes). The distinguishing
feature common to these instances of CD8+ (as well as CD4+) T cell activation is the
appearance on target cell (or APC) surfaces of an unusual antigen: either one that is not
encoded in the organism's genome and hence is bona fide non-self, one that is present but
not normally expressed, one that is normally expressed but at a different level, or one that
appears to be self in all respects yet becomes a target for T cells as a consequence of other
events. Thus "normal vs. aberrant" may be a more appropriate descriptor of what T cells
distinguish than "self vs. non-self." Finally, it should be noted that the classification of
CD4+ and CD8+ T cells as helper and cytotoxic cells, respectively, is not absolute: a
minority of cytotoxic T cells are in fact CD4+, and CD8+ cells can secrete lymphokines
that influence other cells.
Dual nature of the cell surface antigens recognized by T cells
As noted above, the ligands for T cells uniformly reside on the surfaces of other
cells, clearly distinguishing the universe of T-cell antigens from that of B-cell antigens.
B cells, via immunoglobulins (Ig) embedded in their surface membrane (and later
secreted as soluble antibodies), collectively respond to virtually any chemical structure:
protein, carbohydrate, nucleic acid, lipid, as well as organic molecules that do not occur
naturally. These antigens may be on cell surfaces or free in solution, and their
recognition is defined entirely by the molecule's three-dimensional conformation
(reviewed by Davies et al., 1990). T cells respond only to proteinaceous cell surface
antigens, which furthermore must consist of a noncovalent complex between a small
peptide (see below) and an integral membrane protein encoded by the major
histocompatibility complex (MHC).
The MHC is a genetic region originally implicated in studies of tumor
transplantation: the rejection of tumors transplanted from one mouse to another was due
to "major histocompatibility antigens" present on all cells, both normal and neoplastic,
and not to unique tumor antigens (Gorer, 1937; Snell, 1948; reviewed by Klein, 1975).
However, the relationship between this histocompatibility role and an immune function
for the MHC did not become clear until the early 1970s, when several studies pointed to a
requirement for shared MHC specificities between T cells and B cells (or macrophages) in
order to elicit helper T cell function (Kindred and Schreffler, 1972; Katz et al., 1973;
Rosenthal and Shevach, 1973). Then, in a seminal publication, Zinkernagel and Doherty
(1974a) showed unequivocally that virus-specific CTL responses also require shared
MHC specificities between the T cell and the infected target cell, a phenomenon known as
"MHC restriction." Shearer (1974) and Bevan (1975) independently made analogous
observations using CTL specific for trinitrophenyl-modified cell surface proteins or so-
called minor histocompatibility antigens, respectively. (Alloresponses, in contrast, involve
T cell recognition of unshared MHC products on other cells, as discussed in chapter 3).
Molecular genetic studies of the MHC (also called H-2 in the mouse, HLA in the
human) revealed a few dozen highly polymorphic and tightly linked genes clustering into
various regions. Genes in the H-2K, D and L regions (mouse) and the HLA-A, -B and
-C regions (human) code for ca. 45 kDa membrane-spanning polypeptides that, together
with a non-polymorphic, non-MHC-encoded, 12 kDa product termed 32-microglobulin
(12m), make up class I MHC (MHC-I) proteins. Genes in the I-A and I-E regions
(mouse) and the HLA-DR, -DP and -DQ regions (human) code for both (=34 kDa) and
13 (=28 kDa) polypeptides that noncovalently associate to form heterodimeric class II
MHC (MHC-II) proteins. Nearly all cells express MHC-I proteins, albeit at different
levels, but MHC-II expression is limited to certain cell types commonly referred to as
APC (macrophages, dendritic cells, B cells, and a few others). The significance of the
high degree of polymorphism (more than any other known genes) is that each individual
within an outbred population is likely to possess different alleles and hence a
characteristic set of MHC molecules on the surface of its cells; because MHC expression
is codominant, a human or mouse has up to six different MHC-I products (three genetic
loci from each parent, constituting a haplotype) and six MHC-II products. Inbred strains
of mice have fewer, since they are homozygous at the MHC and therefore express only a
single haplotype (H-2b, H-2d, etc.).
MHC restriction of CD4+ T cells has been found to map to MHC-II genes, as a
rule, and that of CD8+ T cells to MHC-I genes. Subsequently, it has been shown that
CD4 and CD8 can bind to non-polymorphic domains of MHC-II and MHC-I molecules,
respectively, and that CD4 and CD8 are likely to have roles in T cell maturation and
activation (reviewed by Janeway, 1992); however, there are also instances in which
cloned T cells seem to function independently of CD4 or CD8 (e.g. Cai and Sprent,
1994). As a consequence of this general partitioning between MHC-I and MHC-II,
CD4+ T cells react only with APC, while CD8+ T cells potentially react with any target
cell type (see table 1, p. 35).
Nature of antigen-specific T-cell receptors
Following the discovery of MHC restriction, there ensued a controversy as to
whether two distinct receptors on a given T cell were required (one for self MHC, one for
the "non-self' component), or whether a single receptor somehow accommodated both
entities (vaguely portrayed as "altered self," in the absence of any real structural model).
Much work proved the single receptor hypothesis to be correct, including experiments by
Kappler, Marrack and colleagues (1981) in which T cells of different specificity and MHC
restriction were fused and the resulting hybridomas recognized only the parental pairings.
The advent of monoclonal antibody technology and of methods for culturing T
cells enabled the production of antibodies to specific T-cell receptors (TcR) (Allison et al.,
1982; Meuer et al., 1983; Haskins et al., 1983; Kranz et al., 1984a), which quickly led to
their molecular characterization. In each case the TcR was a disulfide-linked heterodimer
(=90 kDa). Perhaps surprisingly, the component a and 0 chains (and later, yand 8 chains
for another heterodimeric TcR) displayed many of the properties of Ig molecules: sequence
similarities sufficient to lead to the prediction of an Ig-like domain structure for the TcR,
and regions of hypervariability that might account for antigen specificity (Novotny et al.,
1986; Chothia et al., 1988; Davis and Bjorkman, 1988). The isolation of a large number
of cDNA clones for c and 0 subunits confirmed these features, rooted in a similar overall
genetic organization of TcR genes (reviewed by Davis, 1990) and Ig genes (Tonegawa,
1983) (see also Eisen et al., In press; appendix, p. 317). These apparent similarities belie
the striking contrast between the nature of the ligands for TcR and for Ig; a more
complete understanding of the molecular basis for this contrast will probably have to
await the determination of a complete TcR structure by x-ray crystallography.
MHC-I-restricted antigen presentation to CD8+ CTL
Viral infections generally elicit both a strong antibody response and a vigorous
CTL response, leading in many instances to neutralization of free virions and lysis of
virus-infected cells. Yet the past decade has been a powerful reminder that these
mechanisms do not always eliminate all viruses. Partly because the reasons for escape
from antibody recognition are relatively well-explored, and partly out of disenchantment
following failures in antibody-directed approaches against both tumors and HIV, there
has been a resurgence of interest in understanding and eliciting CTL responses. CTL
have long been said to offer a potentially superior means of protection against viruses
because they target the sites of viral replication. Moreover, unlike antibodies, CTL are
largely specific for conserved, intracellular viral proteins. For example, influenza virus-
specific CTL from both mice (Zweerink et al., 1977) and humans (McMichael and
Askonas, 1978) cross-react with target cells infected by different influenza subtypes,
because a majority of these CTL recognize the conserved nucleoprotein and matrix protein
(Townsend and McMichael, 1985; Yewdell et al., 1985) rather than the highly mutable
surface glycoproteins recognized by antibodies (Wiley et al., 1981; Wilson and Cox,
1990). Despite this, efforts to detect conserved proteins like influenza virus nucleoprotein
at the cell surface, where they should be accessible to T cells, were unsuccessful.
Further pursuit of this conundrum led Townsend and colleagues (1986) to a
conceptual breakthrough when they demonstrated that incubation of uninfected target cells
with synthetic peptides mimicking parts of the nucleoprotein rendered the cells susceptible
to lysis by virus-specific CD8+ CTL. Incubation with whole nucleoprotein was
ineffective, and only certain peptides from the nucleoprotein sequence were active. It has
since become clear that the natural ligand for a TcR (of a CD8+ T cell) is a cell surface
complex consisting of a short peptide and an MHC-I protein (peptide*MHC-I); that under
normal conditions the peptide is produced intracellularly by limited proteolysis
("processing") of newly synthesized ("endogenous") viral proteins and is transported into
a compartment where it can bind to a newly formed MHC-I protein; and that this
physiological pathway can be circumvented by adding to whole cells a synthetic peptide
that binds directly to a population of cell surface MHC-I molecules that are free of
endogenous peptides.
In retrospect, Peter Doherty probably spoke for many when he remarked: "I felt
pretty stupid that I hadn't thought of the peptide, but that's the way science is." (J. NIH
Res., 1991, 3:72). As it turns out, Townsend's experiments worked even though he was
not using the "correct" peptides, in the sense that they did not precisely mimic those made
within cells and therefore those which had stimulated the production of his virus-specific
CTL. But by the time that was clear, no one cared much, for a new period of progress in
understanding T-cell ligands was in full bloom.
At around the same time, studies of antigen recognition by MHC-II-restricted
CD4+ T cells had culminated in the measurement of direct binding between synthetic
peptides (from ovalbumin or lysozyme) and purified MHC-II molecules (Babbitt et al.,
1985; Buus et al., 1986). Evidence that proteins required "processing" (e.g.,
denaturation) in order to serve as effective antigens for CD4+ T cells had been obtained
earlier (Ziegler and Unanue, 1982; Shimonkevitz et al., 1983), but proof of a direct
interaction between antigen and the restricting MHC-II (or Ia) molecule had been a
missing link of sorts. This, together with the identification of a single antigen-specific
receptor on T cells, finally made possible a molecular interpretation of previous work on
so-called immune response (Ir) genes encoded by the MHC (Levine et al., 1963;
McDevitt and Sela, 1965). In short, proteins had to be fragmented before they could
interact with MHC-II molecules to create antigenic determinants recognized by T cells;
failure of a protein to undergo fragmentation into peptides capable of binding to the
available MHC-II molecules could account for MHC-linked immune unresponsiveness to
that protein (Schwartz, 1985; Unanue and Allen, 1987).
This sudden progress toward understanding antigen recognition by CD4 + T cells
did not immediately impact the field of CD8+ T cells, perhaps because these two types of
responses still seemed so qualitatively different. CD4+ T cells were known to interact
only with MHC-II+ macrophages and other APC, which internalize extracellular
("exogenous") antigens (such as ovalbumin and lysozyme), process them in some
undefined way in a low pH endosomal compartment, and then present them at the APC
surface. CD8+ T cells, on the other hand, respond to a completely different set of
antigens: those synthesized within a cell (endogenous), as exemplified by virus-encoded
products. This was convincingly shown by Morrison et al. (1986) using MHC-I- and
MHC-II-restricted influenza virus-specific CTL. But by this time, with publication of the
first results implicating peptides in both MHC-I- and MHC-II-restricted recognition, as
well as data indicating that the variable regions of receptors on MHC-I- and MHC-II-
restricted T cells are encoded by the same pool of genes (Kronenberg et al., 1986), the
commonalities between CD4+ and CD8+ T cells in terms of antigen recognition were
becoming apparent.
The view from above
Then a landmark publication added a new dimension to the field and offered
tantalizing clues of things to come: the first structural determination of an MHC protein,
the human MHC-I molecule HLA-A2, by x-ray crystallography (Bjorkman et al., 1987a).
The structure consisted of four domains of =90 amino acids, three derived from the a
chain (al, a2, and a3) and one comprising 32m. While the membrane proximal a3 and
02m resembled Ig domains, al and a2 paired to form a novel structure: two long
a-helices overlying an 8-stranded antiparallel P-sheet, with an exposed "groove" between
the two a-helices. This groove was proposed to be a binding site for peptides (Bjorkman
et al., 1987b), based on (1) earlier sequence and functional data, (2) the overall
dimensions of the groove (=25 x 10 x 11 A, enough to accommodate a peptide of
between 8 and 20 amino acids), and (3) an additional unexpected and dramatic finding:
between the two a-helices was a continuous region of electron density not attributable to
the HLA-A2 sequence and believed to represent one or more unknown peptides that had
co-crystallized with the protein. A second crystal structure also solved by Wiley and
colleagues (Garrett et al., 1989), that of HLA-Aw68, displayed comparable architectural
features and similarly harbored unassignable electron density in the proposed binding
site, but this time the electron density was distinguishable from that seen with HLA-A2,
suggesting a different composition of putative peptide occupant(s).
Once the structure of an MHC-I molecule strongly suggested a capacity for
peptide binding, and synthetic peptides had been shown to sensitize target cells for lysis
by MHC-I-restricted CTL, several groups attempted to demonstrate peptide binding by
purified, soluble MHC-I molecules. All essentially failed (e.g. Chen and Parham, 1989;
Tsomides and Eisen, 1990). Data from assays based on solid-phase immobilization of
peptides (Bouillot et al., 1989; Chen et al., 1990; Frelinger et al., 1990) or MHC-I
molecules (Kane et al., 1989a) were obtained, but their interpretation was uncertain. In
light of Ka values of _106 M- 1 that had been measured for peptide binding to purified
MHC-II molecules by conventional equilibrium dialysis and gel filtration assays, this
discrepancy was puzzling at first.
Eventually, two clear explanations emerged. First, the synthetic peptides used in
binding assays were usually too long (e.g. a 15-mer in Chen and Parham, 1989), because
they were selected on the basis of cytotoxicity assays. In these assays the peptides added
to target cells need not match precisely the natural ligands they mimic; they can be
substantially longer, for example, and then undergo trimming by proteases in the assay
medium or on cell surfaces to reach the optimal length for binding to an MHC-I protein.
However, at this time there was no precise information about the lengths or sequences of
naturally processed peptides in peptide*MHC complexes. Second, the preparations of
affinity-purified HLA molecules used for in vitro binding assays did not have sufficient
sites available for peptide binding because these sites were already occluded by
endogenous peptides. Of course, this is exactly what the crystal structures had intimated,
but a fuller understanding of why peptides bind to cell surface MHC-I molecules in
cytotoxicity assays and not to isolated MHC-I proteins was not achieved until Ploegh and
colleagues showed that stable MHC-I molecules require peptide as an integral partner,
and that peptides added to whole cells bind to a minority population of functionally
"empty" MHC-I molecules that are unstable at 370C in the absence of added peptide
(Ljunggren et al., 1990; Schumacher et al., 1990).
So many peptides, so few MHC...
A major dilemma - one which had been a cause for skepticism in accepting the
likelihood of a physical interaction between antigen and MHC molecule - still remained
unsolved. How could the small number of distinct MHC products in a given individual
possibly bind in a specific manner to the many thousands of different antigens that must
be presented to T cells? The tremendous variability of antibody and TcR sequences
enabled these molecules to cope with a complex antigenic universe, but MHC molecules
clearly had to be using a different strategy.
Already some clues were available, notably from the crystal structures (Bjorkman
et al., 1987a; Garrett et al., 1989), from T-cell assays showing that MHC proteins vary in
their abilities to present specific peptides (e.g. Carreno et al., 1990), and from a study by
Jardetzky et al. (1990) in which only one or a few peptide side chains appeared to be
important for binding to an MHC-II molecule. Efforts had been made to discern common
features among the peptides recognized by MHC-restricted T cells (Rothbard and Taylor,
1988; Margalit et al., 1987; Stille et al., 1987; Claverie et al., 1988), but in retrospect the
conclusions drawn were quite limited. Gradually, from the accrual of data obtained using
large numbers of synthetic peptides and T cells, or perhaps from a few more crystal
structures, a complete picture of the peptide-MHC-I interaction would have been pieced
together. However, Rammensee and colleagues found a remarkable shortcut.
Having shown that tightly bound endogenous peptides could be separated from
MHC-I molecules by treatment with trifluoroacetic acid (TFA) (R5tzschke et al., 1990a),
much in the same way that Buus et al. (1988) had shown for MHC-II molecules using
acetic acid, Falk et al. (1991a) eluted peptides from isolated MHC-I molecules by
treatment with TFA and performed Edman degradation on the resulting complex mixture
("pool sequencing"). While each amino acid residue was found at virtually every cycle
during the Edman procedure, several key facts about naturally processed peptides
emerged from this study: (1) for a given MHC-I protein (such as HLA-A2), the eluted
peptides contain a predominance of one or two amino acids at certain key "anchor"
positions (e.g. leucine or methionine at position two, and valine or leucine at position
nine); (2) amino acid yields dropped precipitously after 9 cycles, suggesting that most
bound peptides are nonamers (octamers for certain MHC-I molecules); and (3) the
"motifs" characterizing peptide length and anchor positions are distinctive from one
MHC-I protein to another.
The definition of motifs provided an appealing model to explain how a single
MHC-I molecule can bind to a highly degenerate yet restricted set of peptides: a great
number of peptide sequences of the proper length can bind to a given MHC-I molecule,
provided that certain positions have the correct anchor residues, and different MHC-I
molecules have distinctive requirements for these peptide anchor positions. (A sampling
of motifs is given in the table on p. 233). Even with two positions fixed within a
nonameric peptide, a total of over 109 sequences can still satisfy the motif for a particular
MHC-I protein (although not all of these peptides will bind to the MHC-I protein).
This biochemical discovery of shared properties among endogenous MHC-I-
bound peptides fit very nicely with emerging crystallographic data from the laboratories
of Wiley and Wilson. Peptide*MHC-I complexes containing just a single peptide rather
than a complex mixture were obtained and crystallized, revealing important structural
similarities and differences among peptides binding to the same MHC-I molecule
(Fremont et al., 1992; Zhang et al., 1992; Silver et al., 1992; Madden et al., 1993).
"Pockets" within the MHC-I binding site were shown to accommodate peptide side
chains at the positions described as anchors (Garrett et al., 1989; Matsumura et al.,
1992a; Young et al., 1994). Peptides longer than 9 residues could fit by "bulging out" in
the middle, with both peptide termini substantially buried in the binding site (Guo et al.,
1992). Soon, the dual requirements for specificity and permissiveness in peptide-MHC-I
interactions were reconciled by a new paradigm for immunologic recognition, and now it
is difficult to imagine that it could be otherwise.
These motifs have also been useful for the rapid identification of candidate
sequences recognized by T cells when the protein of origin is known (Ritzschke et al.,
1991a; Pamer et al., 1991). However, this approach is not infallible, for several reasons:
(1) some MHC-binding peptides do not conform to the expected motif and therefore will
be missed (e.g. Udaka et al., 1992; Corr et al., 1992); (2) synthetic peptides that are
found to be active need not always correspond to naturally processed peptides, even
when optimized for activity, since heteroclitic reactions can occur for TcR (e.g. Bodmer
et al., 1988) as well as for antibodies (Day, 1990, chapter 12); and (3) nonphysiological
cross-reactions can be observed when target cells are sensitized with high doses of
synthetic peptides, due to artificially high peptide-MHC densities (see below). Despite
these caveats, several individual naturally processed peptides recognized by T cells have
turned out to match precisely the peptides predicted from motifs (van Bleek and
Nathenson, 1990; R6tzschke et al., 1990b; Tsomides et al., 1994), leading to a common
assumption that this will often be the case.
Corresponding findings of peptide motifs and pockets within MHC peptide-
binding sites were later made for MHC-II molecules, although in this case the situation
proved more complex. Naturally processed peptides binding to MHC-II molecules
include sets of nested peptides sharing a core sequence but having different N- and
C-termini (Demotz et al., 1989; Chicz et al., 1992; Nelson et al., 1992). These peptides
tend to be longer than those eluted from MHC-I proteins, ranging from about 12 to 25
residues (Rudensky et al., 1991a; Hunt et al., 1992b). Again, this information correlated
nicely with results from crystallography. The structure of an MHC-II molecule
complexed with endogenous peptides (Brown et al., 1993) or with a single viral peptide
(Stem et al., 1994) revealed two major differences from MHC-I: (1) the MHC-II
peptide-binding groove allows bound peptides to extend out at both ends, rather than
having their termini tucked into the binding site, thereby explaining the length
heterogeneity among naturally occurring MHC-II-associated peptides; and (2) many of
the peptide-MHC-II contacts involve the peptide backbone rather than specific peptide
side chains, implying different mechanisms for degenerate peptide binding by MHC-I and
MHC-II proteins (Stem and Wiley, 1994; see p. 35 and 36).
Origin of the peptide*MHC-I complexes recognized by CD8 + T cells
The generation of endogenous peptide*MHC-I complexes by intracellular events
collectively termed antigen processing is not considered in detail here (reviewed by
Monaco, 1992; Yewdell and Bennink, 1992; Germain and Margulies, 1993; Heemels and
Ploegh, 1995). In essence, CD8+ T cells react with peptide*MHC-I complexes that form
within a target cell's endoplasmic reticulum (ER) as newly synthesized MHC-I molecules
(a chains and 132m) assemble. The peptides to be loaded onto MHC-I molecules are
generated by limited proteolysis in the cytosol and translocated into the ER by an
ATP-dependent peptide transporter made up of MHC-encoded subunits named TAP-1
and TAP-2 (Spies and DeMars, 1991; Powis et al., 1991; Attaya et al., 1992), or in some
cases via TAP-independent pathways (Anderson et al., 1991; Henderson et al., 1992;
Zweerink et al., 1993; Hammond et al., 1993; Zhou et al., 1993). Once inside the ER,
peptides may or may not be subject to further proteolysis (Falk et al., 1990) before
binding to nascent MHC-I molecules which are then exported to the cell surface as mature
peptide-MHC-I complexes.
Given several thousand intracellular proteins potentially available for degradation
in any given nucleated cell, and many-fold higher numbers of peptides therefore
theoretically available for transport into the ER and subsequent binding to MHC-I
molecules, it is apparent that competition among peptides must be a significant feature of
antigen presentation. It may be that only the most tightly-binding peptides compete
effectively for MHC-I binding sites, explaining the slow dissociation rates implied by
endogenous peptide persistence throughout the purification and crystallization of MHC-I
molecules. Certainly peptide selectivity exists at the levels of MHC-I binding (Falk et al.,
1991a; Schumacher et al., 1991) and TAP-mediated translocation into the ER (Shepherd
et al., 1993; Neefjes et al., 1993; Androlewicz et al., 1993), and perhaps also at the level
of proteolysis (Goldberg and Rock, 1992; Driscoll et al., 1993; Gaczynska et al., 1993),
but much remains to be clarified about the generation of MHC-I-binding peptides in vivo.
What is clear is that the peptide*MHC-I complexes ultimately arriving at a cell's
surface represent a sampling of that cell's contents, with some peptides present at
relatively high copy numbers, e.g. several hundred or more identical peptide.MHC-I
complexes per cell (van Bleek and Nathenson, 1990; Falk et al., 1991b; Udaka et al.,
1992, 1993), and many more relatively scarce, e.g. between 1 and 100 complexes per
cell (Hunt et al., 1992a). Most natural MHC-I-binding peptides arise from normal self
proteins and as such are not recognized efficiently by mature T cells that have been
negatively selected for self-reactivity in the thymus. However, the same complexes can
trigger reactions from T cells of an MHC-different individual (alloreactions). For a
peptide from a foreign source such as a virus or an aberrantly-expressed protein as may
occur in a transformed cell, specific CD8+ T cells are expected to respond to the
peptide*MHC-I complex provided its cell surface density is sufficient and there is a TcR
that binds to the complex with favorable affinity and kinetics (see below).
Assays for exogenous peptide binding to MHC-I molecules
A variety of binding assays for the peptide-MHC-I reaction have been established
using either intact cells (Christinck et al., 1991; Benjamin et al., 1991; Luescher et al.,
1991; Tsomides et al., 1991), purified MHC-I molecules that appear to be free of
endogenous peptides when expressed in Drosophila cells (Matsumura et al., 1992b; Saito
et al., 1993) or other transfected cells (Boyd et al., 1992; Ojcius et al., 1993; Fahnestock
et al., 1994), or other approaches (Cerundolo et al., 1991; Silver et al., 1991; Parker et
al., 1992a, 1994; Ruppert et al., 1993; Khilko et al., 1993; Olsen et al., 1994; Sette et al.,
1994b). Each of these experimental systems suffers from certain limitations, a common
one being that the binding of synthetic peptides to fully formed MHC-I molecules may
not accurately mirror events in the ER, where this reaction ordinarily takes place.
Nevertheless, the measured Ka values and other data seem to reflect the specificities
otherwise observed in peptide-MHC-I reactions, and some of the binding assays have
proved useful in predicting potential peptide immunogenicities (Feltkamp et al., 1993;
Celis et al., 1994).
A further reason for measuring equilibrium binding constants for peptide-MHC
reactions is to calculate by means of the Karush equation (Karush, 1970) the number of
peptide*MHC complexes per target cell required to trigger the activity of a given T-cell
clone. Specifically:
r = Ka'c'n/(1+Ka'c),
where r is the number of peptide.MHC complexes per target cell at a free peptide
concentration c that sensitizes target cells for lysis by a given T cell, Ka is the equilibrium
association constant for the peptide-MHC reaction, and n is the number of MHC binding
sites per target cell accessible to extracellular peptide. Because the peptide-MHC reaction
never reaches true equilibrium, and because the peptide is subject to proteolytic
degradation during whole cell binding assays, the minimum value of r that can be
calculated using this equation (using for c the peptide concentration that leads to
half-maximal lysis) represents an upper limit to the number of peptide*MHC complexes
required for T cell activation. As discussed by Kageyama et al. (1995; see p. 62), and in
contrast to earlier studies reporting values of a few hundred (Harding and Unanue, 1990;
Demotz et al., 1990; Vitiello et al., 1990; Christinck et al., 1991), the minimum number
of complexes was recently found to vary over several orders of magnitude depending on
the particular T cell, and could be as low as ten or fewer in optimal combinations.
What determines the efficacy of CTL-mediated target cell lysis?
From the vastly improved resolution in our view of the antigenic ligand for T
cells, can we derive any understanding of what is most important in influencing the
strength of a T cell response? For CD8+ CTL, the response is lysis of target cells bearing
suitable peptide*MHC-I complexes. At least the following factors may be critical to the
outcome: (1) affinity of the TcR for its ligand; (2) off-rate of the TcR-peptide*MHC
reaction (it is assumed that the off-rate of the peptide-MHC reaction is not limiting for a T
cell response, although there are some interesting reports to the contrary (Fairchild et al.,
1993; Nelson et al., 1994); it is also assumed that TcR on-rates are not limiting in
physiological responses); (3) number or density of peptide*MHC complexes on the target
cell; (4) number or density of TcR on the T cell (possibly more important during T cell
development than for mature T cells); (5) coreceptor and accessory molecule interactions
between the T cell and its target (reviewed by Springer, 1990); and (6) lytic pathways of
the CTL (e.g. Eisen, 1990, chapter 19).
T-cell receptors do not exhibit the somatic hypermutation that underlies the
generation of high-affinity antibodies. It was therefore suggested early on (Eisen, 1986)
that high affinities are unlikely for TcR, and moreover that while high affinities may be
useful for antibodies because they allow lower concentrations of antibody to accomplish a
particular amount of binding, the affinities of membrane-associated T-cell receptors need
only surpass a threshold value required to activate cell function, beyond which higher
values might increase the risk of deleterious cross-reactions. The first reported
measurements of TcR affinities in the Ka range of =104-105 M-1 (Matsui et al., 1991;
Weber et al., 1992) appeared to reinforce that view. However, further measurements
have uncovered much higher values, up to =1.5x107 (6x106 at 370C) (Sykulev et al.,
1994; see p. 145), prompting a reevaluation (Eisen et al., In press; see appendix, p. 317).
It now seems that TcR intrinsic affinities for their natural peptide*MHC ligands will vary
widely (e.g. 4103-107 M-1), although probably not up to the very high values exhibited
by some antibodies for antigens (108-1011 M-1). Thus it becomes manifestly relevant to
evaluate the functional importance of differences in TcR affinity in vitro and in vivo.
It is often assumed, implicitly or explicitly, that "high-affinity T cells" (i.e., high
affinity of the TcR for its peptide.MHC ligand) are better effector cells than "low-affinity
T cells." Is this really true? Very little data are available so far to address the question.
For example, it would be of interest to determine whether there is an inverse correlation
between the density of peptide*MHC ligands on the surfaces of target cells and the
required affinity of a CTL's TcR in order to effect lysis of the cells. In a recent study
(Sykulev et al., 1994), ligand density was manipulated by using related synthetic peptides
to sensitize target cells for lysis by a clone of CTL, and the intrinsic affinity of the CTL's
TcR against each peptide*MHC-I ligand was measured; the result was a general
correlation between TcR affinity and the peptide concentrations required to sensitize target
cells for half-maximal lysis (SD50). However, the use of SD50 as a marker for ligand
density is limited because of variations in peptide-MHC-I binding affinities (e.g.
Kageyama et al., 1995). In particular, a synthetic peptide with relatively low affinity for
a restricting MHC-I molecule may need to be added to target cells at a significantly higher
concentration (SD50 value) in order to match the ligand density of a different peptide,
regardless of the ability of a CTL's TcR to recognize each peptide*MHC complex. That
TcR affinity alone is not a sufficient predictor of T cell function is also apparent from a
comparison of two established CTL clones: although their TcR differ =10-fold in affinity
for the respective peptide*MHC ligands, the two CTL are equally effective in lysing target
cells pulsed with synthetic peptide (i.e., same SD50 values) (Sykulev et al., 1994; see p.
145).
Density of the ligand for antigen-specific receptors on T cells
The principal factor in determining T cell efficacy to be considered in what
follows is the cell surface density of peptide*MHC-I complexes. Ligand density
undoubtedly influences the probability of target cell lysis by specific CTL, as is
commonly demonstrated by titration curves with synthetic peptides in cytotoxicity assays.
The role of ligand density in CTL reactions when using synthetic peptides has been
explored (e.g. Alexander et al., 1991; Christinck et al., 1991). Whether the densities of
endogenous peptide.MHC-I complexes are often limiting in vivo is less clear, and is
difficult to investigate. In one study, HIV-infected human target cells were lysed very
poorly in vitro by HIV-specific CTL, even though these CTL were capable of lysing
uninfected target cells pulsed with as little as 1 pg/ml of a synthetic HIV peptide
(Tsomides et al., 1991, 1994). Isolation of the relevant endogenous HIV peptide from
infected cells revealed a maximum of only =12 peptide.MHC-I complexes per cell,
suggesting that low peptide abundance might be responsible for poor killing of infected
cells - even by what would have to be considered a highly efficient clone of CTL.
In the second example, a peptide recognized by an alloreactive (H-2b anti-H-2d)
mouse T-cell clone was found: (1) to be indigenous in H-2b mice ("self') (Udaka et al.,
1992; see p. 121); (2) to bind a self MHC-I product (Kb) almost as well as the allogeneic
MHC-I product (Ld) (Kageyama et al., 1995; see p. 62); and (3) to elicit cytolytic activity
from the same alloreactive T-cell clone in the context of either Ld or Kb, but with a
marked difference in the peptide concentrations required (Dutz et al., 1994; see p. 136).
Since H-2b mice (as well as H-2b mice transgenic for the TcR of this alloreactive clone
(Sha et al., 1988a)) show no signs of autoreactivity, these studies indicate that lack of
recognition by specific T cells of a self peptide*MHC-I complex in vivo is due to its low
cell surface density, not to its absence or to the absence of potentially autoreactive T cells;
as a corollary, increased expression of the complex might well trigger an autoimmune
response (Dutz et al., 1994).
It is worth noting that for reasons of convenience and economy, most studies of T
cell specificity have relied on the use of synthetic peptides. Because peptides can bind to
functionally empty MHC-I molecules on appropriate target cells, and because many
longer peptides undergo degradation during T-cell assays, this approach has been
successful in leading to the identification of antigens recognized by T cells specific for
various types of targets (infected, tumor, allogeneic, xenogeneic, etc.). Often, very high
concentrations of a synthetic peptide are used, e.g. 10-100 AM. At such concentrations,
peptides with even modest affinities for the restricting MHC-I molecules (Ka values of
106-108 M-1) will occupy over 90% of available MHC-I binding sites at equilibrium,
resulting in orders of magnitude more specific peptide*MHC-I complexes than the few
hundred per cell that have been measured for several naturally processed peptides. For
example, the HIV peptide mentioned above will form up to 10,000 peptide*MHC-I
complexes per target cell when added at micromolar concentrations, far higher than its
natural density; other synthetic HIV peptides can readily sensitize target cells for lysis in
T-cell assays even though they are not detectable in infected cells (Tsomides et al., 1994).
At artificially high ligand densities, misleading cross-reactions have also been described
in other viral (Milligan et al., 1990; Speiser et al., 1992) and self (Schild et al., 1990; Dutz
et al., 1994) systems. Thus exclusive reliance on synthetic peptides sharply limits any
possibility for extrapolation to CTL-target cell interactions as they might occur in vivo.
More to the point here, it is not even possible to begin a study of the physiological
role of ligand density until the naturally processed peptides in a given system are known.
In practice, this can be a formidable task precisely because of the limited abundances of
many naturally processed peptides. The strategies that have been devised for the
identification of natural T-cell ligands can be divided into four categories (so far).
The "easiest" case is that of a peptide derived from a protein of known sequence,
such as a viral protein. A relatively small number of cells expressing the antigen of
interest (ca. 108-109) are lysed with TFA to extract MHC-bound peptides as originally
shown by R•itzschke et al. (1990a), and a peptide fraction from this lysate is subjected to
fractionation by HPLC. Individual HPLC fractions are screened in a suitable T-cell assay
(i.e., using a target cell expressing the restricting MHC-I protein but not the peptide, and
ideally with a high density of peptide-free MHC binding sites). The retention time of
each active HPLC fraction is then compared with those of synthetic peptide candidates
based, for example, on the motif for natural peptides associated with the restricting MHC-I
molecule. The method becomes much more discriminating when several different HPLC
conditions (columns, solvents, and gradients) are used to establish a chromatographic
profile of the unknown peptide for comparison with all synthetic peptide candidates.
The earliest identifications of naturally processed peptides all used this approach
(van Bleek and Nathenson, 1990; Riitzschke et al., 1990b; Ri$tzschke et al., 1991a;
Pamer et al., 1991; del Val et al., 1991), which exploits the far greater sensitivity of T
cells than that of chemical analysis when it comes to peptide detection. Specifically, it is
not uncommon to demonstrate T cell activity at a peptide concentration of 1 pg/ml; in an
assay volume of 200 tl1, this corresponds to the detection of some 200 attomoles of a
typical nonameric peptide, several orders of magnitude less than what is required for
chemical sequencing. Van Bleek and Nathenson (1990) employed a radiolabeling
technique to help establish the sequence of a naturally processed viral peptide, but still
relied on chromatographic comparison with synthetic peptides in order to define this
peptide. Some of these early results presaged the discovery by pool sequencing that most
endogenous MHC-I-binding peptides are nonamers (see table 2, p. 38).
The second strategy permits the identification of a completely unknown T-cell
ligand, for instance one expressed on a tumor cell or an allogeneic target cell. In this
case, it becomes necessary to isolate enough material for chemical sequence analysis. For
a relatively scarce peptide, say 100 copies per cell, this means starting with nearly 1012
cells in order to isolate just 15 pmoles of peptide for Edman sequencing, assuming 10%
overall yield. The first successful application of this method was the sequencing by
Udaka et al. (1992, 1993) of two naturally processed peptides recognized by a clone of
alloreactive T cells. Using microcapillary HPLC coupled directly to a mass spectrometer
for peptide detection and sequencing, Hunt and colleagues (1992a) improved sensitivity
by at least one to two orders of magnitude and ultimately determined the sequence of a
melanoma peptide recognized by specific T cells from five patients (Cox et al., 1994).
An important advantage of mass spectrometry over Edman degradation is the ability to
sequence peptides from mixtures. Storkus et al. (1993) found a way to reduce the total
number of cells needed: they used a novel, non-cytotoxic elution procedure to remove
MHC-bound peptides from cultured cells, then allowed the cells to recover and repopulate
their cell surface peptideoMHC-I complexes.
Each of the first two strategies can be applied either with or without purification of
MHC molecules. Extraction of whole cells with TFA is expedient but leads to a much
more heterogeneous mixture for HPLC fractionation, of particular concern when the goal
is purification of an active peptide to homogeneity. Purification of MHC protein followed
by TFA extraction may result in lower yields of peptide, particularly for rapidly
dissociating peptide*MHC complexes, but is necessary in order to establish that a given
peptide is associated with MHC molecules and is not strictly cytosolic.
A third strategy is the identification of naturally processed peptides based on their
abundance and not on their recognition by established T cells. For example, bound
peptides are eluted from purified MHC-I molecules by treatment with TFA, the peptides
are fractionated by HPLC, and peaks that appear prominent by ultraviolet absorbance are
subjected to Edman sequencing. Jardetzky et al. (1991) first sequenced eleven nonameric
peptides associated with HLA-B27 by this approach, and several of these matched known
sequences of abundant cytosolic or nuclear proteins. By mass spectrometry, Hunt et al.
(1992a) sequenced several nonamers associated with HLA-A2, and also discovered in
TAP-deficient cells a family of natural peptides that are derived from signal sequences of
normal cellular proteins (Henderson et al., 1992); Wei and Cresswell (1992)
simultaneously reported similar findings by Edman sequencing. Several groups isolated
MHC-II molecules and their associated peptides (Rudensky et al., 1991a; Chicz et al.,
1992; Nelson et al., 1992; Hunt et al., 1992b; Riberdy et al., 1992; Kropshofer et al.,
1992), and these differ significantly from MHC-I-bound peptides in terms of their
proteins of origin, lengths, and relationships to one another. Some salient features are
highlighted in tables 1 and 2 on p. 35 and 38.
A fourth way of identifying natural T-cell ligands is completely independent of
their abundance in target cells. Pioneered by Boon and colleagues (De Plaen et al., 1988;
Boon et al., 1994), this molecular genetic approach involves transfecting cDNA from a
target cell of interest (e.g. a tumor cell) into an antigen- cell and screening large numbers
of transfectants for their ability to stimulate the relevant T cells. Ultimately the gene
encoding an antigen recognized by these T cells can be sequenced. This technique has
been used to identify the first precursors of T-cell antigens on tumor target cells (van der
Bruggen et al., 1991; Traversari et al., 1992; Brichard et al., 1993; Kawakami et al.,
1994a, b; Coulie et al., 1994). However, candidate peptides based on the gene sequence
must be synthesized and tested for activity, and in order to determine whether an active
peptide corresponds to a naturally processed one, and whether it is present on tumor cells
at a sufficient density to elicit a T cell response, it must be analyzed as described above.
This has been done for a mouse tumor-specific peptide (Wallny et al., 1992a) but not for
any of the human tumor antigens so far described (see chapter 4).
Having identified a naturally processed peptide, it is possible to quantitate its level
of abundance either directly, if Edman sequencing has been employed, or indirectly by
constructing a standard curve for a T-cell assay with the corresponding synthetic peptide.
A sample of natural material from a modest number of cells will suffice to provide a
signal in the T-cell assay that can be correlated with the standard curve. Then, the greater
challenge is to interpret this quantitative information further.
TABLE 1. Comparison between peptide binding to MHC-I and MHC-II molecules.
MHC-I MHC-II
Distribution
Domain structure
Accessory molecule
Typical T cell response
Origin of most bound peptides
Length of bound peptides
Pockets in MHC groove
Peptide N- and C-termini
Many critical contacts
Equilibrium constants (Ka)
Peptide-MHC kinetics
All nucleated cells
fl1, oC2, (X3 + P2m
CD8
Cytolytic activity
Cytosolic (endogenous)
Usually 8-9 residues
Yes
Buried in groove
Peptide side chains
=104-109 M-1 measured
Slow (>=30 min)
Specialized APC
a•l, U2 + P1, P2
CD4
B cell help, DTH
Extracellular/membr. proteins
Variable, =12-25 residues
Yes
May extend outside groove
Peptide backbone
=106-108 M-1 measured
Slow (>=30 min); 2 modes
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(b)HLA-DR1 (class II)
Comparison of MHC-I (HLA-Aw68) and MHC-II (HLA-DR1) structures.
Ribbon diagrams show a peptide (blue) binding above the large P-sheet and
between the cx-helical regions of the MHC protein (green and yellow).
Although the domain organizations of HLA-Aw68 and HLA-DRl differ,
their three dimensional structures are very similar.
Cut-away of the molecular surface of the peptide-binding site of HLA-A2,
with CPK model of HIV peptide ILKEPVHGV, shown in side view.
Figures from Stern and Wiley (1994) kindly provided by L. Stem.
(a) HLA-Aw68 (class 1)
organs, tissues or
cultured cells
homogenization/sonication in TFA
ultrafiltration for collection of
peptide (low MW) fraction
SHPLC fractionation
T-cell assay of fractions
active fraction(s)
detergent solubilization
MHC affinity purification
or immunoprecipitation
TFA elution of MHC-bound peptides
ultrafiltration for collection of
peptide (low MW) fraction
Sequence determina-
tion of individual
T cell epitopes
Sequence determina-
tion of individual
abundant peptides
Pool sequencing for
motif shared by
MHC-bound peptides
Strategies for the identification of naturally occurring peptides associated with MHC
molecules. Starting with whole organs, tissues, or cells, two possible pathways consist
of preparing crude lysates in TFA (left) or first isolating MHC molecules and then
extracting bound peptides with TFA (right). In the first case, ultrafiltrates of whole cell
homogenates are fractionated, the fractions are tested for sensitizing activity in a T-cell
assay, and each active fraction is subjected to repeated rounds of HPLC until suitable for
sequencing by Edman degradation and/or mass spectrometry. In the second case,
peptides eluted from MHC molecules can be fractionated and assayed to identify T-cell
ligands as above, peptides can be sequenced based on relatively abundance by ultraviolet
absorbance, or the crude peptide mixture can be sequenced directly without HPLC
fractionation to establish motifs for peptides associated with a particular MHC product.
TABLE 2. Examples of naturally processed peptides associated with MHC molecules.§
MHC Peptide origin Peptide sequence Reference
Class It H-2Kd Influenza NP 147-155 TYQRTRALV Ritzschke etal., 1990b
H-2Db Influenza NP 366-374 ASNENMETM Rtitzschke etal., 1990b
H-2Kb Vesicular stomatitis van Bleek and
virus NP 52-59 RGYVYQGL Nathenson, 1990
H-2Kb Ovalbumin 257-264 SIINFEKL Ritzschke et al., 1991a
H-2Kd L. monocytogenes
listeriolysin 91-99 GYKDGNEYI Pamer et al., 1991
H-2Ld Mouse a-ketoglutarate
dehydrogenase LSPFPFDL Udaka et al., 1992
H-2Ld Mouse a-ketoglutarate VAITRIEQLS
dehydrogenase PFPFDL Udaka et al., 1993
HLA-A2 HIV type 1 reverse
transcriptase 476-484 ILKEPVHGV Tsomides et al., 1994
HLA-A2 HIV type 1 gag 77-85 SLYNTVATL Tsomides et al., 1994
Class II I-Ab Mouse leukemia virus
envelope 145-157 HNEGFYVCPGPHR Rudenskyetal., 1991a
145-158 HNEGFYVCPGPHRP
I-E a chain 56-73 ASFEAQGALANIAVDKA
Invar. chain 39-53 KPVSQMCR TPLM R
I-Eb Mouse leukemia virus
envelope 454-467 SPSYVYHQFERRAK Rudensky et al., 1991a
454-468 SPSYVYHQFERRAKY
454-469 SPSYVYHQFERRAKYK
BSA 141-154 GKYLYEIARRHPYF
I-Ak Hen lysozyme 48-60 DGSTDYGILQINS Nelson et al., 1992
48-61 DGSTDYGIEQINSR
48-62 DGSTDYGILfJNSRW
52-64 DYGILQINSRWWC
DR1 Invar. chain 105-118 KMRMATPILMQALP Chicz et al., 1992
105-119 KMRMATPLMQAIPM
96-118* LPKPPKPVSK....P
96-119* LPKPPKPVSK...PM
96-120* LPKPPKPVSK...PMG
97-118* PKPPKPVSK...P
97-119* PKPPKPVSK...PM
97-120* PKPPKPVSK...PMG
98-118* KPPKPVSK....P
98-119* KPPKPVSK...PM
99-118* PPKPVSK....P
§ adapted from Tsomides and Eisen (1993a).
t only MHC-I-binding natural peptides that are recognized by established T-cell clones
are shown; sequences identified on the basis of high abundance are not included.
* for brevity, invariant chain residues 106-117 are represented by an ellipsis (...).
Thesis organization
The work summarized in this thesis concerns the naturally processed peptides
recognized by established CD8+ CTL in three distinct systems using virus-infected,
allogeneic, and tumor target cells. Within each system, a better understanding should
ultimately include answers to the following:
* How many different naturally processed peptides are recognized by a single T cell?
* What is the sequence of the active peptide (or peptides)?
* If more than one, what is the chemical relationship among these peptides, and what
does that reveal about physiological antigen processing pathways?
* Is the naturally processed peptide also the most active synthetic peptide (if known)?
* What is the abundance of the naturally processed peptide(s)?
* How does the abundance relate to activation of specific T cells?
* What are the roles of TcR affinity and kinetics in determining T cell activation?
* What is the protein of origin for the naturally processed peptides?
o How general are the results for each class of T cells?
Chapter 1 relates several binding assays using synthetic peptides and MHC-I
molecules that were either affinity-purified prior to the addition of peptide, affinity-
purified after the addition of peptide to cells, or used in situ on intact cells to measure the
binding of peptides. By this last approach, it became possible not only to measure
equilibrium association constants (Ka values) for the peptide-MHC-I reaction, but also to
estimate the number of peptide-MHC-I complexes required to activate various CTL.
To carry out these studies, peptides were radiolabeled using 3H or 1251 (or 1311).
Internal substitution with 3H does not cause any structural perturbations, so 3H was used
as a trace label. Much greater specific radioactivities could be achieved with 1251 (or 1311),
but iodine significantly alters peptide structure and function, so its validity as a reporter
group was questioned. In particular, conventional iodination procedures typically result
in <1% labeling, and labeled molecules were shown here to have strikingly different
biological activities than unlabeled molecules; consequently, new procedures were
developed to obtain stoichiometrically labeled and therefore chemically homogeneous
iodopeptides. This work is described in chapter 1 and in a detailed method included in
the appendix (see p. 282).
Chapters 2, 3 and 4 describe three systems in which naturally processed peptides
were studied. In chapter 2, the viral peptides generated within HIV-infected target cells
and recognized by two A2-restricted CTL clones from HIV-seropositive individuals were
identified. The abundances of these peptides in infected target cells were measured, and a
potential link between peptide abundances and target cell lysis by CTL was considered.
Chapter 3 includes several studies, all centered on the discovery of natural peptide
sequences that sensitize target cells for lysis by an alloreactive (H-2b anti-H-2d) CTL
clone. Chapter 4 summarizes efforts to identify the melanoma peptide recognized by a
line of A2-restricted tumor infiltrating lymphocytes, and the importance of this
information in the context of other recent studies on A2-restricted anti-melanoma T cells.
Relevant publications in which the author was deeply involved are included in
each chapter. In addition, each chapter begins with a short overview to connect the
different studies and describe continuing work.
CHAPTER 1
Peptide binding to affinity-purified MHC-I molecules
and to MHC-I molecules on intact cells
Overview
Peptide.MHC-I complexes on the surfaces of target cells can arise in one of two
ways. Normally, antigenic peptides are generated cytosolically and translocated into
the ER, where they come into contact with newly synthesized MHC-I proteins (a chain
and P2m). Heterotrimeric complexes (c-* 2m-peptide) then assemble for constitutive
transport to the cell surface. (It has also been suggested that further peptide proteolysis
may occur within the ER.) Alternatively, synthetic peptides added to the extracellular
medium can bind directly to mature (but presumably peptide-free) MHC-I molecules at
the cell surface. The existence of this second pathway originally permitted the
discovery that short peptides are recognized by T cells; it is not known to have any
relevance to physiological processes, although it could play a role in peptide
immunization (Aichele, 1990; Kast, 1991; Zhou, 1992), in the induction of immune
tolerance by antigen administration (Khoury et al., 1993), and in the phenomenon of
"cross-priming" (whereby mice immunized with cells bearing an antigen on non-self
MHC molecules sometimes develop CTL that recognize the antigen with self MHC).
In studying antigen recognition by T cells, it is of interest to understand the
densities of peptide.MHC-I complexes achieved by both pathways. To characterize the
complexes formed in the normal (endogenous) pathway, peptides furnished by
intracellular processing mechanisms must first be identified. Chapters 2, 3 and 4 are
concerned with naturally processed peptides and their abundances on virus-infected,
allogeneic, and tumor target cells. In this chapter, ligand densities resulting from the
sensitization of target cells with synthetic peptides are explored by means of a direct
binding assay and the use of uniformly labeled peptides. The study of peptide-MHC
binding using exogenous peptides offers experimental accessibility, allows peptides that
are not produced naturally to be investigated, and provides information about the
number of peptide*MHC complexes required for T cell activation.
At the outset of these studies, it was not yet clear how synthetic peptides interact
with MHC-I products on cells; no in vitro binding assays had yet been established.
Using standard methods (equilibrium dialysis, gel filtration) that had recently been
applied to peptide-MHC-II binding systems, we attempted to measure the binding of
synthetic peptides to MHC-I proteins purified by either papain digestion/ion
exchange/gel filtration or detergent solubilization/immunoaffinity chromatography.
The human MHC-I protein HLA-A2 (A2) was chosen on the basis of (1) the availability
of specific reagents for use in its affinity purification; (2) its known crystal structure;
(3) its prevalence in the population (e.g. =40-50% of Caucasians); and (4) information
about peptides thought to bind A2 because they are recognized by A2-restricted CTL.
The first peptide, from influenza virus matrix protein (KGILGFVFTLTVPSERG,
Gotch et al., 1987), was radiolabeled by acylation with 125I-hydroxyphenyl propionate
ester (Bolton and Hunter, 1973). The N a- and NE-derivatives were separated by reverse
phase HPLC and identified by hydrolysis and amino acid analysis (after blocking free
amino groups with dinitrofluorobenzene). Upon equilibrium dialysis of the labeled
peptides against purified HLA-A2, HLA-B7, or a control protein (ovalbumin), no
binding was found. By gel filtration, the peptide and MHC protein were resolved
completely, except for a trace peak attributable to aggregation of the hydrophobic
peptide. To eliminate the possibility that radiolabeling interfered with the binding
activity of the peptide, a new synthesis was performed manually using 3H-leucine as a
precursor and standard t-boc solid phase chemistry procedures (Stewart and Young,
1984). Still no binding could be detected. Given the sensitivity of the assays, it was
concluded that the equilibrium association constant was <104 M- 1 or that A2 peptide-
binding sites were not available (or both).
A second peptide recognized by A2-restricted CTL from HIV-seropositive
patients (PLTEEAELELAENREILKEPVHGVY, Walker et al., 1989) was internally labeled
with 3H at several positions and also failed to bind purified A2 in vitro. A whole cell
binding assay was developed, in which 125I-labeled peptides were incubated with A2+
lymphoblastoid target cells, A2 was isolated by immunoaffinity purification, and the
extent of peptide binding was quantitated. Using a shorter version of the HIV peptide
that was still capable of sensitizing target cells for lysis by specific CTL
(REILKEPVHGVY), no radioactivity was found to be associated with purified A2.
However, examination of the cell supernatant by HPLC revealed that the radiolabel had
shifted, i.e., the chemically homogeneous iodopeptide added to cells was no longer the
major radioactive peak after a 2 hour incubation at 370C. By a combination of amino
acid analysis, sequencing, and HPLC, the product was shown to be iodotyrosine; either
extracellular medium (containing 10% serum) or isolated cell membranes could effect
virtually complete removal of this C-terminal residue from the peptide.
Extracellular "processing" proved to be the pivotal clue in understanding
peptide-MHC-I binding in our system. A series of synthetic peptides lacking
C-terminal tyrosine was screened for activity by cytotoxicity assays, and one nonamer
(ILKEPVHGV, termed IV9) was at least as active as any known antigenic peptide:
1-10 pg/ml could sensitize target cells for 50% maximal lysis (this concentration was
called the SD50 value), less than one-millionth what was required for the longer peptide
(SD50 >1 ~tg/ml). To measure binding between IV9 and A2, the peptide was
radioiodinated on histidine by carrying out the oxidative reaction at a higher pH than
usual (Wolff and Covelli, 1969), and the mono- and diiodinated products were resolved
by HPLC and characterized by Edman sequencing. Labeled peptide was found to
occupy 0.35% of affinity-purified A2 molecules after a 2 hour incubation with whole
cells; no peptide binding was observed to HLA-B7 or MHC-II molecules on the same
cells. Furthermore, it was possible to show by Edman sequencing that the same
antigenic peptide added to target cells could be recovered intact from peptide*MHC-I
complexes, thereby establishing unambiguously the identity of a peptide eliciting T cell
activity and permitting direct measurement of the dissociation rate for a peptide*MHC-I
complex (Tsomides and Eisen, 1991; see p. 50).
As an indication of extracellular processing, the longer peptide
(REILKEPVHGVY), when iodinated on both histidine and tyrosine and added to cells, was
recovered from purified A2 as IV9 (see figure, below). (An alternative explanation for
this result, that IV9 was a minor contaminant of the longer peptide and was selected by
A2 because of its tight binding (Schumacher et al., 1991), was unlikely because the
radiolabeled peptide had been subjected to several successive HPLC steps.) Finally, the
report by Falk et al. (1991a) of motifs for endogenous peptides associated with MHC-I
molecules, including A2 (leucine or methionine at position two and valine or leucine at
position nine), independently predicted that IV9 would be an A2-binding peptide.
Despite its herculean biological potency, peptide IV9 still exhibited no binding to
affinity-purified A2 by equilibrium dialysis, strongly suggesting that due to occupancy
by unknown endogenous peptides, isolated A2 molecules are simply not competent to
bind added peptides under the conditions used.
Peptides recovered from affinity-purified HLA-A2
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More recently, a quantitative whole cell binding assay was developed to explore
more readily the thermodynamics and kinetics of the peptide-MHC-I reaction for a
variety of different peptides, including unlabeled ones. Stoichiometrically labeled
indicator peptides were found to bind specifically to cells bearing the appropriate
MHC-I molecules, and by Scatchard analysis the equilibrium association constants as
well as the number of accessible peptide-binding sites per cell could be determined. By
inhibition analysis, the Ka values for unlabeled peptides were also measured, and the
use of non-radioactive 1271-labeled peptides confirmed the equivalence between Ka
values calculated by means of inhibition and those measured directly with 125I-labeled
peptides. The Ka values ranged from =109 M- 1 to =104 M- 1 (lower limit of detection).
The time constant for peptide-MHC-I association (the time needed to reach 63% of
equilibrium binding) and the half-life of cell surface complexes were both found to be
several hours using an 125I-labeled peptide (Kageyama et al., 1995; see p. 62).
The law of mass action has been used to measure the fractional occupancy of
antibodies in their reactions with antigens (Karush, 1970). We applied this equation
(see Introduction, p. 26) to the peptide-MHC-I reaction, using values for Ka and n (the
number of specific peptide-binding sites per cell) obtained by Scatchard plot analysis
(Scatchard, 1949), and free peptide concentrations corresponding to the SD50 values
measured in cytotoxicity assays with CTL against HIV-infected, ovalbumin-transfected,
or allogeneic (Ld+) target cells. The principal findings were: (1) an extremely wide
range in the average number of peptide*MHC-I complexes per target cell required to
elicit T cell activity (almost four orders of magnitude); and (2) in optimal settings,
much lower numbers than those previously described, e.g. 1-10 peptide*MHC-I
complexes per cell.
The implications of T cell recognition of target cells expressing 10 or fewer
peptide*MHC-I complexes are intriguing. (1) It suggests that the surveillance function
of CTL can be performed when cells (infected, transformed, or otherwise aberrant)
express very little specific ligand, at least by certain CTL. (Whether cloned T cells
really mirror the activities of CTL in vivo remains an important question.) At the single
cell level, it seems almost incredible that a CTL can consistently ferret out such a small
number of complexes, let alone undergo signal transduction and activation as a result of
ligation of the corresponding number of TcR. (2) The universe of T-cell antigens
presented at the cell surface is larger than previously thought, since peptides present at
<100 copies per cell (at least half of the total (Hunt et al., 1992a)) can be recognized. If
only peptides present at several hundred copies were known to T cells, then a typical
target cell expressing =105 MHC-I molecules (per allele) would only be able to present
up to =1000 different peptide species, even though the potential number of nonamers
expressed by a cell is enormously greater. (3) The biochemical isolation of naturally
processed peptides can be excruciatingly demanding, since at 1 copy per cell (to take
the extreme case), 15 pmoles of peptide (a reasonable amount for Edman sequencing)
would require starting with 15 pmoles of cells (nearly 1013!) - actually more to
compensate for obligatory losses during the purification.
In order to confirm the validity of our calculations that such low numbers of
peptide*MHC-I complexes can trigger T cell function, we have been developing a
system in which a radiolabeled peptide (Ii-QL9-Y5, QLSPY*PFDL) is added to target
cells at its SD50 concentration (10-11 M), and specific peptide*MHC-I complexes are
then measured directly. Since the peptide is stoichiometrically labeled with carrier-free
125I (Tsomides and Eisen 1993b; Schumacher and Tsomides, 1995), its specific
radioactivity (3.5x10 18 cpm/mol) allows the detection of just a few molecules per cell
when using -107 cells. The low numbers of peptide*MHC-I complexes that are
detected generally agree with calculations based on Ka and n as described above, but
are in the process of refinement as of this writing (Joo, Tsomides and Eisen).
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ABSTRACT CD8+ cytotoxic T lymphocytes recognize cell
surface complexes formed by class I major histocompatibility
complex (MHC-I) glycoproteins and antigenic peptides. We
have identified a peptide nonamer (termed IV9) derived from
the human immunodeficiency virus that is over a millionfold
more active (at subpicomolar concentrations) than peptide
analogues longer or shorter by one or two amino acid residues.
Although IV9 does not detectably bind to isolated MHC-I
molecules as measured by equilibrium dialysis, we quantitated
its specific binding in unaltered form to MHC-I on intact cells.
Less than 1% of cell surface MHC-I forms complexes with IV9,
which suffices to trigger maximal cytotoxic T-lymphocyte
activity. By contrast, a peptide dodecamer that includes the IV9
sequence and is active at micromolar concentrations does not
bind to MHC-I on intact cells, raising the possibility that this
longer peptide undergoes processing. Using stoichiometrically
iodinated IV9 to obviate the ambiguities associated with trace
labeling methods, we measured the dissociation kinetics of
purified peptide/MHC-I complexes isolated by affinity chro-
matography and found these complexes to be exceedingly stable
(tl/z = 20-600 hr).
Antigenic peptides arising from endogenously synthesized
proteins (as during viral infection) associate with the two
component chains of class I major histocompatibility com-
plex (MHC-I) proteins (a and P 2-microglobulin) in the endo-
plasmic reticulum to form heterotrimeric complexes which
are transported to the cell surface (reviewed in ref. 1).
Exogenous (chemically synthesized) peptides offered to
MHC-I-expressing cells can also result in complexes that are
recognized by cytotoxic T lymphocytes (CTL) (2). Exoge-
nous peptides have been used extensively to map the spec-
ificity of CTL clones and may also represent a physiological
pathway for antigen presentation (3). Yet the specificity and
mechanism by which exogenous peptides form complexes
with MHC-I and the stability of these complexes under
physiological conditions are not known; in addition, the
nature of the active peptide species in synthetic preparations
has been called into question (4). To understand the dynamics
of binding between MHC-I and exogenous peptides, we have
carried out studies with either purified MHC-I molecules or
intact MHC-I-expressing cells. Our findings lend support to
the idea that a small proportion of MHC-I molecules at the
cell surface are competent to bind exogenous peptides [pre-
sumably because they lack previously bound peptides of
endogenous origin (5, 6)] but that purified MHC-I molecules
do not bind exogenous peptides because of tightly bound
preexisting peptides. Heterotrimeric peptide/MHC-I com-
plexes that form on intact cells are shown to be effectively
irreversible at 37*C.
MATERIALS AND METHODS
Peptide Synthesis and Purification. Peptides were synthe-
sized either manually by conventional solid-phase methods
using tBoc chemistry or on an Applied Biosystems 430A
synthesizer and were analyzed by HPLC and amino acid
analysis. Some peptides (including RY12 and IV9) were
purified by Crs reverse-phase HPLC (Vydac 218TP104) in
aqueous trifluoroacetic acid with a 1%/min (or shallower)
CH3CN gradient. All peptide concentrations were measured
by micro BCA (bicinchoninic acid) assay (Pierce). lodina-
tions were performed by using Na'2 5I and a 4- to 5-fold molar
excess of Na' 27I over peptide to achieve stoichiometric
incorporation by the lodoBead method (Pierce). For histidine
residue iodination, a higher pH (8.2 vs. 7.0) was used to favor
imidazole ring proton dissociation (7). Iodinated peptide
species were separated by HPLC for cytotoxicity assays
(Fig. 1B). Radioactivity of the HPLC eluate was monitored
by using an on-line radioisotope detector (Beckman 170).
Cytotoxicity Assay. CTL assays were performed in dupli-
cate by incubating peptide dilutions and "Cr-labeled JY
lymphoblastoid target cells (HLA-A2', -B7+) for 1 hr at 37*C
and then adding CTL clone 68A62 (8) at a CTL-to-target ratio
of 4-6:1. After 4 hr at 37'C cell supernatants were assayed for
S"Cr release. Total "Cr release was determined by detergent
lysis, and percent specific lysis was calculated as [("Cr
release due to peptide - spontaneous release)/(total release
- spontaneous release)] x 100. Peptide toxicities were
checked by adding medium in place of CTL and were always
<3% specific lysis. Active peptides were each tested three to
five times, with reproducible results. A2-restriction of the
CTL clone was reconfirmed by its inability to lyse RPM17666
target cells (HLA-A2-, -B7') plus peptide (not shown).
HLA Purification. JY cells (109-101o) were pelleted and
lysed in hypotonic medium at 40C as described (9); all
subsequent steps were performed at 40C in the presence of
100 gtM phenylmethanesulfonyl fluoride, 200 pM dithiothrei-
tol, and 0.02% NaN3. Membranes were collected by centrif-
ugation for 60 min at 105.000 x g, solubilized in 4% Brij 58
(Pierce), and passed over six affinity columns arranged in
series as follows (10): Sepharose only, mouse pooled immu-
noglobulin-Sepharose (binds Fc receptors and other mem-
brane proteins), PA2.1-Sepharose (anti-HLA-A2), BB7.1-
Sepharose (anti-HLA-B7), W6/32-Sepharose (anti-MHC-I),
and 9.49-Sepharose (anti-MHC-II). The affinity columns
Abbreviations: CTL. cytotoxic T lymphocyte(s); MHC-I, class I
major histocompatibility complex; MHC-II. class II major histocom-
patibility complex: HIV. human immunodeficiency virus; RT, re-
verse transcnptase.
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were prepared by staphylococcal protein A purification of
each monoclonal antibody, periodate oxidation of the car-
bohydrate moiety in the Fc domains, and covalent coupling
to hydrazide-modified Sepharose. After being washed with at
least 30 column volumes of buffers, each column was eluted
with 50 mM diethylamine*HCI, pH 11/0.2% Brij 58 into 2-ml
fractions containing 1 M Tris-HCI, pH 8. HLA purity was
assessed by SDS/PAGE, and yields (as well as purity) were
further determined by quantitative amino acid analysis.
HLA-Bound Peptide Elution. Purified HLA-A2 and
HLA-B7 were concentrated to remove unbound peptides by
ultrafiltration at 5000 x g (Centricon C10) and then denatured
with 0.5% trifluoroacetic acid (11) for 60 min at 37*C; the
released peptides were collected by ultrafiltration at 5000 x
g and subjected to HPLC fractionation.
Equilibrium Dialysis. A 100-.1 sample of -10 M affinity-
purified HLA-A2, HLA-B7, or buffer only (0.1 M Tris-HCI,
pH 8/0.2% Brij 58/0.02% NaN 3) was separated from 100 Al
of 3 AM 125I-labeled IV9 or ZSI-labeled RY12 (-3 x 105 cpm)
by a 12.000-14,000 molecular weight cutoff membrane (Spec-
tra-Por), and the samples were rocked gently (60 rpm) at
37*C. Each sample was prepared in triplicate. After 5 days,
50 Al from each compartment of each sample was assayed for
1251. Peptide was shown to equilibrate across the membrane
within 12 hr under these conditions.
RESULTS AND DISCUSSION
Identification of the Optintal Peptide. We studied peptide
binding by the human MHC-I molecule HLA-A2 because its
crystal structure has been solved (12) and an A2-restricted
CTL clone against the human immunodeficiency virus (HIV)
reverse transcriptase (RT) has been described (8). This clone
recognizes a 25-residue synthetic peptide from RT (8). We
found that successive truncations of the N terminus to 17. 15,
or 12-residue peptides had no effect on target cell sensitiza-
tion, whereas further truncation to a 9-mer greatly reduced
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the sensitizing activity (Fig. 1). To quantitate specific binding
between the shortest active peptide and A2, we radioiodi-
nated the 12-mer, which contains one histidine and one
tyrosine residue, and separated the mono-, di-, tri-, and
tetraiodinated products from the unlabeled 12-mer by re-
verse-phase HPLC. This alternative to conventional trace
iodination procedures (which label <1% of the molecules)
was considered necessary to ascertain the biological activity
of each labeled product (Fig. 1B) and to quantitate MHC
binding by a chemically homogeneous peptide.
Stoichiometrically monoiodinated 12-mer (termed 1,-
RY12) was incubated for 2 hr at 37*C with JY cells [express-
ing 7 x 105 A2 molecules per cell, determined by using Fab
fragments of the anti-A2 antibody PA2.1 (13)]. The cells were
lysed, their membranes were harvested and solubilized with
detergent, and their MHC-I molecules (A2 and B7) were
purified by affinity chromatography (9, 10), with A2 yields of
50-80% in different experiments. However, no iodopeptide
was found in association with purified A2 (Fig. 2A), although
the specific radioactivity of I1-RY12 and the amount of A2
recovered provided sufficient sensitivity to detect as few as
50 complexes per cell. Unexpectedly, HPLC analysis of the
radioactivity recovered from these cells revealed a shift in
retention time of the radiolabel (Fig. 2 B and C), leading us
to suspect processing of 11-RY12 to a shorter active peptidelacking the C-terminal iodotyrosine and thus accounting for
failure of the iodopeptide to copurify with A2. By a combi-
nation of amino acid analysis, sequencing, and HPLC, we
confirmed the identity of the recovered radioactive material
as iodotyrosine. Serum-containing medium alone did not
cleave iodotyrosine from 11-RY12, but both isolated mem-
brane and cytosolic fractions of JY cells did, suggesting the
existence of a cell-associated activity that processes this
peptide.
To define the active peptide that may be generated from
11-RY12, we tested the biological activity of all possible 8- and
9-mers contained within RY12 that exclude the C-terminal
A
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FIo. 1. Ability of vanous HIV RT peptides to sensitize cells for CTL lysis. (A) Representative peptide titrations: peptides are identified by
the symbols next to their names in B. (B) Peptide sequences and sensitizing doses.
tAll peptides are named by their first and last residue and length.
ýSD5o is peptide concentration giving 50% of maximal specific lysis, which in all cases amounted to 75-90%: "none" indicates no sensitization
at a peptide concentration of 100 pg/ml. SDso values are rounded to the nearest order of magnitude.
*Stoichiometric iodination of histidine or tyrosine residues by one (*) or two (**) iodine (1) atoms.
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FIG. 2. Monoiodinated peptide RY12 added to JY cells does not
copurify with A2 and appears to be processed. (A) HPLC-purified
II1-RY12 at 6 ,g/ml and 106 cpm/pIg was incubated with JY cells for
2 hr at 37*C. HLA was affinity-purified and fractions from each
column were assayed for cpm (9, left axis) and absorbance at 280 nm
(6, right axis). Only the eluate from the anti-A2 column is shown;
eluates from the other columns also contained no cpm above
background. (B) Retention time (38 min) of II1-RY12 purified by
reverse-phase HPLC. (C) Retention time (30 min) of the iodinated
material recovered in the membrane fraction of JY cells after passage
through all affinity columns. This peak was identified as iodotyrosine
(see text).
tyrosine (Fig. 1). Recent work using virus-infected target
cells has shown peptides of this length to be the "natural"
species recognized by other CTL (14, 15). The 9-mer IL-
KEPVHGV (termed IV9) sensitized target cells at a concen-
tration less than one-millionth that needed for RY12 (<1
pg/ml vs. 1 Ag/ml). Other peptides, including both longer and
shorter relatives of IV9, had intermediate activities (Fig. 1).
The remarkable potency of IV9 at picomolar concentrations,
together with the widely held view that the binding sites of
MHC-I molecules are already largely occupied by diverse
peptides of endogenous origin (12), suggested high-affinity
binding between IV9 and the relatively few cell surface A2
molecules that may be accessible for binding to exogenous
peptide under physiological conditions (6).
Isolation of Peptide/MHC-I Complexes. To characterize
these complexes directly from cells, we iodinated 1V9 on its
histidine residue (7) with 125I (and an excess of 127I) and
resolved the unlabeled, mono- and diiodinated species by
HPLC (see Fig. 4, below). Purified monoiodinated IV9
(I1-IV9) at 1 Lg/ml (SDso = 10 pg/mi) was incubated with JY
cells for 2 hr at 37°C, and the MHC proteins (A2, B7, and class
II) were affinity-purified from cell membranes as before. A
large peak of radioactivity, over 70-fold above background,
was coeluted with A2 from the affinity column, whereas no
radioactivity copurified with B7 or with MHC-II (Fig. 3). To
determine whether this radioactivity was still complexed with
A2 after elution from the affinity column, we separated low
molecular weight material by ultrafiltration through a 10,000
molecular weight cutoff membrane (Centricon). We found
over 99% of the total radioactive material still bound to A2.
However, when the complexes were denatured with trifluo-
roacetic acid for 60 min, all of the radioactivity was released
as low molecular weight material that was eluted from an
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FIG. 3. Monoiodinated peptide 1V9 added to JY cells copurifies
with A2 but not with B7 or MHC-II. HPLC-purified Ir-IV9 at 1 /g/ml
and = 106-107 cpm//±g (different experiments) was incubated with JY
cells for 2 hr at 37"C. HLA was affinity-purified and fractions from
each column were assayed for cpm (,. left axis) and absorbance at
280 nm (,. right axis). Control is the eluate from the mouse pooled
immunoglobulin-Sepharose column. The eluate from the W6/32-
Sepharose column contained no cpm above background (not shown).
Five separate experiments yielded closely similar results.
HPLC column at the precise retention time of I1-IV9 on a
highly resolving gradient (Fig. 4). This material sensitized JY
cells for 85% specific lysis by the anti-RT CTL clone,
whereas material from other HPLC fractions or from the
corresponding fraction of B7 peptides had no sensitizing
activity (Fig. 4). Direct Edman sequencing of the sensitizing
HPLC fraction confirmed the IV9 sequence. Thus the A2-
bound radioactive peak was identical to I1-IV9, the input
material, and the binding of this peptide was shown to be
highly specific for A2 (at least 1000-fold greater than binding
to B7 or MHC-II).
Given the specific radioactivity of IV9 and the yield of A2,
the number of IV9/A2 complexes present on peptide-pulsed
cells after 2 hr amounts to 0.35% of the total A2. Since a 2-hr
pulse also sensitizes JY cells for a maximal CTL response,
the roughly 2500 IV9/A2 complexes per cell obtained by
using exogenous IV9 can elicit CTL activity. The minimal
number of complexes is undoubtedly lower because (i) a
saturating concentration of IV9 was used and (ii) incubations
as short as a few minutes also sensitize JY cells (data not
shown). A threshold number of 200-300 complexes has
previously been determined for MHC-II-reatricted T cells
(16), and a similar number was recently published for MHC-
I-restricted T cells (17).
The number of complexes isolated could represent the
number of peptide-free A2 molecules that are available at the
cell surface for binding to exogenous peptide (18). However,
in view of evidence that peptide-free MHC-I molecules are
conformationally unstable unless "rescued" by peptide (or
low temperature) (6, 19), binding is likely to be a dynamic
process dependent on the continual arrival at the target cell
surface of newly exported A2 (20). Assuming a net export of
7 x 10' molecules (one cell's worth for JY) per 12-hr doubling
time. we estimate that A2 molecules reach the cell surface at
a rate of approximately 1000 per min, or 120,000 during a 2-hr
pulse. If all the molecules that are competent to bind exog-
enous peptide are included in this population and their rate of
appearance (rather than the on-rate) limits peptide binding,
then the IV9/A2 complexes detected here represent about
2% of the A2 molecules synthesized in 2 hr. Consistent with
this interpretation, the amount of IV9 specifically copurified
6
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FIG. 4. Monoiodinated peptide IV9 added to JY cells and the
peptide subsequently recovered from the cells' A2 are indistinguish-
able. (A) 1V9 was iodinated with a 4-fold excess of sodium iodide (1251
+ 1271), and the starting material (IV9) and two products (11-IV9 and
12-IV9) were separated by reverse-phase HPLC. Peaks 1, 2, and 3had specific activities of 0, 1.0 x 106, and 2.1 x 106 cpm/±g,
respectively, unequivocally identifying them as IV9, ll-IV9, and
I-IV9; at 18 ng/ml they sensitized JY cells for 76%, 79%. and 62%
specific lysis by CTL, respectively. (B) Rechromatography of I1-IV9(peak 2) indicated a single radioactive peak eluting at 32-32.5 min.
(C) Peptides eluted from purified A2 and B7 were subjected to HPLC
fractionation. One-minute fractions were collected for counting, due
to insufficient counts for peak detection by the on-line radioisotope
detector. Fraction 33 contained peptides that were eluted at 32-33
min. The peptides recovered in fraction 33 from purified A2 and B7
were each assayed for sensitizing activity at a concentration of 18
ng/ml (based on the known specific activity of II-IV9), and they
sensitized JY cells for 85% and 0.6% specific lysis by CTL, respec-
tively. HPLC fraction 33 from the A2-derived peptides was also
sequenced directly on an Applied Biosystems 477A sequencer to give
the complete known sequence of IV9.
with A2 from peptide-pulsed cells was shown to increase with
time of incubation (data not shown). In a different study,
coimmunoprecipitation of an exogenous peptide with the
class I molecule HLA-B27 showed a similar time dependence
(20).
Dissociation Kinetics. The isolation of purified peptide/
MHC-I complexes by nondenaturing methods enabled us to
investigate the kinetics and affinities of binding under phys-
iological conditions. For measurement of an off-rate, IV9/A2
complexes were incubated at 37"C in the presence or absence
of a 3000-fold excess of monoiodinated but nonradioactive
IV9 (iodination carried out with 1271 instead of a mixture of
1251 and 1271). Radiolabeled IV9 that dissociated from com-
plexes was separated from bound IV9 by ultrafiltration at
I
a
c2a032
0.
o0
Cr
:3
0 24 48 72 96 120
time (hours)
FIG. 5. Dissociation of isolated "'sI1-IV9/A2 complexes at 37°C
in the presence (A) or absence (e) of a 3000-fold molar excess of
12711-IV9.
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various times, assayed for radioactivity, and returned to the
incubation mixture to maintain constant volume and peptide
concentrations. Fig. 5 shows that after 120 hr at 37"C, 37%
and 24% of bound peptide had dissociated in the presence and
absence of excess nonradioactive peptide, respectively.
Since the latter figure could reflect denaturation of the
protein, the difference of 13% dissociation after 120 hr was
used to calculate an off-rate constant on the order of 3 x 10- 7
sec - and a half-time of -=600 hr, far greater than the lifetime
of the cells. Even at the other extreme of 37% true peptide
dissociation, the off-rate constant would be 1 x 10- sec 1,
for a half-time of -200 hr. These unusual values indicate that
binding is effectively irreversible at 370C; they argue against
peptide exchange in this system and support the view that
sensitization of target cells for CTL lysis occurs by way of
peptide-free A2 molecules (unless some endogenous peptides
are more loosely bound than IV9, a prospect contrary to
expectation but difficult to distinguish from peptide-free
molecules per se). Long half-times were also derived in a
recent study in which peptides were added to dilute cell
lysates at 4*C (21).
Equilibrium Dialysis. Given such a low off-rate constant,
one can readily calculate a range of possible intrinsic asso-
ciation constants by assuming representative values for the
on-rate constant. Using an on-rate constant of =106
M-t-sec - 1 that is (i) representative for many protein-ligand
interactions and (ii) supported by the rapid kinetics of target
cell sensitization, we estimate the intrinsic association con-
stant could be as high as 3 x 1012 M-1. On the other hand, the
on-rate constant of 1 M-1.sec - 1 established for some peptide/
MHC-II systems [whose binding parameters are known to
differ from class I (22, 23)] would lead to a calculated
association constant of 3 x 106 M- 1, also high enough to
predict detectable binding by equilibrium dialysis. Yet, when
we carried out equilibrium dialysis with 1V9 and purified A2
for 5 days at 37*C we detected no binding. Thus, 3 x 105 cpm
of 2sI-IV9 distributed into compartments containing A2, B7,
or buffer to an equal extent (49.9%, 49.4%, or 49.3% of total
cpm, respectively) under conditions sensitive enough to
detect an association constant 2104 M-1. This result con-
trasts with readily detectable peptide/MHC-II binding by
equilibrium dialysis (22, 23) and is likely due to a high
(perhaps even stoichiometric) occupancy of peptide-binding
sites in purified A2 by unknown peptides (12, 24). Peptide-
free A2 molecules are either unstable to conventional puri-
fication or else too few in number to detect. Consequently,
the lack of detectable binding by equilibrium dialysis also
reinforces our measurement of a very low off-rate constant,
since no peptide exchange occurred during this period.
Physiologically, peptide/MHC-I binding presumably
never reaches chemical equilibrium due to the dynamic
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nature of binding with cells. Nevertheless, the low measured
off-rate constant and implied moderately to extremely strong
binding argue against an earlier impression of markedly low
affinities based on (i) the ability of A2 to interact with many
structurally different peptides in T-cell assays (25) and (ii) our
prior failure to detect binding between purified A2 and
peptides by equilibrium dialysis (26).
Exogenous peptide binding to murine MHC-I is influenced
by the presence of p2-microglobulin ( 2zm) in some cases (27,
28). We found that the CTL response to target cells pulsed
with different RY12 concentrations was reproducibly unaf-
fected by adding exogenous 32m at 10-20 jsg/ml or by
performing CTL assays in serum-free (and consequently
g2m-free) medium, indicating that 32m exchange is not a
primary determinant of peptide binding in this system.
In contrast to our findings with IV9, two recent studies
involving exogenous peptides (both 12-mers) and MHC-I
immunoprecipitated from intact cells detected binding only
by peptides that differed from the peptides that had been
added to cells (4, 20). In one case the MHC-bound peptide
was identified as a 9-mer present as a trace contaminant of the
synthetic 12-mer (the C-terminal 9-mer, consistent with pre-
mature peptide termination during solid-phase synthesis) (4).
Because the radioiodinated tyrosine residue in this 12-mer
was also contained within the sequence of the actual binding
peptide (unlike our 12-mer RY12), the bound 9-mer was
detected. The question of whether sensitizing activities of
peptides longer than 9 amino acid residues are generally due
to (i) the presence of shorter contaminants arising as minor
by-products during chemical synthesis (4), (ii) peptide proc-
essing (as suggested by the release of iodotyrosine from
It-RY12), or (iii) some permissiveness for different length
peptides in peptide/MHC-I binding (21) remains open. It
seems likely that each mechanism may find further support in
different systems. The present work identifying IV9 as an
optimal sensitizing peptide [as active as any peptide so far
reported (4, 14, 15, 29, 30)1 and isolating it in purified
peptide/MHC-I complexes from intact cells represents the
first (to our knowledge) study in which an exogenous peptide
can be recovered unaltered from specific complexes and its
dissociation rate can be measured.
While this work on IV9 was in progress, a remarkable
report appeared revealing that the mixture of total peptides
eluted from immunoprecipitated A2 molecules and subjected
to Edman sequencing contained consensus residues at cer-
tain positions (30). Using the two most prominent consensus
sites, leucine at position 2 and valine at position 9, to screen
putative A2-binding longer peptides, Falk et al. (30) predicted
[from the published RT 25-mer (8)] the IV9 sequence to be an
A2-binding peptide. Our study provides independent exper-
imental confirmation of this prediction. Moreover, our ex-
tensive CTL structure-function data on peptides related to
IV9 (Fig. 1) suggest that the observed motifs are indeed
consensus patterns and are not absolute requirements for
sensitizing activity. For example, two peptides lacking C-ter-
minal valine (IG8 and LG7) are as active as RY12 (SDso0 = 1jtg/ml), although much less active than IV9. Whether these
and other differences in Fig. 1 are due solely to A2 binding or
also reflect T-cell receptor interactions or unknown process-
ing requirements cannot be discerned at the present time.
However, given the applicability of the binding assay de-
scribed here to any peptide containing an iodinatable tyrosine
or histidine residue, the first question can be addressed
directly. It is also important to determine whether peptide
IV9 arises from the endogenous MHC-I pathway after HIV
infection of A2' (or A2-) cells.
Proc. Natl. Acad. Sci. USA 88 (1991)
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Radioiodination with 12I or 1311 is a favored tech-
nique for labeling biologically active peptides or pro-
teins because of high specific radioactivities and conve-
nience in counting y-emissions. Previous studies used
trace labeling, in which fewer than 1% of the molecules
are iodinated. We describe procedures for obtaining
stoichiometrically iodinated and therefore chemically
homogeneous peptides with specific activities exceed-
ing 10" cpm/Mg (= 10 Ci/mmol). By analyzing the pH de-
pendence of iodination on tyrosyl and histidyl residues,
we show that the method described can be applied to
many short peptides and optimized for labeling on tyro-
sine and/or histidine. The power of reverse-phase
HPLC is exploited to resolve multiple products substi-
tuted with different molar equivalents of iodine from
each other and from unlabeled peptide. Specific radioac-
tivity ratios can be used to identify the products, as con-
firmed by Edman sequence analysis under conditions
that separate iodinated tyrosine and histidine deriva-
tives from all other amino acids. We also show that the
biological activities of iodinated and uniodinated pep-
tides can differ by several orders of magnitude in a T
cell assay and demonstrate the usefulness of stoichio-
metric labeling to overcome ambiguities inherent in
studying biological activities with trace-labeled peptides.
O 1993 Academic Press, Inc.
In studies aimed at analyzing the interaction between
a bioactive peptide and its target molecule or cell, it is
frequently desirable to label the peptide for sensitive
and easy quantitation. Radioiodination with '251 or 1311
offers numerous benefits, most notably high specific
radioactivities and convenience in carrying out the reac-
tion and detecting the products. The original develop-
ment of radioiodination procedures concerned the label-
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ing of proteins rather than peptides and as such placed
great emphasis on minimizing protein damage by trace
labeling with carrier-free iodine (1,2) or acylating with
radioiodinated acid ester (3) or imidoester (4) com-
pounds. Trace labeled proteins could be shown to retain
biological activities equivalent to the unlabeled protein
(1,3) and have since found widespread application in
radioimmunoassays and hormone-receptor studies, for
example.
The radioiodination of short peptides devoid of stable
tertiary structure is not restricted by the problem of
denaturation during exposure to oxidative conditions,
although some amino acid side chains (Cys, Met, Trp)
can be affected. However, labeling of a short peptide is
likely to cause significant perturbations in the physical
and biological properties of the peptide. Thus, iodine is
similar in size to a phenyl group and is markedly hydro-
phobic (see below); moreover, the pK, of the phenolic
hydroxyl group of tyrosyl residues is substantially re-
duced by each substitution with iodine (5). Conse-
quently strategies based on trace radioiodination of
peptides carry a very real risk that the labeled and unla-
beled peptides will behave differently, and that failure
to quantitate these differences will lead to false infer-
ences about an unlabeled peptide based on detection of
only the radiolabeled form.
One solution to this problem is the use of internally
radiolabeled peptides. We have incorporated 3H-labeled
amino acids into the solid-phase synthesis of 17- to
25-residue peptides by synthesizing tBoc-protected de-
rivatives (6). While this method has the distinct advan-
tages of not perturbing peptide structure and of a very
long radioisotopic half-life (12.26 years), the specific
radioactivities we achieve are at least 1000-fold lower
than those obtained with radioiodinated derivatives,
and counting /3-emissions from 3H is a destructive pro-
cess, unlike 125I or 131I counting. Moreover, virtually any
peptide can be radioiodinated quickly and on a small
scale (,<1 mg), without the need to prepare 3H-labeled
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amino acid derivatives and commit to de novo synthesis
in order to obtain labeled material. Another approach,
iodination by including suitably protected iodotyrosine
derivatives during solid-phase synthesis, similarly re-
quires de novo synthesis rather than allowing the use of
one batch of a peptide. Thus the most common methods
employed for radiolabeling peptides are based on reac-
tions with 1251 or 1311.
Typically, 0.1-10 mCi of carrier-free "'I (60 pmol-6
nmol) is chemically or enzymatically oxidized to react
with up to 500 pg of a protein or peptide. For a protein of
molecular mass 100 kDa, 500 pg is equal to 5 nmol pro-
tein or approximately 200 nmol tyrosyl residues (on
average). For a peptide of Mr 1000, 500 Ag is 500 nmol.
Thus it can be seen that even with highly efficient meth-
ods for the incorporation of 12sI, these conditions will
lead to labeling of only up to 1% of the iodinatable sites,
i.e., trace labeling. A typical yield of 10 pCi radioiodine
per microgram of protein (M, 100,000) represents the
labeling of less than one atom iodine per protein mole-
cule (having about 40 tyrosyl residues on average). For
short peptides, <1% of the molecules are labeled in most
applications (<15 pCi/pg).
MATERIALS AND METHODS
Peptides
All peptides were synthesized at the MIT Biopoly-
mers Laboratory on an Applied Biosystems 430A using
conventional tBoc chemistry followed by HF cleavage.
Crude peptides were subjected to amino acid analysis,
with results always within 10% of expected values. Pep-
tide purification was performed by C18 reverse-phase
HPLC (Beckman C18 or Vydac C4 10 X 250 mm, 5-pm
particles) on a Beckman HPLC system (Model ll0B
pumps, 165 variable wavelength detector, 170 radioiso-
tope detector, 427 integrator). The standard gradient
went from 5% B to 55% B between 10 and 60 min after
an initial isocratic period, with A = 0.1% trifluoroacetic
acid (TFA 2) in H20 and B = 0.085% TFA in acetonitrile.
Detection was based on absorbance at 220 and 280 nm
as well as radioisotope detection. Peptide sequencing
was performed by Edman degradation on an Applied
Biosystems 477A using an extended gradient (42 min
per cycle) for the detection of iodinated amino acid de-
rivatives. Monoiodotyrosine (Aldrich) and diiodotyro-
sine (Sigma) standards were applied to the sequencer in
order to determine their retention times.
Iodination and Removal of Free Iodine
All steps were carried out at room temperature. For 1
mg peptide, 4 lodo-Beads (Pierce) were washed twice
with 0.1 M sodium phosphate, pH 7.0 (for iodination on
tyrosine) or pH 8.2 (for iodination on histidine or both
histidine and tyrosine) and added to 0.3 ml of the same
buffer in a microcentrifuge tube. Na"1 I (2-40 mCi;
NEN, Amersham, or ICN) was mixed with 30-50 p1 0.1
M Nal 2 7I (Mallinckrodt) and added to the Iodo-Beads
for 5 min in a glove box equipped with a charcoal filter.
A color change to yellow/brown indicated active Iodo-
Beads. Peptide dissolved in 0.5 ml H 20 or phosphate
buffer was added to the oxidized iodide for 30 min (Tyr
labeling) or 45 min (His labeling), with occasional agita-
tion. The mixture was transferred by syringe to a C18
Sep Pak cartridge (Waters) prepared according to man-
ufacturer's instructions with methanol and HO fol-
lowed by 20 ml 0.1% TFA (HPLC solvent A). After the
Sep Pak was loaded and washed with an additional 20
ml solvent A to remove free iodide, two fractions were
eluted with 4 mi 50% solvent B/50% solvent A and 4 ml
100% solvent B (0.085% TFA in acetonitrile). These
fractions were removed from the glove box for drying in
a SpeedVac Concentrator (Savant).
Purification and Specific Radioactivities
The fractions, containing unlabeled peptide and io-
dinated products, were resuspended in 1 ml solvent A,
filtered through 0.45 pm, and injected on a Beckman
HPLC system equipped with a C18 reverse-phase col-
umn (Vydac or Beckman) and an on-line radioisotope
detector. Each peak was collected, dried in a SpeedVac
Concentrator, and taken up in water to determine pep-
tide concentration by Micro BCA Assay (Pierce). The
standard curve was generated from manufacturer-sup-
plied BSA or from unlabeled peptide that had been
quantitated by amino acid analysis. An aliquot from the
BCA assay (usually 10 pl, or 1%) was counted in a
gamma counter (Packard) for calculation of the specific
radioactivities; the counting efficiency of this instru-
ment was determined to be 70%.
T Cell Assay
T cell assays were performed as previously described
(7). In brief, duplicate peptide dilutions were added to
"
6 Cr-labeled JY lymphoblastoid target cells for 60 min
at 37*C in a 5% CO, incubator. The peptide-specific T
cell was then added at a T cell-to-target ratio of 5:1 for 4
h at 37"C, and cell supernatants were assayed for "5 Cr
release. Percentage specific lysis is given by [("5 Cr re-
lease due to peptide - spontaneous release)/(total re-
lease in detergent - spontaneous release)] X 100.
RESULTS AND DISCUSSION
2 Abbreviations used: TFA, trifluoroacetic acid; BCA, bicinchoninic To achieve stoichiometric labeling of peptides, we
acid; BSA, bovine serum albumin; PTH, phenylthiohydantoin. combine the desired quantity of 1251 with a 3- to 5-fold
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FIG. 1. Separation of free iodine from peptide following radiolabel-
ing procedure. Two milligrams of a 12-residue peptide (termed RY12,
sequence REILKEPVHGVY) was radioiodinated with a mixture of 2
mCi '"I and 10 umol '27 in the presence of 8 lodo-Beads. After 30 min
the total volume of 1 ml was loaded on a C18 Sep Pak, washed with 20
mi HPLC solvent A, and eluted with 4 ml 50% B and 4 ml 100% B;
1-ml fractions were collected and 5 $l was removed for y-counting.
Total cpm recovered appear to be less than 2 mCi due to nonlinear
y-counting in fractions containing >10
s 
cpm.
molar excess over peptide of nonradioactive iodide
(127I). Alternatively, '3'I can be used, with a half-life of 8
vs 60 days for "25I and higher energy -y-emissions (with
correspondingly greater demands for effective shield-
ing). This moderate molar excess of total iodide over
peptide enhances the rate of reaction and results in io-
dination of %70-95% of the starting material (see be-
low, Fig. 5). For a given quantity of 12sI (e.g., 20 mCi),
increasing the amount of 127I proportionately dimin-
ishes the specific radioactivities of the products. For in-
stance, a 4-fold molar excess of 127I over peptide results
in the incorporation of at most 25% of the 12sI added (5
mCi); a 10-fold excess would limit radioisotope incorpo-
ration to 10% (2 mCi). To oxidize the iodide we utilize
lodo-Beads, nonporous polystyrene beads derivatized
with N-chloro-benzenesulfonamide (equivalent to im-
mobilized chloramine T-see Ref. (8) and Pierce litera-
ture). The mixture of 127 + 1251 is added to several lodo-
Beads for 5 min at room temperature (activation step
according to the manufacturer's recommended proto-
col), followed by the peptide for 30 to 45 min. During the
initial activation step volatile iodine is generated, as evi-
denced by the development of a yellow/brown color, ne-
cessitating appropriate safety precautions: we perform
all reactions in a capped microcentrifuge tube handled
within a glove box equipped with a charcoal filter. After
the reaction is complete, unreacted iodide is separated
from peptide by passing the mixture over a C18 car-
tridge that retains peptide (Fig. 1). This departure from
the conventional use of ion exchange or gel filtration
chromatography to remove unbound iodide-tech-
niques more appropriate for proteins than for short
peptides-produces highly efficient separations for all
peptides tested.
After elution of the C18 cartridge with acetonitrile,
the radiolabeled material no longer poses a volatiliza-
tion hazard and may be transferred out of the glove box
or other contained area used to handle Na"'I and
Na131 I. The eluted material is a mixture of unlabeled
peptide and various iodinated products (mono-, di-,
triiodinated, etc.), all of which are well-resolved by re-
verse-phase HPLC (Fig. 2 and 3). Retention times of the
unlabeled and labeled peptides on reverse-phase HPLC
invariably increase with the addition of each successive
iodine atom, reflecting the hydrophobicity of iodine.
The integral ratios of specific radioactivities among the
products conveniently serve to identify mono-, di-,
triiodinated, etc. peptides (Table 1). A typical specific
radioactivity obtained under these conditions, 10' cpm/
jg, corresponds to s10 Ci/mmol for a peptide of Mr
1500 and represents labeling with 0.006 mol "~I (and
0.994 mol 1271) per mole peptide. Each chemically homo-
geneous product can be assayed for its biological activ-
ity, thereby ascertaining the effects of substitution with
iodine (Fig. 4 and see below).
Besides tyrosyl residues, which can incorporate up to
two iodine atoms per phenolic side chain, histidyl resi-
dues can also be iodinated in one or two positions, partic-
ularly at higher pH's (9). We successfully labeled pep-
tides stoichiometrically on tyrosine only (Fig. 2, Table
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FIG. 2. Reverse-phase HPLC separation of iodinated and uniodin-
ated peptide containing tyrosine. Two milligrams of the 8-residue
peptide Y8 (sequence SIINYEKL) was iodinated with 20 mCi '~I and
5 pmol 127I at pH 7.0 using 6 Iodo-Beads, injected on a Beckman C18
semipreparative column, and eluted with an acetonitrile gradient of
1e/min at a flow rate of 3 ml/min. Peaks are described in Table 1.
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FIG. 3. Reverse-phase HPLC separation of iodinated and uniodin-
ated peptide containing both tyrosine and histidine. Two milligrams
of the 12-residue peptide RY12 (sequence REILKEPVHGVY) was
iodinated with 20 mCi "I and 10 Mmol 12Il at pH 8.2 using 8 Iodo-
Beads, injected on a Vydac C18 analytical column, and eluted with an
acetonitrile gradient of 1%/min at a flow rate of 1 ml/min. Peaks are
described in Table 1.
1), histidine only (Fig. 4), or both tyrosine and histidine
(Fig. 3, Table 1). In the latter case four major products
are obtained from reverse-phase HPLC fractionation in
addition to unreacted starting material. Specific activity
ratios indicate that these products are mono-, di-, tri-,
and tetraiodinated species, respectively; in some cases
there is a second minor diiodinated derivative eluting
before the first.
TABLE 1
Characterization of lodination Products from
Representative HPLC Separations
Retention Absorbance Specific
Peak time 220 nm activity
No. (min) (%) (cpm/,ug) Identity
Fig. 2B
1 39.2 11 0 I0-Y8
2 43.0 34 1.0 X 107 I,-Y8
3 46.1 55 2.0 x 10' I2-Y8Fig. 3
1 34.7 13 0 10-RY12
2 37.9 18 0.5 X 107 I,-RY12
3 40.4 20 1.0 x 10' I,-RY12
4 41.1 17 1.4 X 107 I-RY12
5 43.5 32 2.1 X 10 I-RY12
Note. The peptides labeled as described in the legends to Figs. 2 and
3 were subjected to specific radioactivity determination in order to
identify their degree of substitution with iodine.
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FIG. 4. T cell assay of iodinated and uniodinated peptide. The
9-residue peptide IV9 (sequence ILKEPVHGV) was stoichiometri-
cally iodinated on histidine with "I2 at pH 8.2 for purposes of bioas-
say. After HPLC separation, the unlabeled, mono-, and diiodinated
derivatives were each tested for their ability to elicit lysis of JY target
cells by a peptide-specific T cell as previously detailed (7).
To define the products precisely, we iodinated a 9-resi-
due peptide containing one tyrosyl residue and one his-
tidyl residue (LY9) with 127I only and subjected each
HPLC-purified major peak to sequence analysis by Ed-
man degradation. The results are summarized in Table
2. By means of a modified gradient (extended by 11 min
per cycle), PTH derivatives of iodinated tyrosine and
histidine can be detected on the sequencer as follows:
monoiodotyr elutes between Val and Trp, diiodotyr
elutes after norleu, and monoiodohis elutes between Ala
and Arg. Thus we could unambiguously determine that
mono- and diiodinated peptides are labeled only on tyro-
sine, triiodinated peptide contains diiodotyrosine and
monoiodohistidine, and tetraiodinated peptide contains
diiodotyrosine and diiodohistidine (see Table 2). In ad-
dition, we found a smaller peak of diiodinated peptide
containing monoiodohistidine and monoiodotyrosine
between the mono- and diiodotyrosine-labeled species
(Fig. 5, unlabeled peak between I,-LY9 and I2-LY9).
This order of products is in agreement with expecta-
tions based on increasing hydrophobicities with iodine
substitution and the greater reactivity of tyrosyl than
histidyl residues in short peptides where tertiary struc-
ture (and therefore reactive site accessibility) is not an
issue.
When we investigated the pH dependence of iodin-
ation on tyrosyl and histidyl residues, we found pro-
nounced effects on the overall efficiency of the reaction
and on the distribution of iodinated products (Fig. 5).
For example, 94% of the LY9 peptide was iodinated at
pH 6.0 and only 71% at pH 9.0; at pH 6.0 the major
product was diiodotyrosine-labeled (60% yield), whereas
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STOICHIOMETRIC PEPTIDE IODINATION
TABLE 2
Sequence Determination of Unlabeled and Labeled Products from the lodination of a 9-Residue Peptide
Edman cycle Residue 1o-LY9 I1-LYS9 1-LY9 Iz-LY9 Y9 4-LY9
1 L 462 (ND) 700 305 901
2 K 507 1045 823 331 905
3 E 416 1062 616 219 610
4 P 413 646 455 209 500
5 V 723 860 556 279 543
6 H 279 770 167 10 12
7 G 426 505 258 123 241
8 V 307 545 278 133 202
9 Y 282 0.7 0.3 1.0 0.8
Note. Products from the reactions carried out as described in the legend to Fig. 5 were subjected to Edman degradation. with the results given
as pmol of the indicated residue (as its PTH derivative). Cycle 9 of the peptide identified as I,-LY9 gave a dominant peak at the retention time
of monoiodotyrosine (between Val and Trp), while cycle 9 of I2-LY9, I-LY9, and I,-LY9 all gave diiodotyrosine (after norleucine). Cycle 6 of
I1-LY9 gave monoiodohistidine (between Ala and Arg) and cycle 6 of 14-LY9 gave diiodohistidine (between Ala and Arg).
at pH 9.0 the major product was diiodohistidine-labeled
(40% yield). Because it is often desirable to generate
various purified iodinated peptide derivatives (i.e., one
or two iodines per tyrosyl residue and one or two iodines
per histidyl residue), we routinely use pH 6.0 or 7.0 to
obtain mostly tyrosine-labeled products and pH 8.2 to
promote iodination on histidine or both tyrosine and
histidine. At each pH iodination can occur on both tyro-
sine and histidine, but the ratios are markedly different
(see Fig. 5). The deliberate use of reaction conditions
that lead to a complex mixture of products is practical
because of the power of reverse-phase HPLC in effi-
ciently separating these products.
The peptides described above all lack tryptophan, me-
thionine, and cysteine, residues that are sensitive to oxi-
dation (also among the least abundant residues in many
proteins). Difficulties arose when Trp was present in
the sequence, presumably because of oxidative damage
to the indole during iodination, yielding a complex mix-
ture of peaks that were not further characterized. In one
9-residue methionine-containing peptide, the expected
mono- and diiodotyrosine-labeled products were ob-
tained, but each resolved into a doublet of peaks on re-
verse-phase HPLC (not shown); the earlier-eluting,
smaller peak of each doublet was assumed to represent
a methionine sulfoxide derivative, as these are known to
elute earlier than their reduced counterparts. All of the
products were well-separated by HPLC, allowing appli-
cation of this labeling method to methionine-containing
peptides.
When we iodinated a peptide containing two tyrosyl
residues at positions 3 and 5, seven of the eight possible
products were isolated by reverse-phase HPLC: one
monoiodinated (I,-Y3), three diiodinated (12-Y3, 12-Y5,
I,-Y3/I1-Y5), two triiodinated (I2 -Y3/I-Y5, It-Y3/I 2-
Y5) and one tetraiodinated (Fig. 6 and Table 3). Thus
even short peptides with two tyrosyl residues can be
subjected to iodination with the expectation of obtain-
ing homogenous labeled derivatives by HPLC.
Our original purpose in obtaining stoichiometrically
iodinated peptides was to analyze their interactions
with cell surface class I MHC glycoproteins (MHC-I).
Certain peptides combine nonqovalently with MHC-I
proteins to form target structures recognized by cyto-
toxic T cells. We previously identified a 9-residue pep-
tide (termed IV9, sequence ILKEPVHGV) from the hu-
man immunodeficiency virus reverse transcriptase that
binds specifically and tightly to HLA-A2, an MHC-I
protein present on cell surfaces in 30-45% of Cauca-
sians (7). Complexes of IV9 and HLA-A2 are recognized
by HIV-specific T cells obtained from an HIV-infected
individual. Thus, addition of IV9 to HLA-A2' cells, fol-
lowed by incubation with these T cells, results in lysis of
the HLA-A2 + cells (cytotoxicity). Because we were inter-
ested in carrying out in vitro binding studies with ra-
dioiodinated peptides and HLA-A2 (6), we used this T
cell assay to assess the effects of peptide labeling on
biological activity.
As shown in Fig. 4, IV9 and its mono- and diiodohisti-
dine derivatives (IV9, I-IV9, I,-IV9) each have mark-
edly different biological activities in the T cell assay.
The peptide concentrations required to sensitize HLA-
A24 cells for 50% specific lysis were 1, 10, or 1000 pg/ml
for IV9 having 0, 1, or 2 iodine atoms per peptide mole-
cule. The 1000-fold difference between unlabeled and
diiodinated IV9 clearly demonstrates the need for cau-
tion in extrapolating results observed with trace labeled
preparations to the unlabeled peptide.
It is important to note that stoichiometric iodination
does not avert altering peptide structure and therefore
activity as a result of labeling; only an internal radiola-
bel (such as 3H, 14C, or 3 5S) can be expected to accom-
plish this. However, by providing chemically homoge-
neous products, stoichiometric iodination does permit
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FIG. 5. pH dependence ofiodination at tyrosyl or histidyl residues.
One milligram of the 9-residue peptide LY9 (sequence LKEPVHGVYI
was iodinated with 5 Amol "'1 at pH 6.0, 7.0, 8.0, or 9.0 using 6 Iodtn-
Beads. The products were resolved on a Vydac Ct semipreparative
column and collected. Chromatographic results are shown for the p-I
7.0 reaction only. lo-LY9 was the same as starting material by reten-
tion Lime. All products were characterized by Edman sequencing as
described in the text and in the tfoo.note to Table 2. Integration was
performed using peak areas for the five peaks identified, with the
resulting yields shown as a function of reaction pH.
unambiguous quantitative analysis of the effects of la-
beling (Fig. 4). Stoichiometrically iodinated peptides
can also provide valuable information about unlabeled
peptides. For instance, the equilibrium constant for the
binding of 12 11t-IV9 to HLA-A2 on intact cells is readily
determined by means of a cell surface binding assay (not
shown). The equilibrium constant for the binding of un-
labeled IV9 (or any other nonradioactive peptide) to
HLA-A2 can then be measured by using such a peptide
as a competitive inhibitor to block the binding of "2 1,-
IV9 to HLA-A2. From the concentration of competitive
inhibitor needed to effect a given level of inhibition (e.g.,
50%), the equilibrium constant for the binding of any
nonradioactive inhibitor to HLA-A2 can be calculated
(10). Using IV9 as an inhibitor, it was found that unla-
beled IV9 binds less well than I,-IV9 to HLA-A2, even
though unlabeled IV9 is far more active than [,-IV9 in
the T cell assay (Fig. 4). These results, to be described
elsewhere in detail, can provide critical insights into the
three-way interaction between peptide, MHC-I protein,
and T cell receptor. Thus, stoichiometrically iodinated
peptides are useful tools for investigating the biological
activities of unlabeled peptides, even though they may
differ considerably. Indeed, it is precisely because of
major differences in the activities of labeled and unla-
beled peptides that the trace labeled peptides commonly
used in binding and other studies may result in signifi-
cant ambiguities. Such ambiguities can be avoided by
stoichiometric iodination procedures that lead to chemi-
cally homogeneous products.
SUMMARY
The stoichiometric labeling procedures described
have been applied to several short peptides (8-25 resi-
dues) containing tyrosyl and/or histidyl residues. In
each case the identification of products after reverse-
phase HPI,C separation was facilitated by the integral
specific radioactivity ratios. Characterization of the io-
dinated products was carried out by Edman sequencing,
confirming the following order of elution for peptides
containing both tyrosine and histidine: unlabeled,
monoiodotyrosine labeled, diiodotyrosine labeled, mono-
iodohistidine and diiodotyrosine labeled (i.e., triiodin-
ated), and diiodohistidine and diiodotyrosine labeled
(i.e., tetraiodinated). The pH dependence of the iodin-
ation reaction is such that tyrosine is the favored site at
pH 6.0-7.0, but an increasing proportion of iodination
occurs on histidine at pH 8.0-9.0, although there is also
more unreacted starting material (Fig. 5). The described
procedures should be useful in any peptide labeling ap-
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FIG. 6. Reverse-phase 1-PLC separation of inodinated products
from a peptlide containing two tyrosines. Three milligrams of the
8-residue peptide RGYVYQEL was iodinated with 20 ,rmol 1211 at pH
(il using 12 lode-Beads, injected on a Vydac C4 semipreparatlve col-
umn, and eluted with an acetonitrile gradient of 1%/min at a flow rate
of 3 mi/min. Peaks were collected, dried, and characterized by Edman
sequencing, with the results shown in Table 3.
STOICHIOMETRIC PEPTIDE IODINATION
TABLE 3
Sequence Determination of Products from the lodination of Peptide RGYVYQEL
Edman
cycle Residue Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 Peak 6 Peak 7 Peak 8
1 R 942 369 321 247 239 539 265 732
2 G 710 512 367 164 401 342 368 327
3 Y 878 - - 143 - - - -
I1-Y - 473 - - 694 - 392 -
I,-Y - - 515 - - 245 - 279
4 V 949 598 440 141 613 427 345 318
5 Y 954 508 548 - - - - -
I1-Y - - - - 627 322 - -
1,-Y - - - 83 - - 220 258
6 Q 673 409 379 93 366 257 187 227
7 E 393 245 211 75 200 117 95 145
8 L 123 74 36 7 51 10 23 52
Note. Each peak obtained from the HPLC separation carried out as described in the legend to Fig. 6 was subjected to Edman degradation.
Results are given as pmol of the indicated residue (as its PTH derivative); mono- and diiodotyrosrne were identified on the basis of the
retention times of standards applied to the sequencer as described in the footnote to Table 2.
plication where a chemically homogeneous product is
desired in order to eliminate the ambiguities inherent in
trace labeling methods. Furthermore, stoichiometri-
cally labeled peptides may be useful in probing the bio-
logical activities of unlabeled peptides.
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Variations in the Number of Peptide-MHC Class I
Complexes Required to Activate Cytotoxic
T Cell Responses1,2
Shigeki Kageyama, 3 Theodore J. Tsomides, Yuri Sykulev, and Herman N. Eisen4
Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139
We determined equilibrium constants for the binding of 16 peptides (based on four T cell epitopes) to three
MHC class I proteins (A2, Kb, and Ld) on intact cells and estimated the number of accessible peptide-binding
sites on these cells. From these results, and the concentrations of peptides required to sensitize target cells for
lysis by CD8+ CTL, we conclude that the critical number of peptide-MHC complexes required per target cell
for the activation of CTL responses varies with different combinations of peptide-MHC complexes and CTL
clones from several thousand complexes to fewer than ten per target cell. The Journal of immunology, 1995,
154: 567-576.
plexes on a target cell that are recognized by a
CD8' CTL are formed from peptides produced
by limited proteolysis of the target cell's proteins. These
peptides bind to nascent class I MHC (MHC-I) molecules
in the endoplasmic reticulum, forming complexes that are
translocated to the cell surface (1). The same complexes.
termed pep-MHC s after Williams and Beyers (2), can also
be formed with synthetic peptides that are added to the
extracellular medium and that bind to a subset of cell sur-
face MHC-I proteins having functionally empty peptide-
binding sites, either because they lack peptide adducts or
contain loosely bound peptides that exchange readily with
the added peptide (3). This mode of addition of extracel-
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lular peptides to cell surface MHC-I proteins is widely
used to form antigenic pep-MHC complexes on target
cells to 1) identify the naturally occurring peptides of pep-
MHC complexes that are recognized by Ag-specific TCR;
2) evaluate the effects of amino acid substitutions on pep-
tide interactions with MHC-I proteins and on pep-MHC
interactions with TCR; and 3) identify peptides that are
capable of bringing about positive or negative selection of
developing thymocytes. Synthetic peptides can also be
used, as shown previously (4-7) and as emphasized here,
to estimate the number of pep-MHC complexes per target
cell required to trigger T cell responses. The minimal num-
ber is of particular interest because it sets an upper limit on
both the number of ligated TCR molecules that are nec-
essary for activating a T cell and on the complexity of the
universe of T cell Ags displayed on the surface of any
given target cell.
To evaluate pep-MHC interactions, some previous stud-
ies measured the binding of peptides to soluble MHC pro-
teins, either isolated from target cells or produced by in-
sect or bacterial cells by rDNA methods (8-23). Other
studies measured the binding of peptides to MHC proteins
in their natural form on intact cells (4, 24, 25). We have
here adopted the latter approach as we were interested in
establishing the equilibrium binding constants for several
sets of closely related peptides to several MHC-I proteins
under conditions that are similar to those used for sensi-
tizing target cells for lysis by CTL. Accordingly, we mea-
sured the binding of peptides to MHC-I molecules on in-
tact cells and related the results to the activities of the
peptides in cytotoxicity assays.
0022-1767/95/$02.00
NUMBERS OF PEPTIDE-MHC COMPLEXES RECOGNIZED BY T CELLS
We analyzed three systems in which the representative
peptide and the interacting MHC-I protein are: 1) the nona-
peptide ILKEPVHGV, termed IV9 (12), from reverse
transcriptase of human immunodeficiency virus type 1 and
HLA-A2; 2) the octapeptide SIINFEKL, termed pOV8
(26, 27) from hen egg OVA and Kb; and 3) the octapeptide
LSPFPFDL, originally termed p2CL (28) and later p2Ca
(29), from murine a-ketoglutarate dehydrogenase and Ld.
In the course of measuring the equilibrium constants we
also determined how many cell surface MHC-I molecules
per target cell are accessible to added synthetic peptides.
The latter values and the equilibrium constants, together
with the peptide concentrations required to sensitize target
cells for half-maximal lysis by CTL, provide a means for
estimating the number of pep-MHC complexes per target
cell required to trigger a CTL's cytotoxic response. We
show here that this number, previously reported to be 100
to 400 per cell (4-7), can vary several thousandfold for
different combinations of peptides. MHC molecules, and
CTL clones. We estimate that, with the most effective
combinations, fewer than 10 complexes per target cell may
be sufficient.
Materials and Methods
Peptide synthesis and purification
Peptides were synthesized on an Applied Biosystems 430A with standard
t-Boc chemistry and were analyzed by reverse phase HPLC and amino
acid analysis (Biopolymers Laboratory. Massachusetts Institute of Tech-
nology). The C-terminal amide of peptide IV9 was synthesized with a
benzhydrylamine resin. All peptides were cleaved by hydrogen fluoride.
Some peptides (IV9. p2Ca, pMCMV) were purified by HPLC on a Beck-
man system 334 with a 4.6 x 250 mm C18 reverse phase column (Vydac
218TP104) and a gradient of S1% solvent B/min, where A = 0.1%
trifluoroacetic acid in H,O and B = 0.085% trifluoroacetic acid in ace-
tonitrile. Peptide concentrations were measured by quantitative ammno
acid analysis or by micro BCA assay (Pierce. Rockford. IL), with either
BSA or the same peptide the concentration of which had been determined
by quantitative amino acid analysis used as a standard.
DNP-modified peptides IV9(DNP) and OV8(DNP) were synthesized
by first preparing the N,-t-Boc derivative of N,-2,4-DNP-t-lysine (Sigma
Chemical Co., St. Louis, MO) with 2-(t-butoxycarbonyloxyimino)-2-
phenylacetonitrile (BOC-ON; Aldrich. Milwaukee. WI). In brief, N,-
DNP-lysine (10 mmol) was slowly added with stirring to a round bottom
flask containing 10 ml of HzO, 25 mmol of triethylamine, and 10 ml of
dioxane. BOC-ON was added (11 mmol). and the reaction proceeded for
3 h at room temperature. Additional triethylamine (10 mmol) was added
after 1.5 h. The mixture was chilled on ice and the oxime by-product was
removed by extraction with cold diethylether. N,-t-Boc-N,-DNP-lysine
was precipitated by acidification of the aqueous phase, extracted with
ether, and dried under high vacuum. The product (80% yield) was neg-
ative by ninhydrin and was dissolved in N-methyl-pyrrolidone (Applied
Biosystems, Foster City, CA) for use in standard solid phase synthesis
with double coupling.
Radioiodinated peptides
These peptides were prepared as described (30). To achieve stoichiomet-
ric labeling, NaI'27 and Nam'I were generally mixed to give a four- to
fivefold molar excess of total iodide over peptide. For efficient labeling
of peptides containing either a single tyrosine or a single histidine resi-
due, the reaction was performed at pH 7.0 or pH 8.2, respectively. Typ-
ically, 1 mg of peptide was iodinated with 20 mCi 'aIt and six lodoBeads
(Pierce) for 30 min. The two products (mono- and di-iodinated) and
remaining unlabeled peptide were resolved by HPLC with a 10 x 250
mm C4 reverse phase column (Vydac 214TP510) and a gradient of 1%
B/min. Peaks were monitored with a UV detector set at 220 and 280 nm
(Beckman 165) connected in series with a radioisotope detector (Beck-
man 170). Specific radioactivities of the chemically homogeneous prod-
ucts ranged from 1 x 10 t6 to 2.5 x 101
6 
cpm/mol, indicating ,1%
labeling with '12I and 99% labeling with U27; although these products
contain a mixture of the two isotopes, they are referred to as 1'2I,-IV9,
12
2-IV9, etc. For stoichiometrically labeled, nonradioactive (cold iodi-
nated) peptides, only 1271 was used in the iodination reaction, to give
products 1271,I-V9, '2712-IV9, etc. Cold iodinated peptide sequences, in-
cluding iodinated residues, were confirmed by Edman sequence analysis
as described (30).
Cell lines
The human cell lines used were the EBV-transformed B cell line JY
(homozygous for HLA-A2, HLA-B7), the T cell line Jurkat (HIA-A9,
A25, B7, B41), Jurkat cells transfected with the gene for HLA-A2 (JA2;
31), the B cell line RPMI7666 (HLA-A3, Aw29. B7, B12), the TxB
hybrid Ag-processing mutant line T2 (HLA-A2, B5), and T2 cells trans-
fected with the genes for L' or Kb (T2-Ld and T2-Kb: 32). The murine
cell line P815, an H-2' mastocytoma. was also used for some L0-binding
experiments. All cells were maintained in K medium (RPMI 1640 sup-
plemented with 10% heat-inactivated FCS. 10 mM HEPES, 2 mM glu-
tamine, 100 U/mI penicillin, 100 Agiml streptomycmn. and 50 AM 2-ME).
Neomycin-resistant JA2. T2-Ld. and T2-Kb cells were additionally sup-
plemented with 250 g/ml G418 (Life Technologies. Gaithersburg, MD).
The CTL used were the murine H-2b anti-H-2d alloreactive clone 2C
(33), the murine Kb-restricted. OVA-specific H-2" clone 4G3 (34), and
the human HLA-A2-restricted, HIV-1 reverse transcriptase-specific
clone 68A62 (35). CTL clones were maintained as previously described.
Direct assay to measure binding of
radioiodinated peptides
Cells were harvested, washed with cold PBS. and resuspended at 107
cells/ml in various media: K medium (for conditions a and e, listed in
Table I, below), K medium plus 0.02% NaN3 and 50 mM 2-deoxyglu-
cose (conditions b and f), or K medium with 0.1% BSA instead of 10%
FCS, plus the protease inhibitors aprotinin (2 .g/ml), PMSF (100 .Ag/
ml), EDTA (5 mM), and todoacetamide (20 gg/ml) (conditions c and d).
A total of 2.5 x 10 cells were then incubated in a total volume of 500
gl per microfuge tube with HPLC-purified radiolodinated peptide at var-
ious concentrations in the presence or absence of a 500-fold molar excess
of an unlabeled peptide known to bind to the same MHC-I protein. Spe-
cific binding was the difference between the total radioiodinated peptide
bound and the amount bound nonspecifically (i.e.. bound in the presence
of excess unlabeled peptide). To measure equilibrium binding constants,
reaction mixtures were incubated with peptide for 7 h at 23*C (conditions
a, b, and c). 2 h at 37*C (condition d), or 16 h at 4*C (conditions e and
f). Incubation times were chosen on the basis of preliminary trials show-
ing no further binding over longer periods (data not shown).
After incubation, tubes were centrifuged for 20 s. The pelleted cells
were then washed rapidly twice, each time with a 20-s centrifugation, and
transferred to tubes containing 400 Al of oil (84% silicon oil. d = 1.050,
and 16% paraffin oil, d - 0.838. v/v) to separate free and cell surface-
bound peptide by centrifugation. In view of the half-time (tn,2) for dis-
sociation of representative peptides (see below), dissociation of bound
peptides during the washes was negligible. The cell pellet, supernatant,
and both supernatants from the initial washes were assayed in a Packard
gamma counter by counting each tube for 10 min and subtracting back-
ground (,-40 cpm) from each count. Equilibrium constants for specifi-
cally bound radioiodinated peptides were determined from Scatchard
plots of bound and free peptide (36). Linear regression was applied to
derive a best fitting line with negative slope equal to the association
constant (K) and x-intercept equal to the number of accessible MHC-I
peptide-binding sites per cell (n). Titrations were conducted in duplicate.
For those experiments performed two to four times, SD were on average
34% of the mean value for K, and 30% of the mean value for n (Table I).
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FIGURE 1. Specificity of radiolabeled peptide binding to MHC-l molecules on intact cells. After incubating cells and peptides
for 7 h at 23*C in a total volume of 500 ,1 of K medium, cells were washed rapidly two times and counted after separating them
from supernatants by centrifugation through a layer of oil. (A), '2si,-IV9 (40 nM) in the absence or presence of 100 AM
unlabeled IV9 was incubated with 2.5 x 106 JY cells (A2, 87), RPM17666 cells (A3, Aw29, B7, 812), jurkat cells (A9, A25, B7,
841), or JA2 cells (Jurkat transfected with A2 by Irwin et al. (31)). (B), 12511-pMCMV (66 nM) in the absence of inhibitor peptide
or in the presence of 50 /M unlabeled pMCMV, p2Ca, or pOV8 was incubated with 2.5 x 106 T2-Kb cells or T2 cells. (C),
'
25 1s-pMCMV (10 nM) in the absence or presence of 50 ~M unlabeled pMCMV, p2Ca, or pOV8 was incubated with 2 x 106
T2-Ld cells or T2 cells in a total volume of 400 •l (rather than 500 plI as in A and B).
Competition assay to measure binding of
unlabeled peptides
To determine equilibrium constants for the binding ot unlabeled peptides
(including -'Il-labeled (cold iodinated) peptides), cells were incubated as
above with a '~I-radioiodinated peptide at a concentration equal to its
dissociation constant and with unlabeled peptide at varying concentra-
tions. At the end of the incubation period the.centrifuged cell pellets and
supernatants were counted in a gamma counter as above. Because unla-
beled peptides were present in large molar exces- over the number of
target cell binding sites, the equilibrium (association) constant (K.) for
unlabeled peptide binding was determined from the Cheng-Prusoff equa-
tion K. = (1+K 1)/lp (37), where K, is the equilibrium (association)
constant of the radiolabeled peptide (Fig. 2 and Table 1), I is the free
concentration of radiolabeled peptide (assumed to be the same as that of
added labeled peptide), and p is the free concentration of unlabeled pep-
tide at which the amount of specifically bound radiolabeled peptide is
reduced to half its level in the absence of competing unlabeled peptide.
Titrations were conducted in duplicate. For those experiments performed
two to four times. SD were on average 39% of the mean K, value (Table Ii).
Cytotoxicity assay
Peptides were incubated in duplicate with 5tCr-labeled target cells (2 X
104 cells/well) for 30 to 60 min at 37"C in 96-well round bottom micro-
titer plates before adding CTL at a CTL;target cell ratio ot 5:1. Assays
were performed in K medium except for peptides p2Ca-SL9 and
p2Ca-A5 (Table 11), in which 0.1% BSA replaced 10% FCS. After ad-
ditional incubation for 4 h at 37*C, plates were centrifuged at 200 X g for
5 min, and 100-(.l aliquots from each supernatant were used to determine
percent specific lysis according to the formula: 100 x ("Cr release into
supernatant - spontaneous release)/(total release in detergent - sponta-
neous release). Spontaneous release values varied from 5 to 20% of total
release. All peptides were devoid of toxicity when incubated with target
cells in the absence of CTL.
Results
Specificity
To distinguish between specific and nonspecific binding of
radiolabeled peptides to intact cells, the binding reactions
were conducted in the absence or presence of a 400- to
1000-fold molar excess of the same peptide in non-iodi-
nated form or another peptide known to bind to the same
MHC-I protein. As shown in Figure IA, nonspecific bind-
ing (residual binding in the presence of excess unlabeled
peptide) amounted to <10% of the total '251,-IV9 peptide
bound to JY cells (homozygous for HLA-A2 and HLA-
B7). Significant binding of this peptide was also evident
on Jurkat cells that express a transfected A2 gene (JA2
cells) but not on untransfected Jurkat cells (A2-) or
RPMI7666 cells -iLA-A2-, HLA-B7').
Previous studies showed that the recognition of a mouse
cytomegalovirus peptide (YPHFMPTNL, termed pM-
CMV) by virus-specific CD8 + CTL was restricted by Ld
(38). This peptide blocked a CD8 + CTL response to a
Kb-restricted peptide (pOV8), indicating that it can also
bind to Kb (27). 1 2I-pMCMV was therefore used as an
indicator peptide to measure the binding of unlabeled pep-
tides to Kb as well as to Ld on T2-Kb and T2-Ld cells,
respectively (see below). As shown in Figure IB, 12It-
pMCMV bound well to T2-Kb cells but not to untrans-
fected T2 cells (Kb-), and the binding to T2-Kb cells was
blocked extensively (-90%) by peptides previously
shown to bind Kb (pOV8. p2Ca (39), and pMCMV). Spec-
ificity for Ld is evident in Figure IC, in which the same
indicator peptide (l25,I-pMCMV) bound to T2-Ld cells but
not to untransfected T2 cells. Its binding to T2-Ld cells
was strongly inhibited by unlabeled pMCMV but only par-
tially inhibited by p2Ca, which binds less well than pM-
CMV to Ld (see Fig. 3, below). Specificity was also dem-
onstrated with peptide pOV8, as this peptide, recognized
by Kb-restricted CTL, blocked the radioiodinated indica-
tor peptide's binding to T2-Kb cells but not to T2-Ld cells
(cf. Figs. 1, B and C).
Equilibrium constants for indicator ('251-labeled)
peptides and the numbers of peptide-binding sites
per cell
The results of incubating a fixed number of A2', Kb+, or
Ld+ cells (JY, T2-Kb, or T2-Ld) with various concentra-
tions of indicator peptides are shown as Scatchard plots in
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FIGURE 2. Binding of radiolabeled peptides to MHC-I molecules on intact cells. After incubating cells with varying con-
centrations of 12s5 -labeled peptides, the cells were harvested and counted as in Figure 1. In A, B, and C, the reaction mixtures
were incubated for 7 h at 23*C in 500 Al of K medium containing 0.02% NaN3 and 50 mM 2-deoxyglucose. In D, incubation
was for 2 h at 37*C in medium that contained a mixture of protease inhibitors (see Materials and Methods) and 0.1% BSA
instead of 10% FCS. After subtracting nonspecific binding (see Figs. 1 and 4), the number of peptide molecules bound per cell
(r) and the concentration of unbound or free peptide (c, in nM) were plotted according to Scatchard (36). A: '251s-IV9 and 2.5 x
106 JY cells. B: '2s51-pMCMV and 2 x 106 T2-Kb cells. Cand D: '2sI5 -pMCMV and 2.5 x 106 T2-Ld cells.
Table I. Equilibrium constants and numbers of peptide-accessible
MHC-1I binding sites on A2', Kb , and Ld' cells under
various conditions
Binding
Sites/Cell
Peptide Cell K, (M-Y (x1000) Conditionsb
'
2i5 2-1V9 JY 4.7 
- 2.6 x 10' 26 " 7 b
2.6 x 107 37 c
1.9 ±0.8 x 108 8.5 ±3.5 e
1.5 x 108  15 f
'
2
s51-pMCMV T2-Kb 7.7 " 1.1 X 106 38 4 a
7.9 x 106 24 b
'
2 l1,-pMCMV T2-Ld 1.9 - 0.3 x 108 39 = 20 a
2.9 X 108  14 b
5.6 x 107 5.8 d
2.9 x 108  18 e
P815 5.9 - 2.5 x 108  13 t3 a
1.4 x 109 4.3 b
SValues without a SD are based on duplicate titrations performed once.
ba, 7-h incubation at 230C in K medium tsee Materials and Methods); b.
same as a, plus 0.02% NaN3 and 50 mM 2-deoxyglucose: c, same as a, plusprotease inhibitors and 0.1% BSA instead of 10% FCS; d. 2 h at 370C in K
medium with protease inhibitors and 0.1% BSA: e. overnight at 41C in K me-
dium; f, same as e, plus 0.02% NaN3 and 50 mM 2-deoxvglucose.
Figure 2. From the linearity of these plots, a single equi-
librium constant was determined for each of the pep-
MHC-I combinations (Table 1). The numbers (n) of
MHC-I sites per cell available for binding to peptides are
given by extrapolation to the x-axis. By replotting the data
according to Klotz (bound peptide per cell vs log free pep-
tide concentration) (40), the values of n found by extrap-
olation in Figure 2 were verified (not shown).
There are 7 X 10W A2 molecules on the surface of JY
cells, as measured with an 125I-labeled F(ab) fragment of
mAb PA2.1 (12). Figure 2A shows that in 7 h at 23*C,
-30,000 of these molecules can bind to exogenous pep-
tide ('2511-IV9). As is now well established, the binding
sites of the remaining A2 molecules are occupied by
tightly bound (slowly dissociating) peptides (12, 41, 42).
T2 cells lack the TAP-1 and TAP-2 peptide transporters
that translocate cytosolically generated peptides into the
endoplasmic reticulum where they can load newly synthe-
sized MHC-I proteins (43). Accordingly, in the absence of
4)
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u t o 10t t 10 to to o to
Free peptide (nM)
FIGURE 3. Inhibition of radiolabeled indicator peptide
binding to Ld. A total of 2.5 X 106 T2-Ld cells were incubated
for 7 h at 230C in 500 pl of K medium with 5 nM 1251,
-
pMCMV and varying concentrations of three nonradioactive
peptides that bind to Ld: 12711-pMCMV, pMCMV, or p2Ca.
Cells were harvested and counted as in Figure 1. Bound pep-
tide (cpm) shown is corrected for nonspecific binding.
added peptides, T2-Kb and T2-L cells have low levels of
stable (peptide-loaded) Kb or Ld at the cell surface (44,
45). But in the presence of increasing concentrations of an
extracellular peptide that can bind to the relevant MHC-I
molecule, up to 40,000 cell surface Kb or 60,000 cell sur-
face Ld molecules can be peptide loaded in 7 h at 23*C
(Fig. 2, B and C). All of these new pep-MHC complexes
consist, presumably, of MHC-I molecules associated with
a single peptide (the one added to the medium).
Equilibrium constants for unlabeled peptides
Representative titrations of three unlabeled peptides, con-
ducted to determine their effectiveness as inhibitors of the
binding of indicator peptide 1251I-pMCMV to T2-Ld cells,
are illustrated in Figure 3. The order of effectiveness was
12711-pMCMV > pMCMV >> p2Ca. (127It-pMCMV is
identical to the indicator peptide except that 1271 was used
in place of 127I + 125I to prepare the monoiodotyrosine
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Table II. Equilibrium constants for peptide binding to HLA-A2,
K', and Ld
Peptide Sequence MHC-I K. (M-')Y
IV9 ILKEPVHGV A2 4.3 ± 2.1 x 106
5.5 x 106
LV8 LKEPVHGV <104
IG8 ILKEPVHG <10 4
IY0O ILKEPVHGVY 4.8 X 105
EV10 EILKEPVHGV 2.4 ± 0.4 x 106
IV9(DNP) ILKCEPVHGV 2.0 X 10'
IV9(NH 2) ILKEPVHGVd 2.8 x 106
I,-pMCMV Y'PHFMPTNL Kb 2.9 ± 2.0 x 106
pMCMV YPHFMPTNL 3.1 "t 1.2 x 10'
p2Ca LSPFPFDL 1.0 ± 0.4 x 10'
pOV8 SIINFEKL 1.5 = 0.7 X 108
pOV8(DNP) SIINFEKCL 1.9 X 108
I,-pMCMV Y¥PHFMPTNL Ld 3.5 ± 1.9 x 108
3.3 x 10's
pMCMV YPHFHPTNL 7.9 ± 5.3 X 10'
1 8 t 0.1 x 1081
p2Ca LSPFPFDL 3.7 ± 0.6 x 10s
1.3 ± 0.5 X 106'
p2Ca-Y4 LSPYPFDL 5.0 X 10s
'Values without a SD are based on duplicate rtirations pertormed once.
bCondition c. (see Table I); all other K. obtained by using condition b.
C Lysine modified by N,-DNP.
dValine modified by carboxyl amide.
eTyroslne stoichiometncally monoiqdinated with ""I
P815 cells: all other K, for Ld obtained by using T2-Ld cells.
derivative of pMCMV.) The corresponding equilibrium
constants, calculated from the concentrations of unlabeled
peptide giving half-maximal binding of 125It-pMCMV to
T2-Ld cells, were 4 x 108 M-', 8 x 107 M'- , and 4 x 10s
M- 1, respectively. These values, together with similarly
measured values for each of the three pep-MHC-I systems
studied (A2, Kb and Ld), are shown in Table II.
Most of the equilibrium constants shown in Tables I and
II were determined at 23*C (room temperature) for a 7-h
incubation in the presence of 0.02% NaN3 and 50 mM
2-deoxyglucose (condition b). However, they were also
measured in the absence of NaN3 and 2-deoxyglucose
(condition a), with 0.1% BSA and a mixture of protease
inhibitors in place of FCS to decrease peptide degradation
by serum and cell surface peptidases (condition c), at 4VC
(conditions e and f), or at 37*C instead of room temper-
ature to approach more closely the conditions used in CTL
assays (condition d). Except for up to fivefold higher bind-
ing constants at 4*C than at 23 or 37"C, these other con-
ditions resulted in binding constants that differed from one
another only to a small extent, e.g., within two- to three-
fold of those measured under condition b.
Determination of the equilibrium constant from
kinetics of the pep-MHC reaction
The rate at which 12sI1 -pMCMV binds to T2-Ld cells is
shown in Figure 4. After correction for nonspecific bind-
ing (see insert, Fig. 4), the concentrations of bound peptide
8 50000
t 40000
30000
20000
10000
z 4O
0 4 8 12 16 20
Time (hours)
FIGURE 4. Rate of binding of radiolabeled peptide to Ld. A
total of 2.5 x 106 T2-Ld cells were incubated for the indicated
times at 230C in 500 p.1 of 0.1% BSA-containing medium with
62 nM 12s51-pMCMV. The insert shows radiolabeled peptide
binding to cells in the absence (A) or presence (0) of a large
excess (>100-fold) of unlabeled pMCMV. The difference at
each time point corresponds to specific cell-bound 1251,_pM-
CMV (0). The kinetics of binding were analyzed according to
P, = a(1 - e"'), where P, is the concentration of MHC-bound
peptide at time t, a is the maximum concentration of bound
peptide (at the free peptide concentration used), and 7 is the
time constant for the pep-MHC reaction (found to be 4.3 hr).
at various times were fit to the equation: Pt = a(1 - e-~'),
where P, is the concentration of MHC-bound peptide at
time t, a is the maximal concentration of peptide bound (at
a free peptide concentration c, taken to be the total peptide
concentration since c >> P), and 7 is the time constant of
the pep-MHC reaction (the time needed to reach 63% of
the equilibrium value). From the best fit, at (at c = 60 pM)
and r were determined. Using a and the total number of
accessible sites (n) derived from the Scatchard plot in Fig-
ure 2C, we calculated the equilibrium binding constant
(Kj for this pep-MHC reaction from Ka = a/(cn-ca). The
resulting Ka, 1.3 x 108 M'-, agreed with the values ob-
tained for the same peptide in equilibrium binding mea-
surements by Scatchard plot analysis (1.9 x 10 M -',
Table I, and 3.5 x 108 M - ', Table II).
The rate constant of association (k+ ) for the pep-MHC
reaction shown in Figure 4, 1.8 x 103 M- ' s - t, was ob-
tained from a = cMrk,+1 (46), where a, c, and 7 are as
defined above and M (the molar concentration of accessi-
ble peptide-binding sites) is calculated from n (the number
of such sites), the number of cells, and the reaction vol-
ume. From this value and the equilibrium binding constant
for the reaction, we determined the rate constant of disso-
ciation (k-_) for IZS1-pMCMV-Ld complexes to be 1.4 X
10-s s-', corresponding to a half-life (tt1 2) of 14 h at
23"C. We also measured k- 1 for this complex at 37"C
directly from the actual rate of dissociation of bound pep-
tide from intact cells (data not shown); the t,,2 value found,
-3 h, was similar to those found by others for the binding
of some nonamers to Db (11) or Ld (16), although shorter
* * 40003
T. 1000
hr4 81216 0
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Table ill. MHC-I binding sites on target cells occupied by peptide at a free peptide concentration (c) that leads to half-maximal lysis of
the target cells (SDo,)'
Synthetic
Peptide MHC-I Ka (M-') SDso (M) r/ni re
IV9 A2 5 X 106 5 x 10-12 <0.0001 o1
12-IV9 5 X 107 1 10'
- 9  0.05 750
IV9(DNP) 2 x 107 1 X 10- 7  0.67 10,000
pOV8 Kb 1.5 x 108  3 x 10 - ' 2  0.00045 9
p2Ca I X 10 s  1 x 10- 6  0.09 1,800
p2Ca Ld 7 X 10s  1 x 10-9 0.0007 21
p2Ca-Y4 5 x 10 s  1X10-9 0.0005 15
p2Ca-A5 5 x 10' 2 x 10- 8  0.09 2,700
p2Ca-SL9 4 x 107 1 x 10- 8  0.29 8,700
1 The numbers of A2, Kb, and Ld molecules measured on lY, T2-K', and T2-Ld cells at 23'C were '-30,000, 40,000, and 60,000, respectively. The corresponding
numbers at 370C are taken to be one-half of these values for purposes of computing r (see Discussion). The SDso values are from References 12 (IV9, 12-IV9), 57(pOV8), 39 (p2Ca-Kb), 28 (p2Ca-Ld), and 51 (p2Ca-A5, p2Ca-SL9) and from the present study (IV9(DNP), p2Ca-Y4, and p2Ca-SL9). K, values for p2Ca-A5 and
p2Ca-SL9 are also from Reference 51.
b Fraction of available MHC-l sites occupied by peptide.
c Pep-MHC complexes per cell.
than the t,it found for dissociation of 1251i-IV9 from af-
finity-purified HLA-A2 (12).
Discussion
The number of pep-MHC complexes per target cell re-
quired to activate a cytotoxic response sets a limit on the
number of ligated TCR molecules required to trigger T
cell activation. Previous studies reported that approxi-
mately 100 to 400 complexes per target are required (4-7).
Given the approximations involved in reaching these es-
timates, the narrowness of this range could mean that es-
sentially a single value, perhaps 200 per cell, is generally
required. The present study provided an opportunity to ex-
amine this possibility.
Linearity of the Scatchard plots shown in Figure 2 and
the agreement between kinetic and equilibrium methods
for determining the equilibrium binding constants for pep-
MHC reactions indicate that the binding of extracellular
peptides to MHC-I molecules on intact cells can be treated
as a reversible bimolecular reaction. Hence at equilibrium,
the fractional occupancy of accessible MHC-I molecules
(r/n) is given by the Karush equation: r/n = (Kac)/(1 +
Kac) (47, 48), where r is the average number of pep-MHC
complexes per target cell, n is the number of MHC-I pep-
tide-binding sites accessible to extracellular peptides, c is
the free extracellular peptide concentration (taken to be the
concentration of added peptide), and Ka is the equilibrium
(association) constant for the pep-MHC reaction.
The results of applying this equation to the equilibrium
binding constants in Tables I and II and the Scatchard
plots of Figure 2 are shown in Table III. For purposes of
calculation, c is taken as the free peptide concentration that
sensitizes target cells for half-maximal lysis in standard-
ized cytotoxicity assays (SDso; 12) conducted here or in
previous studies from this laboratory (see footnote, Table
III). Our principal finding is that an extremely wide range
of values is evident for r/n (the fraction of total accessible
MHC-I peptide-binding sites that are occupied by added
peptide when a half-maximal T cell response is achieved),
from <0.00001 for peptide IV9 (SDso value in the low
picomolar range) to >0.5 for peptides with SDso values in
the nanomolar to micromolar range. From the number of
accessible peptide-binding sites per cell (n), the r/n values
given in Table III can be converted into a correspondingly
wide range of pep-MHC complexes per cell (r), i.e., from
approximately 1 to 20,000 complexes at equilibrium when
the peptide is at its SDso concentration. These findings are
consistent with observations that different CTL raised
against the same peptide require markedly different con-
centrations of that peptide to sensitize a given target cell
for the same degree of lysis (49).
Given the contrast between the wide-ranging estimates in
Table III and those reported previously, it is necessary to
consider the sources of error in our calculation of r from K,,
c, and n. Measurements of equilibrium binding constants (Ka)
for pep-MHC reactions have been made by a variety of ap-
proaches, and in a few cases data are available for particular
pep-MHC combinations that have been examined by more
than one method. The K, for peptide pOV8 (SIINFEKL)
binding to soluble Kb was found by Matsumura et al. to be
0.8 to 2.4 X 108 M-' (expressed as an association constant)
by gel filtration (17, 18), in agreement with our value of
1.5 x 108 M'' for the binding of this peptide to Kb on intact
cells. We found the binding constant for peptide IV9 and
HLA-A2 on intact JY cells to be 5 x 106 M- 1, in agreement
with independent measurements by Saito et al. (18) and Sette
et al. (50). Finally, we found good agreement between the
equilibrium binding constant for It-pMCMV and Ld by Scat-
chard plot analysis (4 x 108 M- 1, Fig. 2) and by kinetic
analysis (4 X 10" M-', Fig. 4). There appear, however, also
to be some disparities. For example, our Ka for the binding of
p2Ca to Ld on intact T2-Ld and P815 cells were 4 x 10s M-
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and 1 x 106 M- 1, respectively, whereas using soluble Ld
Brunmark et al. found 4 x 106 M- 1 (51). The basis for this
difference is not clear but may relate to the different 32-m
subunits associated with Ld heavy chains in the different as-
say systems (human P2-m in T2-Ld cells and mouse 32-m in
P815 cells and in the soluble Ld preparations).
Another source of uncertainty is the free peptide con-
centration, c. Peptide degradation by proteases during cy-
totoxicity assays is known to occur and may even be es-
sential to generate active (MHC-binding) peptides when
longer precursors are added to target cells (14, 29, 52-55).
We evaluated the degradation of peptide '1 Ii-IV9 by in-
cubating the peptide for 4 h in K medium and measuring
its recovery by reverse phase HPLC, under conditions that
resolve the shorter, less active fragments from the intact
peptide. We obtained yields of -50% (data not shown).
Thus, c could be in error by a factor of -2. However, such
an error would not affect our conclusion of a broad range
of r/n values and would only lead to a calculation of fewer,
not more, complexes per target cell required to trigger T
cell responses.
Table III is based on equilibrium constants that were
measured at room temperature (-230C) and on SDso val-
ues that were determined in cytotoxicity assays performed
at 37*C. To estimate r/n at 37"C, the binding of peptide
It-pMCMV to T2-Ld cells was also measured at this tem-
perature. As shown in Figure 2D, pep-MHC binding at
370C could be represented by a linear Scatchard plot, giv-
ing a single equilibrium association constant that differed
only little (three- to fourfold) from that measured at 230C
(cf. Fig. 2, C and D). However, the extrapolated value for
n was ,10-fold lower at 37*C than at 23"C. Values of n
are determined by several processes, including 1) the rate
of synthesis and appearance of peptide-accessible MHC-I
molecules at the cell surface; 2) their rate of decay; and 3)
the rate at which peptides bind to and stabilize these mol-
ecules. Measurements of n are thus subject to more un-
certainty than those of Ka or c. The binding assay at 37"C
shown in Figure 2D was performed in the presence of
protease inhibitors to block peptide degradation, including
0.1 M iodoacetamide, which hinders the production of cel-
lular ATP and may reduce the rate of protein synthesis,
including new MHC molecules; this probably contributed
to an underestimate for n at 37*C. On the basis in part of
ongoing studies, we chose a value of n for T2-Ld cells at
37*C for purposes of calculating r that is approximately
one-half of the number found at 23*C (Table III). In sup-
port of this estimate, a previous study found "-2500
pep-A2 complexes per cell when JY cells were incubated
with peptide I,-IV9 at 37*C, or -15,000 complexes after
correction for affinity purification yields of 10 to 25% (12);
this is about one-half of the number we measured at 23"C
(see Fig. 2A). Notwithstanding these uncertainties in the
actual values of n at 37"C, it is clear that at this temper-
ature there is still an extremely wide variation in r/n and r
values, reflecting mostly the wide variation in SD50o values.
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FIGURE 5. Equilibrium constants (expressed here as disso-
ciation constants) for different peptides binding to HLA-A2
are plotted against the peptide concentrations required for
half-maximal lysis of JY target cells by CTL clone 68A62
(SDso values). (SDso values are reported in Ref. 12.)
Consider, for example, the lysis by 2C CTL of T2-Ld
target cells sensitized with peptides p2Ca (LSPFPFDL),
p2Ca-Y4 (LSPYPFDL), p2Ca-A5 (LSPFAFDL), or p2Ca-
SL9 (SPFPFDLLL). Inasmuch as K. values at 23"C differ
little from those at 37"C (Fig. 2, C and D), the SDso values
found for these peptides mean that in standard cytotoxicity
assays the corresponding r/n values vary from 0.0007 to
0.29 (Table III). If n at 37*C is half that at 23OC, the
respective r values for the four peptides are in the ratio
1:0.75:135:435, i.e., 20, 15, 2700, and 8700 pep-MHC
complexes per cell (or twice these values if n is approxi-
mately the same at 37 and 23*C). Thus, in contrast to
earlier findings that suggested that 100 to 400 complexes
per cell were generally required, the present findings sug-
gest that the number can vary over a range of many thou-
sandfold. It is possible that, broadly speaking, few pep-
MHC complexes are required when the affinity of the TCR
that recognizes them is high and that a large number of
complexes is needed when they and the corresponding
TCR interact with low affinity.
In Figure 5, pep-MHC equilibrium constants (Kd) are
plotted against peptide activities in standardized cytotox-
icity assays, expressed as the peptide concentrations re-
quired to sensitize JY target cells for half-maximal lysis by
the A2-restricted CTL clone 68A62 (SD 5o). The absence
of a simple linear correlation is obvious, i.e., the best
MHC-binding peptides are not always those that elicit T
cell activity at the lowest concentrations. For example,
peptide 12712-IV9 (two iodine atoms incorporated on his-
tidine at position 7) binds approximately 10 times better
than IV9 to A2 molecules, yet has an SDso that is a 1000-
fold higher. This result can be reconciled with the crystal
structure of the IV9-A2 complex (56), since the iodine
substitutions appear to be at a position that would interfere
with recognition of 12-IV9-A2 complexes by the 68A62
TCR. Furthermore, such data are consistent with the re-
cently reported variations that are observed in the affinities of
a given TCR for related pep-MHC ligands (51) or of different
TCR for their respective pep-MHC ligands (57).
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Minimal concentration of peptide that renders target
cells susceptible to lysis by CTL
We estimate that for the loading of cell surface MHC-I
molecules by extracellular peptide in cytotoxicity assays,
the minimal effective concentration of free peptide cannot
be lower than 10-13 to 10- 14 M. This follows because the
minimum concentration is given by m/(Kan), where m is
the number of pep-MHC complexes per target cell (taken
here as one, the smallest number theoretically possible),
Ka is the equilibrium constant for the pep-MHC reaction,
and n is the number of peptide-binding sites per cell. Be-
cause Ka values of 109 M-1 and n values of 104 to 105 per
target cell represent upper limits for the measurements so
far made, it may be expected that in conventional titrations
of peptides (e.g., Fig. 5), reports of target cell sensitization
with peptide at a free concentration of <10- '3 M would
mean that either the pep-MHC equilibrium constant or the
number of accessible MHC-I-binding sites are extraordinar-
ily high, or the minimum peptide concentrations are in error.
The antigenic universe as seen by T cells
A target cell displays on its surface up to several hundred
thousand MHC-I molecules complexed with an array of
peptides representing diverse intracellular proteins, includ-
ing products encoded by pathogens such as viruses (3) and
products that arise from aberrant protein expression in tu-
mor cells (58). Some pep-MHC complexes are particularly
abundant (42, 59-63), whereas others are extremely
scarce (26, 28, 29, 64-66), complicating efforts to isolate
and sequence individual peptides recognized by T cells of
interest (antiviral, antitumor, etc.). If a given MHC-I allele
product (e.g., HLA-A2) is present at 10- copies per tar-
get cell (in the absence of transformation by EBV, which
greatly increases this number (67)), and, as commonly
supposed, a minimum of 100 pep-MHC complexes per
cell are needed for T cell activation, then a maximum of
1000 different peptides can be presented effectively at the
cell surface in association with A2 (or any other given
MHC product). This would mean that many intracellular
proteins are not represented at the cell surface, at least at
levels sufficient for T cell recognition. However, the
present study indicates that lower numbers of complexes
can indeed be recognized for optimal combinations of pep-
tide, MHC molecule, and T cells. Thus the complexity of
the universe of peptide Ags effectively displayed by a tar-
get cell for immunosurveillance by T cells could be con-
siderably greater than 1000. This result also implies that
rare peptide epitopes, present at say 1 to 10 complexes per
target cell, will be all the more difficult to obtain in
amounts sufficient for direct chemical sequencing.
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Summary
Using a chemically homogeneous radiolabeled peptide of high specific activity
(125 11-QLSPYPFDL, 3.5x1018 cpm per mole) we show that at a peptide concentration
(5 pM) causing half-maximal lysis of target cells by a cytotoxic T lymphocyte (CTL)
clone that recognizes the peptide in association with Ld, a class I MHC protein, only 3
peptide molecules on average are bound by Ld per target cell. From the distribution of
Ld on the target cells we suggest that a single peptide-MHC complex per target cell can
trigger activation of the T cell cytolytic response.
Introduction
In the initial antigen-specific event that leads to T cell activation, antigen-
specific receptors on T cells (TcR) react with peptide-MHC complexes (pep.MHC) on
antigen presenting cells or target cells. As shown in innumerable in vitro assays in
which synthetic peptides are incubated with target cells, the intensity of the T cell
response depends upon peptide concentration, which, in turn, affects the density of the
corresponding pep.MHC complexes ("epitopes") on target cells. While the number of
these complexes per cell ("epitope density") appears to be one of the critical
determinants of the outcome of T cell-target cell encounters (e.g., Ashton-Rickardt et
al., 1994; Sykulev et al., 1994a; Tsomides et al., 1995), measuring them is laborious and
only a few values have been reported. In some studies, using radiolabeled peptides and
immunoprecipitating the appropriate MHC protein, the minimum epitope density found
to trigger antigen-specific T cell proliferation and lymphokine production (Harding and
Unanue, 1990; Demotz et al., 1990) or a T cell cytolytic response (Christinck et al.,
1991) was around 100 to 400 complexes per antigen presenting cell.
Another approach for estimating epitope densities has taken advantage of
mutant target cells with a defect in the peptide transporter that results in cell surface
class I MHC molecules largely devoid of stably bound peptides (Heemels and Ploegh,
1995). Because of this defect, widely different epitope densities can be established on
these cells by incubating them with synthetic peptides at various concentrations, and the
average number of pep-MHC complexes formed per target cell at steady state can then
be estimated from: (1) the free peptide concentration; (2) the equilibrium constant for
the peptide-MHC reaction; and (3) the total number of accessible ("functionally
empty") MHC binding sites per cell. Although this approach can be considered to yield
only approximate values, it suggested that the epitope densities required for half-
maximal cytolytic responses by cytotoxic T lymphocytes (CTL) varied from several
thousand pep.MHC complexes per target cell to fewer than ten with different
combinations of MHC proteins, peptides, and CTL (Kageyama et al., 1995). In
addition, two independent models for T cell-target cell interactions have proposed that
activation of a Tcell can be initiated by 3-5 pep.MHC complexes (Brower et al., 1994)
or by fewer than 10 complexes per target cell (Sykulev et al., 1995).
The low values are of interest because, if correct, they focus attention on a
critical question concerning the physiologic activation of T cells: "whether T cell
triggering involves cross-linking TcR molecules, or whether activation occurs by
perturbation of a TcR-multimolecular complex by a single MHC-peptide" (Williams
and Beyers, 1992). Accordingly, we have sought to determine if the low values
previously suggested by indirect approaches and reliance on models can be verified by
measuring directly the number of peptide molecules on antigen presenting cells under
conditions where these cells elicit a half-maximal cytolytic response by CD8+ T cells.
For this purpose we made use of a chemically homogeneous radioiodinated peptide of
exceptionally high specific radioactivity. Prepared with large amounts of carrier-free
1251 and purified by HPLC, the peptide had the same specific radioactivity as carrier-
free 125I (3.5x1018 cpm/mole). With this peptide we found that an average of 3
pep-MHC per target cell could elicit a half-maximal cytolytic T cell response. This
finding and the distribution of Ld on the target cells suggest that the cytolytic response
of some T cells may be elicited by a target cell that bears a single pep.MHC complex.
Materials and Methods
Cells
The CD8+ cytotoxic T cell clone 2C was maintained as described (Kranz et al.,
1984). The human hybridoma T2 transfected with the Ld gene (Alexander et al., 1989)
was cultured in K medium (RPMI 1640 supplemented with 10% heat inactivated fetal
calf serum, 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 gtg/ml
streptomycin, 50 ýtM f-mercaptoethanol) in the presence of 320 jLg/ml G418.
Peptides
Except for the influenza virus matrix peptide GILGFVFTL, which was kindly
provided by Drs. Marlene Bouvier and Don Wiley (Harvard University, Cambridge,
MA) (Bouvier and Wiley, 1994), all other peptides were synthesized by solid phase
t-Boc chemistry in the M.I.T. Biopolymers Laboratory and purified by reverse phase
HPLC. The monoiodinated, nonradioactive form of peptide QLSPYPFDL, termed
127I1-QL9-Y5, was prepared in the same way, using t-Boc-protected monoiodinated
tyrosine (Peninsula, Inc., Belmont, CA). Because the N-terminal glutamine rearranges
to cyclized pyrrolidone carboxylate, the peptide exists in two forms (separable by
HPLC). Both were recognized by 2C cells in association with Ld. The preparations
used here were predominantly in cyclized form. All peptide concentrations were
measured by quantitative amino acid analyses.
Stoichiometric iodination of peptide QLSPYPFDL (QL9-Y5) with 1251
The monoiodinated, radioactive form of peptide QL9-Y5 was prepared by
iodination with carrier-free Na 125I (Du Pont NEN) as described (Tsomides and Eisen,
1993; Schumacher and Tsomides, 1995). Briefly, in a typical reaction, 200 gpg of
purified peptide QL9-Y5 was reacted with 30 mCi Na125 I using 2 Iodo-Beads (Pierce)
for 30 min at pH 6.0. After unbound iodide was removed from the peptide mixture
using a Sep-Pak C18 cartridge (Waters) in a glove box, the labeled peptide products and
unreacted QL9-Y5 were resolved from one another on a 4.6 x 250 mm reverse phase
C18 HPLC column (Vydac) with a 1%/min acetonitrile gradient, using on-line
radioisotope detection (Beckman model 170). Individual radiolabeled products were
dried, resuspended in H20, and aliquots were counted in a y-counter (Packard) with a
known counting efficiency of 75% to determine the peptides' specific radioactivities.
The specific radioactivity of monoiodinated 125 11-QL9-Y5 was the same as that of
carrier-free 125I (3.5x10 18 cpm/mol). The composition of this peptide was further
confirmed by Edman degradation after HPLC purification (Tsomides and Eisen, 1993).
Antibodies
Mouse monoclonal antibodies PA2.1 (IgG1, anti-HLA-A2 (Brodsky et al.,
1979)) and 30-5-7 (IgG2a, anti-Ld (Ozato et al., 1980; Lie et al., 1990)) were isolated
from supernatants of hybridoma cell cultures using protein A affinity chromatography.
Cytotoxicity assay
50 pl of peptides at various concentrations in phosphate buffered saline were
added to 5x103 51Cr-labeled target cells (T2-Ld) and 1.5-2.5x104 CTL (2C) in 150 pl of
K medium in round-bottom wells of microtiter plates. After brief centrifugation (300 g,
5 min) the plates were incubated in a CO2 incubator for 4 hr at 370C. Percent specific
lysis was calculated from the average of duplicates as ((51Cr experimentally released -
spontaneous release)/(total release in 0.1% NP40 - spontaneous release)) x 100.
Flow cytometry
To measure peptide-dependent stabilization of A2 and Ld molecules on T2-Ld
cells, the cells were incubated with various peptide concentrations at 370 C for 6-12 hr.
Expression of cell surface A2 and Ld was detected with antibodies PA2.1 and 30-5-7,
respectively, followed by staining the cell-bound antibodies with FITC-labeled F(ab')2
fragments of goat antibodies to mouse immunoglobulins. The levels of expression of
the MHC proteins were measured by mean fluorescence on a linear scale.
Kinetic analysis of the reaction between I 1-QL9-Y5 and Ld on T2-L d cells
Sixteen tubes, each containing 5x10 7 cells in 5 ml K medium, were incubated
with influenza virus matrix peptide GL9 at 1-2 p.M for 1 hr at 370C. I1-QL9-Y5 was
then introduced into all tubes at 10-10 M. To correct for nonspecific binding of the 125I-
peptide to the cells, peptide YPHFMPTNL (pMCMV, Reddehase et al., 1989) was
added to half the tubes at a final concentration of 1-2x10 -6 M; this concentration is in
great excess over what is required to saturate the Ld binding sites, since the equilibrium
binding constant for the pMCMV-Ld reaction is =2x10 9 M-1 (Sykulev et al., 1994a).
Tubes were slowly rotated on a stirring wheel at 37 0C, and after each hr duplicate tubes
containing the labeled peptide only (to measure total binding) or both the labeled
peptide and the Ld-blocking unlabeled peptide were centrifuged at 40 C. After removing
supernatants, which were counted to measure the free concentration of 125I-peptide, the
cell pellets were washed twice with ice cold K medium, resuspended in 2-3 ml of ice
cold K medium, and layered on 2 ml of silicone-paraffin oil mixture (see above) and
centrifuged at 40 C. After freezing the centrifuge tubes, the tips were cut off to measure
cell-bound 12 5 I-peptide. Dissociation of the labeled cell-bound peptide during
manipulations at 40 C was shown to be negligible (Vturina et al., in preparation).
To determine the rate constant of dissociation (k-1) of I1-QL9-Y5 from Ld,
5x10 5 T2-Ld cells were preincubated in a total volume of 200 pl with 5 pM brefeldin A
(BFA) for 40 min at 370C to block delivery of newly produced MHC molecules to the
cell surface. Peptide 127 11-QL9-Y5 was then added at a final concentration of 4x10 -4 M
and incubation was continued at 370 C. After the cell suspension was subjected to rapid
centrifugation, the supernatant was promptly removed and the cells were washed twice
with ice cold K medium and resuspended in K medium that was pre-heated to 370 C and
contained 5 p.M BFA. An aliquot of the cell suspension was taken immediately (time
zero) and placed on ice. The remaining cells were kept at 37 0C and samples were
removed every 15-20 min, placed on ice, and stained with 30-5-7 anti-Ld antibody as
described above to determine their mean Ld expression by flow cytometry. The results
were analysed as described in the legend to Fig. 2.
Direct measurement of I 1-QL9-Y SLd complexes on T2-Ld cells
The number of I 1-QL9-Y5.Ld complexes on T2-Ld cells was measured directly
with cells that were incubated at 370C for 3 hr (see equilibrium time, Fig. 2) with 12511-
QL9-Y5 at 3 different concentrations: 5x10 -11, 2.3x10-11, and 5x10 -12 M. To 4 tubes,
each prepared with 5x10 7 cells as above, peptide 12 5 11-QL9-Y5 was added to achieve
one of the indicated concentrations in the presence or absence of unlabeled pMCMV at
a concentration in great excess over what was required to saturate Ld. All tubes
contained peptide GL9 at 1-2 pgM to saturate peptide binding sites on A2 (which is
present on T2-Ld cells). After 3 hr cell-bound and unbound 125I-peptide were separated
and measured as above. The number of Ld-bound peptide molecules per cell was
determined from: (1) the difference between total cell-bound cpm measured in the
absence and presence of the Ld-saturating concentration of peptide pMCMV; (2) the
specific radioactivity of 12511-QL9-Y5 (3.5x10 18 cpm/mole); and (3) the number of
cells in the sample. The amount of specifically cell-bound 125I-peptide was the same
when the GL9-saturated cells were incubated for 1 hr at 37 0 C before the addition of
12511-QL9-Y5 and when the 12 5I-peptide and pMCMV were added at the same time.
The distribution of Ld molecules on T2-L d target cells
T2-Ld target cells were labeled with the PKH26 dye according to the
manufacturer's protocol (Zynaxis Cell Science, Inc., Malvern, PA), and they were then
labeled in the standard way with 51Cr. 5x10 3 double-labeled target cells were incubated
with various concentrations of 12 711-QL9-Y5 and 1.5x10 4 2C cells in a total volume of
200 p.1 in round-bottom 96-well plates for 4 hr at 370 C. Percent specific lysis was
determined by counting 51Cr in the supernatants as decribed above. The presence of
PKH26 on the target cells had no effect on their specific lysis by CTL 2C. In parallel,
T2-Ld targets tagged with PKH26 and not 51Cr-labeled were incubated under precisely
the same conditions at the peptide concentrations required for 20 to 80% of maximal
lysis, i.e., 1x10 -12 to 3x10- 11 M, using 24 identical wells for each of the peptide
concentrations tested. Two control 24-well sets of the target cells were also examined
at the same time: the first set contained only target cells and are referred to below as the
"initial" cells; the second set contained the target cells and CTL 2C but no added
peptide. At the end of the incubation period (4 hr) cells from each 24-well set were
pooled, immediately chilled on ice, and stained with 30-5-7 anti-Ld antibody as
described above. After adding propidium iodide (PI) to detect dead cells, all samples
were analysed by flow cytometry on the FACStarPlus Flow Cytometer. About 90% of
the initial target cells were PI-, whether or not they had been incubated alone or with
CTL 2C in the absence of the peptide. However, in the presence of the peptide the
fraction of surviving target cells (PKH26+PI-) was reduced and the decrease was greater
as the peptide concentration increased.
The levels of Ld on the initial and surviving T2-Ld target cell populations
(PKH26+PI-) were compared by flow cytometry by measuring FITC fluorescence
intensity of the antibody-stained cells on a linear scale. The fluorescence of these cells
fell within channels 20 and 520, and this region was divided into 25 equal intervals.
Numbered from 1 to 25, the intervals provided a relative measure of the cell surface
level of Ld. The distributions of Ld on both the initial and surviving target cell
populations were displayed by plotting the percent of all PKH26+PI-FITC + cells for a
given population in each of the numbered (n) intervals. To determined the Ld
distribution on the lysed target cells, we calculated the percent of lysed cells in each
interval ( pk ) from:
n
int s
k Pn -(1-fk ) P n
Pn =  fk
where Pint and Pn are the percentages of "initial" and "survived" target cells,
respectively, in the nth interval, and fk is the fraction of specifically "lysed" cells
determined from released 5 1Cr. Values of Pn were plotted as a function of the
interval number n. Relative weighted average values (means) of Ld expression (Ii ) in
all 3 populations of target cells (initial, survived, and lysed) were calculated as:
25
1 Pn- n
100
Results
Peptide concentration required for half-maximal cytolysis
CTL clone 2C recognizes pep-MHC complexes formed by the class I MHC
molecule Ld and one of several naturally processed peptides whose sequences derive
from oa-ketoglutarate dehydrogenase (Udaka et al., 1993), including p2Ca (LSPFPFDL,
Udaka et al., 1992) and QL9 (QLSPFPFDL); the latter is the most potent Ld-sensitizing
peptide known for CTL 2C, having an SD50 value (concentration required to elicit half-
maximal lysis) of 5 pM (Sykulev et al., 1994b), or about 100-fold less than that of
peptide p2Ca. To estimate the number of Ld-bound peptide molecules per target cell
required to activate 2C cells, we first determined the free peptide concentration that
results in half-maximal lysis using peptide I1-QL9-Y5, a monoiodinated analog of QL9
available in chemically equivalent nonradioactive (1271) and radioactive (1251) forms.
As shown in Fig. 1, the SD 50 value of 11-QL9-Y5 was about equal to that of peptide
QL9, or 5 pM.
Specificity of I1-QL9-Y5 binding to Ld on T2-L d cells
The T2-Ld target cells used in these studies are of human origin and express
HLA-A2. Since the sequence of I1-QL9-Y5 happens to fit the A2 consensus motif (it
has leucine at positions 2 and 9), and this peptide can bind to A2 as well as Ld (Table
1), it was necessary to include in the reaction mixture, along with I 1-QL9-Y5 and T2-Ld
cells, a peptide that could saturate the peptide binding sites of A2 without occupying the
peptide binding sites of Ld. This requirement was met by the influenza virus peptide
GILGFVFTL (Bednarek et al., 1991; Morrison et al., 1992), termed GL9. As shown in
Table 1, on T2-Ld cells that were incubated with GL9 the level of cell surface A2
increased markedly, but the level of Ld was unchanged. Moreover, GL9 at 1 ýtM, a
concentration in great excess over what was required to saturate A2, did not interfere at
all with the Ld-dependent lysis of T2-Ld cells by CTL 2C in the presence of peptide
p2Ca (data not shown). Thus, by including GL9 at 1 [M in all assays, the binding of
I1-QL9-Y5 to A2 could be prevented without interfering with its binding to Ld.
Kinetics of I 1-QL9-Y5 - L d reaction
The rate of binding of I1-QL9-Y5 to Ld on T2-Ld cells was examined to
determine whether this peptide-MHC reaction can approach steady state during
standard CTL assay conditions (4 hr). Visual inspection of Fig. 2 shows that the
number of peptide molecules bound specifically to T2-Ld cells reached steady state in
about 2 hr. When fit to the equation Pt = a(1-e-t/ ), where Pt is the number of peptide
molecules bound specifically per T2-Ld cell at time t, the kinetic data of Fig. 2A yielded
a, the total number of Ld-bound peptide molecules per cell at steady state at the free
concentration shown (1x10 -10 M), and also c, the time constant, i.e., the time required to
reach 63% of the steady state value. This time (¶) was around 50 min. r becomes
longer as the peptide concentration decreases, but it cannot be longer than the reciprocal
of the rate constant of dissociation (k-1) for the peptide-Ld reaction (see Eq. 5a from
Sykulev et al., 1994a).
To measure k-1 we made use of an anti-Ld antibody (30-5-7) that reacts
specifically with Ld if the binding site is occupied by peptide (Lie et al., 1990): when
the peptide dissociates, the resulting empty Ld molecule undergoes rapid denaturation at
370 C. Thus, by loading Ld on T2-Ld cells under conditions where brefeldin A blocked
the delivery of newly synthesized Ld to the cell surface, the time course of Ld-peptide
dissociation could be monitored by flow cytometry using antibody 30-5-7 (Vturina et
al., in preparation; see Materials and Methods). From the results shown in Fig. 2B, the
value of k-1 was found to be 3.3x10 -4 sec -1, yielding an upper limit for t of =50 min.
Thus, even at the lowest peptide concentration used in this study (5 pM, see below) the
I1-QL9-Y5 - Ld reaction approached steady state.
Direct measurement of epitope densities
To measure the binding of I1-QL9-Y5 directly to Ld on target cells, peptide
QL9-Y5 was radiolabeled with carrier-free 125I and incubated at various concentrations
with 5x10 7 T2-Ld cells in a total volume of 5 ml. Free peptide concentrations and the
numbers of specifically bound peptide molecules per cell were determined directly from
the peptide's specific radioactivity, 3.5x10 1 8 cpm/mole. At 3 free peptide
concentrations, 5x10 - 11, 2.3x10 -11 , and 5x10 -12 M, the directly measured average
epitope density values were 50, 40, and 3 pep.MHC complexes per cell, respectively.
In view of the implications of these values, it is necessary to consider possible
sources of error. One potential error is that 12 5I-peptide dissociated from Ld when the
cells were washed to remove free peptide. This possibility was ruled out by measuring
the stability of the peptide-Ld complexes by flow cytometry. The cells were washed at
40 C in =10 min (see Materials and Methods), but at this temperature no dissociation
could be detected over many hr (data not shown). Another source of error arises from
cell counts: we estimate this error to be at most ± 20%. Hence, at the lowest peptide
concentration (5x10 -12 M), the epitope density value in this system was 3 ± 1 pep.MHC
complexes per target cell. With this average number the frequencies in the target cell
population of cells having 0, 1, 2, 3, 4 and 5 pep.MHC complexes per cell would be
0.05, 0.15, 0.22, 0.22, 0.17, and 0.10, respectively, assuming the Poisson distribution to
be applicable. In that event, from the sum of these frequencies (0.91) the titration
shown in Fig. 1 implies that when half the target cells were lysed, most of the lysed
cells would have had fewer than 5 complexes per cell and only about 10-20% of them
would had more than 5 per cell.
Is there selective lysis of T2-Ld target cells expressing higher than the average
number of pep-MHC complexes per cell?
Alternatively, it could be argued that the distribution of Ld molecules on T2-Ld
cells is extremely asymmetric, especially as Ld on these cells is derived from a
transfected gene. In that event only those target cells with Ld levels much above the
average might be preferentially lysed. To test this possibility we compared the
distribution of Ld on the initial target cells, before they were introduced into a CTL
assay, with those that survived after 4 hr when half had been lysed. As shown in Fig. 3,
the Ld distribution was virtually the same on the initial and surviving target cells. By
subtraction it was clear that the lysed target cells also had a similar distribution.
Discussion
With a high specific activity radioiodinated peptide it was possible to establish
directly that with an average of only 3 pep.MHC complexes per target cell, a CD8+ T
cell clone (2C) could be stimulated to make a half-maximal cytolytic response.
Although the levels of Ld expressed on the target cells had a broad distribution, it was
clear (Fig. 3) that there was essentially no preferential lysis of cells having higher than
the average number of Ld molecules. Since the probability of a peptide's binding to Ld
is proportional to the total number of Ld molecules per cell and to the number of
accessible Ld binding sites per cell, the distribution of I 1-QL9-Y5-Ld complexes on the
target cells should match the Ld distribution shown in Fig. 3, with the average number
of 3 cognate pep-MHC complexes per cell corresponding to the position of the weighted
average for total Ld (9h subset) in this figure. The number of complexes on the lysed
cells would thus extend from a low of 1 per cell (3rd subset at the extreme left) to a high
of about 8 (at the extreme right). As seen in the bottom panel of Fig. 3, 67% of the
lysed target cells had 3 or more pep.MHC complexes per cell, but 33% of the lysed
cells had fewer than 3 and 12% had only 1-2 complexes per cell. Given this extremely
low number and the likelihood that pep.MHC complexes are randomly distributed over
the target cell surface, it is likely that a single complex per target cell can render a cell
subject to specific lysis in the 2C system.
Of the directly measured target cell epitope densities required to trigger T cell
activity, the value reported here is the lowest by far. Two parameters that determine
epitope density requirements are the intrinsic affinity of the TcR-pep.MHC reaction and
the stability of the TcR-pep.MHC bond (bond lifetime). As was recently suggested on
the basis of the law of mass action (Sykulev et al., 1995), target cells with epitope
densities of 1-10 pep-MHC complexes per cell can elicit half-maximal cytolytic
responses if the CTL's TcR bind these complexes with an intrinsic affinity of =106 M-1
or higher. Elsewhere we show that the TcR on 2C cells does indeed have such an
affinity for the I1-QL9-Y5.Ld complex (Sykulev et al., in preparation).
How long would a single TcR-pep.MHC bond have to persist to elicit a T cell
cytolytic response? We previously found that the lifetime of the bond formed by the 2C
TcR and the QLSPFPFDL.Ld (QL9.Ld) complex is =1 min under physiological
conditions (intact T cells, 370 C) (Sykulev et al., 1994b). Since peptide I 1-QL9-Y5
behaves very similarly to the QL9 peptide (i.e., it also sensitizes target cells for half-
maximal lysis at 5 pM (Fig. 1) and the I1-QL9-Y5.Ld complex is bound by the 2C TcR
with high intrinsic affinity), it is likely that under physiological conditions the lifetime
of the 2C TcR-I1-QL9-Y5.Ld bond is also around 1 min. For other systems having
lower intrinsic TcR affinities and forming shorter-lived TcR-pep.MHC bonds, higher
epitope densities and a larger number of bonds are probably required.
How can the present findings be reconciled with many previous studies
suggesting that T cell activation requires multivalent ligands to bring about aggregation
or "cross-linking" of TcR molecules on the T cell surface (e.g., Symer et al., 1992)? In
considering the apparent disparity between these findings and ours, we note, first, that
the term "activation" covers a multitude of responses. Some are rapid (minutes to
hours) and do not require transcription of silent genes, while others are slow (requiring
a day or more) and depend upon activation of gene expression. The cytolytic response
is relatively fast (typical assay conditions are 4 hr) and is unaffected by treating the T
cells with inhibitors of transcription or protein synthesis (e.g., Zychlinsky et al., 1991).
That it differs from slow responses, such as cell proliferation or cytokine production, is
evident in "split anergy," whereby an antigen presenting cell lacking costimulatory
components was found to render a CD8+ cytotoxic T cell clone partially anergic, i.e.,
the T cells retained their ability to lyse target cells but proved unable subsequently to
proliferate (a slow response) in response to an effective antigen presenting cell (Otten
and Germain, 1991). Studies in this laboratory have also shown that CTL can be
stimulated under conditions where their cytolytic function is preserved but their
proliferative activity is depressed (Dutz et al., 1992).
A single reactive pep.MHC on a target cell amounts to a monovalent ligand. In
accord with our evidence that such a ligand might trigger a T cell cytolytic response, it
has been reported that an increase in T cell intracellular Ca 2+ concentration, an
extremely rapid response, can be elicited almost as well by the Fab fragment of an anti-
CD3 antibody as by the intact bivalent antibody (Oettgen et al., 1985). It has also been
shown that monovalent Fab fragments from the same anti-CD3 antibody were able to
stimulate IL2 secretion by both syngeneic and allogeneic MHC class II-restricted T cell
clones (Tamura and Nariuchi, 1992). Whether a single pep.MHC on a target cell can be
demonstrated directly to elicit such slow responses is not clear. From the Brower et al.
model (1994) it was deduced that 3-5 pep-MHC complexes could stimulate a T cell to
produce y-INF. However, in that model, class I MHC was adsorbed on plastic to which
relatively long peptides were added (10-15 amino acids in length); whether cytokine
production can be elicited by a similar number of pep-class I MHC complexes in a more
physiological setting remains to be seen.
Although antigen-induced cross-linking and oligomerization of TcR molecules
on the T cell surface are often considered as though they are the same, a distinction
between them emerges from the evidence that a single pep-MHC complex on a target
cell can stimulate a T cell. While a single complex, acting as a monovalent ligand,
cannot literally cross-link T cell receptors, it could conceivably bring about their
oligomerization. That TcR molecules have a propensity to form dimers is suggested by
the recent crystallographic study by Fields et al. (1995), and it can be imagined that
monovalent pep.MHC ligation of a TcR could enhance this tendency, perhaps by
inducing a conformational change in the TcR (e.g., Rojo and Janeway, 1988). In an
analogous situation conformational changes of immunoglobulin resulting from antigen
binding have been demonstrated (e.g., Stanfield et al., 1993).
While a single pep.MHC can react with only a single TcR at any instant, over
time it can engage many of them, reacting repetitively with the same TcR molecule or
serially with many different TcR molecules as recently emphasized by Valitutti et al.
(1995). The number of engagements associated with a given T cell response depends,
in part, on the lifetime of the TcR-pep.MHC bond. The few dissociation rate constants
reported so far indicate that the lifetimes of these bonds range from about 1 to 100 sec
(Sykulev et al., 1994a; Sykulev et al., 1994b; Matsui et al., 1994; Corr et al., 1994), but
how long the bonds have to persist in order to elicit particular responses remains to be
determined.
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Figure legends
Figure 1. Specific lysis of 5 1Cr-labeled T2-Ld target cells in the presence of various
concentrations of peptides p2Ca (LSPFPFDL), QL9 (QLSPFPFDL), and 12711-QL9-Y5,
the monoiodinated form of QL9-Y5 (QLSPYPFDL).
Figure 2. Kinetics of binding of monoiodinated peptide 12511-QL9-Y5 to Ld on T2-Ld
cells at 370 C. A. The rate of binding of 12511-QL9-Y5 at a free peptide concentration of
10-10 M. The increase over time in specific binding of the peptide to Ld is shown by
the filled circles ( 0 ). The solid line represents the best fit of the experimental points
to the theoretical curve described by the single exponential equation for first order
kinetics (see Results for details). Insert: Change in cell-bound radioactivity (cpm) over
time in the presence (0) and absence (•) of a large (10,000-fold molar) excess of the
Ld-binding mouse cytomegalovirus peptide pMCMV. The difference represents
peptide specifically bound to Ld. B. Rate of dissociation of 12711-QL9-Y5 from Ld.
Dissociation was monitored by the loss of peptide-stabilized Ld from the surface of
brefeldin A-treated T2-Ld cells, measured by the disappearance of FITC fluorescence
from antibody-stained cells (see Materials and Methods). The experimental points (U)
were fitted to In (Ft/Fo) = -k 1_" t, where Fo and Ft are the mean fluorescence values on a
linear scale at time zero and time t, respectively. The slope of a plot of In (Ft/Fo) versus
t yielded k-1.
Figure 3. Distribution of Ld and I1-QL9-Y5.Ld complexes on T2-Ld target cells.
Percent of the target cells with different levels of Ld expression is shown for the target
cell populations that were incubated for 4 hr at 370C without the CTL and peptide (the
"initial" population) or with the CTL and the peptide at 5 pM (the "survived"
population). The Ld distribution on the "lysed" cells was determined by difference (see
Materials and Methods). To determine if the distribution shown (upper panel) changed
over 4 hr, target cells expressing low or high Ld levels were sorted, incubated at 370 for
4 hr and examined again (with and without re-staining) by flow cytometry. No change
in distribution in either subset was seen (data not shown).
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Table 1. Peptide binding to HLA-A2 and Ld proteins on T2-Ld cells measured
by enhanced surface expression of these MHC proteins. a
Peptide
concentration
(Rlg/ml)
GILGFVFTL
HLA-A2b
0
0.016
0.08
0.4
2.0
136.4
171
170
177.4
229
QLSPY(I 1)PFDL
LdC
30
26
25
26.07
25.75
HLA-A2b
136.4
NDd
NDd
NDd
172
Ldc
30
53.3
108
172
190
a Mean fluorescence values (linear scale) were determined after 8.5 hr incubation
of T2-Ld cells with the indicated peptides at the concentrations shown.
b Measured using mouse monoclonal antibody PA2.1 (IgG 1, specific for HLA-A2)
and FITC-labeled anti-mouse immunoglobulin.
c Measured using mouse monoclonal antibody 30-5-7 (IgG2a, specific for the al
and a2 domains of Ld) and FITC-labeled anti-mouse immunoglobulin.
d Not done.
--
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CHAPTER 2
Naturally processed peptides recognized by HIV-specific CTL
Overview
The results in the previous chapter showing peptide IV9 to be highly active in
cytotoxicity assays, to bind reasonably well to A2 in appropriate assay systems, and to
form small numbers of peptide*MHC-I complexes when added to target cells at its SD 50
concentration did not provide any information about whether this peptide is actually a
product of antigen processing; that is, can it be detected in HIV-infected target cells?
An answer to this question is a prerequisite for measuring ligand density and attempting
to understand the role of IV9 (or other peptides) in CTL-mediated lysis of infected
target cells.
To approach this problem, we first established new cell lines stably expressing
HIV type 1 (in collaboration with Rick Young and Anna Aldovini). This was necessary
because adding infectious HIV to cell cultures usually only results in a fraction of cells
becoming infected, and these tend to be overgrown by uninfected cells unless fresh
virus is continually supplied. Our strategy was transfection of various human cell lines
with cloned proviral DNA linked to an antibiotic resistance gene (neomycin or
hygromycin). Subsequent selection and maintenance in the presence of antibiotic
ensured a uniformly HIV-expressing population of cells suitable for use as targets in
cytotoxicity assays. Five of the cell lines have been deposited with the NIH AIDS
Research and Reference Reagent Program for future access by other investigators.
The question of ligand density in HIV-infected cells seemed particularly
compelling because of the nature of this infection: as a chronic infection evidently
compatible with long-term cell viability and proliferation, it is distinguished from many
previously studied viral infections (e.g. influenza, vaccinia, Sendai, and vesicular
stomatitis viruses (VSV)), in which host cell protein synthesis shifts toward virus-
encoded products and eventually the infected cells die. Thus, unlike products of lytic
viruses expressed at high levels (e.g. 5-10% of MHC-I sites occupied by a single VSV
peptide (van Bleek and Nathenson, 1990)), HIV-derived products must compete with
the full complement of normal host cell peptides for presentation by a limited number
of MHC-I molecules to CD8+ T cells.
Using two CTL reactive against HIV-infected cells (one specific for reverse
transcriptase (RT) and one for gag), we identified a single naturally processed peptide
recognized by each T cell and determined the absolute abundances of these peptides.
The methodologies, results, and conclusions are given in Tsomides et al., 1994,
reproduced on the following pages. In the end, we found only up to =12 molecules of
peptide IV9 per HIV-infected Jurkat-A2 cell (vs. =400 molecules of gag peptide),
probably accounting for the poor lysis of these target cells by RT-specific CTL (vs.
excellent killing of the same targets by gag-specific CTL). Notably, these two CTL
both recognize uninfected Jurkat-A2 cells pulsed with picomolar concentrations of
synthetic peptides (including peptides not found in extracts of infected cells),
illustrating that such target cell sensitization assays must be interpreted carefully.
Human CTL clones are notoriously difficult to maintain in culture for extended
periods, making longitudinal studies of a particular clone problematic. To circumvent
this predicament, we set out to derive mouse T cell clones specific for HIV and
restricted by A2, with the expectation that mouse CTL would generally be more
amenable to long-term cell culture through the use of known interleukins and other
growth conditions. We immunized A2 transgenic mice (provided by Hidde Ploegh)
with peptide IV9 in complete Freund's adjuvant (details to be elaborated elsewhere) and
eventually obtained several A2-restricted, IV9-specific mouse CTL clones. The
sensitivity of two of these clones (reflected by their SD 50 values) is indicated in the
graph below and compared with that of a human CTL clone having the same specificity.
Of the many issues raised by these preliminary results, one of immediate interest was
whether the mouse CTL could recognize and lyse infected target cells expressing
endogenous levels of antigen; as shown below, good cytolysis was observed using the
human TxB hybridoma cell line T1 as a target. (The density of naturally processed IV9
on T1 cells is estimated to be greater than that on Jurkat-A2 cells by indirect measures
but has not yet been determined because of technical problems in expanding infected T1
cells to the required numbers.)
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Summary
We have established long-term cultures of several cell lines stably and uniformly expressing human
immunodeficiency virus type 1 (HIV-1) in order to (a) identify naturally processed HIV-1 peptides
recognized by cytotoxic T lymphocytes (CTL) from HIV-1-seropositive individuals and (b) consider
the hypothesis that naturally occurring epitope densities on HIV-infected cells may limit their
lysis by CTL. Each of two A2-restricted CD8* CTL specific for HIV-1 gag or reverse
transcriptase (RT) recognized a single naturally processed HIV-1 peptide in trifluoroacetic acid
(TFA) extracts of infected cells: gag 77-85 (SLYNTVATL) or RT 476-484 (ILKEPVHGV). Both
processed peptides match the synthetic peptides that are optimally active in cytotoxicity assays
and have the consensus motif described for A2-associated peptides. Their abundances were 400
and =12 molecules per infected Jurkat-A2 cell, respectively. Other synthetic HIV-1 peptides active
at subnanomolar concentrations were not present in infected cells. Except for the antigen processing
mutant line T2, HIV-infected HLA-A2 + cell lines were specifically lysed by both A2-restricted
CTL, although infected Jurkat-A2 cells were lysed more poorly by RT-specific CTL than by
gag-specific CTL, suggesting that low cell surface density of a natural peptide may limit the
effectiveness of some HIV-specific CTL despite their vigorous activity against synthetic peptide-
treated target cells.
MHC-restricted CTL play a central role in immune re-
sponses against many viruses by destroying virus-
infected cells (1). Unlike antibodies, CD8 + CTL recognize
conserved sequences from intracellular viral proteins in addi-
tion to sequences from virus-encoded cell surface glycopro-
teins (2). CD8+ CTL specific for diverse HIV products
(e.g., gag, pol, nef, env) appear within 1-2 wk of infection,
and the importance of these CTL is suggested by their un-
usually high frequencies: they can often be detected in freshly
isolated PBMC without the in vitro antigenic stimulation
usually required to demonstrate CTL activity in other viral
infections (3-14).
It has been proposed that the CD8 + CTL response to
HIV is one of the main factors contributing to a long asymp-
tomatic period in infected individuals (15, 16). Recent studies
documenting HIV-specific T cells in HIV-exposed but unin-
fected individuals further support a role for these cells in con-
trolling infection (17-19). Yet CTL usually do not succeed
in eradicating HIV (20, 21). Two possible mechanisms for
this failure are viral mutation leading to escape from CTL
recognition (22-25) and altered lymphokine production sec-
ondary to depletion of CD4* T cells. Another possibility
is that the density of many HIV epitopes (i.e., particular
peptide-MHC complexes) on infected cells is too low to trigger
effective lysis of these cells by mature CD8* CTL in vivo.
In considering this third possibility, it is important to dis-
tinguish between acute infection by viruses such as influenza
or vaccinia, in which viral genes are overexpressed at the ex-
pense of host cell protein synthesis, and chronic infection by
HIV, in which cells continue to express their normal com-
plement of self proteins (as evidenced by their ability to grow
and proliferate for long periods; see below). In the latter case,
HIV-derived peptides must compete with a much larger excess
of host cell peptides for presentation by class I MHC
(MHC-I)' proteins to CD8 + T cells. Can a sufficient
I Abbreviations used in this paper: MHC-I,. class I MHC; RT, reverse
transcriptase; SDso, peptide concentration that sensitizes target cells for
half-maximal lysis; TFA, trifluoroacetic acid; VSV, vesicular stomatitis virus.
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number of HIV peptides succeed in occupying MHC-I binding
sites in order to render infected cells good targets for destruc-
tion by CTL? The presence of a vigorous and specific CTL
response in HIV infection implies that the density of HIV
epitopes is sufficient to stimulate the differentiation of
CD8 + precursor T cells into mature CTL (at least on those
cells involved in CTL induction). However, it remains un-
clear whether the number of specific peptide-MHC-I com-
plexes on most HIV-infected cells (i.e., CD4÷ T cells, mac-
rophages) is adequate for efficient killing of these cells by
mature CD8 + CTL.
The density of an HIV epitope on infected cells cannot
be measured without first knowing the precise identity of
the HIV peptide involved. Prior work characterizing HIV
epitopes has relied on vaccinia recombinants (26) and syn-
thetic peptides up to =25 amino acids in length (27, 28).
However, the peptides produced by cellular antigen processing
pathways may or may not be identical to the synthetic pep-
tides used in target cell sensitization assays (29), and so the
exact identities of HIV epitopes in infected cells are not known.
To reveal both the identities and abundances of HIV peptides
presented endogenously by MHC-I molecules, as well as other
properties such as their MHC binding affinities and im-
munogenicities, we have established an assay system based
on several newly developed cell lines that stably and uniformly
express HIV-1 and CTL obtained from HIV-seropositive in-
dividuals.
Materials and Methods
Cells. The following human cell lines were used for transfec-
tions and infections (MHC-I molecules expressed by each cell are
in parentheses): Jurkat (HLA-A9, A25, B7, B41); Jurkat stably trans-
fected with the gene for HLA-A2 and here designated JA2 (kindly
supplied by Dr. Linda Sherman, The Scripps Research Institute,
LaJolla, CA) (30); H9 (HLA-A1, Bw62, Cw6); MOLT4; the TxB
hybridoma T1 (HLA-A2, B5); the antigen processing mutant T2
derived from T1 (both kindly provided by Dr. Peter Cresswell, Yale
University, New Haven, CT) (31); the EBV-transformed B cell line
JY (HLA-A2, B7, Cw7); and the promonocytic cell line U937.
All cell lines were grown in "K" medium (RPMI 1640 supplemented
with 10% heat-inactivated FCS, 10 mM Hepes, 2 mM glutamine,
100 U/ml penicillin, 100 lig/ml streptomycin, and 50 jIM 2-ME).
CTL were derived from PBMC obtained from asymptomatic HIV-
1-seropositive subjects and maintained as described (32, 33).
Transfection with Cloned HIV DNA. The establishment of cell
lines stably expressing HIV-1 proviral DNA was achieved by trans-
fection with plasmid vectors R7neo or R7hyg, modifications of
pHXB2gpt (34) in which selectable marker genes conferring resis-
tance to G418 or hygromycin B, respectively, were inserted in place
of a 255 bp fragment located at the 5' end of the nef gene (35).
The resulting plasmid DNA, which includes the entire HIV-1 ge-
nome except for nef, was purified and linearized by digestion with
XbaI, and transfections were carried out by electroporation as de-
scribed (35). 107 cells (Jurkat, JA2, H9, MOLT4, T1, T2, JY, or
U937) were washed and resuspended in 0.4 ml cold PBS in 0.4-cm
electroporation cuvettes, mixed with 20 1g linearized plasmid DNA,
placed on ice for 5 min, subjected to a single pulse of 250 V, 960jiF (Bio-Rad apparatus; Bio-Rad Laboratories, Hercules, CA), and
returned to ice for 10 min. Measured time constants were 30-40
ms. Cells were then washed and resuspended in K medium for in-
cubation at 37*C in 5% CO2.After 48 h, an aliquot of 200 •l from each culture supernatant
was assayed for HIV-1 production by p24 ELISA (DuPont NEN,
Boston, MA). Depending on the plasmid used, R7neo or R7hyg,
cells were selected with 0.5 mg/ml G418 (GIBCO BRL, Gaithers-
burg, MD) or hygromycin B (Calbiochem-Novabiochem Corp.,
San Diego, CA), a concentration shown to result in the death of
over 50% of untransfected cells within 6 d;JA2 cells already under
selection with 250 jig/ml G418 for A2 expression, were transfected
only with R7hyg and subjected to dual selection. After several weeks
of stable growth and evidence of HIV expression in all cells by
immunofluorescence (see below), cells were maintained and ex-
panded in 162 cm2 cell culture flasks (Costar Corp., Cambridge,
MA) in the presence of 0.25 mg/ml G418 and/or hygromycin B.
HIV-expressing cell lines were named according to the plasmid vector
used: JA2/R7hyg, H9/R7neo, H9/R7hyg, etc.
Immunofluorescence Microscopy and Flow Cytometry. To test for
HIV expression, acetone-fixed cells were stained with a mouse anti-
p24 monoclonal antibody for 30 min at room temperature (36).
After the slides were washed with PBS, cells were incubated with
the F(ab')2 fragment of FITC-conjugated goat anti-mouse IgG
(Cappel Laboratories, Durham, NC or Sigma Chemical Co., St.
Louis, MO) for 30 min at room temperature in the dark. Cells
were then washed, counterstained with 0.5% Evans blue dye in
PBS (Sigma Chemical Co.) for 10 min, washed again, and exam-
ined under a fluorescent microscope. For purposes of visualizing
all cells and calculating the proportion of cells expressing HIV, cells
that had been stained with anti-p24 and FITC-conjugated anti-
bodies were also examined by phase contrast.
All cells were checked to confirm A2 status before transfection
and, for A2* cells, several weeks after being grown under selec-
tion for HIV expression. 5 x 10s cells were stained with 1 jIg
of the anti-A2 monoclonal antibody PA2.1 and with 5 Ag of the
F(ab')2 fragment of FITC-conjugated goat anti-mouse IgG (Pierce
Chemical Co., Rockford, IL) and were then analyzed on an EPICS
C cytofluorimeter (Coulter Corp., Hialeah, FL) or by fluorescence
microscopy (for HIV* cells). CD4 expression before transfection
was also determined using an anti-human CD4 monoclonal anti-
body (Becton Dickinson & Co., Mountain View, CA).
Pepride Synthesis and Chromatogmphy. All peptides were synthe-
sized by standard t-Boc chemistry on a peptide synthesizer (model
430A; Applied Biosystems, Inc., Foster City, CA), analyzed by re-
verse phase HPLC and amino acid analysis, and found to be highly
pure. Peptides were named according to the protein source (gag
or reverse transcriptase [RT]), the first and last amino acid residues,
and the peptide length, e.g., gag-SL9 - SLYNTVATL and RT-
IV9 - ILKEPVHGV. Peptide concentrations measured by Micro
BCA Assay (Pierce Chemical Co.) ranged from 10 to 100% of the
concentrations calculated from dry weights; for peptides gag-SL9
and RT-IV9, precise concentrations were determined by quantita-
tive amino acid analysis. HPLC separations of synthetic peptides
were performed using a 4.6 x 250 mm C18 reverse phase column
(model 218TP104; VYDAC, Hesperia, CA). The gag peptides were
separated on a gradient of 0.25% B/min at a flow rate of 1 ml/min,
with A - 0.1% trifluoroacetic acid (TFA) (Pierce Chemical Co.)
in HzO and B - 0.1% TFA in isopropanol, and the RT peptides
were separated on a gradient of 1% B/min at a flow rate of 1 ml/min,
with A - 0.1% TFA in H20 and B - 0.085% TFA in
acetonitrile.
Natural Peptide Extraction and Fractionation. Cultured cells were
harvested by centrifugation, washed with cold PBS, and stored in
batches of 109 at -70*C. Cells were lysed by adding 15 ml 1%
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aqueous TFA on ice (and additional TFA if needed to bring the
pH below 2), and douncing with 50 strokes. The material was trans-
ferred to a Centriprep 10 ultrafiltration device (Amicon Corp.,
Beverly, MA) and subjected to centrifugation at 2,600 g for several
hours at 40C (37). The ultrafiltrate (molecular mass <10 kD) was
removed (>12 ml), an equal volume of 1% TFA was added to the
retentate, and centrifugation was repeated twice in order to max-
imize the recovery of extracted peptides. Pooled filtrates were dried
by lyophilization and redissolved in 0.1% TFA for fractionation
by HPLC using the conditions described above for either the gag
or the RT peptides. 40 fractions were collected at 1 min intervals
in presiliconized microfuge tubes, dried by SpeedVac (Savant In-
struments, Inc., Farmingdale, NY), and redissolved in H20 with
vortexing.
Cyto icityAssay. CTL assays were performed as described (38),
using SCr-labeled 115EBV cells (an autologous EBV-transformed
B cell line) for CTL line 115Ip, or "1Cr-labeled JY cells for CTL
clone 68A62 when testing synthetic peptides or HPLC fractions.
Results
Establishment of Long-term Cell Lines Stably and Uniformly
Expressing HIV-1. Several human cell lines were chosen for
transfection with HIV-1 proviral DNA linked to a drug re-
sistance gene, including T cells (Jurkat, JA2, H9, and
MOLT-4), a TxB hybrid (T1) and its derivative antigen pro-
cessing mutant cell line (T2), an EBV-transformed B cell line
(JY), and a promonocytic cell line (U937). 2 d after transfec-
tion of each line by electroporation with plasmid R7neo or
R7hyg (35), cell culture supernatants were shown to contain
the HIV-1 p24 core antigen by ELISA. Selection was initi-
ated either at this time or 3 wk later in order to permit infec-
tion of untransfected cells with virus produced by success-
fully transfected cells in the same culture; such infected (as
opposed to transfected) cells also acquired the drug resistance
gene. For convenience, HIV-expressing cell lines are referred
to as HIV-infected even though they may include both trans-
fected and infected cells. After several weeks during which
fresh medium was supplied two to three times per week, all
eight cell cultures were found to be 100% HIV' by p24 im-
munofluorescence (Fig. 1).
JA2/R7hyg (JA2 cells transfected with plasmid R7hyg)
and H9/R7neo were readily expanded to >10 liters over a
period of several weeks by maintaining the cells in log phase.
They have remained HIV + for over 1.5 yr, showing that
HIV expression is compatible with long-term cell viability
and proliferative activity, at least under special circumstances.
H9/R7hyg, Jurkat/R7hyg, and T1/R7hyg were also main-
tained and expanded for several months, whereas MOLT-
4/R7hyg, JY/R7hyg, and U937/R7hyg grew more slowly,
possibly reflecting their greater susceptibility to cytopathic
effects of the virus and the gradual emergence of variants resis-
tant to these effects. Only T2/R7hyg suffered steadily
declining viability, and these cells did not survive beyond a
few months despite evidence of successful transfection and
initial selection of an HIV- population. In light of CD4-
dependent syncytia formation as a mechanism for HIV-
mediated cytopathicity (39), the high CD4 levels in T2 cells
(70-80% higher than TI and U937, the next highest) were
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considered a possible explanation for the singular failure of
these cells to survive infection. However, when T2 cells were
first sorted by FACSO (Becton Dickinson & Co.) for a
CD41ow subset (stable for at least 1 mo at a level 30-40%
higher than T1) and then transfected, the resulting T2/R7hyg
was still only a short-term cell line. Nevertheless, these cells
were uniformly HIV* and could be tested as targets for lysis
by specific CTL along with the other stably transfected lines.
Lysis ofHIV-infected Cel Lines by HIV-specific CTL. HIV-
infected cells were tested as targets for direct lysis by several
HIV-specific CD8" CTL, including the A2-restricted gag-
specific line 115Ip and the A2-restricted RT-specific clone
68A62. CTL line 115Ip readily lysed the A2* HIV-infected
target cells JA2/R7hyg, JY/R7hyg, and T1/R7hyg but not
their untransfected counterparts (Fig. 2, A-C). CTL clone
68A62 specifically lysed target cells T1/R7hyg and JY/R7hyg
(to a lesser extent), but JA2/R7hyg was hardly lysed more
than uninfected JA2 cells (Fig. 2, E-G). The fourth available
A2* HIV-infected target cell, T2/R7hyg, is a mutant cell
line lacking genes for the peptide transporter subunits TAP-1
and TAP-2; it was not lysed by CTL 115Ip despite high levels
of p24 expression (Fig. 2 D). Consistent with this result,
previous studies showed that T2 cells infected with influenza
virus, vaccinia virus, or vesicular stomatitis virus (VSV) failed
to present known viral epitopes to appropriate CD8 + CTL
(40-43); however, these same cells were shown to present
epitopes from Sendai virus (43), HIV-1 env (44), and minigene
expression vectors encoding certain viral peptides (45), ap-
parently via a TAP-independent pathway for loading MHC-I
molecules with cytosolic peptides. Failure to detect lysis of
T2/R7hyg cells under conditions where T1/R7hyg and other
HIV+ cells were efficiently lysed suggests that the TAP
pathway is required for normal presentation of the gag pep-
tide recognized by CTL 115Ip.
Identification of the Optimal Synthetic Peptides Recognized by
Two HIV-specific CTL. Two sets of peptides based on previ-
ously described gag (33, Johnson, R. P., unpublished data)
and RT (32, 38) sequences were synthesized and tested for
their ability to sensitize uninfected A2 target cells for lysis
by the A2-restricted CTL 115Ip and 68A62, respectively. The
peptide with the lowest peptide concentration that sensitizes
target cells for half-maximal lysis (SDso) value (38), i.e., pep-
tide concentration giving 50% of maximal specific lysis, was
defined as the optimal synthetic peptide for each CTL. Results
for CTL 115Ip are shown in Fig. 3 A. Peptides gag-SL9 and
gag-RL10 were both active at picomolar concentrations, and
gag-SL9 consistently had the lowest SDso (=30 pg/ml). The
closely related 9-residue peptides gag-LY9 and gag-RT9 were
10,000-fold less active than gag-SL9, although at micromolar
concentrations even these peptides resulted in >50% specific
lysis of A2 target cells. For CTL clone 68A62, SDso data
from the screening of 18 synthetic peptides derived from RT
residues 469-485 were previously tabulated (38), and some
of the titrations are shown in Fig. 3 B. RT-IV9, the optimal
synthetic peptide for this CTL clone (SDso =1 pg/ml), was
previously shown to associate tightly and specifically with
target cell A2, dissociating with a half-life of 200-600 h (as
its iodinated derivative).
Figure 1. Lymphocyte cell lines transfected with
' HIV-1 DNA stably and uniformly express viral an-
tigen while continuing to proliferate. Cells were
transfected with plasmid R7hyg, grown m the pres-
ence of hygromycmn B for at least 1 mo, and stained
with anti-p24 monoclonal antibody and FITC-
labeled secondary antibody as described in Matenals
and Methods. For each cell line, a single field is
visualized by fluorescence (left) and phase contrast
(right) microscopy. Cell lines shown are JA2/R7bhyg
(A and B), H9/R7hyg (C and D), T1/R7hyg (E
and F), and JY/R7hyg (G and H). For H9/R7hyg
cells, HIV-mnduced syncytia can be seen. Untrans-
fected control cells exhibited no fluorescence under
the staining conditions used.
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Figure 2. HIV-expressmng cell lines are susceptible to lysis by HIV-specific
CTL. Cytotoxicity assays were carned out using the gag-specific CTL
0 line 115Ip (A-D) or the RT-specific CTL clone 68A62 (E-G) and the
s
tCr-labeled target cells indicated at the top of each panel. Lysis of T2
cells by CTL clone 68A62 was not tested. Target cells were either untrans-
fected (0) or had been transfected with plasmid R7hyg at least 1 mo be-
fore and were uniformly positive for HIV expression by p24 immunofluores-
cence (S). In addition, the Bw62-restncted gag-specific CTL lines 35C18
and 35C44, obtained by stimulating PBMC from an HIV-1-seropositive
individual with the 25-residue peptide p17/2 (33), efficiently lysed
H9/R7hyg cells but not untransfected H9 cells (not shown).
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Figure 3. Synthetic peptides define the optimal epitopes recognized by
HIV-specific CTL. Cytotoxicity assays were carried out with (A) the gag-
specific CTL line 1151p and s5 Cr-labeled autologous 115EBV target cells
or (B) the RT-specific CTL clone 68A62 and szCr-labeled JY target cells.
Various concentrations of the synthetic peptides shown were added to target
cells for 1 h at 370C and remained in the assay during the 4-h incubation
of CTL and target cells. Cells were then pelleted and supernatants were
assayed for s5Cr release. All peptides were negative for toxicity (<5%
specific lysis) and were titrated at least twice, with results always within
one order of magnitude. Also tested with CTL 115Ip, but not shown,
were gag peptides LL8, RT9, and ST8, each of which was less active than
gag-LY9. SDso values (peptide concentrations giving 50% of maximal
specific lysis [38]) for the optimally active synthetic peptides gag-SL9 (A)
and RT-IV9 (B) were 30 pg/ml and 1 pg/ml, respectively.
Identification of Two HIV-1 Peptides Produced by Endogenous
Antigen Processing in Infected Cells. To identify the naturally
processed HIV-1 peptides present in HIV-infected cells,
JA2/R7hyg cells were expanded to several liters, and MHC-
bound peptides were isolated by TFA extraction, ultrafiltra-
tion, and reverse phase HPLC fractionation. When the HPLC
fractions were added to uninfected A2 target cells in cyto-
toxicity assays, only a single HPLC fraction had sensitizing
activity for each of the two A2-restricted HIV-specific CTL
examined: fraction 41 for CTL 115Ip (Fig. 4 A) and fraction
32 for CTL 68A62 (Fig. 5 A).
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Figure 4. HIV-expressing cell line JA2/R7hyg produces a single pep-
tide, gag-SL9, for recognition by CTL line 115Ip. (A) 109 JA2/R7hyg
(e) or untransfected JA2 (0) cells were lysed in 1% TFA, homogenized
by douncing, subjected to ultrafiltration in order to isolate a peptide-
containing fraction (<10 kD), and fractionated by C18 HPLC using a gra-
dient of 0.25% isopropanol per min at a flow rate of I ml/min. Fractions
were collected at 1 min intervals, dried, and tested for their ability to sen-
sitize siCr-labeled 115EBV target cells for lysis by CTL 1151p in a 4-h
cytotoxicity assay. Toxicity controls consisting of target cells incubated
with each fraction in the absence of CTL were negative (not shown). (B)
HPLC retention times of the synthetic peptides that can be recognized
by CTL 115Ip are shown under the same chromatographic conditions used
in A. In addition, gag peptides ST8 and RT9 both eluted in fraction 19,
which does not correspond to an active fraction from TFA-extracted
JA2/R7hyg cells.
To identify the active peptides in these fractions, their reten-
tion times were compared with those of all the synthetic pep-
tides that could be recognized by the same CTL. Under an
appropriate set of HPLC conditions (column, solvents, gra-
dient, etc.), peptides differing even slightly in length or se-
quence can be resolved and therefore differentiated based on
characteristic retention times. Thus, of all the active synthetic
gag peptides tested using CTL 115Ip (including all possible
8-, 9-, and 10-mers contained within a longer active syn-
thetic peptide), only gag-SL9 eluted in fraction 41 under the
same HPLC conditions used for the JA2/R7hyg cell extract
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Figure 5. HIV-expressing cell line JA2/R7hyg produces a single pep-
tide, RT-IV9, for recognition by CTL 68A62. (A) 109 JA2/R7hyg cells
were lysed in 1% TFA and prepared as described in Fig. 4 A. except that
HPLC fractionation was performed using a gradient of 1% acetonitrile
per min. Fractions were added to SlCr-labeled JY target cells and tested
for toxicity (A) and for lysis by CTL 68A62 (0). (B) HPLC retention
times of the synthetic peptides that can be recognized by CTL 68A62
are shown under the same chromatographic conditions used in A.
(Fig. 4 B), indicating that the peptide recognized by CTL
115Ip on the surface of HIV-infected cells is gag-SL9. Simi-
larly for CTL 68A62, only synthetic peptide RT-IV9 had
the same retention time as the active HPLC fraction isolated
from JA2/R7hyg cells (Fig. 5 B), indicating that CTL 68A62
recognizes RT-IV9 on HIV-infected cells.
The Abundanceof Two NaturallyProcessed HIV-1 Peptides. To
measure the abundance of the naturally processed peptide gag-
SL9, 109 JA2/R7hyg cells were lysed and treated as de-
scribed above, and the active HPLC fraction was titrated in
a cytotoxicity assay using CTL 115Ip. As shown in Fig. 6
60
50
40
30
20
10
-13 -12 -11 -10 -9 -8 -7
log peptide concentration (g/ml)
32 34 36 38 40 42 44 46 48 50
HPLC fraction number
Figure 6. Each JA2/R7hyg cell contains approximately 400 molecules
of peptide gag-SL9. (A) 109 JA2/R7hyg cells were lysed in 1% TFA and
prepared as described in Fig. 4 A. The active HPIC fraction recognized
by CTL 115Ip was titrated in a standard cytotoxicity assay using 5sCr-
labeled JY target cells. Percent specific lysis values obtained using 10' or
108 JA2/R7hyg cell equivalents per well (i.e., 1 or 10% of the active frac-
tion) are indicated by arrows on a standard curve performed with syn-
thetic peptide gag-SL9 and JY target cells in the same assay. The calcu-
lated recovery was '--100 gag-SL9 molecules per JA2/R7hyg cell. (B) 109
untransfected JA2 cells were lysed as described (open cirles) or were fist
"spiked" with 100 pg synthetic gag-SL9 (solid triangles) or 1 ng gag-RL10
(solid squares). From a comparison of percent specific lysis values due to
TFA-extracted cells and standard curves for each of these synthetic pep-
tides, their overall yields for all steps from cell lysis through cytotoxicity
assay were found to be 25 and 30%, respectively.
A, the amount of peptide recovered from 107 or 108
JA2/R7hyg cells gave 19 or 50% specific lysis, respectively.
These values, compared with the standard curve from a cyto-
toxicity assay carried out under identical conditions with syn-
thetic gag-SL9, correspond to a recovery of =100 peptide mol-
ecules per JA2/R7hyg cell. To estimate the overall efficiency
of peptide recovery, a "spiking" experiment was performed
in which 100 pg synthetic gag-SL9 was added to 109 un-
transfected JA2 cells. Subsequent extraction and fractionation
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steps were identical to the treatment ofJA2/R7hyg cells, cul-
minating in cytotoxicity assay of HPLC fractions using CTL
115Ip (Fig. 6 B). From the percent specific lysis due to either
5 or 20% of the sample in fraction 42 (5 pg or 20 pg if the
overall yield was 100%), comparison to a standard curve for
synthetic gag-SL9 led to an estimated 25% overall yield (e.g.,
20% of the sample gave 33% specific lysis, corresponding
to 5 pg synthetic gag-SL9 on a standard curve generated in
the same assay; standard curve not shown). Similarly, for syn-
thetic gag-RL10 added to untransfectedJA2 cells, the overall
yield was 30%. Since even a very tightly A2-binding peptide
(radiolabeled RT-IV9) completely dissociated from A2 after
60 min of exposure to 1% TFA (38), the calculated yield
likely reflects all steps in the isolation of naturally processed
gag-SL9, including the release of peptide from preexisting
peptide-MHC complexes.
The abundance of naturally processed peptide RT-IV9 was
established similarly by comparison with a standard curve
of synthetic RT-IV9. The amount of peptide recovered from
2 x 108 JA2/R7hyg cells gave the same degree of lysis as
6 x 101 molecules of synthetic RT-IV9 when added to
uninfected A2÷ target cells (i.e., a synthetic peptide concen-
tration of 5 x 10-12 M in a total volume of 200 /l; not
shown). Therefore only =3 molecules of RT-IV9 per HIV-
infected cell were recovered, for a calculated abundance of
=12 molecules per infected cell (assuming a similar overall
yield to gag-SL9 and gag-RL10).
U)
C)
0)
0P(/3
20 22 24 26 28 30 32 34 36 38 40 42 44
HPLC fraction number
Figure 7. Generation of peptide gag-SL9 in HIV-expressing cells is in-
dependent of HLA-A2. JA2/R7hyg cells (solid circles). H9/R7neo cells (solid
triangles), or untransfected JA2 cells (solid squares) were lysed in 1% TFA
and prepared as described in Fig. 4 A. Fractions were tested for their ability
to sensitize S:Cr-labeled 115EBV target cells for lysis by CTL 1151p in
a 4-h cytotoxicity assay. Toxicity controls consisting of target cells incubated
with each fraction in the absence of CTL are included (corresponding empty
symboh). H9/R7neo cells are HLA-A2 -. Retention time of the active frac-
tion does not agree precisely with Fig. 4 A because a different C18 column
was used for this separation. Untransfected JA2 cells fractionated before
H9/R7neo gave no activity, ruling out contamination of the HPLC column.
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Expression ofan HLA-A2-binding HIV-1 Peptide Occurs In-
dependently ofHLA-A2. Given numerous findings by Ram-
mensee et al. (46) that peptides recognized by CTL accumu-
late to detectable levels only in cells expressing the restricting
MHC molecule, we were surprised to find a strong peak of
activity corresponding to gag-SL9 in TFA extracts of the
A2- infected cell line H9/R7neo (Fig. 7). However, it re-
mains unknown whether gag-SL9 binds to a different HLA
molecule expressed by H9 cells, e.g., HLA-A1, Bw62, or Cw6.
Discussion
The reasons for incomplete elimination of HIV-infected
cells by CTL in vivo are not yet understood (20, 21). One
possibility is that high mutation rates in viral proteins could
impair recognition and lysis of infected cells by virus-specific
CTL (22), much as mutations in viral surface glycoproteins
can result in escape from antibody recognition (47). To date,
evidence both for and against the emergence of CTL escape
mutants in HIV infection has been published (23, 24, 48,
49). Another mechanism for diminished CD8' CTL ac-
tivity in HIV infection may be altered lymphokine produc-
tion by "helper" T cells as a result of steadily declining
CD4÷ T cell counts and aberrant CD4+ T cell function
in infected individuals. However, some individuals with
low CD4 + T cell levels retain vigorous CTL activity (50);
furthermore, intact CD8 ÷ CTL function in CD4-deficient
"knockout" mice argues against an absolute dependence of
CTL on CD4+ T cells (51). Here we raise a third possi-
bility: CTL of HIV-infected individuals may be incompletely
effective in eradicating the virus because of a paucity of viral
epitopes expressed on infected cells.
When cells are infected by lytic viruses (including influenza,
vaccinia, Sendai, and VSV), host cell protein synthesis shifts
toward virus-encoded products at the expense of endogenous
("self') protein synthesis. This overproduction of viral pro-
teins gives rise to relatively high levels of viral peptides, which
in turn form high cell surface densities of peptide-MHC-I
complexes and facilitate lysis of the infected cells by virus-
specific CTL. Accordingly, previous studies of naturally
processed viral peptides seen by T cells have made use of lyti-
cally infected cells (52-54). However, infection by HIV (or
by certain other viruses, such as EBV and CMV) can result
in chronic expression of viral proteins for months or years,
along with the full complement of normal self proteins neces-
sary for cell viability and function. In these cases, a relatively
small number of viral proteins (i.e., =10 for HIV) must com-
pete with all the proteins normally expressed in a cell (per-
haps 5,000-10,000) for presentation by a limited number of
MHC-I proteins to CD8* T cells. Can HIV-derived pep-
tides compete with such a vast excess of self peptides and
occupy sufficient numbers of MHC-I binding sites to result
in effective killing of HIV-infected cells by CTL?
Previous studies of peptides recognized by HIV-specific T
cells have relied on vaccinia virus recombinants containing
HIV genes or gene segments and synthetic peptides corre-
sponding to HIV sequences (27, 28). While these studies
have led to the delineation of numerous T cell epitopes, oper-
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ationally defined as synthetic peptides that trigger T cell ac-
tivities in vitro, and to the identification of candidate pep-
tides for vaccine trials (55), little is known about which of
these peptides are actually generated within HIV-infected cells,
their respective abundances, or their likely importance in the
anti-HIV CTL response.
To reveal the identities and abundances of HIV-1 peptides
expressed by infected cells and recognized by HIV-specific
CTL, we developed a panel of stably HIV-infected cell lines
from which naturally processed peptides could be isolated
directly. Adding infectious HIV-1 directly to CD4+ cells as
a method of establishing infection tends to result in cultures
which are only partially infected and which are difficult to
sustain, presumably due to cytopathic effects of the virus.
Therefore to obtain cultures in which all of the cells are produc-
tively infected and can be expanded to large numbers, we
introduced the viral genome by transfection of cloned proviral
DNA containing the entire HIV-1 genome except for nef,
which is not required for viral replication in cell culture and
which was replaced by an antibiotic resistance gene (neomycin
or hygromycin) (35). Cell cultures under continuous antibi-
otic selection were uniformly HIV+ (Fig. 1) and were ex-
panded to many liters while continuing to express HIV for
long periods (over 1.5 yr for JA2/R7hyg and H9/R7neo).
Establishment of the infected B cell line JY/R7hyg, CD4-
by flow cytometry, was also made possible by this technique
of transfection and direct selection. Other HIV-infected A2-
negative cell lines have previously been established for var-
ious studies, including derivatives of A3.01, H9, HeLa-T4+,
and U937 cells (56).
The RT-specific CTL clone 68A62 lysed cell lines
T1/R7hyg and JY/R7hyg reasonably well, but hardly lysed
JA2/R7hyg even at a CTL/target cell ratio of 50:1. Since
JA2/R7hyg was lysed well by CTL 115Ip, these results sug-
gested that levels of the naturally processed peptide(s) seen
by 68A62 may be low on JA2/R7hyg cells. To address this
issue directly, we applied techniques described by Rammensee
et al. (46) to determine the precise identity and abundance
of this naturally processed peptide(s). Briefly, HIV-infected
target cells were treated with TFA, the extracted peptides
were fractionated by reverse phase HPLC, and individual frac-
tions were added to uninfected A2+ cells for cytotoxicity
assay. Because the naturally processed peptides from, say, 108
cells can be loaded onto 104 A2+ target cells in a cytotox-
icity assay, the sensitivity of peptide detection is amplified
by as much as 10,000-fold (or even more if more cells are
extracted, subject to solubility and toxicity limitations). An-
other advantage of this assay system is that both A2* and
A2- infected cells can be examined for the presence of a par-
ticular peptide, since A2+ target cells are used in the final
assay (e.g., Fig. 7). Because the retention time of a given peptide
under well-defined HPLC conditions is highly reproducible,
comparison with synthetic peptide standards allows the nat-
urally processed peptide(s) to be identified and quantitated.
(In contrast, the amount of peptide recovered from 108-1010
cells is typically in the low or subfemtomole range, well below
what is usually required for direct chemical sequencing by
Edman degradation or mass spectrometry.) By these methods
it was established that the single naturally processed peptides
recognized by CTL 115Ip and 68A62 were gag-SL9 and RT-
IV9, respectively (Figs. 3-5). Both peptides matched the op-
timally active synthetic peptides recognized by these CTL,
and both conform to the A2 consensus motif (57).
The abundance of naturally processed gag-SL9 was found
to be =400 molecules per infected cell by measuring the
recovery of this peptide from JA2/R7hyg cells (=100 mole-
cules/cell) and the efficiency of the isolation procedure (25%)
(Fig. 6). Assuming that half the losses are associated with
the HPLC step (50% yield), repeated rounds of HPLC frac-
tionation will result in much more severe losses. For example,
the purification of two overlapping peptides from the en-
zyme a-ketoglutarate dehydrogenase that are recognized by
an alloreactive CTL clone was accomplished by five (58) or
six (59) successive HPLC rounds before sequencing; if each
round was associated with a 50% yield, the cumulative yield
would have been only 1-3%. In this scenario, the natural
abundance of these two peptides is far greater than that of
the HIV-1 gag peptide reported here: since =400 (58) or 7,000
(59) peptide molecules per allogeneic cell were actually re-
covered, their abundances are likely to be as high as 12,000
and 400,000 molecules per cell, allowing for the expected
yields. Such high abundances of naturally processed peptides
in the alloreactive system may result from high levels of their
precursor, a normal cell protein, and probably account for
the appearance of a family of peptides rather than the single
peptide seen by two HIV-specific (as well as other virus-specific
[52-54]) CTL.
The extent oflysis by CTL 115Ip (as much as 80% specific
lysis ofJY/R7hyg target cells) indicates that HIV-1 peptides
can compete with the myriad self peptides generated in the
same cells for binding to MHC-I proteins and transport to
the cell surface. In fact, the levels of gag peptide (=400 mol-
ecules per infected cell) were not much lower than the recov-
eries of two influenza peptides from influenza virus-infected
cells (220-540 molecules/cell, uncorrected for extraction efficien-
cies [60]), despite the significantly different nature of the two
infections (lytic vs. chronic). For VSV-infected cells, however,
van Bleek and Nathenson reported that 5-10% of MHC-bound
peptides were of viral origin, and that these were dominated
by a single octamer, implying a significantly higher abundance
in this system (52). A naturally processed Listeria monocytogenes
peptide epitope similarly was present at >3,000 copies per in-
fected cell (61). But in cells transfected with the ovalbumin
gene and recognized by ovalbumin-specific CTL, only =100
molecules of a sensitizing ovalbumin peptide were recovered
(no correction for extraction efficiency) (62).
In contrast to CTL 115Ip, CTL 68A62 exhibited lower
levels of activity against HIV-infected target cells, and lysed
JA2/R7hyg only poorly even though the optimally active
peptide RT-IV9 was shown to be present in these same cells.
This result can be explained by the relatively low abundance
of RT-IV9 on JA2/R7hyg cells (=12 molecules per cell), con-
sistent with the 10-20-fold lower expression of RT than gag
protein in HIV-infected cells due to a ribosomal frameshift
required for RT expression (63). Since growth ofJA2/R7hyg
cells under selective pressure for HIV expression might have
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resulted in higher than normal levels of HIV-1 peptides, RT-
IV9 could be even more sparse on naturally infected cells.
T1/R7hyg cells, which are lysed better than JA2/R7hyg cells
by CTL 68A62, probably have a higher epitope density, as
suggested by higher levels of p24 antigen (not shown) and
by the fact that uninfected T1 and JA2 cells are similarly sen-
sitive to exogenous RT-IV9 (SDso = 10-20 pg/ml). Thus,
in spite of the extreme sensitivity of CTL 68A62 to synthetic
RT-IV9 (Fig. 3 B) and the demonstration of RT-IV9 in
JA2/R7hyg cell extracts (Fig. 5), CTL 68A62 lyses
JA2/R7hyg cells inefficiently (relative to their lysis by CTL
115Ip, Fig. 2), emphasizing the critical role of epitope den-
sity in lysis of these infected target cells and raising a serious
question as to the likely effectiveness of this CTL clone in vivo.
In this context it is worth noting that when synthetic pep-
tides are added to target cells in cytotoxicity assays, very high
peptide concentrations are often used, e.g., 10-100 pM. At
such concentrations, peptides with even modest affinities for
the restricting MHC molecule (KA = 106-108 M- 1) will oc-
cupy a large fraction of available MHC binding sites at equi-
librium (>99%), resulting in far greater numbers of specific
peptide-MHC complexes than the few hundred per cell often
seen for naturally processed peptides (53, 60, 62, 64). For
example, JY cells have =10,000 A2 molecules available for
binding to exogenous peptides (38), so peptide RT-IV9 (equi-
librium constant for binding to A2 =107 M-' [Kageyama
et al., manuscript submitted for publication]) will form up
to 10,000 peptide-MHC complexes per target cell when added
at micromolar concentrations. Similarly, other synthetic pep-
tides can efficiently sensitize target cells by loading cell sur-
face MHC-I molecules even though these peptides are not
detectable in infected cells and are therefore not actually rele-
vant to the immune response (e.g., gag-RL10, RT-EV10).
Thus epitope identification based on synthetic peptides, while
useful as a preliminary guide, may not accurately represent
CTL-target cell interactions as they occur in vivo.
Overall, our results suggest that HIV-infected cells can
be good targets for lysis by HIV-specific CTL, but that CTL
effectiveness depends critically upon epitope density: the RT-
specific clone 68A62 exhibited poor killing of a target cell
(JA2/R7hyg) that was shown to express only a few copies
per cell of the optimally active peptide. Because the affinities
of antigen-specific T cell receptors for their peptide-MHC
ligands are likely to influence the density of epitopes required
for efficient lysis of target cells, it is still possible that CTL
bearing high-affinity receptors may lyse infected target cells
having very low epitope densities (Kageyama et al., manu-
script submitted for publication; and Sykulev et al. [64a]);
however, no information is currently available regarding T
cell receptor affinities for HIV-specific CTL. The outcomes
of adoptive therapy trials using CTL in HIV-infected humans
(65, 66) may therefore depend on T cell receptor affinities
as well as on the numbers and specificities of the CTL used.
The most effective CTL against HIV-infected cells ultimately
may be those that can recognize the most abundant natu-
rally processed HIV epitopes; using the stably infected cell
lines described here, it should be possible to identify and quan-
titate these epitopes.
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CHAPTER 3
Naturally processed peptides recognized by an alloreactive CTL clone
108
Overview
Alloreactions, in which T cells of a given haplotype respond to target cells of the
same species expressing one or more different MHC products ("allogeneic"), have long
been of interest both because of their importance in graft rejection and because of an
arresting puzzle: the frequency of alloreactive T cells is at least 100 times greater than
that of T cells specific for a conventional foreign antigen, e.g. one encoded by a virus
(Fischer Lindahl and Wilson, 1977; Teh et al., 1977). Two contrasting models were
proposed to account for this phenomenon. In one, the large number of alloreactive T
cells was thought to reflect recognition of a multitude of specific antigens (not yet
known to be peptides) in combination with MHC products (Matzinger and Bevan,
1977). In the other model, a high cell surface density of allogeneic MHC molecules (ca.
105 per target cell, vs. many fewer for a conventional foreign antigen) permits T cells
with low affinity receptors to respond directly to MHC molecules independently of any
specific foreign antigens (Bevan, 1984).
At the outset of the work described in this chapter, one goal was to establish
whether the alloreaction mediated by a well-characterized CD8+ T-cell clone (termed
2C; Kranz et al., 1984a, b; Saito et al., 1984a, b; Sha et al., 1988a, b) is dependent upon
peptides (as components of peptide*MHC-I complexes) or whether MHC-I molecules
devoid of peptides can trigger allorecognition. Studies in which HPLC fractions from
extracts of allogeneic cells were capable of sensitizing target cells for allorecognition
(Heath et al., 1989, 1991; R6tzschke et al., 1991b; Heath and Sherman, 1991) had
provided evidence for the first view, but no specific peptide sequences were known to be
involved in MHC-I-restricted alloreactions.
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CTL clone 2C, derived from an H-2b mouse immunized with H-2d cells, was
known to lyse Ld+ target cells such as the mastocytoma cell line P815 (Kranz et al.,
1984a). Screening other Ld+ cells as targets for 2C led to the identification of certain
cell lines killed only poorly by 2C but killed well by other peptide-specific, Ld-
restricted CTL (in the presence of appropriate peptides). Combined with HPLC
fractionation of Ld+ cells (either whole cell extracts or extracts of affinity-purified Ld
molecules), a scheme was now available for purification of the peptide(s) responsible
for allorecognition by CTL clone 2C (Udaka et al., 1992; see figure, p. 37). Tissues
(spleen, thymus, and later liver and others (Wu et al., 1995; see p. 150)) proved to be
better sources of peptide than cultured cells, and ultimately the sequence of an
octameric peptide was obtained from 263 H-2d mouse spleens by purifying the peptide
to homogeneity through 5 rounds of HPLC under different conditions. Approximately
5-7 pmoles of purified peptide were isolated, just enough for sequence determination by
a combination of Edman degradation and mass spectrometry (Udaka et al., 1992). An
ambiguity at the C-terminus, either leucine or isoleucine, could not be resolved by these
analytical methods, so two peptides were synthesized: p2CL (LSPFPFDL) and p2CI
(LSPFPFDI). Peptide p2CL (later renamed p2Ca) was chosen as the naturally occurring
sequence because: (1) its HPLC retention time agreed with the biological material
(p2CI eluted =1 min earlier); and (2) it was more active in cytotoxicity assays than p2CI.
Although still formally possible that p2Ca confers upon Ld a conformation
which enables it to be recognized by the 2C TcR without any direct contact between
TcR and peptide, an interpretation eagerly promoted by one reviewer of the Udaka et al.
manuscript, the weight of crystallographic evidence from three-dimensional structures
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of MHC-I molecules containing mixtures of peptides (Bjorkman et al., 1987a; Garrett et
al., 1989) or single peptides (Fremont et al., 1992; Zhang et al., 1992; Silver et al.,
1992; Madden et al., 1993), together with the observation that other strongly Ld-binding
peptides do not elicit recognition by the 2C TcR, strongly favors the view that p2Ca is
an integral part of the ligand recognized by 2C. Structural determination of p2Ca*Ld
complexes in association with the 2C TcR should definitively put this question to rest.
To our surprise, not one but three distinct peaks of sensitizing activity for lysis
by 2C were evident in HPLC fractions of extracted tissues or cells. Identification of the
first peptide was followed by isolation (through 6 rounds of HPLC) and characterization
of a second 16-residue peptide containing the entire sequence of the first (p2Cb,
VAITRIEQLSPFPFDL; Udaka et al., 1993). The protein of origin for p2Ca and p2Cb was
revealed by noting 87% sequence identity between p2Cb and human a-ketoglutarate
dehydrogenase (a-KGDH) and then cloning and sequencing part of the corresponding
mouse gene to confirm an exact match with this protein (thereby also verifying the
C-terminal leucine) (Udaka et al., 1993). The unusual length of p2Cb relative to other
MHC-I-binding peptides and its sequence overlap with p2Ca immediately prompted
two questions: (1) was recognition of p2Cb by 2C cells due to a direct interaction
between the peptide and Ld, to degradation of p2Cb (e.g. to p2Ca) during cytotoxicity
assays, or to contamination of p2Cb by small amounts of other peptides? and (2) does
p2Cb represent a physiological precursor of p2Ca, thereby providing an opportunity to
shed light on endogenous antigen processing pathways? The first issue is explored in
Udaka et al. (1993; see p. 132-133). The second remains an active area of investigation,
as described briefly here.
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One of the major proteolytic activities in cytosol is a 700 kDa multisubunit
complex termed the proteasome (or 20S proteasome for its sedimentation coefficient)
(Arrigo et al., 1988; reviewed by Orlowski, 1990; Tanaka et al., 1992; Goldberg, 1992).
An even larger complex responsible for degrading ubiquitin-conjugated proteins, the
26S proteasome, contains the 20S proteasome (Driscoll and Goldberg, 1990). Two of
the proteasome subunits were found to be identical to previously identified (Monaco
and McDevitt, 1982) MHC-encoded products designated LMP-2 and LMP-7 (for low
molecular mass polypeptide) (Brown et al., 1991; Glynne et al., 1991; Ortiz-Navarrete
et al., 1991). Because of their location within the MHC and their induction by
interferon-y (along with class I and II MHC genes and TAP genes), LMP-2 and LMP-7
were seized upon as candidate genes encoding components of the endogenous antigen
processing pathway. These hopes suffered when mutant cell lines with a large MHC
deletion encompassing both LMP and TAP genes regained antigen presenting capability
upon transfection with TAP (but not LMP) genes (Momburg et al., 1992; Arnold et al.,
1992; Yewdell et al., 1994; Zhou et al., 1994). On the other hand, studies using purified
proteasomes (Driscoll et al., 1993; Gaczynska et al., 1993), mice with disrupted LMP
genes (Fehling et al., 1994; Van Kaer et al., 1994), or proteasome inhibitors (Rock et
al., 1994) have shown that the substrate specificity of proteasomes is dependent upon
LMP-2/LMP-7 and that MHC-I expression and/or antigen presentation are altered in the
absence of LMP genes.
With a few recent exceptions (Boes et al., 1994; Dick et al., 1994), previous
studies carried out using purified 20S proteasomes have relied on amino acids or very
short peptides (up to three residues) coupled to fluorescent labels. Inasmuch as
endogenous precursors of antigenic peptides must be longer than octamers or nonamers,
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we sought to exploit the isolation of a naturally occurring 16-mer (p2Cb) by testing
whether it could be converted in vitro to p2Ca or other Ld-binding peptides. Naomi
Fukusen purified 20S and 26S proteasomes according to Tanaka et al. (1986) and
Driscoll and Goldberg (1990), and we exposed highly-purified peptide p2Cb to these
proteasomes and analyzed the products by HPLC and mass spectrometry (with Ioannis
Papayannopoulos and Klaus Biemann, M.I.T. Department of Chemistry). We found
progressive exoproteolytic trimming at the N-terminus to nine residues, as well as
evidence for a single endoproteolytic cleavage between leucine and serine to give an
inactive 9-mer (VAITRIEQL) and an active but not apparently naturally occurring 7-mer
(SPFPFDL) (unpublished data). The significance of these data is still under consideration.
A parallel study addresses the same question by means of the human TxB
hybridoma cell line T1, its derivative mutant line T2 lacking LMP and TAP genes, and a
transfectant of T2 expressing TAP-1 and TAP-2 that was made available to us by Frank
Momburg (German Cancer Research Center, Heidelberg) (Momburg et al., 1992). A
cDNA clone for Ld was obtained from Peter Cresswell (Yale University) and transfected
into T1 and T2/TAP; T2 cells transfected with the same Ld gene were already available
from P. Cresswell. Using these three cell lines - T1-Ld, T2-Ld, and T2/TAP-Ld - we
could determine whether or not the steady-state levels of p2Ca and p2Cb depend upon
TAP and IMP genes. These experiments are still in progress; however, the preliminary
data shown below, as well as cytotoxicity assays in which T2-Ld and T2/TAP-Ld cells
are lysed by 2C cells to exactly the same extent, suggest that p2Ca and p2Cb are present
in all three cell lines, although probably at different absolute and relative levels.
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The third peak of sensitizing activity for 2C cells in HPLC fractions of mouse
tissue extracts ("peak c") has resisted vigorous efforts toward sequence determination
and at present remains enigmatic, except that it is known to be recognized by the same
2C TcR on the basis of inhibition by a monoclonal antibody specific for this TcR
(antibody 1B2, Kranz et al., 1984b). However, a fourth peak of activity found only in
liver extracts contains a peptide that has recently been purified and sequenced (Wu et
al., 1995): it is an octamer with a single phenylalanine-to-tyrosine difference from
p2Ca (LSPYPFDL, hence p2Ca-Y4). This naturally occurring peptide was proposed to
arise from post-translational modification by liver microsomal phenylalanine hydroxylase
(Guroff et al., 1967) of phenylalanine at position four in peptide p2Ca. In view of the
human autoimmune disease primary biliary cirrhosis, in which the major targets of
autoantibodies are a-KGDH and the related pyruvate and branched chain a-ketoacid
dehydrogenases (Burroughs et al., 1992), and recent findings by Connolly (1994) that
peptide p2Ca is immunodominant in certain alloreactions, it seems warranted to explore
whether individuals with this autoimmune disease have CTL specific for peptides
derived from a-KGDH (or the other two dehydrogenases). The possible generation of
antigenic peptides by post-translational modification could represent one pathway by
which normal self-tolerance mechanisms (i.e., negative selection of T cells in the
thymus) are thwarted, although not by any means the only such pathway.
A fifth peptide potentially involved in 2C allorecognition (QLSPFPFDL, termed
QL9) is especially interesting for several reasons. (1) This peptide, originally detected
as a product of the reaction between purified p2Cb and isolated 20S proteasomes, is
more active than any of the naturally occurring peptides recognized by 2C that have
been identified (i.e., p2Ca, p2Cb, and p2Ca-Y4). The SD50 for peptide QL9 is ca.
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10-12 M, comparable to the most active synthetic peptides that have been described in
other systems (Bodmer et al., 1988; Reddehase et al., 1989; R6tzschke et al., 1990b,
1991a; Falk et al., 1991b; Schulz et al., 1991; Tsomides et al., 1991, 1994; Wallny et
al., 1992a; Cox et al., 1994). (2) By virtue of its N-terminal glutamine residue, peptide
QL9 can exist in two distinct forms - one with a free amino terminus and one with
cyclized pyrrolidone carboxylate at the N-terminus (see below) - and both forms are
recognized well by 2C. In fact, the cyclized version of QL9 has an approximately 5- to
10-fold lower SD50 than the linear form (unpublished data). (3) Whether or not QL9 is
a naturally processed peptide remains unknown, despite much effort, but is possible
because cyclized QL9 serendipitously co-migrates with p2Cb on HPLC and linear QL9
co-migrates with p2Ca; thus QL9 may have evaded detection during our original HPLC
mapping of the peptides recognized by 2C. (4) the affinity of the 2C TcR for QL9oLd
complexes is the highest so far measured for any T cell (=1.5x10 7 M- 1, Sykulev et al.,
1994; see below).
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Efforts to detect QL9 in tissue extracts have exploited the absence of a free
amino group in the cyclized form of this peptide. Thus, after a three day incubation at
370C in 1% TFA to achieve quantitative cyclization, extracts of liver (or other tissues)
are chemically modified with amino-reactive reagents (e.g. isothiocyanate groups
attached to glass beads or dinitrofluorobenzene); only N-terminal cyclized, lysine-free
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peptides are unaltered by these protocols. Despite our attempts, it remains uncertain
whether QL9 is a naturally processed peptide or simply an interesting synthetic peptide
involved in a heteroclitic T cell cross-reaction; current data suggest that if it is present,
QL9 is much less abundant than the other naturally processed peptides recognized by 2C.
A list of some of the peptides recognized by 2C and their properties is provided
in the table on p. 120. To date, no other naturally processed peptides recognized by
alloreactive CD8+ T cells are known to have been sequenced.
A second surprise in the original study by Udaka et al. (1992) was the presence
of p2Ca and p2Cb (as well as peak c) in tissues of other haplotype mice besides H-2d
(i.e., H-2b and H-2k). This became more understandable once it was established that the
protein source of p2Ca and p2Cb is a ubiquitous cellular enzyme essential for
intermediary metabolism (Udaka et al., 1993). Since clone 2C originated in an H-2b
mouse, the presence of p2Ca in this haplotype raised the question of whether p2Ca can
be recognized by the 2C TcR in association with a self MHC-I protein (i.e., Kb or Db).
Dutz et al. (1994) showed that peptide p2Ca is in fact recognized by 2C cells in
association with Kb (but not Db), although at 1000-fold higher peptide concentrations
than required for Ld-restricted recognition, and Kageyama et al. (1995) showed that the
affinity of p2Ca for Kb was only =10-fold lower than its affinity for Ld.
Since there is no apparent autoimmune reaction against p2Ca in normal H-2b
mice or in H-2b mice transgenic for the 2C TcR (Sha et al., 1988a), p2Ca.Kb
complexes, although present in these mice, apparently do not achieve a sufficently high
density to elicit a response from 2C cells. Indeed, calculations suggest that =90-fold
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more p2Ca*Kb than p2Ca*Ld complexes are needed to activate 2C, while the amounts of
peptide recovered from H-2b and H-2d tissues are about the same. Commensurate with
these findings, Sykulev et al. (1994) measured an affinity of the 2C TcR for p2Ca*Kb
that is about 700-fold lower than its affinity for p2Ca*Ld (3x103 M-1 vs. 2x106 M- 1).
However, weak TcR reactions are hypothesized for the positive selection of immature
thymocytes, and the possibility that p2Ca might positively select T cells bearing the 2C
TcR remains open, particularly in light of recent work in other systems (Ashton-Rickardt
et al., 1993, 1994) and because positive selection of 2C TcR+ cells has been shown to
depend upon Kb (not Db) and to involve one or more peptides (Sha et al., 1990).
Like p2Ca, the liver-specific peptide p2Ca-Y4 binds to Kb, apparently with a Ka
of =105 M-1 (Wu et al., 1995; see p. 150). However, p2Ca-Y4*Kb complexes are not
recognized by the 2C TcR in cytotoxicity assays, illustrating that a low-affinity T cell
reaction (between the 2C TcR and p2Ca°Kb) nevertheless exhibits striking specificity
(p2Ca and p2Ca-Y4 differ by only a single oxygen atom). This observation supports
the idea of an affinity threshold for eliciting T cell responsiveness, and suggests it may
be =103 M-1, given a high enough ligand density (Wu et al., 1995).
The affinity of the 2C TcR for the QL9*Ld complex, in contrast, is the highest so
far measured for any TcR (=1.5x10 7 M-1, Sykulev et al., 1994; see p. 145). As
elaborated by Eisen et al. (In press; see appendix, p. 317), this relatively high value may
be related to the fact that the reaction between the 2C TcR and QL9-Ld is an
alloreaction; specifically, since T cells are not exposed to complexes of peptides and
allogeneic MHC proteins in the thymus during their development, there is no
opportunity for cells with TcR having high affinities for such complexes to undergo
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negative selection. Some of these cells may thus be positively selected (by low-affinity
interactions with self peptide.MHC complexes) and emerge from the thymus with the
potential for high-affinity alloreactions. This, together with the fact that polyclonal
alloresponses probably involve many different peptide.MHC ligands, may account for
the intensity and high frequency of alloreactions (Matzinger and Bevan, 1977;
Fischer Lindahl and Wilson, 1977).
In addition to its strong reaction with QL9*Ld complexes (alloreaction) and a
presumably weak reaction with one or more peptides in association with Kb (positive
selection), it is likely that CTL clone 2C can recognize a specific foreign peptide (or
peptides) in association with a self MHC-I protein, i.e., its "normal" peptide*MHC-I
ligand. An experiment was undertaken to search for such a putative foreign peptide,
using two libraries of peptides developed by Schumacher et al. (1992) and made
available by Hidde Ploegh. These synthetic peptide libraries contain mixtures of 8-mers
or 9-mers, respectively, based on the sequences of known Kb-binding peptides; their
overall complexity was limited to 432 (8-mers) or 864 (9-mers). Each library was
fractionated by reverse phase HPLC, and the fractions were screened in a cytotoxicity
assay using 2C CTL and T2-Kb target cells. No fractions contained sensitizing activity,
indicating that these libraries probably do not contain the postulated foreign peptide
recognized by 2C cells as part of a self MHC-I (Kb)-restricted response. It remains
possible that a more extensive peptide library would harbor such a peptide.
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Table. Some peptides recognized by CTL clone 2C and their properties.
Peptide Sequence MHC-I Kafor peptide- Ka for 2C TcR- SD50 value
MHC peptide*MHC (M)§
reaction (M-1) § reaction (M -1) t
p2Ca LSPFPFDL Ld 5-10 x 105 2 x 106  10-9 -10-10
Kb 1 x 105  3 x 103  10-6
p2Ca-Y4 LSPYPFDL Ld 5 x 105 10-9 - 10-10
Kb 1 x 105 no activity
p2Ca-Y6 LSPFPYDL Ld 10-9
Kb 10-7
p2Cb VAITRIEQLSPFPFDL Ld 10-7 - 10-8
QL9 QLSPFPFDL Ld 2 x 108  1.5 x 107 5 x 10-12
QL9-Y5 QLSPYPFDL Ld 5 x 10- 11
I1-QL9-Y5 QLSPY *PFDL Ld 2 x 107 5 x 10-12
Values from Kageyama et al., 1995; Sykulev et al., 1994; and unpublished data.
Peptides in boldface are known naturally processed peptides.
§ at 370 C; t at room temperature.
* denotes stoichiometric labeling of tyrosine with 1271 or 1251.
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Summary
The antigenic structures that Initiate T cell responses
to foreign (allogeneic) cells have long attracted con-
siderable Interest. We have purified and sequenced a
peptide from mouse spleen that is recognized In
association with the class I MHC protein H-2L by 2C,
an alloreactive CD8* T cell clone. The peptide (LSP-
FPFDL) greatly enhances the susceptibility of Ld* cells
to lysis by 2C, and this activity is completely blocked
by a clonotypic antibody against the 2C T cell receptor.
Thus, this study characterizes the naturally occurring
peptide moiety of an MHC-llpeptide complex recog-
nized by alloreactive CD8* T cells. The peptide, which
occurs in the thymus of MHC-disparate mice, can be
used to study T cell development in mice expressing
transgenes for the 2C T cell receptor.
Introduction
Several lines of evidence suggest that in its lifetime, a
CD8* T cell recognizes via the same receptor a variety of
different antigenic structures, each consisting of a class I
MHC protein (MHC-I) in association with a peptide. Thus,
mature CD84 T cells can function as cytotoxic T lympho-
cytes (CTL), which characteristically react with peptides of
foreign (e.g., viral) origin in association with syngeneic
("self") MHC-I, i.e., foreign-self complexes. Moreover, the
high frequency of CD8* T cells that recognize any given
allogeneic MHC-I (-,1:100; Erard et al., 1985), taken to-
gether with the large number of different class I MHC al-
leles, indicate that many (probably most) CD8*T cells can
also recognize an allogeneic MHC-I (Bevan, 1977); and
from considerable indirect evidence, it appears that the
structures seen by most alloreactive CTL are formed by
unknown peptides of allogeneic cells in association with
the allogeneic cells' MHC-I, i.e., what might be termed
foreign-foreign complexes (Heath et al., 1989, 1991;
R6tzschke et al., 1991). In addition, during their develop-
ment in the thymus, precursors of CD8+ T cells appear to
respond selectively to unknown thymic peptides in associ-
ation with syngeneic MHC, i.e., self-self complexes (Sha
et al., 1990; Nikolic-Zugic and Bevan, 1990). The number
of different peptide-MHC complexes that can be recog-
nized (foreign-self, foreign-foreign, self-self) suggests
*Present address: Max Planck Institut for Biologie, Abt Immunogene-
tik, Corrensstrasse 42, D-7400 TObingen, Germany
that the specificity of a single T cell receptor (TcR) may be
substantially degenerate.
To learn more about the diversity of antigenic structures
seen by an individual TcR, we are studying the structures
recognized by 2C cells, a clone of alloreactive CD8* CTL.
These cells are particularly useful for this purpose for sev-
eral reasons. First, a clonotypic monoclonal antibody (1 B2)
to the well-characterized TcR of this clone provides a spe-
cific reagent with which to determine unambiguously
whether a particular antigenic complex is recognized by
this TcR (Kranz et al., 1984a). Secondly, genes for this
TcR's a and 1 chain variable domains have been cloned
and sequenced and used to generate transgenic mouse
strains (Saito et al., 1984a, 1984b; Sha et al., 1988a). In
transgenic mice expressing certain MHC-I, T cells that
bear the 2C TcR are deleted in the thymus ("negative se-
lection"), whereas in transgenic mice expressing certain
other MHC-1, these T cells are stimulated to proliferate,
mature, and populate peripheral tissues ("positive selec-
tion"; Sha et al., 1988b, 1990).
The 2C clone was originally derived from an H-2b mouse
(BALB. B strain) that had been inoculated with H-25 cells
(expressing the class I MHC proteins Kd, Ld, and DI) (Kranz
et al., 1984a). 2C cells are specific for Ld in the sense that
they normally lyse only L*-bearing target cells, and this
activity is blocked by some antibodies to Ld. In the present
study, we have succeeded in purifying and determining
the sequence of a naturally occurring peptide octamer rec-
ognized by 2C cells in association with Ld. When synthe-
sized, this peptide, whose sequence is LSPFPFDL, greatly
enhanced the susceptibility of Ld-bearing target cells to
lysis by 2C cells, and this activity was completely blocked
by the clonotypic antibody to the TcR of 2C cells. Hence,
this study characterizes the peptide moiety of a peptide-
MHC-I complex that is recognized by alloreactive CD8*
T cells.
Results
Selection of a Target Cell for Screening Assays
The design of a cytotoxicity assay to screen for peptides
that are recognized by 2C cells in association with Ld de-
pended upon the identification of a target cell that ex-
pressed Ld but was not significantly susceptible to lysis
by 2C until reconstituted with the appropriate peptide(s).
Table 1 lists the target cells that were considered. P815
and A20 cells were rejected because they were lysed very
well by 2C without addition of exogenous peptides. T1.1.1
(L cells transfected with the Ld gene) were promising be-
cause they were killed poorly by 2C cells despite express-
ing reasonable levels of L", but they were rejected because
they were also killed poorly by an unrelated Ld-restricted
CTL clone (8AS) in the presence of the synthetic peptide
recognized by this clone (T2H), perhaps because T1.1.1
cells have low levels of the surface adhesion molecule
ICAM (Table 1). The Sp2/0 myeloma cell line (H-2d haplo-
type), which expresses low levels of Ld and other class I
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Table 1. Selection of a Target Cell Line for the Cytotoxicity Screening Assay
Flow Cytometric Measurement of* s'Cr-Release Due to CTL D
Cell 8A5 Cells and
Cell Ld ICAM Diameter 2C cells Peptide T2H
P815 (100) (100) (1.0) 55, 67 80, 84
A20 53 121 1.1 33, 40 68, 77
82 131 481 1.4 9, 13 50, 59
Sp2/0 8 692 1.4 4, 8 6, 10
T1.1.1 90 12 1.6 6, 8 23, 32
L 2 6 1.6 4, 5 9, 14
I Values are given as percent of the indicated protein (Ld, ICAM) in P815 cells (100%). assuming linearity between fluorescence intensity and the
cell surface density of each protein. Relative cell diameter is based on forward low angle light scattering.
b Values separated by a comma are percent specific s'Cr-release from target cells tested at two CTL:target cell ratios, 1.25:1 and 2.5:1. All values
are averages of duplicates. In assays with CTL clone 8A5, the tumor-specific peptide T2H (see Table 2) was present at a concentration of 100 nM.
MHC proteins (Kd, Dd, and Ld were 42%, 25%, and 2%,
respectively, of the corresponding levels on P815 cells),
was killed poorly. After Sp2/0 was transfected with the
Ld gene under heterologous enhancer (immunoglobulin
heavy chain enhancer, IgH) and promoter (metallothionein
Ila) elements, one of the transfected clones, B2, expressed
high levels of Ld (130% of P815 cells) and yet was still killed
poorly by 2C cells (about 15% specific "1Cr-release under
the assay conditions employed). However, B2 cells could
be lysed nonspecifically in the presence of concanavalin
A by an unrelated CTL (4G3 cells, restricted by Kb, not Ld),
and they were fully competent as specific target cells for
another Ld-restricted CTL (clone 8A5 in the presence of
the known cognate peptide [T2H] for this clone; Lurquin et
al., 1989). These properties indicated that B2 cells were
suitable for our cytotoxicity screening assay.
Several High Pressure Liquid Chromatography
Fractions Sensitize 82 Target Cells for Lysis
by 2C CTL
The peptide fraction (molecular mass < 10 kd) from acid-
denatured homogenates of BALB/c thymus or spleen was
subjected to high pressure liquid chromatography (HPLC)
on a C18 reverse phase column, and the resulting fractions
were tested for sensitizing activity using B2 as target cells
and 2C as CTL in a 5'Cr-release assay. As illustrated in
Figure 1A, three active fractions, a, b, and c, were consis-
tently observed with a thymus extract. The combined ac-
tive fractions were pooled and rechromatographed on the
same C18 column using a much shallower and thus more
highly resolving gradient (0.067% solvent B per min, gradi-
ent program 8). As shown for a thymus extract in Figure
1 B, cytotoxic activity was again seen in three fractions (a,
b, and c), and the broad peak at fraction a occasionally
split into two discernible peaks.
The same activity profile was seen in extracts from
BALB/c spleen or thymus, and also from P815 cells. Frac-
tions a, b, and c from thymus eluted with the same reten-
tion times as the corresponding fractions from spleen (Fig-
ure 2) when samples were run on an analytical scale.
However, fraction a elicited a stronger CTL response from
the spleen preparations, and fraction c tended to give a
higher response from thymus preparations. Fraction a
from thymus was used for additional characterization of
the biological properties of the active components, and
the corresponding fraction from spleen was subjected to
further purification for sequence analysis.
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Figure 1. HPLC Fractionation and Cytotoxicity Assay of Peptides De-
rived from BALBIc Thymus
Low molecular mass components (<10 kd) from homogenates of thy-
mus were fractionated by reverse phase chromatography on a C18
column (Vydac). Fractions were collected at 1 min intervals (at a flow
rate of 1.0 milmin) and subjected to the standard cytotoxicity assay
using s'Cr-labeled B2 cells as targets and 2C cells as CTL (CTL:target
cell ratio = 3:1). Solid line, absorbance at 280 nm; line with filled
circles, percent specific lysis by 2C; line with open circles, percent
specific lysis in toxicity controls consisting of 82 target cells incubated
for 4 hr with each fraction in the absence of 2C CTL. (A) The initial
chromatographic separation, using a gradient of 0.25% B per min
(program 7). (8) Rechromatography of pooled fractions a, b, and con
the same C18 column, using a shallow gradient of 0.067% 8 per min
(program 8).
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Figure 2. HPLC Fractionation and Cytotoxicity Assay of Peptides De-
rived from BALB/c Spleen
Low molecular mass components (<10 kd) from homogenates of
spleen were fractionated by reverse phase chromatography on a C18
column (0.067% B per min, program 8). Fractions were collected at 1
mm intervals and assayed for cytotoxicity as in Figure 1.
Some Characteristics of Active HPLC Fractions
Pronase Sensitivity
Fractions a, b, and c (Figure 1 B) lost their activity in cyto-
toxicity assays after they were incubated with pronase im-
mobilized on agarose beads, but not after they were incu-
bated with agarose beads lacking pronase (data not
shown). Hence, the active components in these fractions
appeared to be peptidic.
Ld Restriction
To determine whether the recognition of peptides in the
three active fractions by 2C cells was L. restricted, various
cell lines were used as targets. Each of the active fractions
enhanced the lysis of those target cells that expressed Ld,
i.e., they were active with Ti1.1.1, B2, and RLd-E2 as target
cells, but not with untransfected L cells (MHC haplotype
H-2k) or RMA-S cells (MHC haplotype H-2b).
Inhibition by Other Peptides That
Associate with Ld
Synthetic peptides that are known to be recognized in
association with Ld by various T cell clones were tested
at high concentrations (5 pM) to determine whether they
interfered with the sensitizing activity of the peptides in the
active HPLC fractions. As shown in Table 2, the activities
of fractions a, b, and c were each inhibited by three pep-
tides (MCMVH, MCMVR, T2H) that are either known to
be recognized in association with L" or that competitively
inhibit the activity of Ld-associated peptides. But they were
not inhibited by two peptides (T2R, OVA2) having no
known association with Ld.
Effect of Peptides on Ld Expression
To determine whether the activity of HPLC fractions that
enhanced lysis of B2 target cells might be due solely to an
ability to increase the density of Ld on target cells, various
peptides known to associate with Ld were tested on RLA-E2
cells. These cells were produced by transfecting the Ld
gene into RMA-S cells (see Experimental Procedures).
After RLd-E2 cells were incubated overnight at 370C with
each of the three Ld-restricted peptides (5 gM) (see Table
2), they were analyzed by flow cytometry with antibody
30-5-7S (specific for the al and a2 domains of Ld; Hansen
et al., 1988) to measure the cell surface density of LI,
and they were also tested as targets for 2C CTL. Surface
expression of Ld increased from 7% (in absence of the
added peptides) to 17%, 23%,.and 10% (of the mean
log fluorescence level in P815 cells), but did not result in
enhanced cytotoxicity by 2C CTL (data not shown). This
observation and the fact that the active peptides in HPLC
fractions a, b, and c from BALB/c thymus and spleen were
doubtless present at only nanomolar or subnanomolar
concentrations (see below) indicate that these peptides
were recognized as components of antigenic complexes
with L , rather than indirectly increasing cytotoxicity be-
cause of enhanced cell surface expression of Ld.
Recovery of Active Peptides from
Affinity-Purified Ld Molecules
The active peptides in spleen and thymus homogenates
could have been derived from the cytosol or from cytosolic
organelles, or they might have been bound by Ld mole-
cules before the homogenates were acid treated. To distin-
guish between these possibilities, we compared an acid
extract of BALB/c thymus with acid-denatured Ldthat had
Table 2. Inhibitory Effects of Synthetic Peptides on the 82-Sensitizing Activities of Peptides in HPLC Fractions a, b, and c
Percent Inhibition of B2-Sensitizing
T2r-Dependenti Activity of HPLC Fraction
T2H-Dependent
Peptide Sequence Lysis by CTL 8A5 a b c
MCMVH YPHFMPTNL 90 85 >90 80
MCMVR YPRFMPTNL 70 70 60 40
T2H ISTQNHRALDLVA 40 60 40
T2R ISTONRRALDLVA <10 <10 <10 20
OVA2* IINFEKLTEWT <10 <10 10 5
SSNVMEER
For all assays, the inhibiting peptide was present at 5 gM. Peptides MCMVR and T2R are analogs of MCMVH and T2H, respectively, with a histidine
to arginine substitution at the position shown. T2H is recognized with LO by CTL clone 8A5 (see also Lurquin et al.. 1989). The ability of T2H at a
concentration of 35 nM to sensitize La-bearing target cells for lysis by 8A5 cells was inhibited by MCMVH or MCMVR but not by T2R or the ovalbummin
peptide OVA2. Thus, MCMVH and MCMVR as well as T2H appear to associate with LO, whereas T2R and OVA2 do not.
aSee Carbone and Bevan, 1990.
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Figure 3. HPLC Fractionation and Cytotoxicity Assay of Peptides As-
sociated with H-2Ld and H-2DO
Following affinity purification of Ld and D4 from P815 cells and TFA
extraction of the respective bound peptides, reverse phase chromatog-
raphy was carried out on a pepS column (Pharmacia) with gradient
program 8 (see Figure 18). For comparison, low molecular weight
material from a BALBc thymus (0.4 g), prepared as in Figure 1, was
fractionated on the same column with the same gradient. Fractions
were collected at 1 min intervals (at a flow rate of 1.0 ml/min) and
subjected to the standard cytotoxicity assay using 'Cr-labeled 82 cells
as targets and 2C cells as CTL (CTL:target cell ratio = 3:1). Solid line,
absorbance at 220 nm; line with filled circles, percent specific lysis due
to fractions from LA; line with triangles, percent specific lysis due to
fractions from Dd; line with open circles, percent specific lysis due to
fractions from the BALBIc thymus extract (see Figure 18 and Fig-
ure 2).
been purified from P815 cells. Ld molecules were affinity
purified with monoclonal antibody 30-5-7S from P815 cell
lysates; for control purposes D" molecules were affinity
purified from the same lysates with monoclonal antibody
34-5-8S (Ozato et al., 1982). The isolated Ld and Dd pro-
teins were then treated with trifluoroacetic acid (TFA), sub-
jected to ultrafiltration, and the filtrates were fractionated
by reverse phase HPLC as before (Figure 1).
As shown in Figure 3, three active fractions were derived
from purified Ld, and none from purified Dd. The first two
active fractions very likely correspond to fraction a of the
thymus extract, since, as noted earlier, this fraction from
thymus samples tended to split into two peaks when a
smaller amount of material was loaded. Fraction c from
purified L" was shown by rechromatography on an analyti-
cal scale to correspond to fraction c of the thymus extract.
However, fraction b in spleen and thymus extracts, eluting
at 53-54 min, was not detected in the acid extract of puri-
fied L".
Direct Sequence Analysis of an Active Peptide
Due to the limited availability of material from thymus and
P815 cells, .a fraction of the spleen was used for further
study. Fraction a was isolated from 26.7 g of spleen (from
263 BALBIc mice) by successive rounds of reverse phase
chromatography on a C18 column using two different gra-
dients as shown in Figure 1. It was then purified further by
three successive rounds of reverse phase chromatogra-
phy on a C8 column at pH 8.5, using the cytotoxicity assay
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Figure 4. Titration of Synthetic Peptides p2CL and p2CI in the Cyto-
toxicity Assay
Targets are "Cr-labeled B2 cells; CTL are 2C; CTL:target cell ratio =
3:1. Dotted horizontal line represents percent specific lysis when no
peptide was added. Vertical arrows on the abscissa point to SDs val-
ues (i.e., peptide-sensitizing doses effecting half-maximal target cell
lysis), which were: "350 pg/ml for p2CL and '6.5 ng/ml for p2CI. T
points to percent specific lysis due to material recovered in fraction a
from 0.6 g of BALB/c thymus after two reverse phase HPLC fraction-
ations as in Figure 1.
after each round to identify an active peak for the next
round. Finally the active fraction from the third C8 chroma-
tography, representing an estimated 4.5 g of spleen, was
subjected to Edman degradation. The analysis revealed
3-5 pmol of peptide, which was just sufficient to determine
unambiguously the first six residues as LSPFPF; the sev-
enth residue was questionably aspartic acid. An aliquot,
estimated from Edman degradation to be about 2 pmol,
was found by mass spectrometry by Drs. I. Papayanno-
poulos and K. Biemann (Department of Chemistry, Massa-
chusetts Institute of Technology) to have a mass of 934.4.
Based on this mass and the Edman data, the peptide was
deduced to be an octamer with the sequence LSPFPFD
plus a C-terminal leucine or isoleucine (indistinguishable
by mass). Accordingly, two peptides were synthesized,
one with leucine and the other with isoleucine at the C-ter-
minus (termed p2CL and p2CI, respectively).
Both synthetic peptides were active in the cytotoxicity
assay with 2C cells, but p2CL was 20 times more active
than p2CI (Figure 4). Within the accuracy provided by col-
lecting fractions at 1 min intervals, synthetic p2CL had the
same retention time as the naturally occurring peptide in
fraction a on HPLC gradient program 8 (Figure 2). Under
the same HPLC conditions, p2CI eluted 1 min earlier than
p2CL. Unlike reports with some other longer synthetic pep-
tides (R6tzschke et al., 1990; Schumacher et al., 1991),
when p2CL was subjected to HPLC, and multiple fractions
were tested in the cytotoxicity assay, activity was found
only in the fraction with the retention time of fraction a
and not in other fractions, even when the column was
deliberately overloaded. We conclude that p2CL corre-
sponds to the active peptide in fraction a from homoge-
nates of BALB/c spleen or thymus or P815 cells, as well
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Figure 5. The F(ab') Fragment of 162 (the Clonotypic Monoclonal
Antibody to the TcR of 2C Cells) Blocks Peptide (p2CL)-Dependent
Lysis of B2 Cells as Well as Lysis of P815 Cells (Including the Increase
in Lysis of P815 Cells Due to p2CL)
2C cells were incubated with the 1B2 F(abJ2 fragment at 150 gg/ml for
30 min at 370C before they were added to p2CL and target cells (either
B2 or P815). The final concentrations of 1B2 F(abz) fragment and p2CL
were 38 sg/ml and ,,15 ng/ml, respectively, and the CTL:target cell
ratio was 3:1.
as from affinity-purified Ld from P815 cells. A protein that
contains the p2CL sequence has so far not been found in
protein sequence data banks.
The peptide in fraction a from thymus was compared
with synthetic p2CL in a S'Cr-release assay. As shown in
Figure 4, p2CL at about 350 pg/ml sensitized 82 target
cells for half-maximal lysis. Slightly more lytic activity was
elicited from fraction a isolated from 0.60 g of thymus (Fig-
ure 4). Since this amount of thymus corresponds to ap-
proximately 6 x 108 thymocytes, we recovered only about
100-200 molecules of the naturally occurring peptide per
cell, assuming the peptide is present in all thymocytes.
The peptide's actual abundance is unclear because the
efficiencies of the extraction and purification procedures,
as well as the extent to which the peptide is present in all
or just a subset of thymus cells, are all uncertain at present.
The T Cell Receptor That Recognizes Peptide
p2CL in Association with Ld
When a cDNA library from 2C cells was originally studied
to characterize the genes that encode the antigen-specific
receptor (TcR) of these cells, one a chain, one P chain, and
one y chain cDNA were sequenced (Saito et al., 1984a,
1984b). Later, a second 0 chain cDNA was sequenced
(Sha et al., 1988a). While there were thus potentially two
(or more) different receptors on these cells, a unique ap3
receptor was subsequently identified by a clonotypic anti-
body (182) (Kranz et al., 1984b). However, the possibility
that 2C cells also have on their surface another TcR, using
the other 0 chain, perhaps in the form of recently described
0-0 receptors (Goverman et al., 1990; Kishi et al., 1991;
Punt et al., 1991; van Meerwijk et al., 1991), has not been
clarified. Therefore, to establish unambiguously the iden-
tity of the receptor that recognizes the p2CL-Ld complex,
we tested whether the lysis of p2CL-sensitized target cells
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by 2C cells is blocked by antibody 182. As shown in Figure
5, the F(ab) 2 fragment of 182 completely blocked the lysis
of p2CL-sensitized B2 and P815 target cells. (It was neces-
sary to use the F(ab) 2 fragment of this antibody because
Fc receptors are present on B2 and P815 cells and can
give rise to peptide- and MHC-independent lysis due to the
182 Fc domain, a process termed "redirected lysis" or
"antibody-dependent cell-mediated" cell lysis.) The strik-
ing effect of the 182 F(ab) 2 fragment clearly established
that the antigenic structure formed by p2CL-Ld is recog-
nized by the same 2C TcR that is expressed on CD8* T
cells of transgenic mice produced by Sha et al. (1988b).
The 3 chain of this receptor is characterized further by
its reactivity with monoclonal antibody F23.1 (Sha et al.,
1988b, 1990), which is specific for 0 chain variable do-
mains encoded by the Vp8 gene segment family (Staerz et
al., 1985).
Discussion
The historic role of the allograft reaction in the discovery
of the MHC, and its importance for analyses of MHC-
dependent processes underlie ongoing efforts to under-
stand the antigenic structures that are recognized by allo-
reactive T cells. A major question is whether the epitopes
seen by alloreactive CD8* T cells reside in allogeneic class
I MHC proteins themselves, regardless of their associated
peptides (Bevan, 1984; Kaye and Janeway, 1984; Portoles
et al., 1989; Millbacher et al., 1991), or in peptide-class
I MHC complexes where unique combinations of particular
peptides with particular MHC proteins determine each epi-
tope (Matzinger and Bevan, 1977; Kourilsky and Claverie,
1989). This paper provides an answer for 2C cells, an
extensively studied alloreactive CD8+ T cell clone: we
show that the well-characterized TcR of this clone recog-
nizes a particular peptide octamer (p2CL) in association
with Ld . This finding underscores recent studies (Heath
et al., 1991; R6tzschke et al., 1991) indicating that most
alloreactive CTL see complexes of MHC-I and unknown
peptides. In the case of an alloreactive CD4' T cell clone
(Panina-Bordignon et al., 1991), the ligand was shown to
be a class II MHC protein (MHC-ll) in association with a
processed form of serum albumin. However, it remains
possible that some alloreactive CTL might recognize pep-
tide-independent epitopes on allogeneic MHC-I (MII-
bacher et al., 1991).
In establishing the sequence of p2CL, our results dem-
onstrate why the peptides associated with MHC-I proteins
that are recognized by other alloreactive T cells have been
so difficult to characterize. Thus, in starting with spleens
from 263 mice, we ended up with just enough material
of sufficient purity for sequence determination of a short
peptide (molecular weight ,1000). We estimate that our
yield of purified peptide (3-5 pmol) amounted to only about
400 molecules per splenic lymphocyte. In contrast to our
results, three earlier studies that established the complete
sequence of natural peptide adducts of class I MHC pro-
teins were all dependent on special circumstances. In two
cases (Van Bleek and Nathenson, 1990; Falk et al.,
1991a), the peptides were of viral origin, and information
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Figure 6. HPLC Fractions from Spleens of MHC-Disparate Mouse
Strains Are Recognized by 2C CTL
Low molecular weight material from spleens of BALBIc (H-.2), BALB.
B (H-2b), and BALB. K (H-2k) mice was prepared, fractionated, and
subjected to cytotoxicity assay as in Figure 1 B.
about candidate sequences from synthetic peptides hav-
ing optimal sensitizing activity on target cells provided
powerful guidelines. No such guidelines are available to
help characterize the peptides recognized by alloreactive
cells. In other cases (Falk et al., 1991b; Jardetzky et al.,
1991; Rudensky et al., 1991a, 1991b), the natural peptide
adducts were sequenced not because of demonstrated
biological activity but on the basis of their high abundance
in purified MHC-I or MHC-II preparations. By establishing
the sequence of a naturally occuring octapeptide that is
recognized by alloreactive CD8' cells, our results reinforce
the emerging generalization that CD8 ÷ T cells see octam-
ers or nonamers in association with class I MHC proteins
(for minireviews see Rdtzschke and Falk, 1991; Tsomides
and Eisen, 1991).
It has been reported (R6tzschke et al., 1991) that natu-
rally occurring peptides associated with one allelic form of
a class I MHC protein are usually not present on cells
expressing other allelic variants of that protein. However,
we have found that acid extracts of tissue homogenates
of spleen or thymus from several MHC-disparate mouse
strains (BALB/c [H-2d], BALB. B [H-2b], and BALB. K [H-21])
have HPLC activity profiles that are essentially indistin-
guishable (Figure 6). The slight amount of variability seen
can be attributed to discrete rather than continuous sam-
pling (1 min fractions) and to extreme heterogeneity in
the starting mixtures loaded onto the HPLC column (i.e.,
tissue homogenates).
Based on our finding that some of the active peptides in
spleen and thymus homogenates from H-2d mice can also
be recovered from affinity-purified Ld, it is reasonable to
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suggest that the active components in corresponding ho-
mogenates from the other mouse strains are likewise as-
sociated with their class I MHC proteins. For instance, our
results with BALB. B tissues suggest that p2CL, shown
here to be an Ld adduct, may bind to Kb or Db. Yet in
transgenic H-2b mice expressing the 2C TcR, thymocytes
bearing this receptor are not subjected to negative selec-
tion (Sha et al., 1988b). Hence, we propose that although
p2CL is present in the thymus of H-2b mice, it is either
bound too weakly by Kb or Db to form a sufficient number
of stable complexes per cell, or such complexes are
formed but are not bound strongly enough by the 2C TcR
to result in negative selection. In the latter case, it is even
conceivable that p2CL is involved in positive selection of
T cells expressing the 2C TcR in transgenic H-21 mice (Sha
et al., 1990). To distinguish between these alternatives,
we are measuring the binding of p2CL to Kb Or Db on intact
H-2b cells, using a recently described procedure (Tsom-
ides et al., 1991).
The presence of p2CL in tissues of MHC-different mice
raises a question about the designation of peptides as
"foreign" or "self." For 2C cells, whose haplotype is H-2b,
the p2CL molecules they see on H-24 target cells (in associ-
ation with Ld) arise in these allogeneic target cells and
are thus clearly foreign. However, if the same peptide is
present in H-2b cells but is invisible to TcRs of H-2b mice,
including the TcR of 2C cells, it is not seen as a self peptide.
Thus, whether a peptide behaves as self or nonself de-
pends not only upon its presence or absence but upon
its capacity to form complexes with self or nonself MHC
proteins that are capable of being recognized by particular
TcRs.
Recently, Falk et al. established by direct sequence
analysis consensus motifs for the mixtures of peptides
associated with several class I MHC proteins (Kd, Db, Kb,
and HLA-A2.1) (Falk et al., 1991b). For Ld, however, they
detected only a single major residue, which was proline
at the second position from the N-terminus. This finding
agrees with the sequences of two Ld-associated peptides
of viral origin (Table 3). However, p2CL, the peptide seen
by 2C cells in association with Ld, has proline at positions
3 and 5. Since p2CL corresponds to one of several active
peaks, it is possible that other active HPLC fractions con-
tain related sequences differing from p2CL by one or two
amino acid residues at the N- or C-terminus. For instance,
it is possible that an Ld-associated peptide in fractions b or
c (Figure 1) lacks the N-terminal leucine of p2CL and has
perhaps an additional one or two residues at the C-termi-
nus and would thus have proline at position 2, in accord
with the proposed motif. The recent discovery that three
peptides bound to the MHC-I protein HLA-A2 share the
same sequence but vary in length (9, 10, or 12 residues)
offers a precedent for finding such a family of closely re-
lated peptide sequences bound to MHC-I (Henderson et
al., 1992). Nevertheless, the biological activity of p2CL
indicates that proline at position 2 is not essential for bind-
ing to Ld. (Another Ld-restricted peptide [T2H, see Table 3]
also lacks proline at this position; Lurquin et al., 1989).
Given the fact that 2C recognizes at least three chro-
matographically distinguishable peptides in association
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Table 3. Synthetic Peptides Recognized with Ld by Cytotoxic T Lymphocytes
Peptide Origin Length Sequence Reference
CONSENSUS 9 -P - Falk et at., 1991b
NP118 LCMV NP 118-126 9 RPQASGVYM Schulz et al., 1991
MCMVH MCMV pp89 168-176 9 YPHFMPTNL Reddehase et al., 1989
T2H tum- P91A 12-24 13 ISTONHRALDLVA Lurquin et al., 1989
p2CL endogenous 8 LSPFPFDL present study
with Ld, the question can be raised as to whether the ligand
directly in contact with the 2C TcR consists of both Ld and
peptide or Ld alone; in the second case, the role of peptide
would be to confer a specific conformation on the Ld mole-
cule. While the latter model still represents a formal possi-
bility, the considerable weight of high resolution crystallo-
graphic evidence strongly favors the view that peptide
forms an important part of the actual ligand seen by a TcR
and that different peptides do not result in different MHC
conformations. Thus Wiley et al. have shown that the
three-dimensional structures of class I MHC molecules are
virtually identical whether they bind a single peptide or a
heterogeneous mixture of peptides (Bjorkman et al., 1987;
Garrett et al., 1989; D. C. Wiley, personal communication),
and recent studies by Wilson and colleagues have shown
that the three-dimensional structures of Kb with three dif-
ferent bound peptides are remarkably similar (I. A. Wilson,
personal communication). Since in our case the Ld mole-
cule is not recognized by 2C when an irrelevant peptide
known to bind Ld is added (Table 2), we conclude that the
correct peptide (p2CL) forms part of the complex recog-
nized by 2C. The existence of three peaks of activity in no
way implies that peptide is not involved directly in recogni-
tion by 2C. The alternative possibility, that p2CL exerts its
effect via specific conformational changes on Ld, remains
theoretical at this point and ultimately can be addressed
conclusively only by structural studies with p2CL, Ld, and
the 2C TcR.
We are currently accumulating additional material to de-
termine the sequences of active peptides in the other frac-
tions of spleen and thymus homogenates and from
affinity-purified Ld. We have determined that all of these
peptides must be recognized by the same TcR that sees
p2CL, because antibody 182 (F(ab) 2 fragment) blocks the
susceptibility of B2 cells sensitized by these peptides to
lysis by 2C cells (as shown in Figure 5 for p2CL). Whether
the active fractions represent peptides that differ from
p2CL by 1 or 2 aa at the N- or C-terminus, as suggested
above, or have the same sequence and represent isomers
(e.g., proline cis-trans isomers), or have entirely different
sequences remains to be determined. Differences in the
sequences may help shed light on the mechanisms by
which MHC-associated peptides are generated. The ap-
parent presence of p2CL (or a closely related peptide) in
the thymus of H-2b mice suggests that this peptide is likely
to provide special opportunities for investigating the devel-
opment of immature T cells in the thymus and the regula-
tion of mature CD8 ÷ T cells in peripheral tissues of 2C
transgenic H-2b mice, as well as in conventional H-2b mice.
Experimental Procedures
Cell Lines
The 2C CTL clone originated in the spleen of a BALB. B mouse (H-2b)
that had been injected with P815 cells (from strain DBA/2, H-2') and
BALB/c spleen cells (H-2') (Kranz et al., 1984a). The anti-tumor clone
8A5 was raised in this laboratory against P911 cells, a nontumorigenic
variant of P815 cells, as described (Maryanskl t al., 1982). The anti-
ovaibumin clone 4G3 was established in this laboratory by Dr. C.
Nagler-Anderson as described by Carbone and Bevan (1990). All CTL
were stimulated weekly in culture with the appropriate irradiated tumor
target cells in K medium (RPMI supplemented with 10 mM HEPES, 2
mM glutamine, 100 Ulml penicillin, and 100 gg/ml streptomycin, plus
10% fetal calf serum) with the addition of rat concanavalin A superna-
tant containing about 20 U/ml 11L2. Tumor cell lines RMA and RMA-S
and the Ld-transfected L cell line T1.1.1 were generous gifts from Drs.
J. Monaco and J. Seidman, respectively (Ljunggren et al., 1990; Evans
et al., 1982).
Cytotoxicity Assay
To measure lysis of target cells, 1 x 10' 'Cr-labeled target cells were
incubated with various numbers of CTL in 200 gil of K medium in
round-bottom microtiter wells. Peptides or peptide-containing samples
in 50 i• of Dulbecco's modified Eagle's medium were added to 50 l1
of target cells suspended in K medium, and after 30 min at 370C, CTL
at a CTL:target cell ratio of 3:1 were added. After brief centrifugation,
the cells were incubated for 4 hr at 370C, and the amount of 5'Cr
released into the extracellular medium was determined. The percent
specific lysis was calculated as 100 x (5'Cr released - spontaneous
release)/(total release in detergent - spontaneous release). Toxicity
controls consisted of peptide plus 'Cr-labeled target cells without addi-
tion of 2C CTL.
Gene Construction and Transfection
The B2 cell line was established by introducing a genomic form of the
Ld gene, a generous gift from Drs. M. Zuniga and L. Hood (Moore et
al., 1982), into the Sp210 cell line using the expression vector pHER.
Developed in this laboratory, pHER is pSV2neo modified to carry the
metallothionein promoter, an immunoglobulin heavy chain enhancer,
and the poly(A) signal from an immunoglobulin K gene. The construct
will be described elsewhere. To subclone the L gene under regulatory
elements of vector origin, an Xhol linker (NEB #1030, New England
Biolab, Beverly, MA) was introduced at a BamHI site, 15 bp 5' of the
initiation codon after eliminating the BamHI site with Si nuclease. At
the 3' end, a BamHI linker (NEB #1021) was introduced at a Pvull site
6 bp downstream of the stop codon. The resulting plasmid, pHERmL',
was linearized at its Hindill site for transfection. The RMA-S transfec-
tant, RLd-E2, was generated by introducing the Ld gene under its own
regulatory elements: a 12 kb Hindtll fragment containing the genomic
L' gene was excised from the plasmid 27-5-27 (Moore et al., 1982) and
cotransfected with pSV2neo linearized at the BamHI site.
Transfections were performed by electroporatton with the Cell Pora-
ter (BRL). Approximately 50 g of linearized DNA with or without 20
gg of linearized pSV2neo was mixed with 2 x 107 cells in 700 lvi of
Dulbecco's modified Eagle's medium and charged at 750 V, 800 .F.
After 24 hr at 370C, G418 (GIBCO) was added to a final concentration
of 1 mg/ml. LO expression was assessed with the conformation-
dependent monoclonal antibody 30-5-7S (a generous gift of Dr. David
Sachs). Before FACS analyses were carried out, RMA-S transfectants
were incubated overnight with an L'-binding peptide derived from
127
MCMV pp89 (Reddehase et al., 1989) in order to increase the cell
surface density of Ld molecules reactive with antibody 30-5-7S (Hansen
et al., 1988). Under these conditions, three out of five G418-resistant
Sp2/0 transfectants and five out of five RMA-S transfectants expressed
increased levels of L. Transfectants with the highest expression were
designated B2 and RAL-E2.
Acid Extraction of Low Molecular Weight Material
from Tissues
Thymus and spleen were from male and female mice, generally 4 to
14 weeks old. Tissues were kept on ice and processed immediately or
quickly frozen at -700C and kept at this temperature until subjected
to acid extraction by adding 1.0 ml of 0.7% TFA per 0.2 g of tissue
and immediately introducing the material into a polytron homogenizer
(Brinkman Instruments, Westbury, NY). Homogenization was carried
out for 2 mm while chilling the sample on ice, and the homogenates
were then sonicated for 2 min at 40C (Model W-225R, Ultrasonics,
Inc.) and kept on ice for an additional 30 min. After centrifugation at
31,000 x g for 30 min, the supernatants were subjected to ultrafiltration
through a Centricon 10 membrane (molecular mass cutoff 10 kd, Ami-
con, Beverly, MA). Filtrates were dried by Speed Vac and redis-
solved in 0.1% TFA for reverse phase HPLC fractionation. Acid extrac-
tion of P815 cells was carried out with homogenates prepared in a
Dounce homogenizer starting with cells at 2 x 100 per mi in 0.7% TFA.
Subsequent steps were the same as for tissue extracts.
Affinity Purification of Ld and Dd
L and Dd proteins were affinity purified from P815 cells by a slight
modification of previously described methods (Mescher et al., 1983;
Tsomides et al., 1991). Briefly, 2 x 10'0 P815 cells were lysed by N2
cavitation, and the resulting membrane fraction was solubilized in
0.5% NP40, 20 mM Tris-HCI (pH 8.0), 1 mM phenylmethylsulfonyl
fluoride. To prepare columns for affinity chromatography, polyclonal
mouse Ig or monoclonal antibodies 30-5-7S (anti-L) or 34-5-8S (anti-
D') were coupled to Affigel-hydrazide (Bio-Rad, Richmond, CA)
through the carbohydrate moiety in their Fc domain after penodate
oxidation. The solubilized membrane fraction was loaded onto the
following columns connected in series: unmodified Affigel-hydrazide,
Affigel coupled to polyclonal mouse Ig, Affigel coupled to 30-5-7S, and
Affigel coupled to 34-5-8S, in that order. After washing the columns
with 125 mM triethylamine acetate (TEAAc) (pH 7.5) and 0.5% NP40,
the bound material was eluted with 125 mM TEAAc (pH 11.0). An
aliquot of the eluate was tested for purity by SDS-polyacrylamide gel
electrophoresis. The remaining material was lyophilized and redis-
solved in 0.7o% TFA for ultrafiltration through a CentrtconlO membrane
to separate bound peptides.
HPLC Fractionation of Tissue and Cell Extracts
Ultraftitrates of acid extracts from tissues or cells were loaded on a
C18 reverse phase column (218TP104, Vydac) in batches of up to 30
mg total peptide per injection. For larger scale purification, a Beckman
C18 semipreparative column was used. HPLC was performed on a
Beckman system equipped with a 421A controller, two 110A pumps,
and a 160 absorbance detector (280 nm) connected in series to an
Applied Biosystems 757 absorbance detector (220 nm). Chromato-
grams from the two detectors were recorded on Beckman 427 and
Hewlett Packard HP3394A integrators. Solvent A was 0.1% TFA, and
solvent 8 was acetonitrile containing 0.085% TFA. The gradient used
for the first round of chromatography was from 5% to 30% 8 over 25
min (1% B per min) followed by a shallower gradient of 0.25% B per
min over 40 min (gradient program 7). Fractions (1.0 ml) collected at
1 min intervals were assayed for their ability to sensitize 82 cells for
lysis by 2C CTL. The active fractions were pooled and subjected to a
second round of chromatography on the same C18 column but with a
shallower gradient of 0.067% B per min (gradient program 8). Active
fractions from the second gradient were subjected separately to further
HPLC purification on a pH-stable C8 column at pH 8.5 (Vydac
228TP104). For this column, solvent A was 125 mM TEAAc (pH 8.5),
and solvent B consisted of 15% buffer A and 85% acetonitrile con-
taining 77 mM TEAAc. For chromatography at pH 8.5, the gradient
was 0.o/1% B per min, starting at 32% B, for 70 min. The fractions with
sensitizing activity were identified by cytotoxicity assay, and the pooled
activity peak was rechromatographed twice on the same pH-stable
column isocratically at 31% B and 24.4% B, successively, using the
cytotoxicity assay after each chromatography to identify the active
fraction(s).
Mass Spectrometry
The active fraction from the final chromatography under isocratic con-
ditions (see above) was analyzed by Dr. loannis Papayannopoulos and
Professor Klaus Biemann by fast atom bombardment mass spectrome-
try to determine the peptide's molecular weight. Identical values were
obtained using either glycerol or N-benzylalcohol as the matrix for
ionization.
Peptide Sequencing and Synthesis
Purified peptides were sequenced by Edman degradation on an Ap-
plied Biosystems instrument, model 477. Synthetic peptides were pre-
pared by standard Merrifield solid phase methods using t-Boc chemis-
try on an Applied Biosystems 430A at the Massachusetts Institute
of Technology Biopolymers Laboratory. Peptide concentrations were
usually measured by micro BCA Assay (Pierce). However, the concen-
trations of p2CL and p2CI were determined by quantitative amino acid
analyses.
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ABSTRACT We previously isolated from mouse spleen an
octapeptide (LSPFPFDL) that in association with the class I
major histocompatibility complex protein Ld is recognized by
the antigen-specific receptor of an alloreactive CD8* T-cell
clone (2C). Guided by an assay dependent upon the same 2C
T-cell receptor, we have now isolated from the same source
another naturally occurring peptide. The second peptide
(VAITRIEQLSPFPFDL) includes the entire octapeptide se-
quence and preliminary evidence suggests that it may be a
natural precursor of the octapeptide. On finding extensive
sequence homology between the 16-mer and part of human
2-oxoglutarate dehydrogenase, we determined the cDNA se-
quence of mouse 2-oxoglutarate dehydrogenase and found that
the deduced amino acid sequence matches precisely the two
naturally occurring peptides, indicating their origin by cellular
processing of this ubiquitous self protein.
CD8+ T lymphocytes recognize short peptides displayed on
the surface of cells (termed target cells) in association with
proteins of the class I major histocompatibility complex
(MHC-I) (1). The peptides appear to be derived by proteo-
lytic cleavage of intracellular proteins. When they arise from
viral or other microbial proteins in infected cells or from
tumor-specific proteins in transformed cells, the resulting cell
surface peptide-MHC-I complexes frequently elicit CD8+
cytotoxic T lymphocytes (CTLs) capable of destroying the
infected or transformed cells. Peptide-MHC-I complexes in
which the peptides are derived from normal self proteins are
also important. When immature CD4+ CD8+ T cells recog-
nize such self peptides in association with MHC-I proteins on
thymic cells, thymocytes that would otherwise develop into
mature potentially autoreactive T cells are clonally deleted.
Self peptides are also likely to be involved in the positive
selection of immature thymocytes. In addition, peptides
derived from normal proteins are recognized in association
with MHC-I proteins by many of the mature CD81 T cells
that react specifically with cells from individuals of the same
species that have different MHC proteins; these "alloreac-
tive" T cells are largely responsible for the rejection of
normal organ allografts (skin, kidney, heart, etc.).
One way to learn about the normal proteins that are
effectively represented as peptide-MHC-I complexes is to
characterize the peptides of normal target cells that are
recognized by alloreactive CD8 + CTLs and from their se-
quences to identify the proteins from which these peptides
arise. In this context we have been studying a CD8 + T-cell
clone termed 2C. A typical alloreactive CTL clone, 2C arose
in a mouse having the H-2b haplotype (BALB.B) in response
to injections of allogeneic cells having the H-2d haplotype
(BALB/c and DBA/2), and it is specifically reactive with one
of the MHC-I proteins (i.e., Ld) from H-2d cells (2). We have
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shown (3) that when trifluoroacetic acid (TFA) homogenates
of mouse spleen or thymus were subjected to ultrafiltration
(Mr < 10,000) and the filtrates were fractionated by reverse-
phase HPLC (RP-HPLC), three distinct peptide-containing
fractions could sensitize Ld+ target cells to lysis by 2C cells.
From the earliest eluting fraction (fraction a), we purified a
single active octapeptide, previously called p2CL and herein
termed p2Ca, and established its sequence (LSPFPFDL).
However, a search of protein sequence data bases with this
octamer failed to identify a matching protein. Furthermore,
the relationship among the three (or more) different peptides
that are present in normal tissue extracts and that can be seen
by 2C cells remained unknown. In the present study we
isolated a single active peptide from the second sensitizing
RP-HPLC fraction (fraction b), determined its sequence and
relationship to p2Ca, and identified the protein source* of
both peptides.
MATERIALS AND METHODS
Cell Lines. The 2C CTL clone (2) was grown as described
in K medium [RPMI 1640 medium supplemented with 10 mM
Hepes, 2 mM glutamine, penicillin at 100 units/ml, strepto-
mycin at 100 ±g/ml, and 10% (vol/vol) heat-inactivated fetal
calf serum]. B2 cells, used as target cells in cytotoxicity
assays and as a source of proteasomes (see Fig. 3, below), are
murine myeloma Sp2/0 cells (BALB/c origin) transfected
with the Ld gene as described (3). RLd-E2 cells, used in
Ld-binding assays (see below), are RMA-S cells transfected
with the Ld gene (3). T2-Ld cells, used as target cells in some
cytotoxicity assays, are the human antigen-processing mu-
tant cell line T2 (4) transfected with the Ld gene; they were
kindly provided by P. Cresswell (Yale University). All Ld
transfectants were maintained in K medium with G418
(GIBCO) at concentrations between 200 and 500 gg/ml.
Cytotoxicity Assay. To screen HPLC fractions for peptides
that can sensitize B2 cells to lysis by 2C CTLs, the fractions
were dried (SpeedVac; Savant), taken up in Dulbecco's
modified Eagle's medium, and tested in cytotoxicity assays
as described (3). Percent specific lysis of target cells was
calculated from released 51Cr as 100 X (experimental release
- spontaneous release)/(total release in detergent - spon-
taneous release). Toxicity controls consisted of peptide plus
51Cr-labeled target cells (2C CTLs omitted).
Purification of Naturally Occurring Peptides. Spleens from
471 BALB/c Kh mice (Max-Planck-Institut, Tilbingen) were
homogenized in 0.7% TFA (3). After the homogenates were
sonicated for 2 min and centrifuged at 31,000 x g for 30 min
at 40C, supernatants were subjected to ultrafiltration through
Abbreviations: MHC, major histocompatibility complex; OGDH,
2-oxoglutarate dehydrogenase: CTL, cytotoxic T lymphocyte; TFA,
trifluoroacetic acid: RP, reverse phase.t The sequence reported in this paper has been deposited in the
GenBank data base (accession no. U02971).
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a Centricon-10 membrane (Amicon) and to successive rounds
of fractionation by RP-HPLC. Active fractions correspond-
ing to peak b were rechromatographed until only a single peak
was detected by UV absorbance. For the first three rounds,
solvent A was 0.1% TFA in H20 and solvent B was 0.1% TFA
in acetonitrile, the column was a SuperPac pep-S (Pharma-
cia), and gradients of 0.1%, 0.067%, and 0.067% solvent B per
min were used, respectively. For the final three rounds,
solvent A was 125 mM triethylamine acetate (pH 8.75) and
solvent B was 31 mM triethylamine acetate in acetonitrile;
the column was a Vydac pH-stable Cs column (228TP104),
and the gradient was 0.1% solvent B per min. Fractions were
collected at either 1-min or 0.5-min intervals.
Peptide Sequencing and Synthesis. From the active fraction
of the final HPLC run of p2Cb (see Fig. 1), 8% was analyzed
by Edman degradation on an Applied Biosystems model 477.
Another aliquot was analyzed by matrix-assisted laser de-
sorption time-of-flight mass spectrometry by Ioannis Papa-
yannopoulos and Klaus Biemann (Department of Chemistry,
Massachusetts Institute of Technology). Peptides were syn-
thesized on an Applied Biosystems model 430A using t-but-
oxycarbonyl chemistry (Biopolymers Laboratory, Massa-
chusetts Institute of Technology). Peptide concentrations
were generally determined by MicroBCA Assay (Pierce).
Because the concentration of peptide p2Ca was underesti-
mated by MicroBCA when manufacturer-supplied bovine
serum albumin was used as the standard (T.J.T., unpublished
observation), p2Ca was quantitated by 6 M HCI hydrolysis
and amino acid analysis or by MicroBCA using amino
acid-analyzed p2Ca as the standard.
Purification of Synthetic p2Cb. After 2 hr at 60"C, synthetic
p2Cb was purified by three rounds of RP-HPLC on a Beck-
man model 334, subjecting fractions after each round to
cytotoxicity assay as described above and selecting the major
peak, corresponding to p2Cb, for the next round. Round one
was on a Vydac C4 semipreparative column (214TP510) using
a gradient of 1% solvent B per min (solvent A = 0.1% TFA
in H20; solvent B = 0.085% TFA in acetonitrile) and a flow
rate of 3 ml/min. The second and third rounds were on a
Vydac diphenyl analytical column (219TP54) and a Vydac CIs
analytical column (218TP104), respectively, using a gradient
of 0.067% solvent B per min and a flow rate of 1 ml/min.
The Mouse 2-Oxoglutarate Dehydrogenase (OGDH) Gene.
From total RNA isolated by acid phenol extraction of Sp2/0
cells, single-stranded cDNA was synthesized using the Su-
perScript preamplification system (BRL). cDNA from 0.35
pg of RNA was used to amplify by PCR a part of the OGDH
sequence in 50 pl by using 10 pmol of the following two
oligonucleotide primers at 55*C for annealing: 5'-GCTATAT-
GACTGCAATTGGGTT-3' and 5'-ATAGTAGCCTTGGT-
TCTTGTGC-3'. The primers correspond to nt 2524-2545 and
2938-2959 of human OGDH (5). The amplified DNA was
cloned into pUC18 at the Sma I site and the nucleotide
sequences of three individual clones were determined by the
dideoxynucleotide method using Sequenase version 2.0
(United States Biochemical). The sequence was confirmed
by independent PCR amplification, cloning, and sequencing.
RESULTS AND DISCUSSION
Isolation and Characterization of Peptide p2Cb. Fraction-
ation of ultrafiltrates of BALB/c mouse spleen or thymus
homogenates by RP-HPLC was found (3) to consistently
yield three fractions (fractions a-c) that were capable of
sensitizing Ld+ target cells (B2) to lysis by 2C CTLs. To
isolate the active peptide from fraction b, we subjected
pooled ultrafiltrates from 471 BALB/c mouse spleens to
successive rounds of RP-HPLC fractionation using different
chromatographic conditions. After six rounds, the active
fraction from what was originally termed fraction b (Fig. 1)
26 36 46
HPLC fraction number
FiG. 1. Chromatogram and cytotoxicity assay from the final step
in the purification of peptide p2Cb from mouse spleen. Solid line,
A229; dotted line, acetonitrile gradient; e, percent specific lysis by 2C
due to fractions collected at 0.5-min intervals. Baseline drift in the
chromatogram arises from triethylamine acetate.
was analyzed. The Edman procedure yielded the sequence
VAITRIEQLSPFPF, which was not complete because the
purified peptide was found by mass spectrometry to have a
molecular mass of 1846 Da. From these results and the known
sequence of the active peptide in fraction a (p2Ca, LSPF-
PFDL), we concluded that the complete sequence of the
active peptide in fraction b (hereafter termed p2Cb) was
VAITRIEQLSPFPFDL (mass, 1846 Da). To verify this con-
clusion a peptide having the 16-residue sequence was syn-
thesized and tested: it had the same RP-HPLC retention
times as naturally occurring p2Cb, and like its naturally
occurring counterpart, it sensitized B2 target cells to lysis by
2C CTLs (Fig. 2). Furthermore, the antigen-specific T-cell
receptor that recognizes peptide p2Ca was also responsible
for the response of 2C cells to peptide p2Cb: clonotypic
monoclonal antibody 1B2 (6), which blocked the 2C-
mediated lysis of p2Ca-sensitized Ld+ target cells (3), had a
similar effect on the response to p2Cb (inhibiting by 90%
2C-mediated lysis of target cells sensitized with p2Cb).
Is p2Cb Recognized as a Full-Length Peptide in Association
with Ld by 2C Cells? The sensitizing activity of synthetic p2Cb
seemed surprisingly high for a peptide of this length, which
is considerably longer than other peptides previously isolated
from normal cells and active in CTL assays (7, 8). The peptide
concentration initially required to sensitize target cells for
half-maximal lysis in our standard cytotoxicity assay [SDso
(9)] was 5 ng/ml, whereas the octapeptide p2Ca had an SDso0
of =300 pg/ml using B2 target cells (3). However, while
synthetic p2Cb was >98% pure by RP-HPLC using the
standard criterion of UV absorbance (220 nm), several con-
80
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Fro. 2. Degradation of peptide p2Cb in medium used for cyto-
toxicity assays. After four rounds of RP-HPLC purification, 2 pg of
synthetic p2Cb was incubated with assay medium for 2 hr and
subjected to ultrafiltration and further chromatography on a C18
column using a gradient of 0.067% solvent B per min. Percent specific
lysis due to fractions from p2Cb incubated with assay medium (e) and
fractions from p2Cb incubated with medium that had been heated to
100*C for 10 min (A) are shown.
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taminating by-products having no detectable absorbance
were evident in the far-more-sensitive cytotoxicity assay.
After purification of synthetic p2Cb by three successive
rounds of RP-HPLC on different columns, its effective sen-
sitizing activity decreased by =20-fold (SDso = 100 ng/ml).
That intact p2Cb may not bind to Ld to a significant extent
was suggested by our earlier finding that fractions a and c but
not fraction b could be eluted from H-2d (P815) cells, sug-
gesting that the active component in fraction b (i.e., p2Cb)
may not bind to Ld (3). If so, the sensitizing activity of
naturally occurring p2Cb could result from its being cleaved
in serum-containing medium during the course of cytotoxic-
ity assays. To test this possibility, purified synthetic p2Cb
freed of contaminating sensitizing components (see above)
was incubated for 2 hr in the serum-containing medium used
for these assays. RP-HPLC analysis of TFA ultrafiltrates of
the incubation mixture revealed several new peaks of bio-
logical activity eluting earlier than p2Cb (Fig. 2). If, however,
the assay medium was first heated in a boiling water bath for
10 min, followed by addition of p2Cb for 2 hr at 37*C,
RP-HPLC fractionation of the mixture and CTL assay of each
fraction showed that the only peak of activity corresponded
to authentic p2Cb (Fig. 2). Thus, it is likely that during the
standard 4-hr cytotoxicity assay both naturally occurring and
synthetic p2Cb are cleaved to some extent by serum pepti-
dases, generating smaller fragments responsible for some or
possibly all of the apparent sensitizing activity of the 16-mer.
It is possible, nevertheless, that intact p2Cb binds weakly
to Ld because we found that this peptide enhanced cell
surface expression of Ld on RLd-E2 cells [RMA-S cells that
lack the peptide transport gene TAP-2 and had been trans-
fected with the Ld gene (3), thereby providing a sensitive
Ld-binding assay (10, 11)]. After RLd-E2 cells were kept
overnight at 260C and then incubated with p2Cb at 10- 5 M for
30 min at 370C, increased surface expression of Ld was
measured by flow cytometry using monoclonal antibody
30-5-7S (12) and a fluorescein isothiocyanate-labeled second-
ary antibody [210 vs. 185 (background) mean log fluorescence
units]; though definite, this effect was much less pronounced
than that due to the octapeptide p2Ca or the Ld-binding
nonapeptide YPHFMPTNL from mouse cytomegalovirus
(13), which increased Ld expression in the same assay to 260
or 310 mean log fluorescence units, respectively.
To determine whether p2Cb-Ld complexes might be rec-
ognized by 2C cells, we measured the level of intracellular
Ca2+ ([Ca2+]) in indo-l-loaded 2C cells 5-6 min after they
were mixed (and briefly centrifuged) with RLd-E2 cells that
had been pulsed with p2Cb or p2Ca at concentrations ranging
from 10- ' to 10-10 M; as in the fluorescence assay above,
RLd-E2 cells were maintained at 26°C overnight before
adding peptides. With both peptides, concentration-
dependent increases in [Ca2+]i were seen, but 15- to 30-fold
more p2Cb than p2Ca was required to elicit the same effect.
Moreover, the maximal increase elicited by p2Cb was lower
than that elicited by p2Ca (-7-fold vs. 10-fold above the
background [Ca2+]i level of 200 jAM). Because the increase in
[Ca2+]i was seen after only 5 min and the assay was carried
out in medium that contained 1% bovine serum albumin in
place of fetal calf serum, the confounding effect of proteolytic
fragmentation was minimized. Although these findings indi-
cate that p2Cb binds weakly to Ld and that its complexes with
Ld may be recognized to some extent by 2C cells, we believe
that the naturally occurring peptide's activity in the cytotox-
icity assays that led to its detection and isolation was due
largely to its cleavage into smaller active fragments (see Fig.
2).
Although peptidases present in fetal calf serum, on cell
surfaces, or released from dead cells introduce uncertainty
about the precise sequences of peptides that elicit T-cell
responses in cytotoxicity assays, this ambiguity is advanta-
Proc. Natl. Acad. Sci. USA 90 (1993)
geous in screening HPLC fractions, as it allows for the
detection of longer peptides (such as p2Cb) that might
otherwise go undiscovered.
Crystallographic studies of peptides bound to MHC-I pro-
teins suggest that the peptide N and C termini are buried in
the MHC-I binding groove so that the binding of peptides
longer than 8 or 9 residues is unlikely unless accommodated
by bulging of the peptide's midsection away from the MHC-I
molecule. A bulge of 8 amino acids in the p2Cb midsection
seems extreme, and it is possible that Ld is more permissive
than other MHC-I proteins and allows several amino acids at
the N terminus of this longer peptide (e.g., VAITRIE) to
extend beyond the binding groove.
Amount of p2Cb Recovered. From the Edman analysis of
naturally occurring p2Cb, we estimate that the 471 spleens
originally extracted had a minimum of 500 pmol of p2Cb (Fig.
1), assuming no loss of peptide during purification and 100%
yield of the N-terminal amino acid as a phenylthiohydantoin
derivative. This value corresponds to a recovery of =7000
molecules of p2Cb per cell, assuming 108 nucleated cells per
mouse spleen, or =20 times more than we estimated for the
p2Ca octamer (3).
Peptide p2Cb as a Possible Precursor of p2Ca. Longer
peptides that may be intermediates in the processing pathway
from intracellular protein to the octamers and nonamers
commonly bound to MHC-I molecules have not yet been
isolated (14). Comparison of the sequences of p2Ca (LSPF-
PFDL) and p2Cb (VAITRIEQLSPFPFDL) suggested that
p2Cb might be such an intermediate. To determine whether
proteasomes isolated from mouse cells can cleave p2Cb to
give p2Ca, synthetic p2Cb freed of contaminants (see above)
was incubated with purified proteasomes, and RP-HPLC
fractions from TFA ultrafiltrates of the incubation mixture
were tested for sensitizing activity. After a 2-hr incubation,
we observed two new peaks of activity (Fig. 3). One, eluting
at 50-51 min in Fig. 3, had the same retention time as p2Ca
using a shallow (and, therefore, highly resolving) gradient on
two different HPLC columns (C18 and diphenyl), but its yield
was too low to establish its mass or sequence. Thus, we
cannot conclude definitively that p2Cb was cleaved to yield
p2Ca; however, notwithstanding arguments against an oblig-
atory role for MHC-linked proteasome subunits in antigen
processing (16, 17), these results provide a basis for further
C,
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FIG. 3. Cleavage of peptide p2Cb by proteasomes purified from
B2 cells. The 20S proteasomes were purified as described (15).
HPLC-purified p2Cb (0.35 g) was incubated in a final volume of 15
Al alone (0o), with purified 20S proteasomes (1.43 Mg) that were
inactivated by 0.2% TFA (a), or with purified 20S proteasomes
activated by dialysis (A). After 2 hr at 370C, 285 pl of 0.2% TFA was
added and the samples were subjected to ultrafiltration in a Micro-
con-10 microconcentrator. The filtrates were dried, dissolved in
0.1% TFA. and loaded on a C18 column using a gradient of 0.067%
solvent B per min. Fractions were tested for sensitizing activity using
2C CTLs and 5 1Cr-labeled T2-Ld target cells at a ratio of 5:1. Toxicity
controls (target cells incubated with each RP-HPLC fraction in the
absence of CTLs) are shown only for the reaction with activated
proteasomes (o) but were the same for the other two reactions.
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study of a possible role for proteasomes (18) in the processing
pathway that leads to p2Ca as final product.
Identification of the Protein from Which p2Cb and p2Ca Are
Derived. A search of protein sequence data bases revealed an
unmistakable similarity between the sequences of p2Cb and
OGDH (also called a-ketoglutarate dehydrogenase) from
yeast (19), Escherichia coli (20), and other bacteria (21). The
sequence of the human homolog, recently determined from
cloned cDNA (5), was even more similar: fourteen out of 16
amino acids in p2Cb were identical (87.5%). Peptide frag-
ments from the homologous pig enzyme (5) also had very
similar sequences (Fig. 4).
If OGDH was the source of peptides p2Ca and p2Cb, the
mouse homolog (whose sequence was not in the data base)
should precisely match the sequences of the two peptides.
Accordingly, we determined a partial sequence of mouse
OGDH by the PCR, using mouse cDNA and 5' and 3'
deoxynucleotide primers that were selected on the basis of
the human OGDH sequence. Fig. 4 shows the partial DNA
sequence of mouse OGDH and the deduced amino acid
sequence aligned with the corresponding sequences of hu-
man, pig, and yeast OGDH. From the complete match
between p2Ca, p2Cb, and mouse OGDH, it is highly likely
that the two natural peptides are derived from proteolytic
cleavage of this normal intracellular protein.
Concluding Remarks. Previous analyses of peptide-
containing HPLC fractions from tissue or cell extracts found
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that most alloreactive CTL clones respond to only one of
many fractions, presumably the one containing a singular
peptide recognized by that clone in association with a par-
ticular allogeneic MHC-I protein (22-25). However, a few
clones (-20% of those examined) responded to two or three
fractions (23). That several fractions can elicit a response by
a single CTL clone has been puzzling: are the peptides in
these fractions related or totally unrelated? The present study
answers this question for CTL clone 2C, for here we show
that two peptides detected by the same T-cell receptor on
these cells share an octapeptide sequence and differ only in
length. The sequence of the longer peptide led to the iden-
tification of the protein source of these peptides, OGDH, an
essential participant in the tricarboxylic acid cycle and pre-
sent in all cells. Since this mitochondrial protein is ubiquitous
and the two peptides are produced from it in cells of all three
MHC haplotypes tested (H-2d, H-2b, and H-2k), this system
may prove useful for analyzing mechanisms of self tolerance.
Neither mass spectrometry nor Edman degradation en-
abled us previously to determine unambiguously whether the
C-terminal residue of p2Ca was Leu or Ile. Therefore, we
relied on cytotoxicity assays and RP-HPLC chromatography
to compare two synthetic peptides with either Leu or Ile at
the C terminus and to conclude that naturally occurring p2Ca
terminated with Leu (3). Confirmation of this conclusion by
the sequence of OGDH (Fig. 4, boxed area) testifies to the
remarkable ability of CTL assays and RP-HPLC, particularly
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FIG. 4. Partial sequence of mouse OGDH and comparison with sequences of human. pig, and yeast homologs. The cDNA sequence of mouse
OGDH is shown in the top line, flanked by the 5' and 3' primers from the human OGDH cDNA sequence (5) (italic type and boxed) used for
PCR. The deduced amino acid sequence of mouse OGDH is compared with the corresponding amino acid sequences of OGDH from humans
(5), pigs (5), and yeast (19). Dash. same amino acid as mouse OGDH: no mark, amino acid not determined (pig only); boxed amino acids,
sequences corresponding to peptides p2Ca and p2Cb. Note. The deduced amino acid at position 68 is incorrectly shown as L (Leu); it should
be H (His).
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in combination, to discriminate between a structural differ-
ence as minor as the position of a single methyl group in Leu
vs. lie.
Naturally occurring longer peptides like p2Cb that may be
precursors of MHC-I-binding shorter peptides, to our knowl-
edge, have not previously been described in virus-infected or
normal cells (7, 8, 26-28). The reason may be that most
attempts to identify the naturally occurring peptides recog-
nized by T cells have relied on affinity purification of MHC-I
proteins as a preliminary step; hence, only peptides that bind
very stably to MHC-I proteins (primarily octamers and
nonamers) are isolated by such approaches (14). By isolating
peptides from whole tissue homogenates, as in this study,
longer putative precursor peptides are more likely to be
detected, providing they are active in T-cell assays, an
activity that may depend upon their being cleaved into
smaller fragments directly responsible for sensitizing activity
in T-cell assays. Longer precursor peptides probably also
have to accumulate to relatively high levels in tissue or cell
homogenates, as is the case with p2Cb, to compensate for the
likelihood that they have lower sensitizing activities than
octamers or nonamers. This combination of requirements
may account for the findings that single CD8+ CTL clones
have not previously identified such precursors in fractionated
tissue or cell homogenates. And yet such precursors for the
octamers and nonamers that bind strongly to MHC-I proteins
are probably commonplace in cells. Their sequence, abun-
dance, and intracellular compartmentalization may help illu-
minate the processing pathways for peptide presentation by
MHC-I proteins.
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A CYTOTOXIC T LYMPHOCYTE CLONE CAN RECOGNIZE THE
SAME NATURALLY OCCURRING SELF PEPTIDE IN ASSOCIATION
WITH A SELF AND A NONSELF CLASS I MHC PROTEIN
JAN P. DUTZ,t THEODORE J. TSOMIDES, SHIGEKI KAGEYAMA, MIMI H. RASMUSSEN and
HERMAN N. EISEN*
Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology,
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Abstract-The alloreactive CD8 ÷ cytotoxic T lymphocyte (CTL) clone 2C was previously shown to
recognize complexes made up of the class I MHC (MHC-I) molecule Ld and an octapeptide
(LSPFPFDL, termed p2Ca) isolated from tissues of H-2d mice. Because peptide p2Ca has also been
found in BALB.B (H-2b) mice, the strain from which clone 2C originated, the question arises as to
whether these T cells can recognize peptide p2Ca in association with a self MHC protein of the H-2b
haplotype. Here we show that 2C CTL do indeed recognize peptide p2Ca in association with Kb on
the surface of H-2b cells or on transfected cells expressing Kb, but that an approximately 1000-fold
higher concentration of this peptide is required to sensitize Kb + than Ld + target cells for lysis by
2C cells. However, the peptide's binding to Kb was not much weaker than to Ld, with only an
approximately 10-fold difference in the respective equilibrium constants. These results predict that
the T cell receptor (TcR) of clone 2C has a much lower intrinsic affinity for p2Ca-Kb complexes
than for p2Ca-Ld complexes, and they provide some quantitative limits on the requirements for
triggering T cell-mediated autoimmune reactivity.
Key words: alloreactivity, class I MHC, natural peptide, autoimmunity, positive selection.
INTRODUCTION
A previous study led to the biochemical isolation and
sequence determination of a naturally occurring peptide
that, in association with Ld, forms a ligand for the
antigen-specific T cell receptor (TcR) of the alloreactive
(H-2b anti-H-2d) CD8' cytotoxic T cell clone 2C (Udaka
et al., 1992). This peptide, an octamer termed p2Ca
(LSPFPFDL), derives from o-ketoglutarate dehydro-
genase, which is present in all cells as it is an essential
component of the Krebs cycle (Udaka et al., 1993). In
cytotoxicity assays, target cells bearing p2Ca-Ld com-
plexes are specifically and effectively lysed by 2C cells. In
mice that are transgenic for the : and P3 genes of the
TcR of 2C cells, thymocytes that express this receptor
(2C-TcR) are eliminated if the mice express Ld,
suggesting that under natural conditions recognition of
the p2Ca-Ld complex by immature thymocytes causes
their "negative selection". If. however, these transgenic
mice express Kb and not Ld, T cells expressing the
2C-TcR are positively selected, leading to their abun-
dance in the periphery, where they account for _ 50%
of all circulating T cells in H-2b mice transgenic for the
*Author to whom correspondence should be addressed at:
Center for Cancer Research and Department of Biology.
M.I.T. E17-128. Cambridge. MA 02139-4307, U.S.A.
+Present address: University of British Columbia. Vancouver.
British Columbia. Canada V6T IZ3.
2C-TcR (Sha et al.. 1988b). Inasmuch as peptide p2Ca
is also detectable in the thymus of H-2b mice (Udaka
et al., 1992), we have asked here whether this naturally
occurring octapeptide can bind to K' (or Db). and if so,
whether the p2Ca-MHC complexes that are formed can
be recognized by the 2C-TcR.
Our results show that the peptide binds to Kb and not
to Db, and that the binding to Kb is not much weaker
than to L". Yet, an approximately 1000-fold higher
concentration of p2Ca is required to sensitize Kb" target
cells than Ld• target cells for 50% maximal lysis by 2C
cells. This great disparity leads to the prediction that the
2C-TcR has a much lower intrinsic affinity for p2Ca-Kb
complexes than for p2Ca-Ld complexes. and helps to
explain why the presence of p2Ca-K" complexes does
not result in overt autoimmune reactions in H-2b mice
transgenic for the 2C-TcR. Finally. the results support
the hypothesis that peptide p2Ca may be one of the
naturally occurring peptides involed in the positive
selection of T cells with the 2C-TcR in H-2b 2C-TcR
transgenic mice.
MATERIALS AND METHODS
Cell lines and cytotoxic T lymphocyte (CTL) clones
B2 cells are Sp2 0 myeloma cells (H-2d) transfected
with the Ld gene (Udaka et al., 1992). T2 cells. a human
TxB hybridoma. are defective in the presentation of
967
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endogenous peptides by class I MHC (MHC-I) proteins
(Alexander et al., 1989); these cells and T2-Ld, T2-Kb,
and T2-Db (T2 cells transfected with the a chain genes
for Ld, Kb, or Db, respectively) were all gifts from Dr P.
Cresswell. RMA-S cells (H-2b), also defective in the
ability to present endogenous peptides with MHC-I
proteins (Kfirre et al., 1986; Townsend et al., 1989), were
a gift from Dr J. Monaco. All of these cells, as well as
EL4 cells (H-2b thymoma) and P815 cells (H-2d mastocy-
toma), were grown in RPMI supplemented with 10%
fetal calf serum, 10mM HEPES, 2 mM glutamine,
100 U/ml penicillin, 100 p/g/ml streptomycin, and 50 p M
fl-mercaptoethanol ("K medium"). The medium used to
grow transfected cells was supplemented with 270 p g/ml
G418 (Gibco BRL).
CTL clone 2C was derived and maintained in culture
as described (Kranz et al., 1984). The anti-PR8 CTL line,
derived from a C57B1/6 mouse (Hosken and Bevan,
1992), recognizes an influenza virus nucleoprotein pep-
tide (NP366, see Table 1) in association with Db. It was
maintained by stimulating 2 x 10' cells weekly in 2 ml K
medium supplemented with 5% rat concanavalin A
supernatant and 25 mM methyl-a-D-mannopyrannoside
together with 4 x 106 irradiated (3000 rads) syngeneic
spleen cells that had been pulsed with 1 pg/ml NP366 for
2 hr and then washed extensively.
Peptides
The peptides used or referred to in this study are
described in Table 1. They were synthesized at the
M.I.T. Biopolymers Laboratory by solid phase tBoc
chemistry using an Applied Biosystems 430A and HF
cleavage and were purified by reverse phase HPLC;
their amino acid compositions were confirmed by amino
acid analysis. In general, their concentrations in solution
were measured by BCA assay (Pierce) using bovine
serum albumin (BSA) as the standard. The exception
was p2Ca: its concentration was grossly underestimated
by BCA assay using a BSA standard and so was
measured by amino acid analysis or by BCA assay using
a p2Ca standard whose concentration had been deter-
mined by amino acid analysis. Stoichiometric iodination
of peptides with 1271 or with a mixture of '"2I + 2'71
followed by reverse phase HPLC purification of each
product was performed as described (Tsomides and
Eisen, 1993a).
Peptide binding to MHC-I proteins
The method used to measure equilibrium constants
for the interaction of p2Ca with Ld or Kb is described
elsewhere in detail (S. Kageyama et al., submitted).
Briefly. the binding of p2Ca was measured by its inhi-
bition of the specific binding of a uniformly iodinated
"indicator" peptide (I1-pMCMV) to Ld or Kb on intact
cells (T2-Ld or T2-Kb, respectively). pMCMV, which can
bind to both LA (Reddehase et al., 1989) and Kb (Dutz
et al., 1992), was stoichiometrically labeled with a mix-
ture of 1S1 + 127I and isolated as its monoiodotyrosyl
derivative I,-pMCMV (termed '25I,-pMCMV for sim-
plicity) (Tsomides and Eisen, 1993a). To measure the
equilibrium constants for the binding of this indicator
peptide to Ld or Kb, intact T2-Ld or T2-Kb cells were
incubated with various concentrations of the peptide for
several hours at 250C in the presence of NaN3 and
2-deoxyglucose, washed twice, and centrifuged through
oil to separate bound from free peptide. To correct for
the nonspecific binding of peptide to the cells, titrations
were carried out in the presence of a 500-fold or greater
molar excess of an unlabeled peptide known to bind
strongly to Ld (pMCMV) or to Kb (pOV8, see Table 1).
Scatchard plots of the resulting specific binding data for
2
'SI,-pMCMV (bound/free vs bound peptide) were linear
and yielded single equilibrium binding (association) con-
stants (K, values): for Ld the K, value was 4 x 10' M -
and for Kb it was 3 x 106 M -.
To measure the KA values for p2Ca and Ld or Kb,
different concentrations of p2Ca were mixed with
'
2SI,-pMCMV and incubated with T2-Ld or T2-Kb
cells, and the bound and free ' 5I,-pMCMV were separ-
ated as described above. Since both the labeled and
unlabeled peptides were substantially in excess over
the number of MHC-I molecules on T2-Kb or T2-Ld
cells, the Chen-Prusoff equation (Chen and Prusoff,
1973) could be applied to calculate the K, value for the
binding of p2Ca to Ld or Kb. Each K. value reported is
the average of three or more experiments; independent
determinations generally agreed to within a factor of
two.
Table I. Peptides used or referred to in the present study
Peptide Sequencea Origin MHC restriction Reference
p2Ca LSPFPFDL x-ketoglutarate dehydrogenase Ld; Kb Udaka et al., 1992; 1993;
present study
pMCMV YPHFMPTNL Murine cytomegalovirus pp89 Ld; Kb Reddehase et al., 1989;
Dutz et al., 1992
pOV8 SIINFEKL Ovalbumin Kb R6tzschke et al., 1991b
VSV8 RGYVYQGL Vesicular stomatitis virus nucleoprotein Kb van Bleek and
Nathenson. 1990
SV9 FAPGNYPAL Sendai virus nucleoprotein Kb Schumacher et al., 1991
NP366 ASNENMETM Influenza virus nucleoprotein Db Townsend et al.. 1986
E1A234 SGPSNTPPEI Adenovirus EIA DD Kast et al.. 1989
aAmino acid residues in bold face refer to presumptive anchor residues for K" and Db (Falk et al., 1991). For Ld. the presumptive
anchor residues are proline at position 2 and leucine at the C-terminus (Corr et al., 1992).
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Fig. 1. Peptide p2Ca binds to Kb and the p2Ca-Kb complex is recognized by 2C cells. S'Cr-labeled
target cells expressing different cell surface MHC-I proteins were compared for their ability to be
sensitized by peptide p2Ca for lysis by 2C CTL. Arrows point to soD, values, i.e. peptide
concentrations at which 50% of maximal lysis is observed: 1I ng/ml for B2 and T2-Ld and
: I pgiml for EL4 and T2-Kb. (a) Comparison of B2 cells (Sp2iO cells transfected with the Ld gene)
and EL4 cells (H-2b haplotype and thus expressing Kb and Db). (b) Comparison of T2 cells singly
transfected with the x chain genes for Ld, Kb, or Dh. termed respectively, T2-Ld. T2-Kb. and T2-Db.
Cytotoxicity assay
S'Cr-labeled target cells (10) were incubated with CTL
in the presence or absence of various peptides or with
reconstituted HPLC fractions in a total volume of 200 plI
K medium in round-bottom 96-well microtiter plates.
After 4 hr at 370C, the plates were centrifuged at 200g
for 5 min and 100 pl supernatant from each well was
analysed for 51Cr. Percent specific lysis was calculated
from the average of duplicate samples as 100 x ("Cr
released - spontaneous release)/(total release in deter-
gent - spontaneous release). Spontaneous release values
varied from 5-20% of total release. Toxicities of syn-
thetic peptides and reconstituted HPLC fractions were
tested by omitting CTL from the assay, and were
negligible unless otherwise noted (specific lysis over
background < 5%).
Peptide competition assay
For some cytotoxicity assays, two peptides (the
cognate peptide and a competing peptide) were added
to assess the degree of competition for the restricting
MHC-I protein. When the CTL were 2C cells (Fig. i),
the cognate peptide p2Ca was added at the concen-
tration required to sensitive Ld+ or Kb+ target cells
for half-maximal lysis [i.e. the SD0o value (Tsomides
et al., 1991)]. In experiments with anti-PR8 CTL.
the cognate peptide NP366 was added to EL4 target
cells at 10pg/ml, the SDo0 for this CTL-target
cell-peptide combination (Fig. 2). After incubating S'Cr-
labeled target cells and CTL with the cognate peptide
plus various concentrations of competing peptide
for 4 hr at 37°C, the supernatants were assayed for
MIMM 31 13--B
"
5 Cr release as described above. The potency of the
competing peptide was expressed as an ic50 value: the
concentration of inhibitor that blocked 50% of the
target cell lysis observed in the presence of cognate
peptide only.
Flow cytometric analysis of MHC-I expression
To measure the cell surface density of Ld or Kb on
T2-Ld, T2-Kb, and RMA-S cells, the cells were incubated
(5 x 10' cells per ml K medium) at 37-C with or without
various concentrations of peptide for 2.5-8 hr. The cells
were then washed in phosphate buffered saline (PBS)
and incubated for 20 min at 4'C with affinity-purified
anti-MHC-I ("primary") antibody (5 gi/ml) in PBS
with 5% fetal calf serum and 0.02% NaN3. The cells
were washed and incubated for 20 min with 15j g/ml
FITC-labeled goat anti-rat Ig when the primary anti-
body was MI/42 [a rat IgG,, monoclonal antibody that
binds to all murine MHC-I proteins except Db (Kane
et al., 1989)] or with 15 p gml FITC-labeled F(ab'), of
goat anti-mouse Ig when the primary antibody was Y3
[anti-Kb monoclonal antibody (Hiimmerling et al.,
1982)) or 28-14-8 [anti-Ld monoclonal antibody (Ozato
et al., 1980)]. We observed that Ml!42 failed to bind
murine MHC-I o chains in association with human
fl2-microglobulin on transfected T2 cells (data not
shown); hence for these cells we used Y3 as the primary
antibody. Live cells (104) were gated by forward and
perpendicular light scatter and scored for fluorescence in
an EPICS-C flow cytometer. The fluorescence values
shown (in arbitrary units) are representative of at least
two independent experiments.
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RESULTS AND DISCUSSION
Peptide p2Ca is recognized by 2C cells in association with
LV or Kh
Previous studies established that the naturally occur-
ring peptide p2Ca can associate with Ld (Udaka et al.,
1992). To determine whether p2Ca can associate with
MHC-I proteins of the H-2b haplotype and whether the
resulting complexes are recognized by 2C cells, we
compared the p2Ca-dependent lysis of EL4 cells (H-2b
haplotype) with that of Ld-expressing B2 cells (Fig. la),
using 2C cells as CTL. Both target cells were killed but
lysis of EL4 cells was very limited and required an
approximately 1000-fold higher concentration of peptide
to achieve 50% maximal lysis. To learn whether the
restricting MHC-I protein on EL4 cells was Kb or Db,
we examined the 2C-mediated lysis of T2 cells that had
been transfected with the t chain gene for one of the
murine MHC-1 proteins Ld, Kb, or Db. p2Ca was
recognized on T2-Ld and T2-Kb target cells, but not on
so40
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Fig. 2. Peptide p2Ca does not bind to Db. p2Ca %as tested for
its ability to block the lysis by a Dh-restricted anti-influenza
virus CTL (anti-PR8) of 5"Cr-labeled T2-Db cells sensitized
with the influenza virus nucleoprotein peptide NP366 (see
Table 1). (a) Lysis of 5 Cr-labeled T2-D" cells by CTL line
anti-PR8 as a function of the concentration of peptide NP366:
the peptide's soD value was :: 10 pg ml. (b) Lysis of T2-Db cells
by anti-PR8 CTL in the presence of NP366 at 12 pg/ml plus
either I pglml EIA234 (a Db-binding peptide from an aden-
ovirus protein, see Table 1) or p2Ca at concentrations up to
10 g/ml. The CTL:target ratio was 5:1.
T2-Db (Fig. lb). As in the comparison of EL4 (H-2b)
with B2 (H-2d) target cells (Fig. la), the concentration of
peptide required to sensitize target cells for 50% maxi-
mal lysis (the SD, value, Tsomides et al., 1991) was about
1000 times higher for Kb-expressing than for Ld-express-
ing T2 target cells. The much greater reactivity of T2-Kb
than EL4 target cells can be attributed to the defective
loading of endogenous peptides onto newly synthesized
MHC-I protein in T2 cells, resulting in a relatively high
cell surface density of Kb molecules that are accessible
for occupancy by exogenous peptide (Hosken and
Bevan, 1990).
Peptide p2Ca does not bind to Dh
Some earlier studies have suggested that peptide-
MHC-I binding is relatively promiscuous: a peptide that
binds to one MHC-I protein may bind to many of them
(Bouillot et al.. 1989: Frelinger et al., 1990; Chen et al.,
1990). Accordingly, we asked whether the absence of
reactivity of 2C cells toward T2-Db incubated with p2Ca
(Fig. lb) arose from failure of p2Ca to bind to Db or
from failure of the 2C-TcR to recognize p2Ca-Db com-
plexes. To distinguish between these possibilities, we
assessed the inhibitory effect of p2Ca on the lysis of
T2-Db target cells sensitized with an influenza virus
peptide (NP366) by an anti-influenza CTL line (anti-
PR8) that is known to recognize peptide NP366 in
association with D' (Hosken and Bevan, 1992). As
shown in Fig. 2, lysis of T2-Db cells incubated with
NP366 at its SD,0 concentration (10pgiml) was not
inhibited by p2Ca at 10 pg;ml, i.e. at a 106-fold excess
of p2Ca over the influenza peptide. As a control, a
known Db-binding peptide (E1A234, see Table 1) readily
inhibited lysis by the anti-influenza CTL line (Fig. 2b).
Thus. while p2Ca can clearly associate with either Ld or
Kb (Fig. lb and see below), it does not bind to a
significant extent to Db.
Sensitization of Kh- target cells by p2Ca is due to the
peptide itself and not to trace amounts of a contaminating
peptide
Since concentrations of peptides far too low to be
detected by UV absorbance can sensitize target cells for
lysis in cytotoxicity assays (R6tzschke et al.. 1990;
Schumacher et al., 1991: Tsomides and Eisen. 1993b), it
was necessary to determine whether the sensitization of
Kb+ target cells by high concentrations of p2Ca was
actually due to this peptide or to unknown trace con-
taminants, which are commonly present in synthetic
peptide preparations. As noted in Fig. 3. under two
different and discriminating reverse phase HPLC frac-
tionation conditions. the peaks for p2Ca and for T2-Kb
sensitizing activity were coincident, demonstrating that
p2Ca and not a minor contaminating peptide is recog-
nized in association with Kb by 2C cells.
The binding affinities of p 2Ca for L' and K'
The requirement for a much higher concentration of
p2Ca to sensitize K - than Ld - target cells (Fig. 1) could
be due to weaker binding of the peptide to K" than to
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Fig. 3. Peptide p2Ca, and not a contaminant of the synthetic
peptide preparation, is responsible for the sensitization of
Kh-expressing target cells. Twenty pg p2Ca was injected into
a Beckman 334 HPLC system equipped with a C18 reverse
phase column (Vydac 218TP104). Fractions were eluted using
a gradient of 0.25% B/min (---) and a flow rate of I ml/min.
with solvent A = 0.1% trifluoroacetic acid (TFA) in water and
solvent B = 0.085% TFA in acetonitrile. The eluate was mon-
itored by absorbance at 220 nm using an Applied Biosystems
757 detector. Each I ml fraction was dried, taken up in 70 pl
K medium, and analyzed in duplicate (20 Ipl/well) in a 4 hr lysis
assay using "Cr-labeled T2-Kh as target cells and 2C as CTL
(*); possible toxicities associated with the fractions were also
tested by omission of the CTL (0). A second HPLC fraction-
ation method using a C4 reverse phase column with 5 p
particles (Beckman) and a shallower gradient (0.167% B/min)
also showed correspondence between 220 nm absorbance and
sensitizing activity on T2-K b target cells (not shown).
Ld or to lower affinity of the 2C-TcR for the p2Ca-Kb
complex than for the p2Ca-Ld complex, or to a combi-
nation of both factors. To compare the binding of p2Ca
to Ld and Kb we used a competition binding assay
(Kageyama et al., submitted) in which the binding of a
stoichiometrically radioiodinated indicator peptide [''Si,-
pMCMV (Tsomides and Eisen. 1993a)] to intact T2-Ld
or T2-K' cells was subjected to competition by p2Ca.
From the concentration of p2Ca required to decrease the
specific binding of '2 I,-pMCMV to target cells by 50%.
and from the independently measured affinities of L' and
Kb for the indicator peptide (see Materials and
Methods), we determined the equilibrium constant (K 4)
for p2Ca binding to Kb to be I x 10' M- (Kageyama
et al., submitted). For p2Ca binding to L , similarly
measured on T2-Ld cells, the K 4 value was 4 x 10' M-';
for this peptide's binding to Ld on P815 cells the value
was 1 x 106 M- , and to soluble Ld molecules it was
4 x 106 M -' (Sykulev et al., 1994). We therefore take the
average binding constant for p2Ca to LU to be
I x 106M -' or about 10-fold higher than its binding
constant to Kb.
In view of these relatively low association constants
(particularly for the p2Ca-Kb interaction), we evaluated
the binding of p2Ca to Ld and Kb by an independent
approach: comparison by flow cytometry of the ability
and this and other peptides to enhance the surface
expression of these MHC-I molecules on mutant cells.
The mutant cell lines RMA-S (H-2b), T2-Kb, and T2-Ld
have greatly reduced levels of surface MHC-I due to
defects in the intracellular loading of these proteins with
endogenous peptides, and these levels can be specifically
enhanced by incubating the cells with peptides that bind
to the relevant MHC-I protein (Townsend et al., 1989;
Hosken and Bevan, 1990). Therefore, we compared the
ability of p2Ca to enhance the surface expression of Ld
or Kb with that of other peptides whose equilibrium
constants for binding to Ld or Kb have been determined
elsewhere. As shown in Fig. 4A, an approximately
330-fold higher concentration of p2Ca than of pOV8
was required to bring about an equivalent increase in the
surface expression of Kb on RMA-S cells (i.e. to the same
mean fluorescence value). For T2-Kb cells an approxi-
mately 1000-fold higher concentration of p2Ca than of
pOV8 was required to achieve the same increase in Kb
expression (data not shown). These large differences
0001 001 01 1 1 10 100
peptide concentration (pg/ml)
Fig. 4. Effect of peptides on cell surface expression of Kb and
LU in the antigen processing mutant cells RMA-S and T2-Ld,
respectively. (A) RMA-S cells were incubated at 37'C with the
indicated concentrations of pOV8 (.) or p2Ca (A) for 8 hr and
then stained with the anti-K' mAb Y3 followed by FITC-la-
beled goat anti-mouse Ig F(ab'),. The fluorescence of live cells
(gated by low angle and 90- scattered light) was measured by
flow cytometry. Fluorescence values were converted to an
arbitrary linear scale from 0 (background) to 100 (maximum).
The concentration of peptide required to elicit 50% of the
maximal response was 0.006 p gml for pOV8 and 2 p2g/ml
for p2Ca (shown by vertical arrows). (B) T2-Ld cells were
incubated with '7 I,-pMCMV (filled squares) or p2Ca (A)
followed by the anti-Ld mAb 28-14-8 and FITC-labeled goat
anti-mouse Ig F(ab'), as above. The concentration of peptide
required to elicit 50% of the maximal response was
-0.007pg,'ml for '2 I,-pMCMV and 41pg ml for p2Ca
(shown by vertical arrows).
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(330-1000-fold) are in approximate agreement with the
large difference in equilibrium constants (K,) for the
binding of pOV8 and p2Ca to Kb: by two different
methods (Matsumura et al., 1992; Kageyama et al.,
submitted), the KA for pOV8 binding to Kb was
1.5 x 10" M-' and I x 108 M-', respectively, whereas
the K, for p2Ca binding to Kb was I X 105 M -, 1000-
fold lower.
A similar analysis using T2-Ld cells, shown in Fig. 48,
revealed that about a 500-fold higher concentration of
p2Ca than of I,-pMCMV was required to elicit an
equivalent increase in Ld expression. This difference also
agrees with the approximately 400-fold difference in
equilibrium constants observed using the competition
binding assay to measure the binding of these peptides
to intact T2-Ld cells: the K 4 for '2SI,-pMCMV binding to
Ld was 4 x 101 M - ', while for p2Ca binding to Ld the K 4
was I x 106 M-' (see above). The convenience of flow
cytometry as an assay for peptide binding to MHC-I
molecules on intact cells has led to its widespread use: it
is therefore noteworthy that differences in equilibrium
constants for peptides binding to the same MHC-I
molecule (although not the actual values of these con-
stants) are fairly well predicted by differences in peptide
concentrations required to elicit an equivalent increase in
MHC-I expression.
Since the affinity of Kb for p2Ca is only about 10-fold
lower than the affinity of Ld for this peptide (see above),
the 1000-fold difference in p2Ca concentrations required
to sensitize T2-Ld or T2-K b target cells for half-maximal
lysis by 2C cells (Fig. lb) suggests that the affinity of the
2C-TcR for the p2Ca-K b complex is very much lower
than for the p2Ca-Ld complex. This expectation has
been verified recently by the finding that these affinity
values are 3 x l0~ M -' (2C-TcR for p2Ca-Kb) and
2 x 106 M - (2C-TcR for p2Ca-Ld), respectively
(Sykulev et al., 1994). Thus the difference in sensitizing
activities of peptide p2Ca using target cells with two
different MHC restriction elements is consistent with the
combined effects of different peptide-MHC-I affinities
and different TcR affinities for the respective pep-
tide-MHC-I complexes (p2Ca-Ld and p2Ca-Kb). It
should be noted that use of transfectants of the same
target cell in each case (i.e. T2-Ld and T2-K b) minimizes
other potential differences between target cells (e.g.
accessory molecule differences). Moreover, we have de-
termined that the number of surface Ld and Kb molecules
accessible for peptide binding on these cells is approxi-
mately the same (6000 and 4000 per cell, respectively,
Kageyama et al., submitted).
The amino acid sequence of p2Ca is compatible with its
binding to Kb and not to Db
Naturally occurring peptides that associate with a
given MHC-I protein are typically eight or nine amino
acids in length and vary in composition at all positions.
except one or two "'anchor" positions where only one or
a few amino acids occur with high frequency (Falk et al.,
1991). For Kb-binding octapeptides. Tyr and Phe are
predominant at position 5 (position 6 for nonamer
peptides), and Leu is the C-terminal residue (position 8
or 9) (see Table 1). In peptide p2Ca, Leu at position 8
fits this motif but Phe occurs at positions 4 and 6, not
at 5. However, the presence in this peptide of proline
residues at positions 3 and 5 could have the effect of
constraining the peptide backbone in such a way that
Phe-4 or Phe-6 takes the place of Phe-5 in promoting
interaction with Kb. This imperfect match may explain
the relatively weak binding of p2Ca to Kb.
The sequence of p2Ca is also in accord with its failure
to bind to Db: Asn at position 5, an anchor residue for
peptide binding to this MHC-I protein, is absent from
p2Ca, which has no Asn anywhere in its sequence.
Interestingly, p2Ca also does not satisfy the consensus
motif for Ld [proline at position 2 and leucine at position
9 (Falk et al., 1991; Corr et al., 1992)); nevertheless, this
peptide binds well enough to Ld (K 1 x 106 M '),
demonstrating that not all MHC-I-binding peptides
must conform strictly to consensus motifs.
CONCLUDING REMARKS
Naturally processed peptides recognized by CTL in
association with cell surface MHC-I proteins on target
cells have been identified for several anti-viral CTL
(R6tzschke et al.. 1990; van Bleek and Nathenson, 1990:
Del Val et al., 1991; Tsomides et al., submitted). For
each of these CTL, as well as for an anti-ovalbumin
clone (R6tzschke et al., 1991 b), a single peptide-MHC-I
complex has been identified. Similarly, when HPLC
fractions from allogeneic cells or tissues have been tested
for their ability to sensitize target cells for lysis by
alloreactive MHC-I-restricted CTL. sensitizing activity
in a single fraction has generally been found (Heath
et al.. 1991: Rdtzschke et al., 1991a). All of these
observations suggest that the antigen-specific TcR of a
CTL clone recognizes to a significant extent only one
peptide-MHC-I complex. regardless of whether the
MHC restricting element is syngeneic with the CTL (for
anti-viral CTL) or allogeneic (for alloreactive CTL).
However, ongoing experience with CTL clone 2C, ex-
tended in the present study. shows that this clone's TcR
can recognize a variety of peptide-MHC-I complexes
(Udaka et al.. 1992, 1993: Wu et al.. in preparation),
albeit with diverse affinities (Sykulev et al., 1994).
CTL clone 2C arose in a BALB.B (H-2b) mouse that
had been immunized with H-2d cells, and this clone
recognizes L' (Kranz et al., 1984) in association with
several naturally processed peptides. at least two of
which represent overlapping sequences derived from the
ubiquitous enzyme x-ketoglutarate dehydrogenase
(Udaka et al.. 1992. 1993). One of these peptides, p2Ca,
is now shown to be recognized by the same TcR in
association with Kb. What makes recognition of the
p2Ca-K b complex of particular interest is that Sha et al.
(1988a. b) have shown that it is Kb, and not Db, that is
required for positive selection of maturing CD8' thymo-
cytes in mice transgenic for the 2C-TcR. Furthermore.
from the effects of various Kb mutations, and the
positions of these mutations in the peptide binding
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groove, they deduced that a self peptide in association
with Kb drives positive selection of 2C-TcR + thymo-
cytes in 2C-TcR transgenic mice (Sha et al., 1990).
Because peptide p2Ca has been detected in the thymus
and other tissues of H-2b mice (Udaka et al., 1992), and
is shown here to bind to Kb (and not to Db) and to
form complexes that are recognized weakly by the
2C-TcR, this octapeptide is an interesting candidate for
a positively selecting peptide in these mice. However,
recent findings (Ashton-Rickardt et al., 1993) suggest
that it is not one but several, and perhaps many,
peptides in the thymus that, in association with the
restricting MHC-I protein, cause positive selection of
CD8' T cells having a given TcR. It will therefore be of
interest to determine whether p2Ca in Kb" mice trans-
genic for the 2C-TcR is only one of many peptides that
can cause positive selection of CD8+ cells having the
2C-TcR or whether, in view of the properties described
here, p2Ca has a special role in positive selection of
these T cells in these mice.
Peptide p2Ca is derived intracellularly from a pro-
tein, i-ketoglutarate dehydrogenase, that is present in
all cells (Udaka et al., 1993). Not surprisingly, the
peptide is present in spleen and thymus of H-2b (as well
as H-2d and H-2k) mice: it has more recently been
found in many other tissues as well (Wu et al., in
preparation) and is doubtless also widely distributed in
the 2C-TcR transgenic mice. Since almost all CD8 ÷ T
cells in these H-2b mice express the 2C-TcR, the ques-
tion arises as to why no evidence for T cell autoreactiv-
ity has been observed in these transgenic animals. One
reason, suggested by the findings in this study, is that
the minimal number of p2Ca-Kb complexes per target
cell required for activating effector function of 2C CTL
(cytolysis) is probably much higher than what is found
normally on cells in rivo; and it is clearly higher than
that required for similar activity in response to
p2Ca-Ld complexes.
Some indication of these numbers can be gleaned
from the equilibrium constants for the binding of pep-
tide p2Ca to Ld and Kb and the number (n) of available
MHC-I binding sites per target cell under conditions
where cells are subject to lysis by 2C in cytotoxicity
assays. As described elsewhere for T2-Kb and T2-Ld
cells under these conditions, the values of n at 37'C are
;4000 and -6000 per cell, respectively (Kageyama
et al., submitted). Taking the free peptide concentration
to be the SD50 value, or peptide concentration required
for half-maximal lysis in cytotoxicity assays, we esti-
mate that a 60-fold higher target cell surface density of
p2Ca-Kb than of p2Ca-Ld is required to trigger cy-
tolytic activity of 2C cells. Nevertheless, the amount of
peptide p2Ca recovered from H-2b and H-2d tissues was
approximately the same (Udaka et al.. 1992). Accord-
ingly, although direct extrapolation from these in vitro
considerations to in rico conditions is fraught with
many uncertainties, we believe it likely that the absence
of overt autoreactivity in H-2b 2C-TcR transgenic mice
is due to the low affinity of the 2C-TcR for p2Ca-Kb
complexes relative to the naturally occurring cell sur-
face density of these complexes, and not to the com-
plete absence of potentially autoreactive T cells or their
natural ligands. According to this model, if the ex-
pression of p2Ca-Kb complexes were to increase sub-
stantially in these mice, e.g. by a large increase in
expression of cell surface Kb or from an excess pro-
duction of the protein from which p2Ca is derived (or
both), an autoreactive response might well ensue. The
significance of similar numerical considerations for as-
sessing a possible role of p2Ca-Kb complexes in posi-
tive selection of 2C-TcR + thymocytes is now also
subject to direct experimental analysis using appropri-
ate assay systems. such as cultured thymus organ grafts
from mice genetically deficient in antigen processing
(Ashton-Rickardt et al., 1993) and transgenic for the
2C-TcR.
In assuming that at least some of the p2Ca extracted
from Kb ÷ tissues is indeed associated with Kb, we have
relied upon three considerations: (1) in H-2d cells, p2Ca
was recovered from immunoprecipitates of Ld (but not
Dd) (Udaka et al., 1992), indicating that this peptide
gains access to the intracellular compartment where
peptide binding to MHC-I takes place (i.e. endoplasmic
reticulum); (2) the mechanism for generating antigenic
peptides and translocating them into the endoplasmic
reticulum is conserved among inbred mouse strains of
different haplotypes (e.g. BALB/c, BALB.B); and (3)
our evidence that p2Ca can be bound by K b, albeit with
a somewhat lower affinity than by Ld. Thus it is highly
likely that at least some p2Ca is associated with Kb in
H-2 b tissues.
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ABSTRACT We report here that the intrinsic affinities of
the antigen-specific T-cell receptors (TCR) of two unrelated
CD8 ÷ T-cell clones for their respective peptide-major histo-
compatibility complex (MHC) ligands are higher than the
values generally thought to prevail for TCR. The TCR of one
clone (2C) binds an allogeneic class I MHC protein (Ld) in
association with an a-ketoglutarate dehydrogenase nonapep-
tide (QLSPFPFDL, termed QL9) with an intrinsic affinity(intrinsic equilibrium association constant) of 1-2 x 10' M-1.
The TCR of the other clone (4G3) binds a syngeneic class I
MHC protein (Kb) In association with an ovalbumin octapep-
tide (SIINFEKL, termed pOV8) with an intrinsic affinity of 1.5
x 106 M-'. A comparison of the two clones, combined with
current views of T-cell repertoire selection in the thymus, leads
us to propose that TCR affinities are generally likely to be
higher for allogeneic MHC-peptide complexes than for syn-
geneic MHC-peptide complexes.
Because the somatic hypermutation that underlies the gen-
eration of high-affinity antibodies is not evident in T cells, it
has long been surmised that the affinities of antigen-specific
T-cell receptors (TCR) for their natural ligands, now known
to be peptide-major histocompatibility complex (MHC) com-
plexes, are likely to be low and in the narrow range (104 to 105
M -1) exhibited by antibodies made early in immune re-
sponses, before the onset of somatic hypermutation. Previ-
ously, however, we showed (1) that one of the two murine
T-cell clones studied here (clone 2C) has a relatively high
intrinsic affinity (2 x 106 M-1) for its ligand: Ld, a class I
MHC protein, in association with an octapeptide (LSPF-
PFDL, termed p2Ca) that derives from murine a-ketogluta-
rate dehydrogenase (a-KGDH) (2, 3). This clone also recog-
nizes Ld in association with several other peptides from
a-KGDH. One of them, the nonapeptide QLSPFPFDL(termed QL9), proved to be exceptionally active in sensitiz-
ing Ld+ target cells (T2-Ld) for lysis by 2C cells. We show
here that the affinity of the TCR on 2C cells for the complex
formed by this peptide with Ld (QL9-Ld) is about 10 times
greater than for p2Ca-Ld and, to our knowledge, is the
highest affinity value found so far for any TCR.
Since the 2C clone arose in a mouse of the H-2b haplotype,
its high-affinity binding of the peptide-Ld complex is an
allogeneic reaction (alloreaction). To compare it with a CD8'
cytotoxic T lymphocyte (CTL) clone that is also highly
reactive cytolytically but recognizes a syngeneic MHC-
peptide complex, we took advantage of clone 4G3. This
clone, which also arose in an H-2b mouse, reacts specifically
with the ovalbumin octapeptide pOV8 (SIINFEKL) in asso-
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
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ciation with Kb. In this syngeneic reaction, the TCR affinity
for its peptide-MHC complex was about 10-fold lower than
in the alloreaction. Though the comparison involves only two
clones, when the findings are considered in light of recent
studies of T-cell repertoire selection in the thymus (4-6), they
lead us to propose that the affinity of a TCR for peptide-MHC
complexes will generally be greater when the MHC compo-
nent is allogeneic than syngeneic.
MATERIAL AND METHODS
Cells. The CTL clones 2C and 4G3 were maintained in
culture by weekly stimulation with irradiated stimulator cells
(P815 and EG7OVA, respectively), as described (7, 8). P815
(H-2d) is a mouse mastocytoma and EG70VA is the EL4
(H-2b) mouse thymoma transfected with the ovalbumin gene(9). The human hybridoma T2 (10) and Ld and Kb transfec-
tants of T2 (T2-Ld and T2-Kb, respectively) were used as
target cells in cytotoxicity assays.
Peptides. Peptides were synthesized by the solid-phase
t-butoxycarbonyl method in the Biopolymers Laboratory of
Massachusetts Institute of Technology and purified by
HPLC. Their concentrations were determined by quantita-
tive amino acid analysis.
Cytotoxicity Assay. Peptides in 0.15 M NaCl/0.02 M sodium
phosphate, pH 7.4 (PBS), were added to 5000 5tCr-labeled
target cells (T2-Ld or T-Kb) and 15.000-25,000 CTLs in
round-bottom 96-well plates in RPMI medium 1640 containing
10 mM Hepes, 2 mM glutamine, penicillin (100 units/mi),
streptomycin (100 gg/ml), 50 /4M 2-mercaptoethanol, and 10%
(vol/vol) fetal calf serum in a final volume of 200 pl per well.
After 4 h at 37°C in a 5% C0 2/95% air atmosphere, specific
lysis of target cells was determined from the amount of 5sCr
released into extracellular medium (a), corrected for sponta-
neous release (b) and total 51Cr content of the target cells (c):
i.e., specific lysis = 100(a - b)/(c - b).
Iodination of Soluble Peptide-MHC Complexes. Expression
of Ld and Kb proteins in Drosophila melanogaster cells and
their isolation from cell culture medium as soluble class I
molecules devoid of stably bound peptide adducts are de-
scribed elsewhere (11). Although up to 50% of purified Kb
molecules contain weakly bound peptides of yeast origin, the
peptide binding sites of Kb can be readily saturated with
appropriate peptides (I. Wilson, personal communication).
These "empty" MHC molecules were loaded with selected
peptides, which were maintained at a high concentration(10- 4 to 10-5 M) throughout to ensure saturation of the MHC
Abbreviations: MHC. major histocompatibility complex: synMHC.
syngeneic MHC: alloMHC. allogeneic MHC: TCR. antigen-specific
T-cell receptor s): a-KGDH. a-ketoglutarate dehydrogenase; CTL,
cytotoxic T lymphocyte.
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peptide binding sites. Soluble peptide-MHC complexes (50jug) were radioiodinated with 2.2 mCi of carrier-free Na'ZSI
(using lodo-Beads, Pierce; 1 Ci = 37 GBq) in 0.05 M sodium
phosphate (pH 8.2) to promote substitution of histidine
residues (12) in the six-histidine-residue extension at the
C-terminal end of the a chain of both Ld and Kb (11).
Equilibrium Binding of Peptide-MHC Complexes to TCR on
Intact T Cells. Two approaches were used to measure the
intrinsic equilibrium association constants (intrinsic affini-
ties) for the reaction of soluble peptide-MHC molecules with
the TCR on T cells. One depended upon the inhibition of the
binding of 125-labeled Fab' fragments of an anti-receptor
monoclonal antibody (1B2), which is specific for the TCR on
the 2C clone (13), by different concentrations of soluble
QL9-Ld complex as described (1).
The second approach measured direct binding of 1 Il-trace-
labeled soluble peptide-MHC complexes to intact T cells. As
it involved no competition with an anti-receptor antibody,
this method could be applied to 4G3 cells (for which an
anti-receptor antibody is not available) and to 2C cells. In a
typical reaction, various concentrations of 1251-labeled pep-
tide-MHC complexes were incubated in a total volume of
25-50 ~l with 3-5 x 10s T cells in 1% bovine serum albumin
in PBS containing 0.02% NaN 3. After 20-25 min, the time
required to reach equilibrium, cell-bound and free 151I-
labeled peptide-MHC were separated by rapid (10-15 sec)
centrifugation through a layer of 84% (vol/vol) silicone (d =
1.050)/16% (vol/vol) paraffin oil (d = 0.838) for radioactivity
measurements. Titrations were carried out in duplicate two
or three times. Corrections for nonspecific binding were
based on control samples in which the specific binding of125I-labeled peptide-MHC complexes to the TCR was
blocked by a 50- to 100-fold molar excess of soluble unlabeled
peptide-MHC complexes. For 2C cells, this correction was
verified by introducing the clonotypic anti-TCR antibody
(1B2) at 5 x 10- 7 M [a 100-fold higher concentration than the
equilibrium dissociation constant for the binding of this
antibody to the TCR on 2C cells (1)]. The residual cell-bound
radioactivity was attributed to nonspecific binding of the
radiolabeled complex. Equilibrium constants and numbers of
TCR molecules per CTL were determined from Scatchard
plot analysis of the binding data using a least squares fit. Lack
of fit errors in the calculated values of equilibrium constants
and numbers of TCR molecules per cell were obtained by
covariance analysis using a standard computer program.
Binding Kinetics of Soluble Peptide-MHC Complexes to
TCR on Intact T Cells. For kinetic studies, which provided a
third approach to determining equilibrium binding constants,
3-5 x 106 T cells (2C or 4G3) were mixed with 125I-labeled
peptide-MHC complexes in 250-500 pl of PBS containing
0.02% NaN 3 and 1% bovine serum albumin. The final con-
centration of ' 25I-labeled QL9-Ld in the reaction mixture was
5-10 nM. Higher concentrations (57-112 nM) of 2 1SI-labeled
pOV8-Kb were required because of the lower affinity of the
TCR on 4G3 cells for the pOV8-Kb complex than of the 2C
TCR for the QL9-Ld complex. At various times. 25-50 Al of
the reaction mixtures was removed to separate cells and
extracellular medium as described above to measure the
concentrations of cell-bound and free 125 -labeled peptide-
MHC. As in the equilibrium binding approach, nonspecific
binding to the cells was evaluated in control samples con-
taining a large excess of unlabeled peptide-MHC complexes.
The amount of specific receptor-bound peptide-MHC com-
plexes, determined as the difference between cell-bound12SI-labeled peptide-MHC in the absence and presence of
excess unlabeled peptide-MHC, was plotted as a function of
time. From the best fit of the experimental points to
RM(t) = a(1 - e-/'), [1]
where Ru(t) is the concentration of receptor-bound peptide-
MHC at time t, we determined the time constant r (the time
required to reach 63% of the equilibrium binding value) and
a (the concentration of receptor-bound peptide-MHC com-
plexes at equilibrium). The rate constant of association,
kM+l, was calculated from the equation kM+l = a/(RTM'r),
where RT is the total concentration of TCR, M is the free
concentration of peptide-MHC complexes, and a and -rare as
noted above. The intrinsic affinity (K, the equilibrium asso-
ciation constant) was also derived from (i) the value of a, (ii)
the total number of cell surface TCR molecules per cell (n),
and (iii) the free peptide-MHC concentration (c): a/n =
Kc/(1 + Kc) or K = a/(cn - ca).
RESULTS
Sensitization of Ld+ Target Cells by Various Peptides from
a-KGDH. As shown in Fig. 1, sensitization of Ld+ target cells
(T2-Ld) for lysis by 2C cells was achieved with 50-100 times
less QL9 than the octapeptide p2Ca, which was previously
the most active known Ld-restricted peptide for 2C cells (2,
3). QL9 was also 1000-10,000 times more potent than two
other nonamers, SPFPFDLLL(SL9) and LSPFPFDLL
(LL9), whose sequences also overlap p2Ca in a-KGDH.
Affinity of the TCR on 2C Cells for the QL9-Ld Complex,
Measured in Competition with an Anti-TCR Antibody Frag-
ment. Because QL9 was so active in sensitizing target cells
for lysis (Fig. 1), it seemed possible that the QL9-Ld complex
might bind with higher affinity than the p2Ca-Ld complex to
the 2C TCR. Accordingly, we compared the inhibitory effects
of soluble QL9-Ld and soluble p2Ca-Ld on the binding of the
12SI-labeled Fab' fragment of antibody 1B2 to intact 2C cells.
As shown in Fig. 2, the QL9-L d complex was a far more
potent inhibitor. From the inhibition data, the intrinsic affin-
ity of this TCR for QL9-Ld was calculated to be 1 x 107 M- t
(Table 1).
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FIG. 1. Specific lysis of transfected T2 target cells by two CD8 +
CTL clones. (Upper) Lysis of T2-Ld cells by 2C cells in the presence
of various concentrations of p2Ca or three nonapeptides (QL9. SL9.
and LL9) having overlapping sequences in murine a-KGDH (3).
(Lower) Lysis of T2-Kb cells by 4G3 cells in the presence of various
concentrations of the ovalbumin peptide pOV8.
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FIG. 2. Binding of soluble QL9-L d to the TCR on 2C cells
measured by inhibition of the binding of 125I-labeled Fab' fragments of
an anti-2C TCR clonotypic antibody (182). B/Bo is the ratio of the
amount of the TCR-bound 12SI-labeled Fab' in the absence (Bo) and
presence (B) of soluble peptide-MHC complexes at the free concen-
trations shown (abscissa). The dashed line represents the best fit of
experimental points (e) to the theoretical binding curve (for details,
see ref. 1). Binding of two other soluble peptide-Ld complexes to the
2C TCR has been described (1) and is shown here for comparison: A
refers to the p2Ca-Ld complex and o refers to the control complex
formed by Ld with a mouse cytomegalovirus peptide (YPHFMPTNL).
Direct Binding of the QL9-Ld Complex to Intact 2C Cells.
To confirm the high binding constant for the reaction of
QL9-Ld with the 2C TCR, we measured the direct binding
over time of this complex (trace-labeled with 12sl) to intact 2C
cells, omitting the competitive anti-receptor antibody (1B2)
fragment. As shown in Fig. 3A. the specificity of the direct
binding was evident from the inhibitory effect of the clono-
typic antibody 1B2 or of an excess of unlabeled QL9-Ld
complex (Fig. 3A Inset). From the best fit of the kinetic
binding data to Eq. 1, it was possible to determine both (i) the
maximal number of specifically bound QL9-Ld complexes
per cell at equilibrium (the term a, corrected for the number
of cells and the volume of the reaction mixture) and (ii) the
time constant r (the time required to reach 63% of the
equilibrium value): 7 was 3.9 min (Table 1) and a (at a free
peptide-MHC concentration of 4 nM) was 10,500 + 2100
bound complexes per cell. Inasmuch as we had previously
determined (and confirmed below, see Fig. 3B) that there are
Table 1. Equilibrium and rate constants for the reactions of TCR
of two unrelated T-cell clones (2C and 4G3) with
peptide-MHC complexes
pOV8-Kb +
Binding 4G3 TCR QL9-L d + 2C TCR
parameter 22-250C 22-250C 370C
Ka, M- 1 1.5 x 106  1.5 x 107  6 x 106
kM+, M-z'sec-' 2.2 x 104 5.3 x 10' 9 x 104
r, min 0.9 3.9 1.1
ku-,. sec - 1  2.1 x 10-2 3.1 x 10- 3 1.5 x 10 -2
t/,, min 0.5 3.7 0.7
Rate constants of association, kM, 1, were calculated from kM+1 =
a/(RTrM-r), where RT is the total concentration of TCR, M is the free
concentration of peptide-MHC complexes, a is the concentration of
the receptor-bound peptide-MHC complexes at equilibrium, andr is
the time constant. Dissociation rate constants, kM-1, and the corre-
sponding half-lifes (r~/,) were calculated from the equilibrium asso-
ciation constants and association rate constants (kM-1 = kM+1/K.) or
measured directly for QL9-Ld by monitoring the rate of dissociation
of bound t125 -labeled QL9-Ld from 2C TCR (data are not shown).
The binding parameters shown are average values derived from two
or more measurements, by using different methods to measure the
binding of QL9-Ld to the 2C TCR. Although the accuracy of the
measurements made with 4G3 cells was lower as a result of the higher
background (Fig. 4A) and lower affinity than was seen with 2C cells.
the results of independent titrations agreed to within a factor of 2.
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Fro. 3. Direct binding of the soluble '251-labeled QL9-Ld com-
plex to the TCR on intact 2C cells. (A) Kinetics of specific binding
of MI-labeled QL9-Ld to 2C cells. The concentration of the free
peptide-MHC complex was 4 nM. (Inset) Accumulation of cell-
bound radioactivity (cpm) with time in the presence (0) and absence
(A) of a large excess of unlabeled anti-2C TCR antibody (1B2). The
difference (e) represents specific binding of the peptide-MHC com-
plex; the fit of these experimental values to Eq. I is shown by the
dashed line (for values of a and 7 see text). (B) Specific equilibrium
binding of '12I-labeled QL9-Ld complexes at various free concen-
trations of this complex to TCR on 2C cells is represented by a
Scatchard plot. B. bound: F. free. The coefficient of correlation of
the least squares fit was 0.98.
close to 105 TCR molecules per 2C cell, the equilibrium
constant was calculated to be 2 x 107 M-1, in agreement with
the value determined in the competition assay of Fig. 2. [In
this calculation, the equilibrium association constant is given
by a/(cn - ca), where n is the number of TCR molecules per
cell. Since the number of TCR molecules per 2C cell varied
in different experiments (1) from 80.000 to 110.000 (100,000
average), the calculated equilibrium constant was accurate to
within a factor of 2.]
This binding constant was further confirmed by measuring
the number of peptide-MHC complexes bound per 2C cell at
equilibrium with various free concentrations of ' 251-labeled
QL9-Ld. These results. shown in the Scatchard plot in Fig.
38, yielded an equilibrium constant of 1.9 ± 0.2 x 107 M- 1.
Extrapolation of the plot in Fig. 3B to infinite free concen-
tration of the peptide-MHC complex yielded a limiting value
of 93.000 ± 5600 binding sites per 2C cell. also in agreement
with the total number of TCR molecules per cell previously
found with the Fab' fragment of the 1B2 antibody (1). Thus.
by three different approaches. the affinity of the 2C TCR for
the QL9-Ld complex was found to be 1-2 x 107 M-1 at 230C
(Table 1) or 5-10 times higher than the previously reported
value for this receptor's affinity for the p2Ca-Ld complex (1).
All of the affinity and kinetic measurements described
above and previously were carried out at room temperature
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(23-25"C). However, to relate the kinetics and affinity of
TCR-peptide-MHC reactions to the physiologic responses of
T cells, it is of particular interest to analyze the reactions at
37*C. Using both the direct binding assay shown in Fig. 3 and
the indirect competition assay of Fig. 2, we found that in
comparison with the binding at room temperature, the equi-
librium constant at 370C was only slightly lower (6 x 106 M-1
vs. 1.5 x 107 M-1) but the association and dissociation rates
were much faster (Table 1).
Direct Binding of pOVg-Kb Complex to TCR on Intact 4G3
Cells. To compare the alloreaction between the 2C cell (H-2b)
TCR and the QL9-Ld complex with a syngeneic reaction (in
which the MHC of the peptide-MHC complex and on the
CTL are the same), we determined the intrinsic affinity of the
TCR of clone 4G3 (8). A comparison between these two
CD8+ clones is particularly appropriate because about the
same concentration (=3 pM) of QL9 and pOV8, their respec-
tive optimally active peptides, was required for half-maximal
lysis of the appropriate T2 target cells (T2-Ld and T2-Kb,
respectively) by 2C and 4G3 cells (see Fig. 1). Both peptides,
moreover, are bound equally well by their respective restrict-
ing class I MHC proteins: for the binding of pOV8 to Kb (14)
and QL9 to Ld the equilibrium constants are 1.2-2 x 108 M- '
(data not shown).
Since anti-receptor antibodies to the TCR of 4G3 cells were
not available, we measured the direct binding of '12I-labeled
pOV8-Kb to these cells (Fig. 4A). It was necessary to use a
I
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FIG. 4. Direct binding of '2I5 -labeled pOV8-Kb complex to the
TCR on intact 4G3 cells. (A) Kinetics. The difference between total
(A) and nonspecific (o) time-dependent binding of the peptide-MHC(shown in Inset) represents specific binding of the complex with time(o). The dotted line represents the fit of the experimental values (0)
to Eq. 1 (for a and r-values see text). (B) Scatchard plot of equilibrium
binding of 1251-labeled pOV8-Kb complex to 4G3 cells. The data
points (o) represent specifically bound complexes (i.e., the differ-
ence between total and nonspecific binding). Least squares fit
analysis of the data yielded a coefficient of correlation of 0.85.
relatively high concentration of this labeled peptide-MHC
complex (57-112 nM) because the 4G3 TCR's affinity for it
was not high (see below). As a result, nonspecific binding was
greater than in the corresponding titration of the 2C TCR (cf.
Figs. 3 and 4). Nevertheless, TCR-bound peptide-MHC
complexes (determined as the difference between peptide-
MHC binding in the absence and presence of a large excess
of unlabeled pOV8-Kb) accumulated over time. The best fit
of experimental values for the time-dependent specific bind-
ing of I-labeled pOV8-Kb to the 4G3 TCR using Eq. 1
yielded a value for a (the amount of peptide-MHC bound at
equilibrium) of 4700 t 500 complexes per cell. From a, the
total number of TCR per cell (10', see below), and the free
peptide-MHC concentration (57 nM), the intrinsic equilib-
rium association constant for the 4G3 TCR reaction with
pOV8-Kb was calculated to be 1 x 106 M-1.
In separate experiments with various free concentrations
of this peptide-MHC complex, the numbers of specifically
bound pOVS-Kb complexes per cell at equilibrium were also
measured. The results, presented as the Scatchard plot in
Fig. 4B, yielded essentially the same equilibrium constant
(1.7 ± 1.1 x 106 M-t). The Scatchard plot extrapolated to
140,000 ±: 50,000 TCR molecules per 4G3 cell (mean ± SEM),
similar to the number of TCR molecules per 2C cell (1). The
association and dissociation rate constants for the pOV8-Kb
reaction with the 4G3 TCR (see Table 1) were also similar to
those reported previously for the reaction of the p2Ca-Ld
complex with the 2C TCR (1).
DISCUSSION
This study resulted in three principal findings. One concerns
the magnitude of the affinities of the TCR on two clones of
widely different specificities for their respective peptide-
MHC ligands. The previous finding that one of these clones
(2C) has a high-affinity TCR (ref. 1, and extended here) might
be ascribed to chance. But the results with the second clone
(4G3) suggest that TCR affinities of this magnitude are not
rare. The earlier reports of CD4 ÷ T cells with TCR affinities
in the 104 to 105 M-' range (15, 16) for class II MHC-peptide
complexes seemed initially to be in accord with the view that
in the absence of somatic hypermutation in T cells, TCR
affinities for their natural ligands would generally be low. It
is doubtful that the difference between these earlier reports
and the present findings reflect a systematic difference be-
tween CD41 and CD8* T cells or between peptide-MHC
complexes involving class I and class II proteins. Instead, it
is likely that the difference simply reflects a very wide range
in TCR affinities for their natural ligands. If so, it will be
important to evaluate the functional efficacy in vivo and in
vitro of T cells whose TCR differ widely in intrinsic affinity.
That TCR intrinsic affinity alone is not a sufficient predictor
of T-cell activity is already evident from the finding here that
although their TCR differ 10-fold in intrinsic affinity for their
optimal peptide-MHC ligands, the two CTL clones we ex-
amined require the same concentrations of their respective
peptides to sensitize target cells for lysis (see Fig. 1). This
difference could be due to a greater number of TCR mole-
cules per cell on 4G3 than on cells (see above) or, perhaps,
to greater numbers of CD8 or other accessory proteins
involved in target cell recognition and lysis.
The second finding of interest arises from the difference
between the MHC proteins that restrict recognition of the
a-KGDH peptide and the ovalbumin peptide. Normally, the
restricting MHC molecules on target cells are syngeneic (self
or synMHC) with respect to the MHC proteins on T cells, but
in alloreactions they are allogeneic (alloMHC). Previously,
the affinities of TCR of three CD4' T cells that were specific
for synMHC class II proteins (and associated peptides) were
in the range 104 to 10s M- 1 (15, 16). The higher affinity (1.5
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x 106 M- 1) found here for the TCR of a CD8+ CTL clone
(4G3) for a peptide in association with a synMHC (Kb) might
reflect the low epitope density of this peptide in the trans-
fected cells (17) used to elicit the 4G3 clone as compared to
the relatively high epitope levels that seem to have been used
to elicit the CD4 ÷ T-cell clones previously studied (15, 16).
The still higher affinity (1.5 x 107 M'- ) for the alloreactive 2C
clone's TCR found here for the QL9-Ld complex raises the
possibility that in general TCR affinities will tend to be higher
for peptide-alloMHC than for peptide-synMHC complexes.
A comparison of only two clones would not ordinarily be
a sufficient basis for advancing such a generalization. How-
ever, the comparison becomes more arresting in light of
recent studies of T-cell maturation. According to these stud-
ies, immature thymocytes bearing presumed high-affinity
TCR for thymic peptide-MHC complexes (which involve
synMHC) are eliminated (18, 19). Since alloMHC proteins
are not present in the thymus. developing T cells having
high-affinity TCR for alloMHC or peptide-alloMHC com-
plexes can escape this "negative selection." Left to serve as
candidates for positive selection, these cells could seed the
periphery with potentially alloreactive cells having TCR with
high affinity for peptide-alloMHC complexes. To test this
suggestion, it will be necessary to compare TCR affinities of
many T-cell clones and polyclonal T-cell populations for
diverse peptide-synMHC and peptide-alloMHC complexes.
If valid, the proposal would help explain the striking (and still
puzzling) propensity of an animal's T cells to react with
unusual frequency and intensity against the disparate MHC
proteins of other individuals of the same species ("alloag-
gression") (20, 21).
The third notable finding concerns the demonstration of
specific binding of peptide-MHC complexes (12 1I-labeled) to
intact T cells. Measurements of TCR affinities still present a
major challenge. So far, the TCR affinities of only three
clones have been published, and in all previous instances.
they have involved competitive binding assays (1, 15,16). We
have shown here, in contrast, that it is possible to measure
the affinity of TCR for peptide-MHC ligands simply by direct
binding of 125I-trace-labeled soluble peptide-MHC com-
plexes to TCR molecules on intact cells. The values mea-
sured in this way have been examined by several approaches
(both kinetic and equilibrium binding), leaving no doubt
about their validity. This direct method opens the way to
measure more easily TCR affinities of many clones and even
of polyclonal populations, because it precludes the need for
laborious genetic engineering to produce soluble TCR (one
for each T-cell clone), or competitive assays that require rare
anti-receptor (e.g., clonotypic) antibodies, or for costly in-
struments that still depend upon genetic engineering. More-
over, the direct measurement makes it possible to readily
measure affinity of native TCR at 37"C, opening the way to
relate systematically, with minimal extrapolation, the kinet-
ics and affinity of TCR reactions with peptide-MHC com-
plexes to the activities of viable T cells against target cells or
antigen-presenting cells.
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Tissue Distribution of Natural Peptides Derived from a
Ubiquitous Dehydrogenase, Including a Novel Liver-Specific
Peptide That Demonstrates the Pronounced Specificity of
Low Affinity T Cell Reactions'
Mei X. Wu, Theodore J. Tsomides, and Herman N. Eisen2
Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
The peptides recognized by CD8 ÷ CTL normally arise by proteolysis of intracellular proteins. To learn whether
these peptides are generated similarly in diverse cell types, we examined the variety and abundance of naturally
processed peptides that derive from a ubiquitous enzyme, a-ketoglutarate dehydrogenase, and are recognized in
association with the class I MHC protein, Ld, by a CTL clone (2C). A characteristic set of three peptides was found
in diverse tissues, but their abundance varied greatly, apparently unrelated to differences in class I MHC expres-
sion, e.g., they were surprisingly abundant in liver. We also found in liver a fourth naturally processed peptide
(p2Ca-Y4, LSPYPFDL) that differs by one oxygen atom from a previously characterized natural peptide (p2Ca,
LSPFPFDL). CTL discrimination between these peptides in association with the same class I MHC protein, Kb,
demonstrates the striking specificity that can be exhibited by low affinity T cell reactions. The Journal of Immu-
nology, 1995, 154: 4495-4502.
he natural ligands of the Ag-specific receptors(TCR) on CD8' T cells are cell surface com-plexes formed by peptides, usually 8 to 10 amino
acids in length, and class I MHC proteins (1, 2). Under
normal circumstances, these peptides arise from proteo-
lytic fragmentation of cytosolic proteins in target cells and
are transferred by transporter molecules into the cells' en-
doplasmic reticulum, where they bind (possibly with fur-
ther proteolytic trimming) to nascent MHC-I proteins,
forming the peptide/MHC complexes that are subse-
quently displayed at the cell surface (3, 4). Although this
"antigen processing pathway" is well supported in broad
outlines by a growing body of evidence, the detailed
mechanisms are obscure, and much of what is known is
based largely on studies of a limited variety of cells, prin-
cipally lymphoid cells and transformed cultured cell lines.
However, under natural conditions, target cells (e.g., virus-
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infected cells or tumor cells or normal cells in allografts)
are extremely diverse and can be found in virtually any
tissue or organ. Whether cellular proteins are processed in
the same way and to the same extent in widely divergent
cell types is, therefore, a matter of some interest.
An opportunity to explore this issue is provided by the
recent identification of the El subunit of the a-ketoglut-
arate dehydrogenase (ca-KGDH)3 complex as the source of
several naturally processed peptides that are recognized in
association with the MHC-1 protein Ld by a CD8- CTL
clone (termed 2C) (5). Since a-KGDH is essential for cell
survival and is thus present in all cells, we have examined
HPLC fractions of homogenates from various tissues for
the presence and levels of a-KGDH-derived peptides rec-
ognized by CTL clone 2C. This approach. in contrast to
simply using diverse cell types as targets in in vitro cyto-
toxicity assays, permits quantitative estimates of peptide
abundance and makes any tissue accessible for analysis,
regardless of its suitability as a target in vitro. Our results
show that the pattern of the processed peptides previously
found in lymphoid cells (5, 6) is largely conserved in all
tissues examined, but with pronounced variations in abun-
dance, i.e., they are surprisingly abundant in liver, less
'Abbreviations used in this paper: r-KGDH, a-ketoglutarate dehvdrogenase;
TFA, triuluoroacetic acid.
0022-1767 95:502.00
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abundant in spleen, kidney, lung, and heart, exceedingly
sparse in skeletal muscle, and undetectable in brain.
In the course of analyzing these tissues, we discovered
another peptide that is recognized by 2C cells in associa-
tion with Ld, and we established its sequence. Found only
in liver, this new octapeptide extends the number of nat-
urally processed peptides with closely related or overlap-
ping sequences that are recognized by the Ag-specific re-
ceptor of 2C cells. It also provides a striking example of
the high specificity of low affinity T cell reactions.
Materials and Methods
Cells and mice
Sp2/0 cells (H-2d) are non-Ig-secreting mouse hybridomas formed by
fusing myeloma cells (P3X63Ag8) with BALB/c spleen B cells. Previous
transfection of Sp2/0 cells with the La gene resulted in a high Lwiex-
pressing clone called B2 cells (6). T2-L a, T2-Kb, and T2-Db cells (T2
cells transfected with the a-chain genes for La, Kb, or Db. respectively)
were generous gifts of Dr. Peter Cresswell (7). CTL clone 2C was de-
rived and maintained as described (8). The clonotypic mAb IB2 is spe-
cific for the TCR a)3 of CTL clone 2C (9, 10). Swiss Webster mouse
livers and brains were purchased from PeI-Freez Biologicals (Rogers,
AR). All cultured cells were grown in RPMI 1640 supplemented with
10% FCS, 10 mM HEPES, 2 N AM L-glutamine. 100 U/ml penicillin, 100
ocg/ml streptomycin, and 50 M /3-mercaptoethanol ("K medium").
Transfected cells were additionally supplemented with 300 atg/ml G418
(Life Technologies, Gaithersburg, MD). BALB/c J mice were bred in the
animal facility at the Massachusetts Institute of Technology (MIT) and
were used at 15 to 30 wk of age.
HPLC fractionation of low molecular mass material
from tissues and cells
Tissues were homogenized in a polytron homogenizer (Brinkmann In-
struments, Westbury, NY) for about 2 min on ice after adding 3 to 5 ml
of cold 1% trifluoroacetic acid (TFA)/g wet weight of tissue, followed by
sonication for 2 min on ice (Model W-225R, Ultrasonics, Inc.). After
standing overnight at 4"C. homogenates were centrifuged at 126.000 X g
for 1 h at 4"C in a TL- 100 centrifuge (Beckman Instruments. Palo Alto. CA).
and the supematants were subjected to ultrafiltration through a Centricon-10
membrane (molecular mass cutoff 10 kDa, Amicon, Beverly, MA). The
ultrauiltrates were dried by SpeedVac (Savant Instruments. Farmingdale,
NY) and redissolved in 0.1% TFA at approximately 5 mg protein/ ml as
measured by bicinchoninic acid assay (Pierce, Rockford, IL). HPLC punfi-
cation for peptide sequencing was performed on a Beckman Model 334 or
a Hewlett Packard Model 1084B HPLC system using reverse-phase columns
218TP104, 219TP54. 214TP54, and 228TP104 (VYDAC. Hesperia. CA)
and various solvent and gradient conditions as described in Table II. HPLC
performed for screening various tissues used a C18 column for two succes-
sive rounds of chromatography, as described in the legend to Figure 1.
Cultured cells were pelleted, sonicated for 2 min in 1% TFA at 2 X
10 S cells/mi, and incubated for I h at 37"C, followed by centrifugation
and the other steps described above for tissues.
Cytotoxicity assay
For cytotoxicity assays, part of each HPLC fraction was added in dupli-
cate to the wells of a round bottom 96-well plate. 5 iCr-labeled target cells
(1 x 10c) and 2C cells at a CTL:target cell ratio of between 5:1 and 20:1
were added in a final volume of 0.2 ml of K medium/well. To control for
possible toxicity of each HPLC fraction. "'Cr-labeled target cells, but no
CTL. were added to a parallel set of wells. After 4 h at 37*C in a 5% CO,
incubator, 5'Cr released into the supemrnatants was measured in a y
counter. Specific lysis of target cells was calculated for each HPLC frac-
tion using the standard formula 100 x (a - b)/(c - b), where "a" is 5 1Cr
release in the presence of CTL, "b" is ~'Cr release in the presence of
target cells and medium alone (spontaneous release), and "c" is -'Cr
release in the presence of target cells and detergent, i.e., 1% NP-40 (total
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release). Spontaneous release values varied from 8 to 15% of total stCr
release.
oa-KGDH activity
ar-KDGH activity was determined essentially as described previously
(11). Various mouse organs were removed, kept on ice during dissection,
and stored at -80*C until used. Frozen material was then weighed and
washed twice with 50 mM 3-[N-morpholinojpropanesulfonic acid, pH
7.0 containing 2.7 mM EDTA, 0.1 mM DTT, 3% (v/v) Triton X-100, 1
mM PMSF, 1 mM benzamidine hydrochloride, and 0.05% (v/v) silicone
antifoam (12). Washed tissues were homogenized for 2 min on ice at 0.3
g/ml of this buffer in a polytron homogenizer, clarified by centrifugation
at 200,000 X g using a TLA-100.3 rotor, and assayed for a-KGDH
activity at 30*C (11) using potassium a-ketoglutarate as substrate in
place of potassium pyruvate. Kidneys were extracted in the same buffer
but with 3% (v/v) FCS and 1 mM tosyl-lysine chloromethyl ketone added
to minimize proteolysis as described (13).
Synthetic peptides
Synthetic peptides used in this study were prepared in the MIT Biopoly-
mers Laboratory using solid phase t-Boc chemistry (Model 430A, Ap-
plied Biosystems, Foster City, CA) and hydrogen fluoride cleavage. Pep-
tides were purified by reverse-phase HPLC. and their concentrations
were determined by micro bicinchoninic acid assay using as a standard a
synthetic peptide solution whose concentration had been determined by
quantitative amino acid analysis.
Flow cytometry
Flow cytometry was used to measure the increase in cell surface density
of Ld or Kb MHC-1 proteins after incubating 5 x 10s T2-Ld or T2-Kb
cells without or with synthetic peptides for 10 h at 37*C in 0.5 ml of K
medium that had been heated for I h at 90"C to inactivate proteases.
Subsequent steps were as described previously (14), using mAbs 28-14-8
or 30-5-7 for L' and Y3 for Kh.
Results
After one round of HPLC of TFA extracts derived from
-1 g tissue (wet weight), several active fractions were
observed for most of the tissues shown in Figure 1. but
their levels of specific lysis were relatively low (e.g.,
7-20% using 0.2 g tissue equivalents/well, data not
shown). To amplify the signals and reduce toxicity effects,
2 g of each tissue were homogenized, and fractions cor-
responding to 46 to 57 min from the first HPLC were
pooled and subjected to a second round of HPLC using a
substantially shallower (and thus more highly resolving)
gradient (0.067% B/min vs 0.25% B/min). Cytotoxicity
assays of fractions corresponding to 0.5 g tissue equiva-
lents/well from the second round revealed three distinct
peaks of activity for most tissues, shown in Figure 1. as in
earlier studies with spleen and thymus (6). The slight dif-
ferences in retention times from the results of Udaka et al.
may be attributed to the use of a different C18 column in
the present study. Nevertheless, from the profiles of
spleen-derived peptides, which provide a common refer-
ence point, we determined that peaks marked a, b, and c in
Figure 1 correspond to those given the same designations
previously (6). The two peptides identified as responsible
for some or all of the activity in peaks a and b, respec-
tively, are p2Ca (LSPFPFDL, formerly called p2CL) (6)
and p2Cb (VAITRIEQLSPFPFDL) (5); the active peptide
in peak c has yet to be characterized.
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FIGURE 1. Cytotoxicity assays of HPLC fractions from acid
extracts of BALB/c tissues. TFA extracts of low molecular
mass material (<10 kDa) from homogenates of brain, mus-
cle, heart, kidney, lung, spleen, and liver were fractionated
by reverse-phase HPLC using a gradient of 0.25% B/min. For
each tissue, 10 fractions containing all of the active material
were pooled and rechromatographed using a shallower gra-
dient (0.067% B/min) on the same C18 column. After the
second round of HPLC, aliquots of each fraction equivalent
to 0.5 g wet weight of tissue/well were added to 96-well
plates for a 4-h cytotoxicity assay using 2C as CTL and "3Cr-
labeled T2-Ld target cells at a ratio of 5:1. A, percent specific
lysis by 2C cells; 0, percent specific lysis in toxicity controls
(no CTL). UV absorbance profiles are not shown. The lower
right panel shows a standard cytotoxicity assay in which syn-
thetic peptide p2Ca is titrated in a 96-well plate and subjected
to identical assay conditions as the HPLC fractions.
In six of the seven tissues shown in Figure 1, the same
peaks were seen, albeit at markedly different levels. In
brain only, no activity was observed. The titration curve
shown in the lower right panel of Figure 1 was established
using synthetic peptide p2Ca but otherwise the same assay
conditions as for the HPLC fractions in the other panels,
affording an opportunity to estimate the amounts of p2Ca
in various tissues. These varied more than 100-fold, from
about 4 ng/g liver to about 0.05 ng/g skeletal muscle to
Table I. Abundances of peptide p2Ca and the oa-KGDH complex
in various tissues of BALB/c mice
Tissue Peptice p2Caa  a-KGDH Activityb
Liver 4.0 313 -3
Spleen 0.4 66 ± 4
Lung 0.2 104 ± 5
Kidney 0.2 76 ± 4
Cardiac muscle 0.1 106 ± 9
Skeletal muscle 0.05 42 ± 2
Brain <0.04 41 - 1
Sng/g wet tissue, not corrected for approximately 25% overall vield of acid
extraction, ultrafiltration, and HPLC fractionation steps.
b U/g tissue, where 1 U is the amount of enzyme required to produce 2
mmol of ferrocyanide ((Fe(CN),)-'4h at 30*C using ferricyanide ((Fe(CN),)-3)
as electron acceptor (11).
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FIGURE 2. Cytotoxicity assay of HPLC fractions from acid
extracts of brain "spiked" with synthetic peptide p2Ca. Two
hundred and thirty nanograms of peptide p2Ca were added
to 2 g of BALB/c brain before homogenization, TFA extrac-
tion, and HPLC fractionation. Ten percent of each HPLC frac-
tion/well was subjected to the standard cytotoxicity assay.
Based on a standard curve for synthetic p2Ca performed in
parallel, the recovery of added peptide was calculated to be
-'25%. A, percent specific lysis by 2C cells; 0, percent spe-
cific lysis in toxicity controls (no CTL). Samples without
added peptide had no activity in fractions 49 to 51 (see Fig.
1, upper left panel).
undetectable levels in brain (Table I). To address the pos-
sibility that peptide p2Ca was produced in brain but not
detected in our assay because it was subject to unusually
rapid destruction, anomalous behavior on HPLC, or un-
usually poor recovery from brain for some other unknown
reason, we added a known amount of synthetic p2Ca to
brain before homogenization. As shown in Figure 2, the
added peptide was recovered from this "spiked" sample
with a yield of about 25%, closely comparable with yields
obtained from similarly spiked samples using other tissues
(15). Hence, peptide p2Ca is not produced in brain at lev-
els that can be detected using standard protocols.
The cytolytic responses of 2C cells to peptides in ho-
mogenates from various tissues were much more pro-
nounced after the second round of HPLC (Fig. 1) than
after the first, probably because the mass of peptides that
compete for binding to Ld on the target cells was much
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greater in the first round. Residual competing peptides in
the second round could have affected the accuracy of our
estimates of peptide abundance. However, the error was
probably small, because at least 70% of the total UV ab-
sorbance was removed by the first HPLC round. More-
over, in control experiments, the amounts of synthetic pep-
tide recovered from HPLC runs were not appreciably
different when peptides were introduced alone or were
"spiked" into homogenates (as in Fig. 2).
The tissues examined in Figure 1 differ considerably in
their expression of MHC-I proteins (16). Detailed studies
by Rammensee et al. (2) emphasized that the presence of
several peptides in tissue homogenates was dependent on
the expression of particular MHC-I proteins; therefore, we
compared homogenates from Sp2/0 hybridoma cells,
which have barely detectable levels of Ld (Fig. 3 and Ref.
6) and B2 cells (a clone of Ld gene-transfected Sp2/0
cells). As shown in Figure 3. B2 cells express over 30-fold
higher levels of Ld than Sp2/0, yet their TFA homogenates
contain indistinguishable HPLC profiles of the peptides
recognized in association with Ld by 2C CTL.
To determine whether wide tissue variation in the levels
of ca-KGDH-derived peptides reflected differences in the
amounts of oa-KGDH El subunit (the source of the pep-
tides recognized by 2C CTL) (5), we measured the en-
zyme's activity in various tissues as an indicator of its
abundance. As shown in Table I, a-KGDH activity was
highest in liver and lowest in skeletal muscle, paralleling
the differences in p2Ca levels in these tissues. However,
the correlation was limited, because enzyme activity was
only seven- to eightfold higher, and the p2Ca level was
about 100-fold higher in liver than in skeletal muscle. The
deviation from a linear correlation was even more appar-
ent in brain: although a-KGDH activity in brain was about
40% of that in liver, no a-KGDH-derived peptides were
detected in brain homogenates (0.5 g tissue equivalents/
well) under standard assay conditions.
The HPLC activity profile from liver, shown in the
lower left panel of Figure 1. revealed that. in addition to
peaks a, b, and c common to most tissues, a fourth peak of
activity with an earlier retention time was observed in liver
extracts from both BALB/c and Swiss Webster mice (but
not C57B1/6 mice). Designated a', the active component in
this peak was isolated for sequence determination starting
from 180 g of mouse liver (Pel-Freez). The livers were
homogenized and subjected to ultrafiltration, followed by
seven successive rounds of HPLC fractionation under dif-
ferent conditions as described in Table II. After each
HPLC round, fractions were tested in the standard CTL
assay, and the active peak (starting with a' in the first
round, Fig. 1) was subjected to a subsequent round, until
the activity was deemed sufficiently pure for sequence de-
termination. About 90% of the active fraction from the
seventh round was analyzed by Edman degradation, and
the remainder was analyzed by mass spectrometry (Drs.
loannis Papayannopoulos and Klaus Biemann, MIT, De-
Sp2/0 82
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FIGURE 3. Relative levels of Ld on Sp2/0 and 82 cells and
cytotoxicity assay of HPLC fractions from acid extracts of
these cells. (Upper panel) 5 x 10s Sp2/0 and B2 cells were
stained with mAbs 28-14-8 (anti-Ld) at 5 .g/ml for 20 min on
ice followed by FITC-labeled F(ab') 2 of goat anti-mouse IgG
(secondary Ab) at 15 /zg/ml. Mean fluorescence values of live
cells were 8.6 (Sp2/0 cells) and 317.8 (B2 cells) on an arbi-
trary linear scale. When a different anti-Ld Ab, 30-5-7, was
used, mean fluorescence values were 10.7 (Sp2/0) and 311.1
(B2). In the absence of anti-Ld Ab, the background fluores-
cence due to secondary Ab was 4.8 (Sp2/0) and 7.7 (82) (not
shown). (Middle and lower panels) 109 Sp2/0 and 82 cells
were homogenized and extracted with TFA, and their low
molecular mass ultrafiltrates were fractionated by HPLC. Ali-
quots from each fraction were added to 51Cr-labeled T2-Ld
target cells and 2C CTL in a 4-h cytotoxicity assay. A, percent
specific lysis by 2C cells: O, percent specific lysis in toxicity
controls (no CTL).
partment of Chemistry). The Edman procedure resulted in
an N-terminal sequence of seven residues, LSPYPFD, and,
from the molecular mass of 951.4, it was inferred that the
complete sequence was LSPYPFDX, where X = leucine
or isoleucine. To distinguish between these possibilities
for the C-terminus, the corresponding synthetic peptides
were compared in a CTL assay. As shown in Figure 4. the
peptide with X = leucine was 20-fold more active than the
one with X = isoleucine. Based on this finding and the
match in HPLC retention time between synthetic peptide
LSPYPFDL and the naturally occurring peptide in peak a'
(Fig. 1), we concluded that the active peptide in peak a' is
LSPYPFDL. Because this sequence differs from that of
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Table II. HPLC conditions used to purify peptide p2Ca-Y4 from mouse liver
Gradient
Duration Flow Rate Active Fraction
Round Column' % 8/min (min) (ml/min) (minm)
1 C18 22 mm (Beckman) 1.0 50 3 38
2 C18 (218TP104) 0.25 43 1 40-41
3 C8 pH stable (228TP104) 0.1 55 1 34-35
4 Phenyl (219TP54) 0.2 50 1 46
5 C18 (218TP104) 0.0375 80 1 45
6 C4 (214TP54) 0.067 60 1 38
7 C18 (218TP104) 0.27 60 1 43-44
d For HPLC rounds 1, 2, 4, 5, and 6 the solvents were A = 0.1% TFA in distilled HzO and B = 0.085% TFA in acetonitrile; for round 3, solvent A = 125 mM
triethylamine acetate (TEAAc), pH 8.5, and solvent 8 = 15% solvent A plus 85% 77 mM TEAAc in acetonitrile; for round 7, solvent A = 0. 1% TFA in HzO, and
solvent B = 0.1% TFA in isopropanol.
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FIGURE 4. Sensitizing activities of synthetic peptides p2Ca
(LSPFPFDL), p2Ca-Y4 (LSPYPFDL), and p2CI-Y4 (LSPYPFDI).
Titrations of peptides p2Cl-Y4 (A), p2Ca (0), and p2Ca-Y4
(0) were added to S'Cr-labeled T2-Ld target cells and 2C CTL
in a 4-h cytotoxicity assay. Arrows on abscissa point to SD50
values (peptide concentrations required for half-maximal ly-
sis): -50-100 pg/ml for p2Ca and p2Ca-Y4 and -1 ng/ml for
p2CI-Y4. Decreased lysis at the highest peptide concentra-
tions may be due to fratricidal lysis of the CTL (29).
peptide p2Ca only by a substitution of tyrosine for phe-
nylalanine at position 4, the active peptide in peak a' is
referred to as p2Ca-Y4.
Based on an earlier discovery that peptide p2Ca can be
recognized by 2C cells not only in association with Ld (an
allogeneic MHC-I) but also in association with Kb (a syn-
geneic MHC-I) (14), peptides p2Ca and p2Ca-Y4 were
each compared for their ability to sensitize T2-Ld, T2-Kb,
and T2-Db target cells for lysis by 2C cells. As shown in
Figure 5, the two peptides were virtually indistinguishable
with Ld+ target cells (as well as Db+ target cells, which
were not lysed in the presence of either peptide), whereas
with Kb+ target cells, only peptide p2Ca was active.
Although they differed markedly in their ability to sen-
sitize T2-Kb cells for lysis, the two peptides were bound
indistinguishably by Kb; as shown in Figure 6, they were
equally effective in enhancing surface expression of Kb
(and also of L0) on T2-Kb (or T2-Ld) cells, indicating that
the phenolic hydroxyl group of p2Ca-Y4 does not interfere
with the peptide's binding to either Kb or Ld. Peptide p2Ca
1o
p2Ca
T2-Kb
T2 -D b
-1
10'- 0 6 1 00 10t- Os
Peptide concentration (pg/ml)
FIGURE 5. Synthetic peptides p2Ca and p2Ca-Y4 are rec-
ognized differently by 2C CTL in association with different
MHC-1 molecules. Target cells were 5sCr-labeled T'-Ld, T2-
K', and T2-Db, and CTL were 2C at a ratio of 5:1.0. peptide
p2Ca-Y4; 0, peptide p2Ca.
is bound less well to Kb than to Ld, as reflected by their
respective equilibrium association constants (14. 17); ev-
idently, the same is true of p2Ca-Y4, as indicated by
closely similar behavior of the two peptides in Figure 6.
Using the clonotypic anti-receptor Ab 1B2 (9). we de-
termined that both p2Ca and p2Ca-Y4 reacted with the
same TCR on 2C cells, i.e., at 50 .Lg/ml, the F(ab'), frag-
ment of 1B2 inhibited by 90% the lysis of T2-Ld cells
sensitized with either of these peptides (data not shown).
Moreover, the same TCR that recognizes p2CaLd" com-
plexes can also recognize p2Ca/Kb (14). Thus, despite the
fact that peptides p2Ca and p2Ca-Y4 were bound equally
well by Kb and differed only by a single oxygen atom, the
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FIGURE 6. Synthetic peptides p2Ca and p2Ca-Y4 are sim-
ilar to each other in their binding to Kb or Ld by flow cyto-
metric analysis. T2-Kb and T2-Ld cells were incubated with
the indicated concentrations of p2Ca (0) or p2Ca-Y4 (0) for
10 h at 370C in heated K medium and were stained with
mAbs 28-14-8 (anti-Ld) or Y3 (anti-Kb) at 5 pg/ml for 20 min
on ice followed by FITC-labeled F(ab') 2 of goat anti-mouse
IgG at 15 /zg/ml for 20 min on ice. Mean fluorescence values
are plotted on an arbitrary linear scale. Dead cells were gated
out by propidium iodide staining.
TCR of 2C cells could clearly distinguish between them
when bound to Kb on target cells.
Discussion
This study of the normal tissue distribution of naturally
processed peptides that derive from the El subunit of
a-KGDH and that are recognized with L' by a CD8 ÷ CTL
clone (2C) reveals striking variation in the abundance of
these peptides in various tissues. Highest in liver (-4
ng/g) and undetectable in brain (<0.04 ng/g), they are
present at relatively high and approximately equal levels
in spleen, kidney, and lung (and also in thymus (6)) and
only at very low levels in skeletal muscle. Despite such
quantitative variation, the peptides were detected as a con-
served pattern of three HPLC peaks in homogenates from
all positive tissues and in roughly constant relative
amounts, suggesting that the same peptide-generating ma-
chinery functions in these diverse tissues (albeit perhaps at
very different levels).
Why are the levels of these peptides so high in liver and
so low in brain? In a previous study, Griem et al. (18)
examined the normal tissue distribution of peptides de-
rived from several minor histocompatibility Ags and rec-
ognized by CD8+ CTL clones in association with Kb or
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Db. Though the sequences of the peptides they studied
were unknown, and the protein sources of these peptides
were not identified, their results and ours are somewhat
similar in that they found relatively high levels in spleen,
thymus, and lung and undetectable amounts in brain and
cardiac and skeletal muscle. They did not, however, see
exceptionally high levels in liver. Moreover, they found
considerable evidence in support of the view that differ-
ences in the abundance of naturally processed MHC-I-as-
sociated peptides in various tissues are determined by tis-
sue differences in the levels of expression of the relevant
MHC-I proteins.
For several reasons, tissue differences in MHC-I expres-
sion do not seem to provide an explanation for the varia-
tion in amounts of a-KGDH-derived peptides seen here.
One reason is the approximately equal abundance of these
peptides in Sp2/0 and B2 cells (Fig. 3), despite barely
detectable levels of Ld on Sp2/0 cells and at least 30-fold
higher levels on B2 cells (Sp2/0 transfected with the Ld
gene) (6). Another reason is the extremely high abundance
of these peptides in liver, far greater than can be accounted
for by Ld-bound peptide alone. Approximately 650 pmol
of p2Ca were isolated from 180 g of Swiss Webster mouse
livers after six rounds of HPLC (not shown), more than 15
times the yield from mouse spleens after the same number
of HPLC steps (6); assuming 50% recovery/HPLC round
and 109 cells/g liver, this suggests the presence of more
than 105 p2Ca molecules/cell on average in liver. Al-
though MHC-I proteins are readily detected in some liver
cells (e.g., bile duct epithelium and Kupffer cells), they
have been variously reported as detectable or absent in
hepatic parenchymal cells and are, in any event, not
present in these cells at a high level (16, 19). Still another
reason is the earlier finding of equal abundance of these
peptides in spleens of the three MHC-congenic mouse
strains BALB/c, BALB.B. and BALB.K (having H-2d,
H-2b, and H-2k haplotypes, respectively) (6). It is un-
likely that each of the active peptides can bind equally
well to MHC-I proteins from these three haplotypes.
For example, peptide p2Ca is known to bind to Kb with
fivefold lower affinity than to Ld and does not bind de-
tectably to Db (14, 17).
It is not clear why the peptides studied by Griem et al.
(18) differ from those studied here in their dependence on
MHC-I expression. An explanation may lie in the rela-
tively weak binding of peptide p2Ca to Ld (Ka, 1 X 106
M- 1) (17) and the even weaker binding of peptide p2Cb to
Ld (5). It may be that the peptides examined by Griem et
al. (18) bind much more strongly to the relevant MHC-I
proteins and that, in general, the dependence of peptide
abundance in a tissue on MHC-I expression is prominent
when the peptide/MHC interaction is strong.
It is also possible that the extremely high abundance of
a-KGDH-derived peptides in liver stems from a high level
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of the a-KGDH complex in this organ. However, a com-
parison of this enzyme's activity in different organs sug-
gests that differences in the tissue abundance of a-KGDH
peptides also cannot be attributed to differences in the
amount of the parent protein (Table I), e.g., the peptide is
40-fold more abundant in liver than in heart, but there is
only -threefold more enzyme in liver. More striking is the
disparity between liver and brain. These tissues differ
-eightfold in a-KGDH activity but at least 100-fold in
abundance of the a-KGDH-derived peptides. Griem et al.
(18) showed that a 20- to 50-fold increase in Kb expression
in brains of mice transgenic for the Kb gene linked to a
glial cell-specific promoter was associated with a 10-fold
increase in abundance of a peptide derived from a minor
histocompatibility Ag. Whether the increases were con-
fined to astrocytes and oligodendrocytes or also involved
neurons is not clear. Neurons do not normally express
MHC-I proteins (16, 20), and it may be that they are de-
ficient in the peptide-generating machinery that is widely
conserved in other cell types. Such a deficiency would
minimize opportunities for neuronal cell destruction by T
cells.
Whatever its basis, the large variation in peptide abun-
dance seen in different tissues has important implications
for T cell-mediated reactions in vivo. For example, recent
studies of melanoma tumor peptides recognized by CD8 +
tumor-infiltrating CTL have identified the source of these
peptides as a normal melanocyte-specific protein termed
MART-1 (21) or Melan-A (22). Messenger RNA for
MART-1 is present in melanoma tumors, normal melano-
cytes, and retinal cells, but although MART-1-specific
CTL lyse melanoma cells and may also react against mela-
nocytes in vivo (e.g., causing vitiligo), they have not ev-
idently caused ophthalmologic disorders, suggesting that
retinal cells (perhaps like brain cells) produce few peptides
that associate with MHC-I proteins.
In addition to its high content of the three previously
established peaks of activity recognized by 2C CTL, we
found that liver contains an additional peptide whose se-
quence differs from the p2Ca octapeptide only by a phe-
nylalanine-to-tyrosine substitution at position 4 (p2Ca-
Y4). The origin of peptide p2Ca-Y4 is unknown. It might
arise from an isozyme for El of the a-KGDH complex
that is expressed only in liver. A more intriguing possibil-
ity is that p2Ca-Y4 might arise from posttranslational hy-
droxylation by liver microsomal phenylalanine hydroxy-
lase (23) of the corresponding phenylalanine residue in
peptide p2Ca. This latter possibility is consistent with our
inability to detect in liver an analog of the naturally oc-
curring 16-residue peptide p2Cb (5) with the correspond-
ing phenylalanine-to-tyrosine substitution, which we
might have expected if p2Ca-Y4 arises from an isozyme
for ca-KGDH.
It is commonly assumed that high levels of specificity in
immune reactions are associated with high affinity inter-
actions. The results obtained here with p2Ca and the new
peptide, p2Ca-Y4, provide an example of the exquisite
specificity that can be exhibited by a low affinity reaction.
The TCR on 2C cells was found previously to bind the
p2Ca/Kb complex with an intrinsic affinity so low as to be
barely measurable (3 x 103 M-') (24), and yet 2C cells
were found to lyse Kb+ target cells specifically, i.e., when
T2-Kb cells were sensitized with p2Ca but not with other
Kb-binding peptides, even though the latter bound with
greater than 1000-fold higher affinity than p2Ca to Kb (14,
17). A more striking example of TCR specificity is seen
here with the failure of peptide p2Ca-Y4 to sensitize Kb+
target cells for lysis by 2C cells. Octapeptides p2Ca and
p2Ca-Y4 differ by a single oxygen atom, and although
they bind equally well to Kb (Fig. 6), only p2Ca can elicit
specific lysis of T2-Kb target cells by 2C CTL (Fig. 5). To
account for this fine discrimination, we suggest that the
affinity threshold for eliciting a cytotoxic T cell response
may be approximately 1 x 103 M- t. The affinity of the 2C
TCR for p2Ca/Kb would thus fall just above this threshold
and for p2Ca-Y4/Kb probably just below; hence, lysis of
T2-Kb target cells is observed when their surface Kb mol-
ecules are loaded with p2Ca but not when they are loaded
with p2Ca-Y4 or with other peptides, no matter how
strongly these bind to Kb.
The view that T cells are highly specific derives from
the commonplace observation that their responses to pep-
tides on APC or target cells can discriminate sharply be-
tween closely related peptides. However, these observa-
tions have not distinguished between two distinctly
different reasons for such T cell discrimination: 1) differ-
ences in peptide binding to target cell MHC proteins and
2) differences in the binding of the resulting peptide-MHC
complexes by TCR on T cells. In the present study, this
distinction is clearly made in Figures 5 and 6, and thus our
results provide unambiguous evidence that a TCR can dis-
criminate between two peptide-MHC complexes that differ
by only a single oxygen atom. Moreover, this distinction is
made by a TCR whose affinity for the recognized peptide-
MHC complex is only 3 X 103 M- ', at the lower edge of
what can be measured.
A structural basis for the proposed difference in 2C TCR
affinities for p2Ca/Kb vs p2Ca-Y4/Kb complexes is sug-
gested by x-ray crystallographic studies of Kb/peptide
complexes by Fremont et al. (25). For a Kh-bound oc-
tapeptide from vesicular stomatitis virus (RGYVYQGL),
the side chain of valine at position 4 points toward the
solvent (i.e., away from the Kb peptide binding site). Since
Fremont et al. found very similar conformations of two
Kb-bound peptides that differ extensively in sequence, and
notwithstanding contrasting results for HLA-A2-bound
peptides (26), it may be reasonable to suppose that the
same orientation applies to the phenylalanine and tyrosine
residues at position 4 of p2Ca and p2Ca-Y4 when bound
to Kb. A lower affinity interaction of the 2C TCR with
p2Ca-Y4/Kb than with p2Ca/Kb would then be under-
standable because the phenolic hydroxyl group of the
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former could interfere with TCR binding due to either
steric or charge effects.
Finally, we wish to call attention to a possible connec-
tion between the unusual abundance of a-KGDH peptides
in liver and the human autoimmune disease, primary bil-
iary cirrhosis (27). The principal autoantibodied in this dis-
ease are specific for various subunits of three homologous
mitochondrial dehydrogenases specific for pyruvate, a-ke-
toglutarate, or branched chain a-ketoacids. Inasmuch as
peptide p2Ca is not only abundant in liver but is also im-
munodominant in certain alloreactions (28), it seems war-
ranted to consider whether individuals with this disease
have CD8 + CTL that are specific for peptides derived
from ac-KGDH or from the structurally and functionally
similar pyruvate dehydrogenase or branched chain a-keto
acid dehydrogenase complexes. Moreover, if p2Ca-Y4 is
in fact generated by post-translational hydroxylation of
p2Ca in liver, this peptide (as well as other peptides that
might be modified on phenylalanine or tryptophan by liver
microsomal hydroxylase) (23) might circumvent normal
thymic self-tolerance mechanisms (i.e., negative selection
of T cells) and thus provide opportunities for autoimmune
reactions.
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CHAPTER 4
Naturally processed peptides recognized by melanoma-specific CTL
158
Overview
The idea of understanding - and ultimately learning to augment - immune
responses against cancer cells has excited immunologists for many decades. Evidence
that tumor cells express specific antigens capable of eliciting vigorous immune responses
originally came from studies of chemically induced tumors in MHC syngeneic mice
(Gross, 1943; Foley, 1953; Prehn and Main, 1957; Klein et al., 1960; Old et al., 1962).
Tumors transplanted from one mouse to another were rejected if the recipient was first
immunized with tumor cells that had been irradiated or were subsequently removed
surgically; moreover, the immunity provided by a tumor was often specific for that
tumor and not others, even from the same mouse, leading to the concept of tumor-
specific rejection antigens. However, concerns were raised that spontaneous tumors,
often nonimmunogenic, might lack such tumor rejection antigens (Hewitt et al., 1976).
T cells specific for tumor rejection antigens were obtained, but early efforts to
elucidate the nature of these antigens failed because they did not elicit an antibody
response and therefore could not be isolated by immunoprecipitation. Boon and
colleagues provided the first detailed molecular information about tumor antigens
recognized by T cells, using mutagenized variants of the mouse mastocytoma P815 that
could induce T cell responses, sometimes against the original tumor (reviewed by Boon
et al., 1994). Their approach was genetic: DNA from one of the immunogenic P815
variants (termed tum- because they did not form tumors) was transfected into P815 cells,
and transfectants were screened for their ability to stimulate T cells. Eventually three
genes encoding tumrn- antigens were cloned, and each had apreviously unknown sequence
differing by a single point mutation from the homologous tum + sequence (De Plaen et
al., 1988; Szikora et al., 1990; Sibille et al., 1990). In light of emerging information that
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T cells recognize short peptides in association with MHC molecules (Townsend et al.,
1986), the mutated peptides presumably responsible for tum- antigens were quickly
identified (Lurquin et al., 1989), and one was later shown to correspond to the naturally
processed peptide obtained from tum- cells (Wallny et al., 1992a) (see table, p. 168).
When a similar approach was used to define tumor rejection antigens on P815
cells (i.e., transfection of P815 DNA into antigen-loss variants selected in vitro by
anti-P815 T cells), the first gene identified had a sequence identical to that of normal
cells (Van den Eynde et al., 1991). In other words, unlike the tum- antigens, a rejection
antigen on P815 cells is not mutated relative to the same sequence in normal mouse
tissues. Why, then, was the immune rejection response against this antigen not
accompanied by autoimmune manifestations? The explanation turned out to be lack of
expression (or low expression) of this gene in normal tissues, including mast cell lines
that do not produce tumors. Nevertheless, this study brought up the possibility that other
tumor antigens would be normal sequences, although many investigators continued to
expect that most anti-tumor T cells would recognize tumor-specific sequences derived
from mutated genes (such as oncogene or tumor suppressor gene products).
Quite distinct from this genetic technique, a direct biochemical approach to the
identification of tumor antigens had emerged from studies on minor histocompatibility
antigens (Rtitzschke et al., 1990a) and virus-encoded antigens (van Bleek and
Nathenson, 1990; Rdtzschke et al., 1990b). Treatment of tumor extracts (or purified
MHC molecules from tumor cells) with TFA separates peptides from MHC molecules,
and fractionation of the resulting peptide mixture by HPLC partially resolves the
endogenous peptides. HPLC fractions are screened in cytotoxicity assays using
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appropriate target cells and anti-tumor CTL, and the peptide(s) in an active fraction can
be enriched by further rounds of chromatography using distinctive conditions (column,
solvents, and gradient) (see figure on p. 37). By this general strategy, the first naturally
processed peptides recognized by anti-viral or alloreactive T cells were isolated and
sequenced (see table 2, p. 38), and several groups set out to match this success for
tumor peptides.
Much of the work on human tumor antigens has focused on metastatic
melanoma. This tumor is readily adapted to long-term culture, and in a majority of
cases tumor-specific T cells can be obtained by incubating autologous blood cells with
melanoma cells (Boon et al., 1994) or by culturing melanoma cell suspensions in high
concentrations of the lymphokine interleukin-2 to select for outgrowth of tumor
infiltrating lymphocytes (TIL) (Itoh et al., 1986). Such TIL were shown by Rosenberg
et al. (1988; Topalian et al., 1989) to mediate dramatic regression of tumor masses in
some patients when expanded ex vivo and reinoculated. Another incentive to study
melanoma came from findings that several melanoma antigens are shared by a majority
of tumors from different patients and are recognized by T cells restricted by HLA-A2,
the most common MHC-I protein among human populations afflicted by melanoma (i.e.
--40-50% of Caucasians) (Darrow et al., 1989; W61fel et al., 1989, 1993; Hom et al., 1991;
Kawakami et al., 1992; Viret et al., 1993). Multiple antigens have also been detected
on renal cell and ovarian carcinomas (loannides et al., 1991; Peoples et al., 1993).
Using the biochemical methods described above, it was possible to demonstrate
several peaks of activity in HPLC fractions from melanoma tumor extracts (Slingluff et
al., 1993; Storkus et al., 1993); since the T cells used had not been cloned, the
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existence of up to =6 active species probably indicated multiple specificities and not
recognition of different peptides by the same TcR. It quickly became apparent that
sequence determination of these peptides was no minor challenge. The absence of any
prior knowledge of their sequences distinguished this problem from that of viral peptide
identification, which always had been guided by the use of synthetic peptides.
Although many naturally processed peptides could be isolated and sequenced on the
basis of their abundance (e.g. the most prominent HPLC peaks by ultraviolet
absorbance), the only precedent for isolating and sequencing a T cell antigen of
unknown origin was the alloreactive 2C system (Udaka et al., 1992).
Two melanoma peptides recognized by A2-restricted T cells have been
identified by direct chemical sequencing. The first report by Cox et al. (1994) made use
of the improved sensitivity of mass spectrometry over Edman degradation for peptide
sequencing. Nevertheless, 4 x 1010 melanoma cells were used for extraction and HPLC
fractionation. The resulting peptide sequence (see table, p. 168) matched exactly that of
gpl00, a protein specific to melanocytes and melanoma. The original abundance of the
peptide could not be established because of losses incurred during purification, but the
actual amount of peptide recovered was estimated at =0.2 peptide molecules per
melanoma cell! Significantly, CTL from five different A2+ patients could recognize
this peptide. A second peptide was isolated from melanoma cells by a novel procedure
using a citrate/phosphate buffer, pH 3.3, instead of TFA to remove peptides (Storkus et
al., 1993); since cells were not lysed under these conditions, continued culture led to
replenishment of MHC-bound peptides by endogenous pathways, and these peptides
were harvested daily for several days to amplify yields by =10-fold and permit
sequencing (see table, p. 168).
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A third report of direct sequencing of a tumor peptide (from an established
mouse lung carcinoma) appears to be unusual in that the peptide is one of the most
abundant MHC-I-associated peptides of the tumor; the peptide sequence matched the
protein connexin 37 except for a C-Q mutation, implying substitution at all three
positions of a single codon (Mandelboim et al., 1994).
Before these successful applications of the biochemical approach, Boon's
method of DNA transfection into antigen-loss variants selected by CTL had also produced
the first sequences of genes encoding human melanoma antigens (van der Bruggen et
al., 1991). The MAGE (for melanoma antigen) genes represent a family of 12 closely
related, previously unknown sequences that are identical in tumors and in normal tissues.
These genes are expressed in tumors of many histological types but not in normal
tissues, with the exception of testis and placenta (De Smet et al., 1994). To identify the
peptide encoded by MAGE-i that is recognized by HLA-Al-restricted T cells, several
synthetic peptides were screened for activity, and one 9-mer was recognized efficiently
(SD 50 = 5 nM, Traversari et al., 1992). Subsequently, other MAGE genes were
similarly found to encode peptides recognized by anti-melanoma Tcells (see table, p. 168).
Moving to A2-restricted CTL and improving the transfection approach by using
COS cells (in which vectors containing the SV40 origin of replication multiply
episomally to very high copy numbers), the Boon group identified two cDNA clones
coding for melanoma antigens: one proved to be the gene for tyrosinase (Brichard et
al., 1993), an enzyme in the pathway of melanin biosynthesis, and the other was a new
sequence they called Melan-A (Coulie et al., 1994). Both genes are non-mutated and
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expressed widely in melanomas as well as in normal melanocytes, leading to their
description as differentiation antigens. By synthetic peptide screening, two active
tyrosinase peptides were identified (Wilfel et al., 1994b).
In parallel, Rosenberg and colleagues had also used a gene transfection approach
to clone the gene for a melanoma antigen recognized by A2-restricted TIL, which they
called MART-1 (for melanoma antigen recognized by T cells, Kawakami et al., 1994a).
Their gene proved to have exactly the same sequence as Melan-A. Kawakami et al.
(1994b) quickly identified an active 9-residue peptide from the MART-1/Melan-A
sequence. A third differentiation antigen, gpl00, was encoded by another gene isolated
by Kawakami et al. (1994c) using T cells and by Bakker et al. (1994) using monoclonal
antibodies. When Kawakami et al. (1994a, c) examined a panel of normal tissues for
the expression of MART-1 and gpl00, they found that in addition to most melanomas
and melanocyte cell lines, these differentiation antigens are expressed in retinal tissue.
A major advantage of the genetic strategy for tumor antigen identification is that
it is unhampered by low abundance of the final peptide product. However, the naturally
processed peptide can only be discerned by testing various synthetic peptides, which is
an imperfect art. For example, reliance on consensus motifs for MHC-bound peptides
may fail to reveal certain active peptides. Once an active peptide is identified, it is not
certain to correspond to a naturally processed peptide, although this is often assumed to
be the case. Furthermore, no quantitative information about the peptide's natural
abundance can be garnered. These limitations can be overcome by chromatographic
and quantitative comparisons between synthetic peptides and a sample of natural
material from a tumor cell extract (e.g. 109 cells). This has not yet been done for the
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tyrosinase, MART-1/Melan-A, or gpl00 synthetic peptides found to be active by the
Boon and Rosenberg groups, so their identification as naturally processed peptides must
remain provisional.
A peptide sequenced from tumor cell extracts by Cox et al. (1994) corresponds
to one of the tyrosinase peptides synthesized by W1lfel et al. (1994b), except for a
single N-+ D difference; whether this represents post-translational deamidation,
artefactual deamidation during the purification, tyrosinase polymorphism, or a different
protein of origin remains unknown.
This sudden surge of information, mostly within the past year (see table, p. 168),
has brought a few surprises and raised some concerns about future immunization plans.
First of all, virtually all of the peptides identified (either biochemically or by
synthesizing peptides based on a gene sequence) have non-mutated sequences. Why
should normal sequences be immunogenic? And what prevents autoimmune reactions
from occurring against other tissues expressing the same antigens?
The apparent breach of self tolerance could have several explanations, each
hypothetical, and serves to highlight the fact that tolerance is not an all-or-none
phenomenon. (1) A normal peptide might be overexpressed on tumor cells, resulting in
its recognition by T cells that do not react against tissues expressing lower levels of
peptide. (2) Several of the peptides identified so far are said to have low binding
affinities for A2, and it is intriguing to speculate that this property may be related to
their failure to induce a more sturdy self-tolerance. (3) The local inflammatory reaction
to a tumor may result in paracrine effects on lymphocytes that elicit activities not
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otherwise observed. The importance of lymphokines such as interleukin-2,
interleukin-4, and GM-CSF in anti-tumor responses has been convincingly shown.
(4) It has been proposed that CTL against these normal sequences may have low-
affinity TcR, because cells with high-affinity TcR would have been deleted or
anergized. (5) It should be noted that screening tissues by Northern blot analysis does
not necessarily reflect the presence of peptide-MHC complexes at the cell surface;
perhaps some of these antigens are tumor-specific at the peptide level, although reports
that certain anti-melanoma CTL can lyse normal melanocytes in vitro (Anichini et al.,
1993; Bakker et al., 1994) suggest otherwise. It may be useful to measure the
abundance of the MART-1/Melan-A and gpl00 peptides in extracts of retinal tissue
(something not yet done even for the tumors themselves). Another worthwhile
experiment may be to test whether individuals without tumors have CTL specific for
peptides from tyrosinase, MART-1/Melan-A, or gpl00.
A second generalization that can be drawn from the table on p. 168 is that a
multiplicity of shared melanoma antigens exists, and their number is likely to increase.
Most of the Rosenberg group TIL lines recognize a single MART-1 peptide, but the
peptide independently isolated by Storkus et al. is a different 9-mer from MART-1.
Both the Rosenberg and Hunt/Engelhard groups identified gpl00 peptides as melanoma
antigens, but they also found two different sequences from the same protein to represent
shared antigens. The Boon lab first implicated tyrosinase as a tumor antigen; more
recently, Topalian et al. (1994) discovered that this protein can also stimulate CD4+
TIL. Given these overlapping yet contrasting results, it appears that several families of
melanoma antigens may be important - and so far only Al- and A2-restricted responses
have been analyzed in any detail.
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What are the prospects for using this new information in melanoma (or other
cancer) immunotherapy? Boon's early results with tum- variants provide hope that
even poorly immunogenic tumors can be rejected by an immune response following
immunization, and he recently outlined a variety of immunotherapeutic modalities
under consideration (Boon, 1993). There are plenty of reasons for pessimism: tumor
escape by antigen loss, tumor escape by MHC downregulation, and so on. These issues
must be investigated. But the greater concern is for safety, given that many of the
candidate immunogens are normal self sequences. Will vaccines based on
MART-1/Melan-A or gp 100 cause ophthalmologic problems? What about MAGE-1 in
testis? There is evidence that melanoma patients with local depigmentation reactions
(vitiligo) have prolonged survival, suggesting that immune responses against
melanocyte differentiation antigens on normal tissues are indeed relevant. Also,
melanoma (but not renal carcinoma) patients treated with interleukin-2 tended to
develop vitiligo. Until the basis for T cell reactivity against these normal sequences is
better understood, it may be hazardous to proceed with immunization; on the other
hand, for some patients with metastatic melanoma the risk may be worth taking.
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Table. Peptides recognized by anti-tumor T cells.§
T cellst MHC sensitizing parent normal tissue shown ref.
restric- peptide protein or distribution to be
tion (SD 50 value) or gene mutated naturally
occurring
primed Ld TQNRALDL
spleens (1 nM)
" Dd GPPHSNNFGY
(8 nM)
" Kd KYQAVTTTL
(25 pM)
" Kb FEQNTAQP
(=10 nM)
PBL Al EADPTGHSY
(5 nM)
f" Cwl6 SAYGEPRKL
(25 nM)
" Al EVDPIGHLY
(=100 nM)
" A2 FLWGPRALV
" A2 MLLAVLYCL
(=10 nM)
" A2 YMNGTMSQV
(=100 nM)
TIU A2 AAGIGILTV
PBL (1-5 nM)
" A2 ILTVILGVL
(210 pM)
LN A2 YLEPGPVTA
(1-10 pM)
TIL A2 LLDGTATLRL
(0.1-1 "M)
P91A
P35B
P198
mutated mutagenized
mastocytoma
mutated "
mutated
connexin 37 mutated Lewis lung
carcinoma
MAGE-1 normal melanomas,
other tumors,
normal testis
MAGE-1 normal "
MAGE-3 normal "
MAGE-3
tyrosinase
normal
normal
tyrosinase normal
MART-l/
Melan-A
MART-1/
Melan-A
Pmel 17
(gp100)
gpl00
no
no
yes
yes
It
melanomas,
melanocytes
possibly* (9)*
normal melanomas,
melanocytes,
retinal cells
normal "
normal
normal
no
yes
yes
no
§ excluding viral peptides and oncogene-encoded peptides used to generate T cells.
t PBL, peripheral blood lymphocytes; TIL, tumor infiltrating lymphocytes; LN, draining
lymph node cells.
* (1) De Plaen et al., 1988; Lurquin et al., 1989; Alexander-Miller et al., 1994; (2)
Szikora et al., 1990; (3) Sibille et al., 1990; Wallny et al., 1992a; (4) Mandelboim et
al., 1994; (5) van der Bruggen et al., 1991; Traversari et al., 1992; De Smet et al.,
1994; (6) van der Bruggen et al., 1994a; (7) Gaugler et al., 1994; (8) van der
Bruggen et al., 1994b; (9) Brichard et al., 1993; Wilfel et al., 1994b; (10) Kawakami
et al., 1994a, b; Coulie et al., 1994; (11) Castelli et al., 1995; (12) Cox et al., 1994;
(13) Bakker et al., 1994; Kawakami et al., 1994c.
Cox et al. (1994) reported the isolation of peptide YMDGTMSQV (N-D at position 3).
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(1)*
(2)*
(3)*
(4)*
(5)*
(6)*
(7)*
(8)*
(9)*
(10)*
(11)*
(12)*
(13)*
Results and discussion
Ed Reilly established two long-term TIL lines from solid melanoma samples
(MEL660 and MEL663) provided by Steve Rosenberg (Reilly and Antognetti, 1991),
and in early 1991 we set out to characterize the melanoma peptide(s) recognized by one
of these lines (TIL660) in association with HLA-A2. We soon demonstrated a single
prominent peak of activity in HPLC fractions of melanoma peptides extracted from
immunoaffinity-purified A2 molecules (below); the shoulder eluting slightly ahead of
the main peak was a reproducible finding.
100
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Numerous trials were performed to optimize the purification scheme for the
active peptide in these melanoma extracts. Ultimately, initial purification of A2
molecules followed by TFA extraction and fractionation was deemed advantageous
because: (1) the mixture of peptides was substantially less complex than that obtained
from extraction of whole cells or purified cell membranes with TFA; and (2) problems
due to nonspecific toxicity of HPLC fractions were severe when using the whole cell
extraction method. The potential disadvantage was reduced yields of the active peptide,
particularly if it proved to have a rapid dissociation rate from its complex with A2. A
large-scale purification of A2 from =10 11 melanoma cells was performed, and the
active peptide was successively enriched through four sets of HPLC conditions using
different columns, solvents, and gradients (details to be given elsewhere). After each
step a satisfactory TIL assay result was obtained using 1% or less of the total sample.
After the fourth HPLC step, three fractions eliciting recognition by TIL660 were
submitted for mass spectrometric analysis. Two candidate masses were consistent with
the observed profiles of activity, i.e. highest in the central fraction and lower in the two
flanking fractions: (M+H) + = 906 and 1007. However, the purified material was
insufficient for fragmentation and sequence determination by mass spectrometry.
Another scale-up to 4x10 11 melanoma cells was undertaken. The active peptide
was purified but once again proved insufficient for sequencing. Meanwhile, problems
with the TIL line began to develop. Human CD8 + T cells are notoriously difficult to
maintain for long periods, and TIL660 was starting to behave inconsistently; occasionally
there was no lytic activity against the autologous melanoma cell, which was used for in
vitro stimulation of TIL660 and which was ordinarily lysed quite well (50-90%).
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Thereafter several results were published from other laboratories, and it became
possible to evaluate whether the melanoma antigen recognized by TIL660 was the same
as that recognized by other anti-melanoma T cells. We showed that most A2+
melanomas were recognized by TIL660, indicating reactivity against a shared
melanoma antigen (see table, below). Thierry Boon made available to us the A2+
melanoma line NA8, which is not a good target for most A2-restricted T cells, as well
as NA8 cells transfected with the gene for tyrosinase or Melan-A (the latter is called
gene Aa). As shown below, TIL660 specifically lysed NA8 cells transfected with Aa
but not untransfected NA8 cells (or NA8 cells transfected with the gene for tyrosinase).
Lysis by TIL660
C-,
C.I)
C.)
60
50
40
30
20
10
5:1 25:1 50:1
CTL:target cell ratio
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MEL660
NA8-Aa
A*- XT A Q
I _L I
Table. Cytotoxicity assays using TIL660.
target cell A2 status Percent specific lysis
(FACS level) 50:1 10:1 1:1
MEL660 A2 +  82.8 52.6
FO-1/neo A2- (2) 1.7 0.9
FO-l/A2 A2+ (56) 56.3 18.8
SK-MEL-5 A2 +  59.3 33.6
SK-MEL-28 A2- 11.6 5.0
MEL660 A2 + (178) 50 39
SK-MEL-30 A2 + (289) 25 14
SK-MEL-75 A2+ (95) 19 13
SK-MEL-37 A2 + (171) 14 12
SK-MEL-119 A2 + (112) 8 4
SK-MEL-133 A2- (1) 1 0
SK-MEL-64 A2- (2) 1 0
SK-MEL-113 A2- (1) 1 0
WM88 A2- (2) 1 0
MEL660 A2 +  92 72 32
NA8 A2 +  24 7.6 2.4
NA8-tyrosinase A2 +  21.2 9.5 5.7
NA8-Aa A2 +  57.1 20.6 6.7
Malme-3M A2+ 72.6 40.2 16.3
HT-144 A2- 19.8 13.9 4.6
SK-MEL-28 A2- 3.1 1.9 0
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Next a series of synthetic peptides from the MART-1/Melan-A sequence was
tested for activity. To our surprise, none was recognized efficiently by TIL660,
including the two different peptides recognized by T cells from the Rosenberg and
Storkus laboratories (see table, p. 168). Moreover, by HPLC retention characteristics,
the active peptide expressed by MEL660 cells appears to differ from both peptides
recognized by the other T cells. If confirmed, this result further supports the idea of
significant heterogeneity in T cell recognition of MART-1/Melan-A. Ongoing work is
directed toward chromatographic comparisons between the naturally processed
MEL660 peptide and the peptides identified as melanoma antigens in other laboratories,
as well as synthesis and testing of other MART-1/Melan-A peptides.
Addendum: A manuscript on the melanoma project was prepared and submitted for
publication in 1996 after this thesis was defended (see p. 178).
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Commentary
T-cell antigens in cancer
Theodore J. Tsomides and Herman N. Eisen
Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
The possibility that immune responses to
distinctive antigens on cancer cells might
aid in the treatment or prevention of
cancer has intrigued immunologists since
the early 1900s. Interest in this possibility
waned when it became apparent that the
regularly seen rejection of tumors trans-
planted from one rodent to another was
due to the recipient's immune response
to antigens (later termed histocompatibil-
ity antigens) present on all cells, both
normal and neoplastic, and not to unique
tumor antigens. Only after the develop-
ment of inbred mouse strains, in which all
members share the same set of histocom-
patibility antigens and accept normal tis-
sue grafts from one another, was the
existence of distinctive tumor antigens
firmly established. Thus, a tumor arising
in one mouse and transplanted to another
of the same strain is usually rejected if the
recipient is prepared ("immunized") by
prior injections of irradiated tumor cells.
Moreover, the immunity elicited by cells
from one tumor is often specific for that
tumor and not others, even those derived
using the same carcinogen (1-4).
Enormous efforts to identify and ex-
ploit tumor-specific antigens have been
made in recent years through the use of
monoclonal antibodies. Some of these
antibodies have proven useful for diag-
nostic purposes such as imaging of me-
tastases, but so far their therapeutic
value remains limited (5). One of the
limitations may be that tumor antigens
recognized by antibodies must be cell
surface components. In contrast, T lym-
phocytes potentially recognize antigens
that arise from any cellular protein. Fur-
thermore, the rejection of transplanted
tumors greatly resembles the rejection of
normal organ allografts, which is charac-
teristically mediated by T cells, not anti-
bodies. More significantly, many human
cancers, especially melanomas and renal
cell carcinomas, are intensely infiltrated
with T cells (tumor infiltrating lympho-
cytes; TILs); these cells, when selec-
tively grown in culture, can lyse the au-
tologous tumor cells and can cause dra-
matic regression of tumor masses when
reinoculated into the patient of origin, as
shown by Rosenberg and colleagues (6,
7). For these reasons, intensive efforts
are under way in several laboratories to
identify the antigenic structures recog-
nized by anti-tumor T cells. The striking
results of one of these efforts are de-
scribed by Kawakami et al. in this issue
of the Proceedings (8).
T cells constitute 1-5% of all cells in
the body. The antigens they recognize
are cell surface complexes formed be-
tween short peptides (generally 8-20
amino acids) and integral membrane pro-
teins encoded by the major histocompat-
ibility complex (MHC) (9-11). Of the two
major T-cell subsets defined on the basis
of CD4 or CD8 expression, CD4÷ T cells
recognize peptide fragments derived
from endocytosed proteins in association
with class II MHC molecules on the
surfaces of specialized antigen presenting
cells (12, 13).
The other major T-cell subset, and the
one of particular interest in relation to
tumor antigens, is CD8+ T cells. These
cells recognize short peptides that arise
within any cell by proteolysis of cellular
proteins (14) and are then transported to
the cell surface in association with class
I MHC (MHC-I) molecules (15). Since a
nucleated cell typically expresses -105
molecules of each of -6 different MHC-I
proteins, there are perhaps 106 peptide-
MHC-I complexes on the surface of any
given cell representing the several thou-
sand different proteins being synthesized
in that cell. Normally, an individual's
CD8+ T cells do not respond to com-
plexes of self peptides and self MHC-I;
however, if a foreign peptide as from a
viral protein, a mutated protein, or even
an overexpressed normal protein occu-
pies a sufficient number of MHC-I mol-
ecules [reported to be "-200 per cell (16)],
CD8+ T cells are activated to lyse the
affected cell. Thus, CD8 ÷ T cells perform
an immune surveillance function, effec-
tively monitoring the contents of virtu-
ally all cells by detecting peptides that are
sampled by MHC-I molecules and dis-
played at the cell surface. The rules gov-
erning exactly which cellular proteins are
represented by cell surface peptide-
MHC-I complexes are only beginning to
emerge, as a result of studies from vari-
ous laboratories over the past 3 years.
For example, direct biochemical isola-
tion of peptides from purified peptide-
MHC-I complexes (or in some instances
from whole cells or tissues), followed by
HPLC fractionation and chemical se-
quencing, has led to numerous sequences
of peptides that are present in cells as
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peptide-MHC-I complexes (17-26).
These peptides are derived from abun-
dant cellular proteins as diverse as his-
tones, heat shock proteins, elongation
factors, metabolic enzymes, and other
MHC molecules. Using a mass spectro-
metric approach, Hunt and colleagues
(27) showed that MHC-associated pep-
tides isolated from cells differ markedly
in amount; some are relatively abundant,
whereas many more are quite rare, per-
haps only a few copies per cell.
Importantly, most of the MHC-associ-
ated peptides so far identified by chemi-
cal sequencing have been obtained by
virtue of their high abundance-for in-
stance, the largest peaks from an HPLC
profile--and not because they are known
to be recognized by a particular clone of
T cells (28). The task of purifying and
identifying an antigenic peptide (or pep-
tides) defined on the basis of its recogni-
tion by a given T cell (such as a TIL) is
substantially more difficult, mostly be-
cause such peptides may be exceedingly
rare. In fact, most of the handful of
known naturally occurring T-cell anti-
gens are from acute intracellular (e.g.,
viral) infections (17, 18, 29, 30) or from a
transfected gene (31), each of which may
well result in higher-than-average cellular
levels of the antigenic peptide. Further-
more, in these cases the sequence of the
protein of origin is usually already
known. and synthetic peptides can be
used to guide identification of the natu-
rally occurring antigen.
Without such prior information, in or-
der to isolate an unknown peptide for
sequence determination nearly 1012 cells
must be used to obtain just 10 pmol of
peptide (generally considered a minimum
amount for complete sequence determi-
nation), assuming 10% overall recovery
and an abundance of 100 peptide mole-
cules per cell. In practice, yields for
multistep purification procedures are
likely to be significantly lower, with cor-
respondingly greater numbers of cells
required. When cultured cells such as
tumor cells serve as the source of an
antigenic peptide, very large scale cul-
tures are therefore required. In one in-
stance in which a T-cell antigen was
isolated without any prior knowledge of
its protein of origin [later seen to be a
cellular enzyme (26)], <7 pmol was re-
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covered after starting with 263 mouse
spleens (25).
Although the strictly biochemical ap-
proach has not yet resulted in any definite
sequences for tumor-specific antigens
recognized by T cells, several groups
have clearly demonstrated the existence
of such peptide antigens in tumor cell
extracts (32-34; T.J.T., E. B. Reilly, and
H.N.E., unpublished data). Moreover,
interest in these peptides is heightened by
the finding that some of them can be
detected in tumors from different individ-
uals, provided the appropriate MHC-I
molecule is present in these individuals
(or introduced into the tumor cells by
gene transfection). For example, mela-
nomas expressing the MHC-I molecule
HLA-A2 share several peptide antigens
recognized by TILs or by anti-tumor T
cells obtained from peripheral blood (35-
40). Because A2 is the most common
human MHC-I protein (present in =-50%
of Caucasians, for example), knowledge
of these particular shared antigens could
give rise to improved diagnostic or ther-
apeutic procedures against melanoma in
this subset of the population.
Pioneering studies by Boon and col-
leagues (41) have established an alterna-
tive approach to tle identification of tu-
mor-specific antigens recognized by
CD81 T cells. This genetic approach,
applicable in principle to other peptide
antigens as well (e.g., from infectious
agents, minor histocompatibility anti-
gens, and targets of autoimmune reac-
tions), has the advantage of being inde-
pendent of naturally occurring peptide
abundances. Starting with a cDNA li-
brary from a tumor cell (e.g., melanoma),
several hundred pools of plasmids are
transfected into COS cells (along with the
appropriate MHC-I gene) or into antigen-
loss tumor cell variants. Transfected
cells are then screened for expression of
the tumor-specific antigen by their ability
to stimulate anti-tumor T-cell clones, and
the procedure is repeated. Ultimately,
Boon and coworkers (42) identified a
family of melanoma antigen (MAGE)
genes that are expressed by human mel-
anomas and some other tumors, but not
by normal tissues. Also by this approach,
the melanocyte-specific gene for tyrosi-
nase was found to encode an antigen
recognized by peripheral blood anti-
tumor T cells in association with A2 (43).
Using similar techniques, Kawakami
et al. (8) now report the gene (MART-I)
for a shared melanoma antigen recog-
nized by TILs from patients with meta-
static melanoma. MART-1 RNA was de-
tected in melanocytes and melanomas,
but not in other cell types, with the ex-
ception of retina. Nine of ten A2-
restricted TIL lines recognized the
MART-1 product. The derived protein
sequence of 118 amino acids did not
reveal significant similarity to any other
sequences in the data bases, offering no
clues as to the nature of the target in this
anti-tumor response. Nevertheless, iden-
tification of the gene for an antigen ex-
pressed by most melanomas and recog-
nized by TILs in association with A2
represents an important advance for un-
derstanding and perhaps manipulating
anti-tumor immune responses.
The next step will be to determine the
sequence of the relevant antigenic pep-
tide, as opposed to that of the gene en-
coding its protein of origin. This can be
accomplished by synthesizing candidate
peptides and testing them for their ability
to sensitize appropriate target cells (e.g.,
A2+ nonmelanocytes) for lysis by the
same T cells (44, 45). The discovery by
Rammensee and colleagues (19) of dis-
tinctive patterns, or motifs, for peptides
binding to specific MHC-I molecules
(e.g., for A2, nonamers with Leu or Met
at position 2 and Val or Leu at position 9)
helps expedite such testing. Most often,
it is assumed that a peptide conforming to
the relevant motif and possessing good
sensitizing activity in vitro corresponds
to the natural epitope.
Since the MART-1 gene is also ex-
pressed in normal melanocytes and in
retina, apparently in the same form, a
question arises as to whether MART-1-
specific T cells react with normal cells,
and, if so, whether such autoimmune
reactions might detract from the useful-
ness of these T cells. Kawakami et al.
indicate that some melanoma patients
experience vitiligo (possibly due to T-cell
reactivity against normal melanocytes)
but that ophthalmologic problems have
not been observed. Clearly, transcription
of the gene for a tumor antigen (such as
MAGE-1, tyrosinase, or MART-1) in a
certain tissue or cell does not in itself
imply that those cells are recognized by
CD8+ T cells specific for the antigen. The
protein product must be made and pro-
cessed into peptides, and these peptides
must compete effectively for binding to
MHC-I molecules with the enormous
number of other peptides generated in the
same cells. Similar considerations apply
to recognition of cells that are infected by
some viruses--e.g., human immunodefi-
ciency virus (HIV); only up to 10 HIV
genes are expressed in concert with per-
haps 5000-10,000 cellular genes, and a
particular viral peptide antigen might or
might not compete with the myriad of self
peptides for representation by a limited
number of MHC-I molecules at the cell
surface.
When a cell (tumor, normal, virus in-
fected, etc.) can be shown to trigger a
cytolytic or other T-cell response, the
relevant antigenic peptide de facto satis-
fies all requirements for T-cell recogni-
tion. However, many cell types are not
available for use as target cells in such
direct assays. Moreover, the physiologi-
cal relevance of most in vitro assays, in
which, for example, T cells usually sub-
stantially outnumber target cells, is diffi-
cult to prove. Therefore, another ap-
proach is to establish the presence of a
particular antigenic peptide biochemi-
cally, by isolating MHC-I molecules and
fractionating their bound peptides by
HPLC. Although insufficient quantities
of an antigenic peptide may be recovered
to enable its direct sequence determina-
tion, its retention characteristics may be
compared with those of known synthetic
peptides, and the exquisite sensitivity of
T cells (some can detect attomole levels
of peptide) provides an unusually favor-
able system for detecting and identifying
the natural peptide. By such an ap-
proach, the presence of a naturally oc-
curring antigenic peptide in any given
tissue or cell type can be determined (17,
18, 29-31, 46).
Once it is shown that a peptide arises
naturally and can be recognized by anti-
tumor (or other) T cells, a further difficult
issue concerns assessment of its role in
vivo. Do such peptides necessarily func-
tion as targets under in vivo conditions or
play a role in eliciting T-cell immune
responses in an organism, and how ef-
fective might these responses be? This
question can also be raised in the context
of studies in which specific T cells are
generated against a putative antigen-
e.g., a viral protein implicated in tumor-
igenesis (47) or an oncogene or tumor
suppressor gene product (48)-and these
T cells are then evaluated for their anti-
tumor effects in vitro or in animal models.
When protection against tumor growth
can be achieved by using T cells obtained
by immunization with transformed cells
or short peptide antigens, is it also the
case that these same antigens are in-
volved in an individual's T-cell immune
response against his or her own (i.e.,
autochthonous) tumor?
Part of the answer lies in knowing
something about the level at which a
given peptide is expressed in target cells.
If only one or a few molecules per cell are
expressed, it is unlikely that very many T
cells can be efficient in recognizing and
lysing these targets. Again, such ques-
tions of abundance can be effectively
addressed by the biochemical approach
to antigenic peptide characterization
(49). Thus, the two techniques are seen to
be complementary: the genetic approach
permits genes for tumor antigens to be
identified, irrespective of the levels of
peptide expression, and the biochemical
approach establishes whether a pre-
sumed antigenic peptide based on a gene
sequence matches the naturally occur-
ring one and allows for measurement of
its abundance.
What is the likelihood that the anti-
genic peptide (or peptides) encoded by
MART-1 is the same as one of the shared
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A2+ melanoma antigens described in sev-
eral other laboratories? Eventually this
question can be addressed in the respec-
tive laboratories by comparing HPLC
retention times of the naturally occurring
antigen isolated from various melanoma
cells with that of the active synthetic
peptide yet to be identified from
MART-1. Alternatively, reactions be-
tween melanomas and anti-tumor T cells
exchanged among different laboratories
can be measured, although this is a lower
resolution approach than HPLC. Kawa-
kami et al. have already determined that
their TILs do not recognize MAGE-1 or
tyrosinase antigens. If different laborato-
ries using different methodologies and
different individuals' T cells ultimately
arrive at the same tumor antigens, there
will be more ground for hope for future
clinical applications.
Both the biochemical and genetic ap-
proaches to antigenic peptide identifica-
tion are costly and time consuming, and
the practical difficulty of maintaining most
human T-cell clones in long-term culture
(particularly CD8+ T cells) imposes a fur-
ther constraint on human studies. Never-
theless, the remarkable potential of this
information in cancer, infectious diseases,
and autoimmune disorders ensures that
much future work will be directed toward
discovering the relevant peptide se-
quences. The greatest coming challenge
may be in learning how to make best use
of this information.
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ABSTRACT
A line of tumor-infiltrating lymphocytes (660TIL) derived by culturing an
HLA-A2+ melanoma (660MEL) in the presence of IL-2 specifically lysed most A2 +
melanoma cell lines. We immunoprecipitated A2 from >1011 660MEL cells, extracted
naturally processed peptides, fractionated them by HPLC, screened the fractions for
recognition by 660TIL, and found a single predominant and a minor peak of activity.
Although too little was recovered of the major 660MEL peptide to establish its
sequence (due to low abundance), HPLC fingerprinting showed that it did not
correspond to any of the known A2-associated melanoma peptides recognized by T
cells, including peptides from tyrosinase, MART-1/Melan-A, gpl00, and MAGE-3.
The major 660MEL antigenic peptide appears to be derived from MART-1/Melan-A
but is neither AAGIGILTV nor ILTVILGVL nor any other MART-1/Melan-A peptide
containing the A2 consensus motif. Thus we define a new melanoma peptide
recognized by A2-restricted TIL and present a chromatographic approach to screening
synthetic peptides that may be naturally processed tumor antigens. The multiplicity of
melanoma peptides recognized by CD8+ T cells, most of which are non-mutated
(including the 660MEL peptide), suggests the existence of unknown mechanisms,
perhaps similar to those operating in autoimmune disorders, whereby T cells that
recognize normal "self' sequences become activated.
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INTRODUCTION
Among human cancers, melanoma has attracted great interest for studying
immune responses to distinctive tumor antigens, largely because both antibodies and
lymphocytes reactive against melanoma cells are commonly found in patients (1, 2). In
the 1980s, cytotoxic T lymphocytes (CTL) reactive against autologous melanomas were
isolated from patients' peripheral blood, lymph nodes, and tumor tissues (3-12). Some
of these CTL were shown to recognize allogeneic as well as autologous melanomas,
provided the melanomas used as target cells expressed the same class I major
histocompatibility complex (MHC-I) molecule, implying the existence of key antigens
shared among melanomas from different patients (13-17). Together with the discovery
that T cell antigens consist of short peptides non-covalently bound to MHC-I molecules
(18), the stage was set for attempts to identify the peptides present on melanoma cell
surfaces and recognized by melanoma-reactive T cells. As of the early 1990s, no such
peptides had been identified (19); since then there has been an explosion of information
regarding the identities of T cell antigens on melanoma cells and a few other cancers
(see below, Table 2). Currently, trials are in progress to assess whether peptide-
induced, tumor-specific immune responses can have significant effects on tumor
progression and on survival (20-23).
Our laboratory has been interested in the identification of naturally processed
peptide antigens recognized by specific CTL in a variety of systems, including HIV
infection, allogeneic responses, and melanoma (24). We wish to understand the reasons
why in certain instances (such as influenza virus infection (25)), T cells are effective in
ridding the host of unwanted target cells, while in other cases (notably HIV infection
and many cancers), abundant and vigorous T cell responses can readily be demonstrated
but apparently are insufficient to eradicate target cells. Some factors thought to limit T
cell-target cell reactions include: poor MHC expression, absence of appropriate
accessory molecules, antigen escape mutations, and low T cell receptor affinity for
peptide*MHC ligands. Recently we explored the possibility that a critical and under-
appreciated parameter in regulating target cell lysis by CTL in vivo is the density of
specific antigens (i.e., naturally processed peptide*MHC-I complexes) on target cell
surfaces (24, 26). Perhaps the number of peptide*MHC-I complexes per target cell is
often below the threshold required for efficient lysis in vivo by existing CTL specific for
that antigen. Because CTL activity is usually studied in vitro using somewhat arbitrary
concentrations of synthetic peptides and high numbers of T cells in standardized
cytotoxicity assays, information about the density of a naturally processed peptide
antigen and how it compares to the density of ligand required for T cell lysis in vivo is
virtually nonexistent. Thus a first step in addressing the potential role of ligand density
in T cell reactions is to determine the identities and natural abundances of various
peptide antigens recognized by T cells.
We describe here our efforts to characterize the peptide(s) involved in
recognition and lysis of a melanoma cell line, 660MEL, by an autologous CD8 + tumor-
infiltrating lymphocyte (TIL) line (660TIL), using biochemical methods similar to those
which had led to the successful identification of naturally processed viral (27, 28) and
allogeneic (29-31) peptides. Despite numerous attempts, we were unable to determine a
particular peptide sequence. However, we found that: (i) 660TIL recognizes an antigen
present on most HLA-A2+ melanomas; (ii) the A2-restricted anti-melanoma response
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of 660TIL is mediated by a single predominant peptide and a second minor peptide;
(iii) the natural abundance of the predominant peptide is likely to be extremely low
(<50 copies per melanoma cell); (iv) by defining a series of HPLC conditions for
elution of the major 660MEL peptide, a "chromatographic signature" of the peptide was
obtained that could be compared with those of other known melanoma peptides
recognized by A2-restricted T cells; (v) the major 660MEL peptide is different from all
other published antigenic melanoma peptides by chromatographic criteria, further
indicating the substantial diversity of A2-restricted anti-melanoma T cell responses;
(vi) the major 660MEL peptide appears to be encoded by the MART-1/Melan-A gene
product (32, 33) but differs from known MART-1/Melan-A antigenic peptides (34, 35);
(vii) the major 660MEL peptide lacks the consensus motif for A2-associated natural
peptides (36); and (viii) like most known peptides recognized by anti-tumor T cells, the
major 660MEL peptide seems to be a "self' rather than a mutated peptide, drawing
attention to the autoimmune nature of CTL responses to melanoma cells.
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MATERIALS AND METHODS
Cell Lines
Cell line 660TIL was established from cryopreserved fresh 660MEL tumor
samples provided by Dr. Steven A. Rosenberg and was maintained as previously
described (37, 38) using serum-free AIM V medium (GIBCO BRL), 1000 U/ml rIL-2
(gift of Hoffman-LaRoche), 500 U/ml penicillin, 50 pg/ml streptomycin, 250 ýtg/ml
amphotericin B, and 2 mM L -glutamine. 660TIL was stimulated with autologous
660MEL cells at intervals of 2-3 weeks and retained anti-tumor CTL activity in
standardized cytotoxicity assays for at least several months (>50% specific lysis at a
CTL:target cell ratio of 50:1), after which cryopreserved 660TIL cells were thawed and
maintained in the same way. The 660TIL phenotype was CD3+CD8+HLA-A2+ , and
lysis of 660MEL by 660TIL was blocked by mAbs OKT3 and OKT8, mAbs against
ICAM and LFA-1, mAbs PA2.6, BB7.2, and PA2.1 against A2, but not by mAb BB7.1
against HLA-B7 (38).
Melanoma cell line 660MEL was established from cryopreserved fresh tumor
and was maintained in monolayer culture using DME supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 500 U/ml penicillin, 50 ptg/ml streptomycin, 2
mM L-glutamine, and 10 mM HEPES, pH 7.3. 660MEL cells were adapted to growth
in 850 cm 2 roller bottles for large scale culture and were harvested by treatment with 5
mM EDTA, pH 8.0, followed by centrifugation. Melanoma cell lines NA8, NA8-Aa,
and NA8-tyrosinase (from Drs. Aline Van Pel and Thierry Boon (39)), FO- /neo and FO-
1/A2 (from Dr. Richard A. Zeff (40)), SK-MEL-30, SK-MEL-37, SK-MEL-64, SK-
MEL-75, SK-MEL-113, SK-MEL-119, SK-MEL-133, and WM88 (from Drs. Alan
Buckler and Nic Dracopoli), and SK-MEL-5, SK-MEL-28, HT-144, and Malme-3M
(purchased from ATCC) were maintained similarly to 660MEL, with the addition of 1
mg/ml G418 (GIBCO BRL) for transfected cell lines NA8-Aa, NA8-tyrosinase, FO-
1/neo, and FO-1/A2. JY target cells are A2 + EBV-transformed B cells, and T2 are A2 +
antigen processing mutant TxB cell hybrids (from Dr. Peter Cresswell).
Peptide Synthesis and Chromatography
Peptides were synthesized by standard t-Boc chemistry on an Applied
Biosystems Model 430A, analyzed by reverse phase HPLC and amino acid analysis,
and found to be >90% pure. Peptide concentrations were generally measured by Micro
BCA Assay (Pierce) and ranged from 10-100% of the concentrations calculated from
dry weights. Several peptides derived from the MART-1 sequence were kindly
provided by Drs. Yutaka Kawakami and Steven A. Rosenberg (34). HPLC was
performed on a Beckman Model 334 equipped with an Applied Biosystems 757
variable wavelength absorbance detector. A characteristic HPLC profile
("chromatographic signature") was determined for each synthetic peptide by recording
the retention time of =1 ptg peptide under three or four rigidly defined HPLC conditions
(column, solvents, gradient, flow rate). HPLC conditions were as follows: (A) C18
column (Vydac 218TP104), solvent A = 0.1% TFA (Pierce) in H2 0, solvent B =
0.085% TFA in acetonitrile (J.T. Baker) ("TFA system"), gradient = 1.0% B/min, flow
rate = 1.0 ml/min; (B) phenyl column (Vydac 219TP54), TFA system, gradient = 0.5%
B/min, flow rate = 1.0 ml/min; (C) C4 column (Vydac 214TP54), TFA system,
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gradient = 0.25% B/min, flow rate = 1.0 ml/min; and (D) pH stable polymeric column
(ymc 2x250 mm), solvent A = 125 mM triethylamine acetate (Applied Biosystems) in
H20, pH 7.1, solvent B = 75 mM triethylamine acetate in acetonitrile, gradient = 0.15%
B/min, flow rate = 0.25 ml/min. HPLC retention times of synthetic peptides were
confirmed by repeat injections and were reproducible to within 1 min for a particular
peptide and chromatographic condition when using the same batch of solvents.
Isolation and TFA Elution of Peptide*HLA-A2 Complexes
Peptide*HLA-A2 complexes were harvested from cultured tumor cells as
previously described (41-43). Essentially, batches of 109-1010 melanoma cells were
pelleted and lysed in hypotonic medium at 40 C; all subsequent steps were performed at
40 C in the presence of 100 gM phenylmethanesulfonyl fluoride, 200 ýpM dithiothreitol,
and 0.02% NaN3. Membranes were collected by ultracentrifugation for 60 min at
105,000 x g, solubilized in 3-4% Brij 58 (Pierce), and passed over a set of four
immunoaffinity columns arranged in series as follows: Sepharose only, pooled mouse
y-globulin coupled to Sepharose, mAb PA2.1 (anti-A2) coupled to Sepharose, and mAb
W6/32 (anti-MHC-I) coupled to Sepharose. The affinity columns were prepared by
staphylococcal protein A purification of each mAb, periodate oxidation of the
carbohydrate moiety in the Fc domains, and covalent coupling to hydrazide-modified
Sepharose (Pierce). After being washed with at least 30 column volumes of buffers,
each column was eluted with 50 mM diethylamine*HC1, pH 11, 0.2% Brij 58 into 2-ml
fractions containing 0.1 volume of IM Tris*HC1, pH 8. A2 purity was assessed by
SDS-PAGE, and yields (as well as purity) were further determined by quantitative
amino acid analysis. Overall yields of A2 were generally =50% (assuming 5 nmol A2
per 1010 660MEL cells, which is based on flow cytometric comparison with JY cells).
In later experiments, immunoprecipitation of peptide*A2 complexes was performed
using soluble PA2.1 and protein A or protein G coupled to Sepharose (Pharmacia);
yields of A2 were comparable to those from immunoaffinity chromatography, while
scale-up was greatly facilitated.
Purified A2 (from the PA2.1 column or batch immunoprecipitation) and non-A2
HLA molecules (from the distal W6/32 column) were concentrated by ultrafiltration at
5000 x g (Centricon-10 membrane, molecular mass cutoff =10 kd, Amicon) and
denatured twice with 0.5% trifluoroacetic acid (44) for 60 min at 370 C. The released
peptides were collected by ultrafiltration and dried by SpeedVac (Savant) evaporation
or lyophilization prior to HPLC fractionation. For some experiments, a small aliquot of
125I-labeled peptide ILKEPVHGV (which binds tightly to A2 on cell surfaces (45)) was
added initially to the melanoma cells as a convenient tracer in order to ensure complete
TFA elution of endogenous peptides from purified peptide*A2 complexes (43).
Extraction of Naturally Processed Peptides from Tumor Cells
In addition to large scale purification of peptide*A2 complexes as described
above, several other methods were tested in trials for the most efficient isolation of
antigenic peptides from cultured melanoma cells (summarized in Figure 1, below). Cell
pellets were extracted directly, without HLA purification, by adding 5-15 ml of cold 1%
TFA in H 20 per 109 cells (plus additional TFA if needed to bring the pH below 2.0),
douncing, and sonicating as described (29). The denatured material was transferred to a
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Centriprep-10 ultrafiltration device (molecular mass cutoff =10 kd, Amicon) and
subjected to centrifugation at 2600 x g for several hours at 40 C (46). The ultrafiltrate
was removed, an equal volume of 1% TFA was added to the retentate, and
centrifugation was repeated in order to maximize the recovery of extracted peptides.
Pooled filtrates were dried by lyophilization and re-dissolved in 0.1% TFA for
fractionation by HPLC. In another trial, extraction with triethylamine, pH 10, or
acetonitrile was performed after TFA extraction in order to determine whether one of
these solvents would lead to a higher yield of an unusual peptide sequence (this was not
the case). In other variations, melanoma cell membranes were prepared and then
extracted with TFA (no HLA purification), or whole cells were solubilized in detergent
for HLA purification (no membrane isolation). HPLC conditions for the fractionation
of naturally processed peptide extracts obtained by any of the above approaches were
identical to conditions A, B, C, and D as described under Peptide Synthesis and
Chromatography.
Cytotoxicity Assays
Cultured melanoma cells to be tested directly as targets for lysis by 660TIL were
labeled with 5 1Cr for 1 h at 37 0 C, washed three times with FBS-containing medium,
and placed in wells of a 96-well round-bottom plate at 5 x 103 cells/well. For synthetic
peptide testing or for screening HPLC fractions of naturally processed peptide extracts,
the samples were first distributed in 96-well plates, dried overnight, and 5 x 103 51Cr-
labeled JY or T2 target cells (both A2+) were added for 1 h at 370 C. 660TIL were then
added at appropriate ratios of CTL:target cells (50:1 unless otherwise noted) for 4 h at
370 C. Percent specific lysis was calculated from the average of duplicates as 100 x
(5 1Cr release into supernatant - spontaneous release)/(total release in detergent -
spontaneous release). In a few assays, mAb MA2.1 and 32m were added to T2 cells in
an effort to increase the sensitivity of peptide detection as reported previously (35, 47,
48), but no increase in specific lysis values was noted. All synthetic peptides and
HPLC fractions were also tested for nonspecific lysis of target cells in the absence of
CTL ("toxicity"), and none was found to be toxic.
Flow Cytometry
Cultured melanoma cells were checked to confirm A2 status and to compare
mean A2 levels. After cells were washed and resuspended in PBS containing 5% FBS
and 0.01% NaN 3 , 5 x 105 cells in 200 pl were placed in wells of a 96-well V-bottom
plate, stained with 1 ptg of the anti-A2 mAb PA2.1 for 20 min on ice, washed twice with
the same buffer, incubated with 5 pgg of FITC-conjugated F(ab')2 fragment of goat anti-
mouse IgG (Pierce) for 20 min on ice, washed twice, and analyzed with an EPICS C
cytofluorimeter (Coulter) or by fluorescence microscopy. Reported mean fluorescence
values are on a linear (not logarithmic) scale.
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RESULTS
660TIL Recognizes a Majority of A2 + Melanoma Cell Lines
The cytotoxic activity of 660TIL against a variety of A2 + and A2- melanoma
cell lines was tested, with autologous 660MEL included in each assay as a positive
control (Table 1). Of eight different A2 + lines, seven were lysed to an appreciable
extent by 660TIL. Susceptibility to lysis did not correlate linearly with mean levels of
A2 expression; for example, SK-MEL-30 had over a five times higher mean level of
A2 than FO-1/A2 but was lysed more poorly. Of seven A2- cell lines, one was lysed
inefficiently by 660TIL. Based on these data and evidence for limited oligoclonality of
TIL after many months in culture (49-52), 660TIL appears to recognize one or more
antigens shared by a majority of A2 + melanomas.
A Single Melanoma Peptide Mediates Most of the A2-Restricted Response of
660TIL
To determine the structure of the peptide antigen(s) responsible for A2-restricted
lysis of melanomas by 660TIL, we examined endogenous peptide*A2 complexes from
large scale cultures of 660MEL cells. First, we performed numerous trials using 109-
1010 melanoma cells and different purification strategies as outlined in Figure 1 (e.g.,
direct extraction of cells with TFA or immunoaffinity purification of A2 followed by
TFA extraction (53)). The optimal method for isolation and fractionation of antigenic
peptides in this system proved to be hypotonic cell lysis, isolation and detergent
solubilization of membranes, A2 affinity purification, and TFA elution of peptides from
purified peptide*A2 complexes (pathway 3). For large scale work (21011 cells), A2
affinity purification by batch immunoprecipitation with mAb PA2.1 (IgG1 subclass)
and protein G-Sepharose was more efficient and convenient than column
chromatography.
Figure 2 shows highly efficient lysis by 660TIL of JY target cells pulsed with
HPLC fractions of A2-bound peptides from 1010 melanoma cells (2.5 x 109 cell
equivalents per well). Fractions 44, 45, and 46 each gave rise to >90% specific target
cell lysis and likely represent a single active peptide eluting over 2-3 min, because in
comparable experiments (e.g., Figure 3A) this activity was largely contained within a
single fraction (no. 44 or 45), and further chromatography of the active fraction(s) under
different chromatographic conditions did not resolve separate peaks of activity (e.g.,
Figure 3B-D). Under a defined set of HPLC conditions (column, solvents, gradient, and
flow rate), peptides differing even slightly in length or sequence can be resolved and
therefore differentiated based on characteristic retention times. HPLC conditions B-D
were especially resolving, such that peptides differing by a single residue and even
isomeric peptides could routinely be distinguished (refs. 26, 29, 31). Thus, the presence
of more than one active peptide in fractions 44-46 would be expected to result in
separate peaks of activity upon re-chromatography (Figure 3B-D).
In addition to the peptide eluting in fractions 44-46 under HPLC condition A
(hereafter referred to as the major 660MEL peptide), a second shoulder of activity was
reproducibly observed in fraction 41 or 42 (e.g., Figures 2 and 3A). This activity was
assumed to represent a second minor peptide present on 660MEL cells. Further
185
purification and characterization of this minor peptide were not undertaken in view of
its comparatively marginal biologic activity. The finding of more than two peaks of
sensitizing activity among similarly derived HPLC fractions in other studies may be
attributable to a greater degree of polyclonality in the T cell populations used (54-56).
Abundance of the Naturally Processed 660MEL Peptide is Quite Low
The natural abundance of the major 660MEL peptide is important for
understanding the role of this peptide in recognition of melanoma cells by 660TIL. In
particular, the question of whether the cell surface density of peptide*A2 complexes is a
limiting factor in melanoma lysis cannot be examined without knowledge of what the
naturally processed antigenic structures are and of their abundances (24). From a
practical standpoint, natural abundance is also of interest in planning purification
strategies.
After four rounds of HPLC (Figure 3), the major 660MEL peptide was judged to
be highly purified based on up to 50-fold enrichment at each round. Accordingly, the
sample was subjected to mass spectrometric analysis but a sequence could not be
derived due to insufficient material. However, we can offer some estimates of natural
abundance. We assume an initial peptide yield of 50% from melanoma cell extraction
and a yield of 50% per HPLC round, values in line with previous studies (26, 31, 57,
58). Based on the ability to detect <1 pmol of known peptide standards by mass
spectrometry, the starting amount of peptide would then be <50 molecules per
melanoma cell. An independent estimate of peptide abundance may be calculated by
assuming an SD50 value of the unknown 660MEL peptide (concentration at which 50%
of maximal lysis occurs (43)). If the SD 50 is 10 pM (comparable to other known
naturally processed peptides in assays similar to those used here (26, 28, 35, 43, 57-
59)), and 1% of the total sample was used in a cytotoxicity assay to give 50% of
maximal lysis (i.e., 4 x 109 cell equivalents per 200 ýtl well), then fewer than ten
molecules of peptide were recovered per melanoma cell. While only approximate, these
estimates indicate that the natural abundance of the major 660MEL peptide is likely to
be extremely low.
The Major 660MEL Peptide is Not One of the Known Melanoma T Cell Antigens
At least ten melanoma peptides recognized by A2-restricted T cells (PBL, TIL,
or LN) have recently been described (Table 2). Eight of these were identified by a gene
cloning approach pioneered by Boon and colleagues (60), and two were isolated
biochemically from cultured melanoma cells. All ten peptides are encoded by the
tyrosinase, MART-1/Melan-A, gpl00/Pmell7, or MAGE-3 genes and have normal, i.e.,
non-mutated sequences. Tyrosinase, MART-1/Melan-A, and gpl00 are expressed by
normal melanocytes as well as melanomas, while MAGE-3 is one of an extended
family of genes (MAGE, GAGE, BAGE (61-63)) expressed by many different tumors
but not by normal tissues (except testis and placenta).
In order to determine whether the major 660MEL peptide recognized by our
660TIL line was one of the known melanoma antigens recognized by other A2-
restricted T cells, we employed two distinct strategies. First, we synthesized the known
melanoma peptides and tested them for sensitizing activity in cytotoxicity assays with
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660TIL. All peptides tested negative; the MART-1/Melan-A peptide AAGIGILTV
(34) consistently exhibited slight activity over background (10-23% lysis at the
extremely high peptide concentration of 100 kM and less at lower concentrations), but
this was far below the activity obtained with HPLC-fractionated natural extracts of the
660MEL peptide (up to 100% specific lysis, see Table 3 and Figures 2 and 3).
To definitively rule out the known melanoma peptides, we devised a second
strategy in which each synthetic peptide was characterized chromatographically with
the HPLC conditions used to purify the 660MEL peptide (Figure 3). By exploiting the
considerable resolving power of serial rounds of HPLC, any given peptide could be
excluded from consideration if its chromatographic signature did not match that of the
naturally processed 660MEL peptide. A precise match would be strong evidence of a
correctly identified sequence. As shown in Table 3, none of the known melanoma
peptides tested had the highly reproducible (±1 min) chromatographic signature of the
major 660MEL peptide. MART-1/Melan-A peptide AAGIGILTV differed in retention
time by 7-8 min from the natural extract under HPLC condition C, effectively ruling out
this peptide as the one we had purified. Interestingly, peptide AAGIGILTV eluted in
fraction 43 under HPLC condition A, very close to the minor peak of activity we
consistently observed in fractions 41-42 of 660MEL extracts (Figures 2 and 3A), and in
view of the slight sensitizing activity demonstrated by peptide AAGIGILTV in 660TIL
assays, it is possible that the smaller peak of natural activity is in fact due to this peptide
(also see below, Figure 4).
660TIL Recognizes a Product of the MART-1/Melan-A Gene
The MART-1/Melan-A gene was independently identified in two laboratories as
the source of melanoma peptides recognized by both TIL and PBL (32, 33) and was
subsequently found to encode a peptide (AAGIGILTV) recognized in vitro by nine of
ten A2-restricted TIL obtained from ten melanoma tumors, including TIL derived
independently by Kawakami et al. from the 660MEL tumor (34). To determine whether
our 660TIL line recognized a product of the MART-1/Melan-A gene, we relied on
cytotoxicity assays using as targets an A2+ melanoma cell line (termed NA8) that is not
recognized by 660TIL or NA8 transfected with the Melan-A gene (termed NA8-Aa)
(39). NA8 cells transfected with the tyrosinase gene were also tested. Figure 4 shows
that our 660TIL recognizes a product generated only in Melan-A-transfected NA8 cells.
Specific lysis of NA8-Aa was somewhat less than lysis of autologous 660MEL cells in
repeated assays. We could not determine whether recognition of NA8-Aa by 660TIL
was due to peptide AAGIGILTV (potentially the minor sensitizing 660MEL peptide
seen in HPLC fractions 41-42) or to a different, unknown MART-1/Melan-A peptide
(i.e., the major 660MEL peptide present in fractions 44-45). If the former is true, then
the major 660MEL peptide might not be derived from MART-1/Melan-A, although we
consider this possibility remote because of the very weak activity of the minor peptide
in HPLC fractions 41-42 and the high levels of lysis of Melan-A-transfected NA8 cells
(Figure 4).
The Major 660MEL Peptide Does Not Possess the A2 Consensus Motif
On the basis of Table 3, the major 660MEL peptide was neither of the two
MART-1/Melan-A peptides known to be recognized by A2-restricted anti-tumor T
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cells. And since the other logical candidates for the 660MEL peptide were short
peptides derived from the 118 amino acid sequence encoded by MART-1/Melan-A, we
tested all of the MART-1/Melan-A peptides that contained the empiric consensus motif
for natural peptides associated with A2, i.e., nine (or ten) amino acid residues with
alanine, isoleucine, leucine, or valine at positions two and nine (or ten) (34, 36). We
employed 660TIL cytotoxicity assays and/or the chromatographic signature approach to
evaluate these synthetic peptides. None of them matched the major 660MEL peptide
(Table 4 and Figure 5), in accord with known limitations in the ability of consensus
motifs to predict all naturally processed antigenic peptides (36).
Because of the slight activity of peptide AAGIGILTV in 660TIL assays (Table
3), we wondered whether the 660MEL peptide could be a closely related MART-
1/Melan-A peptide of unusual length, as some longer A2-binding peptides are known to
occur naturally (64). Also, longer peptides can undergo partial proteolysis in
cytotoxicity assays and thereby reveal sensitizing activities due to shorter degradation
products (28, 30). We tested a number of synthetic peptides ranging in length from nine
to 15 amino acids and flanking the known antigenic sequences from MART-1/Melan-A
(Table 4 and Figure 5); none was biologically active. Finally, we synthesized and
tested two peptides from the MAGE-1 sequence that contained the A2 consensus motif,
as well as two peptides from MART-1/Melan-A that had molecular masses of 1301 and
1007, respectively, because mass spectrometric sequencing efforts had tentatively
suggested the presence of peptides of these sizes in our purified natural extracts. None
of these synthetic peptides matched the naturally processed 660MEL peptide by
cytotoxicity assay or by HPLC fingerprinting (Table 4).
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DISCUSSION
Anti-melanoma T cells obtained from patients' tumor tissues, peripheral blood,
or lymph nodes specifically recognize shared melanoma antigens that consist of short
peptides bound to MHC-I proteins. Ten different peptide sequences from four proteins
(tyrosinase, MART-1/Melan-A, gp 100, and MAGE-3) have recently been identified that
are recognized by anti-melanoma T cells in association with HLA-A2 (Table 2). In this
study, we analyze the naturally processed peptides recognized by a line of tumor-
infiltrating lymphocytes (660TIL) obtained from an A2+ melanoma (660MEL). We
show, through the use of distinctive chromatographic signatures of naturally processed
and synthetic peptides, that the major antigenic peptide isolated from 660MEL cells
differs from the peptides recognized by other A2-restricted anti-melanoma T cells
(Table 3).
Indeed the considerable diversity of melanoma peptides recognized by A2-
restricted T cells is further emphasized by the finding that among the peptides not
recognized by our 660TIL line are peptide sequences from MART-I/Melan-A and
gpl00 that are recognized by an A2-restricted 660TIL line derived independently by
Kawakami et al. from the same melanoma tumor (660MEL) (34, 65). That a single
tumor mass can present multiple antigens to A2-restricted T cells has been shown
previously (54-56). In contrast, virus-infected cells often present one predominant
peptide to anti-viral T cells (27, 28, 66, 67).
Several groups have recently noted the existence of A2-restricted anti-melanoma
CTL that recognize products other than tyrosinase, MART-1/Melan-A, gpl00, and
MAGE-3 (33, 68, 69). Still other genes (MAGE, GAGE, BAGE, p15, MUM-1, gp75)
encode products recognized by anti-melanoma T cells restricted by HLA-A1, A24, A31,
B44, Cw6, and Cwl6 (Table 2 and ref. 70). The peptides so far known to be recognized
by anti-melanoma CTL derive from at least two different sources: (i) melanocyte
differentiation antigens such as tyrosinase, MART-l/Melan-A, gp100, and gp75 that are
expressed in melanomas and normal melanocytes (and also in retina (32)) but not in
other tissues tested; and (ii) tumor-specific antigens from the MAGE, GAGE, and
BAGE families (61-63) that are expressed in melanomas as well as other tumors and in
normal testis but not in normal melanocytes. Altogether, anti-tumor T cells from
individuals with melanoma recognize a remarkable array of peptides from a surprisingly
large number of melanoma-associated proteins (Table 2). An unexpectedly large
number of tumor antigens recognized by host antibodies has also recently been
described (71).
A second striking feature emerging about melanoma antigens recognized by T
cells is that they predominantly have normal "self' (i.e., non-mutated) sequences. The
peptide studied here is also likely to be non-mutated, since 660TIL specifically lysed
A2+ target cells (NA8) transfected with the Melan-A gene, which has no known
mutation (Figure 4). The multiplicity of antigenic peptides that are derived from non-
mutated proteins in melanoma cells and recognized by anti-melanoma T cells stands in
contrast to the decades-old expectation that tumor-associated protein antigens in general
are aberrations - i.e., mutated proteins or proteins normally found primarily in the fetal
state (so-called oncofetal antigens, e.g. ref. 72). As noted previously (e.g. refs. 73, 74),
the "self' nature of antigens recognized by anti-melanoma T cells suggests an analogy
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with autoimmune T cell responses.
How good is this analogy? Self-reactive T cells responsible for autoimmune
disorders such as diabetes have been analyzed using the concept of checkpoints, with
disease states requiring the progression of self-reactive T cells through several stages
(75). Normally, T cells that can recognize self antigens (e.g., insulin-producing
pancreatic 3-islet cells (75), myelin basic protein and other central nervous system
components (76)) can be isolated from healthy individuals without detectable
immunopathology (77). Recent studies similarly indicate the existence of MART-
1/Melan-A-specific T cells in healthy individuals who have no evidence of
autoreactivity against normal melanocytes (such as vitiligo) (78, 79). When self-
reactive T cells are activated to the next stage, they extensively infiltrate antigenic sites
but do not cause target cell destruction. This situation, exemplified by lymphocytic
infiltration in the pancreatic 13-islets of male NOD mice and in young mice in a T cell
receptor transgenic mouse model (75), may be analogous to the presence of anti-
melanoma T cells in melanoma tumors that continue to grow. Finally, in full-blown
autoimmune disease the infiltrating T cells bring about destruction of the target organ.
This stage, pathological in the case of autoimmune disease, is desired when the target
"self' organ is a tumor; however, apart from the successes of Rosenberg et al. in using
tumor-infiltrating lymphocytes for immunotherapy in patients with metastatic
melanoma (80), this stage seems not to be achieved in most clinically detectable human
melanomas.
A difficulty in studying the ability of anti-melanoma T cells to mediate tumor
cell destruction is the inescapably artificial nature of in vitro cytotoxicity assays, in
which CTL stimulated with high doses of IL-2 are added in great excess over target
cells (e.g., 50:1) in a U-bottom well for several hours. While useful as assays, these
conditions probably bear little resemblance to what obtains in a typical tumor,
particularly when synthetic peptides are also added to the assays at massively supra-
physiological levels: e.g., at 10 tiM a peptide having a modest association constant of
106 M -1 would occupy over 90% of available MHC-I binding sites under steady state
conditions (45), resulting in a far greater number of peptide*MHC-I complexes than
achieved by most naturally processed peptides (81). One potential clue to the in vivo
activity of anti-melanoma T cells may come from the presence or absence of local
depigmentation reactions (vitiligo), at least for melanocyte differentiation antigens such
as tyrosinase, MART-1/Melan-A, and gp100. Some anti-melanoma CTL can lyse
normal melanocytes in vitro (82, 83), and there is evidence (i) that melanoma (but not
renal carcinoma) patients treated with interleukin-2 tend to develop vitiligo and (ii) that
melanoma patients with vitiligo have prolonged survival (1, 65). These observations
suggest that antigen-specific T cell responses can be stimulated to destroy normal
melanocytes, and that these T cells might also be stimulated to kill melanoma tumor
cells. Whether this T cell activation is mediated by the expression of particular
costimulatory molecules on target cells, by altered production of cytokines with potent
paracrine activities, by increased levels of specific antigens, or by other influences is
currently an area of intense investigation.
Although the activation of diverse anti-melanoma T cells might account for the
rare "spontaneous" regression for which melanoma is known (2), more often these cells
do not prevent tumor growth. While there are many plausible contributing factors to
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inadequacy of a CD8+ T cell response (e.g., absence of appropriate adhesion or co-
stimulatory molecules, decreased MHC-I expression by tumor cells, low T cell receptor
affinity for peptide*MHC-I complexes), we propose that a critical parameter in
regulating tumor cell lysis in vivo could be the low abundance of naturally processed
peptide*MHC-I complexes (24). Little information is available to address this
possibility, since only two of the peptides listed in Table 2 that are recognized by
human anti-tumor T cells were purified directly from tumor samples. Based on our
experience, the study of Cox et al. (58), and the failure of other laboratories to report the
biochemical isolation of tumor peptides, we suspect that the densities of tumor
peptide*MHC-I complexes may in general be quite low. An apparent exception is
found in the mouse Lewis lung carcinoma, where a naturally processed tumor antigen is
one of the more abundant MHC-I-associated peptides (and is also mutated) (84).
Cells infected by lytic viruses such as influenza, vaccinia, Sendai, or VSV
produce large numbers of viral peptide*MHC-I complexes and may be lysed efficiently
both in vitro and in vivo by specific CTL. Tumor cells, however, might resemble cells
chronically infected by persistent viruses such as EBV or HIV, in which low viral
protein expression results in low densities of peptide*MHC-I complexes at the cell
surface, perhaps accounting for ineffectual destruction of these target cells. We recently
showed that chronically HIV-infected cells contained an average of =12 and =400
copies of two different peptides recognized by human HIV-specific CTL clones, and the
infected cells were lysed much less efficiently by CTL specific for the peptide
expressed at the lower level (26).
Our original goal - isolation of sufficient quantities of the 660MEL antigenic
peptide for sequence determination - proved elusive for several reasons: (i) the
quantity of naturally processed antigenic peptide on 660MEL cells appears to have been
extremely low (<50 copies per cell, see above), forcing us to undertake ever larger scale
cell cultures and HLA purifications (up to 4 x 1011 melanoma cells) in order to recover
an amount of peptide adequate for sequencing efforts; (ii) the longer times required for
peptide*A2 isolation in large scale experiments (several hours) may have permitted
dissociation and loss of the natural 660MEL peptide, depending upon the (unknown)
dissociation kinetics of this particular peptide*A2 complex; and (iii) eventual
difficulties in sustaining the 660TIL line after prolonged culture.
These obstacles, especially low tumor peptide abundance, may also have limited
peptide sequencing programs in other laboratories; only three successful biochemical
isolations of tumor antigens have been reported (35, 58, 84). The majority of peptides
recognized by anti-tumor T cells have been defined by gene cloning methods that
permit identification and sequencing of the genes encoding tumor antigens irrespective
of how low the abundance of the corresponding natural peptides might be (32, 33, 60).
However, these approaches serve to identify a gene, not an antigenic peptide. In order
to determine what peptide sequences are recognized, the deduced gene products must be
scanned for candidate sequences, usually based on empiric consensus motifs (36).
Synthetic peptides are then tested in cytotoxicity assays, often requiring high
concentrations (up to 100 RtM, see Table 2) to demonstrate sensitizing activity, unlike
the few known naturally processed tumor peptides, which are active at pM
concentrations. Wallny et al. took a useful further step for one of the (mouse) tumor
peptides that had been defined at the synthetic peptide level and verified its presence in
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tumor extracts by HPLC criteria (59); to our knowledge this has not yet been done for
any of the human tumor peptides. Until such comparisons are made, and genetically
defined peptides are demonstrated to be on the surface of tumor cells, their exact
identities and hence their natural abundances will remain unknown.
At least four laboratories have assayed HPLC fractions of extracts obtained from
peptide*A2 complexes on melanoma cells and found discrete peaks of sensitizing
activity (refs. 54-56 and this study). Inasmuch as these peaks all represent naturally
processed peptides, it should be possible to determine how many of the currently
defined melanoma antigens (Table 2) are present on tumor cell surfaces in quantities
sufficient to elicit a vigorous CTL response. Toward this end, we developed an
approach to antigen identification based on defining the distinctive chromatographic
signature of a naturally processed peptide for comparison with the signatures of various
candidate synthetic peptides. Clearly, more than one HPLC condition is necessary in
order to achieve high discrimination (Tables 3 and 4). In principle, tumor specimens
and various normal tissues (e.g., melanocytes, retinal cells) as well as cultured tumor
cell lines should all be amenable to screening for the presence of known antigenic
peptides by this approach.
192
ACKNOWLEDGMENTS
We are very grateful to Dr. Steven A. Rosenberg for the original 660MEL tumor
samples, Drs. Aline Van Pel and Thierry Boon for melanoma lines NA8, NA8-Aa, and
NA8-tyrosinase, Dr. Richard A. Zeff for melanoma lines FO-1/neo and FO-1/A2, Drs.
Alan Buckler and Nic Dracopoli for several Sloan-Kettering Institute melanoma lines,
Dr. Alan N. Houghton for HLA typing data, and Drs. Yutaka Kawakami and Steven A.
Rosenberg for MART-1 peptides. We thank Dr. Donald F. Hunt for performing a mass
spectrometric analysis. We also thank Drs. Ioannis Papayannopoulos and Klaus
Biemann for mass spectrometric analyses, Richard F. Cook and the M.I.T. Biopolymers
Laboratory for peptide synthesis, and Sylvia Willaby, Aubrey Jordan, Carol McKinley
and Mimi Rasmussen for valuable technical support.
193
FIGURE LEGENDS
Fig. 1. Strategies used for the isolation of naturally processed melanoma peptide(s)
recognized by TIL. Cultured melanoma cells were pelleted and either extracted directly
with TFA (pathway 1), solubilized in detergent for immunoaffinity purification of A2
molecules and TFA elution of A2-bound peptides (pathway 2), or lysed hypotonically
for isolation of cell membranes followed by extraction with TFA or detergent
solubilization, A2 purification, and TFA elution (pathway 3). Ultrafiltrates from TFA
extracts were fractionated by HPLC, and each fraction was tested for sensitizing activity
in a cytotoxicity assay with A2+ target cells and TIL effector cells. Active fractions
were subjected to repeated rounds of HPLC purification under different conditions until
suitable for analysis by mass spectrometry.
Fig. 2. Cytotoxicity assay of peptides bound to HLA-A2 on melanoma cells. 1010
660MEL cells were lysed hypotonically, membranes were isolated by
ultracentrifugation and solubilized with detergent, and solubilized membranes were
passed over a set of four immunoaffinity columns as described in Materials and
Methods. Each column was eluted and the protein fractions were concentrated and
treated with TFA to separate bound peptides. Peptides extracted from purified A2
(PA2.1 column), purified non-A2 HLA molecules (W6/32 column), and nonspecific
proteins (mouse y-globulin column) were separately fractionated under HPLC condition
A. Fractions were collected at 1 min intervals and tested for sensitizing activity in a
standardized cytotoxicity assay using 660TIL and JY target cells at a CTL:target cell
ratio of 50:1. The shoulder peak at fraction 42 was observed consistently in different
experiments; the small peak at fraction 33 was not always seen. Fractions derived from
the W6/32 and mouse y-globulin columns lacked significant activity (not shown).
Fig. 3. Purification of major melanoma antigen recognized by 660TIL. A2-bound
peptides were obtained from 4 x 1011 cultured 660MEL cells and fractionated by HPLC
as described in Fig. 2, except that immunoprecipitation was performed instead of
affinity chromatography. Active fractions were subjected to re-chromatography under
HPLC conditions A, B, C, and D as described in Materials and Methods, for a total of
four serial rounds of chromatography. HPLC fractions were collected at 0.5 or 1.0 min
intervals and 1-2% of each fraction was tested in standardized cytotoxicity assays using
660TIL and JY or T2 target cells. Ultraviolet absorbance profiles for each round of
chromatography were generally unrevealing, since they did not predict the retention
times of biologically active peptides, and are not shown.
Fig. 4. Cytotoxicity assay of A2 + melanoma cell lines 660MEL, NA8, NA8 transfected
with the tyrosinase gene (NA8-tyrosinase), and NA8 transfected with the Melan-A gene
(NA8-Aa). 660TIL were used as CTL in a 4 h assay.
Fig. 5. Synthesis and screening of peptides flanking known antigenic sequences from
MART- /Melan-A. The indicated synthetic peptides were tested for sensitizing activity
in standardized cytotoxicity assays using 660TIL and JY target cells at a CTL:target cell
ratio of 50:1. Peptides were tested at final concentrations of 100 t g/ml (shown) and 10
jtg/ml. As a positive control, 660MEL target cells were included in each assay and
gave specific lysis values >50-60%. Peptides enclosed in boxes are known melanoma
peptides recognized by A2-restricted TIL in other laboratories (34, 35). ND, not done.
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Table 1. Cytotoxicity assays using 660TIL.
Target cell HLA-A2a Percent specific lysisb
50:1 10:1 1:1
Experiment 1
Experiment 2
Experiment 3
660MEL
SK-MEL-5
FO-1/neo
FO-1/A2
660MEL
SK-MEL-30
SK-MEL-75
SK-MEL-37
SK-MEL- 119
SK-MEL-133
SK-MEL-64
SK-MEL-113
WM88
660MEL
Malme-3M
HT-144
SK-MEL-28
a Numbers in parentheses are mean fluorescence values in flow
cytometric analyses using mAb PA2.1 and FITC-conjugated F(ab')2
fragment of goat anti-mouse IgG.
b Percent specific lysis in cytotoxicity assays at the indicated CTL:target
cell ratios.
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+ (178)
+ (109)
- (2)
+ (56)
+ (178)
+ (289)
+ (95)
+ (171)
+ (112)
- (1)
- (2)
- (1)
- (2)
(178)
82.8
59.3
1.7
56.3
50
25
19
14
8
1
1
1
1
92
72.6
19.8
3.1
52.6
33.6
0.9
18.8
39
14
13
12
4
0
0
0
0
72
40.2
13.9
1.9
32
16.3
4.6
0
Table 2. Peptides recognized by CD8 + anti-tumor T cells, a
CTL MHC Peptideb SD 50  Parent Normal Tissue Shown Refs.
restric- valuec protein or distribution to be
tion or gene mutated naturally
processedd
TONBIRALDL 1 nM
pleens
Ld LPYLGWLVF 5 nM
" Dd GPPHSNNFGY 8 nM
" Kd KYQAVTITL 25 pM
" Kb FEONTAQP =10 nM
PBL Al EADPTGHSY 5 nM
EVDPIGHLY
FLWGPRALV
MLLAVLYCL
YMNGTMSQV
AAGIGILTV
=100 nM
1nM
-10 nM
=100 nM
1-5 nM
" A2 ILTVILGVL 
_10 pM
YLEPGPVTA 1-10 pM
LLDGTATLRL 0.1-1 4M
KTWGQYWQV 1-10 nM
(T)ITDQVPFSV
VLYRYGSFSV
ACDPHSGHFV
0.1-1 4M
=10 nM
P91A mutated mutagenized
mastocytoma
P1A normal "
P35B mutated "
P198 mutated "
connexin 37 mutated Lewis lung
carcinoma
MAGE-1 normal melanomas,
other tumors,
normal testis
MAGE-3 normal "
MAGE-3 normal "
tyrosinase normal melanomas,
melanocytes
tvrosinase normal "
MART-1/ normal melanomas,
Melan-A melanocytes,
retinal cells
AADT1/ A l •11 "
Melan-A
gpl00/Pmel
gpl00
gpl00
gp100
gpl00
CDK4
InIUiliaL
17 normal
normal
normal
normal
normal
mutated
It
"
It
Is
of
diverse
no
no
no
yes
yes
no
no
no
no
po,
no
yes
yes
no
no
no
no
no
UISAVVGTL 100 aM HER2Ineii normal hrci~;. nvairtan~ fl
other tumors
" A2 KIFGSLAFL 100 nM HER2/neu normal " no
'IL A24 (E)AYGLDFYIL 1-10 nM p15 normal melanomas, no
normal tissues
" A24 AFLPWHRLF(L) 0.1-1 nM tyrosinase normal melanomas, no
melanocytes
B44 SEIWRDIDF tyrosinase normal " no
'BL B44 EEKLIVVLF 0.4 nM MUM-1 mutated autochthonous no
melanoma
" Cw6 YRPRPRRY 100 nM GAGE-1,2 normal melanomas, no
other tumors,
normal testis
" Cw16 SAYGEPRKL 25 nM MAGE-1 normal " no
" Cwl6 AARAVFLAL 30 nM BAGE normal " no
primed
a Excluding several viral peptides and oncogene-related peptides that were used to stimulate T cells in vitro.b Underlined residues are mutated. Residues in parentheses indicate that both the 9mer and 10mer are
recognized to a similar extent by T cells.
c SD 50 values (43) are approximate synthetic peptide concentrations at which 50% of maximal lysis occurs in
cytotoxicity assays. Methods vary with regard to incubation of target cells with peptide throughout the
assay or pulsing target cells with peptide prior to adding CTL.d A peptide is considered to be naturally occurring when it is isolated from natural sources or when the
HPLC profile of the synthetic peptide is shown to match that of an active natural fraction.e Cox et al. (58) reported the isolation of peptide YMDGTMSQV (N-4D at position 3); whether this represents
post-translational cellular deamidation, artefactual deamidation during the purification, or a different
genetic origin remains unknown.
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85-87
88-90
91
59, 92
84, 93
94-96
22,97-98
99
39, 48
ssiblye 39, 48
32-34
35
58
83, 100
101
65, 102
65, 102
103
104
105
106
107-108
109
110
62
111
63
"t
TIIU
PBL
1
LN
rIL
n
PBL
'ALT
I
P
Table 3. Comparison of the major 660MEL peptide and other melanoma
peptides known to be recognized by A2-restricted T cells:
660TIL sensitizing activity and HPLC profiles.
Peptide Parent protein Percent HPLC retention time (min)b
or gene specific
lysisa A B C
660MEL peptide unknown 50-100 44-45 40-41 49-50
MLLAVLYCL tyrosinase 2 57 54 9
YMNGTMSQV tyrosinase 2 34 21 29
AAGIGILTV MART-I/ 10-23 43 36 42
Melan-A
ILTVILGVL MART- 1/ 3 50 49 ND
Melan-A
YLEPGPVTA gpl00/Pmell17 6-9 35 29 31
LLDGTATLRL gpl00 5-7 43 36 43
KTWGQYWQV gpl00 3 43 39 43
FLWGPRALV MAGE-3 4 48 46 58
a Percent specific lysis in cytotoxicity assays with 660TIL and JY or T2
target cells at a CTL:target cell ratio of 50:1. Peptides were tested at final
concen-trations of 100 [tg/ml (shown) and 10 ýtg/ml. In each assay a
positive control using 660MEL target cells gave at least 50% specific lysis.
Some assays were performed using mAb MA2.1 and exogenous 32m as
described (35, 47, 48), without significantly different results.
b HPLC retention times are shown under three different sets of
chromatographic conditions (column, solvents, gradient, flow rate) as
described in Materials and Methods. ND, not done.
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Table 4. Comparison of the major 660MEL peptide and some candidate melanoma
peptides: 660TIL sensitizing activity and HPLC profiles.
Peptide Parent Reason for Percent HPLC retention time (min)b
protein testing specific
or gene peptide lysisa A B C
660MEL peptide unknown 50-100 44-45 40-41 49-50
EAAGIGILTV
AAGIGILTVI
PVVPNAPPA
NAPPAYEKL
ALMDKSLHV
RALMDKSLHV
SLHVGTQCA
SLHVGTQCAL
SLQEKNCEPV
APPAYEKLSAEQ
HSYTTAEEA
ILESLFRAV
QLVFGIEVV
MART-1 A2 motife
MART-1 A2 motifc
MART-1 A2 motife
MART-1 A2 motifc
17
ND
3
6
MART-1 A2 motifc 6-12
MART-1 A2 motifc
MART-1 A2 motifc
MART-1 A2 motifc 3-17
MART-1 A2 motifc 0-10
MART-1
MART-1
mass spec
ion 130 1d
mass spec
ion 1007 d
MAGE-1 A2 motifc
MAGE-1 A2 motifc
0-2
0-2
43 40 42
48 40 56
ND ND ND
35 30 31
37 31 35
ND ND ND
ND ND ND
42 41 44
34 35 32
33 30 32
27 9
ND ND ND
ND ND ND
a Same as Table 3, footnote a.
b Same as Table 3, footnote b.
c The consensus motif for A2-binding peptides (36) was interpreted broadly to include
A, I, L, or V residues at positions 2 and 9 of 9mers or at positions 2 and 10 of 10mers.
d See text for details.
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A leading immunologist, in discussing molecular interactions, once noted: "It's
not a matter of yes or no, but of more or less." In that same spirit, this thesis is written.
T cell recognition of antigens depends not only on their presence, but on their levels of
abundance on target cell surfaces. This is likely to be true for antigens recognized by
developing T cells as they mature in the thymus as well as antigens that trigger the
activities of mature T cells. Another parameter likely to be critical to the disposition of
a T cell response is the affinity of a T cell's antigen-specific receptor for particular
ligands. The interplay between these two factors - ligand density and TcR affinity -
represents a fascinating area for future theory as well as practical investigation (e.g. see
Eisen et al., In press; appendix, p. 317).
Intuitively, it seems reasonable (though not by any means obligatory) that a low-
affinity TcR (on a mature cell) will respond only if the ligand is present at a relatively
high density, while a high-affinity TcR may require less ligand for a comparable
response. Yet why should this be so? The function of a TcR is to detect peptide.MHC
complexes on other cells and to transduce signals into the cytosol, where intracellular
mediators can take over. What could underlie the presumptive advantage of a high-
affinity receptor, or conversely, how might a high density of ligand somehow
compensate for a low-affinity interaction? The general problem is not specific to T
cells, although they have their special features, and it may be instructive to borrow a
page from pharmacology (e.g. Bowman and Rand, 1980, chapter 39).
There are two main theories for the relationship between drug-receptor
interactions and the resulting responses. (1) "Occupation theory" holds that response is
a function of the occupation of receptors by an agonist. Assuming that ligation of each
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receptor elicits an all-or-none stimulus, and that these stimuli summate in a linear
fashion to produce some effect, then the amount of effect is proportional to receptor
occupancy, which can be calculated from the law of mass action (i.e., response C
fraction of receptors occupied = Ka.c/[1+Ka-c]). Attempting to apply this to a TcR
reaction with peptide*MHC complexes, the "concentration" of free ligand (c) becomes
the number of specific peptide*MHC complexes per target cell, and the equilibrium
association constant Ka is the intrinsic affinity of a TcR for this ligand. Inasmuch as
fractional occupancy is deemed critical, the actual number of receptors does not show
up here; however, derivation of the above equation assumes that this number is very
low relative to the number of ligands (peptide*MHC complexes), and furthermore that
the "concentration" of free ligand is not appreciably altered by TcR binding, both very
poor assumptions here. A general formulation avoids these assumptions and is
mathematically more complex (e.g. "ligand depletion," Hulme and Birdsall, 1992).
(2) "Rate theory" holds that response is a function of the rate of occupation of
receptors by an agonist. As originally expounded for drug-receptor interactions by
Paton (1961), the basic assumptions are that the stimulus provided by an agonist ligand
is proportional to its rate of association with a receptor and that each combination
between ligand and receptor provides a quantum of stimulation. This leads to the
intriguing conclusion that at equilibrium (rate of association = rate of dissociation), and
given a high concentration of ligand, the maximal response is proportional to the rate
constant for dissociation, i.e. drugs that dissociate rapidly will tend to be potent agonists
while drugs that dissociate slowly from their complex will produce small or negligible
responses (Bowman and Rand, 1980, chapter 39).
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(3) A third theory taking shape in the T cell field also holds the dissociation rate
to be critical, but predicts that stronger responses will correlate with low rather than
high off-rates for the TcR-peptide*MHC reaction.
Clearly the T cell response is a particularly difficult endpoint to model. Unlike
the response of a receptor-bearing cell to soluble drug molecules, T cells respond to
ligands on the surfaces of other cells, and these ligands may often be limiting to the
overall response. Moreover, the ligand itself (1) might be heterogeneous, consisting of
different peptide.MHC combinations with different affinities for the same TcR; (2)
might be unstable, suffering dissociation (loss of peptide) over time; and (3) is
manipulated experimentally by adding synthetic peptides to cells, thereby creating an
additional reaction between peptide and functionally empty MHC molecules that has its
own kinetic and thermodynamic parameters. Perhaps as a result of these complexities,
and given the small number of measurements that have been made of either ligand
density or TcR affinity, no general quantitative theory for T cell-target cell interactions
has yet been promulgated.
It is certainly not the goal of this work to advance such a model. However, an
argument is made that the density of peptide*MHC complexes on target cells is likely to
be a critical factor in any rigorous understanding of T cell responses, and that
determination of natural ligand densities is not possible until the identities of processed
peptides forming endogenous peptide*MHC complexes are known (see also Tsomides,
1996; appendix, p. 301). To this end, the major findings of the work described in
chapters 1-4 can be summarized as follows.
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* Synthetic peptides can be used to measure binding parameters of the peptide-
MHC-I reaction, but only with whole cells or specially engineered "empty" MHC-I
molecules, not with affinity-purified MHC-I molecules that inevitably contain
bound peptides.
* The number of peptide*MHC-I complexes required for T cell activation (r) may be
calculated by measuring Ka for the peptide-MHC-I reaction, the number of
available MHC-I binding sites per cell (n), and the peptide concentration required
for a CTL response (c); in optimal combinations r = Ka-c-n/(l+Ka-c) may be <10.
* A method for producing and purifying stoichiometrically labeled peptides for the
above studies has been developed and optimized; when carrier-free 1251 is used,
maximum specific radioactivities are 3.5x10 18 cpm/mol (monoiodo derivative) or
7x10 18 cpm/mol (diiodo derivative).
* The most active synthetic peptide recognized by an HIV-specific human CTL clone
is a nonamer (RT 476-484, ILKEPVHGV, termed IV9) that effectively sensitizes
target cells for lysis at a free concentration of 1-5 pM; an iodinated derivative of this
peptide binds specifically to a small portion of cell surface HLA-A2 molecules on
JY cells (<0.35%) and dissociates very slowly from these complexes (tl/2 2200 hr).
* The same peptide (IV9) was shown to be present endogenously in chronically and
uniformly HIV-infected target cells that were specially generated for this study; a
maximum of =12 IV9*A2 complexes per cell are present on HIV-infected Jurkat
target cells, which are only poorly recognized by CTL in in vitro cytotoxicity assays.
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* A different peptide (gag 77-85, SLYNTVATL, termed SL9) is also produced in
HIV-infected target cells, but at higher levels (=400 molecules per cell) and with
higher levels of accompanying lysis by a gag-specific CTL clone.
* None of the other synthetic RT or gag peptides that are active in cytotoxicity assays
(some at <100 pM) could be detected in extracts of HIV-infected cells, ruling out
their physiological relevance.
* Several naturally processed peptides were discovered to form the allogeneic
complexes (in association with H-2Ld) that are recognized by a mouse CD8+ T cell
clone (2C); two of these were purified to near-homogeneity from tissue extracts and
sequenced by Edman degradation and mass spectrometry (LSPFPFDL, p2Ca; and
VAITRIEQLSPFPFDL, p2Cb); both come from the ubiquitous cellular protein
a-ketoglutarate dehydrogenase and appear to be highly abundant in mouse tissues of
all three haplotypes examined; p2Ca but not p2Cb co-purifies with Ld molecules.
* In the 2C system, antigen processing is largely conserved across eight different
tissues, although quantitative variations seem likely because differences in the
amounts of peptides recovered far exceed tissue differences in a-KGDH or Ld
levels.
* A third peptide recognized by 2C cells was detected only in liver, and its sequence
contains a single F-*Y modification at position 4 that was speculated to arise
post-translationally (but could also represent an isozyme).
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* A fourth synthetic peptide (QLSPFPFDL, QL9) is recognized by 2C cells at much
lower concentrations than the three known naturally processed peptides, but its
presence in tissues or cells remains uncertain; the TcR of 2C cells recognizes this
fourth peptide with an intrinsic affinity higher than any others so far measured (Ka
-1.5x10 7 M-1).
* Two of the naturally processed peptides (p2Ca and p2Ca-Y4) bind equivalently to
H-2Kb, a self MHC-I molecule, but only one is recognized by the TcR of 2C cells,
illustrating that TcR reactions can be highly specific even when the affinities
involved are very low (ca. 3x10 3 M-1 for the TcR reaction with p2CaoKb complexes).
* Despite the likely physiological presence of p2Ca. Kb "self' complexes in H-2b mice
(including mice transgenic for the 2C TcR), autoimmune responses mediated by the
2C TcR are not observed, suggesting that ligand density falls below a critical
threshold for eliciting such responses; on the other hand, these observations are
consistent with the possibility that p2Ca might participate in the positive selection
of 2C TcR + cells.
* A human melanoma peptide recognized by HLA-A2-restricted tumor infiltrating
lymphocytes was purified, but insufficient amounts were obtained for sequencing;
provisional conclusions about the identity of this peptide are based on its
chromatographic profile compared with those of known melanoma peptides; low
abundance of the melanoma peptide and its likely non-mutated sequence have
interesting consequences for immune recognition of tumor antigens.
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A primary motivation for these studies has been the pursuit of knowledge and
understanding. In a larger scheme, however, the issues addressed here take on
considerable practical importance. One of the driving forces behind efforts to identify
naturally processed peptides is the hope that a new generation of vaccines can be
developed using synthetic peptides (or perhaps DNA encoding immunogenic peptide
sequences (Ulmer et al., 1993; Raz et al., 1994)). Several groups have reported that T
cell responses can be obtained in mice by immunization with peptides in various
formats (± adjuvants, lipid moieties, "helper" components, etc.) (Deres et al., 1989;
Aichele et al., 1990; Kast et al., 1991; Gao et al., 1991; Zhou et al., 1992; Feltkamp et
al., 1993; Tjoa and Kranz, 1994). In some cases, the resulting responses are protective
against subsequent challenges with otherwise lethal doses of a virus or tumor.
Recently, clinical trials of synthetic peptide "vaccines" in human melanoma patients
have been undertaken (this represents a therapeutic mode more than vaccination in the
true sense). A related goal is the blockade of autoimmune T cell reactions through the
use of specific peptides, especially those discovered to have antagonist properties when
they interact with TcR (Sloan-Lancaster et al., 1993; Racioppi et al., 1993; Jameson et
al., 1993; Sette et al., 1994a).
Thus it is hoped that immunization with synthetic peptides will permit T cell
responses to be accentuated or attenuated, depending on the clinical setting. For peptide
vaccines to be successful, they probably will have to satisfy at least the following
criteria: (1) they must elicit many functional CTL whose TcR have relatively high
affinities for specific peptide-MHC-I ligands (it has been suggested but not shown that
lower doses of peptide may result in higher affinity TcR); (2) the peptides recognized
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by these CTL must be naturally processed and presented by target cells in vivo; and (3)
the natural peptides recognized must be present at levels of abundance sufficient to
trigger potent cytolytic activities from the induced CTL. This last issue may be
especially critical for chronic infections (e.g. by HIV) and for tumors, since only a tiny
minority of the peptide.MHC-I complexes on target cell surfaces are expected to
contain relevant antigens; in contrast, when cells are infected by lytic viruses such as
influenza, vaccinia or VSV, protein synthesis (and presumably antigenic peptide
generation) are dominated by the virus. Hence it may bear considering that the nature
of a T cell response elicited by peptide vaccination will be determined not only by the
particular sequences used, but also by the amount of ligand delivered and the amount
expressed naturally: "...more or less."
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The antigenic structures recognized by T lymphocytes dif-
fer fundamentally from those recognized by B lymphocytes.
B cells, through antibody molecules embedded in their cell
surface membrane, collectively recognize an enormous diver-
sity of antigens in solution or on cell surfaces, including native
and unfolded proteins, peptides, polysaccharides, nucleic
acids, steroids, and small organic molecules. The antigen-
specific receptors on T cells are very similar to antibodies
structurally and in the genetic basis for their diversity. Never-
theless, the antigenic structures recognized by T cells consist
almost exclusively of peptides associated with integral mem-
brane glycoproteins known as MHC' proteins (because they
are encoded in a genetic region called the major histocompat-
ibility complex). Thus T cells recognize protein antigens in a
fragmented (or "processed") form on the surface of other cells
expressing appropriate MHC molecules (a phenomenon
termed MHC "restriction" of the T cell response (1)).
The MHC genetic region (also called HLA in the human
and H-2 in the mouse) contains many highly polymorphic,
tightly linked genes, and a particular set of alleles defines a
haplotype. Any given individual in a population has an array
of MHC molecules on the surface of its cells (one haplotype
from each parent, codominantly expressed) which serves as a
signature for that individual (or for the genetically uniform
mice or rats of inbred strains). The essence of MHC restric-
tion is that T cells normally recognize antigens on cells having
the same haplotypes as the T cells themselves but not on cells
of different haplotypes. (However, in the context of organ
transplantation between individuals of different haplotypes,
nonself MHC molecules are targets for a T cell-mediated
rejection response. It was this "allogeneic" reaction which led
to the discovery of the MHC and to the origin of the term
histocompatibility.)
Mature T cells can be divided into two groups based on
their cell surface expression of either CD8 or CD4 glycopro-
teins. Each group interacts with a different set of MHC
molecules, called class I or class II, respectively. MHC mole-
cules of both classes are noncovalently associated heterodi-
mers on the cell surface, but class I is composed of a mem-
brane-spanning 45-kDa a (or heavy) chain and a soluble,
nonpolymorphic 12-kDa subunit (02-microglobulin or light
chain), whereas class II consists of two transmembrane
chains, a (35 kDa) and 0 (29 kDa). Only certain "antigen-
presenting" cells (APC) express MHC-II (macrophages, den-
dritic cells, B cells, and a few others). When CD4' T cells
recognize class II-expressing APC that have reacted with
appropriate antigens, they usually respond by secreting lym-
phokines that influence lymphocytes and other cell types;
hence these T cells are designated helper T cells. However,
' The abbreviations used are: MHC. major histocompatibilitv complex: APC.
antigen-presenting cells; CTL. cytotoxic T lymphocytes: ER. endoplasmc
reticulum: dm, i2-mlcroglobulin.
most nucleated cells express MHC-I, so CD8÷ T cells can
potentially respond to virtually all cell types. In the presence
of a suitable antigen, class I-expressing target cells are specif-
ically destroyed by CD8+ T cells; hence the latter are termed
killer cells or cytotoxic T lymphocytes (CTL).
The division between class I and class II proteins is impor-
tant not only for the different T cell responses provoked, but
because they define different pathways through which pep-
tides are presented to T cells (2). In particular, extracellular
proteins (also termed exogenous) are taken up by APC, par-
tially digested in a low pH endosomal compartment, and the
resulting peptides bound by MHC-II for transport to the cell
surface where they can stimulate CD4' T cells. In contrast,
antigens synthesized within a cell (endogenous), such as viral
proteins, tumor antigens, or so-called minor histocompatibil-
ity antigens, are degraded intracellularly to peptides and
associate with MHC-I for transport to the cell surface where
they flag the cell for recognition and lysis by CD8' CTL. The
separation between the two antigen-processing pathways
(Table I) is not absolute, but it offers a useful framework for
probing the cell biology and biochemistry of each pathway
and for evaluating exceptions. This minireview will concen-
trate on the class I pathway and in particular on the molecular
interactions between antigen and MHC-I prerequisite to rec-
ognition by CD8' CTL.
CD8* CTL Recognize Peptides Derived from
Endogenous Antigens
Viral infection elicits a vigorous CTL response leading to
the specific lysis of infected cells. Experimental studies with
influenza virus have revealed important features of the anti-
viral CTL response (3). Whereas anti-influenza antibodies
recognize subtype-specific, virally encoded glycoproteins ex-
pressed on the surface of infected cells, CTL from both mice
(4) and humans (5) cross-react with target cells infected by
different influenza virus subtypes. This cross-reactivity was
explained by the subsequent finding that most anti-influenza
CTL are specific for conserved, intracellular viral proteins
undetectable at the cell surface (e.g. nucleoprotein, matrix
protein). Thus, cells transfected with the nucleoprotein gene
served as targets for influenza-specific CTL despite the ab-
sence of cell surface nucleoprotein, giving rise to the sugges-
tion that the antigen is converted into fragments (peptides)
which are transported to the cell surface for CTL recognition
(6). This model was confirmed by experiments showing that
incubation of cells with synthetic peptides mimicking parts
of the nucleoprotein rendered the cells susceptible to lysis by
CTL (7). Incubation with whole nucleoprotein was ineffective,
and only certain peptides from the nucleoprotein sequence
were active. Presumably such peptides, substituting for pep-
tides naturally produced from endogenously synthesized an-
tigen, somehow associate directly with MHC-I molecules to
form the complex recognized by CTL.
Subsequent studies with mouse and human CTL by many
workers have identified at least 40-50 different synthetic
peptides recognized in association with various MHC-I mol-
ecules. In addition to virally derived peptides, peptides cor-
responding to sequences from other endogenously synthesized
proteins are recognized specifically by CTL (8), as well as
peptides corresponding to mutated sites responsible for tumor
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TABLE I
Dichotomy in antigen recognition by T cells
T cell Major MHC Target cell Antigen
phenotype function restriction
CD4* CD8- Helper Class II Specialized Extracellular
cell antigen- (exogenous)
presenting
cell
CD8' CD4- Killer Class I Any nucleated Intracellular
cell cell (endogenous)
immunogenicity in mouse cell lines (9). Thus many tumor-
specific antigens (and minor histocompatibility antigens) are
probably peptide fragments recognized at the cell surface by
MHC-restricted CTL, explaining the historical failure of an-
tibodies to detect these antigens.
Evidence for Peptide*MHC-I Complexes
A dramatic and compelling image of how a peptide- MHC-
I complex might look was provided by the 3.5-A x-ray
crystallographic structure of a human MHC-I molecule, HLA-
A2 (10, 11). The structure consists of four domains of approx-
imately 90 amino acid residues each, three derived from the
a-chain (al, a2, and an) and one comprising l2-microglobulin(transmembrane and cytosolic portions of the a-chain were
removed by papain digestion early in the purification). The
membrane proximal a, and 02-microglobulin domains have
tertiary structures resembling immunoglobulin folds, consist-
ent with their known amino acid sequences. The at and a,
domains each have a nearly identical but novel structure
containing four antiparallel f-strands and a long a-helix, such
that when paired these domains form a single platform of
eight f-strands topped by two a-helices. A long groove over-
lying the f-sheet and between the two a-helices was proposed
to be the peptide binding site based on several considerations.
1) Most of the polymorphic residues of HLA cluster in or
near the proposed binding site, accounting for the ability of
different MHC molecules to interact with different peptides.
2) Residues known to be critical for T cell recognition through
the use of natural or engineered MHC variants are similarly
in or near the site. 3) The dimensions of the groove (25
A long x 10 A wide x 11 A deep) could accommodate a peptide
of between 8 amino acids (if fully extended) and 20 amino
acids (if fully coiled into a helix), in accord with the lengths
of synthetic peptides used to elicit T cell responses. 4) Most
intriguingly, a continuous region of electron density not at-
tributable to the HLA-A2 sequence is present in the groove;
this "extra" electron density is believed to represent peptide
or a mixture of peptides still bound to HLA. A second x-ray
structure, that of HLA-Aw68, confirmed these features and
also displayed unassignable electron density in the corre-
sponding site; notably, this electron density was distinguish-
able from that seen with HLA-A2, suggesting a different
composition of putative peptide occupant(s) (12). Even after
structural refinement to 2.6-A resolution the extra electron
densities in the HLA grooves have resisted sequence assign-
ment, supporting the idea that a mixture of peptides may be
included.
Consistent with this inference, the biology of the system
points to considerable degeneracy in peptide binding to MHC
glycoproteins. The cells of an individual vertebrate organism
express only a handful of different MHC-I proteins, probably
up to six in humans (two each at the HLA-A, -B, and -C loci).
Yet this small number of proteins mediates the MHC-re-
stricted recognition of many thousands of peptide antigens by
an equally large number of different T cells. Evidently, each
MHC protein must have the capacity to interact with an
extremely large diversity of peptide sequences. Nevertheless,
binding is not totally degenerate, as MHC proteins vary in
their abilities to present specific peptides (13). In this context,
the extra electron densities seen in the two HLA structures
may be interpreted as different mixtures of tightly bound
peptides which co-purified and co-crystallized with their re-
spective HLA proteins. Such degenerate binding contrasts
profoundly with the highly specific "lock-and-key" mecha-
nism considered a hallmark of immunological recognition and
epitomized by the reaction between antigen and antibody (14)
(and indeed probably also between peptide.MHC complex
and T cell receptor (15)).
What Peptides Bind to MHC-I?
Efforts to understand the structural basis for binding be-
tween peptides and MHC-I proteins have taken several direc-
tions, including: 1) tabulation of synthetic peptides recognized
by MHC-restricted T cells in order to discern common fea-
tures or motifs and develop predictive binding algorithms; 2)
structural characterization of naturally occurring peptides
recognized by MHC-restricted T cells; 3) in vitro binding
studies using synthetic peptides and purified MHC-I mole-
cules; 4) reconstitution of peptide-free MHC-I with a known,
homogeneous peptide for x-ray crystallography; and 5) eluci-
dation of the physiological pathway for generation of peptide.
MHC-I complexes by genetic and cell biological approaches.
Examination of several dozen peptides which elicit MHC-
restricted T cell responses (both class I and class II) led to
the formulation of predictive schemes based on common
structural elements (16-19). The resulting algorithms often
reflect some form of recurrent hydrophobicity (20). While
several predicted synthetic peptides were biologically active
in T cell assays, other peptides found by random screening to
have similar activities did not fit the expected patterns. The
relatively small (but growing) data base of available peptide
sequences may have limited this approach. especially consid-
ering the distinctions in peptide binding by different MHC
proteins. Furthermore, in most cases it is not known which
residues of a given peptide are actually required for MHC
binding, which interact primarily with a T cell receptor, which
serve a role other than for specific binding, and which are
superfluous or artifactual due to their synthetic origin.
Until recently the relationship between synthetic and nat-
urally occurring peptides which bind MHC-I was largely un-
certain, probably because characterization of natural peptides
is challenging from a technical standpoint in view of their
likely heterogeneity and consequent low abundance. Gel fil-
tration fractionation of cell extracts followed by assay of the
fractions for T cell recognition first gave clues as to natural
peptide size (21, 22) and later led to the identification of two
viral peptides (nonamers) whose sequences are contained
within known biologically active synthetic peptides (23). A
third viral peptide recovered directly from immunoprecipi-
tated MHC-I molecules similarly represents a portion (octa-
mer) of a known synthetic peptide (24). Thus in all likelihood
natural peptides are relatively small peptides with no partic-
ular chemical modifications or structural themes yet evident.
Direct binding studies require a source of purified MHC
molecules, which are available in low milligram amounts by
detergent solubilization or papain digestion of membranes
from a large number of cultured cells (e.g. 10" cells, repre-
senting 50-100 liters of culture) (25-27). Conventional bind-
ing assays such as equilibrium dialysis and gel filtration have
yielded abundant binding data for MHC-II systems, with
demonstrable association constants for peptides on the order
of 10" M • (28. 29). However, synthetic peptides known to
interact with MHC-I on target cells fail to reveal appreciable
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binding to the appropriate purified MHC molecules by either
gel filtration (30) or equilibrium dialysis (31). Substantial
binding of detergent-solubilized MI-IC-I to peptides immobi-
lized on plastic surfaces can be detected, but this binding
appears largely indiscriminate with respect to MHC specific-
ity, and it is unclear whether the solid phase environment
favors binding by particular peptides due to physical proper-
ties other than intrinsic binding affinities (32-34). A similar
report, showing more specificity, involved the addition of
peptides to immobilized MHC-I to evoke a T cell response
(35).
It may be that the low binding observed between peptides
and MHC-I in solution accurately reflects an intrinsically low
affinity. If the association constants are as low as 1(0' M-
(consistent with available data), cell surface class I molecules
will be 1% saturated at equilibrium given a peptide concen-
tration of 10-" M to induce half-maximal CTL lysis, and this
might result in sufficient peptide.MHC-I complexes (100-
500/target cell) for CTL recognition. However, this scenario
is by no means the only plausible one. If the x-ray structures
of HLA are taken to include tightly bound peptides, their
dissociation rates must be extraordinarily slow, since purifi-
cation procedures take at least 7-10 days. Therefore the
purified HLA used in binding assays may similarly be occu-
pied by unknown peptides which reduce the concentration of
available binding sites. If such prior complexes exist in a large
(perhaps even near-stoichiometric) proportion, failure to de-
tect binding of labeled peptides by equilibrium dialysis is
understandable and constitutes further support for exception-
ally slow dissociation rates, since otherwise some exchange
would be expected to occur. Assuming cell surface MHI-C-I is
also tightly complexed with unknown peptides, sensitization
of target cells for CTL lysis may involve binding to a small
proportion of peptide-free MHC-I sites on the cell, again
yielding relatively few antigenic complexes per cell. Whether
all purified MHC-I molecules harbor unknown peptides is not
yet known and in fact cannot be determined by x-ray crystal-
lography, as only a small proportion of purified MHC-I (<5%)
crystallizes."
Where Do Peptide-VMLHC-I Complexes Form?
Recent insights into the assembly of peptide. MHC-I com-
plexes derive from studies of a mutant mouse cell line, RMA-
S, having what appears to be a defect in the generation or
transport of endogenous peptides into the endoplasmic retic-
ulum (ER) (36). Ordinarily, nascent class I ca-chains and 04-
microglobulin (0·2m) associate into heterodimers in the ER
and are transported to the cell surface within 30-60 mini of
their biosynthesis (37, 38). In RMA-S cells, a-chains and da2 m
are synthesized normally but largely fail to assemble, so that
cell surface MHC-1 expression is only about 5% of wild-type
levels under standard culture conditions (37 "C). When in-
- . Wiley, personil comnmunscation.
fected with influenza virus, RMA-S cells are not recognized
by class I-restricted CTL, but when incubated with relatively
high concentrations of suitable synthetic peptides from the
virus, they become good targets for CTL and, surprisingly,
express 2-5-fold more MHC-I on their surface (39).
These findings were explained by hypothesizing that syn-
thetic peptides are taken up by RMA-S, somehow gain access
to nascent a-chains and 3.,m in the ER, and promote the
proper folding, assembly, and transport to the cell surface of
peptide. MHC-I complexes. The model implies that cell sur-
face expression of M-IC-I normally depends on the presence
of peptides in the ER to help ca and 021em associate, and that
RMA-S lacks this function. Subsequently, however, increased
surface expression of MHC-I was fortuitously demonstrated
by incubating RMA-S at reduced temperatures (23-31 "C),
and these MHC-I molecules were unstable at 37 TC unless an
appropriate synthetic peptide was added (40). Thus enhanced
MHC-1 expression in the presence of peptides might also be
explained by a stabilization of molecules already at the cell
surface (but not otherwise detected because they are confor-
mationally altered and/or short-lived). Such labile and evi-
dently peptide-free MHC-I molecules could either reach the
cell surface without peptides or could release bound peptides
via dissociation (41).
Further evidence that added peptides can interact with
MHC-I at the cell surface comes from studies using inhibitors
of protein export. Treatment of non-mutant cells with the
compound brefeldin A (which blocks transport from the ER
to the Golgi complex) or the viral product E19 (which specif-
ically binds to and retains MHC intracellularly) prevents the
presentation of endogenous (e.g. viral) antigens but does not
interfere with the presentation of synthetic peptides to CTL
(42-44). Similarly, if cells are "fixed" using glutaraldehyde
(which stops protein synthesis and turnover), presentation of
endogenous antigen but not of added peptide is abrogated
(45). On the other hand, the increased MHC-I detected on
RMA-S cells in the presence of added peptide could result
from either peptide-induced stabilization of cell surface MHC-
I or from association of peptide with MHC-I intracellularly,
much like endogenously arising peptides.
Whether the effect of exogenous peptides on MHC-I takes
place at the cell surface or in the ER (or perhaps both,
depending upon peptide concentration), the properties of
RMA-S and of a comparable human mutant cell line (416, 47)
indicate that most stable MHC-I molecules at 37 'C include
peptide as an integral partner with a-chain and lam. More-
over, _,m can also stabilize MHC-I structure, as shown by an
increased association between peptides and MHC-I when free
flm is added to cells under limiting conditions of peptide (48).
In addition, in uvtro reconstitution of MHC-I from separated
ca-chains and fl2m is more efficient in the presence of either
excess _,m (49) or specific peptides (50); similar effects are
obtained using detergent lysates from RMA-S cells (51). Fi-
nally, distinct MHC-I molecules are known to differ in their
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requirements for 0 2m to form stable cell surface structures(52, 53), and they may differ in their requirements for peptide
as well (54).
How Are Peptides Generated in Viva?
To elicit an effective class I-restricted CTL response, an
endogenous antigen must be degraded into peptide fragments
which can interact with MHC-I (a-chains and f 2m) to form
functional complexes. Since MHC-I is co-translationally in-
serted into the ER (55), and intracellular antigens which do
not enter the ER are recognized by CTL, a cytosolic proteo-
lytic apparatus as well as a mechanism for peptide transport
into the ER must be involved. It is not clear whether peptide
fragments are generated by known or as yet unknown prote-
olytic systems, or how peptides are translocated into the ER,
although recently a member of the protein family designated
"ABC transporters" (for ATP-binding cassette) (56) has been
implicated in the RMA-S mutation (57).
An alternative hypothesis provides for proteolysis within
the ER, and according to the unexpected finding that mouse
cells identical at all genes but MHC-I possess different peptide
profiles, MHC molecules themselves may be involved in the
generation or selection of presented peptides (58). For in-
stance, MHC-I could shield bound peptides from degradation
or serve as a template for proteolysis by other unknown
proteins in the ER. Finally, an unusual pathway proposed for
the generation of peptides 'avoids proteolysis altogether by
theorizing the direct transcription and translation of short
subgenic regions called "peptons" (59).
From Heterodimer to Heterotrimer
However they come about, it is increasingly clear that stable
MHC-I molecules are most often heterotrimers consisting of
a-chain, f 2m, and a short peptide of variable sequence. Asso-
ciation between peptide and MHC-I appears not to arise from
the equilibrium binding of two stable entities, according to
the classical lock-and-key paradigm, but rather as the end
point of a complex assembly process involving three chains.
The natural order of assembly of the heterotrimer and the
factors which govern its stability remain open to question,
but once formed, loss of either soluble component (peptide or
02m) can soon lead to collapse of the overall structure, al-
though cell surface 62m is known to exchange with a2m in the
medium (60). Given the strong similarity between the x-ray
structures of 0 2m as a monomer (61) and as part of HLA
complexes, and the lack of direct contact between 0 2m and
bound peptides, it appears that conformational changes which
accompany heterotrimer formation primarily involve a-chain
and peptide (Fig. 1). Direct physical studies may have to await
the more ready availability of large quantities of MHC-I
protein, but in the meantime the cell biology of this system
remains an extremely active and fruitful area for investiga-
tion.
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Background
Nucleated cells of vertebrate organisms display on their surfaces. a
complex array of structures that sample the cells' contents and that can be
recognized by MHC-restricted T cells [1]. What is the nature of these
antigenic structures? Townsend and McMichael [2] and others [3] showed
that cytotoxic T lymphocytes (CTL) responding to influenza virus infections
in humans and mice are largely specific for conserved, intracellular viral
proteins (e.g. nucleoprotein, matrix protein) undetectable at the cell surface.
This finding could be explained by fragmentation of the intracellular proteins
and transport of the resulting fragments (peptides) to the cell surface along
with class I MHC (MHC-I) molecules [4]. Synthetic peptides mimicking
parts of these proteins effectively bypassed the requirement for intracellular
generation of peptide fragments from intact proteins ('antigen processing'),
and target cells incubated with appropriate synthetic peptides from viral
protein sequences were rendered susceptible to lysis by antiviral CD8+ CTL
[5]. In this chapter we focus on some of the many subsequent advances in the
study of MHC-I-restricted T cell responses. on the nature of peptides binding
to MHC-I proteins, and on the identification of naturally occurring peptides
associated with MHC-I molecules; we consider to a lesser extent class II
MHC (MHC-II)-restricted responses by CD4+ T cells, which are more
extensively treated elsewhere in this volume.
Synthetic Peprides Are Active in T Cell Assays
The availability of well-established chemistries for solid phase peptide
synthesis [6] and the relative convenience of cytotoxicity assays [7] has per-
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mitted the identification of numerous epitopes recognized by CTL clones
and cell lines with a variety of specificities, including viral [8], mycobacterial
[9], parasitic [10, 11], and tumor [12, 13] antigens, as well as normal self
proteins [14, 15]. In some instances T cell specificities were initially mapped
by infecting target cells with recombinant vaccinia viruses in order to
determine which protein was recognized [16], followed by testing a panel of
synthetic peptides from that protein for their ability to sensitize target cells
for lysis by CTL. Boon and co-workers [17] used a genetic approach in which
mutant cells with altered tumorigenicity were analyzed to identify tumor-
specific sequences recognized by T cells.
The principle that synthetic peptides bind directly to MHC glycopro-
teins was firmly established by the measurement of micromolar dissociation
constants for MHC-II molecules using in vitro assays such as equilibrium
dialysis or gel filtration [18, 19]. Analogous data demonstrating specific
peptide binding to MHC-I molecules proved more elusive [20-22], but
approaches in which peptides were added to MHC-I molecules that were
solubilized in detergent-containing solutions [23-25], immobilized on plas-
tic surfaces [26], or present on intact cell surfaces [27-31] made it abundantly
clear that peptide-MHC-I complexes form the antigenic structures recog-
nized by CD8+ T cells [32].
The choice of peptides for synthesis and testing as candidate T cell
epitopes was initially addressed in one of two ways. An overlapping library of
peptides [33] spanning a protein sequence or even an entire genome (e.g. the
human immunodeficiency virus (HIV) genome) could be screened in MHC
binding [34] or cytotoxicity [35, 36] assays to identify any active peptides.
For reasons of economy and precedent, such libraries often consisted of
relatively long peptides (i.e. 20- to 25-mers). Alternatively, efforts to discern
shared patterns among known T cell epitopes were applied toward the
development of predictive algorithms [37-41] that could inform the choice
of peptides to be synthesized [42, 43]. By these procedures it became
apparent that only one or a few peptides from a given protein often
accounted for the bulk of a polyclonal CTL response to that protein [44-49].
Both approaches to epitope identification, however, were conceived in
the absence of any knowledge about the naturally occurring peptides recog-
nized by T cells. Even in those cases where sets of overlapping synthetic
peptides from within a longer peptide sequence were titrated in order to
define the precise length and sequence of the optimally active peptide for a
given T cell clone [30, 47, 48. 50, 51], there was no indication as to whether
the naturally occurring peptide matched precisely the optimally active
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synthetic one. Although considerable information was gathered by screening
synthetic peptides from various sources in target cell sensitization assays, the
relationship between those peptides and the actual peptide epitopes gener-
ated within cells by the antigen processing machinery remained obscure until
more recently.
Properties of Naturally Occurring Peptides
Bjorkman and co-workers [52-54] provided the first clues regarding
naturally occurring peptides associated with MHC molecules when they
solved the crystal structure of the human MHC-I molecule HLA-A2. A deep
groove appearing to be the foreign antigen binding site of the MHC molecule
harbored a continuous region of electron density throught to represent one or
more peptides tightly bound to HLA-A2. The dimensions of the groove were
consistent with its occupancy by octameric peptides if fully extended, or
longer peptides (up to 20 residues) if coiled into a helix or some other
conformation. A second crystal structure, that of HLA-Aw68, had essen-
tially the same overall architecture as HLA-A2, but the unassignable elec-
tron density associated with HLA-Aw68 was distiguishable from that of
HLA-A2 and was similarly resistant to sequence determination [55]. These
features supported the view that each MHC molecule co-purified with a
complex and yet distinctive mixture of self peptides 8-20 residues in length.
The apparent stoichiometic presence of naturally occurring peptides in the
binding groove of crystallized MHC molecules suggested that these peptides
were bound with high affinities, since they did not dissociate during the
several days required for MHC purification: furthermore. stably occupied
peptide binding sites helped to explain the difficulty in measuring binding
constants in vitro by adding synthetic peptides to purified MHC-I molecules
[56].
Falk et al. [57] performed an imaginative and pathbreaking experiment
that shed considerable light on the nature of the peptide mixture present in
the binding groove of MHC-I molecules. Having shown that tightly bound
peptides could be separated from MHC-I molecules by treatment with
trifluoroacetic acid (TFA) [58], much in the same way that Buus et al. [59]
had shown for MHC-II molecules using acetic acid, Rammensee and co-
workers [57, 58] eluted peptides from isolated MHC-I molecules by treat-
ment with TFA and performed Edman degradation on the complex mixture.
At each cycle of the Edman procedure every possible amino acid derivative
was detected, but at certain cycles only one or a few amino acids predomi-
nated; these were designated 'anchor' positions in the eluted peptides and
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were thought to represent conserved features required for strong association
with a particular MHC-I molecule. For instance, the peptides eluted from
HLA-A2 had a preponderance of leucine at position 2 and valine or leucine at
position 9, while peptides associated with the mouse MHC-I protein H-2Kb
largely contained phenylalanine or tyrosine at position 5 and leucine at
position 8. Moreover, the precipitous drop in repetitive yields of the Edman
procedure after the eighth or ninth cycle (depending on the MHC-I molecule)
strongly suggested that most tightly bound peptides were octamers or nona-
mers [57]. These parameters - length and anchor residues - defined a
consensus motif for the natural peptides eluted from each MHC-I molecule.
Peptide-MHC Binding Is Both Specific and Degenerate
The definition of motifs provided an appealing means to reconcile the
dual requirements for specificity and degeneracy in peptide-MHC interac-
tions: MHC proteins differ in their binding specificities for synthetic pep-
tides [60-62], and yet thousands of peptide antigens must be presentable
to T cells by only a handful of different MHC-I molecules present in a
given individual (up to six in humans, as few as two in some inbred mice).
This seeming paradox could now be resolved by two principles: a great num-
ber of peptide sequences of the proper length can bind to a given MHC
molecule, provided that certain positions have the correct anchor residues,
and different MHC molecules have distinctive requirements at their respec-
tive anchor positions (table 1). Even with two positions fixed within an
octameric peptide, a total of over 6 x 107 sequences can still fulfill the
consensus motif for a particular MHC-I protein, more than enough to satisfy
the degeneracy requirement (although not all of these peptides will actually
bind to the MHC protein [63]).
The structural basis for this model of peptide binding was provided by
the description of 'pockets' in the binding grooves of crystallized MHC-I
molecules [54, 55, 64, 65]. While essentially similar in dimensions and
overall shape, at high levels of resolution each MHC protein's binding groove
was defined by characteristic ridges and depressions referred to as pockets.
The detailed intermolecular contacts between bound peptide and MHC
molecule were most vividly revealed by the crystal structures of MHC-I
molecules containing a single peptide [65-68]. These homogeneous peptide-
MHC-I complexes were obtained by taking advantage of the finding that
MHC molecules secreted by Drosophila cells transfected with MHC genes
were devoid of endogenous peptides, and that these 'empty' molecules could
be stoichiometrically occupied by an added peptide [69. 70]. Alternatively,
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Table 1. Motifs for peptides associated with MHC-I proteins
MHC-I Peptide Consensus motif References
protein length
H-2Kd 9 -Y/F------ I/L/V 57, 74
H-2Db 9 ---- N--- M/I/L 57
H-2Kb 8 ---- F/Y -- L/M 57
H-2Ld 9/10 -P ------ (-)L/F/M 57, 76a
HLA-A2.1 9 -L/M------V/L 57
HLA-B27 9 -R------- 131
HLA-Aw68 9/10/11 -V/T ------ (--)R/K 87
HLA-A3 9 -P------Y/K 77
HLA-A2.2Y 9 -------- L 143
HLA-B8 9 -- K/R-KIR----L/I 144
HLA-B53 9 -P------- 145
HLA-B35 9 -P------Y 145
HLA-B7 9/10/11 A/R P R ----- (- -)A/V 146
HLA-A 11 9 -V/L------K/R 141
Qa-2 9 ------ H-L/I/F 147
Only the two or three most prominent residues at each anchor position are listed. See
references for additional residues.
a Soluble, secreted analog of H-2Ld.
free MHC-I heavy and light chains (a and P2m) were reconstituted in vitro in the
presence of synthetic peptides to form stoichiometric peptide-MHC complexes
[67, 71, 72]. The pockets in these monopeptide complexes were found to
accommodate the side chains of residues at the peptide's anchor positions.
The importance of anchor positions in peptide-MHC interactions was
further demonstrated by the synthesis and testing of peptides having the
prescribed anchor residues for binding to a particular MHC molecule and a
residue considered nonspecific (often alanine) at all other positions. For an
MHC-II binding peptide in which systematic substitutions had been made.
only one position was found critical for binding [73]. A similar approach has
been used in studies aimed at defining or verifying various MHC-I binding
motifs [74-77].
W'hy Are Synthetic Peptides Active in T Cell Assays?
Since MHC-I molecules were ultimately shown to bind octamers and
nonamers (with certain exceptions, see below). what accounted for the earlier
results obtained using much longer peptides (e.g. 25-mers) in target cell
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Fig. 1. An ostensibly pure synthetic peptide contains trace contaminants that can
sensitize target cells for lysis by CD8+ cytotoxic T lymphocytes. A synthetic peptide [ 115]
synthesized by standard t-Boc chemistry on an Applied Biosystems 430A was fractionated
on a C18 reverse-phase HPLC column as described, using a gradient of 1% acetonitrile/
min [ 100] (a). One-minute fractions were collected, dried by SpeedVac, and subjected to a
4-hour cytotoxicity assay using 51Cr-labeled B2 target cells and 2C CTL [100] (b).
sensitization or MHC binding assays? At least four possible explanations
have been proposed. of which three are clearly documented. First, it is well
known that synthetic peptides contain trace peptide contaminants, for
instance products arising from failed couplings, rearrangements, or other
side reactions during synthesis [6]. Since some peptide epitopes can be active
in T cell assays at concentrations of < 1 pg/ml [30, 50, 78-81], the biological
activities of many longer peptides probably result from shorter contaminants
present in synthetic preparations (fig. I and [82]). Even after several rounds of
HPLC purification, activities due to contaminating peptides may still not be
completely removed [unpubl. observation], underscoring the need for careful
analysis before attributing sensitizing activities to ostensibly pure synthetic
peptides. In fact, some investigators have exploited the presence of active
contaminants in identifying naturally processed peptides [79] (see below).
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Secondly, cytotoxicity assays are generally carried out in medium con-
taining fetal calf serum, which has been shown to possess proteolytic
activities [83-85]. Thus, longer peptides can be degraded to octamers or
nonamers directly responsible for sensitizing activity during the course of a
cytotoxicity assay (typically several hours). A third possibility, raised to
explain findings obtained with a mutant cell line, was that peptides added to
target cells could be internalized by the cells, where they would play a role in
the intracellular assembly and transport of MHC-I molecules [86]. Presum-
ably this might allow for intracellular degradation of the added peptides to
shorter, more active products. However, the original observations could also
be explained without the need for any internalization process [23].
Finally, in the case of HLA-Aw68, it was shown that peptides longer than
nonamers (10 or 11 residues) can bind directly to the MHC molecule by
retaining anchor residues near their N- and C-termini but bulging out
somewhat from the middle of the groove [87]. The ability of peptides longer
than nonamers to bind directly to MHC-I molecules may be limited to
special instances [88, 89] or may represent a general feature. In any event.
when a synthetic peptide is used to sensitize target cells for lysis by CTL, the
precise identity of the active (MHC binding) peptide is very often unknown.
In retrospect, it is noteworthy that the peptides first used to elucidate the
nature of T cell epitopes (e.g. a 14-mer from influenza virus nucleoprotein
[5]) turned out not to be equivalent to the naturally occurring epitopes (e.g. a
nonamer within the 14-mer [79]). Moreover, sensitization of target cells with
synthetic peptides of any length is effective only because although most cell
surface MHC molecules harbor tightly bound endogenous peptides. a pro-
portion of MHC-I molecules arrives at the cell surface in a receptive state for
binding to exogenous peptides. i.e., peptide-free or containing rapidly disso-
ciable peptides [24, 90-92].
Detection of Naturally Occurring Peptide Epitopes
The next step in learning about naturally occurring peptide epitopes
required knowledge of their individual sequences, abundances, and parent
proteins. However, the extensive heterogeneity of natural peptides asso-
ciated with MHC molecules created a formidable problem for their biochem-
ical characterization: any particular peptide representing a T cell epitope was
likely to be present at a very low abundance. e.g. < 0. 1% of the restricting
MHC molecule. Since roughly 101 molecules of each MHC protein are
expressed on the surface of a normal cell. fewer than 100 such peptide
molecules would then be present per cell (0.1% of 105). and this number is
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apparently still sufficient to trigger T cell activation [27, 93-95]. The isolation
of as little as 15 pmol of such a peptide, an amount typically required for
sequence determination by Edman degradation, would therefore require
about 1011 cells, assuming 100% overall recovery. For this reason the precise
identification of individual naturally occurring T cell epitopes has not come
easily or quickly. However, because of the extraordinary sensitivity of T cells,
some of which can detect < I pg/ml of a specific sensitizing peptide, it was
possible to first demonstrate the presence (but not establish the sequence) of
naturally occurring peptides representing CTL epitopes by lysing only 10s- 109
cells, fractionating the mixtures by HPLC, and subjecting the resulting
fractions to cytotoxicity assay using appropriate target cells [58, 96, 97].
Strategies for the Characterization of Naturally Occurring Peptides
Associated with MHC Molecules
Prediction of Naturally Occurring Peptide Epitopes
Several strategies have been used in efforts to determine the sequences of
naturally occurring peptides associated with MHC molecules. One approach
rests on predicting and testing candidate peptides. First, the sequence of a
protein antigen is examined for peptides containing the correct anchor
residues and of the appropriate length for binding to a relevant MHC-I
protein (table 1). These peptides are synthesized and tested in cytotoxicity
assays, obviating the need to analyze a more extensive peptide library or to
rely on fortuitous activities of longer peptides. Bevan and co-workers [98]
showed that 1 of 11 nonamers selected from the sequence of Listeria
monocytogenes listeriolysin (59 kD) based on the consensus motif for H-2Kd
was recognized by specific H-2Kd-restricted CTL, and that the CD8+ T cell
response to this peptide inhibited L. monocytogenes replication in H-2d mice
[99]. In another instance, the HLA-A2 consensus motif was used to predict a
nonamer within the sequence of an active 25-mer as the epitope recognized
by an HLA-A2-restricted CTL clone [57], and the same nonamer was found
independently of knowledge of the A2 motif to be the most active sensitizing
peptide recognized by this CTL clone [30].
Possible Problems in the Prediction of Naturally Occurring Peptides
Although convenient and clearly superior to first-generation schemes for
predicting T cell epitopes. this approach has some drawbacks. First, empiri-
cal MHC binding motifs are inherently imperfect in that they represent
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composite data for which there are individual exceptions (as implied by the
actual Edman data, in which nonmotif residues are present at the anchor
positions at reduced but measurable frequencies). Indeed, such motifs
cannot be absolute requirements for MHC-I binding, because some peptides
lacking anchor residues still possess sensitizing activities and therefore must
bind with a certain (possibly low) affinity to the restricting MHC-I molecule
[e.g. 30]. Consequently, some T cell epitopes may be either missed altogether
or misidentified by motif-based predictions. For example, although H-2Ld
binding peptides are predicted to have proline at position two [57, 76], at
least two epitopes efficiently recognized by H-2Ld-restricted CTL do not
contain proline at this position. One has no proline [12] and would presum-
ably have been overlooked by relying on the H-2Ld motif; the other, which
was isolated from natural sources and is known to bind well to H-2Ld, has
proline at position three (100]. Moreover, when the corresponding peptide
that would have been predicted by the H-2Ld motif was synthesized and
tested (i.e., same length but with proline at position two instead of three), it
also had comparable biological activity [unpubl. observation]. Similarly, van
Bleek and Nathenson [101] detected natural peptides associated with H-2Kb
that did not possess the anchor residues for binding to H-2Kb.
A related point is that sensitization of target cells by a synthetic peptide
does not imply that the same peptide is present naturally on target cells (e.g.
virus-infected cells for a viral peptide). Assuming that sensitizing activity is
due to the synthetic peptide itself, and not to a more potent contaminant or
degradation product, the natural epitope may still have a different sequence
[102, 103], or, more likely, differ in length from the sensitizing one. It is not
at all surprising that a peptide capable of sensitizing target cells when added
exogenously may not be generated intracellularly or transported into exo-
cytic compartments for binding to MHC molecules (at least in sufficient
quantities to activate T cells - see below). Finally. it is important to note that
empirically derived consensus motifs for naturally occurring peptides (table
1) reflect the influences of antigen processing and transport events as well as
binding to MHC molecules, and as such are almost certainly more restrictive
than motifs based only on MHC binding properties.
One common assumption is that the optimally active peptide in a given
response corresponds to the natural epitope: however. heteroclitic antibodies
that bind more strongly to a cross-reacting antigen than to the immunogen
are well known [104], and in at least one report of a heteroclitic CTL
response, a synthetic mutant peptide was recognized at a 1.000-fold lower
concentration than the wild-type sequence [78]. Furthermore. cytotoxicity
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Table 2. Naturally occurring peptides associated with MHC proteins
MHC Peptide origin Peptide Ref.
protein sequence
T cell epitopes H-2Kd Influenza NP 147 TYQRTRALV 79
H-2Db Influenza NP 366 ASNENMETM 79
H-2Kb Vesicular stomatitis RGYVYQGL 49
virus NP 52
H-2Kb Ovalbumin 257 SIINFEKL 81
H-2Kd L. monocytogenes GYKDGNEYI 98
listeriolysin 91
H-2Ld MCMV pp89 168 YPHFMPTNL 108a
H-2Ld Mouse a-ketoglutarate dehydrogenase LSPFPFDL 100, 115
H-2Kd P815 tumor variant KYQAVTTTL 109
HLA-A2.1 Influenza MP 58 GILGFVFTL 148
I-Ak Hen egg lysozyme (5 sequences) 142
Abundant peptides H-2Kd
HLA-B27
HLA-A2. 1
HLA-A2. 1
HLA-A2.1
HLA-Aw68
HLA-B53
H-2Ld,
I-Ab
I-Eb
I-Ad
I-Ak
HLA-DR 1
HLA-DR 1
HLA-DR3
P815 cells
LG-2 cells
transfected CIR cells
T2 cells
T2 cells
lymphoblastoid cells
transfected C1R cells
transfected L cells
LB27.2 cells
LB27.2 cells
A20-1.11 cells
transfected cells
WT- 100 cells
LG-2 cells
transfected T2 cells
SYFPEITHI
(11 sequences)
(8 sequences)
(4 sequences)
(3 sequences)
(6 sequences)
YPAEITLYW
(8 sequences)
(6 sequences)
(6 sequences)
(9 sequences)
(5 sequences)
16-mer
(20 sequences)
(3 sequences)
Peptides defined by target cell sensitization assays but not shown to be natural products are not included.
a Epitope characterized from cells infected with recombinant pp89-vaccinia virus.
assays reflect two processes: peptide binding to MHC molecules and recogni-
tion of the resulting complexes by T cell receptors. Therefore, it is conceiv-
able that due to constraints imposed by the T cell receptor, the best MHC
binding peptide (e.g. predicted from a motif) may not be the most potent
sensitizing peptide: in such a case either peptide (or neither one) could
correspond to the naturally occurring epitope. Nevertheless, with the rapid
accumulation of data validating the ability of motifs to predict optimally
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149
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150
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active peptides in individual instances [30, 51, 82, 105], and with the finding
that natural epitopes often conform to these motifs (table 2), it is likely that
many investigators will favor the prediction-based approach.
Another limitation of this approach is its failure to provide quantitative
information concerning the abundances and distribution of naturally occur-
ring T cell epitopes. When a synthetic peptide is used in order to sensitize
target cells for lysis by CTL, the number of peptide-MHC complexes formed
per cell (epitope density) is somewhat arbitrarily manipulated by varying the
concentration of added peptide. High epitope densities increase the probabil-
ity that target cells will be lysed by a T cell with the appropriate receptor
specificity, as is commonly demonstrated by peptide titration curves [e.g.
95]. It is likely that the density of a naturally occurring peptide on target cell
surfaces - such as a viral epitope on virus-infected cells - will similarly affect
the ability of target cells to elicit T cell responses. Braciale and co-workers
[106] observed unexpected cross-reactions using influenza virus subtype-
specific CTL and targets sensitized with high doses of synthetic peptides, and
they suggested that these nonphysiologic cross-reactions required much
higher epitope densities than could possibly be achieved by endogenous
antigen processing. Another study demonstrated T cells reactive with normal
self peptides when nonphysiologic concentrations of protein digests were
used to sensitize target cells [107]. Thus, in addition to epitope identity,
epitope density is a critical parameter in efficient recognition of naturally
occurring peptide-MHC complexes by CTL. However, natural epitope densi-
ties cannot be determined by means of target cell sensitization experiments
using only synthetic peptides. This limitation is relevant to practical efforts
to manipulate T cell responses, either by blocking autoreactive T cells or by
immunizing for specific T cell responses.
The practical significance of the abundances of naturally occurring
peptides is illustrated by the following finding: an HIV-specific CTL clone
exhibits poor killing of HIV-infected target cells that naturally produce a
nonameric MHC-I binding peptide from HIV reverse transcriptase [unpubl.
observation], even though the same clone efficiently lyses uninfected target
cells in the presence of < 1 pg/ml of the same synthetic peptide [30]. It
remains to be seen whether low epitope densities account for poor CTL
responses against HIV-infected target cells in this instance or more generally.
or whether increased numbers of specific HIV peptide-MHC-I complexes
could bring about a more effective CTL response. Clearly. however. CTL that
are specific for epitopes present only sparsely on infected cells are likely to
have little or no effect on the course of natural HIV infection. Interestingly. a
239
Identification of MHC-Associated Peptides
distinguishing feature of this and other chronic, long-term infections is that
normal cellular protein synthesis is not inhibited or arrested as it is during
acute infections with viruses like vaccinia, influenza, or vesicular stomatitis
virus. Consequently, naturally processed peptides in chronic viral infections
must compete with a great excess of endogenous self peptides for binding to
MHC-I molecules, and virus-specific complexes may be deficient as a result.
One way to address the limitations described above for motif-based
prediction of T cell epitopes is to compare the chromatographic behavior of a
putative synthetic epitope with that of the corresponding naturally occurring
peptide obtained from cell or tissue extracts [49, 79, 81, 98, 108, 109].
Depending upon the resolving power of the chromatographic conditions
used, this approach can indirectly establish identity (or nonidentity) between
the synthetic and natural peptides. Higher resolution might be attained by
determining through mass spectrometry the molecular masses of peptides
present in an active fraction from a natural source and checking for agree-
ment with the masses of one or more candidate T cell epitopes.
Identification of Natural Peptides That Are Relatively Abundant
The logical extension of such procedures represents a second category of
approaches to the identification of naturally occurring peptides: their purifi-
cation and direct sequence analysis from natural sources, i.e., cells or tissues
(fig. 2). This strategy can be applied to either of two quite different objectives:
definition of T cell epitopes. or characterization of the most abundant
peptides associated with MHC proteins. For the latter goal, the basic
technique generally consists of isolating a particular MHC molecule by
immunoprecipitation or immunoaffinity chromatography, eluting the bound
peptides by treatment with TFA [58, 97] or acetic acid [49], and fractionating
the peptide mixture by reverse-phase HPLC. At this stage the HPLC
chromatogram may reveal prominent peaks by ultraviolet absorbance that
are reasonably well resolved from other peaks, and fractions containing these
peaks can be collected and sequenced by Edman degradation and/or mass
spectrometry.
For sequencing by Edman degradation, the sample must contain one
major peptide. Therefore, more than one round of chromatography may be
required. using different conditions (column, mobile phase, gradient) in
order to alter selectivity at each round. One drawback of Edman sequencing
is a characteristic drop in repetitive yields near the C-terminus due to
washout of the shortened peptide from the sample support: hence more
material is required for a complete sequence than for just the N-terminal
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Fig. 2. Strategies for the identification of naturally occurring peptides associated with
MHC molecules. Starting with whole organs, tissues, or cells, two possible strategies consist
of preparing crude lysates in TFA (pathway 1) or first isolating MHC molecules and then
extracting bound peptides with TFA (pathway 2). In pathway I, ultrafiltrates of whole cell
homogenates are fractionated, the fractions are tested for sensitizing activity in a cytotoxicity
assay, and each active fraction is subjected to repeated rounds of purification until suitable
for sequencing by Edman degradation and/or mass spectrometry. In pathway 2, peptides
eluted from MHC molecules can be fractionated and assayed to identify T cell epitopesjust as
for pathway 1 (pathway 2a). Alternatively, peptides appearing to be relatively abundant in
the HPLC fractionation step by ultraviolet absorbance may be sequenced directly (pathway
2b), or the crude peptide mixture can be sequenced without HPLC fractionation in order to
establish consensus motifs for association with a particular MHC (pathway 2c). Pathways 2b
and 2c, which do not rely on a T cell assay, are applicable to the study of peptides associated
with either MHC-I or MHC-II proteins.
residues (generally a few picomoles). One way to circumvent this problem is
to subject an aliquot of a natural peptide (e.g. 10%) to mass spectrometry in
order to determine its mass, commit the remainder to Edman degradation,
and use the mass to deduce the identities of any residues missing from the
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C-terminus. This strategy was successfully applied to a natural sample
containing a total of <7 pmol [ 100]. Other possible problems with sequenc-
ing by Edman degradation are a potential failure to detect N-terminal
glutamine due to cyclization to pyrrolidone carboxylic acid (enhanced at low
pH) and an absolute failure to detect peptides modified ('blocked') by
covalent modification at their N-terminus; while no such peptides have yet
been isolated from MHC-I or MHC-II molecules, N-formylated peptides are
presented by the mouse nonclassical MHC molecule Hmt [110, 111], and it is
conceivable that a heavy emphasis on Edman sequencing has introduced a
bias against the identification of such peptides from 'classical' MHC mole-
cules.
Sequencing by tandem mass spectrometry - in which a peptide is
ionized, fragmented, and the masses of the fragments analyzed - eliminates
many of these problems: the sensitivity can be greater than sequencing by
Edman degradation, all residues are potentially identified (although methods
that fragment primarily at amide bonds cannot distinguish between leucine
and isoleucine), and, perhaps most usefully of all, the peptide need not be
completely pure [112]. However, the availability of state-of-the-art instru-
mentation and expertise remains limited, while automated Edman sequenc-
ing at the 10 pmol level is performed in many laboratories and institutional
core facilities [113].
Identification of Natural Peptides That Are Recognized by T Cells
The identification of naturally occurring T cell epitopes is a very
different problem from that of sequencing the most prominent peptides
associated with MHC proteins irrespective of their recognition by specific
T cells. In both cases the initial approaches may be similar, but the iderti-
fication of epitopes ultimately depends on T cell assays that can detect
peptides present at attomole levels (< 1 pg/ml. typically in a volume of 200
pl), i.e., far below the level of detection of ultraviolet absorbance or even
radiochemical methods. Thus. peptides constituting T cell epitopes may be
extremely minor components of the total peptide mixture eluted from MHC
molecules (<0.1%), requiring a scale-up of several orders of magnitude in
order to accumulate enough material for sequencing. Although challenging
for this reason, the definition of T cell epitopes by direct isolation and
sequencing is ultimately unambiguous, provides quantitative information
about a peptide's natural abundance and distribution. and is of great
interest for understanding and attempting to manipulate T cell responses
(see below).
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To Purify or Not to Purify the MHC Protein
Isolation of a T cell epitope for structural characterization and quantita-
tion may be pursued with [49] or without [79] first purifying the restricting
MHC molecule by immunoprecipitation or immunoaffinity chromatogra-
phy. The chief advantage of MHC purification is that the association of a
peptide with a particular MHC molecule is proved if the peptide is isolated
from that molecule, and the amount of peptide that is physiologically
relevant (i.e., accessible to T cells) can be estimated. From a procedural
viewpoint, peptide purification is also simplified if only MHC-bound pep-
tides are subjected to HPLC fractionation. However, there are some disad-
vantages: weakly bound peptides may be lost during the purification steps;
protein yields of < 100% will diminish the amount of peptide recovered;
and the process can be laborious, especially for very large numbers of cells
(> 101 may be needed for relatively rare epitopes). Moreover. the reagents
and conditions for efficient immunoprecipitation or immunoaffinity purifi-
cation at the requisite scale have not been established for many MHC
proteins.
An alternative strategy is acid treatment of tissues, whole cells, or
membranes, followed directly by reverse-phase HPLC of the low molecular
weight fraction from such a crude extract (obtained by gel filtration or, more
conveniently, membrane ultrafiltration [114]). This technique bypasses
MHC purification and theoretically leads to higher peptide recoveries, since
peptide molecules that dissociate from peptide-MHC complexes as well as
peptides that are never MHC-bound will all be fractionated and tested.
However, this same feature is also a drawback: there is no assurance that the
peptides recovered by such an approach are physiologically presented to
T cells, since they may not be associated with MHC proteins. In one study,
three natural peptides present in a whole cell extract could sensitize target
cells for lysis by a particular CTL clone; two of these peptides co-purified
with the relevant MHC molecule (Ld), while the third turned out to be a
longer precursor peptide that probably does not bind directly to Ld [100,
1 15]. The other main disadvantage of whole cell extraction stems from the
substantially greater complexity of the mixture subjected to fractionation
and testing. Many rounds of HPLC may be required in order to purify a
single peptide from a whole cell extract. and the presence of cellular
components having nonspecific toxicity in T cell assays can confound the
testing of certain HPLC fractions [unpubl. observation]. Nevertheless. both
strategies - MHC purification and whole cell extraction - have been applied
successfully. and an optimal approach may be to compare yields from both
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peptide procedures on a relatively small scale (e.g. 109 cells) before commit-
ting to large-scale peptide purification; in the process the association of a
peptide epitope with a given MHC protein will be established.
Examples of Naturally Occurring Peptides Associated
with MHC Molecules
The naturally occurring peptides identified so far fall into two major
categories: those peptides that are recognized by specific T cells and are thus
known epitopes, and those peptides that have been examined because of
their abundance in association with MHC molecules irrespective of possible
T cell recognition. Within each category, both MHC-I and MHC-II mole-
cules have been studied (table 2). As discussed above, naturally occurring
peptide epitopes are potentially present at extremely low levels relative to the
most abundant MHC-bound peptides, and their characterization may there-
fore be difficult. However, this need not always be the case: during acute viral
infections, for instance, virus-related peptides may be produced in. abun-
dance and may be represented in MHC complexes at greater levels than other
endogenous peptides.
Known Naturally Occurring Peptide Epitopes
Van Bleek and Nathenson [49] took advantage of this expectation and
immunoprecipitated H-2Kb and H-2Db molecules from 1.3x 10' thymoma
cells that had been infected with vesicular stomatitis virus (VSV) for 7 h and
biosynthetically labeled with ['H]-amino acids for the last 4.5 of these 7 h.
MHC-bound peptides were eluted and fractionated by HPLC, and a natu-
rally occurring viral epitope specifically associated with H-2Kb was identified
by comparison of its HPLC retention time with those of synthetic analogs
and by detection of ['H]-amino acids at certain positions in the natural
peptide. Even though 5-10% of the peptides eluted from H-2Kb were of viral
origin, and one octamer was the dominant viral peptide, probably less than
10 pmol of this peptide was recovered, emphasizing the quantitative de-
mands of isolating natural peptides even under relatively favorable condi-
tions.
Rotzschke and co-workers [79] reported the isolation of two naturally
processed influenza virus epitopes. These epitopes, recognized by H-2Db-
and H-2Kd-restricted CTL, respectively, had previously been mapped to in-
fluenza nucleoprotein residues 366-379 (14-mer) [5] and 147-158 (12-mer)
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[ 116]. Their approach was TFA extraction of 8 x 108 influenza-infected cells,
separation of a low molecular weight fraction by gel filtration, and reverse-
phase HPLC, followed by cytotoxicity assay of the HPLC fractions. Extracts
from infected H-2b and H-2d cells each gave a unique, unmistakable peak of
sensitizing activity. In each case the natural peptide co-eluted with a
contaminant fortuitously present in the longer synthetic peptide prepara-
tion. The synthetic contaminants co-eluting with the natural peptides were
identified by mass spectrometry or by synthesis and HPLC of a shorter
peptide: both were nonamers. The same group also identified a naturally
occurring peptide in a cell that had been transfected with the ovalbumin
gene and that was lysed by an ovalbumin-specific H-2Kb-restricted CTL
clone. They used the sequence of a known sensitizing 19-mer from ovalbu-
min [117] and the H-2Kb consensus motif [57] to predict a candidate
octamer, which was then synthesized and shown to co-elute with the natu-
rally occurring peptide [811].
The first nonviral peptide recognized by CD8+ T cells to be directly
isolated and sequenced from natural sources was the peptide ligand of an
alloreactive CTL clone (100]. Starting with 263 spleens (26.7 g), the active
peptide from one of three sensitizing HPLC fractions was purified by five
rounds of HPLC, using T cells to detect the peptide after each round. By a
combination of Edman degradation and mass spectrometry (see above), the
octameric sequence of this epitope was determined. The protein origin of this
natural peptide was initially unknown, but later work has shown that the
peptide derives from a ubiquitous enzyme essential for intermediary metab-
olism: moreover, the second of three sensitizing activities present in the
original spleen extracts has also been purified and sequenced: it is a longer
precursor of the octamer that does not co-purify with the relevant MHC-I
molecule and is probably cytosolic [115]. Interestingly, the latter precursor
peptide was present at - 100-fold higher levels than the MHC binding
octamer [(115]. These findings directly verified a longstanding hypothesis that
alloreactive T cells recognize specific antigens associated with MHC proteins
much like other T cells [118), and that these antigens are endogenously
produced peptides arising from normal self proteins, at least in the case of
alloreactive CD8+ T cells [119]. In a different study, alloreactive CD4+
T cells were found to recognize processed forms of serum albumin in
association with MHC-II molecules [120]. in accordance with the general
model that CD4+ T cells respond primarily to exogenous antigens [121].
Previous work had identified HPLC fractions from other tissue extracts
that contained unknown peptide epitopes recognized by alloreactive CTL
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[96, 122-124] or seen as minor histocompatibility antigens [58, 125]. In many
cases these fractions correlated with the presence or absence of particular
MHC-I molecules, leading to a model which implicates MHC-I molecules
themselves in the generation and/or accumulation of naturally occurring
peptides [97, 124, 126]. Thus, the MHC-type of a cell appears to influence the
pool of natural peptides that are detectable in extracts from that cell. This
effect appears not to be universal, since the octameric peptide recognized by
the alloreactive CTL clone described above was found at comparable levels in
spleens from mice of all three H-2 haplotypes examined [100].
Quantitative Aspects of Naturally Occurring Peptide Epitopes
In order to determine the abundances of naturally occurring peptide
epitopes on target cells, the titration curves of a synthetic peptide and the
same peptide from a natural source can be compared by cytotoxicity assay
[79-81, 100]. A similar quantitative approach was used to compare the
abundances of a naturally occurring minor histocompatibility peptide in
different tissues [127]. Ideally, recovery of the naturally occurring peptide
should be adjusted for the combined overall yields of the peptide extraction
and fractionation procedures: however, these yields are often unknown, in
which case the resulting estimate represents a lower limit for the abundance
of a natural peptide on target cells. Alternatively, the natural source for a
given peptide (such as a tissue or cell extract) can be supplemented with a
measured amount of an indicator peptide (such as a radioactively labeled
peptide or a DNP modified peptide), and the recovery of the indicator
peptide then provides an estimate of overall losses. In certain cases an
indicator peptide tightly bound to an MHC-I protein may be available [30],
and adding these complexes to a crude natural source will control for the
efficiency of eluting peptides from MHC-I molecules as well as for the
subsequent fractionation steps.
Rammensee and co-workers [80] found that influenza virus-infected
cells each expressed a few hundred molecules of a naturally processed
nucleoprotein peptide; cells transfected with the ovalbumin gene expressed
at least ' 100 copies of the natural T cell epitope from that protein [81], and
a similar number was determined for a peptide representing the mutagen-
induced tumor antigen recognized by a specific CTL clone [109]. We
estimated a recovery of 100-200 molecules per thymus cell of the naturally
occurring peptide recognized by an alloreactive CTL clone [100]. These
values agree with previous estimates of the minimal numbers of peptide-
MHC complexes required to activate T cells [27. 93, 94].
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Naturally Occurring Peptide Epitopes Recognized on Tumor Cells
Synthetic peptides mimicking natural epitopes expressed on the surfaces
of tumor cells in association with MHC proteins have been shown to
constitute effective targets for CTL responses [12, 13, 48]. Several laborato-
ries are engaged in efforts to isolate and sequence naturally occurring tumor-
specific peptides, ascertain their origins and abundances, and attempt to
apply this information to the design of therapeutic approaches [128]. Using a
genetic approach, Boon and co-workers [129] were able to isolate and
sequence genes encoding tumor-specific antigens by transfecting DNA from
human melanoma lines into antigen-loss variants no longer lysed by specific
CTL; from one such tumor-specific antigen the predicted epitope, a non-
amer, was synthesized and found to sensitize HLA-A + target cells for lysis
by melanoma-specific CTL [130]. A similarly identified mouse tumor-
specific peptide was further shown to be the likely naturally occurring epitope
on tumor cells [109]. Other groups are presently engaged in characterization
of tumor antigens by approaches analogous to those described above, i.e.,
direct biochemical isolation and sequencing.
Naturally Occurring Peptides Isolated by Virtue of Their
Relative Abundance
The second broad category of naturally occurring peptides consists of
those found in association with MHC molecules independently of any
known T cells. Since these tend to be abundant peptides, it is likely that
T cells specific for them (and thus potentially autoreactive) would be
negatively selected during T cell development, although the same pep-
tides may be recognized by alloreactive T cells that have matured in an
MHC-different individual. Rammensee and co-workers [57] reported the
sequence of a prominent nonamer eluted from H-2Kd molecules, and
calculated that this peptide occupies - 5% of the H-2Kd molecules on
P815 cells. This unusually high occupancy may indicate that even fewer
natural peptides can be presented at a level required to elicit T cell
responses (2 100/cell) than would be the case if all naturally occurring
peptides were equally abundant. Jardetzky et al. [131] eluted self peptides
from purified HLA-B27 and obtained both a consensus motif (table 1)
and individual sequences after HPLC fractionation of the mixture. Of
eleven nonamers identified, seven matched to known protein sequences,
and these were all abundant cytosolic or nuclear proteins, e.g., histones,
ribosomal proteins, and heat shock proteins, suggesting that naturally
occurring peptides associated with MHC proteins may be biased toward
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representing highly expressed endogenous proteins. Each of these natural
peptides occupied < 0.5% of the HLA-B27 molecules [131]. A summary of
these and other more recent results is provided in table 2.
Hunt et al. [132] recently developed a novel and exceptionally sensitive
approach to the identification of naturally occurring peptides. After
immunoprecipitation and acid treatment of HLA-A2.1 molecules, the eluted
peptides were loaded onto a microcapillary HPLC column interfaced with
the electrospray ion source of a triple quadrupole mass spectrometer. Mass
spectra were recorded every 2 s during elution of the HPLC column,
permitting an assessment of the evident heterogeneity in natural peptide
abundances: 50% of the total ion current was due to = 200 peptides, of which
one-third represented two-thirds of the signal; the remaining 50% was
presumably due to peptides present at very low levels. Of the approximately
200 peptides detected, 10% were present at 150-600 fmol/108 cells (1-4%
occupancy of the HLA-A2.1), and 90% were present at 30-150 fmol (0.2-1%
occupancy). By subjecting selected relatively abundant ions to collision-
activated dissociation, eight sequences were derived, all of which were
nonamers, and four of which could be matched to abundant cytosolic or
nuclear proteins [132].
Applying the same technique to HLA-A2.1 recovered from the antigen
processing mutant cell line T2 [133, 134], Hunt and co-workers [88] discov-
ered a second family of natural peptides that are derived from signal
sequences of normal cellular proteins. These peptides. some of which were
longer than nonamers, could also be detected in acid extracts of HLA-A2.1
from nonmutant cells, albeit at lower levels. In studying the same mutant T2
cells, Wei and Cresswell [89] independently isolated and sequenced a small
number of abundant and unusually long peptides that could be eluted from
HLA-A2. 1, and at least two of these were identical to those found by Hunt et
al. [88]. Whether signal sequence-derived peptides form appreciable
numbers of complexes with MHC-I molecules other than HLA-A2.1 remains
an open question [135].
Naturally occurring peptides have also been eluted from MHC-II mole-
cules, and the results, described in more detail elsewhere in this volume,
contrast in several ways with those obtained from MHC-I systems. In brief,
endogenous peptides associated with MHC-II molecules generally consisted
of sets of nested peptides sharing a core sequence but varying in length from
13 to 25 residues [136-139]. The proteins of origin for MHC-II-associated
peptides are secreted (e.g. serum albumin) or transmembrane proteins,
including the MHC-II-associated invariant chain, consistent with the func-
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tion of MHC-II proteins in presenting exogenous antigens [121]. In agree-
ment with these findings, the binding groove of a crystallized MHC-II
molecule differed from that of MHC-I molecules in such a way as to allow the
N- and C-termini of bound peptides to extend out of the MHC-II groove,
thereby accommodating different length peptides [140].
Concluding Remarks
The ability of T cells, especially cytotoxic CD8+ T cells (CTL), to destroy
virus-infected cells and cancer cells is leading to intensive efforts to develop
peptide-based vaccines aimed at stimulating the production of these cells for
the prevention of infection or for the treatment of chronic infection (e.g.
HIV) or established tumors. For such vaccines to be effective, they must be
able to elicit the production of many cytolytically active CTL that satisfy the
following criteria: their antigen-specific T cell receptors have high affinities
for specific peptide-MHC ligands; the peptide epitopes for these CTL are
present as natural ligands on target cells in vivo; and the peptide epitopes
must exist at levels of abundance sufficient to trigger potent cytolytic
responses (currently thought to be at least 100 per target cell, although this
number may vary for different T cells, especially as a result of differences in
T cell receptor affinities).
What determines the abundances of naturally occurring epitopes on
target cells? One factor is likely to be the competition among an enormous
number of different peptides within a given cell for binding to the cell's
limited number of MHC-I molecules. A typical cell probably produces about
10,000 different proteins, each of which could potentially be represented by a
large number of octameric or nonameric sequences. However, since only a
handful of different MHC-I molecules are expressed per cell, each at a copy
number of = 105, only up to about 1,000 different peptides could theoreti-
cally be displayed (per MHC-I) at an abundance that exceeds the threshold
for triggering a T cell response. The actual number of peptide epitopes may
be lower if many MHC-I molecules are occupied by peptides present at levels
of abundance that are physiologically inconsequential, as is suggested by
some data [132]. Hence it is likely that many of the proteins made by a cell
are not represented on the cell's surface by a sufficient number of peptide
epitopes to trigger a potent T cell response.
For many viruses, this situation does not hinder the efficacy of antiviral
CTL responses because in infected cells the expression of many host genes is shut
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down and most of the proteins made are virally encoded. But with some viruses
viruses, e.g. HIV, infected cells can grow and proliferate over a long period, and
therefore presumably continue to produce the cell's full complement of self
proteins in addition to a small number of viral proteins. In cancer, likewise, only
a very small proportion of the different proteins made by transformed cells may
represent aberrant cancer-specific proteins. Under these circumstances it
cannot be taken for granted that peptides derived from a viral gene or a can-
cer-specific gene will be displayed on the affected cell's surface at a level that
is physiologically significant. For this and other reasons it is important to estab-
lish not only the identities but also the abundances of naturally occurring virus-
or cancer-specific peptide epitopes obtained from infected or transformed
cells.
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ABSTRACT
Peptides and other bioactive materials can be purified from
complex biological sources by reverse-phase high-perfobrmance liq-
uid chromatography (RP-HPLC), provided the mixture is suitably
prepared before injection onto an HPLC system. Ultrafiltration
offers a convenient and rapid snample preparation technique with
numerous advantages over alternative methods such as conven-
tional gel filtration chromatography. We demonstrate the use of
ultrafiltration as an HPLC sample preparation step in the purifica-
tion of peptides bound to class I major histocompatibility complex
(MHC-I) membrane proteins. When ultrafiltration was performed
with a Centricon5 - 10 ultrafiltration device, peptides were efficiently
separated from the a (45 kDa) and Pl2m (12 kDa) chains of MHC-1
proteins and could be subjected to HPLC without further treatment.
Furthermore, even samples as crude as whole cell lysates or super-
natants could be prepared for HPLC in a single ultrafiltration step.
affording a remarkably straightforward route to the purification of
biologically important peptides.
INTRODUCTION
The isolation of highly purified peptides or other bio-
molecules from complex starting materials (e.g., cell super-
natants, cell lysates) can be achieved in a surprisingly small
number of steps, thereby improving yields and reducing the
time required. The excellent resolving power of reverse-
phase high-performance liquid chromatography (RP-HPLC)
allows even the most closely related molecules to be fraction-
ated under a suitable set of conditions (solvents, gradient, col-
umn, flow rate and temperature). Yet, before a sample from a
crude biological source can be injected onto an RP-HPLC
system with the expectation of efficient chromatographic
separation, the sample must be prepared so that it is 1) com-
pletely soluble in the HPLC solvents to be used: 2) free of
dust or other particulates that can clog HPLC tubing; and 3)
free of large hydrophobic protein molecules that irreversibly
bind to reverse-phase columns and deteriorate chromato-
graphic performance. Through the use of Centricon® ultrafil-
tration. all of these conditions can be satisfied conveniently
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and economically, leading to a general strategy for rapid puri-
fication of peptides from complex mixtures.
An area of recent intense interest is the purification of pep-
tides recognized by cytotoxic T lymphocytes, the cells that
mediate immunological reactions against viruses, tumors and
transplants, for example. These peptides are arrayed on cell
surfaces in close association with glycoproteins termed
MHC-I proteins, which consist of an ao-chain (ca. 45 kDa)
and 32-microglobulin (12 kDa). Thus the purification and
characterization of these peptides require their isolation from
either whole cells or purified MHC-I molecules. Buus et al.
and R6tzschke et al. have shown that peptides complexed
with MHC proteins can be dissociated by strong acid, i.e.,
acetic acid (I) or trifluoroacetic acid (TFA) (4). They sepa-
rated peptides from MHC proteins by low-pressure gel filtra-
tion chromatography prior to RP-HPLC analysis. Harvesting
the total peptide fraction by ultrafiltration with a Centricon-
10 or Centriprep@-10 unit offers several advantages such as
greater speed and economy, high recovery, smaller volume
for HPLC injection and concomitant removal of particulates
before HPLC injection.
MATERIALS AND METHODS
The human MHC-I proteins HLA-A2 and HLA-B7 were
purified from JY cells (B lymphoblastoid cell line) by estab-
lished procedures (3,6) with minor changes (7). Human 12-
microglobulin was purchased from Calbiochem (San Diego,
CA). Purified HLA-A2 and HLA-B7 were concentrated and
freed of unbound peptides by ultrafiltration at 5000x g for 40
min using a Centricon-10 concentrator (Amicon, Beverly,
MA). All centrifugations were performed in a Beckman JA-
20 rotor (Beckman Instruments, Fullerton. CA). The proteins
were then denatured by treatment with 0.5% TFA (4) for 60
min at 370 C and the dissociated peptides collected by Centri-
con ultrafiltration. The retentate, containing denatured pro-
tein. was subjected to TFA treatment and ultrafiltration a sec-
ond time, and the two filtrates were combined for RP-HPLC.
Peptide purification was achieved on a Beckman
HPLC system (Model 334) by means of C18 reverse-phase
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chromatography with an acetonitrile gradient in 0.1% TFA
(Vydac 218TP104; The Separations Group, Hesperia, CA)
and/or C8 reverse-phase chromatography at pH 8.5 with an ace-
tonitrile gradient in triethylamine acetate (Vydac 228TP104).
Gradients were 51% acetonitrile per min. Peak detection was
provided by means of UV absorbance at 220 nm and/or 280
nm as well as radioactivity when using radioiodinated peptides.
Fractions were dried in a SpeedVac@ (Savant Instruments,
Farmingdale, NY) before bioassay and re-chromatography of
the fractions exhibiting biological activity. Synthetic peptides
were obtained by conventional solid-phase techniques at the
M.I.T. Biopolymers Laboratory (Cambridge, MA).
RESULTS AND DISCUSSION
The extraction of bound peptides from purified HLA-A2
and HLA-B7 was achieved with TFA as first described by
Rotzschke et al. (4). In several cases, a radioiodinated peptide
thought to bind HLA-A2 was added to JY cells before HLA
purification. The radioactive peptide was subsequently sepa-
rated from purified HLA-A2 by TFA, providing a measure of
the efficiency of peptide extraction by TFA (7). In all cases,
the peptides obtained from HLA were a highly heterogeneous
mixture. Multiple rounds of HPLC fractionation were re-
quired in order to isolate individual peptides.
Prior to RP-HPLC, the peptides dissociated from HLA by
TFA treatment were separated from the protein by Centricon-
10 ultrafiltration (Figure 1). This step 1) ensured that only
compounds soluble in TFA would be loaded onto the HPLC
system; 2) removed dust and particulates as required before
HPLC injection; 3) separated a peptide fraction (<10 kDa)
from the HLA sample (ca. 45 kDa and 12 kDa; see below);
and 4) concentrated the HLA in the retentate for further
Figure 1. Peptide purification scheme based on acid denaturation, ul-
trafiltration and RP-HPLC (see text).
analysis (calculation of yield, sodium dodecyl sulfate poly-
acrylamide gel electrophoresis [SDS-PAGE], etc.). More-
over, the advantages over conventional gel filtration include
greater speed and reproducibility, lower overall cost and
avoidance of the dilution effect inherent in gel filtration. Cen-
tricon ultrafiltration has also been used by others in similar
recent studies (5,9). For the most efficient extraction of HLA-
bound peptides, TFA treatment and ultrafiltration were re-
peated and the two ultrafiltrates were combined for RP-
HPLC. When radioiodinated peptides were used, over 95% of
the radioactivity was measured in the ultrafiltrate by this
method (7). Typical results are shown in Figure 2.
As an alternative to HLA purification followed by TFA
treatment to remove bound peptides, whole cell lysates were
treated directly with TFA (4,8). Centricon-10 ultrafiltration
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Figure 2. Representative results from RP-HPLC fractionation of a pep-
tide mixture recovered from purified HLA-A2 by TFA extraction. Several
peptide peaks are evident in the region from 30-50 min (25%-45% acetoni-
trle in the linear gradient used). The single radioactive peak represents an
HLA-A2-binding peptide (ILKEPVHGV) stoichtometrically labeled on its
histidine and added to JY cells before HLA-A2 purification (7). Based on
the known specific radioactivity of this peptide (ca. 10' cpm/nlg) and our)ield of HLA-A2 (ca. 35 gg per 109 JY cells). this peptide constitutes
0. 1%-0.5% of the total peptide bound to cell surface HLA-A2.
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followed by RP-HPLC led to the characterization of several
biologically active peptides that were dried and re-chroma-
tographed using different sets of HPLC conditions (gradient,
column and pH) until the desired peptides were sufficiently
pure for sequence determination (8). Identification of the bio-
logically important peptides after each round of chromatogra-
phy depended on the use of a cytotoxic T cell assay to screen
HPLC fractions. In each case the replacement of gel filtration
with Centricon ultrafiltration saved considerable time and
provided high yields of peptides ready for HPLC injection.
Because HLA consists of two noncovalently associated
chains, a and 02-microglobulin, we were concerned about the
efficiency of separation of 32-microglobulin (12 kDa) from
the peptide fraction. As shown in Figure 3, virtually all
(>98%) of the 32-microglobulin is retained by the Centricon-
10 membrane (nominal molecular mass cutoff 10 kDa).
Figure 3. Retention of 3z-microglobulin (12 kDa) by the Centricon-10
membrane. 15 jg purified human ~2-microglobulin were denatured in 400
il 0.5% TFA followed by Centricon-10 ultrafiltration to completion ino
visible volume in the retentate). The membrane was washed with 400 ul
0.1% TFA to collect any retained material, and both the retentate ie..
membrane wash) and filtrate were injected onto RP-HPLC. Upper chroma-
togram represents retentate and lower chromatogram is filtrate. Both chro-
matograms are at same scale.
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CONCLUSION
Although gel filtration is often used for the fractionation of
peptides and proteins, non-ideal size exclusion effects due to
interactions with column matrices are well known (2). We
have found that Centricon ultrafiltration offers several impor-
tant advantages for the separation of a peptide mixture from
larger proteins, including speed, convenience and economy.
Moreover, when utilized as a sample preparation step prior to
RP-HPLC fractionation of peptides, ultrafiltration also filters
out dust and other particulates and ensures that large hydro-
phobic proteins will not make it to the HPLC column, where
they can be irreversibly retained. Human 32-microglobulin, a
protein of mass 12 kDa, was completely (>98%) retained by
the Centricon-10 membrane. The method is recommended
for the purification of peptides (or other biomolecules) from
starting mixtures as complex as whole cell lysates or cell su-
pernatants. When large volumes are involved, the larger Cen-
triprep units may be used and/or an additional drying step
(lyophilization, SpeedVac) may be inserted.
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ABSTRACT: Class I major histocompatibility complex (MHC) proteins present peptide antigens to T cells
during the immune response against viruses. Peptides are loaded into newly synthesized class I heterodimers
in the endoplasmic reticulum such that most or all cell surface class I molecules contain peptides derived
from endogenous or foreign proteins. We previously reported the assembly of empty heterodimers of the
murine class I MHC molecule H-2Kd, from denatured heavy and light chains from which endogenous
peptides had been removed [Fahnestock et al. (1992) Science 258, 1658-1662]. Here we measure thermal
stability profiles of empty versus peptide-filled molecules and compare the effects of human versus murine
light chains on the overall stability of the Kd heterodimer. The majority of empty heterodimers are stable
at 37 OC regardless of the species of light chain, indicating that our previous report of the unexpectedly
high thermal stability was an intrinsic property of the Kd molecule and not due to use of a murine/human
chimeric protein. Binding constants are derived for a series of peptides interacting with empty Kd heterodimers.
The dissociation constants of four known Kd-restricted peptides range from 2.3 x 10-7 to 3.4 X 10- 8 M.
Using a series of 24 analog peptides, the effects of length and peptide composition on binding affinity of
one Kd-restricted peptide are explored, and the results are interpreted with reference to the known three-
dimensional structures of class I MHC protein/peptide complexes.
Virally infected cells present antigenic peptides embedded
in class I major histocompatibility complex (MHC)' molecules
to cytotoxic T lymphocytes (Townsend & Bodmer, 1989).
Recognition by a T cell receptor on a cytotoxic T cell is specific
for the particular combination of class I molecule and peptide
on the surface of the infected cell. Crystallographic analyses
of class I molecules have shown that peptides bind in a groove
located between two a-helices on the top surface of the molecule
(reviewed in Bjorkman & Parham, 1990). Pockets at each
end of the peptide binding site contact main-chain atoms of
the N- and C-termini of octamer and nonamer peptides
(Garrett et al., 1989; Saper et al., 1991; Fremont et al., 1992;
Madden et al., 1992; Matsumura et al., 1992a; Zhang et al.,
1992). These pockets (A and F) are lined with highly
conserved residues, while the intermediate pockets (B-E)
contain residues that vary in class I sequences. Elution and
sequencing of endogenous peptides bound to class I molecules
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revealed a preference for peptides that are eight or nine amino
acids in length and elucidated allele-specific sequence motifs
and the presence of "anchor" residues important for allele-
specific binding (Van Bleek & Nathenson, 1990; Falk &
Rammensee, 1990; R6tzschke et al., 1990a,b; Falk et al.,
1991; Jardetzky et al., 1991). For example, peptides that
bind to the murine class I molecule H-2Kd are nonamers that
most commonly have a tyrosine at position 2 and leucine or
isoleucine at position 9 (the anchor residues) (Falk et al.,
1991; Romero et al., 1991; Rammensee et al., 1993).
Class I molecules bind peptides in the endoplasmic reticu-
lum during the assembly of the heavy chain with #2-
microglobulin (02m), the class I light chain (Townsend &
Bodmer, 1989). Under normal circumstances, the majority
of all class I molecules that reach the cell surface are occupied
with a peptide, either derived from a self protein to which the
immune system is tolerant, or derived from a foreign pathogen,
to which the immune system will react. Class I molecules
purified from wild type antigen presenting cells or transfected
eukaryotic cells contain a mixture of endogenous peptides,
and typically less than 1% of the purified protein will bind
exogenous peptide (Chen & Parham, 1989). Assembly of
class I heavy and light chains in the absence of peptide to
make empty class I heterodimers was once thought to be a
structural impossibility (Townsend et al., 1989). However,
recent experiments using mutant cell lines have established
that empty class I molecules can assemble and reach the surface
of cells grown at 26 oC (Ljunggren et al.. 1990; Schumacher
et al., 1990; Townsend et al., 1990). The resulting empty
class I heterodimers are less stable than their peptide-filled
counterparts and rapidly become undetectable by conforma-
tionally sensitive antibodies at physiological temperature unless
stabilized by addition of exogenous peptide (Ljunggren et al.,
C 1994 American Chemical Society
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1990; Schumacher et al., 1990; Townsend et al., 1990; Ortiz
& Himmerling, 1991).
An empty form of a class I molecule would be the ideal
reagent to use for peptide affinity measurements without the
complication of displacing endogenous peptide. We previously
reported the efficient in vitro reassembly of separated and
denatured class I heavy and light chains in the absence of
peptide to make an empty form of H-2Kd, which was shown
to bind equimolar amounts of offered peptide (Fahnestock et
al., 1992). Thermal stability profiles of empty Kd molecules
were compared to profiles of their peptide-filled counterparts
to quantitate the increase in thermal stability provided by
occupation of a peptide. The transition midpoint (Tm) of the
melting curve of peptide-filled Kd was substantially higher
than the Tm of empty Kd (57 *C compared to 45 OC), and a
thermodynamic analysis indicated that the free energy of
stabilization due to peptide binding was 4.4 kcal/mol (Fah-
nestock et al., 1992). Further analysis of the data indicated
that 75% of empty Kd molecules were in a native configuration
at 37 O C, which was unexpected due to the reported instability
of empty class I molecules at physiological temperature.
However, because the reassembled class I heterodimers
consisted of the murine Kd heavy chain complexed to human
02m (Kd/hu#2m), it was possible that the higher than expected
stability of the empty molecules could reflect the greater
stability reported for murine class I heavy chains that are
complexed with human rather than with murine 02m (Hoch-
man et al., 1988).
In this report, we extend our original studies in several
ways: first, we report a method for purifying completely
murine heterodimers (Kd heavy chain complexed with murine
02m; Kd/mf2m) from transfected cells grown in serum free
medium and record thermal stability profiles of Kd/mo2m
for comparison to profiles of Kd/huo2m. Second, we explore
the effects of varying peptide length and composition on the
ability of a Kd-restricted peptide to bind empty Kd het-
erodimers. During preparation of the Kd/m02m protein, we
noted that the majority or all of the Kd/m02m heterodimers
secreted from transfected CHO cells were occupied with
endogenous peptides, whereas -70% of secreted Kd/huo2m
appeared to be empty (Fahnestock et al., 1992). However,
the thermal stability profiles of the empty and peptide-filled
forms of Kd/m32m differ little from the profiles of their Kd/
hu32m counterparts (the Tm of empty Kd/m32m is 42 *C,
the Tm of peptide-filled Kd/m32m is 56 °C), suggesting that
the higher than expected thermal stability originally reported
for Kd (Fahnestock et al., 1992) was an intrinsic property of
this class I molecule and not due to the use ofa nonphysiological
chimeric protein. Finally, we use equilibrium dialysis to derive
an affinity constant for the interaction between a radiolabeled
Kd-restricted peptide and empty Kd and measure the affinities
of other Kd-restricted peptides and peptides of altered length
and amino acid sequence to evaluate the effects of altering the
anchor residues and extending or deleting residues at both
ends of the peptide. Many comparative studies on sets of
related peptides use T cell assays to access effects of alterations
in the peptide sequence. Such assays cannot distinguish
between the effects of peptide alteration on binding to the
MHC molecule and the effects on T cell recognition of the
resulting peptide/MHC complex. In order to separate these
two binding events, a direct measurement of peptide/MHC
binding affinities is required, as is reported here. The peptide
binding studies are interpreted and rationalized using the three-
dimensional structure of the class I peptide binding site.
Fahnestock et al.
MATERIALS AND METHODS
Cell Lines. Stable CHO cell lines expressing secreted Kd/
hu02m or Kd/m02m were generated using a glutamine
synthetase-based amplification system (Bebbington &
Hentschel, 1987) as described (Fahnestock et al., 1992,1994).
In this system, amplification of transfected genes depends
upon increasing concentrations of the drug methionine
sulfoximine. In order to produce a secreted Kd heterodimer,
a stop codon was introduced into the Kd heavy chain gene
after the codon for amino acid 284 (Fahnestock et al., 1992).
An expression plasmid containing the truncated heavy chain
gene was cotransfected with an expression plasmid containing
the complete cDNA sequence of murine (a allele; Daniel et
al., 1983) or chimpanzee 02m. The protein sequence of mature
chimpanzee 02m is identical to human #2m (Lawlor et al.,
1990); thus the protein product from the chimpanzee gene is
referred to throughout this paper as human #2m. Transfected
CHO cells secreting Kd/huo2m were maintained in glutamine-
free aMEM (Irvine Scientific) supplemented with 10%
dialyzed fetal bovine serum (Gibco/BRL) and 100 gM
methionine sulfoximine (Sigma). Transfected CHO cells
secreting Kd/m#2m were maintained in serum-free conditions
as modified from Hamilton and Hamm (1977) (glutamine-
free aMEM supplemented with bovine serum albumin, insulin,
vitamins, trace metals, and 100 tM methionine sulfoximine).
Penicillin (100 units/mL) and streptomycin (100 gg/mL)
were included in all media used.
Protein Purification. Protein was purified from cells
secreting Kd heterodimers by immunoaffinity chromatography
as described (Fahnestock et al., 1992). A column constructed
with the monoclonal antibody 34-1-2 (Ozato et al., 1982) was
used for purification of Kd/hu$2m from supernatants of
confluent cells grown in 10-cm plates. Typical yields were
9-10 mg of Kd/hu02m/L of supernatant, with no detectable
exchange of human #2m for endogenous hamster f2m or
bovine #2m in the medium (Fahnestock et al., 1992). For
purification of Kd/mp2m from serum free medium, an
immunoaffinity column constructed with the monoclonal
antibody Ml/42 (Stallcup et al., 1981) was used. This
antibody recognizes murine class I MHC heavy chains only
when associated with murine 02m (M.L.F., unpublished
observations), allowing separation of Kd/m02m from Kd heavy
chains associated with hamster 02m (Kd/ha#2m). A mobility
difference on SDS-PAGE gels between hamster and murine
132m (Fahnestock et al., 1994) allowed Kd/m#2m and Kd/
ha#2m to be easily distinguished. Protein eluted from the
M1/42 column was verified to be free of hamster 02m by
N-terminal sequence analysis (M.L.F. and P.J.B., unpublished
data) and gel migration behavior. The flow-through material
was saved and purifed by passage over the 34-1-2 immu-
noaffinity column as a source of Kd/hap2m. To obtain
sufficient quantities of Kd/m,2m, cells expressing secreted
Kd/mp2m were introduced into a hollow fiber bioreactor device
(Cell Pharm I; Unisyn Fibertec, San Diego, CA) in serum
free medium, and supernatants were collected daily. The final
yield of purified Kd/m02m protein was 2.5-3.0 mg/L of
supernatant. An additional 1-2 mg/L was purified as Kd/
hap2m.
Acid Elutions of Kd Heterodimers. Purified Kd/hu#2m,
Kd/mo2m, or Kd/hap2m was analyzed for the presence of
bound peptides using established methods (Van Bleek &
Nathenson, 1990; Jardetzky et. al.. 1991). Briefly, 0.25 mg
of protein (quantitated by a BCA assay, Pierce Chemical
Co.) was concentrated to 100 ML in a Centricon 10 (molecular
weight cutoff of 10 000) ultrafiltration device (Amicon;
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Beverly, MA). After dilution with 1.0 mL of 50 mM
ammonium acetate, pH 7.5, the proteins were again concen-
trated to 100 AL, and this procedure was repeated. The washed
protein was then treated with 1.0 mL of 12% acetic acid and
concentrated again to 100 AL in the ultrafiltration unit, and
this elution step was repeated. Using this procedure, the acid
filtrate should contain any eluted peptide material. The acid
eluates were lyophilized and analyzed by automated Edman
degradation using an Applied Biosystems Model 477A protein
sequencer.
Reassembly ofEmpty Heterodimersfrom Separated Heavy
and Light Chains. Empty Kd/hu#2m or Kd/mo2m het-
erodimers were prepared from denatured protein as described
(Fahnestock et al., 1992). Briefly, heavy and light chains
were first denatured in 6.0 M guanidine hydrochloride and
separated from endogenous peptides by gel filtration chro-
matography on a Superose 12 FPLC column (Pharmacia).
Heavy and light chain peaks were pooled and renatured by
dialysis against 20 mM Tris, pH 7.6, 150 mM NaCl, 1 mM
EDTA, 0.2 mM phenylmethanesulfonyl fluoride containing
8 M urea and then twice against the same buffer without
urea. Renatured material was concentrated 8-10-fold in a
Centricon- 10 (molecular weight cutoff 10 000) ultrafiltration
device (Amicon; Beverly, MA) and passed over a Superdex
FPLC size exclusion column (Pharmacia). Fractions cor-
responding to heterodimer were pooled and concentrated.
Circular Dichroism Spectra and Thermal Stability Analy-
ses. A JASCO J-720 spectropolarimeter equipped with a
Peltier thermal control unit and a rectangular cuvette with a
1-mm pathlength was used for CD measurements. Spectra
were recorded from protein samples (0.25-0.4 mg/mL) in 5
mM phosphate buffer, pH 7.0. For measuring melting curves,
the CD signal was monitored at 223 nm while the sample
temperature was raised from 25 to75 *C at a rate of 20 OC/h.
Tm's were calculated by estimating the half-point of the
ellipticity change between the pure native and pure denatured
states.
Peptide Synthesis and Labeling. All peptides were syn-
thesized by automated solid phase methodology on an Applied
Biosystems Model 432A synthesizer using the manufacturer's
standard Fmoc protocol. Preloaded resins were purchased
from Bachem Bioscience Inc. (Philadelphia, PA), and Fmoc-
protected amino acids and additional reagents were from
Applied Biosystems (Foster City, CA). Cleavage from the
resin and simultaneous side chain deprotection was ac-
complished by treatment with 90% trifluoroacetic acid, 2.5%
thioanisole, 2.5% mercaptoethanol and 5% phenol for 2 h at
room temperature. The precipitated, crude peptides were
purified to homogeneity using a preparative C-4 Vydac column
(Hesperia, CA) and a 0.1% aqueous trifluoroacetic acid/
acetonitrile gradient. Peptide composition was confirmed by
amino acid analysis. Lyophilized peptide samples were
resuspended in water. The concentrations of peptides were
estimated spectrophotometrically using the extinction coef-
ficient of tyrosine at 274 nm (1420 M- 1 cm-') (Wetlaufer,
1962) or by a BCA assay (Pierce Chemical Co.). A Kd-
restricted peptide from influenza virus nucleoprotein (amino
acids 147-155; sequence TYQRTRALV; R6tzschke et al.,
1990a) was tritiated by catalytic exchange (Amersham TR7
Tritium Labeling Service) to a specific activity of 1.61 x 109
counts per minute/Mmol. Aliquots were purifed by reverse
phase chromatography on an FPLC PepRPC column (Phar-
macia) prior to use. A portion of the Kd-restricted peptide
was iodinated with 1271 on the anchor tyrosine residue, using
a technique that makes a stoichiometrically iodinated and
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thus chemically homogeneous peptide (Tsomides & Eisen,
1993). Mono- and di-iodinated species were separated using
a C4 reverse phase HPLC column (Vydac) and analyzed by
Edman degradation.
Equilibrium Dialysis. Equilibrium dialysis was performed
in phosphate-buffered saline containing 0.5% gelatin and0.02%
NaN 3 using a Hoefer Microdialyzer EMD 101 (Hoefer; San
Francisco, CA). For Scatchard analyses, eight inside com-
partments [each filled with 100 AL of Kd/hug2m (2 AM)]
were separated from eight outside compartments [each filled
with 100 ML of varying concentrations of 3H-labeled peptide
(0.25-5.0 AM)] by a membrane with a molecular weight cutoff
of 14 000. Dialysis was performed at room temperature for
24 h. Equilibrium was established during this time period,
as no change of binding values was observed with longer
incubations. Samples (50 ML) from each inside and outside
compartment were then collected and transferred to a vial
containing 10.0 mL of Safety-Solve (Research Products
International Corp.) for scintillation counting on a Beckman
LS 5000TD scintillation counter. The concentration of free
peptide after reaching equilibrium was calculated using a
specific activity of 1.61 x 109 counts per minute/Amol. The
concentration of peptide bound to protein was estimated after
subtracting the counts per minute measured in the chamber
without protein from the counts per minute measured in the
chamber that included protein. The data were plotted as
[bound]/[free] versus [bound] and the KD calculated as -(1/
slope). For inhibition studies using unlabeled peptide, the
inside compartments were filled with 100 aL of Kd/hug2m
(2 AM), and the outside compartments were filled with 100
ML of a solution containing 3H-labeled peptide (2 AM) and
varying concentrations of unlabeled inhibitor peptide (0.0-2
mM). For each concentration of inhibitor, the percent
inhibition of peptide binding was calculated by comparing
results to a pair of chambers that did not include inhibitor,
and the percent inhibition was plotted versus the concentration
of inhibitor on a logarithmic scale. The 50% inhibition value
was determined from this graph and used to calculate the KD
of the inhibitor using the following equation (Mfiller, 1983):
KD = (Iso-[ 3H-P]) X (1-1.5b + 0.5b2), where b = percent
peptide binding in the absence of inhibitor (75.2% : 10.7%),
Iso is the concentration of inhibitor required for 50% inhibition,
and [3H-P] is the total concentration of 3H-labeled peptide
(1.0 AM after equilibrium). For each inhibition curve, seven
concentrations of inhibitor were tested in duplicate or triplicate
(although unpredictable leakage of the samples in the chambers
sometimes prevented all samples from being analyzed), with
the eighth chambers of the dialysis blocks tested under identical
conditions in the absence of inhibitor. For the two peptides
that bound with a higher affinity than the 3H-labeled peptide,
the KD was estimated using the following relationship (Cheng
& Prusoff, 1973): KD = I5o/(1 + [3H-P]/KD(labeled peptide)),
where the KD(labeled peptide) refers to the dissociation constant
determined for the labeled peptide by Scatchard analysis.
RESULTS
The Majority of Kd/m02m, but Not Kd/huB2m, Het-
erodimers Secreted from Transfected CHO Cells Are Oc-
cupied with Endogenous Peptides. Kd heterodimers purified
from CHO cells transfected with the Kd and the murine #2m
genes contain a mixture of murine and bovine d2m (Fahnestock
et al., 1992). which suggests that a large portion of murine
i32m was replaced in an exchange reaction by serum-derived
bovine f2m present in the medium (Bernabeu et al., 1984).
When Kd protein was purified from transfected CHO cells
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Table 1: Picomoles of Amino Acids Recovered from Acid Elutions"
cycle number Kd/hu02m Kd/mn2m Kd/haf2m
1 406 872 947
2 280 (Y= 178) 766 (Y= 559) 937 (Y= 757)
3 190 630 666
4 172 412 554
5 134 576 328
6 94 843 375
7 87 263 224
8 55 530 91
9 42 223 45
SFor peptides eluted from equivalent amounts of each protein, the
total yield of amino acids from each sequenching cycle is presented. Only
those amino acid residues that showed an increase in the absolute recovered
compared to the previous cycle were considered significant.
maintained under serum free conditions, N-terminal sequence
analysis showed that a portion of the purified heterodimers
had incorporated endogenous hamster 12m as their light chain
(data not shown). By contrast, Kd heterodimers purified from
cells transfected with the Kd and human 02m genes did not
contain detectable amounts of bovine or hamster 02m
(Fahnestock et al., 1992).
Peptides were eluted (Van Bleek & Nathenson, 1990;
Jardetzky et al., 1991) from equivalent amounts of purified
Kd/m02m, Kd/ha02m, and Kd/hu02m heterodimers and
analyzed by N-terminal sequencing (Table 1). To obtain
homogeneous heterodimeric species of Kd/mf2m and Kd/
hao2m for these analyses, Kd/m02m was separated from Kd/
hao2m on an immunoaffinity column, using a monoclonal
antibody (M1/42; Stallcup et al., 1981) that binds to Kd heavy
chains only when complexed to murine 32m (M.L.F.,
unpublished results). Sequences of peptides isolated from all
three forms of Kd showed a predominance of tyrosine and
proline in the second and fourth positions, consistent with
previously reported characteristics of Kd-restricted peptides
(Falk et al., 1991; Romero et al., 1991; Rammensee et al.,
1993). However, on a molar basis, considerably less peptide
material is found in the acid eluate of Kd/hu#2m as compared
to the eluates of Kd/m#2m or Kd/haB2m. Using thermal
stability profiles and analyses of near UV CD spectra, we had
previously shown that - 70% of the Kd/hu02m heterodimers
secreted from transfected CHO cells behave as empty
molecules, and the sequencing data in Table I and a previous
sequencing analysis (Raghavan et al., 1993) confirm the
estimate that less than half of the purified Kd/hu02m protein
contains bound peptides. Three to four times more peptide
material was eluted from the Kd/m#2m and Kd/hap2m
proteins (based upon the picomoles of tyrosine in cycle 2 in
the acid elutes from the three respective proteins). Assuming
that the amount of peptide material eluted from Kd/huf2m
represents a typical recoverable yield from the 30% of the
protein containing peptides, and that the recoverable yields
of peptides from eluates from Kd/mf2m and Kd/hag2m are
comparable, the 3-4-fold increase in peptide material suggests
that the majority of those species of heterodimers are occupied
with endogenous peptides.
Thermal Stability Profiles of Empty and Peptide-Filled
Kd/m132m and Kd/huO2m Heterodimers AreSimilar. Empty
Kd heterodimers were prepared using previously established
methods (Fahnestock et al., 1992) by reassembling denatured
heavy and light chains in the absence of endogenous peptides.
Heat-induced unfolding of empty Kd/mr2m was monitored
by recording the CD signal at 223 nm while the sample
temperature was increased from 25 to 80 OC, and the resulting
melting curve was compared to that obtained for Kd/huo2m
Fahnestock et al.
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FIGURE 1: Thermal denaturation profiles of empty and peptide-
filled Kd/m#2m (panel A) compared to empty and peptide-filled
Kd/hu#2m (panel B). The CD signal at 223 nm of each protein in
5 mM phosphate buffer at pH 7 was monitored using a l-mm
rectangular cell and a Peltier thermal control unit while the
temperature was raised from 25 to 75 OC at a rate of 20 OC/h. The
data were smoothed using the accompanying J720 software. T.'s
for the melting of the heavy chain (marked with arrows) were derived
by estimating the half-point of the ellipticity change between the
beginning and end of each transition. The melting curves for Kd/
m~2m and Kd/huB2m were collected using two different cuvettes
and are presented as obtained (0, mdeg). Differences in the absolute
numbers for ellipticity shown reflect differences in the offset caused
by different characteristics of the cuvettes. These differences are
irrelevant for the determination of the T..
(Figure 1A,B). As previously reported, empty Kd/huf2m
shows two unfolding transitions, the first (Tm = 45 oC) due
to dissociation and denaturation of the heavy chain and the
second (Tm = 64 oC) from denaturation of the light chain
(Fahnestock et al., 1992). The empty Kd/mB2m melting curve
shows very similar behavior, with the heavy chain melting
transition centered at 42 oC. The #2m melting transition is
not apparent for empty Kd/m02m in Figure 1A, perhaps being
obscured by the CD signal from the melted Kd heavy chain.
Upon addition of a 2-fold molar excess of a Kd-restricted
peptide from influenza virus nucleoprotein (sequence: TYQR-
TRALV; R6tzschke et al., 1990a), the heavy chain dena-
turation transitions for both Kd/mo2m and Kd/huo2m are
shifted to higher temperatures (Tm = 56 OC for Kd/m#2m;
Tm = 57 OC for Kd/hu$2m).
Equilibrium Dialysis Measurements of Binding Affinities
of a Series of Kd-Restricted Peptide Analogs. Empty Kd
heterodimers were used in equilibrium dialysis experiments
to obtain dissociation constants for peptide binding. Because
Kd/m#2m and Kd/hu#2m showed similar thermal stability
profiles to each other in both their empty and peptide-filled
forms and because of the greater ease in obtaining starting
material and reassembling empty heterodimers, we used Kd/
hu82m for affinity measurements. The influenza nucleopro-
tein Kd-restricted peptide (R6tzschke et al., 1990a) used in
the thermal stability studies was labeled to high specific activity
with 3H by catalytic exchange. Equilibrium dialysis was then
performed with empty Kd molecules and the 3 H-labeled
peptide, and the dissociation constant (KD) was obtained by
a Scatchard analysis of the data (Figure 2). Data from six
separate experiments were analyzed in a similar way, obtaining
a value for the KD of (6.9 h 2.3) X 10- 8 M.
A series of unlabeled peptides were next analyzed for their
ability to compete for binding of the 3H-labeled Kd-restricted
peptide. The concentrations of inhibitor peptides that
produced 50% inhibition of labeled peptide binding were
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FIGURE 2: Representative Scatchard analysis of 3H-labeled peptide
binding to empty Kd/hu#2m heterodimers. The dissociation constant,
KD, is calculated as the negative of the inverse of the slope of the line.
For this experiment, Ko = 6.0 x I0- M. Data from six separate
experiments were analyzed in a similar way, obtaining a value for
the KD of (6.9 d: 2.3) x 10-8 M.
determined by plotting the percent inhibition of binding versus
inhibitor concentration (Figure 3). The concentrations
resulting in 50% inhibition were then used to calculate
dissociation constants for the inhibitor peptides as described
in Materials and Methods. As a test of the validity of the KD
values derived from the inhibition studies, an unlabeled version
of the 3H-labeled peptide was used to compete with labeled
peptide for binding. The KD derived from the inhibition
analysis was 1.0 x 10-7 M as compared to the value of (6.9
+ 2.3) x 10-' M derived from the Scatchard analysis (Figure
2), demonstrating that the two methods of affinity constant
derivation give comparable values.
Peptides were synthesized that correspond to extensions of
the Kd-restricted influenza nucleoprotein derived peptide, with
additions at either the N- or C-terminus of the peptide.
Sequences of the peptides and their calculated KD values are
presented in Table 2. Additions to either end had a deleterious
effect on the binding affinity, although additions to the
N-terminus appeared to be tolerated slightly better. The KD
values derived for peptides with one or two amino acid
extensions at the N-terminus (peptides NP2 and NP3; Table
2) indicated that the binding was 750- and 2000-fold weaker
than the binding of the labeled peptide, while the binding of
a peptide with a single addition at the C-terminus (peptide
NP4) showed a weaker affinity than that of the peptide with
two additions at the N-terminus. Lengthening the peptide by
insertion of a single alanine residue in the middle of the
sequence (peptide NP9) had a less deleterious effect, lowering
the affinity by - 130 fold. The effects of deletion at the N-
or C-terminus followed an opposite trend, with a single deletion
.at the C-terminus (peptide NP7) having a less deleterious
effect on binding than a single deletion at the N-terminus
(peptide NP6), while a 7-mer peptide with an amino acid
deleted at both ends (peptide NP8) was not observed to inhibit
labeled peptide binding at concentrations up to 1 mM,
suggesting that the KD is _ 1 mM. Substitutions of the anchor
tyrosine residue at position 2 of the peptide also affected peptide
binding: the conservative substitution of phenylalanine for
tyrosine (peptide NP10) reduced the binding affinity by 65-
fold, whereas no binding was observed if the tyrosine was
replaced bythreonine(peptideNP 11). Analanine-substituted
peptide (peptide NP12) also failed to bind, in agreement with
results of others (Ojcius et al., 1993). Altering the anchor
residue by iodination diminished the ability of the peptide to
bind: a stoichiometrically labeled monoiodinated derivative
(peptide NP13) reduced the binding affinity by •-700 fold,
while the di-iodinated derivative (peptide NP 14) showed even
weaker affinity. When the C-terminal valine of the peptide
L1 Ln
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was replaced by polar and/or large residues, the effects
varied: replacement by charged residues interfered with
binding more than replacement by uncharged residues.
Replacements with both the small polar residue serine (peptide
NP15) and the large nonpolar residue tryptophan (NP16)
reduced the affinity by -400 fold, whereas replacement by
a positively charged (lysine; NP17) or negatively charged
(aspartic acid; NP 8) residue reduced the affinity by 5 orders
of magnitude or to the point that no inhibition was observed
with 1 mM peptide. By contrast to the effects of substitutions
at positions 2 or 9, single substitutions of residues at positions
3-7 with cysteines (peptides NP19 through NP23) had very
little effect on binding. However, simultaneous replacement
of the same five internal residues with prolines or glycines was
detrimental to binding, resulting in a 1000-fold reduction in
the binding affinity (five prolines; NP24) or a 2000-fold
reduction in binding affinity (five glycines; NP25). None of
the altered peptides in the influenza nucleoprotein analog series
were found to have an increased binding affinity. However,
two other Kd-restricted peptides of unrelated sequence (KDI,
Falk et al., 1991; KD2, Romero et al., 1991) were found to
bind with slightly higher affinities than the influenza nucle-
oprotein peptide to empty Kd heterodimers.
DISCUSSION
Class I MHC molecules bind peptides during their assembly
in the endoplasmic reticulum (Townsend & Bodmer, 1989);
thus purified preparations of class I molecules contain mixtures
of endogenous peptides. The presence of endogenous peptides
complicates binding measurements of defined peptides, largely
preventing binding, so that the percent of class I molecules
that can accept exogenous peptide is low (Chen & Parham,
1989). The ideal reagent for the comparison of binding
affinities of different peptides is a class I protein devoid of
endogenous peptides, i.e. an empty molecule. One strategy
to produce empty molecules has been to express the protein
in Drosophila cells (Jackson et al., 1992; Matsumura et al.,
1992b), with the assumption that invertebrate cells do not
have the proper mechanism for intracellular peptide loading
and that the resulting empty molecules will be stable at the
reduced temperature of insect cell culture (27 *C). Indeed,
class I molecules produced in Drosophila cells are capable of
quantitative binding of exogenous peptide (Matsumura et al.,
1992b), allowing the solution of several defined peptide/MHC
crystal structures (Fremont et al., 1992; Matsumura et al.,
1992a).
We previously reported an alternative method for producing
an empty form of the murine class I Kd heavy chain complexed
with human f#2m, referred to as Kd/hu02m (Fahnestock et
al., 1992). The method relies upon a biochemical separation
of endogenous peptides from denatured class I heavy and light
chains, followed by reassembly in the absence of added peptide.
Initial attempts to produce the completely murine heterodimer
(Kd/mf2m) were complicated by exchange of murine f2m
for endogenous hamster 02m and bovine #2m in the medium
(Fahnestock et al., 1992). For this study, we developed a
method to purify Kd/m#2m from CHO cells transfected with
the Kd and murine #2m genes and compared the percent of
purified Kd/m32m molecules that are occupied with peptide
to the percent of Kd/huf32m and Kd/hat2m that contain
peptide. While only ~ 30% of purified Kd/huf2m molecules
contain peptides (Fahnestock et al., 1992), the majority or all
of the Kd/m#2m and Kd/haf2m molecules were occupied
(Table 1). A possible explanation for this difference is related
to our observation that CHO cells transfected with the Kd and
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FIGURE 3: Determination of the 50% inhibition values for unlabeled peptides competing for binding of 3H-labeled peptide NPI to empty
Kd/huf2m heterodimers. Only the data points corresponding to between 10% and 90% inhibition are plotted, since this portion of the inhibition
curve can be approximated by a straight line (Miller, 1983). See Table 2 for peptide names and sequences. (A) Comparison of binding of
unaltered Kd-restricted peptides. (B) Comparison of binding of NPI analog peptides with additions to the N- or C-terminus. (C) Comparison
of binding of NPI analog peptides with insertions or deletions. (D) Comparison of binding of NPI analog peptides with altered residues at
the position 2 anchor residue. (E) Comparison of binding of NPI analog peptides with altered residues at position 9 (the C-terminus). (F)
Comparison of binding of NPI analog peptides with substitutions at positions 3-7. Data for peptides that did not compete for binding of3H-labeled NPI are not shown on the graphs.
human 32m genes consistently produce a much higher yield
of Kd than CHO cells transfected with the Kd and murine
32m genes: -100 mg of Kd/hug2m are recovered/L of
supernatant harvested from cells grown in a hollow fiber
bioreactor device (Fahnestock et al., 1992) compared to -- 2-3
mgofKd/m02mor 1-2 mgofKd/ha#2m. The high proportion
of empty Kd/hu02m molecules produced under these condi-
tions may reflect a limiting peptide supply inside the transfected
CHO cells under conditions of overproduction of a class I
molecule.
In a previous study, we found a surprisingly high thermal
stability for empty Kd/hu82m (Tm of the heavy chain
denaturation = 45 OC), which suggested that ,-75% of these
empty heterodimers are folded at 37 OC (Fahnestock et al.,
1992). These results contrast with studies of the behavior of
empty murine class I molecules at the cell surface, which
become undetectable at 37 OC by immunoprecipitation with
conformationally dependent antibodies unless stabilized by
appropriate peptides (Ljunggren et al., 1990; Schumacher et
al., 1990; Townsend et al., 1990). In order to ascertain if the
unexpected stability observed at temperatures above 37 OC
was due to increased stabilization caused by pairing of the
murine heavy chain with the human 02m light chain (Hochman
et al., 1988), we compared the thermal stability of empty
Kd/mf2m to empty Kd/huf2m. The stability profile ofempty
Kd/m#2m (Tm of the heavy chain denaturation = 42 *C)
revealed only a slight decrease in thermal stability compared
to empty Kd/hu#2m (Figure 1A,B). The equilibrium constant
derived at 37 OC (as described in Fahnestock et al., 1992)
suggests that -70% of the empty Kd/m#2m heterodimers
are folded at the physiological temperature, as compared to
- 75% of empty Kd/hu#2m heterodimers (Fahnestock et al.,
1992). These results are compatible with studies of a soluble
form of the murine class I molecule Kb produced in Drosophila
cells (Matsumura et al., 1992b). The Kb protein (which
behaves as if it is empty) was shown to be immunoreactive
with a conformationally sensitive antibody at temperatures
up to 47 OC, as long as the immunoprecipitation was carried
out in the absence of detergent. Upon addition of 1% Triton
X- 100, the immunoreactivity was lost at 37 OC. If the presence
of the detergent interferes with the association of the heavy
and light chains, the empty heterodimers would dissociate at
temperatures lower than 37 OC, reconciling our stability data
and the Kb data (Matsumura et al., 1992b) with observations
of the instability of empty cell surface class I molecules in
detergent lysates (Ljunggren et al., 1990; Schumacher et al.,
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Table 2: Analysis of Dissociation Constants of Kd-Binding Peptidesa
name length sequence category Iso (AM) KD (M) ratio (relative to NPI)
NPI 9 TYQRTRALV viral 6.9 x 10- 1
NP2 10 ATYQRTRALV NH 2 addition 338 5.2 X 10- 5  754
NP3 11 DATYQRTRALV NH 2 addition 754 1.2 X 10-4 1739
NP4 10 TYQRTRALVE COOH addition 1091 1.7 X 10-4  2464
NP5 13 DATYQRTRALVET both additions no binding
NP6 8 YQRTRALV NH 2 deletion 1441 2.2 x 10-4 3188
NP7 8 TYQRTRAL COOH deletion 414 6.4 x 10-5 928
NP8 7 YQRTRAL both deleted no binding
NP9 10 TYQRATRALV insertion 63 9.6 x 10-6 139
NPIO 9 TEQRTRALV Y - F 37 5.6 x 10-6 81
NPI 1 9 TTQRTRALV Y -T no binding
NP12 9 TAQRTRALV Y -A no binding
NPI3 9 TZQRTRALV monoiodinated 304 4.7 x 10-5 681
NPl4 9 T.XQRTRALV diiodinated 646 1.0 x 10-4 1449
NP15 9 TYQRTRALS V- S 197 3.0 x 10 -5 435
NP16 9 TYQRTRALW V - W 172 2.7 x 10-5 391
NPI7 9 TYQRTRALK V -K 1763 2.7 X 10- 3913
NPI8 9 TYQRTRALD V-D no binding
NP19 9 TYCRTRALV Q-C 2.2 1.9 x 10- 7  2.8
NP20 9 TYQCTRALV R-C 2.6 2.5 X 10- 7  3.6
NP21 9 TYQRKRALV T -C 1.4 6.2 x 10-8 0.90
NP22 9 TYQRTCALV R-*C 7.1 9.5 x l0- 7  14
NP23 9 TYQRTRCLV A-C 2.5 2.3 x 10-7 3.3
NP24 9 TYPPPPE LV five changes 438 6.8 X 10- 5  986
NP25 9 TYGGGGGLV five changes 956 1.5 x 10-4 2174
KDI 9 SYFPEITHI self 0.72 4.7 x 10- 0.68
KD2 9 SYIPSAEKI parasitic 0.49 3.2 x 10- 0.46
KD3 8 YIPSAEKI parasitic 2.5 2.3 x 10-7 3.3
a Peptide name, length, sequence, and category are summarized with the concentration at which peptide inhibited 50% of the binding of a 3H version
of NPI (150) (see Figure 3 for determination of Iso values). KD values are calculated as described in the Materials and Methods using the Iso values
and an average percent bound in the absence of inhibitor of 75.2% (average of 24 experiments with an error range of :10.7%). Peptide NPI isa known
K'-restricted epitope from influenza nucleoprotein (R6tzschke et al., 1990a), peptides NP2 through NP25 are analogs of NPI, peptides NPl3 and
NP14 are stoichiometrically iodinated (Tsomides & Eisen. 1993) forms of NPI, peptide KDI represents the sequence of a prominent self peptide eluted
from Kd molecules on P815 cells (Falk et al., 1991), and peptides KD2 and KD3 are nonamer and octamer versions of a Kd-restricted peptide from
P. berghei circumsporozoite protein (Romero et al., 1991). "No binding" indicates that a peptide did not inhibit binding of the 3H-labeled NPI peptide
at concentrations up to 1 mM.
1990; Townsend et al., 1990). Our data predict that at least the peptide transporter associated with antigen processing
the extracellular portion of an empty class I heterodimer can was disrupted (Ashton-Rickardt et al., 1993). Thus, there
exist as a native folded structure under physiological conditions. may be other mechanisms in addition to the decreased thermal
However, in vivo studies show that surface class I expression stability of empty class I molecules that keep large numbers
is greatly reduced in mutant mice in which the gene encoding of them from remaining at the surface of cells.
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Most studies to detect peptide binding to MHC molecules
have used peptides labeled by iodination of tyrosine residues
(Benjamin et al., 1991; Cerundolo et al., 1991; Christinck et
al., 1991), either within the antigenic peptide sequence or as
an N- or C-terminal addition. The iodine atom is large, similar
in size to a benzene ring (Bolton & Hunter, 1973). Thus
iodination would be expected to introduce steric hindrance as
well as ionic effects that may interfere with the hydrogen
bonding potential of the tyrosine hydroxyl. When a tyrosine
for labeling is added to the beginning or end of the peptide,
the peptide is no longer the optimal length for binding to class
I molecules (R6tzschke & Falk, 1991), and the interactions
of one of the termini with conserved pockets in the class I
peptide binding site (Fremont et al., 1992; Guo et al., 1992;
Madden et al., 1992; Matsumura et al., 1992a) are disrupted.
In addition, traditional iodination procedures label only - 1%
of the peptide molecules, leaving the remainder unlabeled,
complicating the interpretation of inhibition or other experi-
ments performed using a mixture. Other studies use peptides
modified by biotinylation at their N-termini (L6vy et al., 1991),
which would also disrupt interactions with the conserved pocket
for the N-terminal residue. To avoid these problems,
measurements of binding affinity were done with a peptide
labeled with 3H to high specific activity by catalytic exchange.
The binding affinity of a 3H-labeled Kd-restricted peptide
(peptide NP1, Table 2) from influenza virus nucleoprotein
(R6tzschke et al., 1990a) for empty Kd/hu1l2m heterodimers
was measured using equilibrium dialysis. The KD was
determined from multiple experiments as (6.9 ± 2.3) x 10- 8
M, in close agreement with the binding affinity of this peptide
reported by others (Ojcius et al., 1993) and with the value
(KD = 5.0 X 10- 8 M) derived from measuring the binding of
the same 3H-labeled peptide to lipid-linked Kd molecules
expressed on the surface of CHO cells (Fahnestock et al.,
1994).
Binding affinities of a series of unlabeled analog peptides
were determined by quantitation of inhibition of binding of
the labeled peptide. Using the knowledge of the three-
dimensional structures of class I molecules, we can attempt
to interpret differences in peptide binding affinities caused by
altering the Kd-restricted peptide on a structural basis.
Although the three-dimensional structure of Kd has not yet
been determined, the crystal structures of other class I
molecules have revealed a common mode of peptide binding
(Garrett et al., 1989, Saper et al., 1991; Fremont et al., 1992;
Madden et al., 1992; Matsumura et. al., 1992a: Zhang et al.,
1992), so that the structure of Kd and peptides bound to it can
be modeled upon that of known structures of Kb/peptide
complexes (Fremont et al., 1992; Matsumura et al., 1992a;
Zhang et al., 1992). To facilitate the following discussion,
a view of the peptide binding site of Kb, including the location
of pockets A-F, is shown in Figure 4.
Peptides with one or two extensions to the N- or C-terminus
of the Kd-restricted peptide were tested for binding affinity.
The particular residues introduced in the extended peptides
were those amino acids on either side of the nonamer peptide,
based upon the sequence of influenza nucleoprotein (Winter
& Fields, 1981). Extending the sequence beyond nine residues
significantly lowered the binding affinity, with additions at
the C-terminus being more detrimental to binding. The
specific residues added to the C-terminus of the peptide may
have had a particularly deleterious effect upon binding.
Peptides eluted from Kd proteins exhibit a preference for an
aliphatic amino acid at their C-terminus (Falk et al., 1991:
Romero et al., 1991). The side chain of the C-terminal peptide
Fahnestock et al.
FIGURE 4: View of the peptide binding site of H-2Kb with location
of pockets A-F labeled. Kd molecules, used in this study, are expected
to have a similar structure, although the side chains within some of
the pockets are different. This figure was generated with the program
SETOR (Evans, 1993), using coordinates from the Kb structure(Fremont et al., 1992; Zhang et al., 1992).
residue fits into pocket F, consisting in Kd of residues Ser 77,
Ala 81, Phe 95, and Phe 116, assuming a three-dimensional
structure similar to that of Kb (Fremont et al., 1992;
Matsumura et al., 1992a; Zhang et al., 1992). The residue
immediately following the end of the Kd-restricted nonamer
peptide in influenza nucleoprotein is an arginine (Winter &
Fields, 1981). If the additional length of the dodecamer
peptide is accommodated by bulging in the middle (Guo et
al., 1992), the charged C-terminal peptide residue would have
to fit into the F pocket, which is fairly hydrophobic in the Kd
molecule and therefore not likely to tolerate charged hydro-
philic groups. Indeed, in nonamer peptides, the substitution
of the final amino acid for a charged amino acid reduces the
KD to millimolar values (see peptides NP17 and NPl8, Table
2), demonstrating the poor complementarity in peptides of
optimal length between a charged C-terminal residue in the
peptide and pocket F in the Kd molecule. At the peptide
N-terminus, the side chain is exposed to solvent, with contacts
to pocket A made with main-chain peptide atoms (Fremont
et al., 1992; Matsumura et al., 1992a). If the Kd-restricted
peptide with a single extension at the N-terminus (peptide
NP2) binds such that its N-terminal residue is positioned in
pocket A and the extra length is accommodated with a bulge
in the middle, there would be a threonine at position 2 instead
of the required tyrosine. However, this mode of binding seems
unlikely since analysis of a nonamer peptide with a threonine
at position 2 (peptide NP 1) reveals that the threonine
substitution abrogates binding, even though both threonine
and tyrosine are polar amino acids containing a hydroxyl group.
These observations imply that peptides NP2 and NP3 retain
the anchor tyrosine in pocket B and that their extra length is
accomodated by extending the peptide beyond pocket A,
resulting in significantly lower affinities.
For peptide binding to Kb, the opposite phenomenon was
observed: peptides with extensions at the N-terminus bound
more poorly than peptides extended at the C-terminus
(Matsumura et al., 1992b). Thus it appears that individual
class I molecules will differ with regard to their tolerance for
extensions of peptides at the N- or C-terminus, with the
particular residues added being important determinants of
the binding affinity. Our data suggest that versions of a
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restricted peptide with extensions at either end bind with
significantly lower affinity and imply that adding extra residues
for the purpose of labeling a peptide should be avoided.
Although other class I molecules bind either octamer or
nonamer peptides (e.g. Kb; Fremont et al., 1992; Matsumura
et al., 1992a,b), deletion of either the N-terminal, C-terminal,
or both residues of the viral nucleoprotein nonamer peptide
greatly reduced the binding affinity. The N-terminal deletion
had the greater effect, presumably because the resulting
tyrosine at position I cannot simultaneously act as the first
residue by fitting into pocket A and as the anchor residue by
fitting into pocket B. Deletion of the C-terminal residue leaves
a leucine as the final residue, and this side chain fulfills the
Kd preference for aliphatic residues at this position to fit into
pocket F, but the affinity is still reduced by - 1000-fold
compared to the nonamer peptide. These observations imply
that, in vivo, Kd molecules present the nonamer version of the
influenza nucleoprotein peptide, with longer or shorter versions
being significantly reduced in affinity such that a low
percentage if any are presented. However, it is interesting to
note that an octamer and nonamer version of a peptide from
a Plasmodium berghei circumsporozoite protein (peptides
KD2 and KD3; Romero et al., 1991) do not show a large
discrepancy in binding affinities, with the octamer binding
with only 10-fold lower affinity than the nonamer. Thus for
Kd-restricted peptides, the preference for a nonamer or octamer
appears to be dependent on the particular peptide sequence.
As might be predicted, changing the tyrosine residue at
position 2 affects binding affinity. A peptide with phenyl-
alanine at this position (peptide NPIO) still binds with fairly
high affinity, as would be predicted by the finding that some
of the peptides eluted from Kd molecules contained phenyl-
alanine at position 2 (Falk et al., 1991). However, no
detectable binding is seen with an alanine-substituted peptide
(peptide NPI2) or a threonine-substituted peptide (peptide
NPI i). The poor binding of stoichiometric iodinated deriva-
tives (Tsomides & Eisen, 1993) of the Kd-restricted peptide
(peptides NPI 3 and NPI4) demonstrates that the addition of
the large iodine atom, as is commonly done for labeling
purposes, has dramatic effects on the binding properties of
the iodinated peptide compared to the peptide in its original
state. These results suggest that great care must be used in
labeling peptides for binding studies to make sure that the
labeled peptide is not chemically altered in such a way as to
change its binding properties.
The effects of single substitutions at the interior nonanchor
positions were next explored using five peptides in which the
natural residues at positions 3-7 were progressively altered
to cysteine. On the basis of the structure of Kb, positions 3,
6, and 7 are predicted to fit into pockets D, C, and E
respectively, while positions 4 and 5 are predicted to be solvent
exposed (Matsumura et al., 1992a). As expected. altering
peptide residues 4 and 5 to cysteine has very little effect upon
binding (peptides NP20 and NP21, Table 2). Changing
residues 3 and 7 (peptides NPl9 and NP23) also has only
small effect upon binding, suggesting that pockets D and E
in Kd can accommodate a number of different residues, in
accordance with sequencing data of peptides eluted from
purified Kd (Falk et al., 1991). At position 6, a 14-fold
reduction in affinity is seen upon substitution with cysteine
(NP22), suggesting a slight preference in pocket C for residues
other than cysteine. Indeed, in peptides eluted from Kd
molecules, lysine and phenylalanine were frequently found at
this position (Rammensee et al., 1993), implying that pocket
C prefers side chains larger than cysteine. Knowledge of the
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binding affinities of these cysteine-substituted peptides will
allow greater ease of interpretation of future work involving
covalent coupling of cysteine-substituted peptides to a solid
support for kinetic and equilibrium analyses of peptidebinding
using a surface plasmon resonance assay similar to that
reported by Khilko et al. (1993).
A previous report describes competitor analogs of Kd-
restricted peptides synthesized using polyproline or polyglycine
spacers (Maryanski et al., 1990). Dodecamer pentaproline
and pentaglycine analogs were found to compete for binding
ofa 13-mer Kd-restricted peptide, with the pentaproline analog
being the more active. We synthesized comparable nonamer
pentaproline and pentaglycine versions of the Kd-restricted
influenza nucleoprotein peptide (peptide NPl) in order to
measure their binding affinities for empty Kd. The penta-
proline (peptide NP24) and pentaglycine (peptide NP25)
analogs both showed reduced binding compared to the original
peptide, possibly confirming the importance of secondary
anchor residues in peptide binding, as was noted in the binding
of peptides to the human class I molecule HLA-A2 (Ruppert
et al., 1993). By contrast, the dodecamer pentaproline analog
of the 13-mer Kd-restricted peptide was as active as the original
peptide in a functional competition assay (Maryanski et al.,
1990), perhaps because this pentaproline analog was closer
to the optimal nonamer length than the original peptide. We
and the previous workers (Maryanski et al., 1990) both
observed that the polyglycine analog was a less effective
inhibitor, which may be due to the absence of a proline at
position 4 (a frequently observed residue at this position in
sequences of peptides eluted from purified Kd molecules;
Rammensee et al., 1993), or the greater flexibility allowed by
a series of glycines that could adversely affect binding.
The four unaltered Kd-restricted peptides (NPI, KD 1, KD2,
and KD3) represent three different sequences with only the
anchor positions in common, but all bind with fairly com-
parable affinities (KD = 10-7-10- 8 M). These values
represent slightly lower affinities than have been reported for
restricted peptides binding to Kb (Matsumura et al., 1992b)
but comparable or higher than affinities of HLA-A2 restricted
peptides (Ruppert et al., 1993). These results suggest that
optimal peptides binding to Kd and other class I molecules
have KD values in the nanamolar range and that alteration of
anchor residues or the length of the peptide drastically affect
the binding affinity.
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Summary: Maxadilan is a potent vasodilator peptide isolated from salivary glands extracts of the
hematophagous sand fly. Besides effects on the cutaneous vasculature. it has also been shown to
relax rabbit aortic rings while elevating levels of cAMP. As a result of the effects on the skin
and aorta, it was elected to undertake an examination of the tissue distribution of binding sites for
maxadilan. In addition to specific binding in rabbit aorta and spleen, binding was detected in
brain from various species including human, bovine, rabbit, rat and mouse with a kD of between
85 and 201 pM. Competitive displacement of [1251] maxadilan by a number of known
vasoconstrictor peptides, vasodilator peptides and small molecule receptor ligands did not occur
in the rabbit brain preparation. These results suggest the presence of specific binding sites in
mammalian tissue for maxadilan whose endogenous ligand remains unknown. r :995
Acaderic Press. Inc.
When an insect probes for a blood meal in skin, blood vessels are injured and the basic
hemostatic processes of vasoconstriction, coagulation, and platelet aggregation are initiated (1).
To overcome these processes and ensure success at obtaining blood, insects have developed a
number of potent anti-hemostatic compounds in their saliva. The ultimate goal of blood-feeding
by arthropods is to allow completion of the life cycle in which the female needs the stimulus of a
blood meal in order to lay eggs. Males typically do not blood feed. The small size of many
arthropods and rapidity with which they can feed suggests that these compounds are potent
substances that can be exploited in the development of pharmacological agents (1).
During the last several years a number of antihemostatic compounds have been found in
salivary glands of arthropods and it would appear that these substances aid in bloodfeeding.
Some of these substances inhibit platelet aggregation and others effect the coagulation pathway
(2). Two vasodilators have been described - a nitrosovasodilator from Rhodnius prolixus (3) and
maxadilan, a peptide from the sand fly Lutzornyia longipalpis. which acts directly on smooth
muscle cells (4, 5).
Maxadilan is a vasodilator peptide isolated from salivary gland extracts of the sand fly,
the vector of the protozoan disease leishmaniasis. Leishmaniasis occurs in many parts of the
*Corresponding author: (617) 726-4452,fax. ethan_lerner@cbrc.mgh.harvard.edu,e-mail.
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world including Central and South America, the Middle East and Indian subcontinent. The
disease is typically manifest as ulcers on the skin or infection of the liver and spleen. It has been
shown that sand fly salivary gland extracts exacerbate the infectious process by decreasing or
turning off the local immune response of the host. Besides its vascular effects, maxadilan has
immunomodulatory properties and appears to be the substance responsible for the exacerbative
effect (submitted). The ability of maxadilan to dilate blood vessels and modulate immune
responses is similar to the effects of CGRP, which has the additional property of being a
neuropeptide (6,7).
Maxadilan is produced as a 63 amino acid peptide which undergoes C-terminal cleavage
and amidation to a 61 amino acid peptide. It contains four cysteine residues which participate in
the formation of disulfide bonds between positions 1-5 and 14-51. The peptide acts to raise level
of cAMP in rabbit aorta suggesting that it interacts with a cell-surface receptor to mediate its
effects (5).
In previous studies, it was demonstrated that maxadilan was functionally active on rabbit
vessels and human skin but not on rat aorta, dog mesentery or pig or cow coronary vessels (5).
To obtain a picture of the tissue distribution of binding sites for this peptide, maxdilan was
stoichiometrically labeled with 125I to high specific radioactivities (2000-4000 Ci/mmol). The
iodinated peptide was incubated with membrane fractions prepared from a variety of rabbit
tissues. These results, which revealed binding to membrane fractions obtained from rabbit brain,
prompted an investigation of binding of maxadilan in the brain of various species.
Materials and Methods
Preparation of peptide - Recombinant maxadilan produced in E. coli contained the four
additional amino acid residues glycine, serine, isoleucine and leucine at the N-terminus as a
result of construction in the pGEX vector designed for cleavage with thrombin (8). Termed
"GSIL-maxadilan", it was purified to homogeneity using reverse phase HPLC.
Maxadilan was labeled with 1251 using lodo-Beads (Pierce, Rockford, IL). Free iodine
was removed by passing the peptide over a Sep-Pak C18 cartridge (Waters, Marlborough, MA)
and unlabeled peptide was separated from radiolabeled products by reverse phase HPLC (Figure
1) (9). Specific activity was 2000-4000 Ci/mmole in different preparations. As maxadilan does
not contain tyrosine residues, the reaction was carried out at pH 8.2 to promote iodination on
either or both of the histidine residues in the peptide (10). Biological activity was assessed by
stoichiometrically labeling maxadilan with cold 1271 followed by injection into rabbit skin. This
material maintained complete functional activity relative to the unlabeled peptide. It was
inferred from this result that the [125I] labeled material was also biologically active.
Preparation of membranes - Rat, rabbit, mouse and bovine tissue was obtained from Pel-Freez(Rogers, AR). Rat brain material was also obtained from animals purchased from Charles River
Laboratories. Human brain material was kindly provided by Tessa Hedley-Whyte of the
neuropathology service at MGH. Membrane fractions from these tissues were prepared as
described previously (11). Briefly, tissue was placed in 10 vol of ice-cold 50 mM Tris-HCl
buffer (pH 7.6) containing 0.32M sucrose, 5 mM EDTA, I mg/ml leupeptin, 1 mg/ml pepstatin A,
2 mg/ml bacitracin and 10 mg/ml phenylmethylsulfonyl fluoride. Tissue was homogenized with a
polytron PT 3000 (Brinkmann Instruments, Westbury, NY) for 30 s at power level 8 at 4"C. The
homogenate was centrifuged for 10 min at 1000 x g at 4"C. The supernatant was removed, and
the pellet resuspended in 15 ml of homogenizing buffer, homogenized again using the Polytron
at the same setting as the first homogenization, and the homogenate was centrifuged at 1000 x g
for 10 min at 4"C. The combined supernatant was centrifuged at 30,000 x g for 20 min at 4"C.
The pellet was washed two times by successive suspension in 50 mM Tris-HCl buffer containing
1 mM MgCI2, 0.3 % BSA, I mg/ml leupeptin, I mg/ml pepstatin A, 2 mg/ml bacitracin and 10
mg/ml phenylmethylsulfonyl floride.
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Figure 1. Maxadilan (100glg) was iodinated with 20mCi carrier-free Na1 251 and two lodo-Beads
in 0.1M sodium phosphate, pH 8.2. After removal of unreacted iodide, the peptide was loaded
on a reverse phase C4 column to separate labeled and unlabeled maxadilan. Since unlabeled
peptide is essentially removed by this method, specific radioactivity of the labeled peptide may
be calculated for that of carrier-free 1251.
Binding of [125 J] maxadilan - Crude membranes (250-400 mg) were incubated for 2 hr at 4"C in a
final volume of 0.5 ml consisting of 50 mM Tris-HCI buffer (pH 7.6) containing 0.3 % BSA,
ImM MgCl2.1 mg/ml leupeptin, 1 mg/ml pepstatin A, 2 mg/ml bacitracin, 10 mg/ml
phenylmethylsulfonyl fluoride and 70 pM maxadilan in the absence or presence of I ,M
maxadilan. At the end of incubation, samples were assayed for protein-bound radioactivity by
vacuum filtration through GF/C Whatman glass microfiber filters pretreated with 0.5%
polyethylenimine. Filters were then washed with 3 x 3 ml of incubation buffer at 4"C. The
radioactivity trapped on the filters was measured using a gamma counter. Non-specific ['25I]
maxadilan binding was determined by the addition of lM unlabeled maxadilan and represented
between 10-20% of total binding depending upon the tissue preparation. In the Results, specific
binding (total cpm minus non-specific cpm) is shown. Proteins were estimated by the method of
Bradford using bovine serum albumin as standard.
Chemicals - All peptides were obtained from Peninsula Laboratories (Belmont, CA All other
reagents were of analytical grade from Sigma (St. Louis, MO).
Results
Binding of maxadilan to rabbit tissues
Crude membrane homogenates were prepared from various rabbit tissues and assayed for
specific maxadilan binding (Figure 2). Specific binding was noted in aorta, spleen and brain.
Although binding to brain and spleen were seen consistently, binding to aorta was reproducible
for some but not all batches of iodinated maxadilan.
Binding of maxadilan to brain and spleen tissues
Because of the specific binding of maxadilan to rabbit brain and spleen, such tissues from
mouse, rat, bovine and human sources were examined. In all cases, specific binding was noted in
the brain (Figure 3). In the case of spleen, specific binding was only seen in rabbit. The
equilibrium binding and Scatchard analysis of rabbit brain membrane revealed a Kd of 136 pM
(Figure 4). The distribution of [1251] maxadilan binding sites was examined in rat brain, where
binding appeared to be essentially equal across the areas examined including cortex, hippocampus,
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Figure 2. Specific binding of maxadilan to membrane fractions of rabbit tissues. Crude
membrane fractions were prepared from the indicated tissues and incubated with [125lI
maxadilan and excess unlabeled peptide in a competition assay. Specific binding was noted in
brain and spleen.
brain stem, striatum and cerebellum (Figure 5). Specific binding was noted to all areas of human
brain examined including substantia nigra, pons, vermis (anterior portion), medulla/olive, thalamus,
parietal, hippocampus and cerebellar gray and white matters (data not shown). The least binding
40000
30000-
Bovine Rabbit Rat Mouse Bovine Rabbit Rat Mouse
Brain Spleen
Figure 3. Specific binding of maxadilan to membrane fractions of brain and spleen of various
species. Maxadilan binds to all brains examined,including mouse, rat, rabbit and bovine.
Binding to human brain occurred (not shown). Binding to spleen was only noted in rabbit tissue.
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Figure 4. Equilibrium binding and Scatchard analysis of binding of maxadilan to rabbit brain.
Saturable binding occurs and it appears that a single class of high affinity receptors is present.
was noted in cerebellar white matter. This finding correlates well with preliminary
autoradiographic data in which preferential binding occurs in gray matter of rat brain sections (not
shown). The dissociation constants and Bmax values for binding to brain membranes from the
CO HI BS ST CE
Figure 5. Specific binding of maxadilan to areas of rat brain. Crude membrane fractions were
prepared from the indicated tissues and incubated with [125I] maxadilan. CO - cortex, HI-
hippocampus. BS - brain stem, ST- striatum. CE -cerebellum.
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various species and rabbit spleen are noted in Table i. In all cases, it appears that maxadilan binds
with high affinity to a single class of receptors.
Competition between maxadilan and selected receptor ligands
Because maxadilan receptors were present both in the vasculature and the brain, a number
of known vasoconstrictor or vasodilator peptides, also found in brain, and small molecules were
examined for their ability to compete with binding of [1251] maxadilan to rabbit brain. In a
preliminary experiment, a competitive binding assay between a fixed quantity of [125I] maxadilan
and increasing concentrations of unlabeled maxadilan was performed (Figure 6) yielding an IC50
of maxadilan of 2.0+/-.3nM. None of the peptides tested, including, CGRP, amylin, endothelins
and VIP competed with maxadilan (Figure 7). Results of an analogous experiment performed
with small molecule agonists, including receptor ligands (carbachol, dopamine, histamine,
isoproterenol, norepinephrine, serotonin, glycine, GABA and glutamate) and ion channel
blockers (TEA, verapamil, and nifedipine) revealed that none of these small molecules had the
ability to compete with labeled maxadilan binding to brain extracts (not shown).
Discussion
Maxadilan is a vasodilator peptide present in sand fly salivary glands and the fly probably
uses this peptide as an aid in obtaining a blood meal. When sand flies transmit leishmaniasis,
their salivary gland extracts exacerbate this process and recent data indicates that maxadilan
participates in this process (submitted). To examine these cutaneous effects in more detail, an
iodinated probe would be useful. The data presented here reveal that the peptide has been
labeled to very high specific radioactivities (equimolar or greater ratio of 1251 to peptide) with
maintenance of biological activity despite a lack of tyrosines residues.
Because vasoactive molecules might be expected to interact with receptors in a variety of
tissues, a survey was undertaken to examine the binding of labeled maxadilan to membrane
fractions obtained from various rabbit tissues, instead of using this probe to assess binding sites
in skin by autoradiography. Maxadilan was found to bind with high affinity to a single class of
receptors in rabbit aorta and spleen and in brain from a variety of species. The binding in spleen
is consistent with the interaction of maxadilan with cells of the immune system. The studies in
rat and human brain reveal wide distibution of binding and the preferential binding to white
Table 1
Kd and Bmax of maxadilan binding to membrane homogenates
species/tissue Kd (pM) Bmax (fmol/mg protein)
mouse brain 90 80
rat brain 201 95
rabbit brain 136 58
rabbit spleen 85 14
bovine brain 103 27
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Figure 6 Competitive binding assay between labeled and unlabeled maxadilan in rabbit brain.
Crude rabbit brain membranes were incubated with [1251] maxadilan (70pM) and the indicated
concentrations of cold maxadilan. The IC50 for maxadilan was approximately 2nM.
matter suggests that maxadilan is interacting with a neuronal component in the central nervous
system. The result that a high degree of specific binding occurred in brain may, in retrospect, not
be surprising as a number of neuropeptides have vascular effects (12). However, the
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Figure 7. Competition between maxadilan and endogenous brain-derived peptides. The ability
of a number of peptides to compete with labeled maxadilan was determined by competition. i:
no peptide. 2: maxadilan, 3: VIP. 4: CGRP, 5: amylin. 6: neurotensin, 7: bradykinin, 8:
bombesin, 9: oxytocin, 10: somatostatin, 11: angiotensin II. 12: parathyroid hormone, 13:
substance P. 14: endothelin I, 15: endothelin II, 16: endothelin III.
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observations with maxadilan come from the opposite direction - it is an exogenous peptide
whose primary effect is exerted on the vasculature to aid in blood-feeding, and it incidentally
binds to brain membranes. A possible interpretation of the observation that some but not all
batches of the labeled peptide bind to rabbit aorta while all preparations bind to rabbit brain is
that subclasses of a "maxadilan receptor" exist and the iodination process alters the structure of
the peptide enough to "distinguish" between such subclasses.
That maxadilan raises levels of cAMP and appears to bind to a membrane receptor
suggests that it interacts with a member of the G-protein coupled receptor family (13). Coupled
with earlier observations of slight primary sequence homology to CGRP. it is possible that
maxadilan interacts with a subclass of CGRP or related receptors 14). It should be possible to
identify a cell line, rather than whole tissue, which binds and signals upon incubation with
maxadilan. Such a cell line would be useful for functional studies and for expression cloning of
a maxadilan receptor. It is also possible that a maxadilan-like peptide is present in mammals, a
scenario which could be examined in a number of ways including probing western blots of
mammalian brain using antibody to maxadilan or Southern blots of mammalian genomic
libraries using the gene encoding maxadilan as a probe. A positive result could lead to the
identification of a previously unknown neuropeptide.
Identification of a maxadilan receptor or endogenous maxadilan-like peptide will advance
our understanding of how this arthropod-derived molecule works. This result will shed light on
how maxadilan exerts its long-lasting erythema effect and elucidate further the potential
therapeutic role of this potent vasodilator.
Acknowledgments: We thank Herman Eisen for suggestions and help with iodinations. This
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EAL. TJT was supported by NIH Training Grant T32-CA09255.
References
1) Riberiro, J.M.C. (1987) Ann. Rev. Entom. 32, 463-478.
2) Grevelink, S.A., Youssef, D.E., Loscalzo, J, and Lerner, E.A. (1993) Proc Natl Acad Sci
(USA) 90, 9155-9158.
3) Ribeiro J.M.C., Hazzard J.M.H., Nussenzveig, R.H., Champagne, D.E., and Walker, F.A.
(1993) Science 260, 539-541.
4) Lerner, E.A. and Shoemaker, C.B. (1992) J. Biol. Chem. 267, 1062-1066.
5) Grevelink, S., Osborne, J., Loscalzo, J., and Lerner, E.A. (1995) J. Pharm Exp. Ther. 272, 33-37.
6) Nong, Y., Titus, R.G., Ribeiro, J.M.C., and Remold, H.G. (1989) J. Immunol. 143, 45-49.
7) Brain, S.D., Tippins, J.R., Morris, H.R., MacIntyre, I., and Williams, T.J. (1986) J. Invest.
Dermatol. 87, 533-536.
8) Ohnuma, M., Denda, S., Ehama, R., Kanda, F., Lerner, E.A., Tajima, M., and Morikawa, Y.
(1994) In Peptide Chemistry 1993 (Y. Okada, Ed.) 145-148. Protein Research Foundation,
Osaka.
9) Schumacher, T.N.M. and Tsomides, T.J. (1995) In Current Protocols in Protein Science (J.E.
Coligan, B. M. Dunn, H.L Ploegh, D.,W. Speicher and P.T. Wingfield, Eds.) 3.3.1-3.3.19. John
Wiley & Sons, New York.
10) Tsomides, T.J. and Eisen H.N. (1993) Anal. Biochem. 210, 129-135.
11) Wimalawansa, S.J. and El-Kholy, A.A. (1993) Neuroscience 54, 513-519.
12) Hbkfelt, T. (1991) Neuron 7, 867-879.
13) Strader, C.D., Fong, T.M., Graziano, M.P., and Tota, M.R. (1995) FASEB J. 9, 745-54.
Reprinted from Biochemical and Biophysical Research Communications 216, 234-241 (1995)
Copyright C 1995 Academic Press, Inc. Printed in U.S.A.
241
281
Vol. 216, No. 1, 1995
In Vitro Radiolabeling of Peptides
and Proteins
Radiolabeling of peptides or proteins is often performed to enhance the sensitivity of
detection, to quantitate the binding of peptides to other molecules, or for radioimmuno-
assays. The choice of radioisotope depends in part on the amino acid residue(s) to be
modified (Table 3.3.1). The most common and straightforward labeling strategy is
radioiodination with 125I because of its relative ease of use, the high resulting specific
radioactivities (curies per millimole), and the convenience of detecting y emissions.
Radioiodination may also be performed with I'lI, which has a shorter half-life (8 days
versus 60 days for '25), giving higher specific radioactivities but limiting the useful
lifetimes of the labeled products; in addition, 13'I has higher energy y emissions, necessi-
tating more shielding to protect workers.
Iodination at tyrosine or histidine residues using Iodo-Beads (Basic Protocol 1) is the most
convenient method, but chloramine T or Iodogen (Alternate Protocol 1) may give higher
recoveries when working with small quantities of peptide, and lactoperoxidase (Alternate
Protocol 2) results in less oxidative damage and lower specific radioactivities, and is
commonly used when labeling whole cells. Modifications for achieving equimolar or
higher (stoichiometric) rather than trace iodination are presented in Support Protocol 1,
and the optional separation of unlabeled peptide from iodinated products by HPLC is
described in Support Protocol 2. For peptides that do not contain tyrosine or histidine, or
in which labeling of these amino acid residues interferes with biological activity, '5I or
'31Imay be added onto primary amino groups (lysine residues and the peptide N-terminus)
using Bolton-Hunter reagent (Basic Protocol 2).
As an alternative to iodination, peptides or proteins can be labeled with "4C or 3H by
acetylation of primary amino groups using anhydride (Basic Protocol 3), by reductive
alkylation of primary amino groups using aldehyde and borohydride (Alternate Protocol
3), or by alkylation of cysteine sulfhydryl groups (Alternate Protocol 4). Figure 3.3.1
summarizes these radiolabeling strategies as well as the basic iodination reactions. Two
methods are available to label a peptide without altering its structure: 3H labeling by
catalytic reduction of (nonradioactive) '271-labeled peptide (Basic Protocol 4) and de novo
peptide synthesis using a radiolabeled form of any amino acid (Basic Protocol 5).
However, these methods tend to be more expensive and laborious. Finally, selective
Table 3.3.1 Peptide Labeling Strategies
Amino acid residue Label Method Reference
Tyrosine 1, 1311 Chloramine T, lodo-Beads Greenwood et al. (1963)
Histidine, tyrosine 1JI, 131I Chloramine T, lodo-Beads Wolff and Covelli (1969)
Tyrosine 125I, 131I Lactoperoxidase Marchalonis (1969)
Lysine, N-terminus l12, 1311 Bolton-Hunter Bolton and Hunter (1973)
Lysine, N-terminus '4C, 3H Anhydride Fraenkel-Conrat and Colloms
(1967)
Lysine, N-terminus '4C, 3H Aldehyde/borohydride Tack and Wilder (1981)
Cysteine 14C, 3H lodoacetic acid Chersi et al. (1988)
Tyrosine 3H Reduction of 127I Amersham or Du Pont NEN
literature
Any residue '4C, 3H Peptide synthesis Stewart and Young (1984)
Carbohydrate groups 3H Periodate/borohydride Gahmberg and Andersson
(1977)
Copyright @ 1995 by John Wiley & Sons, Inc.
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Figure 3.3.1 Common peptide radiolabeling reactions. (A) lodination on tyrosine. (B) lodination
on histidine. (C) Bolton-Hunter iodination on lysine and N-terminus. (D) Acetylation on lysine and
N-terminus. (E) Reductive alkylation on lysine and N-terminus. (F) Alkylation on cysteine.
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labeling at the N-terminus of a peptide can be performed during peptide synthesis
(Alternate Protocol 5).
All peptide labeling procedures described in this unit are also applicable to larger proteins;
however, with larger proteins there is increased potential for idiosyncratic results because
of tertiary structure and for undesired side reactions because of sensitive amino acid
residues (e.g., tryptophan, methionine, and cysteine in the case of oxidative iodinations).
To some extent these problems may be minimized through the use of milder labeling
procedures (e.g., lactoperoxidase-catalyzed iodination).
NOTE: Various methods for separating radiolabeling agents (e.g., free iodide) from
labeled peptide products are described in Basic Protocol 1 and in uNrrs 8.2 & 8.3, and any
of these methods may be used in conjunction with any of the radiolabeling protocols in
this unit. The choice of separation method should depend primarily on the properties of
the peptide or protein (see Critical Parameters, discussion of iodination work-up).
CA UTION: When working with 12I, 1311, 14C 311, or other radiochemicals, always observe
appropriate safety precautions, including the use of gloves (consider use of a glove box
with a charcoal filter, particularly for >5 mCi iodide), shielding, dosimetry monitoring,
and proper disposal of radioactive waste. Consult a radiation safety specialist to ensure
that all procedures are safe and in accordance with Nuclear Regulatory Commission
guidelines. Oxidation converts iodide to a volatile and hazardous form; peptide-bound
iodine is not volatile, but emits y radiation and remains a potential hazard. Be sure to
perform all steps that may give rise to volatile iodine in an externally vented hood. See
APPENDIX 2B for additional guidelines.
IODINATION AT TYROSINE OR HISTIDINE RESIDUES USING
IODO-BEADS
Iodo-Beads are nonporous polystyrene beads with an immobilized oxidizing agent
(N-chlorobenzenesulfonamide) capable of converting Na' 251 (or Na131I) to its reactive
form (Markwell, 1982). Iodination occurs by electrophilic addition to tyrosine at the two
positions ortho to the hydroxyl group, and on histidine at two imidazole carbon positions
(Means and Feeney, 1971; Fig. 3.3.1). After reaction of a peptide with oxidized iodide,
the mixture is transferred to a solid-phase extraction device (e.g., a Sep-Pak cartridge) to
remove free iodide from the labeled peptide.
Materials
Iodo-Beads (Pierce)
0.1 M sodium phosphate, pH 6.0 or pH 8.5
Carrier-free sodium iodide-125 (Na'lSI; Amersham, Du Pont NEN, or ICN
Biomedicals) or sodium iodide-131 (Na' 31I)
0.1 M sodium hydroxide
Peptide, ideally dissolved in 50.4 ml of water or 0. 1 M sodium phosphate
Methanol
HPLC solvent A: 0.1% (v/v) trifluoroacetic acid (TFA) in water
HPLC solvent B: 0.1% (v/v) TFA in acetonitrile
Filter paper
100-pl syringe with beveled tip, or hot pipettor (i.e., dedicated to radioactive use)
Luer-tipped syringes (1-, 5-, and 20-ml) and one 23-G needle
Solid-phase extraction device (e.g., Sep-Pak or Sep-Pak Plus C18 cartridge, Waters)
Polypropylene or other plastic tubes (12 x 75 mm)
3.3.3
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on tyrosine) or pH 8.5 (for labeling on histidine and tyrosine). Dry on filter paper and
add to 0.5 ml of same buffer in capped microcentrifuge tube or small reaction vial.
For trace labeling use two lodo-Beads; for stoichiometric labeling more may be
needed (see Support Protocol 1).
lodo-Beads are compatible with most salts (including azide), chaotropic agents, and
detergents, but not with reducing agents or organic solvents that dissolve polystyrene
such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). lodo-Beads must
be stored in the presence of desiccant, and have a manufacturer-suggested shelf life of
I year.
2. Add Na'"i (or Na'31 I) to lodo-Beads in the reaction tube using a 100-gl syringe with
beveled tip or a hot pipettor. Cap tube and wait 5 min at room temperature, agitating
the mixture occasionally. Rinse syringe with 0.1 M sodium hydroxide (125I is less
volatile at high pH) and then with water before storing.
The amount of radioactive iodide depends largely on the desired specific radioactivity,
subject to safety and cost limitations: 1 to 5 mCi is typical. Use afresh batch to minimize
loss of radioisotope as volatile molecular iodine. Na1251 is supplied in various concen-
trations of NaOH; the more dilute NaOH solutions are preferable since they are less
likely to alter the pH of the reaction.
3. Add peptide to the reaction. Cap tube and wait 30 min, agitating occasionally.
The amount of peptide is inversely related to the final specific radioactivity, unless
iodinated products are separated from unlabeled peptide (see Support Protocol 2);
0.05 to 2.0 mg is typical. Reaction time can be 45 min or longer if desired, or just 5 to
10 min if oxidation-sensitive residues in the peptide (tryptophan, methionine, cysteine)
are of concern, and should be optimized empirically if needed.
4. During the iodination reaction (or before if more convenient), prepare a Sep-Pak C 18
cartridge by attaching a syringe and passing 5 ml methanol through the cartridge,
followed by 5 ml water and 10 to 20 ml HPLC solvent A. Maintain a flow rate of -2
ml/min, do not reverse the orientation of the cartridge when changing solvents, and
avoid introducing air bubbles or allowing the cartridge to dry out.
Although this Sep-Pak method offers the most efficient separation of unbound radio-
active iodide from the peptide, anion-exchange (UNTT 8 2) or gel-filtration (UNrT 8.3)
chromatography may be used as alternatives, especially for larger peptides at risk of
denaturation under the conditions used in steps 4 to 8 (see Alternate Protocol 1, steps
1 and 4). Dialysis is another alternative for large peptides, but takes much longer
5. Remove the mixture from the reaction tube using a 1-ml syringe fitted with a 23-G
needle. Carefully remove the needle and slowly load mixture onto the preconditioned
Sep-Pak cartridge, collecting the eluate into a radioactive liquid waste container.
6. Wash Sep-Pak cartridge with 20 ml HPLC solvent A, collecting the eluate as
radioactive waste. Neutralize waste with 5 ml of 0.1 M sodium hydroxide.
Unbound radioactive iodide will pass through the Sep-Pak cartridge under these
conditions, while peptide will remain in the cartridge.
7. Elute two fractions from the Sep-Pak cartridge into 12 x 75-mm plastic tubes, the
first using 4 ml of a 1:1 mixture of HPLC solvent A and HPLC solvent B, and the
second using 4 ml HPLC solvent B.
Usually the first tube contains most of the labeled peptide, but a two-step elution
improves overall recovery. Because unbound iodide is now removed, the tubes may be
transferred out of the glove box or other iodination facility, as long as appropriate
shielding is maintained
i I -- *..U 1-1 ,r ) I A A.. -T e I.
8. Dry the tubes in a Speedvac evaporator. Redissolve in water or desired buffer and
pool the two fractions.
9. To determine the specific radioactivity of the labeled peptide, estimate peptide
recovery or analyze an aliquot of the sample for peptide concentration (e.g., by a
colorimetric assay) and simultaneously determine cpm (in a y-radiation counter,
possibly after serial dilutions in the presence of a carrier protein to reach a level of
radioactivity within the linear counting range of the y counter).
Specific radioactivity (in cpm/npg) = measured radioactivity (in cpm/pl) + peptide
concentration (in tg/pl). To convert to millicuries, use 1 mCi = 2.22 x 109 dpm and
cpm = dpm x counting efficiency of y counter (often 50% to 75%, depending on the
instrument).
Alternatively, if iodinated products are to be separated from unlabeled peptide by
HPLC and the molar ratio of incorporated iodide to peptide is known (or estimated),
the specific radioactivity of the peptide may be calculated from that of carrier-free 1251
(or 1311; see Support Protocol 2).
IODINATION AT TYROSINE OR HISTIDINE RESIDUES USING
CHLORAMINE T OR IODOGEN
Instead of using Iodo-Beads, Na125I can be oxidized to its reactive form using soluble
chloramine T (N-chlorobenzenesulfonamide sodium salt; Greenwood et al., 1963), the
solid-phase reagent Iodogen (1,3,4,5-tetrachloro-3a,6a-diphenylglycoluril; Fraker and
Speck, 1978), or the enzyme lactoperoxidase (see Alternate Protocol 2). Although slightly
less convenient than Iodo-Beads, these methods may give higher recoveries when
working with small quantities of peptide (<0.05 mg), which can adsorb to Iodo-Beads.
The reagents are inexpensive and stable, and with lodogen or lactoperoxidase, expose the
peptide to relatively mild reaction conditions.
Additional Materials (also see Basic Protocol I)
Anion-exchange resin, e.g., Dowex 1-X8, chloride form, 100 to 200
mesh (Bio-Rad)
BSA solution: 1.0 mg/ml BSA in PBS, with 0.02% sodium azide (NaN 3)
1.0 mg/ml chloramine T in 0.1 M sodium phosphate, prepared immediately before
use
lodogen (Pierce), dichloromethane, and glass tubes or vials (optional alternate to
chloramine T)
Saturated solution of tvrosine in water (-0.4 mg/ml at 250C)
2.5 mg/ml sodium metabisulfite (NazSzOs) in 0.1 M sodium phosphate, prepared
immediately before use (optional alternate to tyrosine solution)
Pasteur pipet or 1-mi syringe with glass wool plug inserted at bottom
Gel-filtration column, e.g., Sephadex G-10 or G-25 (Pharmacia Biotech), or
Excellulose Desalting Column (Pierce; optional alternate to anion-exchange
column)
1. Suspend Dowex resin in water and pour into plugged Pasteur pipet. Wash with 220
ml BSA solution. Alternatively, equilibrate a gel-filtration column with BSA solution.
Avoid introducing air bubbles into the column and do not allow column to dry out.
Because short peptides (<20 residues) are difficult to separate completely from
unbound radioactive iodide by gel-filtration columns, an anion-exchange column may
be preferred. Highly negatively charged (e. g., phosphorylated) peptides and very short
peptides (<10 residues) may be retained on an anion-exchange column and should
therefore be desalted by solid-phase extraction (see Basic Protocol 1). The desalting
hU.FlU d.ILU hSIS ld b b. i L I-d__
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2a. Chloramine Tprocedure: Place peptide in a small tube and buffer with 0.1 M sodium
phosphate, pH 6.0 or 8.5 (see Basic Protocol 1, step 1); bring the total volume to 100
to 300 gl. Add Na'251 (or Na'3 11), followed by 10 jil chloramine T (freshly prepared),
and mix. Wait I min for reaction to occur.
2b. lodogen procedure:Add sodium iodide to the peptide (as described in step 2a) in a
glass tube previously coated with the solid-phase reagent Iodogen by dissolving the
solid in dichloromethane and blowing off the solvent under a stream of dry nitrogen.
Wait 10 min at room temperature.
lodogen-coated tubes may be stored for many months at room temperature in a
desiccator, protected from light. Because the oxiding agent is water insoluble, peptide
damage is kept to a minimum.
3. Add 50 pA saturated tyrosine solution to quench the reaction.
Alternatively, the reaction may be terminated by adding 10 pl sodium metabisulfite,
although this reducing agent is potentially more damaging to peptides.
4. Load mixture onto a Dowex or gel-filtration column and collect 0.5-ml fractions in
12 x 75-mm plastic tubes, using BSA solution for elution. Monitor fractions with a
hand-held y counter, or count 1-gtl aliquots of each fraction in a y counter to locate
the peptide-containing fractions.
Radiolabeled peptide should pass through the column; unreacted iodide is retained
longer and need not be eluted. Dispose of the entire column as radioactive sharps
waste.
IODINATION AT TYROSINE OR HISTIDINE RESIDUES
USING LACTOPEROXIDASE
Although the degree of oxidative damage to peptides undergoing iodination is difficult to
predict, the lactoperoxidase method results in less oxidative damage than chemical
oxidative procedures (Marchalonis, 1969). lodination is confined to tyrosine. Specific
radioactivities are likely to be lower by this method. Because lactoperoxidase (mass
77,500 Da) will be iodinated during the reaction, it should be used only if the labeled
peptide or protein of interest can be separated from labeled lactoperoxidase by gel
filtration (uNrr8.3), ion-exchange chromatography (UNIT.&2), or some other means. Alter-
natively, it may be possible to use lactoperoxidase coupled to beads, or biotinylated
lactoperoxidase and avidin-coated beads to remove the labeled enzyme (Sigma). Because
the enzyme does not gain access to the cytoplasm, lactoperoxidase-catalyzed iodination
is useful for selectively radiolabeling membrane proteins on whole cells, provided iodide
concentrations are kept low and the proportion of dead cells is very small (Marchalonis
et al., 1971).
Additional Materials (also see Basic Protocol 1)
0.2 mg/ml lactoperoxidase in PBS
0.01% hydrogen peroxide (H20 2) in PBS (diluted from 30% stock immediately
before use)
2 U/ml glucose oxidase in PBS and 0.1 M D-glucose in PBS (optional alternate
to H202)
1. Place peptide in a tube with PBS, ideally at _1.0 mg/ml in a small volume.
2. Add 10 pl of 0.2 mg/ml lactoperoxidase.
Azide should not be present in the reaction as it inhibits lactoperoxidase.
3. Add Nal25I (or Na' 31I), cap tube, and mix.
4. Add 10 gl of H20 2. Wait 10 min at room temperature.
The H20 2 concentration is critical and may need fine-tuning for best results. Alterna-
tively, use a coupled glucose/glucose oxidase system to generate H202 in situ, i.e., treat
with 10 ul of glucose oxidase and 10 p1 of glucose for 10 min at 40C (Hubbard and
Cohn, 1975).
5. Terminate the reaction and remove unbound radioactive iodide (see Alternate Proto-
col 1, steps 1, 3, and 4).
EQUIMOLAR IODINATION TO GIVE HIGH YIELDS OF PRODUCT
Iodination of microgram to milligram amounts of a peptide using low millicurie amounts
of carrier-free Na'lSI (or Na' 31I), such as those suggested in Basic Protocol 1 and Alternate
Protocols 1 and 2, results in trace labeling (iodination of only a small fraction of the peptide
molecules). For example, in a reaction between 1 mCi of '~I (-600 pmol) and 500 gg of
a peptide of mass 1000 Da (500 nmol) or a protein of mass 100,000 Da (5 nmol, or -200
nmol of tyrosine residues on average), there is at most only enough 125I to label well under
1% of the tyrosines. For proteins, trace labeling is often advantageous as it minimizes the
chance that the protein's activity will be lost (Eisen and Keston, 1949; Hunter and
Greenwood, 1962); moreover, a sizable fraction of protein molecules will have one iodine
atom on at least one of its tyrosines. However, for short peptides over 99% of the molecules
remain unmodified, greatly diluting the specific radioactivities that are possible and
complicating the interpretation of experiments in which labeled and unlabeled peptides
differ significantly in their activities (see Support Protocol 2).
To label a higher proportion of a peptide, nonradioactive Na'27I ("carrier") can be added
to 125I, giving a higher yield of iodinated product and resulting in a mixture of chemically
equivalent 125s- and '"I-labeled peptides. Perform all steps for iodination as described
using lodo-Beads (see Basic Protocol 1) or chloramine T or lodogen (see Alternate
Protocol 1), with two modifications. First, add 0.1 M Na'271 in water to the Na25I prior
to using Na'"I in the indicated step. The amount of '271 should be in moderate molar
excess over the peptide (2- to 5-fold) to achieve high yields of iodinated products (70%
to 95%). Further increasing the amount of 1271 unnecessarily diminishes the products'
specific radioactivities: e.g., at a 4-fold molar excess of '"I, only up to 25% of the 12sI
added can be incorporated, at a 10-fold molar excess only 10% can be incorporated. etc.
Second, a sufficient number of Iodo-Beads (or other oxidizing reagent) must be used to
oxidize the total iodide (essentially 1271). Use the manufacturer-determined oxidizing
capacity of 0.55 ± 0.05 imol per Iodo-Bead. Note that Iodo-Beads rapidly develop a
yellow-brown color when stoichiometric amounts of iodide are added; failure to observe
this color indicates deterioration of the beads.
For maximum specific radioactivities, label a small amount of peptide (e.g., 30 jg) with
up to an equimolar amount of 125I (e.g., 40 mCi) and separate the unlabeled peptide from
iodinated products by HPLC (see Support Protocol 2).
It is also possible to iodinate with 127I only, in which case the products will be nonradio-
active but chemically equivalent to the corresponding radiolabeled products. This ap-
proach is useful for practicing the iodination procedure and for assessing the effects of
iodination on a peptide's activity (Tsomides and Eisen, 1993), as well as for preparing an
'
27I-labeled peptide to be reductively tritiated (see Basic Protocol 4).
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Figure 3.3.2 Stoichiometric iodination of
the eight-residue peptide LSPFPYDL and
HPLC separation of the unlabeled starting
material (peak 1) from monoiodinated
(peak 2) and diiodinated (peak 3) products.
Two milligrams of peptide were iodinated
with 20 mCi Na251l and 5 lpmol Na' 27 at
pH 7.0 using six lodo-Beads, injected on a
Vydac C4 semipreparative column, and
eluted with an acetonitrile gradient of
1%0/min at a flow rate of 3 ml/min. The
specific radioactivities of the three peaks
were <10 s cpm/rg, 2.1 x 107 cpm/tg, and
4.6 x 107 cpm/tg, respectively.
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SEPARATION OF UNLABELED PEPTIDE FROM IODINATED
PRODUCTS BY HPLC
Whether trace iodinated with '25I only or stoichiometrically iodinated with a mixture of
125I and 'aI, some peptide will remain unlabeled, and it may be desirable to separate this
unlabeled component from the iodinated products. To obtain chemically homogeneous
radiolabeled peptides, iodinated products can be resolved from each other and from
unlabeled peptideby reversed-phase HPLC. (This optional procedure is distinct from the
obligatory separation of peptide from unbound radioactive iodide by solid-phase extrac-
tion, anion-exchange chromatography, gel filtration, exhaustive dialysis, or other means
as detailed in steps 4 to 8 of Basic Protocol 1.) Because iodine is a bulky, hydrophobic
atom relative to hydrogen, the retention times of iodinated peptides will be greater than
those of their unlabeled counterparts on reversed-phase HPLC columns (e.g., C 18 for
short peptides, C4 for longer or more hydrophobic peptides).
In most iodinations, more than one product will be generated, even if the peptide has only
a single tyrosine (see Fig. 3.3.1). Because the pKa of monoiodotyrosine is lower than that
of tyrosine (Edelhoch, 1962), electrophilic addition of the second iodine atom may be
accelerated relative to the first; however, this reaction will not go to completion even when
iodide is present in molar excess over the peptide. When more than two or three iodinatable
residues (tyrosine and histidine) are present (as in a protein), the labeled products may be
too complex to allow for individual resolution by HPLC, but unlabeled peptide can still
be removed from the radiolabeled mixture. Even peptides as long as 50 to 100 residues
can be separated from their iodinated derivatives by reversed-phase HPLC.
For peptides with a single iodinatable residue, the two products are usually easily
separated by HPLC and can readily be identified by their specific radioactivities, which
are in the ratio 1:2 formonoiodinated and diiodinated peptide, respectively. Figure 3.3.2
shows the result of stoichiometrically labeling 2.0 mg of an eight-residue peptide with 20
cpm
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mCi Na't2I mixed with 5 tmol Na'27I and separating the unreacted, monoiodinated, and
diiodinated products by HPLC. If Edman degradation is available, labeled products may
be characterized directly by detecting the monoiodinated and diiodinated derivatives of
tyrosine and/or histidine (Tsomides and Eisen, 1993). Note that peptides containing
tryptophan, methionine, or cysteine residues may undergo oxidation during iodination.
The resulting oxidized products (both radiolabeled and unlabeled) may appear as separate
peaks on HPLC, complicating the identification of products.
When carrying out stoichiometric iodination with a mixture of 1~I and '"I, specific
radioactivities of the product mixture or of individual HPLC-purified products can be
measured as described for the Iodo-Beads procedure (see Basic Protocol 1, step 9).
However, when trace labeling with "'I only and removing unlabeled peptide by HPLC,
specific radioactivities may simply be calculated as the specific radioactivity of carrier-
free 125I (-2000 Ci/mmol) multiplied by the molar ratio of 125I to peptide (e.g., I for a
monoiodinated derivative, 2 for a diiodinated derivative, etc.). When a mixture of
'SI-labeled products is separated from unlabeled peptide by HPLC but not resolved into
its individual components, the same calculation may be applied by taking the average
molar ratio of '25I to peptide to be the number of iodinatable residues. For example, the
specific radioactivity of a peptide of mass 1000 Da with two tyrosine residues that is
labeled with '•I and separated from unlabeled peptide by HPLC is -5 x 109 cpm/Jtg,
assuming an average of two •"I per labeled peptide.
NOTE: Although HPLC fractions can be analyzed for radioactivity by transferring them
to a y counter, it is preferable to use an on-line radioisotope detector connected in series
with an ultraviolet absorbance detector (see Fig. 3.3.2).
IODINATION AT LYSINE RESIDUES OR N-TERMLNUS USING
BOLTON-HUNTER REAGENT
Many peptides do not contain tyrosine or histidine. Other peptides' function may be altered
if crucial tyrosine or histidine residues are iodinated or if damage to oxidative-sensitive
residues occurs during iodination. An alternate strategy is to label primary amino groups
on lysine residues and/or at the N-terminus of the peptide using Bolton-Hunter reagent
3-(4-hydroxyphenyl)propionic acid N-hydroxysuccinimide ester (Bolton and Hunter,
1973). This reagent introduces a side chain similar to that of tyrosine (see Fig. 3.3.1). Of
course, this method carries the potential drawback of altering peptide function if lysine
residues (or the N-terminus) are critical for activity; unlike the methods above, peptide
charge will be decreased by one unit for each site modified (at pH values below the amino
group's pK. value).
Because lysine's e-amino group and the N-terminal a-amino group have different pK,
values (-10 vs. 8 to 9), it is possible, in principle, to achieve selective labeling by adjusting
the pH (lower pH should favor the N-terminus). However, this is difficult in practice, and
a mixture of products is to be expected from lysine-containing peptides unless the
N-terminal residue is proline (secondary amine) or a protecting group is present on either
lysine or the N-terminus.
'•I-labeled Bolton-Hunter reagent is commercially available in monoiodinated (-2000
Ci/mmol) or diiodinated (-4000 Ci/mmol) form. A cost-saving modification is to prepare
11I-labeled Bolton-Hunter reagent from the less expensive unlabeled reagent by iodin-
ation using Iodo-Beads (see Basic Protocol 1) or chloramine T (see Alternate Protocol 1)
followed by extraction of the product into anhydrous benzene. (In this case it is crucial
to work quickly to minimize hydrolysis, and specific radioactivities will be lower unless
unreacted Bolton-Hunter reagent is removed from the labeled product.) Alternatively, the
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peptide can first be modified with unlabeled Bolton-Hunter reagent and then
radioiodinated using any of the methods previously described. Because '25I-labeled
Bolton-Hunter reagent suffers some degradation by competing hydrolysis during its
reaction with peptide, this alternate approach gives a higher incorporation of radioactivity;
however, it also results in the radiolabeling of any tyrosine or histidine residues present
in the peptide, as well as exposure of the peptide to oxidative conditions.
Materials
0.1 M sodium borate, pH 8.5
0.1% (w/v) gelatin in 0.1 M sodium borate, pH 8.5
'
25I-labeled Bolton-Hunter reagent (Amersham, Du Pont NEN, or ICN
Biomedicals); or substitute unlabeled Bolton-Hunter reagent and iodinate later
Peptide, ideally >1 mg/ml in •100 .1 of 0.1 M sodium borate, pH 8.5
1 M glycine in 0.1 M sodium borate, pH 8.5
Gel-filtration column, e.g., Sephadex G-10
Dry mtrogen tank 
and outlet tubing 
fitted with needle
Polypropylene or other plastic 
tubes (12 x 75 m )
1. Equilibrate a gel filtration column with 0.1% gelatin/0.l M sodium borate, pH 8.5,
to prevent loss of radiolabeled peptide by nonspecific adsorption.
BSA is not recommended as a carrier protein in place ofgelatin because albumin binds
to Bolton-Hunter reagent. If gelatin is undesired in the final preparation (e.g., iodin-
ation is to be performed later), condition the column and then reequilibrate in buffer
of choice. Alternatively, use a Sep-Pak cartridge instead of gel filtration to separate
by-products and salts from the labeled peptide (see Basic Protocol 1, steps 4 to 8).
2. Immediately prior to use, evaporate '25I-labeled Bolton-Hunter reagent to dryness by
inserting a needle through the rubber septum and admitting a gentle stream of dry
nitrogen, using the manufacturer-supplied charcoal trap as a vent to contain any
released volatile radioiodine. Do not splash solution onto upper parts of the vial.
If using unlabeled Bolton-Hunter reagent, prepare a stock solution in anhydrous
organic solvent and dilute into borate buffer at the time of reaction to achieve a 3- to
5-fold molar excess over peptide. Unlabeled Bolton-Hunter reagent is also available
as a water-soluble (sulfo) derivative (at higher cost), obviating the need for organic
solvent and offering an advantage for labeling cell surface proteins because the sulfo
derivative is membrane impermeable.
3. Chill peptide in borate buffer to 00 C on ice. Add peptide to vial containing dried
'
25I-labeled Bolton-Hunter reagent (or freshly dissolved unlabeled Bolton-Hunter
reagent) and wait 15 to 30 min at 00C, agitating the reaction occasionally.
Incorporation is greatest when using high peptide concentrations. Phosphate or
bicarbonate buffers, pH 8.5, may be used instead of borate, but avoid amine-containing
buffers (ammonium, glycine, Tris) as well as azides and thiols. Being an N-
hydroxysuccinimide ester, Bolton-Hunter reagent is sensitive to hydrolysis, with a
half-life of a few hours at pH 7.0 and only -10 min at pH 8.5; however, its reaction
with amino groups is greatly accelerated at the higher pH since more amine is in the
deprotonated (active) form.
4. Add 100 pl of 1 M glycine in 0.1 M sodium borate, pH 8.5, to quench the reaction
and wait 5 min, or use a corresponding amount of Tris or any other amine for
quenching.
Longer incubations at O*C (>4 hr) may improve yields and obviate the need for
quenching by consuming all of the reagent.
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5. Load mixture onto gel filtration column and collect 0.5-ml fractions in 12 x 75-mm
plastic tubes, using borate (or other) buffer for elution. Monitor fractions with a
hand-held y counter, or count aliquots of each fraction in a y counter to locate the
peptide-containing fractions.
6. Resolve products by HPLC if desired and determine specific radioactivities (see
Support Protocol 2).
14C OR 311 LABELING AT LYSINE RESIDUES OR N-TERMINUS BY
ACETYLATION USING ANHYDRIDE
There are two main advantages of labeling with 14C or 3H instead of '"I. First, for peptides
that are unacceptably altered as a result of iodination, different sites may be targeted for
modification (i.e., lysine or cysteine), or the peptide may even be labeled without changing
its structure by replacing carbon or hydrogen atoms with the corresponding radioisotope
(see Basic Protocol 4 and Basic Protocol 5). Second, the half-lives of 1'4C and 'H are much
longer than that of 'I (5760 and 12.26 years, respectively, vs. 60 days), so labeling need
not be done often. However, the specific radioactivities of peptides labeled with ' 4C or
3H are generally correspondingly lower, and the labeling techniques are not as widely
applied as radioiodination. Also, counting P3 emissions involves the use of a liquid
scintillation cocktail and is therefore slightly more cumbersome than counting y emis-
sions.
Acetylation with [14C]- or [3H]anhydride is a simple reaction that will modify amino
groups (lysine and/or the N-terminus of a peptide; Fig. 3.3.1; Fraenkel-Conrat and
Colloms, 1967). The most common side reaction is O-acetylation of tyrosine, which is
reversible under mild alkali conditions (Means and Feeney, 1971).
CAUTION: All procedures should be carried out in an externally vented hood.
Materials
Saturated sodium acetate solution
Peptide, ideally Ž1 mg/ml in <100 pl H,O or sodium acetate
['4C]- or [3H]acetic anhydride (Amersham, Du Pont NEN, ICN Biomedicals,
or Sigma)
Acetic anhydride, unlabeled (optional)
1. Add 1 vol of saturated sodium acetate solution to the peptide (unless already in this
buffer) and cool to 00 C on ice.
2. Add [' 4C]- or [3H]acetic anhydride, with or without 2 molar equivalents of additional
unlabeled acetic anhydride, in four equal installments at 10- to 15-min intervals.
Because the anhydride is rapidly hydrolyzed, addition over several installments is the
preferred method. The use of excess unlabeled anhydride increases the extent of
reaction but dilutes the specific radioactivity of the products (analogous to stoichio-
metric vs. trace iodination; see Support Protocol 1).
3. Remove by-products by gel filtration (UNIrr.a), dialysis (APPENDIX3B), or solid-phase
extraction (see Basic Protocol 1, steps 4 to 8), and count fractions in an appropriate
liquid scintillation cocktail.
Resolution of individual products may be possible by HPLC (see Support Protocol 2).
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14C OR 3H LABELING AT LYSINE RESIDUES OR N-TERMINUS
BY REDUCTIVE ALKYLATION
An alternative two-step procedure used to label peptides is treatment with an aldehyde
followed by reduction of the resulting Schiff base with sodium cyanoborohydride (Fig.
3.3.1; Tack and Wilder, 1981; Jentoft and Dearborn, 1983). Most aldehydes give the
monosubstituted alkylamine product, but formaldehyde goes on to give the dimethyl
product. 14C can be incorporated via the aldehyde, or 'H can be added via labeled sodium
cyanoborohydride. The latter gives higher specific radioactivities, reportedly Ž.50
Ci/mmol. One advantage of this approach over acetylation is that the net charge on amino
groups is not substantially altered (there is only a small change in pKa value).
CAUTION: All procedures should be carried out in an externally vented hood.
Materials
0.2 M sodium borate, pH 9.0
Peptide, ideally 21 mg/ml in 0.1 to 1.0 ml of 0.2 M sodium borate, pH 9.0
[3H]sodium borohydride (Amersham, Du Pont NEN, or ICN Biomedicals) or
[3H]sodium cyanoborohydride (Amersham)
0.01 M NaOH
37% (12.4 M) formaldehyde stock
["C]formaldehyde and unlabeled sodium cyanoborohydride (optional alternative
for labeling with 14C instead of 3H)
1. Add an equal volume of 0.2 M sodium borate, pH 9.0, to the peptide (unless already
in this buffer) and cool to 00C on ice.
2. Dilute formaldehyde stock (12.4 M) to 0.1 to 0.2 M and add to peptide on ice to give
a 2- to 6-fold molar excess over amino groups (e.g., 10 to 20 gl).
More concentrated formaldehyde in this step may lead to peptide cross-linking.
For 'C labeling, use ['4C]formaldehyde in this step.
3. Immediately dissolve [3H]sodium borohydride (or [3H]sodium cyanoborohydride) in
0.01 M NaOH to a final concentration of 1.0 Ci/ml and add to peptide on ice for 10
min. Use a molar ratio of sodium borohydride to formaldehyde of between 0.25 and
0.40 (e.g., 30 to 50 l1).
Sodium cyanoborohydride is a superior reagent for this purpose because it reduces
the Schiff baseformed initially between thepeptide andformaldehyde without reducing
disulfides or aldehydes. [3H]sodium borohydride or [3H]sodium cyanoborohydride
should be stored frozen in small aliquots rather than frozen and thawed repeatedly.
For 14C labeling, use unlabeled sodium cyanoborohydride in this step.
4. Remove by-products by gel filtration (uNrrs.3), dialysis (APPENDIX3B), or solid-phase
extraction (see Basic Protocol 1, steps 4 to 8), and count fractions in an appropriate
liquid scintillation cocktail.
Resolution of individual products may be possible by HPLC (see Support Protocol 2).
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14C OR 3II LABELING AT CYSTEINE RESIDUES USING
IODOACETIC ACID OR IODOACETAMIDE
To label cysteine residues, a peptide is reduced and allowed to react with either iodoacetic
acid (to give the carboxymethyl derivative) or iodoacetamide (to give the carboxamido-
methyl derivative, which is uncharged; see Fig. 3.3.1). For large peptides containing
disulfide bonds, this procedure is often used to denature the peptide irreversibly. Car-
boxymethylcysteine content is readily determined by amino acid analysis following acid
hydrolysis. ["'C]- or [3H]iodoacetic acid and [14C]iodoacetamide are commercially avail-
able for radiolabeling. Possible side reactions are alkylation of histidine, methionine, or
lysine, each of which can usually be controlled by pH and other reaction conditions
(Crestfield et al., 1963; Means and Feeney, 1971).
CAUTION: All procedures should be carried out in an externally vented hood.
Materials
0.5 M Tris-Cl/6 M guanidine.HCl/0.002 M disodium EDTA, pH 8.6
Peptide, ideally Ž1 mg/ml in 0.1 to 1.0 ml 0.5 M Tris-Cl/6 M guanidine.HCl/0.002
M disodium EDTA, pH 8.6
Dithiothreitol
1.0 M NaOH
[14C]- or [3H]iodoacetic acid or ["4Cliodoacetamide (Amersham, Du Pont NEN,
or ICN Biomedicals)
Iodoacetic acid or iodoacetamide, unlabeled (optional)
1. Peptides containing disulfide bonds or significant tertiary structure require reduction
and/or denaturation prior to alkylation of cysteine residues. For this, prepare a
solution of peptide in 0.5 M Tris-Cl/6 M guanidine-HCl/0.002 M disodium EDTA
(pH 8.6), incubate for I hr at 370C, add dithiothreitol (50-fold molar excess over
disulfide), and incubate overnight at 370 C.
2. Cool to room temperature and add desired amount of radiolabeled iodoacetic acid (or
iodoacetamide) dissolved in vio vol of 1.0 M NaOH for 30 min in the dark.
Optionally, include additional unlabeled iodoacetic acid (or iodoacetamide) at a
2-fold molar excess over the dithiothreitol added to increase the extent of the reaction
(analogous to stoichiometric vs. trace iodination; see Support Protocol 1).
3. Remove by-products by gel filtration (uNrrs 3), dialysis (APPENDIX 3B), or solid-phase
extraction (see Basic Protocol 1, steps 4 to 8), and count fractions in an appropriate
liquid scintillation cocktail.
Resolution of individual products may be possible by HPLC (see Support Protocol 2).
3H LABELING AT TYROSINE RESIDUES BY REDUCTION
OF 127 1-LABELED PEPTIDE
It is possible to label one or more tyrosine residues of a peptide stoichiometrically with
'H to a relatively high specific radioactivity (e.g., 50 Ci/mmol). Since 3H substitutes for
hydrogen, the peptide's structure remains unaltered. However, this approach is more
laborious and expensive than the previous methods, requiring the preparation of a
'
27I-labeled peptide that is then catalytically reduced in the presence of tritium gas, leading
to replacement of each 127"I (or other halogen atom) with 3H.
The '"I-labeled peptide precursor can be produced in two ways: by stoichiometric
iodination with 1271 (see Basic Protocol 1, Support Protocol 1, and Support Protocol 2) or
by incorporating a suitably protected '271-labeled tyrosine derivative (either mono-
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iodinated or diiodinated) during de novo peptide synthesis (e.g., N-Boc-O-3-bromo-
benzyl-3,5-diiodo-L-tyrosine, available from Peninsula). The 'TI-labeled peptide is then
submitted to a specialized facility for reductive tritiation (Amersham and Du Pont NEN
offer this service).
INTRODUCTION OF LABELED AMINO ACID RESIDUES
DURING PEPTIDE SYNTHESIS
The most specific and least disruptive labeling procedure is incorporation of a suitably
protected radioactive amino acid into any desired position of a peptide during its
solid-phase synthesis. However, because this requires an entire synthesis rather than use
of just an aliquot of peptide, and because the protected derivatives of radioactive amino
acids are not generally available and therefore must be prepared, it is not commonly done.
Furthermore, introduction of a radioactive amino acid into a peptide synthesizer will be
possible only if the operator of the instrument is prepared to work with radioactive
samples. However, amino acids containing 14C, 3H, or 35S (for methionine) are available,
procedures for attaching various protecting groups to these amino acids are quite well
established, and the result may be an abundant supply of a radiolabeled peptide unper-
turbed in structure and not obtainable by any other means. Specific radioactivities are
typically two to three orders of magnitude lower than for radioiodinated peptides.
The simplest approach is to select a radioactive amino acid that requires protection during
solid-phase peptide synthesis only on its a-amino group and not on its side chain (e.g.,
14C- or 3H-labeled alanine, isoleucine, leucine, valine, or phenylalanine, all available from
Amersham, Du Pont NEN, ICN Biomedicals, or Sigma). If classical t-butyloxycarbonyl
(t-BOC) chemistry is to be used during peptide synthesis, a variety of procedures are
available for attaching t-BOC to a-amino groups (Stewart and Young, 1984); one such
procedure is outlined below for leucine.
Materials
L-Leucine, unlabeled
L-[14C]_- or L-[3H]leucine, I to 5 mCi
Triethylamine
2-(t-butoxycarbonyloxyimino)-2-phenylacetonitrile (BOC-ON, Aldrich)
Dioxane
Diethyl ether, anhydrous
1.0 M HC1, 40C
Separatory funnel
1. Add 131 mg L-leucine (1 mmol) and the desired number of millicuries L-[14C]- or
L-[3H]leucine (supplied in water) to a 25-ml round-bottom flask.
Other amino acids or their side chain protected derivatives can be substituted for
leucine. Unlabeled amino acid is used because the amount of 14C- or 3H-labeled
material is very small in molar terms (e.g., 2 mCi ['H]leucine is <1 m/nol); safety and
cost considerations generally preclude the use of stoichiometric amounts of radiola-
beled amino acid.
2. Add 210 pl triethylamine (1.5 mmol).
3. Add 271 mg BOC-ON (1.1 mmol).
4. Add a mixture of 600 pl. dioxane and enough water to bring the total volume of water
to 600 pl.; e.g., if the radiolabeled amino acid is supplied in 400 pl water, add 600 gl
dioxane and 200 pl water.
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5. Stir with a magnetic stir bar 3 hr at room temperature. The yellow, heterogeneous
reaction will become homogeneous.
6. Add 2 ml water and 2 ml diethyl ether and transfer the reaction mixture to a separatory
funnel.
The aqueous (bottom) layer contains the triethylammonium salt of the t-BOC-amino
acid product; the ether (upper) layer contains an oxime by-product from the reaction
(bright yellow).
7. Drain the aqueous layer and wash it three times with an equal volume of diethyl ether
in the separatory funnel to remove unwanted oxime.
8. Add a small volume of 40C 1.0 M HC1 to bring the aqueous layer to pH 2 and
precipitate the t-BOC-amino acid product.
9. Add an equal volume of diethyl ether to the aqueous layer in the separatory funnel,
shake, and drain off the aqueous layer. Save the ether layer and repeat ether extraction
of the aqueous layer two more times. Pool the combined ether layers into an
Erlenmeyer flask.
The t-BOC-amino acid product now partitions into the ether layer after being con-
verted by HClfrom a salt to the free acid. Some t-BOC-amino acids (serine, threonine)
remain soluble in water and are best extracted if the aqueous layer is first saturated
with NaCl before adding ether
10. Allow the product to crystallize for several hours on ice or overnight at 4°C. First
blowing off some ether with a gentle stream of dry nitrogen gas may be helpful. Wash
the white, crystalline product carefully with cold diethyl ether.
The t-BOC-amino acid should be checked for nonreactivity of its amino group by a
ninhydrin (Sarin et al., 1981) or other analytical test prior to using it in peptide
synthesis.
SELECTIVE LABELING ON N-TERMINUS DURING
PEPTIDE SYNTHESIS
The N-terminus of a peptide that contains one or more lysine amino groups can be
selectively labeled after the peptide has been synthesized by solid-phase methods but
before amino acid side chains (including that of lysine) have been deprotected. For
example, N-terminal acetylation of a newly synthesized protected peptide can be used to
label the peptide with '4C or 3H without affecting lysine residues that might be important
for activity (see Basic Protocol 3). Alternatively, addition of a Bolton-Hunter group allows
subsequent iodination at this position (see Basic Protocol 2); tyrosine, if present, will also
be iodinated unless radiolabeled Bolton-Hunter reagent is used.
Various other reagents can be used to modify a peptide at its N-terminus. For example, a
dinitrophenyl (DNP) group can be attached specifically to the N-terminus of a protected
resin-bound peptide using dinitrofluorobenzene (100 mol equivalents), N,N-diiso-
propylethylamine (20 mol equivalents), and dichloromethane as the solvent for the
coupling reaction (2 hr at room temperature with shaking in the dark; T. Tsomides, unpub.
observ.).
Specific details of the protocols to be used for N-terminal labeling reactions depend on
the particular chemistries involved in the peptide's synthesis and cleavage. In particular,
any label attached selectively to the N-terminus must be stable during the peptide side
chain deprotection step (e.g., hydrogen fluoride or trifluoroacetic acid). In the example
above, DNP is stable during deprotection with trifluoromethane sulfonic acid.
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Background Information
Detection of minute quantities of a peptide
or protein is often made possible by radiolabel-
ing procedures. The most common labeling
strategy, radioiodination with 125I. is relatively
straightforward to perform and low in cost.
Thus, a peptide with two tyrosine residues can
be radiolabeled with 125I to a specific radioac-
tivity of 5 x 109 cpm/gg (see Support Protocol
2), allowing its detection at subfemtomole lev-
els, or several orders of magnitude lower than
absorbance- or fluorescence-based detection
methods (uNrr3.1).
The main drawback of radioiodination
(other than the need to work safely with a
potentially hazardous radioisotope) is that
some peptides may be unreactive or may be
damaged by the introduction of iodine atoms
(each as large as a phenyl ring) or by the
oxidative conditions typically employed dur-
ing the labeling reaction. These problems may
be more acute for a large protein with native
tertiary structure and more oxidation-sensitive
residues (tryptophan, methionine, and cys-
teine) than for a short peptide; nevertheless,
even small peptides can be significantly altered
in their biological activities by iodination. In
most cases these problems can be obviated by
modifying the radiolabeling strategy (see Table
3.3.1).
Standard radioiodination methods rely on
the oxidation of 1251 (in the form of Na1251) to
its reactive state (which can be considered "I'")
for electrophilic addition to the phenolic and
imidazole side chains of the amino acids tyro-
sine and histidine, respectively (see Fig. 3.3.1).
At a pH between 6 and 7, tyrosine labeling
predominates, whereas at a higher pH there is
also labeling on histidine (Wolff and Covelli,
1969; Tsomides and Eisen, 1993). Different
methods of oxidizing the 1251 include lodo-
Beads (aconvenient immobilized form ofchlo-
ramine T; Basic Protocol 1), soluble chlora-
mine T, and lodogen (a water-insoluble reagent
plated onto tubes prior to use; Alternate Proto-
col 1). A gentler oxidative procedure uses the
enzyme lactoperoxidase along with hydrogen
peroxide (Alternate Protocol 2). All four meth-
ods can be expected to give reasonable specific
radioactivities (lowest for lactoperoxidase),
and their relative merits have been assessed for
some peptides (Thean, 1990; Rizzino and
Kazakoff, 1991).
For peptides that lack tyrosine and histidine
or that are unacceptably altered by standard
iodination procedures, an alternate strategy is
to label free amino groups (lysine side chains
and the peptide N-terminus, unless it is proline
or blocked) using an iodinated acylating agent
(e.g., Bolton-Hunter reagent; see Basic Proto-
col 2 and Fig. 3.3.1; Bolton and Hunter, 1973).
This mild coupling reaction avoids direct con-
tact of the peptide or protein with harsh oxidiz-
ing conditions, but the resulting labeled prod-
uct is likely to have a lower specific radioac-
tivity (because Bolton-Hunter reagent suffers
competing hydrolysis during the reaction); a
second drawback is the relatively high cost of
this reagent. A similar though less commonly
tried modification using an iodinated amidinat-
ing reagent (Wood et al., 1975) has the potential
advantage that the positive charge on lysine
(pKa-10) is retained in the final labeled product
(an amidine with pKa 11.5 to 12.5).
Besides labeling with 1'I, it is straightfor-
ward to radiolabel peptides or proteins with '4C
or 3H using various methods (see Table 3.3.1).
This may be desirable if all iodination options
fail, or if it is critical to obtain a radioactive
product devoid of structural alterations. Usu-
ally the products of 14C or3H labeling will have
much lower specific radioactivities than the
products of'125I labeling, reflecting the different
disintegration rates for these radioisotopes
(-35,000 and 75 times lower for '4C and 3H,
respectively, than for 125I). Also, counting 3
emissions requires liquid scintillants and is
therefore less convenient than counting yemis-
sions, which requires no additives to the sam-
ple. However, the longer half-lives of 14C and
3H (5760 and 12.26 years, respectively) render
the resulting products useful for much longer
than 125I-labeled products (tVh -60 days).
A selection of protocols for labeling a pep-
tide with 14C or 3H is given in this unit: acety-
lation on amino groups with acetic anhydride
(see Basic Protocol 3), reductive alkylation on
amino groups with formaldehyde and sodium
cyanoborohydride (see Alternate Protocol 3),
and alkylation on cysteine with iodoacetic acid
or iodoacetamide (see Alternate Protocol 4).
Each of these procedures results in modifica-
tion of the peptide structure, albeit on different
residues than does standard radioiodination
(Fig. 3.3.1). To label a peptide without altering
its structure, two alternatives are available: 3H
labeling by catalytic reduction of (nonradioac-
tive) '17I-labeled tyrosine (see Basic Protocol
4), and de novo peptide synthesis using a ra-
diolabeled (and suitably protected) amino acid
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derivative (see Basic Protocol 5; Stewart and
Young, 1984). These methods are much more
laborious and costly, but may be useful when
modification of a peptide's structure is unac-
ceptable.
Critical Parameters and
Troubleshooting
Amount of radioisotope
The amount of radioisotope to be used is
often a compromise among the desire for high
specific radioactivities (curies per millimole or
cpm per microgram), a practical limit to the
amount of radioactivity that can be afforded
and safely handled, and (particularly for a large
protein) any risk of altering tertiary structure
by excessive substitution or radiation damage.
Commonly, 1 to 5 mCi of 125I (or 1311) is used;
however, it is possible to scale up the 125I and
increase specific radioactivities proportion-
ately, because iodide is almost always limiting
relative to iodinatable sites (e.g., 2 mCi 125I is
only -1.2 nmol). Conversely, lowering the
amount of peptide or protein will also improve
specific radioactivities, but lowering the
amount of substrate too far will cause unaccept-
able losses of material by nonspecific adsorp-
tion to tubes; a practical lower limit is 5 to 10
ýtg of peptide.
Sensitive amino acid residues
During oxidative iodinations, the amino
acid residues at greatest risk for damage are
tryptophan, methionine, and cysteine. The
problem is greatest for tryptophan, as an oxi-
dized indole ring cannot be restored by subse-
quent treatment with a reducing agent such as
dithiothreitol. When these residues are critical
for peptide function, the lactoperoxidase or
Bolton-Hunter methods may be preferred for
1251 labeling.
lodination work-up
Several options are available for the re-
moval of unbound radioactive iodide from a
peptide once the reaction is complete, includ-
ing solid-phase extraction (e.g., using Sep-Pak
cartridges; Basic Protocol 1), anion-exchange
chromatography (uNrr U2), gel filtration (umrT
8.3), and dialysis (APPENDIX 3B). The choice of
desalting procedure will depend on the peptide,
particularly its size and charge. For small pep-
tides the Sep-Pak method works well, because
the peptide binds to the Sep-Pak cartridge,
allowing extensive washing to remove all
traces of free iodide (Tsomides and Eisen,
1993). For larger peptides and proteins, anion-
exchange chromatography (e.g., Dowex col-
umn) and gel filtration are popular, as the pep-
tide is eluted immediately while iodide is re-
tained on the column. To ensure that the
removal of unbound iodide is complete, many
investigators precipitate a radiolabeled protein
with trichloroacetic acid (TCA) to determine
the proportion of TCA-precipitable counts. Di-
alysis is a time-consuming but effective
method for removing traces of iodide, provided
the peptide is large enough to be retained by
the dialysis membrane used.
Note that for highly negatively charged pep-
tides, there may be some retention on anion-
exchange columns. For peptides of 10 to 20
amino acids, separation of labeled peptide from
free iodide may be poor on an anion-exchange
or gel-filtration column because the peptide's
molecular mass is so close to the exclusion limit
of the column. For such peptides the Sep-Pak
method may be advantageous.
Once unbound radioactive iodide has been
removed, the labeled peptide mixture can be
used as is, or the individual products can be
separated from each other as well as from the
unreacted peptide that is almost always present
(see Support Protocol 2). If unlabeled peptide
is removed by reversed-phase HPLC, the spe-
cific radioactivity of the labeled peptide will be
maximized and will equal the specific radioac-
tivity of carrier-free 125' (-2000 Ci/mmol) mul-
tiplied by the number of 12I atoms incorpo-
rated per peptide molecule.
Poor iodination results
Table 3.3.2 gives potential causes and pos-
sible remedies for poor iodination results.
Anticipated Results
In radioiodinating a purified protein, it is
customary to aim for incorporation of up to one
1251 atom per protein molecule, i.e., -20 giCi/tg
for a protein of molecular mass 100,000 Da.
For short peptides it is rare to label all the
molecules, but specific radioactivities are typ-
ically on the same order (e.g., 20 g.Ci/tg for a
peptide of mass 1000 Da, representing only 1%
of the peptide labeled and 99% unlabeled).
More labeled peptide is obtained when nonra-
dioactive 1271 is added during the iodination
reaction (see Support Protocol 1). For example,
Figure 3.3.2 shows the results of iodinating an
eight-residue peptide with 20 mCi 125I and 5
gLmol 127I, followed by separating the products
from unlabeled peptide by HPLC.
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Table 3.3.2 Troubleshooting the lodination Reaction
Problem Potential cause Possible remedy
Poor iodine Peptide contains reducing agent, HPLC-purify or desalt peptide prior
incorporation e.g., from synthesis/cleavage to use
Peptide contains detergent or HPLC-purify peptide
other component that becomes
iodinated
Tyrosine/histidine residues are Treat peptide with denaturing agent
unreactive because of tertiary Use alternate strategy, e.g.,
structure Bolton-Hunter reagent
Iodo-Beads are unreactive Test for color (see Support Protocol
1); use fresh lot
Poor peptide Solubility problem Change solvent system or adjust pH
recovery
Failed elution from Sep-Pak Replace with ion exchange, gel
filtration, or dialysis
Nonspecific losses Increase amount of peptide or add
carrier protein (after iodination
reaction)
Use chloramine T instead of
Iodo-Beads
Labeled peptide Tyrosine is crucial for activity lodinate for shorter time and/or use
unreactive less label
Use alternate strategy, e.g.,
Bolton-Hunter reagent
Other peptide damage Use alternate strategy
Time Considerations
Each of the listed protocols is easily com-
pleted within a few hours (not including HPLC
purification if chosen), and with practice can
be done in even less time. The resulting radio-
active peptides will, of course, decay according
to the half-life of the radioisotope used (or in
some cases faster, if there is radiation damage).
To calculate specific radioactivity after t days,
simply multiply the initial specific radioactiv-
ity by 2 (- t0M), where t½ is the half-life of the
radioisotope (60 days for 1251).
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CHAPTER 12
ROLE OF LIGAND DENSITY
IN T CELL REACTIONS
Theodore J. Tsomides
BACKGROUND
Studies in the early 1970s revealed a requirement that T lympho-
cytes responding to antigens on other cells (B lymphocytes or mac-
rophages) must share MHC specificities with the antigen-bearing cells
they recognize in order to become functional helper T cells.' 3 Zinkernagel
and Doherty unequivocally showed that virus-specific cytotoxic T lympho-
cyte (CTL) responses also require shared MHC specificities between
the T cell and the virus-infected target cell C"MHC restriction").' Sub-
sequently, molecular genetic studies led to characterization of the highly
polymorphic genes of the MHC and to sequencing of the genes en-
coding subunits of the antigen-specific T cell receptor (TCR). Details
of the tripartite interaction between antigen, MHC protein, and TCR
did not begin to emerge until the mid-1980s. when landmark studies
of Townsend et al showed that the antigens recognized by T cells are
short peptides (generally 8-25 amino acids in length),s and x-ray crys-
tallographic structure determinations provided striking images of MHC
molecules complexed with mixtures of cellular peptides" ' or individual
synthetic peptides. "s " The 1990s have seen an explosion of informa-
tion regarding peptide-MHC interactions and an accompanying height-
ening of interest in applying this information to clinical areas such as
autoimmunity, vaccine design, and immunotherapy (e.g., refs. 12-15).
The modern view of MHC function is conveyed by the term "an-
tigen presentation." Class I MHC (MHC-I) molecules sample the con-
tents of a cell by binding to short peptides that result from partial
degradation of cytosolic proteins. These peptides are translocated into
the endoplasmic reticulum (see chapter 3), where they come into con-
tact with newly formed MHC-I molecules that are then transported
to the cell surface.' Hence the MHC-1 molecules of a cell undisturbed
by any pathologic process are loaded with peptides derived from nor-
mal cellular proteins. These noncovalent peptide.MHC-1 complexes will
not ordinarily be recognized by the host's own T cells because of im-
mune tolerance to self, but they will be recognized by T cells from an
MHC-different (allogeneic) individual. Some proportion of MHC-I
molecules at the surface of a tumor cell or a cell invaded by a virus or
other pathogen will carry peptides that are recognized by host T cells,
MHC Molecules: Expression. Assembly and Function, edited by
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either because the peptide sequences are foreign to the responding or-
ganism or because tolerance to native sequences is somehow breached.
The minimum number of peptide.MHC-I complexes per target cell
needed to elicit T cell function varies in different systems (see below),
but for the sake of argument suppose that an average minimum num-
ber is =100. Since nucleated cells of vertebrate organisms express about
half a dozen different MHC-1 proteins at their surface, each typically
at a level of 10'-101 molecules per cell, the universe of antigens po-
tentially recognized by MHC-I-restricted T cells (mostly CD8* CTL)
will then consist of up to a few thousand different peptides represent-
ing the internal contents of each cell of an organism.
Class II MHC (MHC-II) molecules also bind peptides and present
them to T cells (mostly CD4" helper T cells), but in this case the pep-
tides are derived from extracellular or membrane-associated proteins.
MHC-II function will not be treated here (see chapters 6 and 13),
although similar principles probably apply to T cell recognition of
peptide-MHC-I and peptide.MHC-II complexes. This chapter will
consider the peptides recognized (as peptide.MHC-I complexes) by CD8"
CTL and the broad question of what factors may limit the efficacy of
CTL-mediated lysis of target cells. A viewpoint that the density of
naturally processed peptide-MHC-I complexes is often a critical deter-
minant of CTL function will be presented.
THE STUDY OF PEPTIDES RECOGNIZED BY CD8& CTL
The peptides recognized by CD8* CTL were first studied by add-
ing synthetic peptides to appropriate target cells (generally transformed
cell lines expressing the MHC-I protein restricting a particular CTL
clone), thereby sensitizing the target cells for lysis by CTL.1" By screening
sets of synthetic peptides (e.g., derived from viral protein sequences),
optimally active peptides could be identified that sensitized target cells
at extracellular concentrations < 1 pM. Often these peptides were -nine
amino acids in length. However, it remained unclear whether the same
peptides arose physiologically (e.g., during viral infection) or merely
mimicked the naturally processed peptides, which might have differ-
ent N- or C-termini (reviewed in ref. 18).
Why is this distinction between naturally processed and active syn-
thetic peptides of more than passing interest? One of the factors likely
to influence the degree of lysis by CTL is the density of peptide-MHC-I
complexes on target cells, termed ligand density or epitope density
(Fig. 12.1). Ligand density on natural CTL targets such as tumors,
virally infected cells, or self tissues in autoimmunitv cannot be deter-
mined until the precise identity of a relevant naturally processed pep-
tide is known. Therefore studies using only synthetic peptides, while
of enormous value in mapping out T cell epitopes and defining the
conditions required for CTL lysis, fail to permit analysis of the role of
ligand density in host T cell reactions in situ.
Information regarding naturally processed peptides was obtained
following the realization that purified or cell surface MHC molecules
(both MHC-I and MHC-II) harbor tightly-bound endogenous pep-
tides that can be removed by acid treatment."'• 0 The first natural pep-
tides were isolated from virally infected cells and identified using virus-
specific CTL.?2 1L Other natural peptides were isolated and sequenced
based on their relative abundance in purified MHC preparations rather
than on their recognition by specific CTL.•'"'" Falk et al showed that
acid treatment of MHC-I molecules followed by Edman sequencing
of the resulting peptide mixtures yielded patterns which they called
motifs: e.g., for the human MHC-I molecule HL--A2.1, bound peptides
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Fig. 12. 1. Factors that might
Target cell limit the efficacy of Tcell
* density of peptide.MHC complexes on target cells or antigen presenting cells responses.
* suitable peptides not generated or transported into endoplasmic reticulum
* peptides present at cell surface but quantity insufficient for effective T cell
response
* antigen escape mutations thwart effective T cell response
* poor MHC-1 expression (e.g., neuronal cells)
* physiological lifetime of peptide.MHC complexes (peptide dissociation rate)
T cell-target cell interaction
* affinity of the TcR for peptide-MHC complexes
* kinetics (on-rate and/or off-rate) of the TcR-peptide.MHC reaction
* coreceptor and adhesion molecule interactions between T cell and target cell
T cell
* density of TcR on the T cell
* density of adhesion molecules on the T cell
* functional status of T cell (e.g., lymphokine requirements, lytic capacity of a CTL)
* T cell tolerance/anergy
tended to be nonamers with Leu or Met at position two and Val or
Leu at position nine. :2 These motifs accorded well with structural in-
formation from x-ray crystallography 2: " and encouraged the predic-
tion of T cell epitopes from parent protein sequences.28 32 More re-
fined techniques for predicting which peptides can bind strongly to a
given MHC protein and be recognized by T cells have since been de-
veloped (see chapter 10). However, the number of proved naturally
processed peptides recognized by known CTL has remained surpris-
ingly limited (Table 12.1).
In order to characterize a naturally processed T cell epitope, sev-
eral steps are required. First, the peptide must be identified. This re-
quires a sufficient number of cells from which to isolate the peptide and
a means for its detection. For example, in order to identify a naturally
processed tumor peptide recognized by anti-tumor CTL, a relatively
large number of tumor cells is needed, depending upon the peptide's
abundance, the sensitivity of the detection method, and the overall
efficiency (yield) of the isolation procedure. Assuming that an unknown
peptide is present at a level of 100 molecules per cell (cf. Table 12.1)
and that a 50% yield is possible, more than 10" cells are needed to
obtain just 10 pmol of peptide. Peptide sequencing by Edman degra-
dation generally requires at least this much peptide:- 3-" mass spectrometry,
while not as routinely available, offers the chance to sequence far lesser
amounts of peptide. ' 3 6 "37 Once a suitable starting number of cells is
available, the purification scheme must be chosen. This involves several
choices, including whether to isolate MHC molecules by immunoaffinity
methods or simply lyse whole cells without MHC purification; each
approach has its advantages and disadvantages.: "• • A third strategy has
been described in which intact cells are treated with a citrate/phos-
phate buffer to release MHC-bound peptides without rupturing the
cells, which then regenerate peptide.MHC complexes.- 8"-
Peptide detection during the purification must rely on a suitable
assay, and by far the most sensitive is bioassay with a specific clone of
T cells: sensitivities of _10 -12 M have been obtained for several CTL,
and a theoretical limit of 10-'"-10-14 M has been postulated. 40 Thus,
crude mixtures of peptides obtained from whole cells or from isolated
MHC molecules are fractionated by HPLC, each fraction is tested for
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Table 12.1. Measured ligand densities for naturally processed peptides recognized by CD8* CTL'
Peptide MHC-I Peptide Estimated Calculated Ref.
recovery yield ligand
per cell density
Sequence Source
TYQRTRALV influenza NP 147-155 H-2Kd 220-540 =100% 220-540 22, 51
ASNENMETM influenza NP 366-374 H-2Db 55 25% 220 22, 51
RGYVYQGL vesicular stomatitis H-2Kb 5-10% of 21
virus NP 52-59 total peptide
SIINFEKL ovalbumin 257-264 H-2Kb 88 >88 70
GYKDGNEYI L. monocytogenes H-2Kd 15-20% 800 32, 87
listeriolysin 91-99
KYGVSVQDI L. monocytogenes H-2Kd 50% 3500 87
p60 217-225
LSPFPFDL mouse a-ketoglutarate H-2Ld 400 10% 4000 33
dehydrogenase
VAITRIEQLSPFPFDL mouse a-ketoglutarate H-2Ld 7000 5% 140,000t  34
dehydrogenase
KYQAVTITL P198 gene from H-2Kd 100 >100 49
mutagenized P815 cells
ALWGFFPVL lymphoblastoid (IY) cells HLA-A2.1 1500 90% 1600 ' 36
(assumed)
YLEPGPVTA gp1OO from melanoma HLA-A2.1 0.23 !12% 22 37
ILKEPVHGV HIV-1 reverse transcnptase HLA-A2.1 3 25% 12 41
476-484
SLYNTVATL HIV-1 gag 77-85 HLA-A2.1 100 25% 400 41
* naturally processed peptides for which ligand densities have not been determined are not listed.
t includes peptide not bound to L".
activity in a T cell assay, and the active fraction(s) are subjected to
further rounds of purification and finally to direct sequencing. If there
is insufficient purified peptide for sequence determination by chemi-
cal methods (Edman degradation, mass spectrometry), it may be pos-
sible to identify the peptide indirectly by comparing the HPLC reten-
tion times of the naturally occurring sample (determined by T cell assay)
with those of several synthetic peptides that are good candidates for
the naturally processed peptide." 2 "4 ' At least two or three different
HPLC columns or conditions should be used in order to assign a pep-
tide sequence by this indirect method. The various strategies discussed
above are outlined in Figure 12.2.
In addition to these biochemical approaches, Boon and colleagues
pioneered a molecular genetic approach to identifying natural T cell
epitopes. ''4 This involves transfecting cDNA from a target cell of interest
(e.g., a tumor cell) into a cell that lacks the epitope and screening
large numbers of transfectants for their ability to stimulate the rel-
evant T cells. Ultimately the gene encoding an antigen recognized by
these T cells can be sequenced. This technique has been used to iden-
tify the first precursors of T cell antigens on tumor target cells. Can-
didate peptides based on the gene sequences are then synthesized and
tested for activity.v 5"" An important advantage is that the method is
not limited by the abundance of naturally processed peptides, which is
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sometimes very low (Table 12.1).
However, in order to determine organs, tissue
whether an active synthetic pep- cultured cell
tide corresponds to a naturally 1
processed one, it is necessary to 7
analyze the chromatographic homogenization/sonication in TFA
pattern of the synthetic peptide
relative to a naturally occurring
sample. This has been done for
a mouse tumor-specific peptide,49  ultrafiltration for collection of
but not for any of the human peptide (low MW) fraction
tumor antigens so far identified
by the genetic approach.
Once a naturally processed
peptide has been identified, its reverse phase HPLC 2a.
abundance at the cell surface fractionation
(ligand density, expressed as an
average number of peptide.MHC CTL assay of fractions
complexes per cell) can be mea-
sured. This is usually accom- I 2a 2b
plished by synthesizing the same - active (sensitizing) fraction(s)
peptide and titrating the synthetic 2a
peptide in a T cell assay to es-
tablish a standard curve. A syn- Sequence determination Sequence deterthetic peptide can be character- of individual of individ
ized in terms of its concentration Tcell epitopes abundant pe
required to elicit 50% of maxi-
mal activity in a T cell assay (SDS0
valueSo). The amount of a natu-
rally occurring sample that contains the peptide at or near its SDR, Fig.
value is then determined, allowing a quantitation of ligand density. ' ' s ' nat
MHAlternatively, if Edman degradation or mass spectrometry is used to ts
sequence a naturally processed peptide, peptide abundance may be es- prej
timated directly. A3.34.'".37 (TF,
Because losses are unavoidable during peptide isolation and analyv- ecu
sis, the overall yield of recovered peptide must be estimated in order TFAwhi
to calculate an absolute abundance. One practical method for estimat- frac
ing yield is to add a precisely known amount of synthetic peptide to a cyt
pellet of cells not containing this peptide, and then proceed with ex- sub
traction and quantitation of the synthetic peptide exactly as is done unt
for the naturally processed peptide. This method does not give a yield torn
for the efficiency of peptide separation from MHC protein (usually by pe
extraction with trifluoroacetic acid, TFA), but serial TFA extraction Tce
has been shown to result in the release of 100% of a tightly-bound .-it,
radioactive peptide from HLA-A2.1, " so the vield obtained in such a tive
"spiking" experiment can be considered an overall yield of peptide re- byI
covery. Naturally processed peptides for which ligand densities have dinr
been determined are listed in Table 12.1. ,;.n
WHAT DETERMINES THE EFFICACY
OF CTL-MEDIATED TARGET CELL LYSIS?
MHC-1-restricted CD8' CTL play a central role in immune re-
sponses against many viruses, influenza virus for example, by destroy-
ing virus-infected cells.s -' " CTL specific for diverse human immuno-
deficiency virus (HIV) products (e.g., gag, pol, nef, env) also appear
within 1-2 weeks of infection," • '" and the importance of these CTL is
suggested by their unusually high frequencies: they can often be detected
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in freshly isolated peripheral blood without the in vitro antigenic stimu-
lation required to demonstrate CTL activity in other viral infections.
Yet the presence of these CTL is clearly insufficient to eradicate HIV
in most cases. Similarly, despite the relative ease of isolating CTL from
certain tumors such as human melanoma,56 there is a failure of T cells
to contain these tumors. Why are CTL responses sometimes highly
effective, sometimes not?
The factors that might limit T cell responses can be grouped into
three broad categories (Fig. 12.1): (1) factors intrinsic to the target
cell, such as the number of specific peptide-MHC complexes and their
physiological lifetime at the cell surface; (2) the quality of the T cell-
target cell interaction, including the intrinsic affinity and kinetics of
the reaction between TCR and peptide.MHC complexes; (3) factors
related to individual T cells (e.g., TCR density, adhesion molecule den-
sity) or to the T cell compartment as a whole (e.g., tolerance/anergy).
Measurements of the affinities of different TCR for their pep-
tide-MHC ligands pose a significant technical challenge, both because
TCR and peptide.MHC are large membrane proteins and because special
techniques are required to generate sufficient quantities of homoge-
neous peptide.MHC complexes. By several approaches, the intrinsic
equilibrium constants for some TCR-peptide-MHC reactions have now
been determined, and they span a large range from -103-107 M-' (ex-
pressed as association constants) (reviewed in ref. 57). While not ap-
parently as high as the intrinsic equilibrium constants of some anti-
bodies for antigens (up to 10Io M-')," this wide variation nevertheless
contrasts with earlier expectations that TCR reactions would generally
be of low affinity. Furthermore, the kinetic measurements made for
TCR-peptide.MHC reactions indicate that these reactions approach
equilibrium rapidly (usually within -1 minute), so that the extent to
which TCR molecules become engaged by peptide-NMHC complexes
in a T cell-target cell encounter is largely dependent upon intrinsic
equilibrium constants."7 Thus it is important to evaluate the functional
importance of differences in TCR affinity among T cells.
It is often assumed, implicitly or explicitly, that "high-affinity T cells"
(i.e., high affinity of the TCR for its peptide.MHC ligand) are better
effector cells than "low-affinity T cells." To date, very little data are
available to evaluate this idea. For example, it seems intuitively rea-
sonable that there may be an inverse correlation between the density
of peptide-MHC complexes on target cells and the required affinity of
a CTL's TCR to effect lysis of the cells. Figure 12.3 illustrates an
empirical relationship between TCR affinity and ligand density for several
peptides, and shows that peptide.MHC complexes present at lower den-
sities are indeed recognized by TCR with higher intrinsic affinities. It
is important to note that correlations between TCR affinity and pep-
tide activity (e.g., SDo value) are worse than those between TCR af-
finity and ligand density because SDso is only a crude indicator of
ligand density (due to variations in peptide-MHC binding affinities,
see below). In particular, a synthetic peptide with relatively low affin-
ity for the restricting MHC-I molecule must be added to target cells
at a significantly higher concentration (SDso value) in order to match
the ligand density of a different peptide, regardless of the affinity of a
TCR for each peptide.MHC complex. (Similar considerations apply
to efforts aimed at demonstrating a correlation between dissociation
rate of the TCR-peptide.MHC reaction and peptide activity.59) The
correlation between TCR affinity and ligand density is probably too
imperfect to permit the prediction of either from the other: for example,
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Fig. 12.3. Relationship between TCR affinity
(equilibrium association constant of the
TCR.peptide.MHC-l reaction) and ligand den-
sity at half-maximal T cell lysis (as calculated in
Table 12.2). CTL is clone 2C except for ligand
SIINFEKL.K , which is recognized by ovalbumin-
specific CTL clone 4G3. Original references
cited in Eisen HN, Skulev Y, Tsomides TI. The
antigen-specific T-cell receptor and its reactions
with peptide MHC complexes. In: Haber E, ed.
Adv Protein Chem Academic Press 1996; in
press.
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in Figure 12.3 the TCR of CTL clones 2C and 4G3 differ 10-fold in
affinity for the pepride.MHC ligands QLSPFPFDL.Ld and SIINFEKL.Kb.
respectively,60 but the densities of these two ligands at half-maximal
lysis are essentially identical. However, for a single CTL recognizing
different peptides in association with the same MHC protein (e.g.,
clone 2C in Fig. 12.3), a rough inverse correlation between TCR af-
finity and ligand density is apparent.
ROLE OF LIGAND DENSITY
CTL function depends critically upon ligand density. This is most
apparent in cytotoxicity assays in which appropriate synthetic peptides
are added at increasing concentrations to target cells, thereby increas-
ing the degree of target cell lysis.-''.1 One way to quantitate the de-
pendence of T cells on ligand density is to determine the minimum
number of peptide-MHC complexes required to elicit a T cell response.
The first estimates of minimum ligand densities involved incubating
target cells (or antigen presenting cells) with '2'I-labeled peptides at
minimally active concentrations. The restricting MHC protein, together
with its associated peptides, was then immunoprecipitated and the number
of 25I-labeled peptide.MHC complexes per target cell determined. These
results indicated that around 100-400 complexes were required for
cytokine production by CD4' T cell hybridomas- 6'- or for lysis of tar-
get cells by CD8" T cell lines.'"
A more recent approach to determining minimum ligand densities
invokes the law of mass action as applied by Karush: 6S
r - Ka.c.n/(l+K,.c)
where r is the number of peptide.MHC complexes per target cell at a
free peptide concentration c that sensitizes target cells for lysis by a
given T cell, Ka is the equilibrium association constant for the peptide-
MHC reaction, and n is the number of MHC binding sites per target
cell accessible to extracellular peptide at saturating concentrations. Because
the peptide-MHC reaction probably never reaches true equilibrium,
and because the peptide is subject to proteolytic degradation during
whole cell binding assays, the minimum value of r that is calculated
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using this equation (using for c the peptide concentration that leads
to half-maximal lysis, i.e., the SDso value) represents an upper limit to
the number of peptide-MHC complexes required for T cell activation.
To calculate r values by means of this equation, we developed a
quantitative whole cell binding assay to measure equilibrium constants
for different peptide-MHC-I combinations as well as the number of
specific peptide-binding sites per cell.4o Stoichiometrically radiolabeled
indicator peptides"667 were found to bind specifically to cells bearing
the correct MHC-I molecules, and by Scatchard analysis values for K.
and n were determined. By inhibition analysis, K, values for unla-
beled peptides could also be measured, and the use of nonradioactive
"'I-labeled peptides confirmed the equivalence between K, values cal-
culated by means of inhibition and those measured directly with 12'I-
labeled peptides. The K, values for peptide-MHC reactions ranged from
-104-10" M-'. Notably, the best MHC-binding peptides were not al-
ways those that elicited T cell activity at the lowest concentrations.
For example, peptide '"I2 -ILKEPVHGV (two iodine atoms incorpo-
rated on histidine at position seven) bound approximately 10 times
better than ILKEPVHGV to HLA-A2.1, yet had an SD50 that was
200-fold higher. Table 12.2 shows that calculated ligand densities for
half-maximal T cell lysis vary over several orders of magnitude depending
on the particular T cell, peptide, and MHC protein and can be as low
as ten or fewer complexes per cell in optimal cases.
Because of unavoidable assumptions in the calculation of r above,
and in view of the intriguing result that such low numbers of
peptide.MHC-I complexes can trigger T cell function, a direct verifi-
cation of ligand density was performed. A peptide recognized efficiently
by CTL clone 2C (QLSPYPFDL) was stoichiometrically labeled with
carrier-free ' I to a specific radioactivity of -2000 Ci/mmol. or 2.5 x 10'
cpm/nmol. This unusually high specific radioactivity permits direct
counting of the peptide molecules bound to -10' target cells when
Table 12.2. Ligand densities leading to half-maximal lysis of target cells'
Synthetic MHC-I CTL Ka for Peptide conc. Number of MHC-I Ligand
peptide pep.MHC-1 for half-maximal peptide-binding density
reaction (M-i) lysis (SDso) sites per cell (n) (r)
ILKEPVHGV A2.1 68A62 5 x 10' 5 x 10- -' 1.5 x 10 = 1
II
ILKEPVHG A2.1 68A62 5 x 107 1 x 10-9  1.5 x 10, 750ILKEPVHGr
DNP
I A2.1 68A62 2 x 10' 1 x 10- 1.5 3 10i 10.000ILKEPVHGV
SIINFEKL Kb 4G3 1.5 x 10" 3 x 10-2 2 x 104 9
LSPFPFDL Kh  2C 1x 10 1 x 10-6 2 x10 1800
LSPFPFDL L 2C 7 x 103 1 x 10- 3 x 104 21
LSPYPFDL Ld 2C 5 x 10 I x 10-9  3 x 104 1
SPFPFDLLL Ld  2C 4 x 107 1 x 10-8  3 x 104  8600
QLSPFPFDL Ld  2C I x108 5 x 10-12  3 x 104 15
Data trom ret. 40 and reterences clted therein and unpublished work.
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peptide is added at its SDso0 concentration. Minimum ligand densities
thus determined were found to agree closely with those calculated from
K,, SDs0 , and n (manuscript in preparation).
T cell recognition of target cells expressing fewer than 10
peptide.MHC-I complexes has several interesting implications: (1) It
creates some uncertainty regarding the importance of TCR crosslinking
in signal transduction. At the single cell level, it seems almost incred-
ible that a CTL can consistently ferret out such a small number of
complexes, and then undergo signal transduction and activation as a
result of ligation of a correspondingly small number of TCR. (2) It
suggests that the surveillance function of CTL can be performed when
target cells express very little specific ligand, at least by certain CTL.
(Whether cloned T cells mirror the activities of CTL in vivo remains
an important question.) (3) The universe of T cell antigens presented
at the cell surface is larger than previously thought, since peptides present
at < 100 copies per cell (at least half of the total"4 ) can be recognized.
(4) The biochemical isolation of naturally processed peptides can be
excruciatingly demanding, since at I copy per cell (to take the ex-
treme case), 10 pmol of peptide (a minimal amount for Edman se-
quencing) would require starting with > 6 x 1012 cells.
It is worth noting in this context that screening for T cell epitopes
with a panel of synthetic peptides at high concentrations may be mis-
leading, because at typical screening concentrations (10-100 PM), many
peptides will form artificially high ligand densities. Peptides with even
modest affinities for the restricting MHC molecule (K, values of
106-108 M-') will occupy over 90% of available MHC binding sites at
equilibrium, resulting in orders of magnitude more specific peptide-MHC
complexes than the few hundred per cell that have been measured for
several naturally processed peptides (Table 12.1). For example, at high
concentrations many synthetic peptides of different lengths from HIV-1
reverse transcriptase will sensitize target cells for lysis by HIV-specific
CTL clone 68A62, s" but only one of those peptides is detectable in
HIV-infected target cells and therefore relevant to the immune response.-'
Similar observations of nonphysiologic crossreactions have been made
in influenza and other systems." ""' Thus, epitope identification based
on synthetic peptides, while useful as a preliminary guide. may not
accurately represent CTL-target cell interactions as they occur in vivo.
The preceding discussion of ligand density pertains to synthetic
peptides added to target cells. Whether the densities of endogenous
peptide.MHC ligands are limiting in vivo is much less clear, and is
difficult to investigate. As mentioned earlier, the first requirement is
precise knowledge of the naturally processed pepride(s) that constitute
a T cell ligand. This may be achieved by indirect methods (compare
the chromatographic profile of the naturally processed peptide with
those of candidate synthetic peptides), 2 1.2 2.32" 0'.4 ' by direct biochemi-
cal isolation of an active naturally processed peptide, 3-'" or by a ge-
netic approach (clone the gene, test synthetic peptides, and verify ac-
tive synthetic peptides by chromatographic comparison to a sample
containing the naturally processed peptide).""" Measured ligand den-
sities for proved naturally processed peptides recognized by CD8' CTL
vary from 2 2 to several thousand complexes per target cell, as listed
in Table 12.1.
An example of the role of endogenous ligand density is provided
by two human HIV-specific CTL clones, 68A62 (anti-reverse tran-
scriptase) and 115Ip (anti-gag)."' Whereas CTL 115Ip efficiently lysed
a panel of HIV-infected target cells. CTL 68A62 exhibited lower lev-
els of activity against infected target cells and barely lysed one of the
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infected cell lines (A2), even though the same CTL clone could lyse
uninfected target cells pulsed with as little as I pM of synthetic pep-
tide ILKEPVHGV from reverse transcriptase (termed IV9). The level
of expression of endogenous peptide IV9 was found to be quite low
in HIV-infected JA2 cells: - 12 molecules per cell, versus - 400 mol-
ecules of the gag peptide, suggesting that low peptide abundance is
likely to be responsible for poor killing of infected JA2 cells by what
would have to be considered a highly efficient clone of CTL. A differ-
ent HIV-infected target cell expressing higher levels of endogenous IV9
was lysed to a far greater extent by CTL 68A62. Thus, in spite of the
extreme sensitivity of CTL 68A62 to synthetic peptide IV9 and the
demonstration of naturally processed IV9 in HIV-infected cell extracts,
these CTL lyse certain infected cells quite inefficiently, raising the pos-
sibility that low ligand densities of naturally processed HIV peptides
may limit the effectiveness of some HIV-specific CTL in vivo.'" The
generality of this observation and its implications for efforts to en-
hance CTL immunity against HIV remain unknown.
In a second example, a peptide recognized by an alloreactive (H-2b
anti-H-2d) mouse T cell clone (2C) was found: (1) to be indigenous
in H-2b mice ("self");" (2) to bind a self MHC-I product (Kb) almost
as well as the allogeneic MHC-I product (Ld);40 and (3) to elicit cy-
tolytic activity from the same alloreactive T cell clone in the context
of either Ld or Kb, but with a marked difference in the peptide con-
centrations required.72 Since H-2b mice (as well as H-2b mice transgenic
for the TCR of alloreactive clone 2C) show no signs of autoreactivity,
these studies indicate that lack of recognition by specific T cells of a
self peptide.MHC-I complex in vivo is due to its low cell surface den-
sity, not to its absence or to the absence of potentially autoreactive
T cells; as a corollary, increased expression of the complex might well
trigger an autoimmune response. '
Recently, several groups have identified peptides recognized by human
anti-melanoma T cells." - "1' 9' 45 4 • '-- A striking feature of these results is
that the peptides are all apparently nonmutated sequences of normal
self proteins. Two obvious questions are why these nonmutated se-
quences are immunogenic, and what prevents autoimmune reactions
from occurring against other tissues expressing the same antigens. There
are several potential explanations, although none is yet proved: (1) The
nonmutated sequences might be overexpressed on tumor cells, result-
ing in recognition by T cells that do not react against tissues express-
ing lower levels (ligand densities) of the same peptides. (2) The local
inflammatory reaction to tumors may result in paracrine effects on
lymphocytes and thus in activities not otherwvise observed. (3) The
peptides may have low binding affinities for MHC-I molecules, and
this property may be related to their failure to induce a more sturdy
self-tolerance. (4) CTL against the nonmutated sequences may have
low-affinity TCR, because cells with high-affinity TCR would have
been deleted or anergized.
Apart from ligand density, an equilibrium parameter, the kinetics
of peptide-MHC reactions (particularly the dissociation rates) may be
important factors in limiting T cell responses. The first kinetic data,
obtained for MHC-II, indicated unusually slow on- and off-rates for
the peptide-MHC reaction (half-life = 5-10 hours at 370C).80 Later
studies found evidence for rapid formation of a quickly dissociating
peptide-MHC-II complex that slowly converts to a stable complex (half-
life >30 hours)."' Others have found that the half-lives of peptide.MHC-II
complexes vary widely, with selective persistence of the most stable
complexes helping to account for the striking immunodominance of
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certain peptides.81 Thus, a rapidly-dissociating peptide.MHC-II com-
plex might be ineffective at eliciting T cell responses, including those
that result in T cell tolerance. For example, it has been suggested
that rapid dissociation of a self peptide derived from myelin basic protein
might fail to induce tolerance toward this peptide, leaving poten-
tially autoreactive T cells that could cause autoimmune encephalomyelitis
if activated by crossreacting viral peptides. 3"' s4 It remains to be seen
whether such a mechanism is correct and whether it may also apply
to peptides interacting with MHC-I proteins. The time constant
for peptide-MHC-I association (the time needed to reach 63% of
equilibrium binding) and the half-life of cell surface complexes were
both found to be several hours using an I'SI-labeled peptide.10 In
general, the long half-lives of peptide-MHC reactions make it seem
as though kinetics do not usually limit T cell responses to endogenous
ligands. 50.80.85.86
CONCLUDING REMARKS
The promise of T cells, especially CD8- CTL, to destroy virus-
infected cells and tumor cells is motivating intensive efforts to de-
velop peptide-based vaccines that can stimulate the production of CTL
capable of preventing infection or treating chronic infection (e.g., HIV)
or established tumors. For this reason it is extremely important to
understand the reasons why CTL are not always completely effective.
Among the possible reasons listed in Figure 12.1, low densities of en-
dogenous peptide-MHC ligands are especially likely to be an impor-
tant factor in limiting T cell responses in vivo. Since it cannot be taken
for granted that peptides derived from a viral protein or a tumor an-
tigen will be displayed on the affected cell's surface at a level that is
sufficient to induce cell lysis, it is important to establish not only the
identities but also the abundances of naturally processed viral and tu-
mor peptides recognized by CTL. High-affinity T cells may be able to
compensate for low ligand densities to a certain extent (Fig. 12.3), so
that measurements of TCR affinities will continue to be important.
Ideally, for peptide-based vaccines to be effective, they should be able
to elicit the production of many cytolytically active T cells that satisfy
the following criteria: (1) their antigen-specific receptors have high
affinities for specific peptide.MHC ligands; (2) the optimal epitopes
for these CTL are present as naturally processed ligands on target cells
in vivo; and (3) the peptide.MHC ligands exist at levels of abundance
that are sufficient to trigger potent cytotoxic responses.
REFERENCES
1. Kindred B, Shreffler DC. H-2 dependence of co-operation between T
and B cells in vivo. J Immunol 1972; 109:940-943.
2. Katz DH. Hamaoka T. Dorf ME er al. Cell interactions between
histoincompatible T and B lymphocytes. The H-2 gene complex deter-
mines successful physiologic lymphocyte interactions. Proc Natl Acad Sci
USA 1973; 70:2624-2628.
3. Rosenthal AS, Shevach EM. Function of macrophages in antigen recogni-
tion by guinea pig T lymphocytes. I. Requirement for histocompatible
macrophages and lymphocytes. J Exp Med 1973; 138:1194-1212.
4. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cy-
totoxicity in lymphocytic choriomeningicis within a syngeneic or
semiallogeneic system. Nature 1974; 248:701-702.
5. Townsend ARM, Rothbard J. Gotch FM et al. The epitopes of influenza
nucleoprotein recognized by cytoroxic T lymphocytres can be defined with
short synthetic peptides. Cell 1986; 44:959-968.
311
MHC Molecules: Expression, Assembly and Function
6. Bjorkman PJ, Saper MA, Samraoui B et al. Structure of the human class I
histocompatibility antigen, HLA-A2. Nature 1987; 329:506-512.
7. Brown JH, Jardetzky TS, Gorga JC ct al. Three-dimensional structure of
the human class 11 histocompatibility antigen HLA-DRI. Nature 1993;
364:33-39.
8. Fremont DH, Matsumura M, Stura EA et al. Crystal stuctures of two
viral peptides in complex with murine MHC class I H-2Kb. Science 1992;
257:919-927.
9. Zhang W, Young ACM, Imarai M ct al. Crystal structure of the major
histocompatibility complex class I H-2Kb molecule containing a single viral
peptide: Implications for peptide binding and T-cell receptor recognition.
Proc Nad Acad Sci USA 1992; 89:8403-8407.
10. Silver ML, Guo H-C, Strominger JL et al. Atomic structure of a.human
MHC molecule presenting an influenza virus peptide. Nature 1992:
360:367-369.
11. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human
class II MHC protein HLA-DRI complexed with an influenza virus pep-
tide. Nature 1994; 368:215-221.
12. Feltkamp MCW, Smits HL, Vierboom MPM et al. Vaccination with cy-
rotoxic T lymphocyte epitope-containing peptide protects against a tumor
induced by human papillomavirus type 16-transformed cells. Eur J
Immunol 1993: 23:2242-2249.
13. Celis E, Tsai V, Crimi C et al. Induction of anti-tumor cytotoxic T lym-
phocytes in normal humans using primary cultures and synthetic peptide
epitopes. Proc Natl Acad Sci USA 1994; 91:2105-2109.
14. Sette A, Alexander J, Ruppert J et al. Antigen analogs/MHC complexes
as specific T cell receptor antagonists. Ann Rev Immunol 1994;
12:413-431.
15. Chicz RM, Urban RG. Analysis of MHC-presented peptides: applications
in autoimmunity and vaccine development. Immunol Today 1994;
15:155-160.
16. Monaco JJ. A molecular model of MHC class-l-restricted antigen pro-
cessing. Immunol Today 1992: 13:173-179.
17. Townsend A, Bodmer H. Antigen recognition by class i-restricted T lym-
phocytes. Ann Rev Immunol 1989: 7:601-624.
18. Tsomides TJ, Eisen HN. Identification of naturally occurring peptides
associated with MHC molecules. In: Sette A. ed. Chemical Immunology.
Basel: Karger, 1993:166-196.
19. Buus S. Sette A. Col6n SM et al. Autologous peptides constitutively oc-
cupy the antigen binding site on Ia. Science 1988; 242:1045-1047.
20. R6tzschke O, Falk K, Waliny H-J et al. Characterization of naturally oc-
curring minor histocompatibility peptides including H-4 and H-Y. Sci-
ence 1990: 249:283-287.
21. van Bleek GM. Nathenson SG. Isolation of an endogenously processed
immunodominant viral peptide from the class I H-2Kb molecule. Nature
1990: 348:213-216.
22. Rotzschke O, Falk K, Deres K et al. Isolation and analysis of naturally
processed viral peptides as recognized by cytoroxic T cells. Nature 1990:
348:252-254.
23. Jardetzky TS, Lane WS. Robinson RA et al. Identification of self pep-
tides bound to purified HLA-B27. Nature 1991; 353:326-329.
24. Hunt DF. Henderson RA, Shabanowitz J et al. Characterization of pep-
tides bound to the class I MHC molecule HLA-A2.1 by mass spectrom-
etry. Science 1992: 255:1261-1263.
25. Rudensky AY. Preston-Hurlburt P, Hong S-C et al. Sequence analysis of
peptides bound to MHC class 11 molecules. Nature 1991; 353:622-627.
312
Role of Ligand Density in T Cell Reactions
26. Chicz RM, Urban RG, Lane WS et al. Predominant naturally processed
peptides bound to HLA-DRI are derived from MHC-related molecules
and are heterogeneous in size. Nature 1992; 358:764-768.
27. Riberdy JM, Newcomb JR, Surman MJ et al. HLA-DR molecules from
an antigen-processing mutant cell line are associated with invariant chain
peptides. Nature 1992; 360:474-477.
28. Falk K, Rotzschke O, Stevanovic S et al. Allele-specific motifs revealed by
sequencing of self-peptides eluted from MHC molecules. Nature 1991:
351:290-296.
29. Matsumura M, Fremont DH, Peterson PA et al. Emerging principles for
the recognition of peptide antigens by MHC class I molecules. Science
1992; 257:927-934.
30. Madden DR, Gorga JC, Strominger JL et al. The three-dimensional struc-
ture of HLA-B27 at 2.1 A resolution suggests a general mechanism for
tight peptide binding to MHC. Cell 1992; 70:1035-1048.
31. Young ACM, Zhang W, Sacchettini JC et al. The three-dimensional struc-
ture of H-2Db at 2.4 A resolution: Implications for antigen-determinant
selection. Cell 1994; 76:39-50.
32. Pamer EG, Harty JT, Bevan MJ. Precise prediction of a dominant class I
MHC-restricted epitope of Listeria monocytogenes. Nature 1991;
353:852-855.
33. Udaka K, Tsomides TJ. Eisen HN. A naturally occurring peptide recog-
nized by alloreactive CD8" cytotoxic T lymphocytes in association with a
class I MHC protein. Cell 1992; 69:989-998.
34. Udaka K, Tsomides TJ, Walden P et al. A ubiquitous protein is the source
of naturally occurring peptides that are recognized by a CD8" T-cell clone.
Proc NatI Acad Sci USA 1993; 90:11272-11276.
35. Mandelboim O, Berke G. Fridkin M et al. CTL induction by a tumour-
associated antigen octapepride derived from a murine lung carcinoma.
Nature 1994; 369:67-71.
36. Henderson RA, Cox AL. Sakaguchi K et al. Direct identification of an
endogenous peptide recognized by multiple HLA-A2.1 specific cytotoxic
T cells. Proc Nad Acad Sci USA 1993; 90:10275-10279.
37. Cox AL. Skipper J,. Chen Y et al. Identification of a peptide recognized
by five melanoma-specific human cytoroxic T cell lines. Science 1994;
264:716-719.
38. Storkus WJ, Zeh HJ III, Maeurer MJ et al. Identification of human mela-
noma peptides recognized by class I restricted tumor infiltrating T lym-
phocytes. J Immunol 1993; 151:3719-3727.
39. Castelli C, Storkus WJ, Maeurer MJ et al. Mass spectrometric identifica-
tion of a naturally processed melanoma peptide recognized by CD8- cy-
totoxic T lymphocytes. J Exp Med 1995; 181:363-368.
40. Kageyama S, Tsomides TJ, Sykulev Y et al. Variations in the number of
peptide-MHC class I complexes required to activate cytotoxic T cell re-
sponses. J Immunol 1995; 154:567-576.
41. Tsomides TJ, Aldovini A, Johnson RP et al. Naturally processed viral
peptides recognized by cyrotoxic T lymphocytes on cells chronically in-
fected by human immunodeficiency virus type 1. J Exp Med 1994;
180:1283-1293.
42. De Plaen E, Lurquin C, Van Pel A et al. Immunogenic (turnm-) variants of
mouse tumor P815: Cloning of the gene of rum- antigen P91A and iden-
tification of the tum- mutation. Proc Natl Acad Sci USA 1988;
85:2274-2278.
43. Boon T, Cerottini J-C. Van den Eynde B et al. Tumor antigens recog-
nized by T lymphocytes. Ann Rev immunol 1994; 12:337-365.
313
MHC Molecules: Expression, Assembly and Function
44. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an
antigen recognized by cytolytic T lymphocytes on a human melanoma.
Science 1991; 254:1643-1647.
45. Traversari C, van der Bruggen P, Luescher IF et al. A nonapeptide en-
coded by human gene MAGE-I is recognized on HLA-A! by cytolytic T
lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;
176:1453-1457.
46. Brichard V, Van Pel A, Wilfel T et al. The tyrosinase gene codes for an
antigen recognized by autologous cytolytic T lymphocytes on HLA-A2
melanomas. J Exp Med 1993; 178:489-495.
47. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding
for a shared human melanoma antigen recognized by autologous T cells
infiltrating into tumor. Proc Nadl Acad Sci USA 1994; 91:3515-3519.
48. Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differ-
entiation antigen recognized by autologous cytolytic T lymphocytes on
HLA-A2 melanomas. J Exp Med 1994; 180:35-42.
49. Wallny H-J, Deres K, Faath S et al. Identification and quantification of a
naturally presented peptide as recognized by cytotoxic T lymphocytes spe-
cific for an immunogenic tumor variant. Internat Immunol 1992;
4:1085-1090.
50. Tsomides TJ, Walker BD, Eisen HN. An optimal viral peptide recog-
nized by CD8* T cells binds very rightly to the restricting class I major
histocompatibility complex protein on intact cells but not to the purified
class I protein. Proc Natl Acad Sci USA 1991; 88:11276-11280.
51. Falk K, Ratzschke O, Deres K et al. Identification of naturally processed
viral nonapeptides allows their quantification in infected cells and sug-
gests an allele-specific T cell epitope forecast. J Exp Med 1991;
174:425-434.
52. McMichael AJ, Gotch FM, Noble GR et al. Cyrotoxic T-cell immunity
to influenza. New Engi J Med 1983; 309:13-17.
53. Doherty PC, Allan W, Eichelberger M. Roles of ap and -y T cell subsets
in viral immunity. Ann Rev Immunol 1992; 10:123-151.
54. Nixon DF, Broliden K, Ogg G et al. Cellular and humoral antigenic
epitopes in HIV and SIV. Immunology 1992; 76:515-534.
55. Venet A. Walker BD. Cytocoxic T-cell epitopes in HIV/SIV infection.
AIDS 1993; 7 (suppi 1):S117-S126.
56. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lym-
phocytes infiltrating human melanomas. J Immunol 1989; 142:3714-3725.
57. Eisen HN, Sykulev Y, Tsomides TJ. The antigen-specific T-cell receptor
and its reactions with peptide.MHC complexes. In: Haber E, ed. Adv
Protein Chem Academic Press 1996; (in press).
58. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced
during immune responses. Proc Natl Acad Sci USA 1995: 92:1254-1256.
59. Matsui K. Boniface JJ, Steffner P et al. Kinetics of T-cell receptor bind-
ing to peptide/l-Ek complexes: correlation of the dissociation rate with
T-cell responsiveness. Proc Nati Acad Sci USA 1994; 91:12862-12866.
60. Sykulev Y. Brunmark A. Tsomides TJ et al. High-affinity reactions be-
tween antigen-specific T-cell receptors and peptides associated with allo-
geneic and syngeneic major histocompatibility complex class I proteins.
Proc Natl Acad Sci USA 1994; 91:11487-11491.
61. Alexander MA, Damico CA, Wieties KM et al. Correlation between CD8
dependency and determinant density using peptide-induced. Ld-rescricted
cytoroxic T lymphocytes. J Exp Med 1991; 173:849-858.
62. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC
class II/peptide complexes necessary for T-cell stimulation. Nature 1990;
346:574-576.
314
Role of Ligand Density in T Cell Reactions
63. Demotz S, Grey HM, Sette A. The minimal number of class II MHC-
antigen complexes needed for T cell activation. Science 1990; 249:
1028-1030.
64. Christinck ER, Luscher MA, Barber BH et al. Peptide binding to class I
MHC on living cells and quantication of complexes required for CTL
lysis. Nature 1991; 352:67-70.
65. Karush F. Affinity and the immune response. Annals NY Acad Sci 1970;
169:56-64.
66. Tsomides TJ, Eisen HN. Stoichiometric labeling of peptides by iodina-
tion on tyrosyl or histidyl residues. Analyt Biochem 1993: 210:129-135.
67. Schumacher TNM, Tsomides TJ. In vitro radiolabeling of peptides and
proteins. In: Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield
PT, eds. Current Protocols in Protein Science. New York: John Wiley &
Sons, Inc 1995:3.3.1-3.3.19.
68. Milligan GN, Morrison LA, Gorka J et al. The recognition of a viral
antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is lim-
ited by the availability of the endogenously processed antigen. J Immunot
1990; 145:3188-3193.
69. Speiser DE, Kyburz D. Stiibi U et al. Discrepancy between in vitro mea-
surable and in vivo virus neutralizing cyrotoxic T cell reactivities. Low
T cell receptor specificity and avidity sufficient for in vitro proliferation
or cytotoxicity to peptide-coated target cells but not for in vivo protec-
tion. J Immunol 1992; 149:972-980.
70. Ratzschke O, Falk K, Stevanovic S et al. Exact prediction of a natural
T cell epitope. Eur J Immunol 1991; 21:2891-2894.
71. del Val M, Schlicht H-J, Ruppert T et al. Efficient processing of an anti-
genic sequence for presentation by MHC class I molecules depends on its
neighboring residues in the protein. Cell 1991; 66:1145-1153.
72. Dutz JP, Tsomides TJ, Kageyama S et al. A cytotoxic T lymphocyte clone
can recognize the same naturally occurring self peptide in association with
a self and a nonself class I MHC protein. Molec Immunol 1994;
31:967-975.
73. van der Bruggen P. Bastin J, Gaiewski T et al. A peptide encoded by
human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lym-
phocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol
1994; 24:3038-3043.
74. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene
MAGE-3 codes for an antigen recognized on a melanoma by autologous
cytolytic T lymphocytes. J Exp Med 1994; 179:921-930.
75. van der Bruggen P, Szikora J-P, Boal P et al. Autologous cytolytic T
lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing
HLA-Cw*1601. EurJ I mmunol 1994; 24:2134-2140.
76. Wdlfel T, Van Pel A. Brichard V et al. Two tyrosinase nonapeptides rec-
ognized on HLA-A2 melanomas by autologous cyrolytic T lymphocytes.
Eur J Immunol 1994; 24:759-764.
77. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the
immunodominant peptides of the MART-1 human melanoma antigen
recognized by the majority of HLA-A2-rcstricted tumor infiltrating lym-
phocytes. J Exp Med 1994; 180:347-352.
78. Bakker ABH, Schreurs MWJ, de Boer AJ et al. Melanocyre lineage-spe-
cific antigen gpl00 is recognized by melanoma-derived tumor-infiltrating
lymphocytes. J Exp Med 1994: 179:1005-1009.
79. Kawakami Y, Eliyahu S. Delgado CH et al. Identification of a human
melanoma antigen recognized by tumor-infiltrating lymphocytes associ-
ated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994:
91:6458-6462.
315
MHC Molecules: Expression, Assembly and Function
80. Buus S, Sette A, Col6n SM et al. Isolation and characterization of anti-
gen-Ia complexes involved in T cell recognition. Cell 1986; 47:1071-1077.
81. Sadegh-Nasseri S, McConnell HM. A kinetic intermediate in the reaction
of an antigenic peptide and I-Ek. Nature 1989; 337:274-276.
82. Nelson CA, Petzold SJ, Unanue ER. Peptides determine the lifespan of
MHC class 11 molecules in the antigen-presenting cell. Nature 1994;
371:250-252.
83. Fairchild PJ, Wildgoose R, Atherton E et al. An autoantigenic T cell
epitope forms unstable complexes with class II MHC: a novel route for
escape from tolerance induction. Internat Immunol 1993; 5:1151-1158.
84. Mason K, McConnell HM. Short-lived complexes between myelin basic
protein peptides and IAk. Proc Natl Acad Sci USA 1994; 91:12463-12466.
85. Cerundolo V, Elliott T, Elvin J et al. The binding affinity and dissocia-
tion rates of peptides for class I major histocompatibility complex mol-
ecules. Eur J Immunol 1991; 21:2069-2075.
86. Olsen AC, Pedersen LO, Hansen AS et al. A quantitative assay to mea-
sure the interaction between immunogenic peptides and purified class I
major histocompatibility complex molecules. Eur J Immunol 1994;
24:385-392.
87. Pamer EG. Direct sequence identification and kinetic analysis of an MHC
class I-restricted Listeria monocytogenes CTL epitope. J Immunol 1994;
152:686-694.
316
Antigen-Specific T Cell Receptors and Their Reactions
with Natural Ligands: Complexes Formed by Peptides
with Major Histocompatibility Complex (MHC) Proteins
Herman N. Eisen, Yuri Sykulev, and Theodore J. Tsomides
Center for Cancer Research and Department of Biology,
Massachusetts Institute of Technology E17-128,
40 Ames Street, Cambridge, MA 02139
tel. (617) 253-6406; fax (617) 258-6172
317
Table of Contents
I Overview
II. History and Background
III. TcR Genes
IV. TcR Protein
V. TcR Ligand: Peptide-MHC Complexes (Pep-MHC)
VI. T Cell Responses to Pep-MHC
A. Affinity: Intrinsic Equilibrium Constants of TcR-Pep-MHC Reactions
B. Kinetics
C. Time Required to Approach Equilibrium
D. Epitope (Pep-MHC) Density
E. TcR-Pep-MHC Engagement: An Affinity Model
1. TcR Affinity Ceiling
2. Kinetic Control of T Cell Responses
F. Specificity, Degeneracy, and Molecular Mimicry
VII. TcR Accessory Proteins
A. CD3 and i
B. CD4 and CD8
VIII. Altered Peptide Ligands: Partial Agonists and Antagonists
IX. MHC Restriction by Self and Nonself MHC: The Paradox of Alloaggression
X. Concluding Remarks
XI. References
318
Abbreviations
Ig, immunoglobulin; mAb, monoclonal antibody; CDR, complementarity determining
region(s); MHC, major histocompatibility complex (genes or proteins); MHC-I, class I
MHC (gene or protein); MHC-II, class II MHC (gene or protein); CTL, cytotoxic T
lymphocyte(s); TcR, antigen-specific T cell receptor(s); DTH, delayed-type
hypersensitivity; APC, antigen presenting cell; ER, endoplasmic reticulum; pep.MHC,
noncovalent complex between peptide and MHC protein; peptide-MHC, reaction
between peptide and MHC protein; TcR*pep-MHC, noncovalent complex between TcR
and pep-MHC; TcR-pep-MHC, reaction between TcR and pep.MHC.
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L Overview
The most distinctive feature of the vertebrate immune system is its ability to
recognize an enormous number of organic molecules and molecular complexes, termed
antigens, distinguishing broadly between those that are foreign to the responding animal
(nonself) and those that are indigenous (self). This property is due to antigen-specific
receptors on lymphocytes, small cells that comprise =5 percent of all cells in the body
(i.e., estimated at 1011 to 1012 out of ca. 1013 cells in an adult human). The receptors
on the two major classes of lymphocytes, B and T cells, are similar structurally but
profoundly different functionally. On B cells the receptors are immunoglobulins (Ig)
embedded in the cell surface as integral membrane proteins; in response to recognition
of antigens, B cells produce large amounts of the receptors and secrete them as soluble
antibody molecules. The antigen-specific receptors on T cells (T cell receptors or TcR)
are also Ig-like cell surface integral membrane proteins; their recognition of antigens
triggers T cells to exercise a great variety of functions, but not to secrete the receptors.
Both Ig and TcR molecules are heterodimers, each subunit consisting of two or
more domains, with each domain having a characteristic three-dimensional shape called
the "Ig fold." The N-terminal domains (termed variable or V domains) differ in amino
acid sequence from one lymphocyte clone to another, the variable domains of each
heterodimer pairing to form a single antigen binding site that determines the unique
ability of each clone to recognize and respond to one or a few similar antigens out of the
millions of different ones to which an individual animal can respond. The enormous
diversity of B and T cell receptors arises from the many germline gene segments that
encode them; as each lymphocyte matures, different combinations of these segments
are joined (combinatorial diversity) and additional variations in sequence are introduced
at the junctures (junctional diversity), leading to an immense number of variable
domain sequences.
Despite extensive similarities in amino acid sequence between Ig and TcR and
in the organization and recombination of the gene segments that encode them, these
receptors differ remarkably in the universe of antigens they recognize. The antigens
recognized by antibodies (or their membrane-bound form on B cells) vary enormously:
physically they may be soluble, colloidal, particulate, or parts of virions or microbial or
eukaryotic cells, and chemically they may be proteins, peptides, carbohydrates, lipids,
nucleic acids, or any of a limitless number of diverse small organic molecules. In
contrast, the TcR reviewed here normally recognize and respond only to complexes
formed between small peptides and a specialized set of proteins encoded by the major
histocompatibility complex (MHC). Because MHC molecules (sometimes called
histocompatibility antigens) are integral membrane proteins, these complexes (termed
pep-MHC) are confined to cell surfaces, and a T cell's TcR is therefore normally able to
recognize antigenic complexes only on the surfaces of other cells, called antigen
presenting cells or target cells. Inasmuch as both TcR and their natural pep.MHC
ligands are embedded in cell surface membranes, analysis of their interaction at the
molecular level poses a major challenge. Later in this review we focus on how this
challenge is being met and emphasize recent results that illuminate the way in which
TcR react with (i.e., "recognize") their natural pep-MHC ligands, particularly the TcR
on those T cells (called cytotoxic T lymphocytes, or CTL) that destroy other cells
(termed target cells).
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II. History and Background
The immune system has been under study for around a hundred years, but it is
only in the past thirty years that T and B cells have been distinguished and only in the
past ten that TcR molecules and the genes encoding them have been identified.
Nevertheless, for decades before T cells and TcR emerged as recognized entities, their
existence was foreshadowed by certain antigen-specific inflammatory responses
produced by injecting antigens into the skin of individuals with previous exposure to
that antigen, either through natural infection or deliberate inoculation ("immunization").
Around 1890, Koch first showed that the injection of tubercle bacilli (or a mixture of
proteins called "tuberculin" from supernatants of tubercle bacilli cultures) elicited an
intense inflammatory response in guinea pigs if they had been previously infected with
these microorganisms. The responses appeared 12-48 hr following antigen injection,
and similar "delayed-type hypersensitivity" (DTH) responses, always specific for the
original inciting antigen, were subsequently demonstrated with crude protein mixtures
from many other microbes (bacteria, fungi, and later viruses) and sometimes following
deliberate immunization with purified proteins (e.g., ovalbumin) or even with small
organic molecules applied to the skin, providing they reacted in situ to form covalent
derivatives of skin proteins (as with 2,4-dinitrochlorobenzene, or a catechol in the case
of poison ivy).
In contrast to the late appearance of DTH responses, many other antigen-specific
skin responses appear almost immediately, e.g., within 1 min or sometimes up to 2-3 hr.
Because the transfer of serum antibodies from an immunized to a nonimmunized
(naive) individual confers on the recipient the same prompt antigen-specific responses,
it was clear that these rapid ("immediate-type") responses were mediated by antibodies.
But serum failed to transfer the delayed-type responses (e.g., to tuberculin). Although
efforts were made to reconcile these failures with a role for special antibodies, it came
to be widely believed that antigen-specific cells rather than soluble antibody molecules
were the direct mediators of DTH responses. This belief was supported by the finding
that DTH responses could be transferred to naive recipients with inflammatory cells
from immunized donors, although the transferred cells were complex mixtures of
leukocytes that probably included some antibody-forming cells. The resolution of all
doubt ultimately came after T cells were distinguished from B cells, largely through
studies involving extirpation of the thymus from newborn mice. These studies led to
the establishment of a clear dichotomy between those lymphocytes that develop from
immature precursors in the thymus (T cells) and those that develop to maturity in the
bone marrow (B cells). B cells were shown to be the source of Ig and antibodies, and T
cells were shown to be required for the optimal production of antibodies. In addition,
highly purified populations of T cells could transfer DTH responses, suggesting that T
cells bear receptors that recognize antigens.
Early studies on the nature of the antigen-recognizing receptors on T cells were
marked by intense disagreements arising largely, it appears in retrospect, because the T
cell populations studied were often contaminated by small numbers of B cells and
because reliance was placed almost exclusively on serological analyses using anti-Ig
antisera. Antigen-specific molecules on T cells were variously suggested to be Ig
molecules firmly attached to T cells, or to be some other (non-Ig) type of cell associated
protein, or not even to be protein but rather some other type of informational
macromolecule. The debate was ultimately resolved by the development of monoclonal
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antibody (mAb) technology and the ability to grow T cell clones in culture. Using mAb
raised against T cell clones, one a malignant lymphoma and the others normal T cells,
three independent studies succeeded in immunoprecipitating a T cell surface protein
that was unique for cells of the immunizing clone (Allison et al., 1982; Meuer et al.,
1983; Haskins et al., 1983). The clonally specific (or clonotypic) protein was in each
case a disulfide-linked heterodimer (=90 kDa), consisting of a relatively acidic
membrane-bound a chain and a more basic membrane-bound 0 chain.
The idea that these clone-specific heterodimers were antigen-specific receptors
was strengthened by two findings. First, antibodies against them could block antigen-
driven responses of the corresponding T cell clones (Lancki et al., 1983). Second,
amino acid sequences of proteolytic fragments from isolated a and 0 subunits suggested
that, like Ig heavy and light chains, they had some regions where amino acid sequences
varied from clone to clone and others where these sequences were invariant (Kappler et
al., 1983; Meuer et al., 1984; McIntyre and Allison, 1983). The isolation and
sequencing of cDNA clones for the 3 subunit (Yanagi et al., 1984; Hedrick et al., 1984;
Saito et al., 1984a) and then for the a subunit (Saito et al., 1984b; Chien et al., 1984)
finally demonstrated unambiguously that the clonally diverse heterodimers greatly
resembled Ig and had all the characteristics expected of cell surface integral membrane
proteins serving as antigen-specific receptors. Moreover, introduction of genes for both
the a and 0 subunits into a T cell clone having unrelated specificity transferred the
donor cell's antigen-specific responsiveness to the recipient cell (Dembic et al., 1986;
Saito et al., 1987).
In the course of searching a T cell cDNA library for clones for the a and 3
subunits, cDNA for a third related subunit was found (Saito et al., 1984a). Termed y,
the third gene turned out to encode an Ig-like chain that paired with the product of a
fourth gene, 6, to form a y8 heterodimer (Chien et al., 1984). Closely similar to the a(X
TcR, y6 heterodimers are another type of antigen-specific receptors, found on a subset
of T cells located primarily in epithelia. 78+ cells constitute about 1-5% of peripheral T
cells in mice and humans; these TcR will not be considered further here, as their
natural ligands are not as well defined as those recognized by ap TcR and the function
of 16 T cells is still not entirely clear.
Ten years before the molecular identity of the up TcR began to take shape,
several observations pointed to the special character of its natural ligands. By
transferring T cells to athymic ("nude") mice, Kindred and Shreffler (1972) saw that
these cells reacted only when the T cells and the recipients had the same MHC type.
The ineffectiveness of MHC-disparate T cells could not be attributed to their immune
elimination in the recipient, because athymic mice do not reject allografts. It was
therefore concluded that the MHC "must play an active role in ensuring cooperation
between B and T cells."
Shortly thereafter, in vitro studies of T cell enhancement of the production of
antibodies by B cells (Katz et al., 1973) and of T cell responses to antigens presented by
macrophages (Rosenthal and Shevach, 1973) also indicated that successful T cell
responses required the responding T and B cells, or T cells and macrophages, to have
the same MHC type. Then, in a seminal publication, Zinkernagel and Doherty (1974)
reported that virus-infected target cells were lysed by T cells from a mouse infected by
that virus only if the target cells expressed the same MHC products as the infected
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animal. Work with different antigens revealed similarly that antigen-specific lysis of
antigen-bearing target cells by cytotoxic T cells depended upon target cell expression of
a proper MHC protein (Shearer, 1974; Bevan, 1975; Gordon et al., 1975). This dual
requirement of antigen recognition, referred to as "MHC restriction" (Zinkernagel and
Doherty, 1979), has since been found to be characteristic of all op TcR mediated
reactions.
To explain MHC restriction, two models were proposed. In the two-receptor
model, T cells have one receptor for an MHC product and another one for antigen, and
both have to be occupied for a successful T cell response (Cohn and Epstein, 1978).
According to the alternative one-receptor model, each T cell has a single type of
receptor that recognizes an antigen.MHC complex. The one-receptor model was
ultimately shown to be correct by various approaches. In one, a hybridoma resulting
from the fusion of two cells recognizing antigen "A" and MHC "X" or antigen "B" and
MHC "Y" responded specifically to cells expressing either A + X or B + Y but not to
those expressing A + Y or B + X, indicating that the T cell did not see the antigen and
the MHC product separately (Kappler et al., 1981). The antigen-MHC complex was
sometimes referred to as "altered self' because in this context the restricting MHC is
indigenous (self) with respect to the responding T cells and is therefore
nonimmunogenic, while the antigen is foreign (nonself) and somehow alters the
character of self MHC so as to elicit a reaction.
Mature T cells bearing apx TcR fall into two groups, each marked by one of two
cell surface glycoproteins. Termed CD4 and CD8 (formerly called Lyt-1 or Lyt-2,3 in
the mouse), both are present on immature ("double positive") T cells in the thymus, and
one of these is lost by what appears to be a stochastic process (Corbella et al., 1994) to
yield "single positive" (CD4+ or CD8+) mature T cells. Some mature CD4+ T cells,
termed helper (Th2) cells, are required for optimal B cell responses, while other helper
cells (Th 1) produce cytokines that cause inflammation, as in DTH responses. In
contrast, CD8+ T cells, which also produce some cytokines, behave primarily as
cytotoxic T lymphocytes (CTL), lysing target cells that bear appropriate antigen.MHC
complexes.
The CD4/CD8 T cell dichotomy also extends to the types of MHC protein that
restrict antigen recognition. Class I MHC proteins (MHC-I) restrict antigen recognition
by CD8+ T cells, and class II MHC proteins (MHC-II) restrict antigen recognition by
CD4 + T cells (Table I). Virtually all cells express MHC-I and can present peptides to
CD8+ cells, whereas only specialized cells (principally macrophages, dendritic cells and
B cells) express MHC-II for interactions with CD4+ cells. By common usage, cells that
present pep-MHC-II complexes to CD4+ cells are called "antigen presenting cells"
(APC), whereas those that present pep-MHC-I complexes to CD8+ CTL are termed
"target cells."
Once it became established that a single heterodimeric receptor on T cells reacts
with an antigen displayed on the surface of another cell, and that the antigen includes
both a self (restricting) MHC protein and a bona fide foreign element (such as a virus-
encoded product), it was reasonable to assume that the MHC protein and the foreign
protein combine to form an antigenic complex in the plasma membrane of the target cell
(e.g., Cohen and Eisen, 1977). However, the subsequent finding that T cells responding
to viral infections are paradoxically specific for intracellular proteins that are not found
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at the cell surface (e.g., influenza virus nucleoprotein: Townsend and McMichael,
1985; Yewdell et al., 1985) led Townsend and colleagues to the discovery that short
peptides (ca. 8-25 amino acids in length) derived from internal viral proteins, can
sensitize target cells bearing appropriate MHC molecules for lysis by CD8+ T cells
(Townsend et al., 1986).
It has since become clear that: (1) the natural ligands for TcR are cell surface
complexes each consisting of a short peptide and an MHC protein (pep-MHC); (2)
under normal conditions the peptides are produced intracellularly by limited proteolysis
("processing") and are transported into the endoplasmic reticulum (ER) where they can
bind to newly formed MHC proteins; and (3) this physiological pathway can be
circumvented by adding to whole cells synthetic peptides that bind directly to a subset
of cell surface MHC molecules that are free of naturally processed peptides or bind
them weakly. The idea that fragmented protein antigens, i.e., peptides, can be
recognized by T cells had actually emerged from earlier studies of Unanue and Allen
(1987) on antigen presentation to CD4+ T cells by MHC-II + APC. Indeed the first
unequivocal and quantitative demonstration of binding between a defined peptide and
an MHC molecule was obtained for MHC-II (Babbitt et al., 1985).
In mice and humans, MHC-I proteins are encoded by genes at three linked loci
(termed K, D, and L in mice and A, B, and C in humans), and MHC-II proteins by
several genes at two or three linked loci (termed IA and IE in mice and DP, DQ, and
DR in humans). Most of these genes are extremely polymorphic, some having as many
as 50 (or more) allelic variants. Any particular individual inherits alleles for only a
small number of MHC proteins, at most six MHC-I and six MHC-II in humans, due to
heterozygosity at each gene locus. Some inbred mouse strains have only two MHC-I
and a single MHC-II protein. Remarkably, however, these few proteins can effectively
present an enormous number of different peptides to a vast number of TcR, each MHC
protein having the capacity to bind to thousands of different peptides with equimolar
(1:1) stoichiometry. Although some peptides can be bound by more than one MHC
protein, each MHC protein binds to distinctly different sets of peptides. How each of
these protein molecule is able to bind so many different peptides and yet retain a
significant degree of selectivity has become clear as a result of striking advances over
the last five years, particularly in the solution of several three-dimensional structures of
crystallized pep-MHC complexes (see Section V, below).
III. TcR Genes
The genes that encode TcR c and 0 chains are assembled in developing T cells
in the thymus by the juxtaposition of variable (V), diversity (D), and joining (J) gene
segments to form VJ or VDJ or VDDJ exons, separated by a short intron from an exon
for the constant (C) domain. The great similarity in organization of TcR and Ig gene
segments is striking (Davis, 1990) and include the canonical heptamer and nonamer
signal sequences adjacent to TcR V, D and J segments; these signal sequences are
almost the same for TcR and Ig genes and, indeed, are interchangeable (Yancopoulos et
al., 1986).
TcR 0 gene segments are spaced over 700-900 kb of human (or mouse) DNA,
with an array of multiple VP segments separated from two tandemly duplicated
sequences each including one Dp, six Jp, and one Cp segment. All of these segments
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have the same transcriptional orientation except for one downstream VP segment
(Fig. 1). TcR a gene segments are also distributed in a long linear array, but
surprisingly these were found to be interrupted by J and C sequences of the TcR 8 chain
(Chien et al., 1984). The pairing of a 8 with a y chain forms the 78 heterodimeric
receptor on the small subset of T cells (y6+) referred to above. Because a single locus
contains gene segments for both a and y chains, the rearrangements and expression of a
and y genes are regulated by an intricate process (Winoto and Baltimore, 1989; Diaz et
al 1994). Evidently, a V gene from the same upstream array in this locus can join either
to J8 (or D8 and J8 segments), to form a complete VJ8C6 (or VDSJ8CS) sequence for a
8 chain, or to one of many Jo segments to form a complete VJaCa sequence for an a
chain. In T cells that express an up TcR, the joining of a V gene to a Ja eliminates 8
gene sequences and thus precludes expression of a 8 chain. In T cells that express )7
receptors, the joining of a V segment to D and/or J8 takes place first and evidently
suppresses subsequent rearrangements involving a gene segments.
Despite many similarities in the organization of Ig and TcR genes and their
extensive amino acid sequence homology, they differ in some important respects as
noted below.
Localization of Hypervariable Sequences in TcR V Domains. In Ig there are
three especially variable ("hypervariable") regions in V domains of light and heavy
chains, and x-ray crystallographic studies show that these form the boundaries of
antigen binding sites of antibodies (Davies et al., 1990). Because they determine the
complementary fit of antibody to antigen, they are referred to as "complementarity
determining regions," or CDR (i.e., CDR1, CDR2, and CDR3).
Comparison of the amino acid sequences of a and P variable (V) domains from
many TcR have shown that, in contrast to Ig, the CDR1 sequences of up TcR vary very
little, the CDR2 sequences vary only slightly more, but that the CDR3 sequences vary
greatly in length and sequence. The great variation of CDR3 reflects the very large
number of TcR J gene segments as compared with those for Ig genes (e.g., ca. 50 Ja
and 12 Jp segments in contrast to 4 JH and 5 JK segments for murine Ig). As discussed
below, the extensive variation in CDR3 and J sequences suggests that the most diverse
element of the pep-MHC ligand that binds to a T cell receptor, the peptide moiety,
makes contact with the receptor's CDR3 region, whereas the less variable flanking a-
helical regions of the MHC protein make contact with CDR 1 and CDR2.
Alternative RNA Splicing. Alternative splicing of RNA transcripts of Ig genes
plays a critical role in modifying the 3' ends of messenger RNA in order to generate
proteins that are secreted as antibodies or retained as cell surface antigen-specific B cell
receptors. In contrast, RNA splicing is not involved in the expression of TcR genes,
and TcR molecules are not secreted; they invariably remain as integral membrane
proteins on T cell surfaces.
Isotype Switching. Gene sequences for the V domains that determine the
specificity of antibodies for antigens can be spliced to one of several different
immunoglobulin C regions to yield various forms of heavy chains called isotypes.
Different Ig isotypes have different functional roles: for example, certain ones bind to
receptors on B cells and macrophages, certain others can be transported across the
placenta, and others bind to receptors on mast cells to mediate anaphylactic reactions.
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During the course of normal B cell differentiation, "switching" of isotypes can occur
(with no change in antigen specificity). For TcR, there is no comparable switching
because there are no forms homologous to Ig isotypes.
Somatic Mutation. A distinctive feature of the antibodies produced in response
to antigenic stimulation is the progressive increase over time in intrinsic affinities of the
antibodies made against an antigenic epitope. These changes are the result of extensive
somatic mutation that takes place in the V, D, and J regions of rearranged Ig genes
during prolonged or repeated antigenic stimulation, together with selection by the
antigen of B cells producing high-affinity antibodies (for a minireview see Foote and
Eisen, 1995).
Comparisons among the sequences of several hundred V regions from TcR a
and 0 mRNA or cDNA failed to reveal systematic evidence for somatic mutation, as the
sequences nearly always matched one or another of the germline sequences (Davis,
1990). The important implication is that progressive increases or "maturation" in the
intrinsic affinities of TcR does not occur, and thus TcR affinities for their ligands will
generally reflect the distribution of affinities arising from germline sequences and
variations introduced by joining V, D, and J gene segments. Recently, however, Zheng
et al. (1994), in a careful analysis of lymphocytes in lymph node germinal centers
(where B cells undergo somatic mutation), found evidence for somatic mutation of TcR
V regions. Whether antigen selection of the mutated T cells takes place, as it does for B
cells, is not yet clear.
Allelic Exclusion. In a newly developing, immature thymocyte, productive (in-
frame) rearrangement of a Vp gene segment in one chromosome prevents
rearrangement of additional Vp gene segments on the other chromosome (Van
Meerwijk et al., 1991; Malissen et al., 1992). However, Va segments on both
chromosomes rearrange at the same time and can continue to rearrange until a complete
ap TcR is formed and the cell is stimulated (by "positive selection" in the thymus) to
mature into a single positive T cell (CD4+ or CD8+). As a result, almost one-third of
mature T cells in the periphery carry two productively rearranged a genes and have on
their surface two TcR species, differing in a chain but having the same P chain
(Padovan et al., 1993; Heath and Miller, 1993; Mason, 1994).
Because antibodies can bind via their constant (Fc) region to certain receptors
(called FcR) on target cells, some antibodies to a TcR can mimic the TcR's natural
ligand and trigger "redirected lysis" of an FcR+ target cell by CTL expressing that TcR
(Kranz et al., 1984b), even though the target cell lacks a pep.MHC complex that is
recognized by the TcR. Thus, a target cell expressing FcR was shown to be lysed by a
CTL having two TcR, call them al01i and a2p 1, in the presence of either antibody to al
or antibody to a2, indicating that each TcR of such a two-receptor T cell can, when
ligated via its Va domain, trigger T cell activation (Padovan et al., 1993). This
circumstance raises interesting possibilities, not yet critically tested, that a mature two-
receptor T cell that is stimulated to proliferate via one TcR will result in an increased
number of cells expressing both TcR molecules, perhaps increasing the possibility of
reactions with different pep-MHC. Because the two receptors on such a T cell would be
expected to have different specificities, they might increase opportunities for reactions
against autoantigens or MHC-disparate cells (see Section IX, below). Experiments with
mice transgenic for a TcR P subunit suggest, however, that in antigenically stimulated T
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cells there may be unknown mechanisms that hinder expression of a nonutilized TcR
(Hardardottir et al., 1995), as with Ig receptors on B cells transfected with multiple KC
chain genes (Lozano et al., 1993).
IV. TcR Protein
Once the primary structures of a large number of T cell receptors became known
through the sequences of their V, D, J and C genes, it became possible to look for clues
regarding their tertiary structures. It was obvious on the basis of sequence homologies
that TcR belong to the so-called immunoglobulin superfamily. That is, the domains of
a heterodimeric TcR (VaVp and CaCf) were expected to have the same chain topology
and secondary structure elements as the canonical Ig fold (reviewed elsewhere in this
volume). However, this observation did not lead to an understanding of how TcR
recognize an antigenic universe consisting of relatively few MHC proteins combined
with a great many different peptides (thousands for each MHC protein).
Further analyses of sequence homologies between Ig and TcR (roughly 25-30%
identity between the two groups) led to more detailed structural predictions. Following
the first complete cDNA sequence of the TcR, Novotny et al. (1986) aligned the
sequences of TcR a, 0, and y chains with those of Ig of known three-dimensional
structure and concluded that a TcR molecule was likely to possess a single antigen
binding site that is essentially no different from that of an Ig. Later, Chothia et al.
(1988) identified 40 amino acid residues critical for the conserved structure of Ig
variable domains, either because they serve as framework residues or because they are
crucial for interdomain contacts (VL-VH or VH-CH1), and compared these with the
corresponding residues in =200 TcR Va and Vp sequences. They found a high
percentage of the same or very similar residues at these positions, often 90+% identity,
and they also found important similarities in the distribution of hypervariable regions
between Ig (three such regions per VL or VH chain) and TcR (Va and Vp chains). As
mentioned above, these noncontiguous hypervariable regions combine in the three-
dimensional folded structure of an Ig to form the antigen binding site, and are termed
complementarity determining regions, or CDR. Unlike Ig, however, the first and
second predicted CDR of a TcR are much less variable than the third, called CDR3
(approximately residues 95-105 from the N-terminus).
Building upon the freshly made discovery that peptides are an integral part of
the antigenic structures recognized by T cell receptors, Davis and Bjorkman (1988)
proposed a model for T cell recognition in which two CDR3 regions (from Va and Vp)
interact primarily with peptide, while CDR1 and CDR2 (each from both Va and VP)
interact with the two a-helices flanking the peptide binding site. These authors also
emphasized the greater diversity in a TcR's CDR3 regions than in CDR1 and CDR2;
the latter are fully encoded by germline V genes, of which there are relatively few,
whereas CDR3 is formed by the joining of V and J genes (in TcR a and y) or V, D and J
genes (in TcR 3 and 8). Because of prevalent N-region additions at these junctions (due
presumably to terminal deoxynucleotidyl transferase), as well as other mechanisms for
diversification, TcR variability is highly concentrated in the CDR3 region (Davis and
Bjorkman, 1988).
Since the MHC sites in contact with a TcR are generally less variable than the
peptide residues recognized by a TcR, the above model provided a rationale for the
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greater sequence diversity of CDR3 than of CDR1 or CDR2; it also accommodated
functional data from studies in which variations only in the CDR3 residues within a set
of T cell clones affected peptide recognition but not MHC specificity (Fink et al., 1986;
Winoto et al., 1986). Furthermore, this model, independently suggested by Chothia et
al. (1988) and by Claverie et al. (1989), was consistent with the dimensions observed in
the first crystal structure of an MHC protein (Bjorkman et al., 1987a): the peptide
binding groove is =10 A wide and 25 A long (Fig. 2), while the spacing between the
predicted CDR3 segments in the TcR is -=10-15 A. The two CDR3 regions were
therefore projected to interact with =5 residues of a bound peptide (Claverie et al., 1989;
see also Section IX, below).
In a revealing study, Jorgensen et al. (1992) immunized mice transgenic for
either the ox or the P chain of a particular TcR with a series of variant peptides.
Analysis of the T cell responses in these mice indicated that some peptide variants
elicited T cells having complementary changes in the CDR3 regions of their TcR;
furthermore, the contact sites for two peptide side chains could be assigned to either the
TcR VO or Vp chain.
To date no three-dimensional structure of a complete TcR molecule has been
reported. Such a structure is eagerly awaited, not only to illuminate the structure of the
TcR itself, but hopefully to explain in molecular terms how the TcR's universe of
antigens is limited to pep-MHC complexes, while that of antibodies is virtually
limitless. The recently reported structure of a TcR 0 chain revealed Ig-like domains and
three CDR loops plus an additional hypervariable loop whose significance is not yet
clear (Bentley et al., 1995).
V. TcR Ligand: Peptide*MHC Complexes (Pep.MHC)
Beginning with Townsend and colleagues (Townsend and Bodmer, 1989), a
common method for studying the ligands recognized by T cells on various target cells
(e.g., virus-infected, tumor, or allogeneic cells) has been to add synthetic peptides to
different target cells that express an appropriate MHC protein, forming pep-MHC
complexes that can elicit a measurable T cell response. This approach has been
successful in part because the added synthetic peptide need not match precisely the
natural ligand (e.g., a processed viral peptide); it can be substantially longer, for
example, and then undergo limited trimming by proteases in the assay medium or on
cell surfaces to reach the optimal length for binding to an MHC protein. However, in
some instances it is important to know the exact identity of a naturally processed
peptide, in order, for instance, to determine the number, or density, of specific
pep-MHC complexes on the surfaces of target cells (reviewed in Tsomides and Eisen,
1993a).
An understanding of the relationship between the synthetic peptides that can be
used to elicit T cell responses and the naturally processed peptides that are generated
within cells has rested on two principal lines of investigation: (1) x-ray crystallographic
determination of MHC structures; and (2) direct biochemical isolation and sequencing
of endogenous peptides associated with MHC molecules. The nature of the MHC and
its ligand was greatly illuminated when the first crystal structure of an MHC protein, the
human MHC-I protein HLA-A2, was solved by Bjorkman et al. (1987a). The molecule
consisted of four domains of =90 amino acids each, three derived from an a chain (cl,
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U2, and a 3) and one comprising 32-microglobulin (32m). While the membrane
proximal a3 and P2m domains resembled Ig domains, o a and ;2 paired to form a novel
structure: an 8-stranded antiparallel 3-sheet underlying two long a-helices (Figs. 2 and
3). Between the two ca-helices was a continuous region of unassigned electron density
later shown to represent a complex mixture of peptides that copurified with HLA-A2;
since A2 purification takes several days at least, this observation proved to be the first
clue that some naturally processed peptides can form extremely stable complexes with
MHC-I proteins, often having dissociation half-lives in the tens of hours (Cerundolo et
al., 1991; Tsomides et al., 1991; Olsen et al., 1994). The crystal structure of HLA-A2
furthermore suggested that the unknown peptides harbored between the two oa-helices
might be between 8 and 20 amino acids in length, based on the approximate dimensions
of the binding site (25 x 10 x 11 A) (Bjorkman et al., 1987b).
More precise definition of some natural ligands was achieved through an acid
elution technique used to separate peptides from MHC molecules (Buus et al., 1988;
Ritzschke et al., 1990a), followed by characterization of the resulting peptides. The
first naturally processed peptides to be identified were viral products obtained from
infected cells (van Bleek and Nathenson, 1990; Rijtzschke et al., 1990b), and these were
8 or 9 residues long. Other MHC-I associated peptides present at relatively high levels
were resolved by HPLC and sequenced by Edman degradation (Jardetzky et al., 1991;
Corr et al., 1992) or by a mass spectrometric approach pioneered by Hunt and
colleagues (1992a); these proved to arise from a variety of intracellular components
and were often 8 or 9 residues in length, though sometimes longer (Henderson et al.,
1992; Wei and Cresswell, 1992). Rammensee and colleagues then performed a critical
experiment in which they subjected the total pool of peptides eluted from MHC-I
molecules to sequencing by Edman degradation (Falk et al., 1991a). While they found
each amino acid at virtually every cycle during the Edman procedure, they discovered
several key facts about naturally processed peptides: (1) for a given MHC-I protein
(such as HLA-A2), the eluted peptides contained a predominance of one or two amino
acids at certain key "anchor" positions (e.g., leucine or methionine at position two, and
valine or leucine at position nine); (2) amino acid yields dropped precipitously after 9
cycles, suggesting that most bound peptides are nonamers (octamers for certain MHC-I
molecules); and (3) the "motifs" characterizing peptide length and anchor positions
were distinctive from one MHC-I protein to another.
These motifs have been highly useful for the rapid identification of candidate
peptides recognized by T cells when the parent protein sequence is known (Ri$tzschke
et al., 1991a; Pamer et al., 1991). However, this approach is not infallible for several
reasons: (1) some MHC-binding peptides do not conform to the expected motif and
therefore will be missed (e.g., Udaka et al., 1992); (2) synthetic peptides that are found
to be active need not always correspond to naturally processed peptides, even when
optimized for activity, since heteroclitic reactions can occur for T cell receptors
(Bodmer et al., 1988) as well as for antibodies; and (3) nonphysiological cross-
reactions can be observed when target cells are sensitized with high doses of synthetic
peptides, due to the resulting artificially high pep.MHC densities (Milligan et al., 1990;
Schild et al., 1990; Dutz et al., 1994; Tsomides et al., 1994). Despite these caveats,
several naturally processed peptides recognized by T cells have turned out to match
precisely the peptides predicted from motifs (Ritzschke et al., 1990b; van Bleek and
Nathenson, 1990; Ratzschke et al., 1991a; Pamer et al., 1991; Tsomides et al., 1994)
(Table II), leading to the reasonable assumption that this will often be the case.
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All the biochemical information about naturally processed peptides bound to
MHC-I molecules fit neatly with the emerging crystallographic data. Monopeptidic
pep-MHC complexes were obtained and crystallized, revealing important structural
similarities and differences among peptides binding to the same MHC-I molecule
(Fremont et al., 1992; Zhang et al., 1992; Madden et al., 1993). Pockets within the
MHC binding site were shown to accommodate peptide side chains at the positions
described as anchors (Garrett et al., 1989; Matsumura et al., 1992a; Young et al., 1994).
Peptides longer than 9 residues could fit by bulging out in the middle, with both peptide
termini substantially buried in the binding site (Guo et al., 1992). Within a short time, a
coherent picture of how a single MHC molecule can bind to a highly degenerate but
restricted set of peptides was assembled.
Comparable findings (peptide motifs, MHC pockets) were later made for MHC-
II molecules, although in this case the situation proved more complex. Naturally
processed peptides binding to MHC-II molecules turned out to include sets of nested
peptides sharing a core sequence but having different N- and C-termini (Demotz et al.,
1989; Nelson et al., 1992; Chicz et al., 1992). These peptides tended to be longer than
those eluted from MHC-I proteins, ranging from about 12-25 residues (Rudensky et al.,
1991; Hunt et al., 1992b). Again, this information correlated well with the results of
crystallography. The structure of an MHC-II molecule complexed with endogenous
peptides (Brown et al., 1993) or with a single viral peptide (Stern et al., 1994) revealed
two major differences from MHC-I: (1) the MHC-II binding groove allows bound
peptides to extend out at both ends, rather than having their termini tucked into the
binding site, thereby explaining the length heterogeneity among naturally occurring
MHC-II-associated peptides (see Fig. 3B); and (2) many of the peptide-MHC-II
contacts involve the peptide backbone rather than specific peptide side chains, implying
different mechanisms for degenerate peptide binding by MHC-I and MHC-II proteins
(Table I).
Once it was appreciated that purified MHC-I molecules are normally occupied
by stably bound endogenous peptides, the failure of early attempts to demonstrate
significant peptide binding to purified MHC-I molecules (Chen and Parham, 1989;
Tsomides and Eisen, 1990) became understandable. Soon, techniques based on whole
cell binding assays (Christinck et al., 1991), MHC-I immunoprecipitation from cell
lysates (Cerundolo et al., 1991), or in vitro binding to empty MHC-I molecules purified
from transfected Drosophila (Matsumura et al., 1992b; Saito et al., 1993) or other
(Boyd et al., 1992; Ojcius et al., 1993; Fahnestock et al., 1994) cells enabled the
measurement of equilibrium binding constants for a wide variety of peptide-MHC-I
reactions. Parker et al. (1992; 1994) used P2m dissociation as a surrogate indicator for
the stability of pep-MHC-I complexes, and Olsen et al. (1994) found that peptides bind
well to purified MHC-I molecules at reduced temperatures. Each of these experimental
systems suffers from certain limitations, a shared one being that the binding of synthetic
peptides to fully formed MHC-I molecules may not accurately mirror events in the ER,
where this reaction ordinarily takes place. Nevertheless, these equilibrium values seem
to reflect the specificities otherwise observed for peptide-MHC-I reactions, and similar
measurements have proved useful as indicators of potential peptide immunogenicity
(Feltkamp et al., 1993; Celis et al., 1994; Sette et al., 1994).
Given the ability to measure equilibrium constants for the peptide-MHC
reaction, the number of pep-MHC complexes per target cell required to trigger the
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activity of a given T cell clone can be estimated in assays where T cell activity depends
upon the concentration of synthetic peptides (added to extracellular medium). The
estimates are based on the Karush (1970) form of the law of mass action (Day, 1990):
r = K-c.n/(l+K.c), (1)
In Eq. 1, (r) is the number of pep.MHC complexes per target cells, (K) is the
equilibrium association constant for a peptide-MHC reaction, (c) is the free
concentration of peptide that sensitizes target cells for a particular level of lysis (e.g.,
half-maximal) by a given CTL, and (n) is the total number of MHC binding sites per
target cell accessible to extracellular peptide. For several reasons, the calculated values
of r should be regarded as only reasonable approximations, e.g., because the peptide
may be subject to proteolytic degradation during the assays. More importantly, the
number of accessible sites (n) changes over time as newly synthesized MHC molecules
migrate to the target cell surface and some (unknown) proportion have accessible
peptide-binding sites, either because the sites are empty or occupied by rapidly
dissociating natural peptides that exchange readily with peptides in the extracellular
medium. Nevertheless, Eq. 1 yields reasonable approximations for those peptides
whose reactions with MHC (on intact cells) reaches steady state within a short time
(e.g., 2-3 hours).
As discussed below, and in contrast to earlier studies reporting values of a few
hundred (Harding and Unanue, 1990; Demotz et al., 1990; Vitiello et al., 1990;
Christinck et al., 1991), the minimum number of activating complexes per target cell
was recently found to vary over several orders of magnitude depending on the particular
T cell, MHC-I molecule, and peptide used, from several thousand per target cell to
fewer than ten in optimal combinations (Kageyama et al., 1995) (see Section VI.D,
below).
How do the pep-MHC complexes recognized by T cells arise? CD8+ T cells
react with pep-MHC-I complexes that form within a cell's ER as newly synthesized
MHC-I molecules assemble (reviewed by Monaco, 1992; Yewdell and Bennink, 1992;
Germain and Margulies, 1993; Heemels and Ploegh, 1995). The peptides are generated
by limited proteolysis in the cytosol and translocated into the ER by MHC-encoded
peptide transporters, TAP ("transporter associated with antigen processing") (Spies et
al., 1991), or in some cases via TAP-independent pathways (Anderson et al., 1991;
Henderson et al., 1992; Zweerink et al., 1993; Hammond et al., 1993; Zhou et al.,
1993). Once inside the ER, peptides may or may not be subject to further proteolysis
(Falk et al., 1990; Yewdell et al., 1994) before binding to nascent MHC-I molecules,
which are then exported to the cell surface as mature pep-MHC complexes.
Given several thousand intracellular proteins potentially available for
degradation in any given nucleated cell, and many-fold higher numbers of peptides
theoretically available for transport into the ER and subsequent binding to MHC-I
molecules, it is apparent that competition among peptides must be a significant feature
of antigen presentation. It may be that only tightly-binding peptides compete
effectively for MHC-I binding sites, explaining the slow dissociation rates that have
been measured. Certainly peptide selectivity exists at the levels of MHC binding (Falk
et al., 1991a; Schumacher et al., 1991) and TAP-mediated peptide translocation into the
ER (Shepherd et al., 1993; Neefjes et al., 1993; Schumacher et al., 1994), and perhaps
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also at the level of proteolysis (Goldberg and Rock, 1992), but much remains to be
clarified about the generation of MHC-I binding peptides in vivo.
What is clear is that the pep.MHC-I complexes ultimately arriving at a cell's
surface represent a sampling of that cell's contents, with some peptides present at
relatively high copy numbers, e.g., several hundred to perhaps several thousand
identical pep.MHC-I complexes per cell, and a greater number of peptides relatively
scarce, e.g., between 1 and 100 complexes per cell (van Bleek and Nathenson, 1990;
Falk et al., 1991b; Hunt et al., 1992a; Udaka et al., 1992; Tsomides et al., 1994). Most
natural MHC-I-binding peptides arise from an individual's normal self proteins and are
not recognized efficiently by that individual's mature T cells, which are purged of most
self-reactive cells as they develop in the thymus ("negative selection") or rendered
unresponsive (anergic) in the periphery (Schwartz, 1989). However, peptides from a
foreign protein, e.g., originating from a virus or other intracellular microbe (Townsend
and Bodmer, 1989), or an anomalous self protein, such as a tumor cell's mutated protein
(Lurquin et al., 1989; Mandelboim et al., 1994), can (in association with a self MHC-I
protein) elicit and react with CD8+ T cells. Peptides from certain normal (nonmutated)
self proteins in some tumors can also be recognized, in association with MHC-I, by T
cells that react against the tumor (Boon, 1994); for example, CD8 + T cells that can be
isolated from excised human melanomas (Kawakami et al., 1994a, b; Coulie et al.,
1994; Castelli et al., 1995; Bakker et al., 1994; Tsomides et al., 1996) or lymph nodes
(Cox et al., 1994) have recently been shown to recognize peptides from nonmutated
melanocyte-specific proteins in association with HLA-A2. The underlying requirement
for all of these responses to be productive is that the abundance of the naturally
processed pep.MHC complex is sufficient and the TcR affinity and kinetics are
favorable (see Section VI, below).
CD4+ T cells, in contrast to the CD8+ cell, react with pep-MHC-II complexes on
specialized APC (e.g., macrophages, dendritic cells, B cells). Peptides that bind to
MHC-II proteins generally arise from integral membrane proteins or from endocytosed
proteins, either soluble or membrane-associated (Tables I and II). These peptides are
produced in special endosomal organelles by a set of cellular proteases that differ from
those that generate MHC-I-binding peptides. Newly synthesized MHC-II molecules,
complexed with a nonpolymorphic invariant chain, traffic into this endocytic pathway
(Neefjes et al., 1990) and come into contact with the available peptides. There, the
invariant chain is partially degraded, allowing some of the peptides to bind to MHC-II
molecules under acidic conditions (pH optimum =5.0) and leading to egress of
pep.MHC-II complexes to the cell surface. Studies aimed at quantitating the binding
between synthetic peptides and MHC-II molecules succeeded before those involving
peptide-MHC-I reactions (Babbitt et al., 1985; Buus et al., 1986; Jardetzky et al., 1990;
Roche and Cresswell, 1990; Roof et al., 1990; Rothbard and Gefter, 1991). As with
MHC-I binding peptides, immunodominance describes the phenomenon whereby only
one or a few peptides from a given protein is bound efficiently by a given MHC-II
molecule and presented to T cells, accounting for the bulk of a polyclonal T cell
response to that protein.
Of considerable biological interest are the kinetics of the reactions between
peptides and MHC proteins. The first kinetic data, obtained for MHC-II, indicated
unusually slow on- and off-rates for the peptide-MHC reaction (e.g., tl/2 off = 5-10 hr
at 370 C, Buus et al., 1986). Sadegh-Nasseri and McConnell (1989) subsequently found
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evidence for rapid formation of a quickly dissociating complex that slowly converted to
a stable form (tl/2 off >30 hr); the long half-life for peptide dissociation was shown to
limit the association rate for an added peptide (Tamp6 and McConnell, 1991). These
kinetically distinguishable pep-MHC-II complexes correlated with different behaviors
in SDS-polyacrylamide gel electrophoresis: the short-lived complex dissociated into
MHC-II o and P subunits, whereas the more stable complex migrated as an intact
heterotrimer (a, 3, peptide) (Sadegh-Nasseri and Germain, 1991, 1994; Stern and
Wiley, 1992).
More recently, Nelson et al. (1994) found that the dissociation half-times of
pep.MHC-II complexes vary widely, with selective persistence of the most stable
complexes on APC helping to account for the striking immunodominance of certain
peptides. Conversely, a rapidly-dissociating pep.MHC-II complex might be ineffective
at eliciting T cell responses, including those that result in T cell tolerance. Thus,
Fairchild et al. (1993) and Mason and McConnell (1994) have suggested that because of
rapid dissociation a self peptide from myelin basic protein might fail to induce T cell
tolerance toward this peptide. The failure would leave potentially autoreactive T cells
that could eventually cause autoimmune encephalomyelitis if activated by cross-
reacting viral peptides (see Oldstone, 1987; Wucherpfennig and Strominger, 1995;
Section VI.F). It remains to be seen whether such a mechanism may also apply to
peptides interacting with MHC-I proteins. A related possible mechanism for evading
tolerance could be extrathymic post-translational modification of a self peptide, leading
to inadequate negative selection of T cells specific for the modified peptide (Wu et al.,
1995).
VI. T Cell Responses to Pep.MHC
The intensity of mature T cell responses to pep-MHC complexes on other cells
is greatly affected by the cell surface abundance of these complexes and by small
changes in peptide sequence, as illustrated in Fig. 4. When the same T cells and target
cells (or APC) are used in the representative assays shown, synthetic peptides with
closely related sequence can differ as much as a million-fold in the concentrations
required for half-maximal intensity of the responses they elicit (SD50 values, Tsomides
et al., 1991). In attempts to account for these enormous differences, some T cell-target
cell systems have been analyzed extensively in terms of: (1) the affinity of a T cell's
TcR for particular pep-MHC complexes; and (2) the abundance of these complexes on
target cells ("epitope density").
As discussed below (Section VI.C), TcR reactions with pep-MHC complexes
approach equilibrium rapidly, indicating that intrinsic equilibrium constants for these
reactions ("TcR affinities") can be relevant to understanding the responses illustrated in
Fig. 4.
A. Affinity: Intrinsic Equilibrium Constants of TcR-Pep.MHC Reactions
Several approaches have been used to determine the equilibrium constants of
TcR-pep.MHC reactions. They include: (1) competition assays in which soluble
pep-MHC complexes compete with 12 5I-labeled antibodies (or Fab' fragments) for
binding to TcR on intact T cells; and (2) direct binding of soluble, 125I-labeled
pep-MHC complexes to TcR on intact cells, or unlabeled complexes to TcR molecules
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that are produced in soluble form by genetic engineering and immobilized on a solid
support. All of these approaches have so far yielded reasonably consistent results
(Table III), establishing confidence in: (1) the accuracy of the measured TcR
equilibrium constants; and (2) the functional similarity of the genetically engineered,
soluble analogs of TcR and MHC proteins to their native, membrane-associated forms.
The first measurement of an intrinsic TcR-pep.MHC equilibrium constant
involved competition for the TcR on intact CD4+ T cells between a soluble pep-MHC-II
complex and 12 5 I-labeled Fab fragments of an antibody to the TcR's VP domain
(Matsui et al., 1991). The free pep.MHC concentration that inhibited binding of the
12 5I-Fab by 50% was 5x10 -5 M. This value (Kd) and the other equilibrium constants
discussed here are all expressed below as association constants (Ka = 1/Kd) (Table III).
A slightly higher Ka was found in another study that used a soluble TcR to inhibit the
response of an intact CD4+ T cell (measured by the T cell's cytokine production) to an
intact APC; by comparing the inhibitory effect of soluble TcR with the inhibitory effect
of an anti-MHC Fab' fragment, it was estimated that the TcR's intrinsic affinity for the
pep.MHC-II complex was =105 M-1 (Weber et al., 1992), a result that should be viewed
with the understanding that it was indirect and based not on a measured physical
interaction between TcR and its ligand but on production of IL2.
The equilibrium constants determined by Matsui et al. (1991) and Weber et al.
(1992) (2x104 M- 1 and =105 M- 1, respectively) were consistent with the often expressed
expectation that TcR affinities would generally fall in the low range exhibited by
antibodies having germline V domains (i.e., not somatically mutated) sequences (e.g.,
Eisen, 1986; Davis, 1990). However, TcR with much higher intrinsic affinities were
subsequently found by Sykulev et al. (1994a): in a binding assay involving the 1251-
labeled Fab' fragment of an anti-clonotypic antibody to the TcR on a CD8 + T cell clone
(2C) in competition with a soluble pep.MHC complex (formed by the MHC-I protein
Ld and an octapeptide from co-ketoglutarate dehydrogenase, LSPFPFDL, termed p2Ca
(Udaka et al., 1992, 1993)), the TcR affinity was found to be 1.5x106 M-1 (Table III).
Later, the same TcR was found to have a 10-fold higher affinity (1.5x107 M -1)
for a related pep.Ld complex in which the peptide differed from p2Ca only by an
additional glutamine residue at the N-terminus (QLSPFPFDL, QL9) (Sykulev et al.,
1994b). Given this high intrinsic affinity, it proved possible to measure the direct
binding of QL9-Ld complexes (trace-labeled with 1251) to TcR on intact 2C cells,
obviating the need for indirect measurement by competition with an anti-receptor
antibody. The values obtained by direct and indirect approaches were in close
agreement, indicating the feasibility of measuring TcR affinities on diverse T cell
clones without requiring rare (e.g., clonotypic) anti-TcR antibodies. Thus, in a direct
binding assay with an 12 5I-labeled soluble pep.MHC complex formed by the MHC-I
protein Kb and an octapeptide from ovalbumin (SIINFEKL, pOV8), the affinity of the
TcR of an ovalbumin-specific CD8 + CTL clone (4G3) was found to be 1.5x106 M-1,
another high-affinity reaction (Table III).
Whether the low affinities of the reactions between TcR on CD4+ T cells and
pep-MHC-II complexes and the much higher affinities of the reactions between TcR on
CD8+ T cells and pep-MHC-I complexes represent consistent differences between
CD4+ and CD8+ clones is, perhaps, possible. The differences found so far more likely
reflect a wider range of intrinsic affinities for TcR-pep.MHC reactions than had been
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expected. Among the relatively small number of intrinsic affinities determined for TcR
reactions with pep-MHC ligands, the highest values are similar to those often
encountered for mAb against protein antigens (ca. 107 M-1 ). However, in view of the
absence of extensive somatic mutation in TcR genes, it is doubtful that TcR affinities
will match the highest intrinsic affinity values found for antibody reactions with protein
antigens, which are often in the range of 108 to 109 M- 1 and can be as high as 1010 M-1
(see Foote and Eisen, 1995, and Section VI.E.1, below).
B. Kinetics
Given the structural similarities between TcR and Ig molecules, the question
arises as to whether TcR reactions with their natural ligands are similar kinetically to
those of antibodies with antigens. To study TcR kinetics, the main approaches taken so
far are much like those used to measure TcR affinities, e.g., they involve TcR molecules
on intact T cells or genetically engineered TcR that are produced as soluble molecules
and subsequently immobilized on a solid support for analysis by an optical method
(surface plasmon resonance). Both approaches were used to study the reaction between
the TcR of the CD8+ T cell clone 2C (2C TcR) and the octapeptide p2Ca that it
recognizes in association with Ld. Based on competition between soluble p2Ca-Ld
complexes and an 125I-labeled Fab' fragment of a clonotypic antibody for binding to the
2C TcR, the association and dissociation rate constants were found to be 1.1x104 M -1
sec-1 and 5.5x10-3 sec -1, respectively, at 250C. For the higher affinity reaction of the
same TcR with the closely related pep-MHC complex QL9.Ld, the on-rate constant was
slightly higher and the off-rate constant considerably lower than for p2Ca-Ld (Sykulev
et al., 1994a, b) (Table IV).
Using soluble p2Ca-Ld complexes and soluble 2C TcR (Slanetz and Bothwell,
1991), Corr et al. (1994) measured their interaction by surface plasmon resonance. In
this procedure, pep-MHC complexes flow over TcR produced in soluble form and
bound covalently to a dextran surface by carbodiimide chemistry. The binding of
pep-MHC complexes to TcR results in a local increase in refractive index, which is
measured by a shift in resonance angle. Experimental data were fit to a single
exponential equation, as for a conventional bimolecular reaction, as well as to a double
exponential equation to improve the fit. Both analyses yielded essentially the same
dissociation rate constant (2.0-2.6x10 -2 sec-1), which was 4-5 times larger than had
been measured using the TcR on intact 2C cells. This disparity could be due to
different pep.Ld complexes used in the two studies; the surface plasmon resonance
study made use of a diverse population of Ld molecules that had been isolated from
mammalian cells and probably contained a variety of endogenous peptides in addition
to the cognate peptide p2Ca, i.e., pep.Ld complexes that might have bound weakly and
dissociated more rapidly from the TcR than homogeneous p2Ca-Ld complexes used to
study the TcR on intact cells. Of the two association rate constants found by surface
plasmon resonance (Corr et al., 1994), the lower value agreed with the on-rate constant
measured with intact 2C cells (Sykulev et al., 1994a).
The rate constants measured for the TcR of another high-affinity CD8 + CTL
clone, 4G3, and its natural ligand, the ovalbumin peptide SIINFEKL plus Kb
(pOV8-Kb), were determined by direct binding of pOV8-Kb to the TcR on intact 4G3
cells and were similar to those found for the 2C TcR reaction with one of its known
natural ligands, p2Ca-Ld (Table IV).
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Matsui et al. (1994) also used surface plasmon resonance to analyze the
reactions between soluble TcR from a CD4+ T cell clone (2B4) and each of three
closely related cytochrome c peptides complexed with IEk, an MHC-II protein. In
keeping with the very low affinity of this clone's TcR for these pep.MHC complexes
(Table III), the on-rate constants were extremely low (0.9-1.7x10 3 M-1 sec-1) and the
dissociation rates were rapid (tl/2 off values of 2-12 sec, Table IV) (see also Section
VI.E.2).
Temperature Effects. All of the kinetic measurements recorded in Table IV
were made at 25 0 C. The few made at both this temperature and 37 0C showed: (1) a
small increase in association rate constant at the higher temperature (presumably due to
higher diffusion coefficients at 37 0 C than at 250C); and (2) only an approximately 5-
fold increase in dissociation rate constant. The equilibrium constant in this case was
thus only slightly lower at 370C than at 250C (Table V).
Summary of On- and Off-Rates for TcR-Pep.MHC Reactions. The kinetic
measurements made to date indicate that the association rate constants for TcR-
pep.MHC reactions range from =103 to =105 M-1sec- 1. In contrast, the intrinsic on-rate
constants for antibody reactions with protein antigens are generally about 105 to 106 M-
1 sec-1, the latter probably representing an upper limit arising in part from diffusion
rates of proteins (Mason and Williams, 1980; Foote and Milstein, 1991; Foote and
Eisen, 1995).
TcR tend to dissociate faster from pep.MHC complexes than antibodies from
protein antigens, with TcR ti/2 off values varying from a few seconds to 1-2 min, and
tl/2 off values for antibody-protein antigen complexes generally ranging from a few
min to an hr or more. These differences reflect the generally higher intrinsic affinities
of antibodies than TcR for their respective ligands, probably due to antigenic selection
of B cells having somatically mutated Ig genes and the absence of a comparable process
for T cell selection in vivo. High intrinsic affinities can greatly enhance the efficacy of
antibody molecules in solution, but they are less likely to have a correspondingly large
impact on cell surface TcR, which is enormously multivalent (ca. 105 TcR molecules
per mature T cell). It has been suggested that, overall, an affinity ceiling for TcR (=10 7
M-1) is about 1000-fold lower than the affinity ceiling for antibodies (=1010 M -1) (see
Foote and Eisen, 1995, and Section VI.E. 1, below).
In general, the on- and off-rates of TcR reactions with pep.MHC complexes are
much faster than the rates involved in the reaction of peptides with MHC proteins. For
some peptide-MHC reactions, association rate constants are slow (100-104 M-1 sec-1,
Corr et al., 1994), and several hours (at room temperature) are often required to
approach equilibrium (Kageyama et al., 1995). These reactions also tend to have long
dissociation half-times, ranging from =1 hr to >100 hr (Buus et al., 1986; Cerundolo et
al., 1991; Tsomides et al., 1991; Olsen et al., 1994), although in some instances they
may be as short as 20 min (Fairchild et al., 1993; Mason and McConnell, 1994), or even
less (Vturina et al., in preparation).
C. Time Required to Approach Equilibrium
T cells move continuously over other cells (Chang et al., 1979), but within 2-6
min of establishing contact with a suitable target cell, a T cell's response to antigen can
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be detected by an increase in the T cell's intracellular Ca2 + concentration (Poenie et al.,
1987; Su et al., 1993). Can the reaction between TcR on the T cell and pep-MHC on
the target cell reach a steady state within this brief interval?
Equilibrium is approached asymptotically at a rate that is generally defined by
the time constant r, the time required to form 63% (i.e., 1-l/e) of the equilibrium
number of receptor-ligand complexes. By measuring the net rate of accumulation of
specific TcR*pep-MHC complexes on intact CD8+ 2C cells, Sykulev et al. (1994a, b)
found that t was =3 min for p2Ca-Ld at 250 C and =1 min for QL9-Ld at 370 C. t varies
with the pep-MHC concentration, becoming longer as the ligand concentration
decreases, but it cannot be longer than approximately the half-time for dissociation (the
ti2 off value). This limit follows because 1/t = (k+1 )(L)+(k. 1), where (L) is the free
pep-MHC concentration and (k+l) and (k-1) are on- and off-rate constants, respectively,
for the TcR-pep-MHC reaction. Thus, for the most stable TcR-pep.MHC binding
reaction measured so far (2C TcR + QL9.Ld), the t 1/2 off was 0.7 min at 370C (Table
V), indicating that equilibrium for this reaction is approached in less than a minute. For
reactions where t1t2 off values are shorter, equilibrium is approached even faster.
D. Epitope (Pep*MHC) Density
Many observations imply that the intensity of a T cell response depends upon
the number of pep.MHC complexes ("epitopes") the T cell recognizes on another cell.
For example, in the assays shown in Fig. 4 the extent of the CTL cytotoxic response
varies with peptide concentration, which affects the total number of the corresponding
pep-MHC complexes on target cells ("epitope density"). In another example, HIV-
infected cells expressing low levels of processed viral peptides were lysed more poorly
by HIV-specific CTL than infected target cells expressing higher levels of the same
peptides (Tsomides et al., 1994). Other studies pointing to a critical role for epitope
density include the effects of peptide concentration on the fate of developing
thymocytes (positive and negative selection, Ashton-Rickardt et al., 1994) and the
demonstration of nonphysiological T cell cross-reactions when high concentrations of
synthetic peptides were added to target cells (Milligan et al., 1990; Schild et al., 1990;
Dutz et al., 1994).
The first attempts to measure epitope densities involved incubating target cells
(or APC) with 125I-labeled peptides at minimally active concentrations. The restricting
MHC protein, together with its associated peptides, was then immunoprecipitated and
the number of 125I-labeled pep-MHC complexes per target cell determined. The results
indicated that a minimum of around 100-400 complexes were required to elicit cytokine
production by CD4 + T cell hybridomas (Harding and Unanue, 1990; Demotz et al.,
1990) or lysis of target cells by CD8+ T cell lines (Christinck et al., 1991).
Subsequent studies of antigen recognition by CD8+ CTL made use of mutant
target cells (RMA-S, T2) with a defect in the transporter (termed TAP) that translocates
peptides from the cytosol, where they are generated, into the ER (Townsend et al.,
1989; Ljunggren et al., 1990; Schumacher et al., 1990; Cerundolo et al., 1990). In such
cells newly synthesized MHC-I proteins arrive at the cell surface membrane deficient in
bound peptides (e.g., peptide-free or with weakly bound peptides derived, perhaps, from
protein signal sequences), and they then undergo rapid denaturation (at 370C) unless
stabilized by the binding of synthetic extracellular peptides. By raising the extracellular
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concentration of peptide, the cell surface epitope density is increased, resulting in
greater target cell lysis by CTL. The free concentration of peptide required to sensitize
target cells for half-maximal lysis (called the SD 50 value, Tsomides et al., 1991) is a
useful indicator (though not in itself a measure) of the density of pep-MHC complexes
needed to elicit CTL-mediated lysis. Similarly, for stimulated CD4 + T cells that
respond by proliferating and producing cytokines, increasing the concentration of
extracellular peptide increases the responses.
Cytotoxicity assays are typically carried out for 4 hr (Fig. 4), and for many
peptides their reactions with MHC on the target cell reaches equilibrium (steady state)
during this time. Hence, for these peptides an estimate of the average epitope density
(r) on target cells may be calculated from the free concentration of synthetic peptide (c)
in extracellular medium, the equilibrium association constant for the peptide-MHC
reaction (K), and the total number of pep.MHC sites available for binding peptide (n),
the later being determined with saturating concentrations of the peptide. (Eq. 1 above, r
= K-c-n/(1+K.c)). Using this approach, Kageyama et al. (1995) determined the epitope
densities required to effect half-maximal lysis of target cells in a study involving sixteen
peptides and three MHC-I proteins on intact cells (Kb, Ld, and HLA-A2). With
different combinations of peptides, MHC proteins, and T cell clones, the epitope
densities required for half-maximal lysis were found to vary from several thousand
pep-MHC complexes per target cell to fewer than ten. The significance of this wide
range emerged from the subsequent development of a quantitative model for CTL-
target cell interactions (see Fig. 5 and below).
To check the accuracy of epitope densities determined according to Eq. (1), the
amount of an 125I-labeled peptide (Ii1-QLSPFPFDL, termed I1-QL9-Y5) that binds to Ld
(an MHC-I protein) on intact cells was measured directly, taking advantage of a method
for preparing radioiodinated peptides with extremely high specific radioactivities
(3.5x10 18 cpm per mole of monoiodinated peptide, the same as the specific activity of
carrier-free 1251 (Tsomides and Eisen, 1993b)). The epitope densities found by this
direct approach and those calculated by Eq. (1) (Sykulev et al., submitted) agreed well
(to within a factor of two). When the same high specific activity peptide (12 511-QL9-
Y5) was added to target cells at a concentration that resulted in half-maximal
cytotoxicity (SD 50 =5 pM), only an average of 3 peptide molecules were bound to Ld
per target cell. Since these few peptide-Ld complexes were probably distributed at
random over the target cell surface it appears that in CTL:target cell conjugates a single
pep-MHC on the target cell may be able to trigger a T cell's cytotoxic response (Sykulev
et al., submitted). A single complex can bind at any instant to only a single TcR
molecule (i.e., engage in univalent binding). It seems therefore that univalent ligation
of a TcR, without aggregation or cross-linking several TcR molecules, can elicit a
cytotoxic T cell response. Whether more complex responses, which require the
activation of previously silent genes (as in cytokine production), can also be triggered
by univalent TcR ligation is not clear.
To measure epitope densities of naturally processed ("endogenous") peptides on
the cells that produce them requires a different approach. At low pH, peptides
dissociate rapidly from pep.MHC complexes (Buus et al., 1988; Ri~tzschke et al.,
1990a), and in one effective procedure cells are treated briefly (ca. 1 min.) with isotonic
buffer at pH=3, stripping peptides from cell surface MHC (Storkus et al., 1993). The
peptides can then be fractionated by HPLC and particular peptides detected by bioassay
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with specific clones of CTL: sensitivities of <10-12 M peptide have been obtained for
several CTL-peptide-target cell systems (Bodmer et al., 1988; Reddehase et al., 1989;
Tsomides et al., 1991; Ritzschke et al., 1990b; Falk et al., 1991b; Ritzschke et al.,
1991a), and a theoretical limit for peptide at 10-13-10 -14 M has been postulated
(Kageyama et al., 1995). In each case the efficiency of peptide recovery must be
quantitated for an accurate assessment of natural peptide abundance (reviewed in
Tsomides and Eisen, 1993a; for examples see Table II, above). While current efforts
emphasize identification of the natural epitopes involved in T cell responses to tumor
cells, allografts, cells infected by viruses or other pathogens, target cells of autoimmune
reactions etc., a reasonable next step will be to measure the abundance of these epitopes
in order to find out whether epitope densities commonly limit T cell responses
(Tsomides, 1996).
E. TcR-Pep*MHC Engagement: An Affinity Model
The intensity of the T cell response has been widely assumed to be determined,
in large measure, by TcR affinity for pep.MHC complexes and the number of these
complexes on target cells (epitope density). The preceding section dealt with epitope
density; here we focus on TcR affinity. Since the TcR-pep-MHC reaction approaches
equilibrium rapidly (see Section VI.C, above), equilibrium constants for this reaction
could govern the outcome of T cell-target cell encounters. However, TcR molecules
and pep.MHC complexes are confined to the surface membrane of T cells and target
cells, respectively. Hence the question arises as to whether their interaction can be
described in terms of the law of mass action, which is generally concerned with
interactions that involve freely diffusable reactants. Nevertheless, in developing a
quantitative model for the antigen recognition step in the activation of T cells, Sykulev
et al. (1995) assumed from the law of mass action that
(TcRopep-MHC) = (K) (TcR) (pep.MHC), (2)
where (TcRopep-MHC) and (pep-MHC) refer, respectively, to the number per target cell
of pep-MHC complexes that are or are not engaged by TcR molecules, and (TcR) is the
concentration of unengaged TcR molecules (assumed to be the same as the total TcR
concentration because only a very small proportion of a mature T cell's TcR molecules
engage pep.MHC complexes in any particular cell-cell interaction). K , the "TcR
affinity", is the equilibrium association constant for the TcR-pep.MHC reaction. The
total epitope density, designated (pep-MHC)o, was assumed to equal the sum of TcR-
bound and unbound pep-MHC; hence by substituting (pep-MHC)o - (TcRopep-MHC)
for (pep.MHC), they obtained:
log (pep-MHC) o = log (TcR*pep.MHC) - log { (K) (TcR)/[ 1 +(K) (TcR)] } (3)
On the assumption that [TcR*pep-MHC] is fixed for a given level of T cell
response (e.g., half-maximal cytotoxicity) and a particular T cell-target cell system, Eq.
2 describes the relationship between total epitope density and TcR affinity. A
satisfactory fit was found between Eq.3 and experimentally determined values for total
epitope density required for half-maximal T cell cytotoxic responses and TcR affinity
for several TcR-pep.MHC reactions (Fig. 5). As shown in this Figure and predicted by
Eq.3, over a wide range of affinity values (<104 to ca. 106 M-l1), the log (base 10)
epitope density was a linear function of log (base 10) TcR affinity with a slope of minus
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one. The agreement between this relationship and the law of mass action suggests that
in a T cell-target cell conjugate TcR molecules on the T cell and pep-MHC complexes
on the target cell come to occupy the same volume and react as though in solution. The
validity of this model should become evident when its predictive ability is put to the
test: since the product of epitope density and TcR affinity is constant (over the linear
range shown in Fig. 5), with a peptide whose target cell epitope density at a half-
maximal cytotoxic response is known, the model can predict the affinity of the
responding T cell's TcR. Whether the predicted affinity values will prove to be correct
remains to be seen.
1. TcR Affinity Ceiling
Eq. 3 predicts that at TcR affinities above some upper level ("affinity ceiling")
the epitope density values plateau at a lower limit (Fig. 5), which corresponds for a
specified level of response (half-maximal cytotoxicity) to the minimal number per
target cell of ligated pep-MHC complexes. From the limited amount of data available at
high affinity values the minimum epitope density value was seen to fall between 1 and
10 pep-MHC complexes per target cell (for TcR affinities above approximately 5x10 6
M-1). The model's prediction was supported by the subsequent finding (made with the
high specific activity radiolabeled peptide) that an average of 3 pep.MHC complexes
per target cell were sufficient to elicit half-maximal target cell lysis by a CTL clone
whose TcR's affinity for these complexes was sufficiently high (above 106 M- 1).
Although the precise value of the TcR affinity ceiling is not well defined by the
available experimental data (Fig. 5), in principle it equals the reciprocal of the effective
TcR concentration. This concentration remains to be defined. From the best fit
between experimental data and Eq. 3, plotted as the solid line in Fig. 5, the
concentration may be about 10-7 M, a value that can be justified by the number of TcR
molecules per mature T cell (=105, see Matsui et al., 1991; Sykulev et al., 1994a,b), and
the fact that with extensive changes of T cell shape and surface area, the cell surface
TcR molecules occupy over time a volume that approximates the T cell's volume (ca.
10-6 .1l per cell).
2. Kinetic Control of T Cell Responses
Equations 2 and 3 and the results shown in Fig. 5 assume that in T cell-target
cell encounters the TcR-pep.MHC reaction essentially reaches a steady state, and that
TcR affinity is a critical determinant of the response. Under some conditions, however,
it is possible that rates of dissociation of pep.MHC from TcR, rather than equilibrium
constants, might determine the response. In particular, if TcR-pep.MHC bond lifetimes
were close to the bond residence time required to activate a signal transduction
pathway, dissociation rate differences could be decisive. This possibility is evident
from a study by Matsui et al. (1994). Markedly different concentrations of three similar
peptides were needed to elicit equivalent responses by a CD4+ T cell hybridoma whose
TcR had about the same low affinity (=104 M-1) for all three peptides in association
with the MHC-II protein IEk. Based on the belief that these peptides interacted equally
well with IEk (and thus formed the same epitope densities at the same peptide
concentrations), it was concluded that the different peptide concentrations required to
elicit the T cell response might relate to the differences found in t1/2 off values of the
TcR from the respective pep.MHC complexes (2-12 sec). Thus, while the affinity
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model described above emphasizes the average number of TcR-pep-MHC bonds
present at any instant under steady state conditions, an alternative view suggests that
under some circumstances the TcR-pep.MHC bond lifetime might play a decisive role.
Just how short the lifetime would have to be to serve as an independent controlling
factor in a T cell response is not clear.
In Section VI.D it was noted that a single pep.MHC on a target cell can activate
a T cell cytotoxic response. At any instant a single complex can bind to only one TcR
molecule, but over time it can bind to one or a few TcR molecules repetitively or
serially to many different TcR molecules, as proposed by Valitutti et al. (1995). Since
it was suggested that many serial engagements enhance T cell responses, Valitutti et al.
(1995) predicted that high TcR-pep-MHC dissociation rates, which are generally
associated with low-affinity reactions, would promote T cell responses. Other studies,
however, show that high-affinity TcR-pep.MHC reactions, which are generally
associated with slow dissociation rates, enhance T cell cytotoxic responses (Sykulev et
al., 1994a,b).
F. Specificity, Degeneracy, and Molecular Mimicry
It seems to be widely believed that high levels of specificity in immune
reactions are manifestations of high-affinity interactions. However, measurements of
TcR affinities have shown that exquisite specificity can be manifested by very low-
affinity reactions. The lowest TcR intrinsic affinity measured so far, for the reaction of
the 2C TcR with the naturally occurring peptide p2Ca (LSPFPFDL) in association with
Kb, is 3x10 3 M- 1 (Table III). Even with this low affinity it was possible for 2C CTL to
lyse target cells bearing p2Ca.Kb complexes (Sykulev et al., 1994a; Dutz et al., 1994),
and, moreover, to exhibit a striking degree of specificity: as shown in Fig. 6, p2Ca and
another naturally occurring octapeptide that differ only by a phe-* tyr substitution
(LSPYPFDL, called p2Ca-Y4) are clearly distinguished by 2C CTL in cytotoxicity
assays with Kb+ target cells (T2-Kb) (Wu et al., 1995). Though both peptides bind
equally well to Kb, T2-Kb cells sensitized with p2Ca were lysed, whereas those
sensitized with p2Ca-Y4 were not. This pronounced difference could be explained if
the 2C TcR affinity for the p2Ca-Kb complex (3x103 M- 1) were just above the affinity
threshold required for a cytotoxic response (we assume it to be =1x103 M -1) and the 2C
TcR affinity for the p2Ca-Y4-Kb complex were just below it. It is also possible that it is
not the lower affinity per se, but rather perhaps a faster off-rate that is responsible for
failure of the ineffective complex to elicit a cytotoxic response. (Low-affinity reactions
of antibodies are also capable of exhibiting high levels of specificity (Sykulev et al.,
1992, 1993); such reactions underlie the important practical use of antibodies against
polysaccharides of blood group substances and bacterial cell walls as diagnostic
reagents for typing blood cells or Salmonella.)
In distinguishing sharply between two pep-MHC complexes that differ only by a
single oxygen atom in their respective peptide adducts, the TcR of CTL clone 2C
matches the highest level of specificity exhibited by the most discriminating antibodies
or enzymes. Comparable levels of discrimination are also suggested by the widely
different concentrations of closely related synthetic peptides that are required to elicit
responses by a given T cell clone (e.g., Fig. 4). However, unless the cell surface
pep.MHC densities formed by the different peptides are known, large differences in T
cell responses could result from differences in epitope densities of the corresponding
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complexes rather than differences in TcR affinities for these complexes.
Degeneracy. In contrast to the high level of specificity described above (e.g.,
Fig. 6), the specificity of a given TcR can also appear be quite low, as evidenced by
reactions with a wide variety of different pep.MHC complexes. Thus, a T cell arising in
the course of viral infection characteristically reacts with a peptide of viral origin plus
one of the infected individual's own MHC proteins (a "foreign-self" complex). And
such a T cell, like most others, can also react with a different MHC protein from another
individual of the same species (allogeneic MHC, or "alloMHC") (Nahill and Welsh,
1993; see Paradox of Alloaggression, below), and each of these alloreactions may
involve a particular peptide in association with the alloMHC molecule (e.g., Udaka et
al., 1992; see Section IX, below). Moreover, this T cell would have been stimulated to
mature in the thymus (positive selection) by reaction of its TcR with thymic peptides in
association with indigenous MHC proteins (Schwartz, 1989; von Boehmer, 1994;
Ashton-Rickardt and Tonegawa, 1994; Hogquist et al., 1994).
The cross-reactions exhibited by T cells with sets of peptides having closely
related or overlapping sequences, as in Fig. 4, are readily understandable. More
interesting are the cross-reactions of viral or bacterial peptides with T cells that react
with apparently unrelated self peptides, e.g., myelin basic protein found in the central
nervous system (Wucherpfennig and Strominger, 1995; see also Selin et al., 1994).
These cross-reactions can involve peptides having no amino acids in common except
the few that serve as "anchors" to bind to MHC protein, a situation aptly described by
the term "molecular mimicry" (Oldstone, 1987). Another example involves CTL clone
2C, which recognizes the naturally occurring a-KGDH peptide p2Ca (LSPFPFDL, see
Table II) in association with Ld: this T cell also reacts with the Ne-2,4-
dinitrophenylated form of an HIV peptide (ILKEPVHGV) in association with the same
MHC protein (Ld) (Tsomides, unpublished data). Growing evidence suggests that
cross-reactions due to molecular mimicry play an important role in stimulating
autoreactive T cells (those having specific reactivity with a self peptide plus a self MHC
protein), thereby triggering autoimmune disorders (Wucherpfennig and Strominger,
1995).
Since Vox and VB domains have so much amino acid sequence similarity to VL
and VH domains, why should the range of cross-reactions appear to be so much greater
for TcR than antibody molecules? Cross-reactions are certainly commonplace with
antibodies, but they usually are readily understandable with even a superficial view of
the cross-reacting structures. This is the case even for "strange" cross-reactions, e.g., as
seen in the ability for antibodies raised against the 2,4-dinitrophenyl group to bind
vitamin K3 (2-methyl-1,4-naphthaquinone) (Michaelides and Eisen, 1974). However,
as noted above, the variety of pep-MHC that can be recognized by any particular TcR
seems far greater than the variety of antigens that react with an antibody. One possible
explanation is that the Va-V3 binding site is much more flexible than the VL-VH
binding site and can adapt its conformation to fit many different ligands. Such
flexibility could account for the difficulties currently being experienced in obtaining
well-ordered TcR crystals for structure analysis.
A more likely explanation is that T cell reactions with pep.MHC can be detected
with far greater sensitivity than antibody-antigen reactions: e.g., peptides at 10-12 M
can elicit half-maximal responses (see Fig. 4) and TcR-pep.MHC reactions having
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affinity values as low as 10-3 M can result in target cell lysis (Fig. 6); an antibody
reaction having such a low intrinsic affinity would ordinarily not be detectable. The
great multivalency of T cells (=105 TcR molecules per T cell), the abundance of some
pep-MHC ligands on many target cells plus the ability of very few cognate pep.MHC
complexes (<10 per target cell) to elicit T cell responses, and the amplifying effect of
signal transduction in T cells must all contribute to the extraordinary sensitivity of T
cell reactions and the correspondingly great range of their cross-reactions.
VII. TcR Accessory Proteins
A. CD3 and C
The antigen-specific heterodimeric (cap) TcR exists at the cell surface as part of
a large multichain complex that includes the four invariant chains of CD3 (y, 8, and two
F chains) plus the structurally distinct ý molecule, which is found in most T cells as a
disulfide-linked homodimer. On some T cells an alternatively spliced form of C, termed
rl, is present as Crl heterodimers (reviewed by Ashwell and Klausner, 1990; see also
Irving and Weiss, 1991). Immunoprecipitation (Blumberg et al., 1990) and quantitative
immunofluorescence analysis (Punt et al., 1994) showed that there are two F chains per
•4p TcR molecule on intact T cells; the exact stoichiometry of the ý chain homodimer
or Cil heterodimer with other chains of the TcR complex is not clear.
When cDNA for the a, 0, and y TcR subunits were first isolated and sequenced
(Hedrick et al, 1984; Saito et al., 1984a, b), the deduced amino acid sequences revealed,
curiously, a positively charged residue in the otherwise hydrophobic transmembrane
domain. The CD3 y, 8, and e subunits and ý chain turned out to have in their
hydrophobic transmembrane domains a negatively charged amino acid residue,
suggesting that these charged sites are involved in assembling TcR heterodimers with
the CD3 and ý complex (see Davis, 1990).
CD3 chains immunoprecipitate together with cp TcR molecules. molecules
do not coprecipitate with ap, but their essential involvement in the TcR complex is
indicated by the fact that their expression, like that of CD3 y, 8, and e, is required for
cell surface expression of the op TcR. Minor truncations or alterations of ý structure
can abolish TcR function, as revealed by loss of responsiveness to antigens (reference).
The binding of antibodies to TcR or CD3 molecules on intact T cells activates
two major signal transduction pathways, one resulting in hydrolysis of
phosphatidylinositol-4,5-diphosphate and transient increases in intracellular Ca2 +, the
other leading to tyrosine phosphorylation of cytoplasmic domains of CD3 subunits and
the C dimer (reviewed by Weiss and Littman, 1994). None of these subunits exhibit
intrinsic kinase activity; they appear to be substrates for Fyn, a member of the Src
family of tyrosine kinases that coprecipitates with CD3 (Samelson et al., 1990).
Similarly, the Src family member Lck interacts with cytoplasmic domains of CD4 or
CD8 (Rudd et al., 1988).
A critical role for the cytoplasmic domains of CD3 and ý chains in TcR-
mediated signaling is evident from experiments involving T cell hybridomas transfected
with genes for chimeric proteins that consist of various extracellular domains linked to
cytoplasmic domains of CD3 or ý; antibodies to the extracellular domains of these
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chimeric proteins elicited T cell responses (Wegener et al., 1992; Letourneur and
Klausner, 1992). Mutational analyses of the cytoplasmic domains revealed an "antigen
recognition activation motif"' (ARAM) that includes tyrosine and leucine (i.e., DIE-Y-
-L/I(-)6_8Y--L/I) (reviewed by Weiss, 1993). The ARAM may serve as a
phosphorylation site, allowing the recruitment of other intracellular molecules via SH2
domain-phosphotyrosine interactions. Thus, TcR ligation results in intracellular
tyrosine phosphorylation of CD3 and C and recruitment of signaling proteins that bind
specifically via their SH2 domains to phosphotyrosine. One of these signaling proteins,
ZAP70, is associated with the phosphorylated form of ý (Chan et al., 1992). There are
three copies of ARAM per C chain but only one copy in each of the CD3 chains,
structural features that may be related to different requirements for inducing diverse
signaling pathways. For example, Sloan-Lancaster et al. (1994) found a different extent
of ý chain phosphorylation after challenging a clone of CD4+ T cells with different
peptides of related sequence in association with a MHC-II protein (see Section VIII,
below).
B. CD4 and CD8
As noted in Section II, the mutually exclusive expression of cell surface
glycoproteins CD4 and CD8 on mature T cells distinguishes between the two major T
cell lineages. During development in the thymus, immature T cells express both
markers (CD4+CD8 + or double positive cells); these cells make up the majority of
thymocytes and appear to undergo commitment stochastically to either the CD4 + or
CD8 + single positive phenotype as they mature (Davis et al., 1993; Chan et al., 1993).
CD4 is a single chain transmembrane glycoprotein, while CD8, which consists of two
membrane-associated polypeptides, can be either an xa homodimer or an a 0
heterodimer; functional distinctions between them are not yet clear (see Weiss and
Littman, 1994). In humans and mice, =60% of peripheral ap TcR + cells are CD4+ cells
and the rest are CD8+. The preponderance of CD4+ over CD8+ cells is not universal,
however, and in the African green monkey =80% of peripheral T cells are CD8 + and
=10% CD4+ (Ennen et al., 1994).
CD4 and CD8 are both members of the Ig superfamily, and each has a positively
charged CDR-like loop that protrudes from the N-terminal domain (CD4 or CD8a) and
is thought to make contact with an invariant region of MHC-II or MHC-I molecules,
respectively (Wang et al., 1990; Ryu et al., 1990; Leahy et al., 1992). The binding of a
soluble, genetically engineered MHC-II protein (HLA-DR4) to a soluble, immobilized
preparation of CD4 was reported to have an equilibrium constant of lxI05 M- 1
(Cammarota et al., 1992).
If a CD8 molecule on a T cell binds to precisely the same pep.MHC-I complex
on the target cell that is bound by the T cell's TcR, the CD8-MHC-I interaction would
be expected to enhance the overall stability of the TcR*pep.MHC-I complex, and the
same would be expected for CD4 and pep.MHC-II complexes. However, no evidence
for such stabilization was found when the binding of soluble pep.MHC complexes
(either class II or class I) to TcR on intact CD4+ or CD8 + T cells was measured (Matsui
et al., 1991; Sykulev et al., 1994a). These negative results are in accord with the
finding of the same equilibrium constant for the TcR-pep-MHC-II reaction as measured
with soluble pep.MHC and either intact CD4 + T cells or genetically engineered,
immobilized TcR (Matsui et al., 1994). Recently, however, Luescher et al. (1995) have
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succeeded in showing with intact T cells and a photoaffinity-labeled soluble pep-MHC-I
complex that CD8 can modulate the TcR-pep-MHC interaction. Different monoclonal
antibodies to CD8 a and CD803 chains appeared to have different effects on the CD8-
MHC-I interaction; while most anti-CD8 antibodies were inhibitory, some enhanced
CD8-MHC binding, suggesting that small conformational changes in the CD8 protein
might influence its interaction with MHC. It is possible that the extent of interaction of
CD4 and CD8 with MHC proteins may depend upon the particular TcR and pep-MHC
complexes involved.
VII. Altered Peptide Ligands: Partial Agonists and Antagonists
Until recently, the TcR was generally viewed as an on-off switch, with its
binding site vacant or occupied by ligand, and the liganded form, in sufficient amount
and stability, causing the T cell to become activated. Surprisingly, however, it has
turned out that ligand binding can result in various manifestations of T cell activation,
depending upon the ligand (Evavold and Allen, 1991; De Magistris et al., 1992;
Alexander et al., 1993; Jameson et al., 1993; Racioppi et al., 1993; Sloan-Lancaster et
al., 1993; Vignali and Strominger, 1994). This phenomenon was strikingly evident with
a peptide derived from hemoglobin, Hb64-76 (GKKVITAFVEGCK), in association
with IEk (Sloan-Lancaster et al., 1993). Antigen presenting cells bearing this pep-MHC
complex stimulated a characteristic activation response by a CD4+ T cell clone: T cell
proliferation, cytokine secretion (IL2, IL3, 8-IFN), and hydrolysis of intracellular
inositol phosphates. However, when the peptide was modified by a single ala---ser
substitution at position 70 and presented with IEk, the same T cells responded only
partially; they failed to proliferate, produce cytokines, or hydrolyze inositol
phosphates, but they were able to express high levels of IL2 receptors and LFA-1 (an
adhesion molecule), indicating that they could make a limited response to the altered
peptide. Moreover, T cells exposed to the altered peptide were unable to proliferate in
response to the unaltered, optimally active (agonist) peptide Hb64-76 for several days.
The persistent absence of proliferation in response to an immunogenic peptide
appears to correspond to what was described earlier as T cell anergy, a state resulting
from the stimulation of CD4+ T cells via TcR ligation in the absence of a second
"costimulatory" signal (see Mueller et al., 1989). Costimulation for most T cells is
provided by engagement of the T cell surface molecule CD28 by a protein ligand on
APC called B7 for which various subtypes have been described (reviewed by Linsley
and Ledbetter, 1993; June et al., 1994; Jenkins, 1994). Anergy has been described for
various CD4 + T cells (ThO, Thl, and Th2) as well as for CD8 + T cells. Its hallmark is
aberrant T cell responsiveness to TcR engagement, notably failure of ligand binding to
drive T cell proliferation but preserved ability to trigger other manifestations of T cell
activation, such as production of cytokines or lysis of target cells.
The anergic state induced by an altered peptide ligand (a partial agonist or an
antagonist peptide) has been found to be characterized by aberrant signal transduction
(Sloan-Lancaster et al., 1994; Madrenas et al., 1995). Binding of agonist pep.MHC
complexes to a TcR results in a distinctive pattern of tyrosine phosphorylation of
cytoplasmic domains of CD3 components and C chains. Since some altered peptides
(partial agonists) induced a modified pattern of C chain phosphorylation, anergy is
likely to result from activation of an anomalous signal transduction pathway.
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The responses elicited by altered peptide ligands parallel to a large extent the
activation of T cells by various monoclonal antibodies to the TcR or CD3. However,
the signal transduction events evoked by these surrogate ligands do not completely
mimic those resulting from physiological ligands (pep.MHC complexes). For example,
pep.MHC complexes and antibodies to the E subunit of CD3 can both trigger tyrosine
kinase activity, but this response is inhibitable by cAMP only when the physiologic
stimulus is used (Klausner et al., 1987). Moreover, various anti-TcR and anti-CD3
antibodies can differ considerably from one another in the concentrations required to
elicit a given T cell response; although these differences seem not to correlate with
variations in the antibodies' affinities for TcR, it should be borne in mind that Fab
fragments were used to measure the affinities, but intact (bivalent) antibodies were used
to study the effects on T cell activation (or inhibition) (Rojo and Janeway, 1988; Rojo et
al., 1989; Yoon et al., 1994).
Given the complexity of the multisubunit structure that includes the o4p TcR,
various CD3 subunits and ý chains, and probably CD8 and CD4 as well, it is likely that
there are many different opportunities for various ligands that bind to the TcR complex
to activate different signaling pathways. Whether the different responses elicited by
agonist and partial agonist peptides (in pep.MHC complexes) and by various anti-TcR
antibodies result from differences in affinity or kinetics (e.g., bond lifetimes), or both,
remains to be determined. Not surprisingly, an additional complexity is that the
different effects elicited by various altered peptide ligands can differ among the various
T cell clones that are raised against the same pep-MHC. The biologic significance of
these complex effects is indicated by the finding that some naturally processed peptides
of viral origin act as antagonists (or partial agonists), even at extremely low
concentrations, for some anti-viral CTL (Klenerman et al., 1994; Bertoletti et al., 1994).
IX. MHC Restriction by Self and Nonself MHC: The Paradox of Alloaggression
All of the oap TcR molecules on an individual's mature T cells are imprinted, as
it were, with the capacity to recognize that individual's own MHC proteins (syngeneic
MHC or "synMHC") in the form of pep.MHC complexes. The basis for this imprinting
is emerging from studies of T cell maturation in the thymus (e.g., reviewed by von
Boehmer, 1994). Immature double positive (CD4+CD8 +) thymocytes are stimulated to
mature into single positive (CD4+ or CD8+) T cells through "weak" interactions of their
TcR with pep-MHC complexes on thymic epithelial cells (positive selection), whereas
double positive cells that interact "strongly" with these complexes on thymic cells of
hematopoietic origin undergo programmed cell death (negative selection). Although
the peptides involved in these reactions have not been identified, and the kinetics,
affinity, and specificity of the reactions in the thymus are all unknown, it is clear that
the MHC proteins involved in both positive and negative selection are clearly
indigenous, i.e., synMHC. As long as they can associate with a synMHC, an enormous
number of different foreign peptides can be recognized by one or another of the clonally
diverse TcR on the mature T cells that migrate out of the thymus; in other words,
antigen recognition is normally restricted by synMHC.
Paradoxically, however, the same mature T cells can also react specifically with
different MHC proteins from other individuals of the same species (alloMHC), and
these reactions, like those restricted by synMHC, generally involve pep-MHC
complexes (Ritzschke et al., 1991b; Udaka et al., 1992), if only in some cases because
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the peptide's presence is required to stabilize the MHC molecules at 370 C. As described
in Section II, MHC genes are the most polymorphic known; for example there are over
50 allelic variants of the murine gene Kb. The frequency of an individual's T cells that
can react with any particular alloMHC is so high (e.g., =1:100, Fischer Lindahl and
Wilson, 1977; Erard et al., 1985), that virtually every TcR must be able to recognize not
only a peptide restricted by synMHC but also a peptide (probably a different one)
restricted by an alloMHC molecule.
CTL clone 2C, referred to above (e.g., Tables III-V), is an example of such an
alloreactive clone. It arose in an H-2b mouse immunized with H-2d cells and responds
specifically to Ld (one of the three MHC-I proteins on H-2d cells) in association with a
peptide (termed p2Ca) that derives from the cellular protein a -ketoglutarate
dehydrogenase (a-KGDH) (Kranz et al., 1984a; Udaka et al., 1992, 1993). Genes for
the a and 13 subunits of the TcR on 2C cells have been expressed as transgenes in mice
with different MHC haplotypes (Sha et al., 1988a, b). In mice with the H-2d haplotype,
double positive thymocytes that express transgenes for the 2C TcR undergo
programmed cell death and fail to develop into mature T cells (negative selection),
probably because of strong interactions in the thymus between this receptor and
p2Ca-Ld complexes. However, in mice that lack Ld and have the H-2b haplotype (the
background haplotype in which the 2C cell arose), double positive thymocytes having
the 2C TcR are positively selected by Kb (synMHC), presumably as a result of weak
interactions with pep-Kb complexes (whose peptides are still unknown). Thus, most
peripheral T cells in H-2b 2C TcR transgenic mice express the 2C TcR, and despite
having been positively selected by Kb they are able to react strongly with Ld in
association with p2Ca (and related peptides from a-KGDH). To compound this
paradox the 2C TcR's affinity for the pep-alloMHC ligand p2Ca-Ld is unusually high;
indeed, it has been suggested that TcR affinity for pep-alloMHC complexes will
generally tend to be higher than for pep-synMHC (Sykulev et al., 1994b, and see Fig. 7).
Why should a TcR restricted by synMHC also be restricted by an ostensibly
unrelated alloMHC, and why might TcR affinity for pep*alloMHC tend to be higher
than for pep-synMHC? The answers probably stem from the fact that TcR genes and
MHC genes segregate independently. In an outbred population the TcR genes inherited
from each parent must encode a TcR repertoire that is so highly diversified it can
recognize and be restricted by virtually any MHC protein of the species. (If this were
not the case, many of each individual's MHC proteins would be wasted, i.e., incapable
of participating in the recognition of antigenic peptides.)
This broad repertoire is then narrowed down in each individual by positive and
negative selection in the thymus to become restricted for antigen recognition by any one
of the allelic MHC gene products in that individual. Through negative selection,
immature T cells whose TcR happen to have high affinity for synMHC will be actively
eliminated, while those that have low affinity for synMHC will escape this fate, whether
or not they happen to have high affinity for alloMHC - because, by definition,
alloMHC are not present in the normal animal. Hence a mature T cell, having survived
negative selection and been positively selected, will have a very low but presumably
significant affinity for synMHC (see below), but may have a high affinity for one or
more alloMHC proteins. The resulting hypothetical distribution of TcR affinities for
synMHC and alloMHC before and after thymic selection is illustrated in Fig. 7.
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Differences between TcR affinities for pep-synMHC and pep-alloMHC
complexes might be clarified if they could be resolved into two separate affinities, one
for the peptide moiety and one for the restricting MHC protein. Some help in arriving
at an estimate for these individual affinities may eventually be provided by the three-
dimensional structures of TcR*pep.MHC complexes in which the intrinsic affinity of
TcR for the pep.MHC is known. Meanwhile, a crude model can be put forward by
considering the pronounced amino acid sequence similarities between TcR and
antibodies (see Section IV, above) and the crystal structures of antigen-antibody
complexes (Amit et al., 1986; Davies et al., 1990).
In the complex formed by lysozyme and the Fab fragment of an anti-lysozyme
antibody, approximately 17 amino acid side chains of the antigen, presenting a solvent
accessible area of 650 A2 , make contact with the antibody's binding site. The intrinsic
affinity for the interaction of lysozyme with this Fab fragment at 250C is about 3x10 8
M-1 (Bhat et al., 1994; Foote and Winter, 1992), or 11,450 calories per mole of antigen
bound. Hence the antigenic epitope contributes, per mole bound, =20 cal per A2 of
accessible ligand area, or close to the 25 cal per A2 estimated for various protein-
protein interactions (Janin and Chothia, 1978). In applying this estimate to TcR-
pep.MHC reactions, it is notable that x-ray crystallographic analyses of several
pep.MHC complexes have shown that about 70 to 80% of the solvent accessible area of
the peptide moiety is buried in the MHC binding groove (Fremont et al., 1992; Madden
et al., 1993; Zhang et al., 1992). For example, the exposed area of octamer or nonamer
peptides bound to Kb or Db and available to interact with a TcR was only about 175 A2,
despite marked differences in peptide sequence (Young et al., 1994), suggesting that
perhaps quite generally peptides may be expected to contribute =3500 cal per mol
bound, with the rest of the binding energy of the TcR-pep-MHC reaction coming from
the MHC component.
Consider, for example, the reaction of the alloreactive CTL 2C with QL9-Ld, a
pep-alloMHC complex (Table III). With an affinity of 1.5x10 7 M -1 (Sykulev et al.,
1994b), AGo = 9700 cal per mole ligand bound (at 250 C) or, deducting 3500 cal for the
peptide's contribution, =6000 cal per mole alloMHC (Ld) bound. It follows that the
hypothetical equilibrium constant for the reaction of the 2C TcR with Ld, independent
of associated peptide, is =3-4x10 3 M - 1. Since this low affinity value can support a
cytotoxic response (Sykulev et al. 1994a), providing the epitope density is high enough
(Dutz et al., 1994; see also Fig. 6), these estimates can explain why some alloreactive
CTL appear to react with alloMHC, regardless of associated peptide adducts (Riitzschke
et al., 1991b; Elliott and Eisen, 1990; Vturina et al., in preparation). Although these
notions are consistent with the view that thymic selection generates mature T cell
populations having, on average, higher affinities for pep-alloMHC than for
pep-synMHC, careful analyses of many synMHC- and alloMHC-restricted T cell clones
and ultimately of polyclonal T cell populations will be required for an adequate test of
the hypothesis.
X. Concluding Remarks
In the approximately ten years since the TcR was first identified, the naturally
processed peptides that serve in association with MHC-I or MHC-II proteins as the
receptor's natural ligands have been extensively characterized. A start has been made
towards establishing the abundance of these ligands on target cells and APC,
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determining the kinetics and affinities of their reactions with TcR, and correlating these
values with the magnitude of TcR-mediated responses by intact T cells. More extensive
analyses of this kind, as well as measurements of TcR*pep-MHC bond lifetimes, should
provide a solid basis for understanding the great variations in magnitude of T cell
responses and help explain why different pep-MHC having only slightly altered
peptides can elicit very different responses.
Much of the progress made to date has been facilitated by the use of a small
number of stable T cell clones or T cell hybridomas. Are these cells authentic
representatives of normal T cells? Most T cells undergo senescence or apoptosis in vivo
in response to repeated ligand binding to their TcR, and only a rare T cell can be
successfully established as a cultured clone by current techniques, e.g., only one or two
clones from an optimally immunized mouse. Given the idiosyncratic nature of each
clone it would be useful to be able to generate and study large numbers of individual
clones and even more useful to develop rigorous methods for analyzing polyclonal T
cell populations. Beyond these challenges is the far greater one of applying the
accumulating information about the TcR and its reactions to manipulate T cells and
their responses in vivo, augmenting them against epitopes on pathological targets (e.g.,
cancer cells and HIV-infected cells) or suppressing them in autoimmune disorders.
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Figure Legends
Figure 1. Arrangements of V (variable), D (diversity), J (junction), and C (constant)
TcR gene segments in three loci in the mouse genome. Transcriptional orientation is
indicated by arrow. (From Davis, 1990)
Figure 2. Ribbon diagram of MHC-I and MHC-II proteins. Shown for the MHC-I
heterodimer are three domains of a or heavy chain (the polymorphic al and (x2
domains, which together form the peptide-binding groove, and the conserved X3
domain) and the 32-microglobulin or light chain. Shown for the MHC-II heterodimer
are the two domains for each subunit, i.e. the polymorphic al and 31 domains, which
form the peptide-binding groove, and the conserved a2 and P2 domains. Although
there is virtually no sequence identity between MHC-I and MHC-II proteins, their
three-dimensional structures are remarkably similar (Brown et al., 1988). Courtesy of
L.J. Stern and D.C. Wiley.
Figure 3. Ribbon diagram of a top view of the peptide-binding sites of MHC-I and
MHC-II proteins (HLA-A2 and HLA-DR1, respectively). Note that the peptide adduct
is generally larger (10-20 amino acids) in MHC-II than in MHC-I (8-10 amino acids)
proteins. Courtesy of L.J. Stern.
Figure 4. Responses of T cells to target cells sensitized with various concentrations of
cognate peptides or their structural analogs. (A) Cytotoxic responses by a CD8+ CTL
clone (2C) to a naturally occurring octapeptide p2Ca from a -ketoglutarate
dehydrogenase and three overlapping nonapeptides from this protein (QL9, SL9 and
LL9) presented by the MHC-I protein Ld on Ld-transfected target cells (T2-Ld)
(Sykulev et al., 1994b). (B) IL-2 production by a CD4+ T cell hybridoma (2B4) in
response to peptides from cytochrome c of mouse (MCC) or pigeon (PCC) presented by
the MHC-II protein IEk on IEk-transfected CHO cells (Matsui et al., 1994).
Figure 5. Relationship between target cell epitope density required for a half-maximal
T cell response (target cell lysis) and the intrinsic affinity of TcR-pep.MHC reactions.
The solid line corresponds to the best fit between Eq. 3 and experimentally determined
values for epitope density and affinity (K), and to a TcR concentration of 10-7 M.
Curves that fit the experimental data about as well, but are based on limiting epitope
densities of 1 or 3 pep-MHC complexes per target cell are shown by the dashed lines.
(From Sykulev et al., 1995)
Figure 6. TcR on CD8+ CTL clone 2C distinguishes sharply between two naturally
processed peptides, p2Ca and p2Ca-Y4, in association with the same syngeneic MHC-I
protein, Kb. (Upper) Specific lysis of T2-Kb target cells by CTL 2C in the presence of
various concentrations of p2Ca (A) and p2Ca-Y4 (A). (Bottom) Binding of p2Ca and
p2Ca-Y4 to Kb as shown by peptide-stabilized expression of Kb on T2-Kb cells,
measured by fluorescent staining with a monoclonal anti-Kb mAb and flow cytometric
analysis. (From Wu et al., 1995)
Figure 7. Hypothetical distribution of intrinsic TcR affinities in populations of T cells
recognizing pep-synMHC (solid line) and pep-alloMHC (dashed line) complexes before
(A) and after (B) thymic selection.
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TABLE I. Comparison between peptide binding to MHC-I and MHC-II molecules.
MHC-I MHC-II
Distribution
Domain structure
Accessory molecule
Typical T cell response
Origin of most bound peptides
Length of bound peptides
Pockets in MHC groove
Peptide N- and C-termini
Many critical contacts
Equilibrium constants (Ka)
All nucleated cells
al,  O2, C3 + N2m
CD8
Cytotoxic activity
Cytosolic (endogenous)
Usually 8-9 residues
Yes
Buried in groove
Peptide side chains
=104-109 M -1 measured
Specialized APC
a1, C2 + 01, P2
CD4
B cell help, DTH
Extracellular/membr. proteins
Variable, -12-25 residues
Yes
May extend outside groove
Peptide backbone
=106-108 M -1 measured
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TABLE II. Examples of naturally processed peptides associated with MHC molecules. a
MHC protein Peptide origin Peptide sequence b  Reference
Class I H-2Kd Influenza NP 147-155 TYQRTRALV R6tzschke et al., 1990b
H-2Db Influenza NP 366-374 ASNENMETM Ritzschke et al., 1990b
H-2Kb Vesicular stomatitis van Bleek and
virus NP 52-59 RGYVYQGL Nathenson, 1990
H-2Kb Ovalbumin 257-264 SIINFEKL RStzschke et al., 1991a
H-2Kd L. monocytogenes
listeriolysin 91-99 GYKDGNEYI Pamer et al., 1991
H-2Ld Mouse a-ketoglutarate
dehydrogenase LSPFPFDL Udaka et al., 1992
H-2Ld Mouse a-ketoglutarate
dehydrogenase VAITRIEQLSPFPFDL Udaka et al., 1993
HLA-A2.1 HIV- 1 reverse
transcriptase 476-484 ILKEPVHGV Tsomides et al., 1994
HLA-A2.1 HIV-1 gag 77-85 SLYNTVATL Tsomides et al., 1994
Class II IAb Murine leukemia virus
envelope 145-157 HNEGFYVCPGPHR Rudensky et al., 1991a
145-158 HNEGFYVCPGPHRP
I-E ca chain 56-73 ASFEAQGALANIAVDKA
Invariant chain 39-53 KPVSQMRMATPLLMR
IEb  Murine leukemia virus
envelope 454-467 SPSYVYHQFERRAK Rudensky et al., 1991a
454-468 SPSYVYHQFERRAKY
454-469 SPSYVYHQFERRAKYK
BSA 141-154 GKYLYEIARRHPYF
lAk Hen egg lysozyme 48-60 DGSTDYGILQINS Nelson et al., 1992
48-61 DGSTDYGILQINSR
48-62 DGSTDYGILQINSRW
52-64 DYGILQINSRWWC
HLA-DRl Invariant chain 105-118 KMRMATPLLMQALP Chicz et al., 1992
105-119 KMRMATPLLMQALPM
96-118c LPKPPKPVSK...P
96-119c LPKPPKPVSK.. .PM
96-120c LPKPPKPVSK.. .PMG
97-118c PKPPKPVSK...P
97-119c PKPPKPVSK.. .PM
97-120c PKPPKPVSK.. .PMG
98-118c KPPKPVSK...P
98-119c KPPKPVSK...PM
99-118c PPKPVSK...P
a adapted from Tsomides and Eisen (1993a).b only MHC-I binding natural peptides that are recognized by established T-cell clones are shown;
MHC-I binding sequences identified on the basis of their relatively high abundance are not included.
c for brevity, invariant chain residues 106-117 are represented by an ellipsis (...).
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TABLE III. Equilibrium association constants for the binding of peptide-MHC complexes to TcR.
T-cell clone Peptidea MHC Equilibrium Methodb Referencec(CD4 or CD8) constant (Ka)(M-1)
Name Sequence Class Allele
5C.C7 (CD4) MCC ANERADLIAYLKQATK II IEk 2.0x104  competition (1)
228.5 (CD4) MCC(99E) ANERADLIAYLEQATK II IEk 1.9x10 4  competition (1)
14.3.d (CD4) HA110-120 CFERFEIFPKE II IEd  2.0x10 5  competition (2)
2C (CD8) QL9 QLSPFPFDL I Ld  1.0x10 7  competition (3)
QL9 QLSPFPFDL I Ld  2.0x10 7  direct (3)
p2Ca LSPFPFDL I Ld  2.0x10 6  competition (4)
SL9 SPFPFDLLL I Ld 1.4x10 4  competition (4)
p2Ca-A3 LSAFPFDL I Ld 2.0x104  competition (4)
p2Ca-A5 LSPFAFDL I Ld 1.6x10 4  competition (4)
p2Ca-A8 LSPFPFDA I Ld  1.7x10 6  competition (4)
p2Ca LSPFPFDL I Kb 3.0x10 3  competition (4)
pVSV RGYVYQGL I Kb <3.0x10 3  competition (4)
pOV8 SIINFEKL I Kb <3.0x10 3  competition (4)
p2Ca LSPFPFDL I Ld 1.0x10 6  s.p.r. (5)d
p2Ca LSPFPFDL I Ld  8.0x10 6  s.p.r. (5)d
4G3 (CD8) pOV8 SIINFEKL I Kb 1.5x10 6  direct (3)
2B4 (CD4) MCC ANERADLIAYLKQATK II IEk  1.5x10 4  s.p.r. (6)
MCC(102S) ANERADLIAYLKQASK II IEk 1.0x10 4  s.p.r. (6)
PCC ANERADLIAYLKQTAK II lEk 1.9x10 4  s.p.r. (6)
a peptide MCC is from mouse cytochrome c, PCC from pigeon cytochrome c, HA from influenza virus
hemagglutinin, p2Ca and related peptides from mouse ct-ketoglutarate dehydrogenase (Udaka et al., 1992,
1993), pVSV from vesicular stomatitis virus, and pOV8 from ovalbumin.b competition: soluble pep-MHC inhibits the binding of an 125 1-labeled Fab' fragment of an anti-TcR Ab to
TcR on intact T cells, or binding of soluble TcR to pep-MHC on intact APC inhibits the response of CD4+
T cells to the APC; direct: binding of 125 1-labeled soluble pep-MHC to TcR on intact T cells:
s.p.r.: surface plasmon resonance of soluble pep-MHC binding to immobilized soluble TcR.
c (1) Matsui et al., 1991; (2) Weber et al., 1992; (3) Sykulev et al., 1994b; (4) Sykulev et al., 1994a; (5) Corr
et al., 1994; (6) Matsui et al., 1994.
d Ka values calculated from association and dissociation rate constants using two different models (see Table IV).
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TABLE IV. Kinetic constants for the binding of peptide-MHC complexes to TcR.
T-cell clone Ligand k+l tl/2 off T Methodb Referencec
(CD4 or CD8) (peptide-MHC)a (M-lsec-1) (sec) (sec)
2C (CD8) QL9.Ld 5.3x104 222 234 direct (1)
QL9-Ld 3.8x10 4  275 396 competition (1)
p2Ca-Ld 1.1x10 4  126 182 competition (2)
p2Ca-Ld 2.1x10 4  27 38d s.p.r. (3)e
p2Ca-Ld 2.6x105 35 50d s.p.r. (3) e
4G3 (CD8) pOV8-Kb 2.2x10 4  30 48 direct (1)
2B4 (CD4) MCC.IEk 0.09x10 4  12 18d s.p.r. (4)
MCC(102S).IEk 0.2x10 4  2-5 3-10 d s.p.r. (4)
PCC.IEk 0.17x10 4  8 lid s.p.r. (4)
a peptide sequences given in Table III.
b methods outlined in footnote to Table III; s.p.r. = surface plasmon resonance.
c (1) Sykulev et al., 1994b; (2) Sykulev et al., 1994a; (3) Corr et al., 1994; (4) Matsui et
al., 1994.
d t values were not reported; they are calculated here using the relationship l/' =
(k+1 )(L)+(k. 1), where L is the free pep-MHC concentration and k+1 and k-1 are on-
and off-rate constants, respectively, for the TcR-pep.MHC reaction; under
physiological conditions (k+l)(L)<<(k- 1) and r is thus effectively determined by l/kl.
e k+l and t1/2 values were derived from nonlinear least squares fit analysis of exper-
imental data, with the TcR-pep-MHC reaction modeled as either a classic bimolecular
reaction (upper line) or a two-step reaction (fast and slow, lower line); in the latter
case only the fast component of k+l and the slow component of tl/2 are given.
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TABLE V. Temperature dependence of the equilibrium and rate constants
for the reaction between the 2C TcR and the QL9.Ld complex.a
Binding parameter 2C TcR + QL9-Ld
25oCb 370C
Ka (M-1) 1.5x10 7  6.0x10 6
k+1 (M-lsec-1) 5.3x10 4  9.0x10 4
x (min) 3.9 1.1
kl1 (sec-1) 3.1x10 -3  1.5x10 -2
tl/2 (min) 3.7 0.7
a data from Sykulev et al., 1994b. QL9 sequence given in Table III.
b room temperature (220C-250 C).
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